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profiles (measured by FPLC and enzyme linked assays) showed marked 
increases in total serum cholesterol (CHO) in the animals receiving HC diet, 
which tended to be reduced by VasoCare’” treatment (Control: 5.1 Z!Z 0.7, HC 
alone: 31 i 3, and HC and VasoCare’“: 24 + 6 mM [B vs. C, p = 0.11). 
Conclusion: We conclude that VasoCare’” treatment substantially re- 
duced the development of atherosclerosis at early stages, and may induce 
regression of established atherosclerotic lesions in a model of human familial 
hypercholesterolemia. 
[ 1022-50 1 Elevated Plasma Level of Asymmetric 
Dimethylarginine (ADMA) is Associated With 
Coronary Artery Disease Independent of the 
Traditional Atherosclerotic Risk Factors 
John A. Vest, Ali Fard, Mary Suleski, Robert Sciacca, Alfonso F.J. Prieto, 
Lars Berglund, Todd A. Bryant, Melissa A. Kazanowski, Anthony 
R. Magnano, Carol Cardinale, Marco R. DiTullio, Paul J. Cannon, 
Allan Schwartz, LeRoy E. Rabbani, Shunichi Homma. Columbia University, 
New York, NY USA 
Background: Asymmetric dimethylarginine (ADMA) is a recently discov- 
ered endogenous inhibitor of nitric oxide (NO) synthase detectable in human 
plasma. Increased plasma ADMA levels have been found in patients with 
hypercholesterolemia, impaired NO-mediated endothelial function, and have 
been correlated with intima-medial thickness of the carotid artery. However, 
no data are available on the potential association between ADMA and coro- 
nary artery disease (CAD). In this study, we sought to determine if plasma 
levels of ADMA are elevated in patients with angiographically-proven 2 or 
3-vessel CAD independent of the traditional atherosclerotic risk factors. 
Methods: Fifty-three volunteers undergoing coronary angiography were 
included in the study. The subjects were divided into two categories, those 
with,no significant CAD (control: n = 23) versus those with 2 or 3-vessel CAD 
(n = 30). Various atherosclerosis risk factors including history of smoking, 
gender, diabetes, systolic and diastolic blood pressures, as well as plasma 
lipids were obtained. Plasma levels of ADMA, symmetric dimethylarginine 
(SDMA), and L-arginine were measured by high performance liquid chro- 
matography. 
Results: Plasma ADMA levels averaged 1.1 i 1.0 umol/L and 2.01 
4 1.5 umol/L, SDMA levels averaged 0.9 f 0.1 umol/L and 1.1 i 0.3 
umol/L, and L-arginine levels averaged 56 f 18 umol/L and 53 rt 22 umol/L 
in the control and CAD groups, respectively. ADMA level was associated 
with multivessei CAD (p < 0.03, odds ratio = 1.9; 95% confidence interval 
1 .I-3.5 per unit increase in ADMA). The association between multivessel 
CAD and ADMA remained after adjustment for other known coronary risk 
factors including age, gender, diabetes, HTN, and cigarette smoking (p < 
0.05). Cholesterol was not included in this analysis due to the number of 
missing values, however, plasma total cholesterol levels were not significantly 
different between the groups (control: 202 i 49 mg/dL, n = 16; CAD: 191 
f 36 mg/dL, n = 22). Furthermore, none of the risk factors studied were 
significantly correlated with ADMA levels. 
Conclusions: 1. Plasma ADMA level is increased, independent of the 
traditional atherosclerotic risk factors, in patients with multivessel CAD. 2. 
This study supports the concept that elevated plasma ADMA may be an 
independent risk factor for the development of atherosclerosis. 
/ 1022-51 / VasoCard” Treatment Inhibits Progression of 
Atherosclerosis in LDL Receptor (LDL-R) 
Deficient Mice 
Saeid Babaei, David W. Courtman, Duncan J. Stewart. Terrence Donnelly 
Heart Center, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, 
Canada 
Background: VasoCare’” therapy, involving ex vivo treatment of blood ele- 
ments by heat, oxidation and UV light, has been shown to modulate immune 
responses. Since immune mechanisms may be involved in atherosclero- 
sis, we hypothesized that VasoCare’” treatment will inhibit atherosclerosis in 
LDL-R (-/-) mice. 
Methods: Three groups of LDL-R (-/-) mice were studied using two 
protocols: a first control group (A) was fed normal chow; a second control 
group (5) received high cholesterol (HC) diet alone for either 8 or 12 weeks: 
the third group (C) received HC die? t VasoCare” treatment at 4 weeks 
(early) or at 8 weeks (late) of dietary intervention, and atherosclerotic area 
(AA) relative to total aortic area (TA) was assessed at 8 and 12 weeks, 
respectively by quantitative morphometry of oil red 0 staining. 
Results: HC mice exhibited substantial aortic lipid deposition which was 
profoundly reduced by treatment with VasoCare’” (AtVTA ratios in groups B: 
0.16 k 0.1 (8 wk) and 0.17 f 0.01 (12 wk) vs. VasoCare’“: 0.04 f 0.03 (early) 
and 0.04 f 0.02 (late): p < 0.05 and p < 0.01 respectively). VasoCare’” also 
produced marked reduction in xanthelasma and limb swelling. Lipoprotein 
1022-52 Retroviral Transfection of the Arterial Wall With 
Tissue Factor Pathway Inhibitor Inhibits Cyclic 
Flow Variations in Endothelial-Injured and 
Stenotic Rabbit Carotid Arteries 
Plino Cirillo, Paolo Golino, Paolo Calabrb, Massimo Ragni, 
Davide D’Andrea, Vincenzo Manganiello, Massimo Chiariello. Division of 
Cardiology: University of Nap/es “Federico II’: Naples, Italy 
Background: Tissue Factor Pathway Inhibitor (TFPI), the natural inhibitor of 
the extrinsic coagulation pathway, recently produced by recombinant DNA 
technology, has potent antithrombotic effects. However, these effects are 
accompanied by a marked prolongation of PT and PTT. 
Methods: To determine whether local transfection of the arterial wall with 
the TFPI gene would result in antithrombotic effects without affecting PT and 
PTT, rabbit TFPI gene was amplified from mRNA with RT-PCR and then 
subcloned in a vector containing a tag of 6 histidine (His) residues. The 
TFPI with the 6 His was then cloned into a retroviral vector (pRETRO-ON), 
containing the packaging signal (@) for assembling of viral particles. As 
control, a repotter gene (green fluorescent protein, GFP) was also cloned 
into pRETRO-ON. Permissive packaging cells (Phoenix), stably transfected 
with the Gag, PO/ and fnv retroviral genes, but lacking $, were trans- 
fected with either TFPI or GFP in p-RETRO-ON, yielding recombinant mature 
retroviruses (retroTFPI; retroGFP) replication defective. Gene expression in 
p-RETRO-ON is regulated by a promoter which is under control of a tetracy- 
clin-responsive element, such that expression is switched on in the presence 
of doxycyclin (Dox), a tetracyclin analogue. RetroTFPl and retroGFP were 
used to transfect rabbit carotid arteries in viva. A segment of one artery 
was transfected with retroTFPl and a segment of the other artery with ret- 
roGFP (direct injection of the retroviral suspension). The animals were then 
allowed to recover. Forty-eight hrs later, both carotid arteries distal to the sites 
of transfection were damaged and a constrictor was placed around them. 
Cyclic flow variations (CFVs), due to recurrent thrombosis, developed in all 
animals (n = 6) in both arteries. After 30 min of CFVs, Dox was given as an 
i.v. bolus (3 mg/kg) + 300 pg/kg/hr, to induce expression of TFPI and GFP. 
Results: In all animals, CFVs were completely inhibited after 2.20 i 
0.4 hrs in the arteries transfected with retroTFPI, while t. hey remained 
unchanged in the contralateral vessels transfected with retroGFP. Immuno- 
histochemistry for r-TFPI, with antibody against the 6 His tag revealed a 
significant expression of TFPI in the artery transfected with retroTFPI; in 
contralateral arterial segments TFPI expression was absent, while UV light 
observation revealed significant expression of GFP. PT and PTT were not 
altered when CFVs were inhibited, as compared to values obtained before 
Dox administration. 
Conclusions: Transfection of the arterial wall with TFPI results in potent 
antithrombotic effects without altering coagulation parameters. 
I_j 1022 53 Prolonged Antiplatelet Therapy Prevents Late Thrombosis After Radiation Therapy in Patients 
With In-Stent Restenosis 
Ron Waksman, Balram Bhargava, Maeve Taffle, R. Larry White, Lowell 
F. Satler, Roxana Mehran, Kenneth M. Kent, August0 D. Pichard, Martin 
B. Leon. Washington Hospital Center, Washington DC, USA 
Background: lntracoronary radiation (IR) both with B and y emitters has 
been shown to reduce recurrent in-stent restenosis (ISR). High rates (up to 
10%) of late thrombosis (>30 days after the procedure) were reported follow- 
ing IR and new stenting with short term of antiplatelet therapy. The purpose 
of this study was to determine whether prolonged (6 months) antiplatelet 
therapy would reduce the incidence of late thrombosis after IR. 
Methods: Prolonged antiplatelet therapy (Clopidogrel 75 mg QD and 
Aspirin 325 mg QD for 6 months) were given to 52 consecutive patients with 
ISR who were enrolled into different radiation protocols utilizing y (Ir-192) 
and B (90 SrN and P32) emitters. The dose range in these trials was 14-20 
Gy with calculated maximum dose to the vessel wall between 35-60 Gy. 
Prior to IR patients underwent intervention with balloon (n = B), laser (n = 
17) and rotational atherectomy (n = 27). Re stenting was performed in 18 of 
the procedures (34.6%). All patients completed at least 2 months of clinical 
follow-up (mean of 94 & 26 days). 
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Results: All patients underwent successful intervention and radiation 
procedure to 37 native arteries and 15 saphenous vein grafts with ISR. The 
mean patient’s age was 62.5 f 12.2 with male predominance of 82%. The 
mean length of the irradiated segment was 59.2 * 20.4 mm and 6 patients 
(12%) underwent radiation therapy in 2 vessels. At clinical follow-up one 
patient had cardiac death associated with arrhythmia and one patient had 
subacute thrombosis associated with MI at 21 days. None of the patients in 
this cohort had presented with late thrombosis or acute Ml. 
Conclusions: Late thrombosis as a complication of IR appears to be 
controlled under prolonged antiplatelet therapy. Complete 6 months angio- 
graphic follow-up and comparison with short-term antiplatelet therapy in a 
similar cohort of patients will be available at presentation. 
I 1022 54 Detection of Vulnerable Atheroma by 
Laser-Induced Fluorescence 
Ko Arakawa, Kikuo Isoda, Toshio Shibuya, Akira Yoneyama, 
Tadashi Shinohara, Kousuke Hagisawa, Fumitaka Ohsuzu. National 
Defense Medical College, Saifama, Japan 
Background: Vulnerable atheroma tends to have thin fibrous cap, lipid pools 
and reduced internal plaque collagen. One of the active components of oxi- 
dized LDL lysolecitin (LPC) which is related to a formation and progression 
of atherosclerosis and is found in necrotic core. The aims of this study were 
whether or not 1) LPC can be detected in necrotic core by laser-induced 
fluorescence spectroscopy, 2) fluorescence spectrum (FS) of LPC can dis- 
criminate necrotic core from normal an atheroma, and can detect vulnerable 
atheroma. 
Methods: FS was recorded from cadaver arteries and from known chem- 
ical constituents in plaque. 
Results: 155 FS were recorded for classification of atherosclerotic plaque. 
LPC emitted bright fluorescence with marked spectral shifts to red of approx- 
imately 500 nm. Similarities between the FS of plaque and collagen, normal 
artery and elastin, and LPC and necrotic core were noted. A classification 
algorithm based on a collagen elastin and LPC spectral decomposition can 
classify atheroma, normal artery and necrotic core fluorescence spectra 
with accuracy of 92.3%. Removal of atheroma was performed by removing 
lo-pm thickness of atheroma with a cold microtome. FS were recorded after 
each IO-pm thickness of atheroma removal in eight samples. Approaching 
to necrotic core, FS changed from collagen constituent dominant pattern 
to LPC dominant pattern. The thickness of fibrous cap correlated with the 
spectral collagen-to-LPC content ratio (r = 0.84, p c 0.001). 
Conclusion: FS useful for identification of necrotic core and vulnerable 
atheroma. 
L-4 1022 55 In Vivo Physiologic Heating of Rabbit 
Atherosclerotic Plaques Induces Macrophage 
Apoptosis: A New Approach to Plaque 
Stabilization 
Khawar GUI, Morteza Naghavi, Said Saidaty, Ward Casscells, Alan Cohen, 
James T. Willerson. University of Texas, School of Medicine, Houston, TX, 
USA 
We have previously shown the effects of gentle heating on the induction of 
apoptosis in plaque macrophages ex viva. Here we asked whether heating 
could cause macrophage apoptosis in viva. 
Methods: Watanabe hypercholesterolemic rabbits were fed a choles- 
terol-rich diet for six months to develop lesions in their aortas. The aorta was 
then exposed and heated internally, with a cooled ablation catheter (Cardiac 
Pathways) using a radiofrequency generator (Radionics) at 42” C for 15 min- 
utes The heated specimens were harvested, then fixed and TUNEL-stained 
for apoptosis. 
Results: In 11 rabbits heated at 42” C for 15 minutes, the percentage 
of apoptosis in the intimal layer in the internally heated aorta was 30.3 Z!Z 
23.1 as compared to 5.7 f 8.9 for the control. Friedman test was significant 
at 0.020 level. For the medial layer, the percentage of apoptosis was 2.9 5 
1.56 in the internally heated aorta as compared to 1.5 f 2.5 for the control. 
Friedman test was not significant at 0.164. 
Conclusion: We conclude that gentle heating of rabbit aorta in vivo 
induces significant macrophage apoptosis in the intimal layer. 
1 1022-56 ( Cycle-Oxygenase Inhibitor Diclofenac Improves 
Chlamydia Pneumoniae-Induced Endothelial 
Dysfunction 
Petru Liuba, Erkki Pesonen, Kenneth Persson, Anders Forslid, 
Pdivi Karnani, llari Paakkari. University of Lund, Lund, Sweden; University 
of Helsinki, Finland 
Background: We have previously reported that Chlamydia pneumoniae 
(C pneumoniae) infection induces endothelial dysfunction due to impaired 
nitric oxide (NO) availability. In the present study we wanted to study the 
possible role of the cycle-ocygenase pathway in the C pneumoniae-induced 
endothelial dysfunction in apolipoproteinE (apoE)-knockout mice. 
Methods: 24 mice, 7-8 week old, were infected every 2 weeks with C 
pneumoniae over 12 weeks. An equal number of mice sham- inoculated 
with phosphate buffered saline were used as controls. Eight infected mice 
and 8 controls were killed at 2, 6, and 12 weeks respectively, after the first 
inoculation. In order to study vascular relaxation, ascending aorta rings were 
successively exposed to methacholine in the absence or in the presence 
of N- G--nitro-L-arginine methyl ester (L-NAME), a nitric- oxide synthase 
inhibitor, and diclofenac. 
Results: In the absence of inhibitors, the aorta rings from the infected mice 
relaxed significantly less than those from noninfected mice (p < 0.05) at 6 and 
12 weeks. In the presence of L-NAME, the methacholine-induced vasodilator 
response was even more impaired in infected animals as compared to the 
controls at all time points. When diclofenac was added to L-NAME, the 
muscarinergic relaxation was increased in the infected mice at 2 and 12 
weeks (p < 0.05). No difference in relaxation response was recorded in this 
regard in non-infected mice. 
Conclusion:. Repeated infection with C pneumoniae progressively im- 
pairs the endothelium-dependent relaxation of the mouse aorta. Both lowered 
NO activity and endothelium derived cycle-oxygenase-dependent constrict- 
ing factors (prostanoids, superoxide anions or both) may contribute to the in- 
fection induced endothelial dysfunction, Cycle-oxygenase inhibitors may play 
a beneficial role in improving endothelial dysfunction in relation to Chlamydia 
pneumoniae infection. 
L-d 1022 57 Use of Electrical Stimulation to Prevent 
Atherosclerosis in the Abdominal Aorta 
(Experimental Study) 
Valeri Chekanov, Guennady Tchekanov, Michelle Maternowski, 
Mohammed Mortada, Ruben Eisenstein. Hearf Care Associafes, Sinai 
Samaritan Medical Center, Milwaukee, W/, USA 
Background: Low frequency electrical impulses prevent new atherosclerotic 
plaque from developing in previously diseased vessels and may decrease 
the extent of previous pathological damage in these structures. 
Methods: Rabbits were placed on a high cholesterol diet (HCD) for 11 
week to induce atherosclerosis. No electrical stimulation (ES) was applied 
to the control series, In the experimental series ES was applied for 8 weeks 
(3V, 30 CPM - series I; 4V, 60 CPM - series II) to the psoas major muscle 
close to the abdominal aorta. The stimulator was implanted on the other side 
of the aorta. The range of atherosclerosis estimated by pathological review 
was 0 to 4+. 
Results: 
C I II c 1 II 
After 11 weeks of HCD the level of atherosclerosis in the control rabbits 
was between 3+ and 4+. In rabbits submitted to ES it was between 0 and I+. 
ES applied to the abdominal aorta did no influence the level of cholesterol 
(1111-1954 mg/dL in controls; 894-1876 mg/dL in series I and II), nor the 
level of atherosclerosis in the coronary arteries (3.5+ in controls; 2.6-3.3~ in 
series I and II). 
Conclusion: Electrical stimulation applied close to the abdominal aorta 
decreases the level of atherosclerotic buildup in rabbits placed on HCD. 
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/ 1022 58 Effects of Red Wine, Alcohol and the Red Wine Flavonoid, Quercetin, on Isolated Coronary 
Resistance and Conductance Arteries 
Steve V. Rendig, J. Dave Symons, John C. Longhurst, Ezra A. Amsterdam. 
University of California, Davis, California, USA 
Background: Moderate consumption of alcohol, and of red wine in particular, 
may lower the risk of coronary heart disease. The mechanism of this effect 
is unknown, but could include a coronary vasorelaxant action. 
Methods: We assessed the effects of red wine, ethanol and a major 
flavonoid constituent of red wine, quercetin, in isolated coronary resistance 
(80-150 /-Lm, i.d.) and conductance (300-525 pm, i.d.) vessels of the rab- 
bit. Vessei wall tension was measured in isolated segments (= 1 mm length) 
maintained in a wire-type myograph at 37” C and preconstricted with 30 mM 
K’. 
Results: At an alcohol concentration equivalent to moderate consumption 
(14 mM), and slightly below the legal blood alcohol limit for driving in some 
states (0.08%; 17 mM), red wine evoked a slight, transient, statistically 
significant (p < 0.05) constrictor effect in resistance and conductance vessels 
(13.0 * 4.0%, n = 3; 6.5 f 0.7%, n = 5, respectively). Ethanol alone at this 
concentration was without effect. At 15-25 min after red wine administration, 
tension was similar in red wine-treated (resistance: -9.6 f 7.2%, n = 2; 
conductance: -3.5 & 1.2%, n = 3), ethanol-treated and time control vessels, 
Quercetin (5.6, 8 and 30 JLM) produced significant endothelium-independent 
relaxation in resistance (-32.4 i 3.5%, n = 10; -47.1 f 2, n = 7; -82.3 f 
5.5, n = 8, respectively) and conductance (-19.7 f 2.9%, n = 8; -31.8 rt 
4.3%, n = 8; -72.5 f 7%, n = 8) arteries, This effect was significantly greater 
in resistance vessels at the two lower concentrations. 
Conclusions: These preliminary data suggest that red wine and ethanol 
do not evoke a significant vasorelaxant effect in coronary arteries at con- 
centrations associated with moderate consumption. However, quercetin, one 
of the predominant flavonoids in fruits, vegetables, red wine and tea, elic- 
its marked coronary artery vasorelaxation in an endothelium-independent 
manner. 
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) 1023-41 / Hypertriglyceridemia is a Risk Factor for Arterial 
Endothelial Dysfunction in Asymptomatic 
Westernized Chinese 
Kam S. Woo, Ping Chook, Shu W. Chan, Chris W.K. Lam, David 
S. Celermajer. The Chinese University of Hong Kong, China; The Chinese 
Hospital, San Francisco, CA, USA 
Background: Age and smoking have a less impact on arterial endothelial 
dysfunction in rural Chinese in mainland-China than westernized Whites, 
suggesting a relative protection in rural Chinese. 
Methods: To evaluate the impact of hypertriglyceridemia (prevalent in 
most modernized societies) on development of endothelial dysfunction in 
modernized Chinese, 160 asymptomatic westernized American Chinese (mi- 
grated to U.S.A. for >I0 years) in San Francisco (aged 20-70 years) were 
studied. Flow-mediated dilatation (FMD) of brachial artery (endothelium- 
dependent) was measured by high resolution ultrasound in 28 subjects (mean 
age 47.9 i 14.5 year, 14 males) with highest quartile blood triglyceride (High 
TG), and compared with 28 age and gender-matched subjects with lowest 
quartile blood triglyceride (Low TG). 
Results: The 2 groups were matched for total and low lipoprotein choles- 
terol, blood pressures and glucose, but body mass index (BMI) was higher 
and high density lipoprotein cholesterol (HDL-C) was lower in High TG group. 
FMD was significantly lower in High TG: 
Triglyceride (mmol/L) 
HDL-C (mmol/L) 
BMI 
FMD (%) 
NWtTld 
0.82 zt 0.17 
1.5zko.4 
22.3 A 2.5 
8.6 i 2.4 
High TG 
2.02 + 0.9 
1.2io.4 
25.4 zt 3.9 
7.1 * 2.0 
P-Value 
<O.OOl 
0.008 
0.001 
0.01 
Triglyceride but not BMI or HDL-C was independently associated with 
impaired FMD on multivariate analysis (Multiple R = 0.6, F value = 2.6). 
Conclusion: Hypertriglyceridemia is an independent risk factor for en- 
dothelial dysfunction in westernized Chinese, with great implication in ath- 
erosclerosis prevention. 
/ 1023-42 ( Antioxidant Nutrient Supplementation and 
Brachial Reactivity in Patients With Coronary 
Artery Disease (CAD) 
Ronald McKechnie, Melvyn Rubenfire, Lori Mosca. University of Michigan 
Hospitals, Ann Arbor, Ml, USA 
Background: Epidemiologic studies have shown a correlation between an- 
tioxidant intake and CAD, however clinical trials have been inconsistent. We 
evaluated the effect of combined antioxidant supplementation on endothelial 
function and its correlation with low density lipoprotein (LDL) oxidation in 
patients with established CAD. 
Methods: In a double-blinded, placebo-controlled 12 week trial, 18 pa- 
tients (mean age 62.4 + 8.1 years) were randomized to 1) placebo; 2) 4OOlU 
of vitamin E, 500 mg of vitamin C, 12 mg of beta-carotene (mid-dose); or 3) 
8OOlU of vitamin E, 1,000 mg of vitamin C, 24 mg of beta-carotene (high dose) 
daily. Endothelial function was evaluated by percent and absolute change in 
brachial artery diameter in response to reactive hyperemia induced by occlu- 
sion-release, and in response to cold pressor testing (CPT). Baseline and 12 
week values of LDL oxidation (measured by lag phase), brachial reactivity, 
dietary composition, serum antioxidants and lipids were measured. 
Results: Plasma levels of alpha-tocopherol, vitamin C and beta-carotene 
significantly increased in the treatment groups. Improvement in lag phase 
was observed in all 3 groups, but greater in the treatment arms. Brachial 
reactivity significantly improved within the placebo group in response to CPT 
(5.8% f 4.3%, 0.29 cm f 0.21 cm, p < 0.05) and occlusion-release (2.2% + 
1.9%, 0.09 cm f 0.06 cm, p 4 0.05) while the mid-dose group only showed 
significant improvement in response to CPT (3.7% & 2.5%, 0.16 cm i 0.1 cm, 
p f 0.05) and the high dose response did not reach statistical improvement 
using either method. No significant correlation existed between change in 
lag phase and change in endothelial function. Only baseline high density 
lipoprotein cholesterol (HDL-C) (CPT%, r = 0.46, p < 0.05) and change in 
dietary (not including supplements) vitamin C intake (CPT% r = -0.63, CPT 
absolute r = -0.56, p < 0.05) were significant predictors of brachial reactivity. 
Change in vitamin C intake maintained significance in multivariate analysis 
controlling for age, baseline brachial reactivity and change in serum lipid 
values (LDL-C, HDL-C). 
Conclusion: Despite favorable changes in LDL oxidation, combined an- 
tioxidant supplementation was not associated with improved brachial re- 
activity. These data suggest that antioxidant supplementation has variable 
effects on surrogate markers of CAD and may not actually improve clinical 
outcomes, while dietary antioxidant intake may play a more functional role in 
secondary CAD prevention. 
) 1023-43 1 Enhanced Reduction of Fasting Total 
Homocysteine Levels With Supraphysiological 
Versus Standard Multivitamin Dose Folic Acid 
Supplementation in Renal Transplant Recipients 
Andrew G. Bostom, Andrew J. Beaulieu, Reginald Y. Gohh, David Hakas, 
Haewook Han, Paul F. Jacques, Jacob Selhub. Brown Universi@ 
Providence, RI; Tufts llniversi& Boston, MA, USA 
Background: Mild fasting hyperhomocysteinemia, a common potential ar- 
teriosclerotic risk factor among renal transplant recipients (RTR), can be 
effectively treated with combined B-vitamin supplementation featuring sup- 
raphysiological doses of folic acid. No controlled studies have compared the 
efficacy of standard multivitamin (0.4 mg/day) vs. supraphysiological dose 
folic acid supplementation in this regard. 
Methods: We block randomized 60 chronic, stable RTR based on their 
screening fasting total homocysteine (tHcy) levels to 3 groups of 20 subjects 
treated for 12-weeks with folic acid at either 2.4 mg/day (group I), 0.4 mg/day 
(group 2), or 0.0 mg/day (group 3). All 60 subjects also received 50 mg/day 
vitamin B6, and 0.4 mg/day vitamin 612. 
Results: The mean % reductions (&SE) in fasting tHcy were: group 1 = 
32.3% (f2.4%); group 2 = 23.4% (*2.3%); and group 1 = 19.1% (f2.3%). 
Final on treatment values (mean with 95% Cl) were, group 1: 11.3 bM 
(10.5-12.1); group 2: 13.4 PM (12.6-14.2); group 3: 14.0 FM (13.2-14.8). 
Matched analysis of covariance adjusted for pretreatment tHcy, folate, & 
albumin levels, change in creatinine during the study, & cyclosporine A 
use, revealed significant overall group differences (p = 0.005), & significant 
differences between groups 1 & 2 (p = 0.038) and 1 & 3 (p = O.OOl), but not 2 
& 3 (p = 0.153). Moreover, a post-hoc logistic regression analysis of subjects 
with pretreatment tHcy levels 2 15 yM (n = 21) indicated that a significantly 
greater proportion of those in group 1 vs. group 2 achieved post-treatment 
tHcy levels < 12 I.LM: group 1 = 5/10 (50%); group 2 = l/Ii (9%); [odds ratio 
= 7.7, 95% Cl = 1 .I-57.5; p = 0.047]. 
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Conclusion: A supraphysiological dose of folic acid is superior to stan- 
dard multivitamin dosing for the reduction of fasting tHcy levels in chronic, 
stable RTR, gauged as either changes in mean tHcy levels, or the proportion 
of individuals with pre-treatment hyperhomocysteinemia whose tHcy levels 
are normalized by treatment. 
1 1023-44 1 Angiotensin Converting Enzyme Inhibition 
Improves Endothelial Dysfunction and Myocardial 
lschemia 
Abhiram Prasad, Rita Mincemoyer, Joseph Arevalo, Arshed A. Quyyumi. 
NHLBI, N/H, Bethesda, MD, USA 
Background: ACE inhibition is known to improve endothelial dysfunction in 
atherosclerosis partly by enhancing bradykinin (BK) activity. We investigated 
whether enalapril (EN) improves myocardial ischemia in pts with stable CAD 
and whether this correlated with improvement in endothelial dysfunction. 
Methods: The effect of oral EN (2.5-20 mg, mean 11 .I mg daily for 10 
days) on exercise (EX)-induced ST depression (STD) was investigated in 30 
CAD patients with mild symptoms. Forearm blood flow (FBF) response to 
BK (6.25-400 ng/min), an endothelium-dependent vasodilator, was studied 
before and after EN using forearm plethysmography. 
Results: Oral EN therapy reduced resting heart rate and blood pressure 
and improved the duration of EX to 1 mm STD (by 100 s, P = 0.01) and total EX 
time (by 40 s, P = 0.007, Table). The rate-pressure product (RPP) at these 
time points remained unchanged after EN. BK-mediated forearm dilation 
was enhanced by EN; at the 25 nglmin dose, FBF increased from 7.6 to 11.6 
ml/min/dL (p < 0.01.). There was no correlation between the magnitude of 
improvement of the BK response and the change in treadmill EX parameters. 
Thus, ACE inhibition improves EX-induced myocardial ischemia in patients 
with CAD by improving EX capacity to onset of ischemia. Enhancement of 
BK and reduction in angiotensin II by ACE inhibitors may contribute to these 
beneficial effects. 
Resting Resting 1 mm STD 1 mm STD Peak EX Peak EX 
HR MAP Time(s) RPPX103 Time(s) RPPXlO3 
Baseline 77 102 612 13.2 732 15.5 
EN 74* 96** 720*” 13.6 772** 14.7 
HR = heart rate (bpm), MAP = mean BP (mmHg), RPP = rate pressure product, * = P < 
0.05, ** = P < 0.01. 
1 1023-45 1 Bradykinin Induced Tissue Plasminogen Activator 
Release is Enhanced by Angiotensin Converting 
Enzyme Inhibition but Not Angiotensin II 
Receptor Antagonism in Healthy Man 
Catherine Labinjoh’ , David E. Newby’,‘, Neil R. Johnston’, Nicholas 
A. Boon*, David J. Webb’. ‘Clinical Pharmacology Western Genera/ 
Hospital; ‘Department of Cardiology, Royal Infirmary Edinburgh, UK 
Background: It has been suggested that angiotensin converting enzyme 
(ACE) inhibitor therapy may exert a beneficial effect on the endogenous 
fibrinolytic balance through actions on bradykinin. The aim of the present 
study was to determine the acute effect of bradykinin on the acute local 
release of tissue plasminogen activator (t-PA) during ACE inhibition and 
angiotensin II receptor antagonism. 
Methods: Blood flow and plasma fibrinolytic factors were measured in 
both forearms of eight healthy males who received unilateral brachial artery 
infusions of the endothelium-dependent vasodilators, substance P (2-8 
pmol/min) and bradykinin (100-1000 pmol/min), and the endothelium-inde- 
pendent vasodilator, sodium nitroprusside (2-8 Ng/min). These measure- 
ments were performed on 3 occasions following one week of double blind 
therapy with placebo, losartan 50 mg or quinapril 40 mg once daily. 
Results: During placebo therapy, sodium nitroprusside, substance P and 
bradykinin produced dose-dependent increases in the blood flow of infused 
forearm (ANOVA, p < 0.001 for all). Despite similar increases in blood flow, 
sodium nitroprusside did not affect plasma t-PA concentrations. In contrast, 
substance P and bradykinin caused dose-dependent increases in plasma 
t-PAconcentrations in the infused forearm (ANOVA, p < 0.001 for all). Whilst 
there were no differences in substance P induced t-PA release, bradykinin 
induced release of t-PA was greater during treatment with quinapril than with 
placebo or losartan (3-way ANOVA, p < 0.001). 
Conclusions: We have shown a selective augmentation of bradykinin 
induced t-PA release during ACE inhibition but not during angiotensin II 
receptor antagonism. This has potentially important implications for under- 
standing the beneficial mechanisms of action of ACE inhibitors in heart failure 
and ischemic heart disease. 
) 1023-46 1 Losartan Improves Endothelium-Dependent 
Vasodilation in Patients With Non-Insulin 
Dependent Diabetes Mellitus 
Hideki Watanabe, Masaaki Kakihana’ KlNU Medic&Association Hospital, 
Mitsukaido; ’ lbaraki Prefectural University, Ami, Japan 
Background: Endothelial function is impaired in patients with diabetes melli- 
tus due to increased oxidative stress. Angiotensin II activates NADH/NADPH 
oxidase, and plays an important role in increased oxidative stress. 
Methods: To evaluate the effect of losartan, an angiotensin II receptor 
antagonist, on endothelial function in patients with non-insulin-dependent 
diabetes mellitus (NIDDM), twenty four patients with well-controlled NIDDM 
were randomized to receive losartan (50 mg/day, L group, n = 12) or placebo 
(P group, n = 12). We also studied 12 age-matched, non diabetic control 
subjects (C group). By use of high resolution ultrasound with a 7.5-MHz 
transducer, the brachial artery diameter was measured at rest and during 
reactive hyperemia (endothelium-dependent) and again at rest and after 0.3 
mg of sublingual nitroglycerin (NTG) (endothelium-independent). We also 
measured plasma TBARS (thiobarbituric acid reactive substances) levels as 
an index of oxidative stress. Measurements were performed at baseline and 
1 month after taking losartan or placebo. 
Results: At baseline, brachial artery diameters were comparable among 
the three groups. Flow-mediated dilatation (FMD, % increase during reactive 
hyperemia) in the L and P groups were significantly lower than that in the 
C group (3.6 & 1.4%, 3.8 f 1.3%, 15.3 Z!Z 2.5%; L, P, C groups, p < 0.01) 
and plasma TBARS levels (nmoliml) in the Land P groups were significantly 
higher than that in the control group (2.6 f 0.5, 2.4 f 0.6, 0.7 f 0.3; 
L, P, C groups, p < 0.01). NTG-induced dilatation (NID, % increase after 
nitroglycerin) were comparable among the three groups (22 f 13%, 24 f 
12%, 25 & 11%; L, P, C groups). At 1 month, FMD in the L group was 
significantly higher than that in the P group (9.6 f 3.1% vs 3.9 f 1.7%, p < 
0.05). NID did not change in the three groups after 1 month. PlasmaTBARS 
level was significantly decreased in the L group (p < 0.05) as compared with 
the baseline levels (L group: 0.8 f 0.3; P group: 2.2 f 0.5). 
Conclusion: Losartan may improve oxidative stress and restore endothe- 
lial dysfunction in patients with NIDDM. 
( 1023-47 ( Tetrahydrobiopterin Restores Endothelial 
Function in Human Coronary Arteries in Vivo 
Yukihiro Fukuda, Hiroki Teragawa, Keishi Matsuda, Fumiharu Miura, 
Hidekazu Hirao, Tadakatsu Yamada, Yuji Muraoka, Yukihito Higashi, 
Togo Yamagata, Hideo Matsuura, Goro Kajiyama. first Department of 
Internal Medicine, Hiroshima University Hiroshima, Japan 
Background: Deficiency of tetrahydrobiopterin (BHb), an essential cofactor 
of nitric oxide (NO) synthase, causes both impaired NO activity and in- 
creased super oxide formation. It has been postulated that supplementation 
of BH4 improves endothelial dysfunction in patients with atherosclerosis. We 
evaluated the effects of BH4 on endothelial function in coronary arteries. 
Methods: In 13 patients with atypical chest pain and angiographically 
normal coronary arteries, the coronary blood flow (CBF) was calculated by 
quantitative coronary angiography and Doppler flow velocity measurements 
after intracoronary infusion of various drugs as follows; 1) Ach only (3 Fg/min 
and 30 kg/min over 2 min), 2) co-infusion of Ach and BH4 (0.25 mg/min), and 
3) co-infusion of Ach and BH4 after the infusion NG-monomethyl-L-arginine 
(L-NMMA; 40 mol/min for 5 min). 
Results: During the coinfusion of BH&, Ach significantly enhanced CBF 
(from 82 f 15% and 143 f 22% to 132 f 21% and 204 f 24%, 3 fig/min 
and 30 Fg/min respectively, p < 0.05). The infusion of L-NMMA, an NO 
synthase inhibitor, abolished the BHd-induced enhancement of coronary 
vasorelaxation evoked by Ach. 
Conclusion: lntracoronary infusion of BHa may augment endothelium- 
dependent vasodilation in coronary arteries through an increase in NO re- 
lease, suggesting that deficiency of BH4 is involved in the pathogenesis of 
disturbance in endothelium-dependent vasodilation. 
1023-48 Synthetic Progestin improves 
Endothelium-Dependent Vasodilator 
Responsiveness Comparable to Natural Progestin 
in Healthy Postmenopausal Women 
Kwang Kon Koh, Dong Kyu Jin, Sun Kyu Lee’. Cardiology; ‘Radiology 
Gachon Medical School, Inchon, Korea 
Background: We have previously shown that estrogen (E) improved en- 
dothelium-dependent vasodilator responsiveness in postmenopausal women 
(PMW). Considerable experimental and animal studies suggest that syn- 
thetic, not natural, progesterone may negate the favorable effects of E. 
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Methods: We administered micronized progestin (MP) 200 mg or medrox- 
yprogesterone acetate (MPA) IO mg for 10 days with conjugated equine 
estrogen (CEE) 0.625 mg for 25 days during 8 weeks to 20 PMW in a 
randomized, double-blind, crossover study. 
Baseline CEE + MP CEE + MPA 
FMD (%) 4.62 f 2.66 7.41 * 3.46*’ 7.54 * 4.45** 
NTG (%) 13.25 zk 3.84 11.42 zt 4.76 13.54 i 4.73 
Fibrin0 (mg/ml) 227 f 36 199151 217160 
‘* = P < 0.01 vs. Baseline. Data = mean =k SD. MPA or MP combined with CEE sig- 
nificantly improved brachlal artery FMD. Of note, there were no significant differences 
between CEE + MPA and CEE + MP regarding FMD and fibrinogen (fibrin@. 
Conclusion: Improvement in NO bioactivity may account for the cardio- 
vascular benefit of synthetic or natural progestin combined with estrogen in 
healthy PMW. 
1 1023-49 1 Effect of Low and Standard Dose of Estrogen 
Replacement Therapy Upon Endothelial Function 
in Menopausal Women at Risk of Coronary Events 
Filippo Leonardo, Francesco Pelliccia, Giuseppe Mercuro’ , 
Elena Cerquetani, Paolo Pagnotta, Sergio L. Chierchia, Sandra Zoncu’ , 
Giuseppe MC. Rosano. Dept. of Cardiology lstituto San Raffaele Milan0 
and Roma; 1 Dept of Cardiology University of Gag/&y k/y 
Background: Estrogen replacement therapy (ERT) improves endothelium- 
dependent flow-mediated dilatation in postmenopausal women (PMW). Pts 
with cardiovascular disease or at risk of coronary events are older than 
women taking ERT for menopausal symptoms and often complain of side 
effects when treated with doses of ERT normally used for perimenopausal 
women. Low dose ERT is better tolerated by elderly women, but at present 
little is known regarding the cardiovascular effect of such dosages. 
Methods: The aim of this double-blind single cross-over study was to 
evaluate forearm vascular reactivity in 1.5 PMW (mean age 65 i 5 yrs) 
with ‘2 risk factors for coronary artery disease receiving either low (0.3 
mg) or standard (0.625 mg) dose of conjugated equine estrogens (CEE). 
PMW were randomized to receive CEE at low or high dose for a period 
of 1 month and were then crossed to the complementary treatment for 1 
additional month. Forearm vascular reactivity (flow mediated dilatation, FMD, 
and forearm blood flow, FBF) were evaluated at baseline (B) and at the end 
of each treatment regimen with high resolution Doppler ultrasound. Brachial 
artery diameters and flow were measured at rest, during reactive hyperemia, 
recovery and after s.I. nitroglycerine. 
Results: Both regimens significantly increased FMD compared to B (14 
f 3% vs 13 i 3% vs 7 + 4%; standard vs low vs B, p < 0.01) and hyperemic 
FBF (27 i 9% vs 25 f 8% standard vs low, NS). Compared to B, brachial 
artery resistances were reduced by both treatment regimens (-15 Z+ 4% vs 
-16 ZIZ 6%, standard vs low, p = NS). An increase in nitroglicerine-induced 
brachial artery blood flow was observed after both treatment regimens (8 f 
2% vs 6 i 4%, standard vs low, NS). 
Conclusion: Low dose ERT with CEE has an effect on endothelial func- 
tion and FBF and resistances comparable to that of standard dose. These 
data suggest that low dose ERT with CEE may prove to be beneficial and 
may avoid side effects due to over-treatment in PMW at risk for cardiac 
events. 
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1 1024-9 1 Treatment of Pseudoaneurysms With Thrombin 
Injection: Multicenter Experience 
Emile R. Mohler Ill, Marc E. Mitchell,.Jeffrey P. Carpenter, Joshua 
A. Beckman, Marie Gerhard. University of Pennsylvania School of Medicine, 
Philadelphia, PA; Harvard Medical School, Boston MA, USA 
Background: The standard noninvasive treatment of pseudoaneurysms was 
ultrasound guided compression (UGC) but now includes thrombin injection. 
The problems with UGC include pain at the site of compression and long 
compression times; especially for large pseudoaneurysms. Recently ultra- 
sound guided pseudoanurysm injection with thrombin has gained popularity, 
We report a multicenter experience with this technique that details the clinical 
utility and limitations of this emerging vascular laboratory procedure. 
Methods: The medical records of all patients diagnosed with pseudoa- 
neurysm in the vascular laboratory who underwent thrombin injection over the 
past year were reviewed for patient characteristics and clinical outcome. This 
period of time was chosen as both institutions began performing thrombin 
injection of pseudoanurysms one year ago. 
Results: There were 35 patients (17 male) with a mean age of 71.2 years. 
One patient also had an arteriovenous fistula. The majority of patients were 
receiving one or more antiplatelet agents. All patients underwent injection of 
pseudoaneurysm with bovine thrombin. The mean largest diameter of the 
active aneurysm sac was 3.0 cm, range 1.5 to 5.0 cm. Thirty two patients 
developed the pseudoaneurysm after cardiac catheterization, 2 were associ- 
ated with lower extremity bypass grafts and 1 occurred post operatively after 
coronary artery bypass surgery. Successful thrombosis of the aneurysmal 
sac was achieved in all cases including two patients anticoagulated with 
heparin. In one case, UCG was used to close a small active region of a sac 
that did not completely thrombose after thrombin injection. There were no 
local complications after injection. One patient suffered a pulmonary embo- 
Ius. This was not likely related to the procedure as thrombus retrieved by 
embolectomy contained marrow and bone fragments. 
Conclusions: Thrombin injection for treatment of pseudoaneurysms is 
safe and effective; even in patients receiving anticoagulation. This proce- 
dure should be considered as the initial therapeutic approach for peripheral 
pseudoaneurysms. Further study is needed to determine if patients with 
aneriovenous fistulas can also safely undergo thrombin injection of their 
pseudoanuerysm. 
l--L.l 1024 10 Treatment of Post Catheterization Pseudoaneurysms With Ultrasound Guided 
Percutaneous Thrombin Injection 
Jeffrey W. Olin, Lucy LaPerna, Debra Goines, Mary Beth Childs, 
Kenneth Ouriel. C/eve/and Clinic Foundation, C/eve/and, Ohio, USA 
Background: This prospective study was undertaken to test the safety and 
efficacy of a new method to treat post catheterization pseudoaneurysms (PA) 
using ultrasound guided thrombin injection (Tl). 
Methods: From April 1998 thru August 1999, 56 consecutive PA were 
treated with il. Using color duplex ultrasound, the most superficial cavity 
was centered directly under the ultrasound transducer. Bovine thrombin 
was reconstituted into a 1,000 u/ml concentration and injected under direct 
ultrasound guidance into the most superficial PA chamber using a 19-22 
gauge needle. 
Results: There were 28 males and 28 females [mean age 69 years, 
range 29 to 861. The PA was located in the groin in 54 patients (pts) and the 
arm in 2 pts. Twenty (36%) pts were receiving either heparin or warfarin at 
the time of the TI. Most pts were also receiving either aspirin or clopidogrel. 
The mean number of chambers was 1.4 (range l-3). The TI successfully 
obliterated the PA in 54 of 56 (96%) pts. The PA thrombosed within seconds 
in most pts. In 2 pts the PA reopened when checked the next day. Both pts 
has successful closure with a second injection. Of the two failures, the first 
patient in the pilot study had two attempted TI and refused further attempts. 
No thrombin was injected into the PA. The second patient was 107 kg and 
had successful TI on the follow-up ultrasound. However several days later 
she had a rapidly expanding groin hematoma and anemia. The patient was 
taken to the OR for groin exploration and repair of the PA. There were no 
complications associated with TI; specifically, no patient experienced arterial 
or venous thrombosis. 
Conclusion: Percutaneous ultrasound guided TI was safe and effective 
in treating post catheterization PA. There were no side effects and 96% of 
pts were successfully treated, irrespective of systemic anticoagulation. TI is 
the initial treatment of choice for pts with post catheterization PA. 
1024-l 1 Angiographic Guidance Technique Dramatically 
Decreases Vascular Complications in 1,004 
lntraaortic Balloon Pump Cases 
David E. Allie, William R. Ladd, Richard P. Abben, Samuel J. Stagg III, 
James B. Lam, Bart C. Denys, Michael W. McElderry, Craig M. Walker. 
Cardiovascular Institute of the South, Lafayette, Houma, Louisiana, USA 
Background: Vascular complications continue to be a major source of 
morbidity and mortality associated with intraaortic balloon pump (IABP) 
placement. An angiographic guidance technique and strategy in the car- 
diac catheterization lab was developed in an effort to decrease vascular 
complications. 
Methods: Between 1991 and 1998, 1,004 consecutive percutaneous 
placed IABP cases were retrospectively reviewed and 35 periprocedural 
parameters analyzed including: mean age, 66 years (38-93); mean IABP 
248A ABSTRACTS - Hypertension, Vascular Disease & Prevention JACC February 2000 
duration, 34 hours: and indications: acute coronary ischemic syndromes 
(including post myocardial infarction) 38% (382/l ,004); peri percutaneous 
transluminal coronary angioplasty, 28% (281/1004); preoperative high risk 
cardiac surgery, 19% (191/1004); congestive heart failure/cardiomyopathy, 
7% (70/1004); and miscellaneous, 6% (60/1004). All patients had distal aortic 
with bilateral iliac angiography (15-20 cc total contrast) performed immedi- 
ately before IABP placement. Angiographic guidance, factors included size 
and tortuosity of vessel, degree and pattern of atherosclerotic disease, occur- 
rence of bulky atherosclerotic debris, and aneurysmal dilatation. Fifteen per 
cent (150/1004) of IABP approaches were altered after angiography and 42 
(4.2%) required immediate iliac artery percutaneous transluminal angioplasty 
(PTA) or PTA/stent. A 9.5 Fr IABP was used in all cases. 
Results: Major vascular complications occurred in 19 patients (1.9%) 
and included 1 aortic dissection resulting in death; 6 limb ischemia requiring 
surgical embolectomy; 9 femoral artery bleeding requiring surgical repair; 
and 3 requiring late pseudoaneurysmal repair. There were no fasciotomies, 
amputations, or contrast-related renal failures. Nine patients (0.9%) died with 
IABP in place. There were 30 (3%) minor hematomas not requiring surgery 
and 3 minor wound infections. 
Conclusion: Angiographic guidance of IABP placement dramatically de- 
creases major vascular complications and further underscores the need for 
cardiologists to acquire peripheral vascular skills in the cardiac catheteriza- 
tion lab. 
1 1024-l 2 1 Prospective Trial to Determine the Time of 
Pressure Bandage Application After Cardiac 
Catheterization 
S.P. Schoen, S. Abadshjan, W. Kuebler, R.H. Strasser. University of 
Heidelberg, Department of Cardiology, Germany 
Background: Supine bed rest after cardiac catheterization is a major ex- 
pense factor in health service. Also the use of sophisticated closure systems 
is costly and expensive. In recent years, the use of thinner cathetersystems 
was made possible by improvements in x-ray technique, visual display units 
and materials. The possibility of shortening bed rest and the time of conven- 
tional pressure bandage (CPB) has not been investigated so far. Therefore, 
we carried out a prospective, randomized study to determine the shortest 
necessary duration of CPB time after cardiac catheterization without incre- 
ment in local vascular complications at the puncture site. 
Methods: In Seldinger technique a 5F-sheath was placed in the A. 
femoralis and 7500 I.U. Heparin i.a. were applicated as a bolus. After an- 
giography, i.v. administration of 5 ml Protamin CN 1000 and removal of the 
sheath, 15 minutes of manual compression was applied before a standard- 
ized CPB was placed over the puncture site. 100 patients were randomized 
in each of the CPB groups: 4, 6, 12 and 24 hours of compression. After 
removal of the CPB and immediate repeal of bed rest, the puncture sites 
were inspected and ultrasound of the groin performed within 12 h. Total num- 
bers of complications were divided in no-treatment-requiring events (mild 
hematoma) and treatment-requiring complications (bleedings, aneurysmata 
spuriae, a.-v.-fistulas). 
Results: After a CPB time of 4 h the rate of treatment-requiring compli- 
cations was 10%. In the group with 6 h of CPB these complications were 
significantly reduced down to 3%. Interestingly a further reduction of compli- 
cation rates could not be achieved by longer compression times (up to 24 h). 
In contrast, no correlation between the incidence of no-treatment-requiring 
events and CPB times was observed within this time frame. 
Conclusions: This is the first controled trial which determines the neces- 
sary minimal duration of CPB after cardiac catheterization, On the basis of 
these data, a reduction of CPB time after catheterization with a 5F-system 
down to 6 h is justified. A further shortening of compression time is asso- 
ciated with an increase of complication rates at the puncture site. However 
longer CPB times up to 24 h do not result in a further reduction of local vas- 
cular complications. These data also show, that after cardiac catheterization 
with a 5F-sheath in patients without anticoagulation the use of costly closure 
systems is not indicated. 
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I 1025 17 Protective Effects of the Combination of Non Hypotensive Doses of Valsartan and Enalapril in 
Spontaneously Hypertensive Rats With 
Endothelial Dysfunction 
Marc de Gasparo, Patrick Hess, Jean-Paul Clozel. Novartis Pharma AG, 
Base/; A&e/ion, A//scbwi/, Switzerland 
Background: Chronic nitric oxide inhibition exacerbates hypertension and 
nephrosclerosis in spontaneously hypertensive rats (SHR), resulting in an 
50% mortality rate within 2-3 months. The goal of the present study was to 
evaluate if the combination of non hypotensive doses of the ATI receptor 
blocker, valsattan and an ACE inhibitor, enalapril would be protective in SHR 
with endothelial dysfunction. 
Methods: Valsartan (5 mg/kg/day, n = 40), enalapril (1 mgfkg/day, n = 30) 
and the combination (Val 5 mgikg-Ena 1 mg/kg, n = 30) were administered 
in drinking water in SHR aged 22-24 weeks and receiving L-NAME (50 mg/l 
in drinking water) to inhibit nitric oxide synthase. Survival rate was monitored 
over 11 weeks. Blood pressure was recorded by tail cuff measurement at 
time of peak effect. Plasma creatinine was determined at 4 weeks. 
Results: Survival rate was 48% in the control group, 61 and 78% (p < 
0.01) in Ena and Val 5 respectively. With the combination Val + Ena, the 
survival rate reached 90% (p < 0.01). Blood pressure measured at time of 
peak effect remained unaffected by the treatments (Control: 277 f 3; Val 5: 
270 + 3; Enal: 280 Lt 3; Val + Ena: 273 f 3 mmHg). Plasma creatinine at 4 
weeks was equally and significantly decreased (p < 0.01) following treatment 
(control: 90.4 + 8.9; Val5: 65.9 f 2.3; Enal : 67.6 f 3.0; Val + Ena 59.7 f 1.2 
fimol/l). Interestingly, this effect on plasma creatinine was associated with a 
normalisation of plasma potassium (from 4.42 * 0.08 to 4.12 f 0.07 mmol/l), 
whereas neither Val or Ena alone decreased plasma potassium (4.57 f 0.07 
and 4.31 f 0.1 mmol/l, respectively). 
Conclusion: These results suggest that a decrease in blood pressure 
is not necessary to improve survival in SHR with endothelial dysfunction. 
Moreover, the combination of non hypotensive doses of an ATI receptor 
antagonist and an ACE inhibitor has protective effects unrelated to blood 
pressure decrease. These effects might be related to a more complete local 
blockade of the renin-angiotensin system. 
L.---d 1025 18 Greater Endothelial Protection by the Vasopeptidase Inhibitor Omapatrilat Compared to 
the ACE-Inhibitor Captopril in Salt Induced 
Hypertension 
Thomas Quaschning, Livius V. d’uscio, Thomas F. Ltischer. Cardiology, 
University Hospital Zijrich and Cardiovascular Research, lnsfitute of 
Physiology: University of Ziirich, Switzerland 
Background: Omapatrilat represents a new class of drugs capable of inhibit- 
ing both angiotensin converting enzyme (ACE) and neutral endopeptidase. 
It therefore contributes to neurohumeral modulation which might improve 
endothelial function in cardiovascular diseases. The present study investi- 
gated the effect of omapatrilat in comparison to the ACE inhibitor captopril 
on systolic blood pressure (SBP) and endothelial function in a model of salt 
induced hypertension. 
Methods: Salt sensitive Dahl rats (n = G/group) on standard or salt- 
enriched (4% NaCI) chow were treated with either omapatrilat (36 mglkgid), 
captopril (94 mg/kg/d) or placebo over a period of 8 weeks. Endothelium- 
dependent and -independent vascular function was assessed as relaxation 
of isolated preconstricted aortic rings to acetylcholine (0.01300 pmol/L) and 
sodium nitroprusside (0.01-300 pmol/L). 
Results: Administered doses of omapatrilat and captopril controlled SBP 
of salt-feeded Dahl rats to a similar extent (162 f 5 vs 164 f 7 mmHg re- 
spectively) compared with placebo treated animals in which SBP increased 
to 196 i 6 mmHg. Endothelium-dependent relaxation was reduced by high 
salt diet from 99 f 5% to 31 f 4 (p < 0.005) and improved by omapatrilat 
or captopril to 86 IIZ 7% vs 56 f 5% (p < 0.005) respectively. Omapatri- 
lat ameliorated endothelium-dependent relaxation to a significantly greater 
extent than captopril (p < 0.05) but still did not restore endothelial function 
completely. In animals on standard chow, omapatrilat altered neither blood 
pressure nor endothelial function significantly. 
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Conclusion: Despite comparable decrease in blood pressure at lower 
dosage, omapatriiat is superior to captopril in improving endothelium-depen- 
dent relaxation. Therefore, the vasopeptidase inhibitor provides a new ther- 
apeutic approach for treatment of patients with cardiovascular diseases. 
1025-f g Systemic and Pulmonary Hemodynamic Effects 
of ETA Receptor Antagonism 
Julian Halcox, William H. Schenke, Rita Mincemoyer, Julio A. Panza, 
Arshed A. Quyyumi. N/H, Bethesda, MD, USA 
Background: The predominant pressor effect of the potent vasoconstrictor 
endothelin-I is mediated via activation of ETA receptors (ETAR). We therefore 
studied the hemodynamic consequences of ETAR antagonism in patients 
with normal LV function with and without hypertension. 
Methods: A 60 min infusion of BQ-123 (a selective ETAR antagonist, 
total dose 12 kg i.c.) was given to 41 patients (pts) undergoing cardiac 
catheterization; 88% with coronary artery disease and 58% hypertensive 
(meanBP [mBP] 2 110 mmHg). We measured heart rate (HR) and systemic 
arterial pressure (mBP) in all pts. Mean pulmonary arterial (mPAP) and PA 
wedge (PWP) pressures and cardiac output (CO) were also measured in 
24 pts. Systemic (SVR) and pulmonary (PVR) vascular resistances were 
calculated. 
Results: Significant reductions in mBP, mPA, PWP and SVR were ob- 
sewed with BQ-123. HR increased but there was no significant change in 
CO or PVR. 
BQ-123 NBP mPA PWP SVR PVR HR C.O. 
0 min 114 17.9 9.9 23 1.6 76 5.0 
60 min 104 15.4 6.3 20.3 1.4 79 5.2 
D <O.OOl <O.Ol co.01 <O.OOi 0.13 <O.OOl 0.17 
The magnitude of fall in BP, SVR and PA after BQ-123 negatively corre- 
lated with the baseline values of these parameters (r = -0.65 [p < O.OOl], 
-0.57 [p < O.Oi] and -0.68 [p < O.OOi] respectively). Furthermore, the ob- 
served fall in BP in hypertensive subjects was greater than in normotensives 
(-12.2 i IO vs -4.1 i 5 mmHg, p < 0.01). 
Conclusion: ETnR stimulation contributes to resting systemic but not 
pulmonary vasoconstrictor tone in pts with normal LV function, an effect that 
appears to be independent of changes in CO. Endogenous ETAR activation 
appears to be greater in hypertensive individuals. 
1025-20 ACE Inhibitor Associated Cough - How Reliable 
is the Information From the Package Insert? 
Franz H. Messerli, Zhanbin Feng. Ochsner Medical Institutions, New 
Orleans, Louisiana, USA 
Background: Dry cough is a common, annoying side effect of all ACE 
inhibitors. The present study was designed to assess the incidence of the 
ACE inhibitor related a reported in the literature and to compare it with the 
incidence of cough as reported by the Package Insert (P.I.). 
Methods and Results: In a Medline search from 1989 to the present we 
identified a total of 86 randomized controlled studies, in a total of 26,482 
patients, dealing with the incidence of ACE inhibitor related cough. Cough 
was significantly more common in women than in men (11.4% vs 6.2%, p i 
O.OOi), in African-Americans than in Whites (8.9% vs 4.4%, p < O.OOl), and 
in Asians than in Whites (11.6 vs 4.4% p < 0.001). The incidence of cough 
in the literature averaged 7.4%; however, it progressively increased almost 
threefold (Figure) over the past decade. In contrast, the incidence of cough 
reported in the P.I. averaged 1.79% and while it modestly increased over 
the same period, it remained consistently several-fold lower than reported in 
the literature. Similarly, there was a sevenfold difference in the incidence of 
patients who discontinued ACE inhibitor therapy because of cough between 
the literature (2.6%) and the P.I. (0.37%). 
Conclusions: The P.I. information is deceptive - the true incidence of 
ACE inhibitor related cough and percentage of patients withdrawing from ACE 
inhibitors is several-fold higher than reported in the P.I. This misinformation 
seems, at least to some extent, to be the result of marketing strategies of the 
manufacturers of ACE inhibitors, 
1 1025-21 1 Change in Systolic Function and Midwall 
Mechanics After One Year of Antihypertensive 
Treatment: The LIFE Study 
Kristian Wachtell, Vittorio Palmieri, Richard B. Devereux, Michael H. Olsen, 
Vasilios Papademetriou, Markku S. Nieminen, Gunnar Smith, 
Gerard Aurigemma, Bjorn Dahlof. G/o&up University F&pita/, Glostrup, 
Denmark: The New York Hospifal-Cornell Medical Center, NY USA 
Background: We have recently shown that hypertensive patients with left 
ventricular (LV) hypertrophy have decreased midwall mechanics, but the 
effect of antihypertensive therapy remains unclear. 
Methods: Echocardiograms were recorded at baseline in 861 unmedi- 
cated patients with stage I-III hypertension and LVH determined by ECG 
(Cornell voltage duration > 2,440 mm x msec or Sokolow Lyon: SVI + 
RV5IRVG > 38 mm) after 14 days of placebo treatment. A follow-up echocar- 
diogram was done after 1 year of blinded treatment with either losartan or 
atenolol, and in some cases supplemented with thiazide and calcium antag- 
onist in order to achieve target blood pressures (BP) of 140/90 mmHg. 
Results: Baseline systolic BP (SBP) was reduced from on average 174 
* 21 to 150 f 20 mmHg, diastolic BP (DBP) from 95 Z!Z 11 to 84 f 10 
mmHg. LV mass was reduced from 234 i 56 to 207 f 50 g (all p < 0.001). 
Endocardial fractional shortening (FS) (33 i 5%) and ejection fraction (61 
f 8%) remained unchanged while midwall FS increased from 15.4 f 2.0 
to 16.4 & 2.0% (p i O.OOl), end-systolic stress decreased from 183 f 48 
to 174 + 48 kdynes/cm2 and stress-corrected midwall shortening increased 
from 97 & 13 to 102 f 12% (p < 0.001). Increase in midwall FS correlated 
to decrease in LV mass (r = -0.296, p < O.OOl), DBP (r = -0.113, p < 
0.01) and SBP (r = -0.086, p < 0.05). Multiple regression analysis yielded a 
model where LV mass and BP reduction all where negatively independently 
associated with midwall FS. Increase in stress corrected-midwall shortening 
was independently associated with LV mass reduction (fi = -0.29, p < 0.001) 
and increased SBP (B = 0.18, p < 0.01). 
Conclusion: Antihypettensive therapy reduce LV mass and increases 
midwall FS and LV contractility, with less impacting endocardial FS. Reduction 
of LV mass and BP independently increase midwall FS and LV contractility. 
/ 1025-22 / The Impact of Gender, Age, and Body Mass Index 
on the 24-Hour Efficacy of Antihypertensive 
Therapy 
William B. White, William J. Elliott, Mary F. Johnson, Robert J. Anders, 
Henry R. Black. University of Connect&f School of Medicine, Farmington, 
CT; Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL, USA 
Background: Not enough data are available on the effects of age, gender, 
and body mass index (BMI) on the efficacy and safety of commonly-used 
antihypertensive drugs. Thus, we determined the impact of these parameters 
on changes in 24-hour and early-morning blood pressure (BP) and heart rate 
following treatment with the chronotherapeutic formulation (COER-24’“) of 
the calcium antagonist, verapamil. 
Methods: To provide statistical power for subset analyses, data were 
pooled from 3 placebo-controlled, randomized, clinical trials of COER-vera- 
pamil (180 to 540 mg once nightly) that evaluated 398 patients with stage I 
to Ill essential hypertension. Ambulatory BP and heart rate monitoring was 
performed at the end of 4 weeks of placebo therapy (baseline) and following 
8 weeks of double-blind therapy (treatment) in 272 men vs 126 women, 270 
younger (<60 years) vs 128 older patients, and 229 obese (BMI > 28 kg/m*) 
vs 165 non-obese patients. The primary efficacy measures were changes 
from baseline in 24-hour and early-morning BP and heart rate, and were 
analyzed using ANCOVA between subgroups. 
Results: Compared with men, women demonstrated greater reductions 
in both 24-hour BP (-15.1/-10.4 vs -108-8.2 mm Hg, P < 0.001/P = 
0.003) and early-morning BP (-19.1/-13.5 vs -144-11.8 mm Hg, P = 
-0.003/0.016). Older patients showed larger reductions in early-morning 
heart rate (-6.6 vs -4.9 beat/min, P= -0.030) and 24-hour heart rate (-5.7 
vs -4.4 beat/mm, P = 0.021) compared with younger patients. No major 
effects of BMI were observed on blood pressure or heart rate. Side effect 
profiles were similar in men and women; in older patients, constipation was 
slightly more common than in younger patients (11.7% vs 9.9%): in obese 
patients, constipation was much less common than in non-obese patients 
(5.7% vs 18.3%). 
Conclusions: Gender, age, and body mass index may have important 
clinical impacts on antihypertensive drag efficacy and tolerability. These data 
demonstrate the importance of evaluating these parameters more routinely 
in controlled clinical trials of antihypertensive drag therapy. 
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1_1 1025 23 Longterm Effect of Weight Reduction on Arterial 
Pressure at Rest and Durinq Exercise in Obese 
Hypertensives 
Reinhard G. Ketelhut, Ulrich Behr, lngomar W. Franz. Universif&Xsk/inikum 
Char& Berlin; K/ink Wehrawald, Todtmoos, Germany 
Background: Some aspects of the relationship between obesity and hyper- 
tension are still rather limited. Therefore a study was designed to evaluate 
the influence of weight reduction on blood pressure (BP) in obese hyperten- 
sives and to compare the long-term effect on BP with constant overweight 
hypertensive,subjects. 
Methods: In 27 obese hypertensives (aged 39 +Z 12 years, 2 females, 
25 males, body-mass-index > 30 kg/m*) BP was measured at rest and 
during submaximal ergometric exercise (50 to 100 watts, increments IO 
watts/minute) before and after weight reduction. 
Results: After 7 f 5 months a mean weight redution of 6.7 * 3 kg could be 
achieved. BP decreased significantly from 155 f 14/101 ZIZ 7 to 134 & 13/88 
rt 8 mmHg at rest and from 202 i, 12/112 f 7 mmHg to 182 i 15/99 f 7 
mmHg during exercise (at 100 watts) (p < 0.001). The decrease in BP during 
ergometric testing after weight reduction was more intensive than what we 
found using diuretics, prazosin and an ACE-inhibitor in hyperensive controls. 
It was in the range of a moderate calcium channel blocker medication but 
substantially lower when compared with beta-blocking agents, After a further 
follow-up of 39.5 f 24 months weight reductions remained unchanged in 17 
subjects (minus 6 ic 2.9 kg) just as BPS at rest (139 f 16/89 i- 6 mmHg) 
and during exercise (183 f II/96 f 10 mmHg). In contrast, in 25 untreated 
obese hypertensive controls with a nearly constant body weight (79.4 f IO 
kg-79.7 & IO kg) arterial pressures even increased significantly from 153 f 
9/98 f 5 mmHg to 158 f II/111 + IO mmHg at rest (p < 0.05) and from 
205 i 22/115 f IO mmHg to 215 i 27/119 f 11 mmHg (p < 0.001) during 
ergometric exercise (100 watts) after the follow-up. 
Conclusion: Weight reduction reduces BP at rest and during exercise 
in obese hypertensives. The decrease in BP is still effective after long-term 
follow-up if body-weight remains reduced, whereas unchanged overweight 
increases BP during follow-up. Thus weight reduction implies a beneficial 
effect in the management of hypertension comparable to that of drug therapy 
and should be applied as first-line therapy in obese hypertensives. 
I 1025 24 Effects of Aerobic Training on Normotensive Subjects With Exaggerated Blood Pressure 
Response to Exercise 
Nobuyuki Miyai, Mikio Arita, lkuharu Morioka, Kazuhisa Miyashita, 
lchiro Nishio, Shintaro Takeda. Wakayama Medical University, Wakayama, 
Japan 
Background: An exaggerated blood pressure (BP) response to exercise 
is an independent risk factor for the development of hypertension. This 
study was designed to clarify the effects of aerobic training on resting, 
exercise and 24-h ambulatory BPS (ABPM) and left ventricular (LV) structure 
in normotensive subjects with exaggerated BP response to exercise. 
Methods: Thirty-four normotensive sedentary men (44.5 f 8.0 yrs) with 
exaggerated BP response to exercise (zage-adjusted 9Othpercentile) were 
participated in a randomized controlled crossover trial. After baseline ex- 
aminations, the subjects were randomly assigned to either a training group 
or a sedentary control group for 12 weeks. The conditions were reversed 
after washout period for 8 weeks. The aerobic training program consisted 
of 45-min ergometric exercise at anaerobic threshold more than 3 times a 
week. The treatment effects were evaluated using the method of 2-period 
crossover trials (Hills and Armitage). 
Results: Compared with the end of the control period, body mass index 
decreased after training by 0.6 (p < 0.05) and physical working capacity at 
a heart rate of 75% of maximal heart rate increased by 21% (p < 0.01). The 
training-induced reduction in resting BP was not observed. During exercise 
test, significant decrease was observed in systolic and diastolic BPS (203.7 
f 18.6/101.4 f 12.0 mmHg vs. 182.1 & 22.4/92.8 f 9.6 mmHg, p < 0 
01) and plasma norepinephrine levels (0.42 f 0.16 vs. 0.31 f 0.17 rig/ml, 
p < 0.01).at the same submaximal workloads. In ABPM, daytime systolic 
and diastolic BPS significantly decreased (134.1 f 8.3/79.8 f 7.7 mmHg 
vs. 128.5 f 9.50’6.3 i 7.0 mmHg, p < 0.05), but neither nighttime nor 
average 24-h BP changed. The M-mode echocardiographic and Doppler 
derived parameters such as LV mass index, LV fractional shortening and the 
ratio of A/E unchanged. 
Conclusions: These findings suggest that aerobic training reduced an 
increased-sympathetic nervous tonus in normotensive individuals with exag- 
gerated BP response to exercise, and there is a close relationship between 
this reduction and BP variability during daytime activities. 
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L-L- 1044 50 Activation of Mitogen Activated Protein Kinases by Monocyte Chemoattractant Protein-l in Human 
Endothelial Cells is Suppressed by Cerivastatin 
J&g Kreuzer, Martina Werle, Christiane Viedt, Daniela Durst, 
Wolfgang Kubler. Medizinische K/ink 111, UniversM Heidelberg, Heidelberg, 
Germany 
Background: It has been suggested that statins, beside their cholesterol 
lowering action, may also exhibit a cholesterol independent beneficial effect 
on atherogenesis through effects on cellular signal transduction. As activation 
of mitogen activated protein (MAP) kinases has been implicated in atheroge- 
nesis we investigated the effect of cerivastatin on monocyte chemoattractant 
protein-l (MCP-I) dependent activation of MAP kinases in endothelial cells. 
Methods and Results: Human umbilical venous endothelial cells were 
incubated for 12 h with cerivastatin (0.01-I GM). Cells were then incubated 
with MCP-I (0.01-100 rig/ml) and activity of c-Jun amino terminal kinase 
(JNK), p38MAPK and extracellular signal regulated kinase (ERK) was as- 
sessed by immunocomplex kinase assay. Presence of the MCP-I CCR-2 
receptor was verified using RT-PCR. MCP-I lead to a time and concentration 
dependent induction of JNK, p38MAPK and ERK with a maximum at 15 and 
5 minutes, respectively. Preincubation of the cells with cerivastatin at con- 
centrations as low as 0.1 PM was associated with a significant decrease of 
all three MAP-kinases. Cell viability, which was examined using trypan blue 
dye exclusion was not affected by cerivastatin. 
Conclusion: The results point to a new effect of MCP-I, demonstrat- 
ing that besides its chemotactic activity for monocytes, it can also activate 
MAP-kinases in endothelial cells. The data also demonstrate that this activa- 
tion can be prevented by the HMG-CoA-reductase-inhibitor cerivastatin. This 
mechanism may contribute to the beneficial effects of statins in the course of 
atherogenesis. 
1044-51 Estradiol Inhibits Nuclear Factor-KB Binding 
Activity In Vitro and In Vivo 
Martina Briickmann’ , Birgitt Salbach’, Siegfried Lang’, Thomas von Hoist*, 
Wolfgang Kiibler’ , Peter B. Salbach’. ‘Dept. of Cardiology; 2Gynaeco/og)r 
University of Heidelberg, Heidelberg, Germany 
Background: Several lines of evidence indicate that the oxidative stress 
sensitive nuclear transcription factor-kappa B (NF-KB) is closely linked to the 
development of atherosclerosis. N&B regulates the expression of multiple 
genes involved in the pathogenesis of atherosclerosis (e.g. proinflammatory 
cytokines, chemokines and adhesion molecules). Estradiol (E2) isconsidered 
to modulate progression of cardiovascular disease. Hormone repacement 
therapy (HRT) in postmenopausal women is associated with a reduced 
risk for cardiovascular disease. The aim of the study was to evaluate the 
effect of E2 on cytokine-stimulated NF-KB activation in human umbilical vein 
endothelial cells (HUVEC) and to examine the effect of HRTon NF-KB activity 
in ex vivo isolated mononuclear cells from postmenopausal women. 
Methods: HUVEC were pretreated with of E2 (1000 ngiml) for 48 h before 
a 30 minute stimulation period with the cytokines tumor necrosis factor-a 
(TNF-a) or interleukin-I ,9 (IL-l B). Healthy postmenopausal (n = 20) women 
were treated with estrogen/progestagen HRT for 6 weeks [2 mg E2 alone (n 
= 7) or in combination with cyclic (n = 7) or continous (n = 6) progestagen 
norethisteronacetat (1 mg/day)]. NF-KB binding activity in nuclear extracts of 
1) HUVEC and 2) ex viva isolated mononuclear cells was measured by an 
Electrophoretic Mobility Shift Assay (EMSA)-based detection system. 
Results: TNF-or (10-100 U/ml) and IL-I fi (IO-100 U/ml) stimulate activa- 
tion of NF-KB in HUVEC in a time and dose dependent manner (p < 0.001 
for the lowest dose used). Pretreatment of HUVEC with E2 (1000 rig/ml) 
inhibits the cytokine-induced activation of NF-KB up to 31.3% (p < 0.01, n = 
15 experiments). After 6 weeks of HRT NF-KB activity in nuclear extracts of 
ex vivo isolated mononuclear ceils was reduced by 41% compared to levels 
before HRT (p = 0.001). 
Conclusion: Estradiol has an inhibitory effect on NF-KB activity in cy- 
tokine-stimulated endothelial cells and in ex vivo isolated mononuclear cells 
from postmenopausal women under HRT. By inhibiting NF-KB activity estra- 
diol may regulate expression of inflammatory proatherogenic genes, thereby 
modulating progression of cardiovascular disease. 
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/ 1044 52 Troglitazone Reduces the Atherosclerotic Lesion I 1044 54 lschemic Preconditioning Mast Cell Histamine of Apolipoprotein E-Deficient Mice Release: Microdialysis of Isolated Rat Hearts 
Masaaki Miyata, Sadatoshi Biro, Koji Orihara, Hideyuki Eto, Chuwa Tei. 
Kagoshima Universifl: Kagoshima, Japan 
Background: Troglitazone, a peroxisome proliferation-activated receptor- 
gamma activator, is a new class of drugs that can be used to improve in- 
sulin resistance in type II diabetes (non-insulin-dependent diabetes mellitus, 
NIDDM). It is also a radical-scavenger, because it has a similar structure with 
or-tocopherol (vitamin E). Apolipoprotein E (apoE)-deficient mice develop 
atherosclerotic lesions resembling those observed in humans and are used 
as a mouse model of atherosclerosis. So far, there are no reports to see the 
effect of troglitazone on atherosclerosis in vivo. The purpose of this study 
is to evaluate the effect of troglitazone on atherosclerosis in apoE-deficient 
mice. 
Methods: At 4 weeks of age, male apoE-deficient mice were weaned 
from mother and fed on powdered F-2 chow diet alone (control group, n 
= 8) or F-2 chow diet with 0.2% troglitazone added (troglitazone group, n 
= 8). At 16 weeks of age, mice were sacrificed and atherosclerotic lesions 
in the aortic root were measured by a quantitative assay. Total cholesterol, 
HDL cholesterol, triglyceride, fasting blood sugar and HbAlc levels were 
measured. Antioxidant effect of troglitazone was determined by measuring 
the accumulation of conjugated diene in the oxidation of LDL induced by 
CuCls. 
Results: There were no significant differences in body weight, total 
cholesterol, HDL cholesterol, triglyceride, fasting blood sugar or HbAlc levels 
at 16 weeks of age between control and troglitazone groups. The atheroscle- 
rotic lesions of the troglitazone group were about 40% smaller than those of 
control group (control group; 138304 & 51456 @rns vs. troglitazone group; 
88346 i 33746 pm*, p < 0.05). In the conjugated diene assay, troglitazone 
prolonged the lag-phase time of conjugated diene formation in a dose-depen- 
dent manner and protected LDL from oxidation induced by CuClz. 
Conclusion: Troglitazone has antioxidant activity and reduces the athero- 
sclerotic lesion of apoE-deficient mice. These findings suggest that troglita- 
zone may prevent the progression of atherosclerosis in patients with NIDDM. 
1 1044-53 / Cardiac Adenylyl Cyclase lsotypes V and VI are 
Differentially Regulated After P-Adrenergic 
Stimulation in Stable Transfected Smooth Muscle 
Cells 
Heike Maringer-Liedtke, Steffen Schon, Renate Ihl-Vahl, Ruth H. Strasser. 
Department of Cardiology; University of Heidelberg, Germany 
Backround: Chronic Stimulation of the B-adrenergic signal transduction 
pathway leads to a reduced responsiveness of the b-adrenergic (B-AR) 
system accompanied by a decreased adenylyl cyclase (AC) activity. It is still 
unknown if the cardiac AC isozymes are differentially regulated by B-AR 
stimulation and if intrinsic AC activity may modulate this desensitization 
process. 
Methods: Cardiac isozymes of adenylyl cyclase, AC V and AC VI, were 
cloned into the eucaryotic expression vector pTracer under the control of the 
CMV promotor. AC c-DNA clones were stable transfected into the smooth 
muscle cell line DDT, MF-2. Transfection effeciency was verified with the 
green fluorescent protein GFP after Zeocin selection. AC activities of trans- 
fected cells were determined with AC assays. lsozyme specific mRNA was 
determined by RT-PCR. 
Results: After chronic treatment of stable transfected cells with Isopro- 
terenol (10m4 M, 18 h), the responsiveness to B-AR stimulation was signifi- 
cantly reduced in the control cells (-80%) and the transfected cells (AC V: 
-89%: AC VI -84%), as expected. Direct stimulation of AC by Forskolin was 
significantly reduced in AC V (-62%) accompanied by a slightly decreased 
amount of AC V specific mRNA (-15%). AC activity in AC VI transfected 
cells, in contrast, was reduced by only (-21%) and unexpectably the mRNA 
specific for AC VI increased by (+54%) after 18 h prestimulation with Isopro- 
terenol (Table). 
Chronic C0llitd 18 hiso COlltrOl 18hiso 
pre-treatment no-pre-treatment pre-treatment no-pm-treatment pre-treatment 
in AC-assay 
Stim. in AC-assay lsoproterenol lsoproterenol Forskolin Forskolin 
pTracer 14li76 29+17 369i149 276zk52 
ACV 400*177 44116 1462+525 56Oi 137 
AC VI 151 zk72 2513 523i115 4.15 i 86 
Siamak Davani, Patrice Muret, Bernard Royer, Jean-Pierre Kantelip, 
Jean-Pierre Bassand, Herve Millart. Laboratoire Pharmacologic 
Fondamentale, Facuite de Medecine, Besancon; Reims, France 
Background: It has been proposed that the cardiac mast cell mediator re- 
lease may be involved in the antiarrhythmic effect of ischemic precondition- 
ing. The aim of this study was to investigate the feasability of intramyocardium 
kinetics of histamine release by microdialysis and ascertain if the histamine 
release is implicated in the antiarrhythmic effect of preconditioning in the 
isolated rat heart. 
Methods: A 30 min. normothermic preconditioning model followed by 30 
min. reperfusion was carried out in the control group (n = 9). In the precon- 
ditioning group (n = 8) there was a 5 min. global ischemia followed by 10 
min. of reperfusion. The mast cell-stabilizing group received the disodium 
cromoglycate (10 wM, n = IO). The fourth group received a mast cell de- 
granulator, the compound 48/80 (1 yglml, n = IO). A microdialysis probe 
was implanted in the left ventricular myocardium to obtain cardiac histamine 
release measured by an immunoenzymatic method. 
Results: In the control group, a 30 min. global ischemia increased the 
histamine release (13.3 f 1.6 nM, mean i SEM). The reperfusion histamine 
release (18.4 i 6.5 nM) was significatly different from the basal concentration 
(1.9 i 0.5 nM, p < 0.05) which was associated with a maximal length of se- 
vere arrhythmia. The preconditioning modified this histamine release kinetic 
with an early mast cell degranulation (9.7 f 1.5 nM) and a lack of reperfu- 
sion histamine release. The preconditioning group also showed a significant 
decrease in total length of severe arrhythmia (p x 0.05, preconditioning vs 
control). In the disodium cromoglycate group, the repetfusion histamine re- 
lease was decreased (3.1 & 0.7 nM) and associated with a maximal length 
of severe arrhythmia. In the C48/80 group, the increase in the reperfusion 
histamine released (21.2 It 5.0 nM) was associated with a maximal length of 
severe arrhythmia. 
Conclusion: These results showed firstly the feasability of kinetic his- 
tamine release in myocardium interstitial fluid on the isolated rat heat-f and 
secondly that mast cell degranulation does not directly play a role in the 
antiarrhythmic effect of preconditioning. 
[1044-55 1 Chronic Long Term Nitrate Therapy: Any 
Cytogenetic Effect in Humans? 
Maria G. Andreassi’ , Nicoletta Botto’ , Silvia Del Ry, Maria G. Colombo’ , 
Daniela Giannessi, Cristina Vassalle, Walter Lubrano, Andrea Biagini’ , 
Eugenio Picano. ‘Laboratory of Cellular Biology G. Pasquinucci Hospital, 
Massa; CNR lnstitufe of Clinical Physiology Pisa, Italy 
Background: Nitrates act as donors of nitric oxide, a molecule of recognized 
potential genotoxicity. To assess whether long term nitrate therapy may in- 
crease genotoxicity, we evaluated two widely accepted tests, chromosome 
aberration (CA) and micronucleus (MN) assay, in peripheral human lympho- 
cytes of patients with or without long-term exposure to nitrate therapy. At the 
same time, micronucleus induction and cell proliferation after treatment “in 
vitro” with sodium nitroprusside (SNP) as NO donor was also evaluated. 
Methods: We evaluated 27 patients under nitrate treatment since ~4 
years and 18, age and sex-matched subjects. For each subject, 100 meta- 
phases, screening for chromosome aberrations and 1000 binucleated cells 
(BN) were scored forthe evaluation of micronuclei frequency. “In vitro”whole 
blood cultures were treated with increasing SNP concentrations (O-40 PM). 
Results: The frequency of CA was not significantly higher in the drug- 
treated with respect to control group (2.1 i 0.28 vs. 1.6 & 0.28, p = 0.39). 
The frequency of micronucleated lymphocytes (MNBN) was higher in the 
nitrate group (6.5 f 0.88 vs. 3.5 f 0.71, p = 0.023). “In vitro”results indicated 
a dose-dependent increase in the frequency of MNBN with increasing SNP 
concentrations Cytotoxicity and cell cycle delay, with a statistically significant 
decrease of the proportion of BN and nuclear division index (NDI), was also 
observed: 
ENPluM MNBN (%J MN f%o) BN I%) NDI 
0 4.00 il.83 4.00 + 1.83 65.90 i 4.00 1.78 5 0.02 
5 8.25i 1.65 9.25zk 1.65* 46.4Oi 1.20*" 1.47i 0.02* 
10 13.00 zk 1.87* 13.50-i- 1.44* 27.90* 0.20*** 1.29 * 0.01** 
20 16.25 *4.23** 17.75i3.40'** 42.05i5.75*" 1.42 rt 0.05* 
40 10.50 zk 2.50 11.50 + 3.50 33.ooi 1.00*** 1.39 & 0.15* 
All values are expressed as mean + S.E (n = 4); *p < 0.05, **p < 0.01, “**p .Z 0.001 vs 
control 
Conclusion: This newly characterized upregulation of the mRNA ex- 
pression after chronic B-AR stimulation is isozyme specific for AC VI and 
counteracts the p-agonist-mediated desensitization process, 
Conclusions: Our result suggest a possible genotoxic activity for nitrate 
therapy. Further studies focused on the possible link between nitrate therapy 
and genotoxicity are warranted at this point. 
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1 1044-56 1 The Cholesterol Absorption inhibitor SCH58235 
and Lovastatin Synergistically Lower Plasma 
Cholesterol and Inhibit the Development of 
Atherosclerosis 
Harry R. Davis, Robert W. Watkins, Douglas S. Compton, John A. Cook, 
Lizbeth Hoos, Kathyrn Pula, Margaret van Heek. Scbering-Plough 
Research Institute, Kent/worth, N.J., USA 
Background: SCH58235 ((1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)(3S)- 
hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone) is a potent inhibitor of 
cholesterol absorption, leading to significant decreases in plasma choles- 
terol levels in cholesterol-fed animals and in patients with primary hyper- 
cholesterolemia. In animals fed cholesterol-free diets, SCH58235 causes 
only modest reductions in plasma cholesterol levels, due to upregulation of 
hepatic cholesterol biosynthesis. We assessed the hypocholesterolemic ef- 
fect of SCH58235 in combination with lovastatin in non-cholesterol-fed dogs, 
then evaluated this combination on the development of atherosclerosis in 
cholesterol-fed rabbits. 
Methods: SCH58235 (0.007 mg/kg) alone and in combination with lovas- 
tatin (0.625, 1.25, 2.5, and 5 mgikg) was evaluated for plasma cholesterol 
effects in non-cholesterol-fed dogs for 2 weeks. SCH58235 (0.5 mg/kg), 
lovastatin (1 mg/kg), or their combination was evaluated for their effect on 
atherogenesis in rabbits fed a 1% cholesterol diet. 
Results: Neither SCH58235 (0.007 mg/kg) nor lovastatin (5 mg/kg) alone 
had any effect on plasma cholesterol levels in normocholesterolemic dogs, 
but their combination caused a synergistic 50% reduction in plasma choles- 
terol. SCH58235 in combination with lower doses of lovastatin also caused 
synergistic plasma cholesterol reductions of 20%, 24%, and 35% at doses of 
0.625, 1.25, and 2.5 mg/kg, respectively. In rabbits with pre-established hy- 
percholesterolemia, lovastatin (1 mg/kg) had no effect on plasma cholesterol 
levels or atherosclerosis, whereas SCH58235 (0.5 mg/kg) alone significantly 
reduced plasma cholesterol (-67%) primarily in the VLDL + LDL fractions, 
and this reduction was enhanced by lovastatin. Aottic atherosclerosis was 
reduced by SCH58235 both alone and in combination with lovastatin, with 
the combination causing a greater reduction. 
Conclusion: SCH58235 in combination with an HMG CoA reductase 
inhibitor may synergistically reduce plasma cholesterol levels in patients with 
hypercholesterolemia, even under restricted dietary intake of cholesterol, 
which may result in a greater reduction in the progression of atherosclerosis, 
1 1044-57 1 Endothelial Nitric Oxide Synthase is a Site of 
Superoxide Synthesis in Endothelial Cells Treated 
With Glyceryl Trinitrate 
Wayne H. Kaesemeyer, Alison A. Ogonowski, Liming Jin, Ruth B. Caldwell, 
R. William Caldwell. Medical College of Georgia, Augusta, Georgia, USA 
Background: Previous studies have shown superoxide (O;-) production 
by endothelial cells (EC) treated with activators of endothelial nitric oxide 
synthase (eNOS) or glyceryl trinitrate (GTN), an NO donor. When L-arginine 
(L-arg) supply is limited, eNOS produces O;- utilizing oxygen as its principal 
substrate. The purpose of this study was to test the hypothesis that eNOS is 
a site of O;- synthesis in EC in response to GTN. 
Methods: Production of O;- by bovine aottic EC (passages 3-5) was de- 
termined by spectrophotometrically measuring superoxide dismutase-inhib- 
ited reduction of ferricytochrome C to ferrocytochrome C. Cells were incu- 
bated in buffer without L-arg. O;- production was measured using EC either 
untreated or treated with GTN (lo-‘jM), (30 min) alone or with GTN after pre- 
treatment with nitro-L-arginine methyl ester (L-NAME), L-arg, or the inactive 
isomers D-NAME or D-arg, (all 5 x 1 Om4M) (n = 6-7/group). 
Results: Treating cells with GTN increased O;- production from 70 to 
155 pmol min-’ (106.cells)~‘, an increase of 121% (A). This rise was 
prevented with either L-NAME or L-arg pretreatments (B). Neither D-NAME 
nor D-arg inhibited the rise in O;- production in response to GTN (C). 
Conclusions: eNOS is a site of O;- synthesis in EC in response to 
GTN. L-NAME and L-arginine reduce O;- synthesis in response to GTN. 
Scavenging of O;- by L-NAME or L-arg does not appear to be responsible 
for this effect as their D-isomers did not prevent O;- formation. In addition to 
being a donor of NO, GTN may produce O;- ion via activation of eNOS. 
1044-58 Cardioprotection Afforded by Estrogen on 
Adrenergic Nerve Terminals in Menopause 
Depends on Hormonal Effectiveness 
Bernard A. Eskin, Jay Roberts, David S. Snyder. Medical College of 
Pennsylvania and Hahnemann University School of Medicine, Pbi/ade$hia, 
Pennsylvania, USA 
Background: Prior studies in rats from our laboratory show that the cardio- 
protective effects of estrogen may be mediated by its prevention of nore- 
pinephrine (NE) release at the adrenergic nerve terminal. We tested this 
theory by correlating estrogenic activity with NE presynaptic cardiac release 
in the female rat. 
Methods: Female F344 rats were ovariectomized (ovarx) or sham-oper- 
ated at 3 months of age and given injections of vehicle (0.1 ml/kg; 0.9% 
NaCl with 1% Tween 80). Conjugated equine estrogens (0.6 mgfkg), delta 
8,9-dehydroestrone (0.2 mg/kg) or 17 alpha-dihydroequilenin (3 mg/kg) were 
added for 90 or 270 days. Estrogen action was evaluated by serum luteiniz- 
ing hormone (LH) concentrations, pituitary and uterine weights (UWs), and 
vaginal smears. Cardiac synaptosomes (resealed nerve terminals) were pre- 
pared from each heart, incubated with [3H]-NE, and exposed to 50 mM K+ to 
evaluate NE release. 
Results: As expected, UWs in sham-operated animals were 7-fold higher 
when compared to those of ovarx rats. Estrogen therapies increased the UWs 
4-fold in ovatx animals at 90 days; however, after 270 days the estrogen 
replacement increased UWs such that they were similar to those of the sham 
rats. These results were reflected in estrogen’s effect on the synaptosome, 
as estrogen was able to protect the heart from excess NE better after 270 
days than 90 days, probably by reducing NE secretion andfor reuptake, 
as previously presented. Pituitary weights, vaginal smears and serum LH 
demonstrated this difference as well. 
Conclusion: Estrogen prevents excessive NE release in the rat heart, 
which may guard the heart from the cardiotoxic effects of NE. Estrogen’ ac- 
tion on NE release depends on the efficacy of estrogen on its target tissues. 
Thus, estrogen may have a protective mechanism through reduction of auto- 
nomic abnormalities responsible for arrhythmias, fibrillations and myocardial 
damage. 
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1 1045-l 7 1 Neurohormonal Effects of Vasopeptidase 
Inhibition With Omapatrilat in Hypertension 
Stephen Aronoff, Ravi Saini, Robert Guthrie, Sid Rosenblatt. University of 
Texas Southwestern Medical Center; Da//as, Texas; Bristol-Myers Squibb 
Company, Princeton, New Jersey USA 
Background: Omapatrilat is a potent vasopeptidase inhibitor (VPI) which 
simultaneously inhibits neutral endopeptidase and angiotensin converting 
enzyme. 
Methods: This was a randomized, double-blind, placebo-controlled, multi- 
center study in 278 patients with hypertension (seated diastolic blood pressure 
[SeDBP] 95-110 mm Hg). Two dose regimens (starting IO mg, regimen I, or 
starting 20 mg, regimen II) of omapatrilat or matching placebo were adminis- 
tered for 8 weeks followed by elective titration at Week 2 to 40 mg and at Week 
4 to 80 mg for SeDBP? 90 mm Hg. At selected sites, neurohormonal effects of 
omapatrilat were assessed in 73 patients. Plasma ACE, renin activity (PRA), 
Placebo (%) Reaimen I (%) Reaimen II (%) 
Urinary ANP (O-4 h after dose) 
Urinary ALDO (O-4 h after dose) 
Plasma ANP (2 h after dose) 
Trough plasma ACE activity 
Trough PRA 
Trough SeSSP/SeDBP (mmHg) 
n=ni ‘n=26 n=25 
+5 +3E~2~ +452a 
-10 -40 -42 
+19 ~46 +39 
-3 -7oa -62a 
+ll +425a +480a 
-6.01~5.7 -1&‘-1z.7b -1g.5b/-1ub 
ap < 0.05 VS baseline; bChange from baseline to Week 8; p < 0.001 vs placebo 
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atrial natriuretic peptide (ANP), urinary ANP and aldosterone (ALDO) levels 
were measured at baseline and at Week 8 of double-blind therapy. 
Results: Statistically significant changes were observed in mean uri- 
nary ANP, trough plasma ACE activity and PRA. Mean plasma ANP level 
was markedly increased; mean urinary ALDO was substantially decreased 
compared to placebo (see table). 
Conclusion: Neurohormonal changes observed in omapatrilat-treated 
patients are consistent with significant vasopeptidase inhibition and are as- 
sociated with significant reductions in BP. 
1045-I 8 The Beneficial Effect of Low Dose Dopamine in 
Heart Failure is Mediated by Aldosterone 
Inhibition as Well as a Direct Hemodynamic Effect 
David B. Dyke, Robert J. Cody. University of Michigan, Ann Arbor, Michigan, 
USA 
Background: Low dose dopamine infusion (LDDI) at 2-3 mcgikglminute, 
is commonly used to induce or augment diuresis in individuals with severe 
or decompensated heart failure. This is presumed as secondary to a direct 
vasodilator effect, but there are few data in heart failure to evaluate this mech- 
anism. We therefore evaluated the hemodynamic, renal and neurohormonal 
effects of LDDI in patients with moderate to severe heart failure. 
Methods: Fifteen patients with moderate (12) or severe (3) heart failure 
were studied, with mean age 53 f Il. Medications over than digoxin and 
diuretics had been held for 3 to 4 days prior to study. Hemodynamic status 
was determined by right heart catheterization. This was followed by steady 
state para-amino hippurate and inulin renal clearances, and plasma renin 
and aidosterone determination. Baseline values were obtained, followed by 
infusion of dopamine at 2 mcg/kg/min, over 2 hours. Plasma dopamine 
levels increased from 98 =t 159 to 18.9 x IO3 f 14.9 x IO3 pg/ml during the 
infusion. 
Results: The hemodynamic characteristics were a cardiac index of 1.93 
i 0.37 L/minim’, mean arterial pressure of 85 i 8 mmHg, right atrial pressure 
8.7 rt 7.7 mmHg, pulmonay wedge pressure 23 * 11 mmHg, and systemic 
vascular resistance of 1668 & 25 d*s/m’. In response to dopamine, there 
was an increase of renal blood flow (403 f 194 to 566 f 257 mlimin, p < 
O.Ol), with associated reduction of renal vascular resistance (287 f 151 to 
171 + 69 mmHg*min/l, p < O.Ol), filtration fraction (29 rt IO to 25 i IO%, p 
< O.Ol), and mean arterial pressure (93 + 13 to 82 f 12 mmHg, p < 0.001). 
In response to renal vasodilation, glomerular filtration rate increase (67 f 36 
to 80 i 39 ml/min, p < 0.05), as did urine flow rate (1.3 f 0.7 to 2.4 * 1.3 
ml/min, p < 0.01). Although there was no significant change in plasma renin 
activity (12.8 + 16 to 14.3 f 24 ngimlihr), plasma aldosterone decreased 
from 30.1 + 17 to 17.9 + 7.1 ngidl (p < 0.001) 
Conclusion: In summary, steady state infusion of dopamine was as- 
sociated with a renal vasodilatoy response. Significant reduction of aldos- 
terone, independent of renin activity, was noted, suggesting a direct effect 
of dopamine, rather than an overall reduction of renin system activity. In re- 
sponse to this combined hemodynamic and anti-aldosterone effect, there was 
a significant improvement of renal function and urinary flow rate. Whether this 
effect is maintained during longer term dopamine infusion, requires additional 
study. 
I 1045 19 Novel TXA2 Receptor Blockade, BAY u 3405, Prevent MCP-1 Expression, Macrophage 
Infiltration, and Plaque Instability in an 
Atherosclerotic Rabbit Model 
Toshiaki Ishizuka, Takemi Matsui, Kouji Matsumura, Bonpei Takase, 
Kimio Satomura, Akira Kurita. National Defense Medical Colege, 
Tokorozawa, Saifama, Japan 
Background: Macrophage infiltration appears to be an important role of 
plaque instability in acute coronary syndromes. Monocyte chemoattractant 
protein-i (MCP-I) is the major chemotactic factor for macrophages. We have 
previous shown that TXA2 receptor antagonists diminished the expression 
of MCP-I in vascular endothelial cells. The aim of this study was to evaluate 
the effect of a potent TXA2 receptor antagonist BAYu3405 (BAY; Bayer, 
Japan) on the macrophage accumulation and vascular morphology in an 
atherosclerotic rabbit model. 
Methods: We injured the abdominal aorta (AA) of New Zealand white 
rabbits by balloon catheter (2F Fogaty) and fed the rabbits a diet with 1% 
cholesterol. They were randomized to receive 10 mg/kg/day of BAY (n = 8) 
or no treatment (n = 6). After 8 weeks, the morphology of AA was evaluated 
by 0.018 inch angioscope (6000 pixels). Macrophages in AA sections were 
stained with an antibodies against rabbit macrophage (RAM-II). Absolute 
areas of RAM-II staining in the intima and media were quantitated by the 
density of total macrophage by computerized morphometry. Plasma (AA) 
MCP-1 was measured by the ELISA kit. 
Results: Compared with the untreated rabbits, the BAY group showed 
white colored and non-occulsive plaques by angioscopy. The mean area 
stained for macrophages occupied in the neointima was significantly lower 
in the BAY group compared with the untreated group (1.9 f 2.0 vs. 24.3 f 
14.7%; p < 0.01). Plasma MCP-1 levels in the BAY group were significantly 
lower than the untreated group (201 f 73 vs. 1126 i 548 pgiml; p < 0.01). 
Conclusion: In a rabbit atherosclerotic model, BAY prevents the mono- 
cyte infiltration through the MCP-I downregulation and stabilizes the plaque. 
Vascular wall morphology by angioscope gave us an useful information for 
decting valunerable plaques. 
1045-20 Interaction of Sildenafil With CAMP Mediated 
Vasodilation in Vivo 
Christoph Schalcher, Karin Schad, Ruth Schindler, Erwin Oechslin, 
Christoph Scharf, Gabor Suetsch, Osmund Bertel, Wolfgang Kiowski. 
Division of Cardiology Departmenf of lntemal Medicine, University Hospifal 
Ziirich, Ziirich, Switzerland 
Background: Sildenafil (Sil) inhibits phosphodiesterase 5 (PDE 5) prevent- 
ing the breakdown of cGMP and, thereby, potentiates biological effects of 
cGMP. In vitro, increased cGMP levels inhibit PDE 3, which breaks down 
CAMP. However, it is unknown whether Sil increases biological effects of 
interventions leading to increased CAMP levels in vivo. 
Methods: Forearm blood flow (FBF (ml/min/lOO ml), plethysmography) 
responses to brachial artery infusions (4 min each) of nitroglycerin.(NTG, 
0.0313, 0.0625, 0.125 ug/min/lOO ml tissue; n = 10) which increases cGMP 
levels and to isoproterenol (Iso 1.2, 4.0, 12.0 nglmini100 ml tissue; n = 10) 
which increases CAMP levels were assessed at baseline and 80 min after 
oral administration of 50 mg Sil in healthy male volunteers. 
Results: Sil did not decrease blood pressure but increased heart rate 
(58.7 to 62.17 bts/min (p < 0.05)). FBF in the non-infused arm increased from 
2.9 to 4.3 after Sil (n = 20, p < 0.01). NTG increased FBF dose-dependently 
by 1.8, 2.8 and 4.3 before and by 2.1, 4.0 and 5.7 after Sil from respective 
preinfusion baseline values (mean difference 0.9, p < 0.05). Iso increased 
FBF by 2.6, 6.0 and 9.2 before and by 5.2, 9.2 and 13.9 after Sil from 
respective preinfusion baseline values (mean difference 3.59, p < 0.01). 
Conclusions: Sil resulted in marked arterial vasodilation and compen- 
satory increase in heart rate and markedly enhanced the arterial vasodilator 
response to NTG. The increased vasodilator response to Iso is compatible 
with an interaction between increased cGMP levels and PDE 3 and raises the 
possibility of enhanced biological effects of interventions leading to increases 
of CAMP in the presence of Sil. 
L-L-! 1045 41 Effects of Selective and Non-Selective 
Beta-Receptor Antagonism on QT Interval 
Response to Exercise and Recovery in LQTl Type 
of Long QT Syndrome 
Heikki Swan, Kirsi Piippo, Matti Viitasalo, Kimmo Kontula, Lauri Toivonen. 
Department of Medicine, Helsinki Univefsifl: Helsinki, Fin/and 
Background: We investigated the effects of cardioselective and nonselective 
beta-blockers on QT interval behavior in LQTI type of long QT syndrome 
(LQTS) patients (LQTI) during and after exercise. 
Methods: QT interval dynamics during exercise and subsequent recovery 
was examined in IO LQTI patients (age 38 f IO years) at repeated exercise 
stress tests baseline, during intravenous infusion of beta-l -selective adrener- 
gic blocking agent esmololol (3 mg/kg/min) and after infusion of non-selective 
beta-antagonist propranolol (0.1 mg/kg). QT intervals were recorded at heart 
rates (HR) 90, 100, 110 and 120 beats per minute during and after exercise. 
Results: Beta-I-adrenergic antagonist esmolol shortens QT interval more 
than non-selective propanolol during exercise (figure, left panel). During 
recovery phase, only esmolol resulted in QT interval shortening compared to 
baseline study (figure, right panel). 
90 100 110 120 120 110 100 90 
Hean rate (BWCiSB) Hea” rate (leco”eIy, 
Conclusions: Propranolol, the most widely used beta-antiadrenergic 
agent in LQTS has beneficial effects on ventricular repolarization less af- 
ter physical exercise. Beta-i selective therapy seems more favorable than 
nonselective in the LQTI subtype of long QT syndrome. 
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I . 1045 42 Effects of Losartan on Endothelium-Dependent Vasodllation in Patients With Chronic Heart 
Failure 
Hideki Watanabe, Masaaki Kakihana. KlNU Medical Associafion Hospital, 
Mitsukaicio; lbaraki Prefectural University Ami, Japan 
Background: Endothelial function is impaired in patients with chronic heart 
failure (CHF) due to increased oxidative stress. Angiotensin II activates 
NADH/NADPH oxidase, and plays an important role in increased oxidative 
stress. 
Methods: To evaluate the effect of losattan on endothelial function in 
patients with CHF, twenty four patients with CHF treated with ACE inhibitors 
(EF < 40%, NYHA class II or Ill) were randomized to receive losartan (50 
mg/day, L group, n = 12) or placebo (P group, n = 12). We also studied 12 age- 
matched control subjects (C group). By use of high resolution ultrasound with 
a 7.5MHz transducer, the brachial artery diameter was measured at rest and 
during reactive hyperemia (endothelium-dependent) and again at rest and af- 
ter 0.3 mg of sublingual nitroglycerin (NTG) (endothelium-independent). We 
measured plasma TBARS (thiobarbituric acid reactive substances) levels as 
an index of oxidative stress. Measurements were performed at baseline, 1 
month and 6 month after taking losattan or placebo. 
Results: At baseline, brachial artery diameters were comparable among 
the three groups. Flow-mediated dilatation (FMD, % increase at reactive 
hyperemia) in the L and P groups were significantly lower than that in the 
C group (6.8 f 1.8%, 7.1 f 1.6%, 17.2 f 2.3%: L, P, C groups, p < 0.01). 
Plasma TBARS levels (nmol/ml) in the L and P groups were significantly 
higher than that in the C group (2.4 f 0.4,2.2 rt 0.5, 0.8 f 0.2; L, P, C groups, 
p < 0.01). NTG-induced dilatation (NID, % increase after nitroglycerin) were 
comparable among the three groups (22 f 13%, 21 f 12%, 22 & 10%; L, P, C 
groups). At 1 month, FMD, NID and TBARS levels did not change compared 
with the baseline. At 6 month, FMD in the L group was significantly higher 
than that in the P group (L group: 9.2 f 2.7%, P group: 3.8 f 1.9%, p < 
0.05). NID did not change. Plasma TBARS level was significantly decreased 
in the L group (p < 0.05) compared with the baseline (L group: 0.9 f 0.3; P 
group: 2.0 f 0.6) 
Conclusion: Losartan may improve oxidative stress and restore endothe- 
lial dysfunction in patients with CHF. 
1045-43 Variability of Fibrinolytic and Hemostatic Factors 
in Premenopausal Women 
LeRoy E. Rabbani, Nicole A. Seminario, Robert R. Sciacca, Hong Jun 
Chen, Elsa-Grace V. Giardina. Cenbr for Women’s Health, Columbia 
University: New York, NY USA 
Background: Plasminogen activator inhibitor (PAI-I), von Willebrand factor 
(vWF), and fibrin D-dimer are reported to predict risk in coronary artery 
disease. In premenopausal women, random isolated concentrations of these 
factors are used as baseline (control) levels without consideration that cyclical 
and diurnal changes may occur in PAI-I, vWF and fibrin D-dimer as they do 
for estradiol. 
Methods: Our goal was to establish the cyclical variation in the concen- 
tration of these 3 factors. Thus, 19 premenopausal women, mean age 33 f 
7 yrs, had estradiol, PAI-I, vWF, and fibrin D-dimer determined at the same 
time on days 2, 9, 16 and 23 of the menstrual cycle using respective ELlSAs. 
Results: Estradiol concentration increased incrementally during the men- 
strual cycle as both PAI-I and D-dimer decreased, vWF had a bimodal effect, 
peaking at day 9 and day 23 of the menstrual cycle. 
Estradiol, Fibrinolytic and Hemostatic Levels Over I Month 
Days 2&l 912 16+2 
Estradiol (pg/ml) 35 * 15.2 74 i 50.7* 65 i 45.5” 
PAI-1 (nglml) 42Lt21.0 41 f24.3 33f 17.2 
D-dimer 400 * 216 389 zt 268 349 * 209 
23zk2 
99 f 57.4’ 
32 f 16.3* 
330 * 18d 
(mlU/ml) 
vWF (mlU/ml) 917 + 462 1062 i 448t 826 i 474 1028 zt 444 
*p < 0.01 from day2 f 1; tp < 0.05 from day2 =k 1; *p < 0.05 from day 16 -t 2 
Conclusion: Dynamic changes in concentrations of PAI-I, vWF and fibrin 
D-dimer are found in premenopausal women establishing cyclical variability 
dependent on the time of cycle. This variability in hemostatic and fibrinolytic 
factors may have ramifications for understanding coronary artery disease in 
women. 
1045-44 Elevated Levels of Monocyte Chemoattractant 
Protein-l in Postmenopausal Women - Effect of 
Hormone Replacemeni Therapy 
Martina Briickmann’ , Birgitt Salbach”, Siegfried Lang’, Thomas von Hoist’, 
Wolfgang Kiibler’ , Peter B. Salbach’. ‘Dept. of Cardiology; ‘Gynaecology 
University of Heidelberg, Heidelberg, Germany 
Background: Premenopausal women are at lower risk of coronary heart dis- 
ease compared to age-matched males. After menopause the rate of athero- 
genesis accelerates progressively. Postmenopausal hormone replacement 
therapy (HRT) is associated with a reduction in the incidence of cardiovas- 
cular events. The mechanisms underlying the beneficial effects of female 
sexual hormones are not completely understood. Monocyte chemoattractant 
protein-i (MCP-I), a chemokine that is expressed in atherosclerotic lesions, 
is thought to play a major role in stimulating the migration of blood monocytes 
into early developing atherosclerotic lesions. The aim of this study was to 
evaluate the impact of menopause on serum levels of MCP-I and to investi- 
gate the influence of oral HRT on MCP-I levels in healthy postmenopausal 
women. 
Methods: Healthy pre- (n = 30) and postmenopausal (n = 35) women 
were included in this study. Postmenopausal women were treated with either 
2 mg oral 17fi-estradiol (E2) alone (n = 15) or in combination with cyclic 
progestagen norethisteronacetat (n = 20) for 6 months. Levels of MCP-1 
were analyzed in duplicate by commercially available ELISA kits. Statistical 
analysis was performed by student’s t-test. 
Results: In postmenopausal women levels of MCP-I increased by 25.2% 
compared to the premenopausal group (437.9 f 27.3 pg/ml vs 349.7 i 15.8 
pg/ml, p = 0.01). Oral HRT in postmenopausal women induced significant 
changes in estradiol values (8.4 f 0.8 pg/ml before HRT versus 120.4 f 14.8 
pg/ml after 6 months of HRT, p < 0.0001) and FSH values (84.1 f 4.6 mu/ml 
before HRT versus 26.9 5 4.2 mu/ml after 6 months of HRT, p < 0.0001). 
After 6 months of HRT there were marked reductions in MCP-I serum values 
(-18.25%, p < O.OOOl). There were no significant differences within the two 
treatment groups. 
Conclusion: The onset of menopause results iti a significant increase in 
serum levels of MCP-1, likely due to the lack of female sexual hormones in 
postmenopausal women. Hormone replacement therapy induces a reversal 
of the elevation of MCP-I levels. By regulating MCP-I levels in vivo female 
sexual hormones may modulate initiation and progression of atherosclerotic 
lesions. 
1045-45 Tamoxifen is Not Detrimental to Endothelial 
Function in Women With Breast Cancer 
Paul J.L. Ong’ , Helena Linardou’, Helen Graham*, Philip Savage’, R. 
Charles Coombes’, Peter Collins’. ‘Depf of Cardiac Medicine, National 
Heart and Lung Institute, imperial College School of Medicine, London; 
‘Dept of Medical Oncology, imperial Colege School of Medicine, London, 
UK 
Background: Tamoxifen (T) has mixed estrogen agonist and antagonist 
properties. Its potential adverse effect on the cardiovascular system as an 
estrogen antagonist has not been studied. 
Method: Three groups of postmenopausal women (median age 56 yr) 
with breast cancer (BC) were studied. Patients in group 1 (n = 10) with newly 
diagnosed BC were studied before and after 4 wk on T. Group 2 women (n = 
6) had been receiving long term T and were studiedvvhile on T and 4 wk after 
stopping it. The final group of 6 subjects were in BC remission and did not 
take T. Ultrasound assessment of endothelial function was done prior to and 
4 wk after the initiation or discontinuation of T with the non-treatment group 
acting as control. All imaging was made by a single investigator blinded to 
the therapeutic status of the subject. Brachial artery diameter was measured 
by at baseline and 1 min after reactive hyperemia. 
Results (figure): There was no change in FMR in patients before com- 
pared to 4 wk after starting T (4.06 f 1 .I 3% vs 3.97 f 0.95% respectively, 
mean i SE, p = 0.96). There was no significant change in FMR on withdraw- 
ing from T (1.84 f 1.21% vs -0.42 f 0.88% on T vs off T, mean f SE, p = 
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0.36). FMR in subjects taking T was no different from the control group (3.17 
+ 1.05% vs 3.16 i 0.72% respectively, p = 0.995). 
Conclusion: Tamoxifen does not adversely affect endothelial function in 
postmenopausal women with breast cancer. 
104548 Different Anti-ischemic Effect of Estrogen and 
Testosterone in Men and Women With Coronary 
Artery Disease 
Giuseppe M.C. Rosano, Filippo Leonardo, Francesco Pelliccia, 
Elena Cerquetani, Sergio L. Chierchia, Sandra Zoncu’ , Cristiano Sarais’, 
Giuseppe Mercuro’ De@. of Cardiology lstituto San Raffaele Mi/ano and 
Roma; ‘Dept of Cardiology University of Cagliarx Ha/y 
Background: Acute and chronic estrogen and testosterone administration 
have been shown to improve exercise-induced myocardial ischemia in men 
and women with CAD. It is not known whether the two hormones have a 
different effect in the two sexes. 
Methods: Twenty-four pts (12 men, 12 women) entered a double blind trial 
to evaluate the anti-ischemic effect of either one month replacement therapy 
with conjugated equine estrogens (CEE, 0.3 mg) or dihydrotestosterone 
(DHT, 5 mg). All pts underwent an exercise test according to the modified 
Bruce protocol at baseline and at the end of each treatment phase. 
Results: GEE significantly improved time to 1 mm ST depression (STD) 
and exercise time in women while a non significant increase in time to 1 mm 
STD was observed in men. Conversely DHT improved time to 1 STD and 
exercise time in men but not in women. 
Baseline CEE DHT 
Women 
Time to 1 mm STD 340*110 425zt121” 382i113 
Head Rateat mm STD 118zt21 132h33” 124126 
Exercise time 4709~164 534i143* 496+152 
Wead Rate at Peak Exercise 131rt18 142i23* 134i20 
MelI 
Tome to 1 mm STD 360*116 390 * 1095 455i135* 
Head Rate at 1 mm STD 120118 128&24§ 135Lt17* 
Exercise time 46OU32 47Oh127 520&146* 
Heart Rate at Peak Exercise 135121 138119 135*31 
* = p < 0.05, 5 = p for trend < 0.01 
Conclusion: Sex hormones have a different anti-ischemic effect in men 
and women. However, while testosterone is effective only in men CEE seem 
to have a positive effect in both sexes. 
104547 Effects of Droloxifene, a New Selective Estrogen 
Receptor Modulator (SERM), on Blood Pressure 
and the Renin-Angiotensin System in Healthy 
Post-Menopausal Women 
K. Bridget Brosnihan, David M. Herrington, David MacLean. Wake Forest 
University School of Medicine, Winston-Salem, North Carolina; Pfizer, Inc., 
Groton, Connecticut, USA 
Background: Estrogens downregulate ACE and AT, receptors-hypotensive 
effects that may be offset by estrogen-associated Na+ and water retention. 
Little is known about the effects of SERMs on blood pressure (BP) regulation. 
We compared effects of conjugated estrogen (E) and droloxifene (D), a 
tamoxifen analogue, on BP and circulating elements of the renin-angiotensin 
system. 
Methods: BP measurements and plasma samples were obtained from 24 
healthy postmenopausal women before and after 6-weeks of treatment with 
either E 0.625 mg/day or D 60 mgiday, with a 4-wk washout period between 
treatments. 
Results: D significantly lowered standing systolic (140 f 4 vs 130 i 4 
mmHg; p x 0.01) and diastolic (75 * 2 vs 66 i 2 mmHg; p < 0.01) BP. This 
occurred despite increases in angiotensin (Ang) II (19.6 +. 1.8 vs 26.1 f 2.2 
(D) pmol/ml, p x 0.05). E also raised Ang II (20.1 i. 1.7 vs 26.0 * 1.5, p 
c: 0.05) but did not change systolic or diastolic BP. D and E lowered ACE 
activity 6-8% (p < 0.05, for both), but did not change plasma renin activity 
or Ang I. 
Conclusions: D is the first SERM shown to lower BP in women. This BP 
effect, in the face of elevated Ang II levels, is consistent with AT, downregu- 
lation and/or potent vasodilating effects of D through nitric oxide, bradykinin, 
or other modulators of vascular tone. 
I 1045 48 The Anti-lschemic Effect of Chronic Testosterone 
Replacement in Man is not Related to its 
Peripheral Conversion Into Estrogens 
Giuseppe M.C. Rosano, Filippo Leonardo, Francesco Pelliccia, 
Elena Cerquetani, Roberto Patrizi, Sergio L. Chierchia, Sandra Zoncu’, 
Giuseppe Mercuro’ Dept of Cardiology lstituto San Raffaele Milan0 and 
Roma; ‘Dept. of Cardiology University of Cagliary, Italy 
Background: Recent studies have shown that acute administration of Testos- 
terone (T) improves exercise-induced myocardial ischemia in men. However, 
it is not known whether this effect is related to its peripheral conversion into 
estrogens. 
Methods: The aim of the present study was to evaluate whether chronic 
administration of testosterone improves exercise-induced myocardial is- 
chemia and whether the effect is related to its peripheral conversion into 
estrogens. To this end, 16 male pts (mean age 62 f 5 yrs) with angio- 
graphically proven CAD entered a double blinded single cross-over study 
evaluating the effect of one month T replacement with either Dihydrotestos- 
terone (DHT) or Testosterone undecanoate (TU), orally. After antianginal 
therapy withdrawal, pts underwent, according to the Modified Bruce protocol, 
3 exercise tests at baseline (B) and at the end of the one month therapy, with 
either DHT or TU. 
Results: All pts showed at least 1 mm ST segment depression at B but 
only 14 pts had a positive exercise test after either DHT or TU. Compared 
to B, both DHT and TU significantly prolonged time to 1 mm ST segment 
depression (322 rt 126 set vs 455 f 148 set vs 430 * 132 set; B vs DHT 
vs TU; p < 0.01 vs B) total exercise time (550 f 124 set vs 620 f 142 set 
vs 600 f 138 set; B vs DHT vs TU; p < 0.01 vs B) and time to angina (410 
i 142 set vs 480 i 168 set vs 470 f 172 set; B vs DHT vs TU; p < 0.01 
vs B). DHT and TU significantly increased heart rate at the onset of 1 mm 
ST segment depression compared to B (130 f 26 vs 134 f 23 vs 116 i 14 
set; DHT vs TU vs B; p < 0.01 vs B) and at peak exercise (143 i 16 vs 140 
+20vs133f12sec;DHTvsTUvsB;p~0.01vsB) 
Conclusion: Chronic testosterone administration improves exercise-in- 
duced myocardial ischemia in male pts with CAD. Since DHT does not 
undergo peripheral conversion into estrogens, this anti-ischemic effect is 
purely related to the effect of testosterone upon the vessel wall and not to its 
peripheral conversion into other steroids. 
104549 Effects of Synthetic Progestin on Nitric Oxide 
Bioactivity and Markers of Inflammation in 
Healthy Postmenopausal Women 
Kwang Kon Koh, Sung Hee Yang’, Min Soo Sohn, Dong Kyu Jin. 
Cardiology ‘Menopause, Gachon Medical School, Inchon, Korea 
We have previously shown that estrogen improved nitric oxide (NO) bioactiv- 
ity and reduced markers of inflammation in postmenopausal women (PMW). 
Experimental and animal studies suggest that synthetic progesterone may 
negate the favorable effects of estrogen. We administered micronized pro- 
gestin (MP) 200 mg or medroxyprogesterone acetate (MPA) IO mg for IO 
days with conjugated estrogen (CEE) 0.625 mg for 25 days during 8 weeks 
to 20 PMW in a randomized, double-blind, crossover study. 
FMD f%) 
Baseline 
4.62 5 2.66 
CEE+MP 
7.41 zk 3.46”’ 
CEE+MPA 
7.54 * 4.45** 
E-S (&~irnl) 41.7 * 15.0 35.9 4 13.1** 32.Oh 11.7**+ 
ICAM- @g/ml) 358rt143 3131135 3oa* 114* 
VCAM-I (no/ml) 846*278 661 +209** 672*182’* 
* = P < 0.05; ** = P < 0.01 vs. Baseline.+ = P < 0.05~ GEE + MF’. Data = mean h SD. 
CEE + MPA or MP significantly improved brachial artery flow-mediated 
dilation (FMD). Of note, there were no significant differences between CEE + 
MPA and CEE + MP. Improvement in NO bioactivity andreduction of inflam- 
matory cell adhesion molecules may account for the cardiovascular benefit 
of synthetic or natural progestin combined with estrogen in healthy PMW, 
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L---I-i 1046 9 Rapid Improvement of Enclothelial Function After Lipid-Lowering Therapy With Cerivastatin Within 
Two Weeks 
Stefan John, Johannes Jacobi, Christian Delles, Markus P, Schlaich, 
Markus Schneider, Roland E. Schmieder. Deparfmenf of Medicine /y 
Universify Erlangen-Niirnberg, Germany 
Background: Impaired endothelium dependent vasodilation (EDD) plays 
a pivotal role in the pathogenesis of atherosclerosis and acute coronary 
syndromes in hypercholesterolemia. We investigated whether improvement 
of endothelial function can be achieved already with short-term lipid-lowering 
therapy. 
Methods: In a randomized, double-blind, placebo-controlled trial we stud- 
ied 35 patients (52 f 11 yrs) with LDL-cholesterol ,160 mgfdl (197 & 44 
mg/dl) randomly assigned to either cerivastatin (0.4 mg/d) or placebo. EDD 
of the forearm vasculature was measured by plethysmography and i.a. in- 
fusion of acetylcholine (ACh 12, 48 lg/min) and endothelium independent 
vasodilation by i.a. infusion of nitroprusside (NP 3.2, 12.8 figlmin). 
Results (xi SEM): LDL-cholesterol decreased after 2 weeks of treatment 
(cerivastatin -33 f 8% vs placebo + 2 f 4%, p < 0.001). Endothelium 
dependent increases in forearm blood flow improved after 2 weeks therapy 
with cerivastatin compared to baseline (ACh 12 &min: 22.3 f 5.2 vs 11.2 
* 1.9 ml/min/lOO ml, p i 0.01 **; ACh 48 wg/min: 31.2 f 6.3 vs 19.1 f 
3.1 ml/minllOO ml, p < 0.05 *). The dose response curves are shown in 
the figure: after (o), before therapy (0); placebo group (- after, 0 before). 
Similar results were found when EDD was expressed as percent change 
from baseline. Moreover, patients on cerivastatin had an improvement of 
endothelium dependent vasodilation already after 2 weeks compared to 
placebo (ACh 48 pg/min: +203 & 85% [cerivastatin] vs -26 f 71% [placebo], 
p < 0.05). 
40 
b.,r,inr I I  , I  
acetylcholine pg/min 
Conclusion: Short-term lipid-lowering therapy with cerivastatin improved 
endothelial function already after 2 weeks in hypercholesterolemic patients. 
This rapid improvement of NO-bioavailability suggests a role for lipid-low- 
ering therapy not only for prevention but also for therapy of acute coronary 
syndromes. 
1 1046-I 0 1 Myocardial Blood Flow in Young Adults: 
Predictors and the Effect of HMG-CoA Reductase 
Inhibition 
Reijo Laaksonen, Tuula Helle, Risto Vesalainen, Olli Raitakari, 
Juha Laakso, Terho Lehtimaki, Pirjo Nuutila, lrina Elovaara, Olli Jaakkola, 
Tiina Solakivi, Hannu Jokela, Kari Punnonen, Pekka Saikku, 
Kaisa Salminen, Juhani Knuuti. Universitiy of Tampere, Jampere; Turku PET 
Cenfre, Turku, fin/and 
Background: It has earlier been observed that serum lipid and lipoprotein 
levels inversely correlate with coronary blood flow in CAD patients and statin 
treatment has been shown to improve myocardial blood flow in these patients. 
In this study we aimed to clarify predictors of myocardial blood flow in young 
healthy adults. We also assessed the effect of pravastatin on myocardial 
blood flow in these subjects. 
Methods: The study was randomized, double blind and placebo con- 
trolled (n = 44). Myocardial blood flow was measured with positron emission 
tomography (PET) and oxygen-15labeled water before and after six months 
pravastatin (40 mg/day) or placebo treatment. Blood samples for lipid and 
lipoprotein as well as other blood flow predictor candidate assessments were 
collected at baseline and at the end of the follow-up. 
Results: Unexpectedly, the adenosine-induced blood flow correlated di- 
rectly with lipids and lipoproteins. No associations were observed between 
myocardial blood flow and homocysteine, Chlamydia Pneumoniae, CRP, 
adhesion molecules, body iron stores, PAI-I, LDL oxidation or antioxidant 
vitamins. The average basal and adenosine induced myocardial blood re- 
mained practically unchanged during the follow-up in both treatment groups. 
But interestingly, a covariance analysis (adjusting with change either in TC, 
LDL-C, apoB or LDL fraction protein concentrations) demonstrated a signifi- 
cant difference in the change of induced flow and CFR in favor of pravastatin. 
After adjusting with LDL fraction protein CFR decreased in the placebo 
(-0.58) but increased in the pravastatin group (+0.90); p < 0.02. 
Conclusions: We suggest that lipids and lipoproteins might associate 
directly with adenosine induced flow in healthy subjects, since they contribute 
significantly to blood viscosity, which in turn is related to shear stress induced 
NO release. On the other hand these results also strongly support the view 
that pravastatin acts beneficially beyond its lipid lowering effect. 
1 1046-I 1 1 Non-Lipid Lowering Effects of Statin Medication 
in Patients With Coronary Heart Disease 
Christoph Bickel, Hans J. Rupprecht, Stefan Blankenberg, Gerd Hafner’ , 
Gerd Rippin*, Jiirgen Meyer. II. Medical Clinic, University Mainz; ‘Clinic of 
Clinical Chemistry University Mainz; 2Department of Medical Statistics and 
Documentation, University Mainz, Germany 
Background: Despite statin therapy is well established in primary and sec- 
ondary prevention of coronary heart disease, it remains unclear if only lipid 
lowering or also non-lipid lowering properties of statins are responsible for 
the significant cardiovascular event reduction. Therefore we examined the 
non-lipid effects of statin therapy by measuring coagulation and inflammation 
markers and adhesion molecules. 
Methods: In 950 patients with angiographically proven coronary heart dis- 
ease 277 patients were treated with statins for a minimum of 4 weeks before 
blood sample was taken, 643 patients did not take a lipid lowering drug. The 
following laboratory parameters were determined: cholesterol (CHOL), HDL- 
cholesterol (HDL), LDL-cholesterol (LDL), triglyceride (TG), von Willebrand 
factor (vWF), thrombin-antithrombin-complex (TAT), plasmin-wBantiplasmin 
complex (PAP), d-dimer (DD), high sensitive CRP (hs_CRP), serum amyloid 
A (SAA), interleukin 6 (116) and soluble P-selectin (p-selectin). 
Results: The following results - representing median (25%-/75%-inter- 
quartile) -were measured: 
statin fn = 277) no lipid druo fn = 673) D-value 
CHOL (mgkfl) 
LDL (mg/dl) 
HDL (mg/dl) 
TG (maIdI) 
“Wi (ii, 
TAT @g/ml) 
PAP @g/ml) 
DD bgll) 
hs_CRP (mg/l) 
SAA (mgll) 
IL6(pg/ml) 
o-selectin (no/ml) 
“ .  
221 (193/250) 217(191/247) 
140(113/169) 139 (116/166) 
45 (37157) 44 (37/53) 
153 (109/207) 
162 il30/224j 
2.6 (1.9/4.6) 
391 (272/544) 
103.0 (76.5/155.0) 
4.33 (1.84/10.81) 
10.20 (515121.90) 
9.47 (5.12/l&66) 
112.6 (82.01146.0) 
142(iOl/li5) 
208 (154/283) 
3.3 (2.3/5.4) 
476(338/662) 
130.0 (92.8/214.3) 
7.62 (2.80119.99) 
15.90 (6.23/56.27) 
14.40(7.21/28.06) 
127.8 f93.8/162.4) 
n.s.* 
Il.!%* 
ML* 
Its.* 
0.0001 
0.0005 
0.0001 
0.0001 
0.0001 
0.0001 
0.0001 
0.001 
*not significant (p > 0.05) 
Conclusion: Although we found no difference in lipid status between 
patients under statin therapy and without any lipid lowering drug therapy, we 
evaluated a reduction of coagulation and inflammation markers and adhesion 
molecules in statin treated patients. Despite of its lipid lowering potency the 
clinical benefit of statin therapy is also mediated by its non lipid lowering 
properties in reducing coagulation status and inflammatory response. 
l---l! 1046 12 The Influence of Short-Term Therapy With Simvastatin on Inflammatory Profile in 
Hypercholesterolemic Patients 
Ewa Deskur, Andrzej Wykretowicz, Jaromir Furmaniuk, Magdalena Kempa, 
Henryk Wysocki. Department of Cardiology - lnfensive Therapy University 
of Medical Sciences, Poznafi, Poland 
introduction: Endothelial injury caused by chronic inflammation has been 
postulated to play an important role in atherogenesis. Increased concentra- 
tions of several markers of inflammation, such as interleukin-6 (IL-6), lipid 
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peroxides and nitric oxide (NO), have been found in individuals with coro- 
nary artery disease and hypercholesterolemia. Lipid-lowering therapy with 
HMG-CoA reductase inhibitors (statins) has been shown to improve survival 
in hypercholesterolemic patients after myocardial infarction and to exert a 
direct anti-ischemic effect, possibly by attenuating inflammatory activity in 
vessel wall. 
The aim of our study was to evaluate prospectively serum IL-6, TBARS 
concentrations (as lipid peroxidation end-products) and nitrate/nitrite levels 
(as NO final products) in hypercholesterolemic patients treated with simvas- 
tatin. 
Methods and Results: Peripheral blood samples were collected from 20 
hyperchoiesterolemic individuals (mean serum cholesterol level 303 i 8.71 
mg/dl) before and after 8 and 12 weeks of cholesterol-lowering therapy with 
simvastatin (20 mg/day). Serum TBARS levels significantly decreased after 8 
weeks of treatment (3.52 f 0.27 wmoi/l vs 4.53 i 0.41 ~mol/l, p = 0.008) and 
remained decreased at 12th week of therapy (3.70 f 0.29 ~mol/l). Serum 
NO concentrations were significantly reduced at 12th week (25.27 f 2.63 
fimol/l vs 29.39 f 2.88 pmolil, p = 0.024). No significant changes in IL-6 
serum levels were found (1.87 f 0.19 pg/ml before treatment, 1.78 i 0.16 
pgiml at 8th week, 1.84 f 0.16 pg/ml at 12th week). 
Conclusion: Short-term treatment with simvastatin significantly reduces 
lipid peroxidation markers as well as nitric oxide final products. The IL-6 
levels remains unaffected by the therapy. 
’ L--.-A 1046 21 Reduction of LDL-Cholesterol and Elevation of HDL-Cholesterol in Subjects With Primary 
Hypercholesterolemia by SCH 58235: Pooled 
Analysis of Two Phase II Studies 
Leslie J. Lipka, Alexandre P. LeBeaut, Enrico P. Veltri, Lillian E. Mellars, 
Harold L. Bays, Paul B. Moore. Schering-Bough Research Institute, 
Kenilworth, New Jersey; L-MARC, Louisville, Kentucky, USA 
Background: Data from two multicenter, placebo-controlled, double-blind, 
randomized, parallel group IP-week studies of SCH 58235 (ezetimibe, 
USAN), a novel inhibitor of intestinal absorption of cholesterol, were pooled 
to evaluate the drug’s effect on lipid parameters in subjects with primary 
hypercholesterolemia. 
Methods: Following dietary stabilization (NCEP Step I or stricter diet), 
lipid-lowering drug washout and a 6 week placebo lead-in period, subjects 
with baseline low-density lipoprotein cholesterol (LDL-C) ~130 mg/dl, 1250 
mg/dl and triglycerides 5300 mgidl were randomized to SCH 58235 (0.25, 1, 
5, or IO mg), or placebo in the Dose Response Study, or SCH 58235 (5 mg 
or IO mg dosed in the AM or PM) or placebo in the Dose Regimen Study. 
Results: The table below depicts the pooled mean percent reductions in 
lipid parameters from baseline at endpoint: 
Treatment Group 
Placebo (n = 87) 
SCH 58235 5 (n = 124) mg 
SCH5823510mo(n=118) 
Mean% Changefrom Baselineat Endpoint (i-SE.) 
LDL-C HDL-C Triglycerides 
-0.4 i 1.1 -0.2 zt 1.0 -1.3i2.9 
-15.7i0.9a 2.9 i 0.9a -5.8 i 2.4 
-18.5 i o.@ 3.5 i 0.9= -4.9 i 2.5 
a p < 0.05 vs. placebo: b p < 0.05 vs. 5 mg 
Both doses of SCH 58235 significantly reduced LDL-C and raised high- 
density lipoprotein cholesterol (HDL-6). 68% of subjects treated with 10 mg 
of SCH 58235 and 54% of subjects treated with 5 mg achieved greater than 
15% reduction in LDL-C. 22% and 15% of subjects treated with 10 mg or 
5 mg of SCH 58235, respectively, achieved greater than 25% reduction in 
LDL-C. 
Conclusion: SCH 58235 produced a significant reduction in directly mea- 
sured LDL-C as well as an increase in HDL-C. Further clinical investigations 
of this novel cholesterol absorption inhibitor are warranted. 
1046-22 Lipoprotein Lipase and Hepatic Lipase Activities 
Modulate Progression of Coronary 
Atherosclerosis and the Effectiveness of Lipid 
Lowering Therapy 
Johan W. Jukema, Hans Jansen, John J.P. Kastelein, Aeilko 
H. Zwinderman, Ad J. van Boven, Albert V.G. Bruschke. Leiden University 
Medical Center, Leiden; Interuniversity Cardiology institute of the 
Netherlands, Utrecht, the Netherlands 
Background: Lipoprotein lipase (LPL) and hepatic lipase (HL) actitvities are 
involved in triglyceriderich lipoprotein and HDLchol metabolism and therefore 
may influence progression of coronary atherosclerosis (CA). However data 
on this possible association are lacking. Purpose of this study was to analyze 
the impact of LPL and HL activities on the progression of CA and its response 
to pravastatin (PRA). 
Methods: All patients (pts) were participants in the lipid lowering (PRA 
vs placebo (PLA)) angiographic regression trial REGRESS, investigating 
symptomatic pts with a total cholesterol 4-8 mmol/l (155-310 mgidl). The 
coronary angiograms were assessed by quantitative coronary analysis. 
Results: In 688 pts both LPL and HL were measured according to stan- 
dardized techniques. LPL and HL activities were then divided in tertiles (low 
medium high) and the low LPL-low HL-group (LL, n = 93) was compared with 
the high LPL-high HL-group (HH, n = 83); other group comparisons yielded 
no significant correlations with regard to progression of CA. For LL and HH 
baseline results were respectively: total-chol 5.82 (225) vs 6.28 (243) mmol/l 
(mg/dl), p = 0.001; LDL-chol 4.12 (159) vs 4.53 (175), p = 0.001; and HDL- 
cholO.90 (35) vs 0.99 (38) p = 0.013. Other baseline labiclinicallangiographic 
parameters did not differ between the LL and HH groups. 
Progression of CA, expressed as average decrease in Minimum Obstruc- 
tion Diameter (MOD) in the PLA group was 0.12 mm for LL and 0.17 mm for 
HH (p = 0.38), and in the PRA group it was -0.03 (regression) for LL vs 0.26 
for HH (p = 0.05). 
Conclusions: Thus, LPL and HL activities modulate progression of CA 
and effectiveness of lipid lowering therapy, i.e. PRA showed a very favorable 
effect on CA in the LL group, whereas in the HH group no favorable effect of 
PRA on progression was observed. 
/ 1046-23 1 Coronary Plaque Regression Over Twelve Months 
is Correlated With Increase in High-Density 
Lipoprotein Cholesterol Levels During Therapy 
David T. Linker, Linda R. Bossett, Stephanie G. Cooper, Joseph 
W. Chambers, Douglas K. Stewart, Santica M. Marcovina, B. Greg Brown. 
Division of Cardiology, University of Washington, Seatfle, WA, USA 
Background: lntracoronary ultrasound measurement of plaque volume al- 
lows differences in plaque regression due to varying intensity of lipid lowering 
therapy to be determined. We investigated the relationship between changes 
in blood lipids and plaque volume. 
Methods: Twelve subjects with known coronary artery disease and el- 
evated low-density lipoprotein cholesterol (LDL) were randomized to either 
40 mg pravastatin and diet (PD), or 40 mg pravastatin, 2 gm niacin, 9 gm 
cholestyramine and diet (PNCD). Each had a catheterization before initiating 
therapy and after one year of therapy, with a motorized pullback at 0.5 mm/s 
of an intracoronary ultrasound catheter (30 MHz, 2.9 Fr, CVIS) performed 
in a non-stenotic vessel and recorded on video tape. A lesion or area was 
identified on both sequences, and the plaque area computed for each image 
where this could be identified in the area of interest Plaque volume was 
calculated using the method of disks. Blood samples were taken at baseline, 
4 months, 9 months and 12 months for analysis of total cholesterol, triglyc- 
erides, low-density lipoprotein, high-density lipoprotein cholesterol (HDL), 
Apo A-l, Apo B, Lp(a), triglycerides, and lipoprotein particle size. 
Results: The PNCD group showed significant reduction in plaque vol- 
ume for all individuals over the study year, while the PD group showed no 
significant change (see table). The difference between the two groups was 
highly significant (P = 0.016). Although there was a significant reduction in 
LDL in both groups, there were no other significant differences between the 
two groups, except for the percent change in HDL (p = 0.005). All patients 
who increased their HDL by >4% during the study period showed plaque 
regression, regardless of group (see graph). 
Plaque, HDL & LDL%A vs. treatment 
PD PNCD 
Plaque %A 7.0 zk 19.1 -19.91 12.2* 
HDL %A -3.9 * 13.7 26.3i 15.5'" 
LDL %A -31.0* 11.8 -35.Oi20.6' 
* p = 0.018; -* f~ = 0.005; ‘p = 0.38, NS 
PlaqueAvs.EIJLA 
0 %HDLA 50 
Conclusions: We conclude that changes in plaque burden can be de- 
tected within a twelve month period, and that this early change is associated 
with an increase in HDL during therapy. 
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( 1046-24 1 Cholestagel, a Novel, Highly Potent, Polymeric 
Bile Acid Sequestrant Significantly Lowers LDL 
Cholesterol 
William lnsull’ , Phillip Toth, William Mullican, Donald Hunninghake, 
Michael Davidson, Timothy Olson ‘, David Davidson2, Joanne Donovan’. 
For fhe Cholesfagel Investigators; ‘Bay/or College, Houston, TX; “GelTex 
Pharmaceuticals, Inc., Waltham, MA, USA 
Background: Colesevelam hydrochloride (Cholestagel@) is a nonabsorbed 
polymer that blocks the enterohepatic circulation of bile acids, thereby up- 
regulating hepatic cholesterol 7”-hydroxylase and increasing conversion of 
cholesterol into bile acids. Bile acid sequestrants decrease the risk of cardiac 
events, but have low compliance rates. 
Methods: In this randomized, double-blind, placebo-controlled 6 month 
dose ranging study in patients with type Ila hypercholesterolemia (LDL 
cholesterol 130-220 mg/dL, mean baseline 158 mg/dL), an 8 week NCEP 
Step I-diet preceded 24 weeks of treatment. 
Results: Maximum LDL-C reduction occurred by 2 weeks of treatment 
and was maintained throughout the study. Cholestage14.5 g/day lowered me- 
dian LDL-C by 20%. All treatment groups had small but significant increases 
in HDL-C. 
Percent Change in Fasting Plasma Lipid Parameters (Ill Population) 
LDL-C Total-C 
Dose n mean ITlea” 
Placebo 88 0 1 
Choke&gel 2.3 g 99 -9* -4* 
Cholestagel3.0 g 90 -12* -6* 
Cholestage13.8 g 95 -15’ -7* 
Cholestage14.5 g 94 -18* -10’ 
t p-value < 0.05; *p-value < 0.001 within group change 
HDL-C TG 
median median 
-1 5 
3* 9+ 
4* 57 
3* 10* 
3* IOf 
The overall incidence of side effects was comparable between treatment 
and placebo groups. 
Conclusion: Cholestagel was safe and effective monotherapy for type 
Ila hypercholesterolemia. Compared to historical data with other bile acid 
sequestrants, colesevelam hydrochloride was 4-6 times more potent, and the 
incidence of treatment related gastrointestinal side effects was not statistically 
different from placebo. 
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1066-41 A Prospective Study of Genetic Susceptibility to 
Infection and the Severitv. Proaression, and 
Regression of Coronary ither&clero&, Plasma 
Lipid Levels, Clinical Events, and Response to 
Fluvastatin 
Conclusion: The Qig2R variants of PONl are not associated with sever- 
ity, progression, or regression of coronary atherosclerosis, plasma lipid levels 
clinical events, or response to treatment with fluvastatin. 
Shahin Tavackoli, Carolyn Cahilly, Do-Sun Lim, Laura Ferlic, J. Kay Dunn, 
J. Alan Herd, Antonio Gotto, Christie M. Ballantyne, Ali J. Marian. Bay/or 
College of Medicine, Houston, Texas, USA 
( 1066-43 ( The Fibrinogen p Gene Hind Ill -148 
Polymorphism and Prevalent Cardiovascular 
Disease: The Framingham Heart Study 
Background: Infection with gram-negative bacteria is implicated in the patho- 
genesis of coronary artery disease (CAD). Lipopolysaccharides (LPS), pro- 
duced by bacteria, bind to CD14 receptors on surface of macrophages and 
induce release of inflammatory cytokines, which can contribute to CAD. A 
C-260T polymorphism in CD14 gene is associated with myocardial infarc- 
tion in 2 case-control studies. We prospectively studied association of this 
polymorphism with the severity, progression, and regression of CAD, plasma 
lipid levels, clinical events, and response to fluvastatin in the Lipoprotein and 
Coronary Atherosclerosis Study (LCAS) cohort. 
DaLi Feng’, Klaus Lindpaintnes, Martin G. Larson3, Christopher 
J. O’Donnel13, lzabella Lipinska’ , Patrice A. Sutherland3, Ralph 
B. D’Agostino4, Daniel Levy3, Geoffrey H. Tofles. ‘Cardio/ogy,Division, 
B/-Deaconess Medical Center; *Cardiology Division, Brigham & Women’s 
Hospital, Harvard Medical School, Boston; 3NHLBl’s Framingham Heart 
Study, Framingham; 4Deparfment of Mathematics, Boston Universit): MA, 
USA; 5Royal North Shore Hospital, Sydney, Australia 
Methods: Genotypes were determined by polymerase chain reaction 
and restriction mapping with Haelll enzyme in 370 subjects. Fasting plasma 
lipids and quantitative coronary angiograms were obtained at baseline and 
2.5 years following randomization to fluvastatin or placebo. 
Background: Fibrinogen is an independent risk factor for cardiovascular 
disease. Although we and others have shown that the fibrinogen ,8 gene 
Hind U-148 polymorphism modifies fibrinogen levels, the relation between 
this polymorphism and cardiovascular risk remains uncertain. We therefore 
studied subjects from the Framingham Heart Study to determine whether this 
polymorphism was associated with prevalent cardiovascular disease. 
Results: Baseline and final plasma levels of HDL, LDL, triglyceride, and Methods and Results: Genotype and phenotype data were obtained in 
other lipoproteins, mean number of coronary lesions, total occlusions, num- 3180 subjects. The polymorphism was determined by PCR-based restriction 
ber of subjects with 21 coronary lesion or total occlusion and the mean fragment length polymorphism analysis. The allele frequencies of cutting (HI) 
minimum lumen diameter (MLD) and lesion-specific MLD on baseline coro- and non-cutting (H2) alleles were 0.81 and 0.19, respectively. There were 
nary angiogram were not significantly different among the genotypes (N: CC no significant differences in genotype distribution among subjects with or 
= 100, CT = 184, TT = 86). There was no genotype-treatment (with fluvas- without cardiovascular disease (p = 0.51). Similar results were obtained for 
tatin) interaction with respect to plasma lipid levels, angiographic indices of men and women, p = 0.92 and 0.52, respectively. 
CAD, and clinical events. The CC genotype was weakly associated with new 
total occlusion and clinical events in the placebo group. 
21 new total occlusion 
Clinical events 
cc (37) 
6 (16%) 
9 (24%) 
CT (76) 
.2 (3%) 
6 (8%) 
TT (41) 
3 (7%) p = 0.024 
4 (10%) p = 0.049 
Conclusion: The C-262T variants of CD14 are weakly associated with 
development of coronary occlusion and clinical events, which is masked by 
fluvastatin therapy. Overall, susceptibility to infection conferred bythe C-262T 
variants is, at most, a modest risk factor for CAD and clinical events. 
1 1066-42 1 A Prospective Study of Paraoxonase Gene 
Variants and the Severity, Progression, and 
Regression of Coronary Atherosclerosis, Plasma 
Lipid Levels, Clinical Events, and Response to 
Fluvastatin 
Sharon Turban, Francisco Fuentes, Laura Ferlic, Ramon Brugada, J. 
Kay Dunn, J. Alan Herd, Antonio Gotto, Christie M. Ballantyne, Ali 
J. Marian. Baylor College of Medicine, Houston, Texas, USA 
Background: Paraoxonase (PONI) is a HDL-associated enzyme that pro- 
tects against oxidation of LDL. PONl has an arginine (R)lg2 glutamine (Q) 
polymorphism, which has been associated with coronary artery disease 
(CAD) in some but not all case-control studies. We prospectively studied the 
association of PONI genotypes with the severity, progression, and regres- 
sion of CAD, plasma lipid levels, clinical events, and response to treatment 
with fluvastatin in a well-characterized cohort. 
Methods: Genotypes were determined by polymerase chain reaction and 
restriction mapping with A/w/ enzyme in 356 subjeCts in the Lipoprotein and 
Coronary Atherosclerosis Study. Fasting plasma lipids were measured and 
quantitative coronary angiograms were obtained at baseline and 2.5 years 
following randomization to fluvastatin or placebo. 
Results: Baseline and final plasma levels of HDL, LDL, triglyceride, and 
other lipoproteins were not significantly different among genotypes. 
QQ (N = 1771 QR (N = 142) RR (N = 37) 
# of qualifying lesions 2.68 i 1.8 
# of total occlusions 0.35 i 0.62 
21 qualifying lesion 
?l total occlusion 
Mean MLD (mm) 
zl new lesion (%) 
51 new total occlusion 
A MLD (mm) 
Clinical events 
154 (87%) 
49 (28%) 
1.67 + 0.40 
50 (28%) 
8 (5%) 
-0.13 zk 0.27 
28 (16%) 
2.71 zk 2.1 
0.34 + 0.66 
116 (82%) 
37 (26%) 
1.68 zk 0.43 
32 (23%) 
5 (4%) 
-0.08 + 0.22 
22 (15%) 
I  
2.81 * 2.15 
0.19 zk 0.46 
32 (86%) 
6 (16%) 
1.63 zk 0.37 
5 (14%) 
2 (5%) 
-0.14 ?c 0.16 
3 (6%) 
There was no genotype-treatment (with fluvastatin) interaction with re- 
spect to plasma lipid levels and angiographic indices of coronary atheroscle- 
rosis. 
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HI/H1 HI/H2 H2/H2 
CVD (n = 513) 65.7% 31 2% 3.1% 
Non CVD In = 2667) 66.0% 29.9% 4.1% 
Conclusion: In the Framingham Heart Study, the Hind III p-148 poly- 
morphism was not associated with prevalent cardiovascular disease even 
though this polymorphism modified fibrinogen levels. These data suggest 
that genotype induced change in fibrinogen level may be of less prognostic 
significance than the change in fibrinogen that is an inflammatory response 
to atherosclerosis. Prospective studies are needed to evaluate whether this 
polymorphism is a genetic marker for cardiovascular risk. 
1 1066-44 1 Functional Significance of G-33A Promoter 
Mutation of Thrombomodulin Gene and Its 
Influence on Plasma Soluble Thrombomodulin 
Level in Patients With Coronary Artery Disease 
Yi-Heng Li, Jyh-Hong Chen, Bi-lng Chang, Jia-Chung Lin, Hua-Lin Wu, 
Guey-Yueh Shi, Wei-Chuan Tsai, Ting-Hsing Chao, Liang-Miin Tsai, 
Li-Jen Lin. National Cheng Kung University Medical Center, Tainan, Taiwan 
Background: Thrombomodulin (TM) is an important endothelial anticoagu- 
lant protein. Increased plasma soluble TM level was found in patients (pts) 
with coronary artery disease (CAD). Our recent study has shown that the 
G-33A promoter mutation of TM gene is a genetic risk factor for CAD. The 
aim of the study was to investigate the functional effect of G-33A promoter 
mutation on TM gene expression and its influence on plasma soluble TM 
levels. 
Methods: DNA fragments from the 5’-flanking region of the TM gene 
(-401 to +145), with and without G-33A mutation, were amplified by poly 
merase chain reaction (PCR). The PCR products were digested and fused 
into the luciferase repotter gene. Transient transfections with the promoter/ 
luciferase reporter gene plasmids and galactosidase reporter plasmids into 
endothelial cell culture were performed to examine the influence of this mu- 
tation on TM promoter activity. Furthermore, plasma soluble TM levels were 
determined with enzyme-linked immunosorbent assay kits in 206 consecutive 
pts with CAD diagnosed with coronary angiography. Screening for TM G-33A 
promoter mutation (GA + AA genotypes) in these pts was conducted using 
PCR, single-strand conformation polymorphism, and direct DNA sequencing. 
Results: Luciferase reporter gene assays using the 5’-flanking region of 
the TM gene containing G-33A mutation showed a significant decrease (-36 
i 12%) in transcriptional activity compared with those that did not contain the 
mutation. In all, the soluble TM level was significantly higher (47.0 f 27.4 vs 
39.0 f 17.2 ngimi, p < 0.05) in pts with normal genotype (n = 153; age 63.8 
* 10.7 years; male 73.2%) than that with G-33A mutation (n = 53; age 63.2 
* 11.3years; male 68.0%). Furthermore, the solubleTM level increased with 
the extent of CAD (36.1 f 14.9 vs 46.6 f 18.4 vs 54.8 f 35.9 ng/mL in I-, 2-, 
and 3-vessel disease, p < 0.001) in pts with normal genotype. But in pts with 
G-33A mutation, there was no difference of soluble TM in I-, 2- or 3-vessel 
disease (38.6f 17.2 ~~37.0 + 15.3vs42.0f 18.4ng/mL, p= NS). 
Conclusions: The results suggest that G-33A promoter mutation of TM 
gene reduces endothelial TM synthesis and influence the plasma levels of 
soluble TM in pts with CAD. 
1066-45 Increased Risk of Carotid Atherosclerosis in 
Association With Genetic Mutations of 
Angiotensinogen 
Brendan M. McQuillan, Caroline Chapman, Joseph Hung, Peter 
L. Thompson, John P. Beilby. Heart Research Institute, Sir Char/es Gairdner 
Hospital and Clinical Biochemistry, PathCentre, Queen Elizabefh /I Medical 
Centre, Perth, Western Australia, Australia 
Background: Genetic polymorphisms of the renin angiotensin system have 
been implicated in the pathogenesis of hypertension and atherosclerostic 
cardiovascular disease. Recently described genetic mutations of the an- 
giotensinogen (ATG) and angiotensin II type I receptor (ATR) genes remain 
to be evaluated for their potential roles in these disease processes. 
Methods: We examined if genetic mutations of the ATG gene (M235T 
and G-GA) or the ATR gene (A1166C) are risk markers for carotid atheroscle- 
rosis, hypertension or vascular disease (myocardial infarction or stroke) in 
a randomly selected cross-sectional population, consisting of 1111 subjects 
(558 males, 553 females), aged 53 (SD * 13, range 27 to 77) years. All 
subjects were assessed for vascular risk factors and underwent B-mode 
carotid ultrasound examination for intima-media thickness (IMT) and focal 
plaque. Increased IMT was defined as subjects with mean IMT in the upper 
quintile for the entire cohort. The ATG and ATR gene polymorphisms were 
determined by PCR techniques. 
Results: In the cohort overall, the ATG gene M235T and G-GA genotypes 
were significantly associated with mean carotid IMT after adjustment for age, 
gender and conventional risk factors (both P < 0.05). Among females, the 
M235T TT genotype was predictive of increased IMT (P = 0.02) and focal 
plaque (P = 0.02) while the G-sA AA genotype predicted increased IMT (P= 
0.009) but not plaque (P= 0.13). No significant association was demonstrated 
in males or among subjects overall between either ATG gene mutation and 
increased IMT or plaque (all P P 0.05). No significant association was ob- 
served between the ATR gene AH~~C mutation and carotid atherosclerosis. 
There was also no association between any of the genetic polymorphisms 
studied and the risk of hypertension or a history of vascular disease (all P > 
0.05). 
Conclusion: In this cross-sectional population, genetic mutations of ATG 
(M235T and G-sA) were associated with mean IMT overall, and predicted 
increased IMT and plaque in females. Neither ATG nor ATR gene mutations 
were associated with the risk of hypertension or vascular disease. Further 
studies are required to evaluate a possible sex-specific role of these muta- 
tions in vascular disease. 
/ 1066 46 An Interleukin-10 Promoter Haplotype May Protect Against Coronary Artery Disease 
Nicholas P. Jenkins, Nicholas H. Brooks, Christopher Perrey, Vera Pravica, 
Paul J. Sinnott, Ian V. Hutchinson. Department of Cardiology Wythenshawe 
Hospital, Manchester; Department of Immunology: Manchester University 
Medical School, Manchester, UK 
Background: Plaque inflammation is strongly implicated as a major factor 
predisposing to plaque disruption and myocardial infarction (Ml). lnterleukin 
(IL)-10 is a potent anti-inflammatory cytokine which may limit plaque in- 
flammation. Polymorphisms have been described at positions -1082 (G/A), 
-819 (C/T), and -592 (C/A) of the IL-10 promoter, which occur in linkage 
disequilibrium as three haplotypes (GCC, ACC, ATA), inherited combinations 
of which are associated with high, intermediate or low in vitro IL-I 0 synthesis. 
We examined the influence of these haplotypes on the presence and clinical 
course of coronary artery disease (CAD). 
Methods: 148 age and sex matched Caucasian patients with either stable 
angina and no history of Ml, or confirmed Ml (on the basis of World Health 
Organisation criteria for definite Ml or pathological Q waves), were identified 
at the time of elective coronary angiography. 330 unmatched healthy controls 
had previously been recruited from the general population. Genomic DNA 
was obtained from a venous sample using ethanol precipitation, and geno- 
typic analysis performed using a polymerase chain reaction with sequence 
specific oligonucleotide primers, followed by agarose-gel electrophoresis. 
Results: Mean (SD) age was 59.6 (7.4) years, and 86% were male. 
High IL-10 producers were less frequent amongst patients with myocardial 
infarction than those with stable angina, although this was not statistically 
significant (9% and 19% respectively, P = 0.1, OR 0.45, 95% Cl for OR 
0.17-I .19). Thefrequencyof high IL-10 producers in the combined group was 
significantly lower than that of the control group (14% and 30% respectively, 
P =Z 0.001, OR 0.39, 95% Cl for OR 0.23-0.65), and was associated with a 
lower GCC haplotype frequency (44% and 51% respectively, P = 0.05) 
Conclusions: A promoter haplotype associated with high IL-IO synthe- 
sis occurs infrequently in Caucasian patients with CAD, and may confer 
additional protection against myocardial infarction. 
1 1066-47 1 A Common Mutation in p22phox Component of 
NADPHlNADP Oxidase is Associated With 
Progression of Coronary Atherosclerosis 
Carolyn Cahilly, Christie M. Ballantyne, Laura Ferlic, J. Kay Dunn, Do 
Sun Lim, Shahin Tavackoli, J. Alan Herd, Antonio Gotto, Ali J. Marian. 
Baylor College of Medicine, Houston, Texas, USA 
Background: Oxygen free radicals are involved in the pathogenesis of ath- 
erosclerosis. A series of pro and anti-oxidant enzymes, such as NADPH 
oxidase, maintain the redox state. A major component of NADPH oxidase 
is p22phox, which is expressed in vascular wall. We prospectively studied 
the association of the histidine (H)7z tyrosine (Y) mutation in p22phox with 
the severity, progression, and regression of coronary artery disease (CAD), 
plasma lipid levels, clinical events, and response to fluvastatin in a well-char- 
acterized cohort. 
Methods: Genotypes were determined by polymerase chain reaction and 
restriction mapping with Rsal enzyme in 368 subjects in the Lipoprotein and 
Coronaty Atherosclerosis Study (LCAS). Fasting plasma lipids and quantita- 
tive coronary angiograms were obtained at baseline and 2.5 years following 
randomization to fluvastatin or placebo. 
Results: Baseline and final plasma levels of HDL, LDL, triglyceride, and 
other lipoproteins, baseline severity of CAD and clinical events were not 
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significantly different among the genotypes (N: HH = 157, HY = 172, YY = 
39). However, those with the mutation showed more progression and less 
regression of CAD (p = 0.002) and had greater loss in mean minimum lumen 
diameter (MLD) (p = 0.006) and lesion-specific (LS) MLD (0.038). There was 
no genotype-treatment (with fluvastatin) interaction with respect to plasma 
lipid levels and angiographic indices of coronary atherosclerosis. 
valine at position 1667 is highly conserved and may be involved in channel 
inactivation. 
Conclusion: LQT3 patients are susceptible to malignant drug-induced 
QT prolongation and cardiac events. Antimalarial drug halofantrine can even 
on therapeutic doses induceventricular tachycardia and atrioventricular block 
in these patients. 
Placebo group 
Progression (%) 
Regression (%) 
Mixed change (%) 
Mean MLD loss (mm) 
LS MLD loss (mm) 
HH (N = 62) HY (N = 73) YY(N=17) 
17 (27) 35 (46) 6 (47) 
11 (16) 1 (1) 0 (0) 
34 (55) 37 (51) 9 (53) 
-0.03 5 0.22 -0.17zk 0.26 -0.15 f0.15 
-0.06 zt 0.03 -0.16 i 0.03 -0.15~kO.06 
Conclusion: The H7aY mutation in ~22 @‘Ox, which is involved in produc- 
tion of oxygen free radicals in the vessel wall, is associated with progression 
of coronary atherosclerosis in LCAS population. 
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I 1066 48 Toll-Like Receptor-4 is Expressed in Human Coronary Atherosclerotic Plaques and 
Upregulated by Oxidized Low Density Lipoprotein 
in Macrophages 
Xiaoou Helen Xu, Prediman K. Shah, Emmanuelle Faure, Lisa Thomas, 
Daniel Luthriger, Xiao-Ping Xu, Juli Yano, Sanjay Kaul, Boyan Cercek, 
Moshe Arditi. Atherosclerosis Research Center, Division of Cardiology and 
Pediatric lnfecfious Disease, Cedars-Sinai Medical Center, Los Angeles, 
California, USA 
Background: Toll-like receptor 4 (TLR-4) a human homologue of Drosophila 
Toll, is a signaling protein involved in innate immunity, and has recently been 
found to be the signaling receptor for bacterial lipopolysaccharide. TLRs 
activate signal transduction pathway leading to nuclear factor-uB (NF-KB) 
activation. Activation of NF-KB has been shown to be involved in the patho- 
genesis of atherosclerosis. 
Method: To investigate a potential role of TLR-4 in atherogenesis, we 
studied TLR-4 expression and localization in human coronary atheroscle- 
rotic plaques using double immunohistochemical staining for TLR-4 and 
macrophages (M@), and the regulation of TLR-4 by oxidized low density 
lipoprotein (ox-LDL, IO, 20 and 50 fig/ml) in cultured human monocyte- 
derived macrophages using RT-PCR. 
Results: Strong expression of TLR-4 was seen in 5 out of 5 human 
coronary atherosclerotic plaques. Majority of TLR-4 staining (75 i 19%) was 
seen particularly within lipid rich regions and co-localized with M+. TLR-4 
mRNA expression (RT-PCR) was increased by 50% to 100% after exposure 
to ox-LDL in a dose dependent manner, as compared to control and native 
LDL. 
Conclusion: We show for the first time that TLR-4 is expressed in human 
coronary atherosclerotic plaques, in particular within lipid rich regions and 
localized in M$. TLR-4 mRNA was upregulated by ox-LDL in cultured human 
monocyte-derived macrophages. These observations suggest that TLR-4 
may be involved in atherogenesis. 
1 1066-49 1 Antimalarial Drug Halofantrine Induces 
Ventricular Tachycardia in Patients With Long QT 
Syndrome Caused by a Mutation of the Cardiac 
Sodium Channel Gene SCN5A 
Kirsi Piippo, Sam Holmstrom, Heikki Swan, Matti Viitasalo, Marja Raatikka, 
Kimmo Kontula, Lauri Toivonen. Helsinki University Hospital and 
Department of Medicine, University of Helsinki, Helsinki, Finland 
Background: Mutations of four potassium channel genes (KCNQI, HERG, 
minK and mirP) and the sodium channel gene SCN5A cause congenital form 
of long QT syndrome (LQTS). Several pharmacological agents are known to 
prolong ventricular repolarization by blocking the HERG channel responsible 
for the rapid potassium current Ikr. We describe here a novel missense mu- 
tation of the SCN5A gene in two LQTS patients with drug-induced ventricular 
tachycardia. 
Methods: Two patients, 16-year old boy with clinically established LQTS 
and his asymptomatic 40-year old mother, experienced documented torsades 
de pointes during halofantrine therapy. DNA samples of the probands were 
collected and subjected for sequence analysis of the SCNSA gene. 
Results: In both patients regular doses of halofantrine resulted in recur- 
rent syncopal spells within 24 hours. Compared to basal values, halofantrine 
prolonged the QTc interval from 460 to 580 ms and from 500 to 740 ms, with 
transient Mobitz II type heart block. A novel missense mutation (V16671) was 
detected in the S5/IV transmembrane domain of the SCN5A gene. It was 
present in heterozygous form in the two probands and three asymptomatic 
family members. The mutation was absent in 50 normal control subjects. The 
11067-50 1 Abnormal Autonomic Response to High Altitude 
Exposure in Acute Mountain Sickness 
P.A. Lanfranchi, P. Baderna, L. Spagnolatti, G. Cremona, R. Colombo, 
G. Mazzuero, P. Wagner, P. Giannuzzi. Salvafore Maugeri Foundation 
IRCCS, Veruno (NO), Italy; Dept. of Physiology UCSD, USA 
Background: Acute Mountain Sickness (AMS) is a complex syndrome which 
frequently occurs in lowlanders ascending to high altitude. Usually self-lim- 
ited, AMS can progress to life-threatening cerebral and/or pulmonary edema. 
A possible involvement of the autonomic nervous system in the genesis of 
symptoms has been suggested, although the exact mechanism is still unclear. 
Methods: To evaluate the autonomic cardiovascular function during AMS 
due to acute exposure to high altitude, 42 unacclimatized mountaneers (10 
F, 32 M, mean age 37 f IO yrs) were studied after reaching 4559 m altitude 
(Rifugio R. Margherita, Monte Rosa, Italy) (HA). They underwent medical 
history, physical examination, arterial oxygen saturation, EKG, R-R variability 
(mRR, sdRR, Total variance, Lfnu, Hfnu, LF/HF), baroreflex sensitivity (BRS) 
by means of a non-invasive technique (alpha-index) and Lake Louise score 
for definition of AMS. At HA, 18 subjects (43%) had AMS (Lake Louise score 
> 3). No differences were found between subjects with and without AMS 
z terms of anthropometric data and respiratory function. In contrast, the 
subjects with AMS were older (42 f 10 vs 34 f 9 yrs, p < 0.05) and had a 
lower LFnu (56 f 24 vs 75 f 21, p < 0.05). Considering haedache, which is 
the main neurological symptom of the syndrome, symptomatic subjects still 
had lower LFnu (55 f 21 vs 79 f 22, p < O.Ol), lower LF/HF (4.8 f 4.0 vs 
9.8 f 9.1, p < 0.05) and lower BRS (4.8 * 2.9 vs 9.4 i 5.1 ms/mmHg, p 
< 0.01). Twenty three subjects repeated the protocol at low altitude (200 m; 
LA). In these subjects, indexes of sympathetic activation increased from LA 
to HA (increased HR, reduced RR variability with enhanced LFnu, p < 0.01). 
However, among them, AMS subjects (n. 11) showed at HA a less degree 
of sympathetic activation than asymptomatic subjects (A% Lfnu 21 f 36 vs 
137 + 166%, p < 0.05). 
Conclusions: These results provide evidence that AMS is associated 
with an altered autonomic cardiovascular response to acute exposure to high 
altitude. However, the role of the autonomic neural control in the genesis of 
AMS has still to be clarified. 
L--L- 1067 51 Characteristic Head-Up Tilt Responses of Pediatric Chronic Fatigue Syndrome 
Li Fan, Deborah M. Friedman, Anniece Woods-Brown, Martin Fisher, 
Leonard Krilov, Arshed Quyyumi, Marc Ovadia. North Shore U. 
Hospital/NYU Schl. Med. and Ped. Rsch Ctr of Long /s/and Jewish Med. 
Ctr, Clinical Research Centers of Cornell Unk Med. Co//., NY; National 
institutes of Health, Bethesda, MD, USA 
Based on Head-Up Tilt (HUT) testing, studies of Chronic Fatigue Syndrome 
(CFS) have suggested that CFS related syncope and hypotension are forms 
of neurally-mediated hypotension (NMH), which predicts improvement with 
p-blockade. This prediction has never been tested in a controlled study. 
We therefore undertook a study of CFS in the young using detailed phys- 
iologic head-upright tilt testing. Control HUT was compared with HUT after 
p-blockade with esmolol to distinguish between NMH, and Dysaufonomia 
which is defined as orthostatic hypotension worsened by fl-blockade. 
Methods: A consecutive series of CFS patients (n = 31) were evaluated 
after 3 days of salt-abstinence. CFS was diagnosed by Centers for Disease 
Control (CDC) criteria (1994, 1988). Physiologic HUT protocol included (1) 
control HUT (60”, 49 min) until hypotension at time t, (2) supine p-blocker load 
(esmolol 500 @g/kg bolus) followed by (3) HUT during p-blockade (esmolol 
200-350 pg/kg/min, 60’, 15 mins or t + 5 mins). Esmolol-withdrawal HUT 
and isoproterenol HUT were performed to increase sensitivity for NMH. 
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Results: Patients (age = 15.8 & 2, 60% female) had symptoms of fatigue 
(1 OO%), syncope (55%) and/or presyncope (90%). Immediate orthostatic 
hypotension was present in only 2 pts. Tilt BP and HR responses were com- 
pared between control HUT and esmolol HUT: maximal HR was decreased 
from 114 + 17 to 95 i 15 bpm (p ic O.OOOl), change in supine to tilt maximal 
HR went from 45 f 15 to 27 f 12 bpm (p < O.OOOl), supine SBP was 
decreased from 116 & 10 to 110 i 8 mmHg (p < 0.0007) and maximal SBP 
was decreased from 125 f 9 to 116 i IO mmHg (p < O.OOOl), consistent 
with dysautonomia but not NMH. 17131 patients had positive control HUT 
(time to positivity 24.4 & 14.4 mins). 19131 patients had positive esmolol 
HUT where esmolol caused earlier postural hypotension than control in 13 
patients (time to positivity 11.2 rt 9.2 mins vs 27.1 rt 14.8 mins) or caused 
postural hypotension after negative control tilt in 4 patients. Findings of NMH 
were present in only 4/31 pts. 
Conclusion: The pediatric CFS has a characteristic HUT response with 
delayed orthostatic hypotension. This is worsened by ,&blockade, suggesting 
pediatric CFS-related syncope is consistent with dysautonomia. (Supported 
by CFIDS Association and NIH grant MO1 RR/06020/08) 
1067-52 Central Alpha-2 Adrenoceptors Have no Role in 
the Pathogenesis of the Vasodepressor 
Component of Carotid Sinus Hypersensitivity 
S.W. Parry, M. Baptist, J.J. Gilroy, M. Hutchinson, R.A. Kenny. 
Cardiovascular Investigation Unit and MRC Centre for Brain Ageing, 
University of Newcastle, UK 
Up-regulation of central alpha-2 adrenoceptors has been proposed as the 
primary lesion responsible for the vasodepressor (VD) component of carotid 
sinus hypersensitivity (CSH). Testing this hypothesis via direct in vivo studies 
in humans is impossible, so we addressed this issue through use of yohim- 
bine, a central alpha-2 adrenoceptor antagonist. Patients with CSH have a 
variable VD response depending on the degree of bradycardiafasystole in- 
duced by carotid sinus massage (CSM), so we controlled for this confounder 
by asking patients with pacemakers implanted for CSH to participate. 
Objective: To assess whether yohimbine attenuates or abolishes the va- 
sodepressor component of CSH following CSM in patients with pacemakers 
implanted for CSH. 
Design: Double-blind, randomized, placebo-controlled cross-over trial 
Subjects: Consecutive patients with CSH referred for pacemaker implan- 
tation through our syncope facility with minimum VD of 20 mmHg on CSM 
post-pacing. 
Intervention: Intravenous yohimbine and normal saline administered in 
randomized double-blind fashion a minimum of 48 hours apart to ensure 
elimination of active drug (ti 7 hours). CSM was performed pre- and post- 
each injection with continuous ECG and beat-to-beat blood pressure (BP) 
monitoring. 
Yohimbine dose 0.063 mg/kg sufficient to provoke rise in BP (proxy for 
alpha-2 adrenergic antagonism). 
Statistics: Paired t test for differences in BP pre and post yohim- 
bineisaline, 3 way ANOVA with patient, intervention and side of CSM as 
dependent variables. Results 18 subjects, 9 female, mean age 73.9 years 
(sd 8.31), none taking medications influencing alpha-2 adrenoceptor func- 
tion. Mean rise in BP post-saline +I5 mmHg, post-yohimbine +40 mmHg (p 
= 0.0037). No significant differences were found in VD following yohimbine 
or saline (see table). 
CSM Pre-saline Post-saline Pre-yohimbine Post-yohimbine P= 
Mean systolic 0.763 
VD (mmHg) 
Conclusion: Central alpha-2 adrenergic hypersensitivity is not a factor in 
the pathogenesis of the vasodepressor component of CSH. 
Results: 
Group A Group B Group C 
Baseline Peak MS Baseline Peak MS Baseline Peak MS 
CA Diam (cm) 0.61*0.05 0.65f0.07* O&3+0.07 0.65f0.07 0.71+0.07+ 0.6810.08 
TAM (cm/s) 2017 23zlz6 19*6 23zt8* 1814 l&t9 
Flow [ml) 378&128 475&120* 365zL133 4451153* 419zti16 374i137 
Elasticity (%) 813 11*5 7.212.6 6.Ozt4.6 6.6zlz3.8 5.212.3 
Values are mean & SD, ‘p < 0.05 vs baseline, fp < 0.05 vs. groups A and B, ANOVA. 
Elasticity is % change in CA diameter in systole and diastole, TAM = Time 
averaged mean velocity. There was a similar magnitude of increase in heart 
rate and mean blood pressure in response to mental stress in the 3 groups. 
Mental stress-induced change in CA diameter was 5.2 f 3.6, 4.8 i 9.2 and 
-3.3 f 7.8% in groups A, B and C (P < 0.05 group A vs C and group B 
vs C) and change in flow was 34 f 63, 24 5 24 and -9 f 30% in groups 
A, B and C (P < 0.05 group A vs C). CA intima media thickness was 0.045 
f 0.025, 0.056 + 0.018 and 0.099 f 0.06 cm in groups A, B and C (P < 
0.05 group A vs C and group B vs C) and correlated with CA %diameter 
change (r = -0.32, p = 0.047). Baseline systolic blood pressure correlated 
with stress-induced change in CA diameter (r = -0.34, p = 0.03), and in TAM 
(r = -0.43, p = 0.008). 
Conclusion: 1) Mental stress causes CA vascular dilation and increase 
in cerebrovascular blood flow in normal human subjects 2) CA vasodilation 
and increase in cerebrovascular blood flow are impaired in HTN 3) Mental 
stress-induced CA reactivity may be used to assess cerebrovascular flow 
reserve and endothelial function. 
1067-54 increases in Leptin Levels, Sympathetic Drive and 
Weight Gain in Obstructive Sleep Apnea 
Bradley G. Phillips, Masahiko Kate, Ian Choe, Krzysztof Narkiewicz, Virend 
K. Somers. University of lowa, Iowa City lowa; Mayo Clinic, Rochester, 
Minnesota, USA; Medical University of Gdansk, Gdansk, Poland 
Background: Patients with obstructive sleep apnea (OSA) are frequently 
obese and are predisposed to weight gain. They also have heightened 
sympathetic drive. We reasoned that noradrenergic activation of alpha-3 re- 
ceptors on adipocytes would inhibit leptin production, predisposing to obesity 
in sleep apnea. We therefore tested the hypothesis that obesity and pre- 
disposition to weight gain in OSA is associated with low levels of plasma 
leptin. 
Methods: We prospectively studied 32 male patients (43 i 2 years) with 
OSA who were newly diagnosed and never treated, and who were free of 
any other diseases. Control measurements were obtained from 32 similarly 
obese closely matched male subjects (38 i 2 years) who were free of any 
sleep disordered breathing on overnight polysomnography. Neither patients 
nor controls were on any medications. We measured muscle sympathetic 
activity (MSNA), plasma leptin, height, weight, percent body fat, heart rate 
and blood pressure and obtained weight histories over the year prior to entry 
into the study. 
Results: Leptin levels were 13.7 f 1.3 rig/ml in patients with OSA com- 
pared to 9.2 f 1.2 rig/ml in controls (p = 0.02). Sleep apnea patients had 
a 5.2 f 1.7 kg weight gain over the year prior to diagnosis compared to 
similarly obese control subjects who gained 0.5 f 0.9 kg (p = 0.04). MSNA 
in patients with OSA (n = 16) was 46 + 4 bursts/minute compared to 30 & 4 
bursts/minute in control subjects (n = 18) (p = 0.01). 
Conclusion: Plasma leptin levels are elevated in newly diagnosed other- 
wise healthy patients with untreated sleep apnea, beyond the levels seen in 
similarly obese control subjects without sleep apnea. Higher leptin levels in 
OSA, independent of body fat content, suggests that OSA is associated with 
resistance to the weight reducing effects of leptin. 
1067-53 Mental Stress induced Flow Responses in the 
Carotid Artery are Significantly Impaired in 
Hypertensive Subjects 
Tasneem Z. Naqvi, Greg Neymen, Hanh K. Huynh, 
Heidar Sadeghi-Razlighi, C. Noel Bairey Merz. Cedars-Sinai Medical 
Center/UCLA School of Medicine, Los Angeles, CA, USA 
Background: Hypertension (HTN) is associated with impaired coronary and 
peripheral vascular flow reserve, however, its effects on cerebral flow reserve 
remain unclear. 
Methods: High-resolution ultrasound (IO MHz) of the carotid artery (CA) 
was performed before and during mental stress (MS) in 13 young healthy 
volunteers (26 i- 6 yrs, group A), 14 older healthy volunteers (51 f 9 yrs, 
group B) and in 14 patients with HTN (55 i 12 yrs, Group C). Mental stress 
was induced by Stroop Color Word Conflict or Math Test. 
l----d 1067 55 Normalization of Coronary Flow Reserve After Coronary Stenting and a l- and (Y 2-Adrenergic 
Antagonists 
Luisa Gregorini, Jean Marco, Carlo Palombo, Irene Bossi, 
Michaela KozBkov&, Francesco Donatelli, Salvatore Romano, 
lsabelle Marco, Monique Bernies, Christian Jordan, Jean Fajadet, 
Gerd Heusch. Clinique Pasteur, Toulouse, France; Ospedale 
Maggjore-/RCCS, CNR-Clinical Physiology Institute, University of Milan and 
Pisa, /ta/y; Abt. Pathophysiologie, Universit&sklinikum, Essen, Germany 
Coronaty flow reserve (CFR) remains impaired after coronary stenting (S). 
We hypothesized that ol-adrenergic constrictor tone might act to limit CFR. 
In 30 patients undergoing S for an 85 f 5% stenosis and in 15 presumed 
normal controls we evaluated CFR with quantitative coronary angiography 
and intracoronaty flow wires (Cardiometrics). Fifteen minutes after S we 
investigated if CX,-(urapidil 10 mg ic) or ap-(yohimbine 2 mg ic) antagonists 
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superimposed on top of 140-pg/kg/min adenosine infusion might normalize 
the capacity of coronary artery to dilate. CFR was measured before-S, soon 
after-S, 15-min later and after superimposing 011- or ala-antagonists on top of 
adenosine. Epicardial vessels cross sectional area (GSA) was quantitatively 
measured at the wire tip level. The figure shows CFR results (*SD). 
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Conclusions: Both tit- and ala-blockade normalized CFR. 01, -blockers 
mainly dilated conduit vessels CSA, whereas az-blockers dilated only mi- 
crovessels and mainly increased blood flow velocity. 
aortic pressure and hyperemic coronary flow velocity. Measurements were 
averaged over 5 cardiac cycles. 
Results: Hemodynamic variables and peak coronary flow velocity were 
comparable between two pacing modes during hyperemia (AP vs AVP, aver- 
age peak velocity: 62.7 vs 58.1 cm/.sec, mean AoP: 95 vs 96 mmHg, PCWP: 
6.7 vs 8.3 mmHg, Cl: 3.5 vs 3.5 I/min/m2). However, IHDVPS during AVP 
was significantly reduced when compared with that during AP (1.48 vs 2.35 
cm/sec/mmHg, p < 0.05). 
Conclusion: The present study showed that contrary to atrial pacing, 
ventricular pacing is accompanied by reduced diastolic arterial coronary 
conductance. This abnormality may contribute to undesireble change in 
myocardial perfusion in patients with ventricular pacing during daily activity 
and might lead to LV dysfunction in the future. 
1 1067-58 1 High Coronary Blood Flow Velocity and Reynolds 
Number Predict Clinical Outcome After Coronary 
1067-56 Coronary Blood Flow Autoregulation in Left 
Angioplasty 
Ventricular Hypertrophy: Higher Closing Scott Kinlay, Jasmine Grewal, Deborah Manuelian, James Fang, Andrew 
Pressures in African-Americans P. Selwyn, John A. Bittl, Peter Ganz. Brigham & Women’s Hospital, Boston, 
MA. USA 
Mikhail Torosoff, Patricia A. Kuhner, Jan L. Houghton. Albany Medical 
College, Albany N): USA 
Background: Instantaneous intracoronary pressure-flow recordings in pa- 
tients with left ventricular hypertrophy (LVH) demonstrate elevated zero-flow 
(closing) pressures with unchanged pressure-flow slopes suggesting shift 
in coronary autoregulation to the right. African-Americans suffer more mor- 
bid sequela of hypertension and LVH then their Caucasian counterparts, 
however, studies of racial differences in coronary autoregulation are lacking. 
Background: Laminar blood flow may reduce leukocyte infiltration and 
smooth muscle cell proliferation in the arterial intima. However with stenoses, 
laminar flow becomes disturbed as flow velocity exceeds a Reynolds number 
of 200 at the entrance to a stenosis or 400 within a stenosis. 
Methods: Coronary blood flow was assessed in 111 patients using 
Doppler wire velocity measurements and quantitative coronary angiogra- 
phy at baseline and after intracoronay infusion of adenosine. Instantaneous 
pressure-flow slopes (ml/min/mm Hg) and closing pressures (mm Hg) were 
determined using least-square linear regressions. Twenty-five African-Amer- 
icans (14 with LVH) and 39 Caucasians (9 with LVH) had valid regression 
models. 
Methods: We estimated the blood flow velocity and Reynolds number in 
coronary arteries after 109 successfullaser-angioplasty cases and examined 
the risk of adverse clinical outomes up to 6 years. Blood flow velocity was 
measured using a validated TIMI frame counting technique and electronic 
calipers were used to measure vessel lengths and diameters. Cox-propor- 
tional hazards analysis was used to estimate the relative risk (RR [95% Cl]) 
of a clinical event. 
Results: Instantaneous pressure-flow slopes were not significantly af- 
fected by the presence of LVH. However, African-Americans (p < 0.005) 
and/or patients with LVH (p < 0.001) had significantly elevated baseline 
and hyperemic closing pressures. Combination of LVH and African-Ameri- 
can race was characterized by the highest hyperemic closing pressures (52 
f 3.3, p < 0.01). Even in the absence of LVH, African-Americans had hy- 
peremic closing pressures exceeding those in Caucasians with LVH (48.3 f 
4.5 vs 44.8 & 3.9). Baseline closing pressures in African-Americans with or 
without LVH was similar to that in Caucasians with LVH (64.2 f 3.8 and 61 .I 
f 3.1 vs 63.7 f 4.0). Lowest baseline and hyperemic closing pressures were 
observed in Caucasians without LVH (51.4 f 2.2 and 39 f 2.7). 
Conclusion: Compared to Caucasians, African-American patients demon- 
strate higher closing pressures at baseline and during hyperemia. Left ventric- 
ular hypertrophy in African-Americans results in disproportionate elevation 
of hyperemic closing pressures. Magnitude of these differences suggests 
pronounced effect of race on coronary vasomotor autoregulation. 
Results: 42 patients developed at least one of the clinical outcomes over 
292 patient-years of follow-up (PTCA = 27, CABG = 7, Ml = 6, death = 
2). Final minimal lumen diameter (mm) (RR = 0.83 [0.47, 1.451) or percent 
stenosis (RR = 1.09 [0.73, 1.641) were not significantly related to clinical 
outcome. However, after adjusting for age, lumen diameter, and unstable 
angina, the risk of an event was significantly higher in those with an average 
target vessel velocity >250 mm/s (RR = 2.3 [I .3, 4.31)) a Reynolds number 
>200 at the reference segment (RR = 2.1 [l.l, 4.01) or a Reynolds number 
>400 within the residual stenosis (RR = 2.5 [1.3, 4.81). 
Conclusion: Measures of blood flow that indicate non-laminar or dis- 
turbed flow at the residual stenosis after angioplasty are associated with a 
worse clinical outcome. Avoidance of disturbed blood flow should become an 
important target for strategies to reduce restenosis and disease progression. 
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Takeomi Murata, Katsuya Hata, Hideyuki Takaoka, Hiroya Kawai, 
Toshiro Shinke, Masakazu Nanahoshi, Daisuke Tsuzuki, Yoichi Kijima, 
Yoshiaki Ueda, Hidenari Matsumoto, Soichiro Ohta, Yoko Miyata, 
Yoshio Yamanaka, Ryohei Yoshikawa, Mitsuhiro Yokoyama. Kobe 
1068-9 Lipid Peroxidation Product 4-Hydroxy-P-Nonenal 
Acts Synergistically With Serotonin in Inducing 
Vascular Smooth Muscle Cell Proliferation 
University Hospital, Kobe, Japan Takuya Watanabe, Raibabu Pakala, Claude R. Benedict, Takashi Kataqiri. 
Background: Recent studies have shown that development of LV dysfunc- 
tion was more common in patients with ventricular than in those with atrial 
pacing. However, the effects of right ventlicular pacing which causes asyn- 
chronous LV contraction and relaxation on coronary flow dynamics have not 
been fully understood. We clinicaly investigated coronary flow dynamics in 
the setting of atrioventricular sequential pacing (AVP) or atrial pacing (AP). 
Division of Carcliolog~~ University of Texas, Houston, TX, USA; Third - 
Department of Internal Medicine, Showa Universifl: Tokyo, Japan 
Objective: Atherosclerotic lesion formation is in part mediated by inflam- 
matory and oxidative mechanisms. To characterize the potential role of 
lipid peroxidation products in atherogenesis, we assessed the effect of 
4-hydroxy-2-nonenal (HNE), a component of oxidatively modified lipids, and 
its interaction with serotonin (5HT) on vascular smooth muscle cells (VSMCs) 
proliferation. 
Methods: We studied IO patients with chest pain syndrome without any 
ECG abnormality at rest. A coronary Doppler guidewire was introduced to 
the proximal portion of left anterior descending coronary artery. 2 minutes 
after introducing AP or AVP at a rate of 15 beats/min above the resting heart 
rate, we administrated 8 mg of papaverine into the left coronary artery, mea- 
sured hemodynamic variables, maximum hyperemic coronary flow velocity, 
and obtained the instantaneous hyperemic diastolic velocity-pressure slope 
index (IHDVPS) as an index to mid-late diastolic arterial coronary conduc- 
tance during each pacing mode. IHDVPS was determined by calculating the 
slope of the linear diastolic segment of the relation between instantaneous 
Methods: Growth-arrested rabbit VSMCs were incubated with different 
concentrations of HNE in the absence or presence of 5HT. VSMCs prolifera- 
tion was examined by increases in [3H]thymidine incorporation into DNA and 
cell number. 
Results: HNE and 5HT stimulated DNA synthesis in a dose-dependent 
manner. HNE had a maximal effect at a concentration of 1 bM (143% of the 
control) and 5HT at 50 MM (211%). When added together even non-mitogenic 
concentrations of HNE (0.01 PM) and 5HT (5 PM) synergistically induced 
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DNA synthesis to 285%. These effects on DNA synthesis were paralleled by 
increases in cell number. A 5HT2 receptor antagonist LY 281067 (IO Fg/mL) 
and pertussis toxin (10 ng/mL) inhibited only the effect of 5HT. Protein tyrosine 
kinase inhibitor erbstatin A (IO wM) completely inhibited the effect of HNE and 
slightly those of 5HT and HNE + 5HT. Protein kinase C inhibitor Ro 31-8220 
(0.1 PM) completely inhibited effects of HNE, 5HT, and HNE + 5HT. Further, 
the synergistic effect of HNE + 5HT on DNA synthesis was reversed to the 
control level by combined use of LY 281067 (IO @g/mL) and antioxidants 
N-acetylcysteine (400 wM), vitamin C (200 PM), or vitamin E (20 MM). 
Conclusions: Our results suggest that HNE acts synergistically with 
5HT in inducing VSMCs proliferation. Combined use of both antiplatelet and 
antioxidant therapies may be useful for the prevention of VSMCs proliferative 
disorders associated with atherosclerosis and restenosis after angioplasty. 
/ 1068 10 lmmunolocalization of Oxidized 
Phosphatidylcholine and Apolipoprotein B in the 
Progression of Human Coronary Atherosclerotic 
Plaques 
Yoshiaki Tsukamoto, Makiko Ueda, Allard C. van der Wal, Chris M. van der 
Loos, Ryushi Komatsu, Yoshihiro Ikura, Masayuki Oogami, 
Toshihiko Matsuo, Hiroyuki Itabe, Tatsuya Takano, Anton E. Becker. 
Academic Medical Center, Amsterdam, The Netherlands; Osaka City 
University Medical School, Osaka, Japan 
Background: Previous experimental studies have shown that oxidized low 
density lipoprotein (OxLDL) plays a key role in atherogenesis and uptake 
of OxLDL by macrophages leads to the generation of foam cells. However, 
some studies have suggested that a lipid core does not develop simply from 
foam cell necrosis, but from a complex interaction of tissue lipoproteins, 
cells, and extracellular matrix. To verify the role of OxLDL in the development 
and progression of human coronary atherosclerotic plaques, in particular, in 
the formation of transitional plaques from early lesions to more advanced 
coronary plaques, we studied the presence of oxidized phosphatidylcholine 
(OxPC), an oxidation specific epitope of OxLDL, and apolipoprotein B (Apo 
B), using immunohistochemical techniques. 
Methods: One hundred and forty-eight segments of coronary arteries 
were harvested at autopsy. Antibodies were used against smooth mus- 
cle cells (SMCs), macrophages (M@s), endothelial cells, T lymphocytes, 
Apo B and OxPC. For the identification of cell types that stain positive 
for OxPC or Apo B, immunodouble (OxPC/Apo B and SMC/M@) and triple 
(SMC/M@/OxPC) stainings were also performed. 
Results: Fibrous plaques containing abundant SMCs without M@ showed 
no staining for OxPC or Apo B. In contrast, fibrous plaques with dense de- 
position of extracellular matrix at the deep intima showed positivity for Apo 
B, but no staining for OxPC. At a lipid core of an atheromatous plaque, there 
was strong positivity for Apo B: but generally no staining for OxPC. However, 
M@derived foam cells around a lipid core revealed distinct positivity for both 
OxPC and Apo B. 
Conclusion: These results strongly suggest that in the development 
and progression of coronary atherosclerosis in humans, not only foam cell 
formation but also direct deposition of lipoproteins in extracellular intimal 
tissues may play an important role. 
/ 1068 i 1 Stretch-Induced Activation of Cardiac Ja/dSTAT 
Pathway is Augmented in the Rat Hypertensive 
Hearts: Role of Endogenous Angiotensin II 
Asuka Yasaka, Wataru Hayashida, Yasuki Kihara, Koichi Inagaki, 
Yoshitaka Iwanaga, Shigetake Sasayama. Kyofo University Graduate 
School of Medicine, Kyofo, Japan 
Background: JaWSTAT (janus kinase/signai transducer and activator of 
transcription) pathway has been implicated in the development of cardiac 
hypertrophy. We studied whether this pathway is involved in stretch (me- 
chanical load)-induced signal transduction in the hypertensive hearts, using 
the Dahl salt-sensitive (DS) rats. 
Methods: The DS rats fed high-salt diet developed systemic hypetten- 
sion (230 i. 17 mmHg) and compensated concentric left ventricular (LV) 
hypettrophy (LVibody weight: 2.8 f 0.3 g/kg) at the age of 11 weeks (LVH, 
n = II), whereas the rats fed low-salt diet maintained normal blood pressure 
and LV weight (1.9 + 0.2 g/kg, controls, n = 9). The heart was isolated and 
perfused on the Langendotff preparation. Equivalent stretch (diastolic wall 
stress = 30 kdyne/cm2) was imposed on the isovolumic, contracting heart 
by LV balloon dilatation at adjusted diastolic pressure of 25 mmHg (controls) 
or 36 mmHg (LVH). Then, LV myocardial samples were obtained. Activation 
(tyrosine phosphorylation) of Jak kinases and STAT proteins was assayed 
by the immunoprecipitation-western blot analysis. 
Results: In the control rats, stretch rapidly induced activation of cardiac 
Jaki/2 and Tyk2, which was followed by activation of STATlw peaked at 15 
minutes. In the LVH rats, the maximal activation of Jak kinases and STAT was 
more pronounced (Jakl:l.8-fold, Jak2:2.0-fold, Tyk2:l.Cfold, and STATla: 
2.2-fold of the control rats, all p < 0.05) and sustained to 30 minutes. Car- 
diac angiotensin converting enzyme mRNA level (quantitative RT-PCR) and 
endogenous angiotensin II production (radioimmunoassay) were increased 
(2.9- and 1.7-fold, respectively, p < 0.05) in the LV myocardium of LVH rats, 
indicating the presence of enhanced cardiac renin-angiotensin system in this 
model. Pretreatment with an angiotensin AT1 receptor antagonist, valsalfan 
(1 PM, 15 minutes) suppressed the increased STATla activation in the LVH 
rats to a comparable level of that in the control rats. 
Conclusion: The present data suggest that Jak/STAT pathway plays an 
important role in the progression of LV hypertrophy against the increased 
mechanical load due to hypertension. The augmented Jak/STAT activation 
is partially mediated by increased local production of angiotensin II via AT1 
receptor-dependent pathways. Thus, cardiac Ja!&TAT pathway may be a 
potential target for pharmacological intervention of pathological hypertrophy. 
I 1068 12 Inhibition of Vascular Cell Adhesion Molecule Expression by High Density Lipoproteins 
Dale T. Ashby, Kerry-Anne Rye, Jennifer R. Gamble, Mathew A. Vadas, 
Philip J. Barter. Royal Adelaide Hospital, Adelaide, Australia 
Background: High density lipoproteins (HDLs) have been shown in vitro 
to inhibit the expression of adhesion molecules on endothelial cells. These 
studies investigate the effects of HDL subpopulations, HDL composition 
and acute-phase HDLs on vascular cell adhesion molecule-l (VCAM-I) 
expression in endothelial cells. 
Methods: The HDLs were isolated from human plasma by sequential ul- 
tracentrifugation. HDL apolipoprotein composition was modified by displacing 
apoA-I with apoA-II or serum amyloid-A (SAA). The various HDL populations 
isolated were added at increasing concentrations to cultures of human um- 
bilical vein endothelial cells (HUVECs). The cells were then stimulated with 
tumour necrosis factor-a and VCAM-I expression was determined by flow 
cytometry. 
Results: All types of HDLs tested inhibited VCAM-I expression in a 
concentration dependent manner. HDLs was a superior inhibitor of VCAM-I 
expression than HDLZ when added to the cells according to apoA-I or total 
cholesterol concentration. Acute phase HDLs containing SAA were as effec- 
tive as unmodified HDLs in the inhibition of VCAM-1 expression. Altering the 
apolipoprotein composition of the HDLs by displacing the apoA-I with either 
apoA-II or SAA made no difference to the inhibitory ability of the HDLs. HDLs 
were broken down into their lipid and protein components and neither of 
these alone had any inhibitory effect on VCAM-1 expression in the HUVECs. 
Reconstituted HDLs containing only apolipoproteins and phospholipids had 
the ability to inhibit VCAM-I expression in the HUVECs. 
Conclusion: The ability of HDLs to inhibit endothelial VCAM-I expression 
is independent of their apolipoprotein composition and the HDLs need both 
apolipoproteins and phospholipids to be present. 
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/ 1069 17 Cardiovascular Disease and Prognosis in Adults 
with Glucose Disorders: The Strong Heart Study 
Jennifer E. Liu, Vittorio Palmieri, Mary J. Roman, Jonathan N. Bella, 
Richard R. Fabsitz, Elisa T. Lee, Thomas K. Welty, Barbara V. Howard, 
Richard B. Devereux. Weill Medical College of Cornell University, New York, 
NK USA 
Background: Diabetes mellitus (DM) is an established risk factor for car- 
diovascular (CV) morbidity and mortality. However, whether the relations 
of this association to concomitant cardiovascular (CV) risk factors and left 
ventricular (LV) abnormalities are unclear. 
Methods: We analyzed LV structure and function and conventional CV 
risk factors in relations to CV events (Es) (n = 130) and death (D) during 
3 year follow-up in participants in the 2nd the Strong Heart Study (SHS) 
examination with normal glucose tolerance (NGT) n = 888; impaired glucose 
tolerance (IGT) n = 457 or diabetes mellitus (DM) n = 1643 by WHO criteria. 
Results: Participants with IGT or DM were slightly older (60, 60 yrs) with 
higher body mass index (BMI 32, 32 kg/mz), higher systolic blood pressure 
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(SBP) (133, 129 mm Hg) and higher proportion of women (66%, 69%) as 
compared to participants with NGT (age 59 yrs, BMI 29, SBP 133 mmHg, 
51% woman; all p < 0.05). LV mass and LV mass inclexed/heightz.7 were 
highest in the IGT and DM groups (158 and 164 gm; 42 and 44 gm/htZ,7) 
as compared to the NGT group (152 gm and 38 gm/htz.7, p < 0.001). Ejec- 
tion fraction (EF) and stress-corrected midwall shortening were lowest in the 
DM group (62%, 102%) as compared to IGT (64%, 107%) and NGT (63%, 
107%). The CV morbid Es was 6.0% in the DM group as compared to 2.7% 
in the non-DM group (RR 2.2,95%CI 1.5-3.3). The CVD was 1.8% in the DM 
group as compared to 0.7% in the non-DM group (RR 2.6, 95%CI 1.2-5.6). 
Comparing to the participants with NGT group, those with IGT had slightly 
higher incidence of CV death (0.9% vs 0.6%, RR 1.5, 95%CI 0.4-5.7). In 
multivariate analyses adjusting for age, gender, BMI, hypertension, systolic 
blood pressure, LV mass and serum LDL-cholesterol, DM remained inde- 
pendently associated with CVEs (RR 1.96, 95%CI 1.3-3.0) and showed less 
strongly to CVD (RR 2.0, 95%CI 0.9-4.5, p = 0.07); substitution of LVEF for 
LV mass left DM independently associated with CVEs (RR 1.9, Cl 1.3-3.0) 
and confirming a clear trend-association with D (RR 2.0, 95%CI 0.9-4.4). 
There was no difference in prevalences of CVEs or D between IGT vs NGT 
in multivariate analysis. 
Conclusion: DM and IGT are associated with higher LV mass, lower 
systolic LV function and higher CVD. DM is independently associated with 
CV morbid events and deaths after adjusting for LV status and conventional 
risk factors. 
1069-l 8 Relation of Insulin to Left Ventricular Geometry 
and Function in African-American and White 
Hypertensive Adults: The HyperGEN Study 
Richard B. Devereux, Giovanni de Simone, Vittorio Palmieri, 
Albert Oberman, Paul N. Hopkins, Dalane W. Kitzman, DC. Rao, Donna 
K. Arnett. Weill Medical College of Cornell Universi% New York, NY; USA 
Background: Although it has been suggested that the trophic effects of 
insulin (I) might contribute to left ventricular (LV) hypertrophy in hypertension, 
few population-based data exist to test this hypothesis or to assess the 
potential impact of insulin level on LV systolic function or diastolic filling. 
Methods: Fasting plasma I levels (log-transformed) in 1,512 non-dia- 
betic African-American or white hypertensive participants in the Hypertension 
GeneticEpidemiologyNetwork(HyperGEN)echocardiographysubstudywere 
compared to measurements of LV geometry and function, with adjustment for 
potentially confounding effects age, gender, body mass index and height. 
Results: In simple correlation analysis, a weak positive relation (r = 
0.066, p = 0.01) existed between LV mass and log I, principally due to strong 
correlations (r = 0.49-0.50) of both variables to body mass index. Partial 
correlation, adjusting for age, gender, race, body size and systolic blood 
pressure, revealed a modest negative relation between log I and LV mass (r 
=. 11, p < 0.001) due to a negative relation of log I with LVchamber dimension 
(r = 0.12, p < 0.001) and no significant relation of log I to LV wall thicknesses; 
these results were confirmed in additional analysis controlling for a positive 
relation (r = 0.19, p < 0.0001) of log I to heart rate. After adjustment for 
covariates, there were no significant relations of log I to LV ejection fraction, 
stress-corrected midwall shortening or cardiac output; however, log I was 
negatively related to the E/A ratio of diastolic transmittal flow (r = -0.12) and 
the isovolumic relaxation time (r = -O.Og)(both p < 0.002). 
Conclusions: After adjustment for body mass index and other covariates, 
log I in non-diabetic hypertensives is weakly related to lower LV chamber size, 
LV mass and to markers of LV diastolic filling. Thus, I does not play a major 
independent role in the pathogenesis of hypertensive LV hypettrophy or 
dysfunction. 
1 1069-l 9 1 Left Ventricular Mass and Metabolic Syndrome: 
The HyperGEN Study 
Giovanni de Simone, Vittorio Palmieri, Jonathan N. Bella, Aldo Celentano, 
Albert Oberman, Dalane W. Kitzman, Paul N. Hopkins, Yuling Hong, Donna 
K. Arnett, Richard B. Devereux. For HyperGEN Investigators; Weill Medical 
College of Cornell Universify, New York, NY; USA 
Background: A combination of metabolic risk factors (MRF: obesity (body 
mass index >30 kg/m’), diabetes (fasting glucose ~126 mg/dl or medi- 
cations), hypercholesterolemia (>200 mg/dl or medications) is frequently 
associated with arterial hypertension. 
Methods: 2,096 hypertensive (95.7% treated, 1,293 women, 1,348 blacks) 
and 393 normotensive (196 women, 207 blacks) participants from Hypertension 
Gene!ic Epidemiology Network Study were selected to investigate whether 
combined MRF are associated with higher prevalence and severity of LV 
hypettrophy (H). Imaging and Doppler echocardiograms were performed lo- 
cally in 4 centers and read centrally. LV mass (M) was indexed for height2.7 
or fat-free mass (FFM, bioelectric impedance). 
Results: Obesity, hypercholesterolemia, diabetes and prevalent cardio- 
vascular diseases were more frequent among hypertensives than in nor- 
motensives (all p < 0.0001). After controlling for age, gender and race, 
systolic blood pressure (SBP), LVM/height2.7 and LVM/FFM increased with 
increasing numbers of MRF. LVM/heightz.7 and LVM/FFM increased with in- 
creasing numbers of MRF even adjusting for SBP in addition to age, gender 
and race (all p < 0.001). Prevalence of LVH was associated with older age, 
prevalent cardiovascular events, presence of significant valve regurgitation, 
hypertension, central fat distribution, black race and independently increased 
with increasing number of associated MRF (all p < 0.001). 
Conclusions: Additional exposure to metabolic risk factors independently 
contributes to the magnitude of LV mass, supporting the need of a global 
cardiovascular prevention in the management of arterial hypertension. 
1 1069-20 1 Aggregation of Metabolic Abnormalities, 
Overweight and High Blood Pressure, in Young 
Subjects Followed Up for a lo-Year-Period. The 
Rio de Janeiro Study 
Andrea A. Brandlo, Roberto Pozzan, Maria Eliane Magalhses, Aytton 
P. Brandso. State University of Rio de Janeiro, Rio de Janeiro, Brazil 
Background: Early identification of cardiovascular risk factors (RF) has 
been emphasized in order to promote primary prevention. We investigated 
the aggregation of high blood pressure (BP), overweight, and metabolic 
abnormalities in young subjects, according to their BP and body mass index 
(BMI) obtained 10 years earlier. 
Methods: 211 young subjects (111 M) were evaluated at a IO-year fol- 
low-up visit, stratified according to their BP and BMI obtained at their schools 
in 1987/88 (12.69 & 1.65 y) and at the hospital in 1997/98 (21.60 & 2.01 y). 
BP was measured 3 times, and the third measure was used for analysis. Sub- 
jects were considered normotensive when BP percentile was 550 at school 
or <140/90 mmHg at the hospital; hypertensive when BP percentile was ?95 
at school or 3140/90 mmHg at the hospital. The cut-off points for BMI were 
85th percentile at school and 25 kg/m’ at the hospital. At each evaluation, 
subjects were classified as normotensive with normal BMI (N/N), normoten- 
sive with overweight (N/O), hypertensive normal (H/N), hypertensive with 
overweight (H/O). After 10 years, BP, BMI, cholesterol (C), tryglicerides (TG), 
LDL-C, HDL-C, glucose and insulin (I) were measured after 12 h of fasting. 
Results: 1) Groups were not differentiated by age or sex; 2) From 93 
N/N at school, 77 (82.8%) remained N/N, 11 (34.4%) became N/O, 1 (4%) 
H/O. From 9 N/O, 2 (22.2%) remained N/O, 5 (55.6%) became N/N, 2 
(22.2%) H/O. From 71 H/N, 15 (21 .I%) remained H/N, 43 (60.6%) became 
N/N, IO (14.1%), H/O. From 38 H/O at school, 12 (31.6%) remained H/O, 9 
(23.7%) became N/N, 16 (42.1%) N/O (x2 = 78.13 p < 0.0001); 3) Group 
H/O at school had higher BP and BMI (p < O.OOOl), C (p < 0.02), TG 
(p < 0.01) and log I (p < 0.02) IO years later; 4) Of the N/N 100% had 
normal I (~30 ng/dL), while 11.4% in H/O and 14.3% in N/O had abnormal 
values (p < 0.03); 5) After IO years;95 (93.1%) normotensives remained 
normotensives (Gl), 38 (34.9%) hypertensives remained hypettensives (G2), 
7 normotensives became hypertensives (G3) and 71 hypertensives became 
normotensives (G4). In Gl, 81.1% remained without overweight; in G2, 
31.6% remained overweight and 26.3% became overweight; in G3, 28.6% 
remained overweight; and in G4, 60.6% remained without overweight and 
12.7% were no longer overweight (x2 = 43.89 p < 0.0001); 6) Looking for 
RF aggregation, in Gi, 74.5% didn’t have any RF, while 91.8% from G2 had 
1 to 3 RF (p < 0.0001); 7) In logistic regression, BMI was the only variable 
correlated with abnormal BP (p < 0.02). 
Conclusion: Early BP alterations, mainly if associated with overweight, 
were markers for metabolic abnormalities, higher BP and BMI in young 
-subjects, IO years later. This outcome reinforces the concept that primary 
prevention should begin early in life. 
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1069-21 Genetic Influences of Obesity and Blood Pressure 
Kazuko Masuo, Hiroshi Mikami, Hideki Kawaguchi, Toshio Ogihara, Michael 
L. Tuck’ Osaka Universiry Medical School, Suita City Osaka, Japan; 
‘Sepulveda VA Medical Center, Sepulveda, CA, USA 
Background: It is well known that obesity is a leading factor for hypertension. 
However, the precise relationships between genetic influence of obesity 
(family history of obesity), obesity (BMI) and blood pressure level (BP) was 
not fully clarified. This study was conducted to clarify the contributions of 
genetic influences of obesity to BP level, sympathetic activity, plasma insulin 
and leptin levels. 
Methods: A positive family history of obesity (FH+) was defined as both 
parents were obese (BMI > 26 kg/mz), and a negative family history of 
obesity (FH-) was defined as both parents were lean (~22 kg/m2). 22 lean, 
young normotensives (NT) with FH-, 13 obese NT with FH-, 16 lean NT with 
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FHc and 21 obese NT with FH+ were measured BP, pulse rate, BMI, plasma 
norepinephrine (NE), insulin and leptin after overnight fast. All subiects were 
men and non-diabetic. The study design was the 4.corners methob. 
Results: BP, pulse rate and NE were significantly higher in obese FH+ > 
obese FH- > lean FH+ > lean FH- (mean BP: iOO*# > 93* > 91# > 86 
mmHg, NE: 341**# > 268* > 196# > 129 pgiml, *P < 0.05, *“P < 0.01 vs 
lean NT, #P < 0.05 vs FH-). In obese NT, plasma leptin level in FH+ was 
higher than FH- (13.4*# > 9.1 rig/ml), but in lean NT, plasma leptin was 
similar between FH+ and FH- (5.3, 3.4 ngiml). Obese NT had higher fasting 
plasma insulin than lean NT (23.4 vs 7.8 fiU/ml), but insulin level in FH+ was 
similar to that in FH-. Only in FH+ subjects regardless of BMI, plasma NE (r 
= 0.38, P x 0.05) and leptin (r = 0.49, P i 0.01) correlated with those in their 
parents, but those relations were not noted in FH-. 
Conclusion: These results suggest that a positive family history of obe- 
sity (genetic factor of obesity) -induced sympathetic overactivity is more 
closely linked to BP elevation than hyperleptinemia and hyperinsulinemia. 
It is probable the sympathetic activation with genetic influences of obesity 
is a major mechanism of obesity-related hypertension. On the other hand, 
hyperleptinemia appears to relate with genetic factor-induced BP elevation 
only in obese, not lean, subjects. Hyperinsulinemia and hyperleptinemia may 
be ancillary factors. Genetic factor of obesity associated with sympathetic 
overactivity and hyperleptinemia is one of the predictors of BP elevation. 
/ 1069-22 / importance of Obesity and Hypertension to the 
Relation Between Age and Left Ventricular Mass 
Rafael Kuperstein, Patrick Hanly, Mitra Niroumand, Chris O’Connor, 
Jeffrey Perl, Kristina Thornley, Zion Sasson. Mount Sinai Hospifal and Saint 
Michael’s Hospital, Toronto, Canada 
Background: Obesity and hypertension (HTN) are both major determinants 
of left ventricular mass (LVM). They often coexist and tend to increase 
with age. The effect of age on LVM is controversial, partly because of the 
confounding effects of obesity and HTN in previous reports, and exclusion of 
significant obesity in others. 
Methods: We prospectively measured LVM in 879 (676 men) consecutive 
mostly obese patients undergoing cardiopulmonary testing. Mean age was 
49.2 f 12.3 (16 to 92 years). Mean BMI was 33.3 f 8.1 (16 to 75.6 kg/m*). 
522 patients were obese (BMI > 30 kg/m*) and 58 had a previous history 
of coronary artery disease (CAD). 2D guided M-mode echocardiographic 
measurements were made according to the ASE criteria. LVM was calculated 
(Devereux formula) and corrected for height (LVM/Ht). Clinical data was 
obtained by history and review of medications. 
Results: In multivariate analysis, using age as a continuous variable and 
including obesity and HTN as factors, we found that in lean individuals and 
in obese normotensives age had no effect on LVM/Ht. When obesity and 
HTN coexisted, age had a significant effect on LVM/Ht. The inclusion of CAD 
in the model did not change our findings (table). Similar results were found 
when analyzing men and women separately. 
Table: Muitivariaie analysis of the effect of age (correded for CAD) on LVM/Ht in relation 
to obesity and HTN 
Normotensive Hypertensive 
n LVM/Ht (g/m) P n LVM/Ht (g/m) P 
Lean 311 87.1 * 20.0 ".S. 46 95.7 f 31.2 n.s. 
Obese 339 109.3 * 37.5 n.s. 183 119.7 f 32.7 0.004 
For every decade of increasing age, LVM/Ht increases by 6.5 g/m in 
obese hypettensives. 
Conclusion: Age appears to be an independent determinant of LVMiHt 
only in the subgroup of patients with concomitant obesity and hypertension. 
1069-23 Obesity and 24-Hour Blood Pressure Variation 
Alexander Butkevich, Robert A. Phillips. Mount Sinai Medical Center, New 
York, New York, USA 
Background: Obesity is associated with increased risk of hypertension and 
cardiovascular events. We examined the hypothesis that obesity is also 
associated with blunted nocturnal blood pressure decline (dipping). Since 
hypertensive non-dippers have a greater risk of cardiovascular events than 
dippers with similar levels of blood pressure, decreased dipping may explain 
in part why the absolute risk of cardiovascular events is higher in hypertensive 
individuals with high than with low body mass indices (BMls). 
Methods: We examined the frequency of dipping in 217 untreated sub- 
jects (age 52 i 15 yr) referred for 24-hour ambulatory blood pressure (BP) 
monitoring to our institution. Subjects were divided into quintiles of BMI. Dip- 
ping was defined as nocturnal (IOPM-7AM) decrease of 10 mmHg in systolic 
BP. 
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Results: Increase in BMI over 27 kg/m’ was associated with a significant 
decrease in the frequency of nocturnal dipping (figure). In a multiple logistic 
regression analysis adjusting for age and sex, the odds ratio of BMI > 27 for 
non-dipping was 3.1 (P < 0.001). 
Conclusion: Obesity is associated with decreased nocturnal BP dipping. 
This may account in part for increased risk of cardiovascular events in obese 
individuals. 
I 1069 24 Echocardiographic Comparison of Left Ventricular Structure and Function in 
Hypertensive Patients With Primary 
Aldosteronism and Essential Hypertension 
Ronen Goldkorn, Jon Blumenfeld, Dawn Fishman, Richard B. Devereux, 
Alexei P. Yurenev. New York Hospital-Cornell Medical Cenfer, New York, 
New York, USA; The Russian Cardiovascular Research Institute, Moscow, 
Russia 
Background: In experimental renovascular hypertension, aldosterone has 
been implicated in myocardial remodeling and fibrosis, but it is uncertain 
whether excess aldosterone affects left ventricular (LV) structure and function 
in hypertensive patients. 
Methods: LV structure and function were compared by echocardiography 
between age and sex matched patients with primary aldosteronism (PA) and 
essential hypertension (EH) Hypertensive patients from the Cardiovascular 
Center of the New York Hospital -Cornell Medical Center in New York and the 
Russian Cardiovascular Research Institute, Moscow, Russia, were studied. 
The sample included 35 patients with PA and 35 controls with EH matched for 
age, sex, and blood pressure. LV mass, endocardial and midwall fractional 
shortening, and circumferential end-systolic stress (cESS) were calculated. 
The observed/predicted midwall shortening ratio was used as an index of LV 
performance corrected for afterload. 
Results: PA and EH patients had comparable LV dimensions, wail thick- 
ness, mass, mass/BSA, and mass/height2.7. Endocardial and midwall frac- 
tional shortening, and afterload-corrected midwall shortening were similar in 
PA and EH groups from both clinics. Moreover, logistic regression analy 
sis using blood pressure, body mass index, height, gender, and center as 
covariates failed to identify statistical differences in LV geometry or systolic 
function between PA and EH patients. 
Conclusion: Patients with PA, a state characterized by chronic aldos- 
terone excess, had similar LV geometry and systolic function to EH patients 
matched for age, gender and blood pressure. This argues against important 
independent associations between aldosterone and these aspects of LV in 
human hypertension. 
ORAL 
18321 Thrombosis: Clinical Investigation 
Monday, March 13, 2000, 9:15 a.m.-IO:30 a.m. 
Anaheim Marriott, Marquis Northeast 
9:15 a.m. 
832-l Acute Antithrombotic Effect of a Front-Loaded 
Regimen of Clopidogrel on Arterial Thrombus 
Formation in Patients With Atherosclerosis on 
Aspirin 
GQrard Helft, Julio I. Osende, Stephen G. Worlhley, Oswald0 Rodriguez, 
Azfar G. Zaman, Eli Lev, Michael Farkouh, Valentin Fuster, Juan 
J. Badimon, James H. Chesebro. Mount Sinai School of Medicine, New 
York, New York, USA 
Background: Clopidogrel is an effective treatment in the setting of coronary 
stent implantation. A limitation is the time required to achieve its antithrom- 
botic effects. Our objective was to investigate whether a front-loaded regimen 
(FR) of clopidogrel could accelerate its antithrombotic activity compared to 
the standard regimen (SR). Patients (n = 24) with atherosclerotic disease on 
chronic aspirin therapy were randomized to receive a front-loaded (300 mg 
day 1 with 75 mg daily thereafter) versus the standard (75 mg day 1 with 7.5 
mg daily thereafter) regime. 
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Methods: Thrombus formation was assessed blindly with a previously 
validated ax viva perfusion chamber system, using blood drawn from the 
brachial vein, at two hours the first day and at day 8, at shear conditions typical 
of a mild coronary stenosis (1690/s). Thrombus formation was measured 
using computer assisted planimetty (~ms/mm). Platelet aggregation was 
determined in platelet-rich plasma (PRP) using ADP (10, 5, 2.5 PM). Platelet 
activation was assessed by flow cytometric analysis of ADP-induced (0.12 
and 0.6 JLM) platelet surface binding of fibrinogen. 
Results: In the FR, the thrombus decrease was already significant and 
maximal at 2 hours, as no further significant reduction was noted at day 8. 
There was no significant reduction in thrombus formation at 2 hours in the 
SR. Both groups showed a similar reduction in thrombus formation at day 8 
(see table). 
Patients Baseline 2 hours 
Front-Loaded 14316i5946 10870 i 5931* 
Standard 13971 i 6357 11691 + 8547 
*P < 0.05, versus baseline. Values as mean + SD. 
day 8 
9948 f 6994’ 
9830 f 3123* 
Similar findings were obtained with platelet aggregation and activation, 
confirming a significant (p < 0.01) inhibition in platelet reactivity in the FR 
group at 2 hours, but not at this time point in the SR. 
Conclusions: Afront-loaded regimen of clopidogrel achieves asignificant 
antithrombotic effect at 2 hours, an effect not achieved with the standard 
regimen, in patients with known atherosclerotic disease already on aspirin. 
This provides the basis for the efficiency of a loading dose of clopidogrel in 
acute coronary syndromes and coronary stent implantation. 
9:30 a.m. 
I 832 2 Argatroban Provides Effective and Safe Anticoagulation in Patients With Heparin-Induced 
Thrombocytopenia: A Prospective, Historical 
Controlled Study 
Bruce E. Lewis, Diane E. Wallis, William Matthai. For the ARG-911 Study 
Investigators; Loyoia University Medical Center, Maywood, IL; and the 
University of Pennsylvania, Philadelphia, PA, USA 
Background: Heparin-induced thrombocytopenia (HIT) is an immune-medi- 
ated syndrome caused by heparin usage, with complications ranging from 
thrombocytopenia alone to thrombocytopenia with thrombosis. This prospec- 
tive, historical controlledstudyevaluated the efficacy and safety of argatroban, 
a direct thrombin inhibitor, as anticoagulant therapy in patients with HIT. 
Methods: Continuous intravenous argatroban was administered starting 
at 2 ugikglmin for, on average, 6 days to 304 patients with HIT. Two study 
arms included patients having at enrollment thrombocytopenia alone (HIT 
arm, N = 160) or thrombocytopenia with thrombosis (HIlTS arm, N-144). 
Dosage was adjusted to maintain the activated partial thromboplastin time 
(aPTT) 1.5-3x the baseline value. Clinical outcomes during a 37-day study 
period were compared with those of 193 controls (HIT arm, N = 147; HITTS 
arm, N-46). 
Results: The incidence of the primary efficacy endpoint, a composite of 
all-cause death, ail-cause amputation or new thrombosis, was significantly 
reduced in the argatroban-treated patients versus controls in the HIT arm 
(25.6% vs. 38.8%, P = 0.014) with a trend in the HITTS arm (43.8% vs. 
56.5%, P = 0.131). In addition, by time-to-event analysis of the composite 
endpoint, significant between-group differences favored argatroban in both 
the HIT arm [P = 0.010, hazard ratio = 1.68 (95% Cl: 1.12-2.51)] and 
HITTS arm [P = 0.014, hazard ratio = 1.75 (95% Cl: 1.10-2.76)]. Argatroban 
therapy, relative to controls, also significantly reduced new thrombosis and 
death due to thrombosis in both study arms. Further, argatroban-treated 
patients rapidly achieved adequate anticoagulation and, relative to controls, 
significant platelet count improvement. Bleeding events were not different 
between the groups. 
Conclusion: Argatroban anticoagulation, compared to historical controls, 
improves clinical outcomes, without increasing bleeding risk, in patients with 
HIT syndrome. Argatroban is therefore an effective and safe therapeutic 
option for these critically il l patients who require anticoagulation. 
9:45 a.m. 
832-3 Losartan Therapy Reduces Thrombin-Receptor 
Agonist-Induced Platelet Aggregation 
Pave1 J. Levy, Carla Yunis, John Owen, K. Bridget Brosnihan, 
Salah Kivlingh, Carlos M. Ferrario. Hypertension & Vascular Disease 
Center, Wake Forest University School of Medicine, Winston-Salem, North 
Carolina, USA 
Background: Losartan is a selective, competitive antagonist of the TxA2 
receptor in experiments using isolated vascular strips and whole animals (Li 
et al.). However, there has been no evidence that AT1 blockade may reduce 
platelet aggregability in humans treated with an angiotensin receptor blocker. 
Methods: We examined changes in thrombin-receptor agonist-induced 
platelet aggregation (TRA) in 9 untreated controls and 9 Stage 1 or 2 essential 
hypettensives (28% men, 72% white, age 46 & 12 yr.). After a 4-wk washout 
period hypertensive subjects received 2 wk of placebo followed by 4 wk of 
losattan 50 mg/QD. Both subjects and end-points were blinded for treatment 
assignment. 
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Results: A 24% increase in the EC50 of TRA-induced platelet aggregation 
was observed in losattan-treated subjects, compared to no increases in the 
placebo-treated hypettensives and normal controls (Figure). These effects 
we independent of age, gender, race or changes in BP. 
Conclusion: This data demonstrates for the first time a novel antiplatelet 
effect of losartan at therapeutic doses, in essential hypertension subjects, 
The cardioprotective effect of losattan contributing to the reduction in cardiac 
sudden death observed in the ELITE trial may be related to a reduction in 
platelet aggregability. 
1O:OO a.m. 
1 832-4 1 Comparative Effects of Paroxetine and Nefazodone 
on Human Platelet Aggregation and Vascular 
Reactivity 
Eliza Geer, Josiah Child, Daichi Shimbo, Saul Maayani, Satish Reddy, 
Juan Badimon, Valentin Fuster. Mount Sinai School of Medicine, New York, 
New York, USA 
Background: Depression is associated with increased risk of cardiac death 
among survivors of myocardial infarction (Ml). Paroxetine, the treatment of 
choice for depression in patients with cardiovascular disease, was recently 
shown to inhibit nitric oxide synthase (NOS) activity in vivo as well as reduce 
exercise tolerance. suggesting that it may not be the ideal agent for treating 
depressed patients with cardiovascular disease. The etiology of the increased 
risk for cardiac death associated with depression may be related to the 
up-regulation of the serotonin 2A (5-HT2A) receptor. Nefazodone, an atypical 
antidepressant that is equally efficacious for treating depression, blocks the 
5-HT2A receptor as well as the uptake pump. We sought to investigate the 
platelet and vasoactive properties of paroxetine and nefazodone. 
Methods: Using an impedance model, we compared whole blood platelet 
aggregation (to ADP, collagen, and serotonin/epinephrine (5-HT/EPI)) in 
5 subjects after in-vitro pre-treatment with paroxetine or nefazodone. In 
addition, we used an ex-vivo organ bath model with Spraque-Dawle rat 
artery (n = 4) to test the effects of paroxetine and nefazodone on carbachol 
induced endothelial dilatation and 5-HT induced vasospasm. 
Results: Paroxetine significantly increased platelet aggregation at 6 min- 
utes by 17% (95% Cl, ii-35%) and significantly inhibited carbachol induced 
endothelial dilatation (from 66.8% to 34.5% of the total relaxation achieved 
with sodium nitroprusside). In contrast, nefazodone inhibited platelet aggre- 
gation to 3 I.LM ADP by 22% (95% Cl, 1429%) and reduced the aggregation 
to 5-HT/EPI by 87% (95% Cl, 50-l 00%). In rat artery, nefazodone nonsig- 
nificantly increased endothelial dependent relaxation (66.8% to 74.9%), and 
inhibited 5-HT induced vasospasm. 
Conclusions: Paroxetine and nefazodone appear to possess properties 
that may substantially influence their effectiveness in treating the increased 
cardiac risk associated with depression. Given the association between de- 
pression and cardiovascular disease, antidepressant agents with anti-platelet 
effects may have significant clinical implications. Traditional antidepressants, 
such as paroxetine, may not be ideal agents to treat post-MI depression. Due 
to its anti-platelet effects, nefazodone may prove to be a more appropriate 
agent for treating depressed patients with cardiovascular disease. 
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832-5 Oral Consumption of Purple Grape Juice Inhibits 
Platelet Function and Increases Platelet-Derived 
Nitric Oxide Release 
Crawford Parker, Leslie Deak, Balz Frei, John D. Folts, Jane E. Freedman. 
Georgetown University Medical Center, Washington, D. C.; University of 
Wisconsin Medical School, Madison, Wisconsin, USA 
Moderate red wine consumption is inversely associated with coronary is- 
chemia. Red wine and purple grape juice (PGJ) contain flavonoids with 
antioxidant and antiplatelet properties believed to be protective against car- 
diovascular events. Acute cardiac events, caused by platelet activation and 
thrombosis, are also associated with decreased platelet-derived nitric ox- 
ide (NO) release. Therefore, we investigated the effect of oral consumption 
of PGJ on platelet function and NO release. Normal healthy subjects (n = 
22) consumed PGJ (7 cc/kg/day) for 14 days. After consumption of PGJ, 
platelet aggregation induced by ADP, collagen, and the PKC-dependent ag- 
onist PMA decreased by 18.3%, 32.1%, and 33.2% for ADP, collagen, and 
PMA, respectively, as compared to baseline (P x 0.05, P < 0.05, P < 0.0003, 
respectively). As measured with an electrochemical detector, platelet NO re- 
lease increased after consumption of PGJ from 3.5 pmol/l OS platelets to 6.0 
pmol/lO* platelets (P 5 0.05, n = 11). Because superoxide interacts with NO 
and limits its bioavailability, we measured platelet superoxide release in a 
lumiaggregometer before and after PGJ consumption. After PGJ consump- 
tion, platelet superoxide release decreased 35% as compared to baseline (P 
5 0.04, n = 18). In addition, consumption of PGJ led to increased plasma 
cu-tocopherol levels (15.6 f 0.7 JLM to 17.6 + 0.9 PM; P 5 0.008) but plasma 
vitamin C levels were unchanged. These data indicate that oral consump- 
tion of PGJ decreases platelet aggregation, increases platelet-derived NO 
release, and decreases superoxide production. These findings may be due 
to antioxidant-sparing or direct effects of the flavonoids found in PGJ. These 
observations represent a potential mechanism for the beneficial effects of 
purple grape products, independent of alcohol consumption, in cardiovascu- 
lar disease. 
ORAL 
/833/ Outcomes Evaluation in Acute Coronary 
Syndromes 
Monday, March 13, 2000, 9:15 a.m.-l 0:30 a.m. 
Anaheim Marriott, Marquis Northwest 
9:15 a.m. 
833-l Physician Characteristics and Variation in Treatment 
for Acute Myocardlal Infarction 
Jersey Chen, Martha J. Radford, Yun Wang, Harlan M. Krumholz. Yale 
University New Haven, Connecticut, USA 
Background: Whether physician characteristics other than specialty con- 
tribute to variation in the patterns of care after acute myocardial infarction 
(AMI) has not been extensively studied. 
Methods: After linking physician characteristics from the American Medi- 
cal Association’s Physician Mastetfile with 41676 physicians treating 108963 
Medicare beneficiaries hospitalized with AMI in 1994-95 in the national Co- 
operative Cardiovascular Project, we examined whether the use of aspirin or 
beta-blockers after AMI varied by physician employment setting or duration 
from medical school graduation. 
Results: Among patients without contraindications to therapy, we found 
significant differences in the use of therapy according to physician em- 
ployment (solo, partnership, group) for the use of aspirin (51.7%, 54.6%, 
56.5%) and beta-blockers (46.2%. 48.1%, 50.4%) at admission, and for the 
use of aspirin (71.5%, 75.6%, 79.6%) and beta-blockers (46.3%, 50.6%, 
53.3%) at discharge. We also found differences according to year of med- 
ical school graduation (~1970, 1970-1979, ~1980) for the use of aspirin 
(52.6%, 54.7%, 57.1%) and beta-blockers (47.1%, 49.1%, 50.3%) at admis- 
sion, and for the use of aspirin (72.2%, 76.5%, 80.0%) and beta-blockers 
(49.1%, 51.0%, 53.5%) at discharge. These differences remained significant 
in logistic regression models which adjusted for patient demographics, clini- 
cal presentation and comorbidity, hospital characteristics, geographic region 
and physician specialty. 
Conclusion: Physicians who were more recently trained and who were 
employed in larger groups were more likely to prescribe aspirin and beta- 
blockers after AMI. These findings suggest that physician characteristics 
other than specialty are potentially important factors in explaining variation 
in treatment for AMI in the elderly. 
9:30 a.m. 
833-2 The Prognostic Value of Troponin in Patients With 
Non-ST-Elevation Acute Coronary Syndromes: 
A Meta-Analysis 
Paul A. Heidenreich, Thomas Alloggiamento, Vivian Hagan, 
Kathryn Melsop, Kathryn M. McDonald, Alan S. Go, Mark A. Hlatky. Palo 
A/to VA Palo A/to, California; Stanford University Stanford, California, USA 
Background: Troponin T and I are used to identify high-risk patients with 
chest discomfort suggestive of ischemia. We reviewed the published literature 
to determine the predictive value of troponin level on risk of death for patients 
with non-ST-elevation acute coronary syndromes. 
Methods: We identified cohort studies repotted through 1998 using MED- 
LINE and EMBASE databases. Studies were included if they reported tro- 
ponin T or I levels and subsequent death in patients with suspected non-ST- 
elevation acute coronary syndromes. Studies were excluded if they were of 
case-control design, or if they only included patients with myocardial infarc- 
tion. Summary estimates of relative risk were determined using fixed effects 
models. 
Results: There were 13 trials that fit the inclusion criteria (3 comparing 
troponin T and I, 8 of troponin T alone, and 2 of troponin I alone, Table). 
The mean age of the included patients was 61 years, 67% were male, and 
the median follow up was 4 weeks. Three studies used rapid bedside tests. 
The mortality rate for troponin negative patients was 1.9% compared to 
6.7% for troponin positive patients. The summary relative risk was 3.9 (95%, 
confidence interval 2.9 to 5.3). There was no clear difference in mortality 
between patients with positive troponin T and troponin I (p = 0.10). 
Troponin Trials Negative test % Positive test % Summary 
(DeathsiTiotal) (Deaths/Total) RR (9woCI) 
I 5 1.6 (3712356) 6.3 (7511199) 5.0 (3.4-7.5) 
T 11 2.2 (6112781) 8.0 (9711206) 3.4 (2.54.7) 
Both* 13 1.9 (6813634) 6.7 (123/1849) 3.9 (2.9-5.3) 
* If trials reported both T and I data one marker’s result was randomly selected for the 
combined analysis. 
Conclusions: The risk of death is approximately 4-fold higher in patients 
with suspected non-ST-elevation acute coronary syndrome and a positive 
troponin test. 
9:45 a.m. 
833-3 Hospital Characteristics and Treatment of Acute 
Myocardial Infarction: Role of Ownership and 
Teaching Status 
Saif S. Rathore, Andrew J. Epstein, Kevin P. Weinfuti, Alan K. Berger, 
William J. Oetgen, Bernard J. Gersh, Kevin A. Schulman. Georgetown 
University Medical Center, Washington, DC; Mayo Foundation, Rochester, 
MN; Delmarva Foundation for Medical Care, Easton, MD, USA 
Background: Hospital ownership and teaching status may influence treat- 
ment of myocardial infarction (MI). 
Methods: We linked data from the Cooperative Cardiovascular Project, a 
sample of Medicare beneficiaries treated for Ml between l/94 and 2/96 and 
the 1995 American Hospital Association Survey to examine the influence of 
hospital characteristics on MI treatment. Patients age 65 years and older with 
hospital data (n = 153,346) were classified into 9 groups based on a com- 
bination of hospital ownership (public [PUB], not-for-profit [NFP], for-profit 
[FP]) and teaching status (Council of Teaching Hospitals [COTH], non-COTH 
teaching [SOME], none [NON]). Logistic regression models evaluated the 
provision of aspirin on admission (ASA-ADM) and discharge (ASA-ADM) and 
,&blockers on discharge (j3-BLK). Models adjusted for patient demographics, 
treatment contraindications, illness severity, physician specialty and hospital 
features including rural location, geographic region, cardiac care facilities, 
Ml volume, Medicare volume and casemix. NFP-NON hospitals were the 
referent group. 
Results: Influence of teaching status varied by hospital ownership. Pa- 
tients treated at NFP hospitals with any teaching program were more likely 
to receive ASA-ADM (NFP-COTH OR: 1.64,95% Cl: 1.52,1.78; NFP-SOME 
OR: 1.20,95%CI: 1.14, 1.27),ASA-DIS(NFP-COTHOR: 1.17,95%CI: 1.10, 
1.26; NFP-SOME OR: 1.14,95% Cl: 1.08,1.20) and fl-BLK (NFP-COTH OR: 
1.17, 95% Cl: 1.05, 1.32; NFP-SOME OR: 1.14, 95% Cl: 1.08, 1.20). In con- 
trast, patients at PUB hospitals were more likely to receive therapy only if 
treated at PUB-COTH hospitals (ASA-ADM OR: 1.64, 95% Cl: 1.30, 2.07; 
ASA-DIS OR: 1.75, 95% Cl: 1.45, 2.11; fl-BLK 0R:NS). Finally, patients at 
FP hospitals were less likely (OR < 1.00) to receive ASA-ADM, ASA-DIS 
and B-BLK regardless of teaching status. 
Conclusion: Ml treatment varies by hospital ownership and teaching 
status combinations. 
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I 833 4 Effect of Managed Care Market Share on Treatment 
of Fee-for Service Patients With Myocardial 
Infarction 
Paul A. Heidenreich, Mark McClellan, Craig D. Frances, Laurence C. Baker. 
Palo Alfo VA Palo Alto, California; Sfanford University Stanford, California, 
USA 
Background: Managed care (HMO) activity may affect the medical care for 
non-enrollees if it alters local market structure or physician behavior. We 
wished to determine whether greater HMO market share is associated with 
greater use of recommended therapies for fee-for-service Medicare patients 
with myocardial infarction. 
Methods: We used chart review (Cooperative Cardiovascular Project) 
data from 129,596 fee-for-service Medicare patients residing in metropolitan 
areas. HMO market share was determined from surveys for each of 320 
metropolitan areas in the U.S. Ideal candidates for use of beta-blockers, 
aspirin, ACE inhibitors and coronary angiography, were determined using 
previously published guidelines. 
Results: After adjustment for metropolitan area characteristics, ideal ther- 
apy candidates residing in areas with high levels of managed care (230% 
market share) were more likely to receive beta blockers and aspirin dur- 
ing hospitalization and discharge, but were less likely to receive coronary 
angiography (Table) than were ideal candidates residing in areas with low 
managed care (<I 0% market share). Adjusted 1 -year mortality was similar 
(relative risk of death in high HMO vs. low HMO areas: 0.94, 95% confidence 
interval 0.90 to 0.99). 
Medication 
ASA in-howital 
ASA at discharge 
B-blocker in-hospital 
B-blocker at discharge 
Angiography 
in-hospital 
Ideal Use 
Candidates % 
45.902 84 
Use High HMO Area/Use Low 
HMO Area Ratio 
(95%CI) 
1.02 (1 .oo to 1.041 
33;926 76 I .05 ii .02 t0 I .08j 
16,504 50 1.11 (1.04to1.19) 
14,747 48 1.15(1.05to1.25) 
28,328 50 0.90 (0.84 to 0.97) 
ACE inhibitor at discharge 9,468 61 0.99 io.90 t0 i .07j 
Conclusions: Elderly patients with fee-for-service insurance that resided 
in areas with high HMO activity were more likely to receive appropriate aspirin 
and B-Blocker treatment but less angiography. 
lo:15 a.m. 
833-5 Who Gets Left Ventricular Function Assessment 
After Acute Ml? A Population-Based Study in 
Olmsted County, MN 
Tauqir Y. Goraya, Guy S. Reeder, Steven J. Jacobsen, Susan A. Weston, 
Veronique L. Roger. nlrapo C/inic, Rochester, II&‘, USA 
Background: Knowledge of left ventricular (LV) function in acute Ml patients 
helps predict outcome and select appropriate candidates for specific medical 
(ACE inhibitors) and surgical (CABG) therapies. While this suggests that LV 
function assessment should be performed in all MI patients, little is known 
about the overall use, time trends and selection factors of such testing in 
community dwelling persons with acute Ml. 
Methods: The use of tests measuring LV function (echocardiography, 
radionuclide and LV angiography) was examined in residents of Olmsted 
County, Minnesota who were hospitalized for an acute Ml (ICD9 code 410, 
n = 2710), between 1979 and 1994, to test the hypothesis that LV function 
was being measured more frequently over time. Patient demographic and 
clinical characteristics were examined for their association with the use of 
these diagnostic tests. 
Results: For the study period, 67% of the patients underwent an assess- 
ment of LV function within 90 days of the acute MI. Utilization rates increased 
between 1979 and 1985 (23% to 72%, P for trend 0.003) but did not change 
significantly thereafter (79% in 1994, Figure). More men than women (71% 
vs 62%, P < O.OOl), underwent an evaluation of LV function. While patients 
who had testing for LV function were significantly younger (median age 69 
vs 75 years, P < O.OOl), size of MI, as reflected by peak CK, was similar in 
the two groups. Patients not subjected to an evaluation of LV function had a 
higher Charlson comorbidity index (P < 0.001) and were more likely to have 
a history of prior MI or heart failure (ICD9 codes 428 and 402, P < 0.001). 
46% of those with a prior history of CHF did not undergo an evaluation of LV 
function within 90 day after the index Ml. 
Conclusions: These population-based data suggest that, despite an 
increase in their use with time, tests for LV function afler acute MI remain 
underutilized even in a setting with widespread availability like Olmsted 
County, Minnesota. Lower use of these tests in women and sicker patients 
(older, greater comorbidity, history of Ml or CHF) highlights the need to 
analyze the impact of this practice on outcome. 
ORAL 
pzbg Molecular Cardiology: Vascular Injury and 
Cardioprotection 
Monday, March 13,2000, 1l:OO a.m.-l 2:15 p.m. 
Anaheim Marriott, Marquis Northeast 
II:00 a.m. 
1 841-I 1 The Endothelial Cell-Specific Angiogenic Factor 
Deli Mediates Smooth Muscle Cell Adhesion and 
Migration 
Mehrdad Rezaee, Kalyani Penta, Thomas Quertermous. Cardiovascular 
Medicine, Stanford UniversiQ Stanford, CA 94025, USA 
Background:The developmental endothelial cell locus-l (Dell) gene en- 
codes a matrix protein that is specifically expressed in endothelial ceils 
associated with vascular development in the embryo and in pathological an- 
giogenesis in the adult. Deli contains epidermal growth factor repeats similar 
to those found in notch family proteins, with one of the EGF repeats contain- 
ing the RGD recognition motif commonly recognized by cell surface integrins. 
Dell has been shown to have angiogenic activity in the chick chorioallantoic 
membrane and other angiogenesis assays. In order to investigate a potential 
role for Dell in the assembly of the blood vessel wall, experiments have 
evaluated the ability of Dell to mediate fundamental activities of smooth 
muscle cells. 
Methods and Results: Functional studies demonstrated that Dell pro- 
motes adhesion of human aottic smooth muscle cells (VSMCs) in a dose- 
dependent fashion at concentrations of 5-50 nM. Competition experiments 
with RGD containing peptides suggested that adhesion was integrin medi- 
ated, with olv-specific peptides blocking adhesion of VSMCs to Dell by 85%. 
In addition, a blocking antibody directed against 0rvg3 decreased adhesion by 
58%, while antibodies to oil, 012, ~3, or5, and or6 failed to inhibit adhesion. Fur- 
thermore, Dell promoted migration of VSMCs in a modified Boyden chamber 
system and this activity was shown to compete for vitronectin-induced mi- 
gration. Plating of VSMCs on Deli was associated with clustering of olva3 
integrin receptors in focal contacts, phosphorylation of cytoplasmic signaling 
molecules in these structures, and the organization of actin filaments. 
Conclusions: These data indicate that Dell can function as a chemoat- 
tractant and adhesion molecule for VSMCs by signaling through the ava3 
integrin receptor. The expression of Dell by endothelial cells involved in 
blood vessel formation implicates this novel protein in the recruitment and 
assembly of smooth muscle cells in the vessel wall. Through combined activ- 
ities initiating angiogenesis and supporting development of the vessel wall, 
Dell may have a unique ability to promote stable vascular formation in the 
context of native and therapeutic angiogenesis. In addition, reactivation of 
Dell expression in regions of vascular injury may mediate smooth muscle 
cell migration and proliferation through integrin-mediated signaling. 
11:15 a.m. 
1 841-2 1 Cytomegalovirus Infection of Human Macrophages 
Induces Increased Expression of Scavenger 
Receptor CD36 Gene and Cell-Surface Glycoprotein 
Benjamin D. Horne, John F. Carlquist, Jessica Habashi, Joseph 
B. Muhlestein, Jay Greenwood, Jeffrey L. Anderson. LDS Hospital & U of 
Utah, Salt Lake Cifx Utah, USA 
Background: Foam cells arc the hallmark of coronary atherosclerosis, 
largely consisting of macrophages filled with oxidized low-density lipopro- 
tein (ox-LDL). Macrophages bind ox-LDL for uptake via the scavenger re- 
ceptor CD36. Other evidence suggests an association for cytomegatovirus 
(CMV) with coronary artery disease. We tested whether CMV infection of 
macrophages increases expression of CD36 gene and cell-surface receptor 
protein. 
Methods: Human macrophages from the monocytic leukemia cell line 
THP-1 were treated in one of three ways: infected with CMV, treated with 
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a non-specific stimulant phorbol 12-myristate 13-acetate (PMA), or left un- 
treated (controls). Cells from each group were analyzed by reverse tran- 
scription polymerase chain reaction to determine mRNA expression. Flow 
cytometry measured CD36 protein expression in other cells of each type 
by treatment with either a non-specific isotype-control antibody or a specific 
anti-CD36 antibody. 
Results: CMV infection resulted in increased CD36 gene transcription 
(upper figure) and increased cell-surface expression (lower lefl & upper 
figures) compared to uninfected control cells. 
MV-infected Cells 
Conclusion: In vitro infection of human macrophages by CMV increases 
the expression of CD36 mRNA and receptor glycoprotein. This result not only 
supports the idea that infection contributes to atherosclerosis, but provides a 
possible mechanism contributing to atherogenesis. 
II:30 a.m. 
/ 841-3 1 Plasma Lipoprotein (a) is Predictive of a History of 
Vascular Disease But Not the Risk of Carotid 
Atherosclerosis 
Brenda” M. McQuillan, Joseph Hung, Christine Chin, Mark Nidorf, Peter 
L. Thompson, John P. Beilby. Heart Research Instifufe, Sir Charles Gairdner 
Hospital and Clinical Biochemistry, PathCenfre, Queen Hizabeth II Medical 
Centre, Perth, Western Australia, Australia 
Background: Lipoprotein (a) (Lp(a)) is thought to be an important risk marker 
for cardiovascular disease. It is uncertain, however, whether its effects are 
mediated predominantly via prothrombotic pathways or in the formation of 
atherosclerosis. 
Methods: We examined if Lp(a) is associated with the risk of carotid 
atherosclerosis, family history of premature coronary artery disease (CAD) 
or a personal history of CAD or stroke in a randomly selected cross-sectional 
population, consisting of 1111 subjects (558 males, 553 females), age-range 
27 to 77 (mean i SD, 53 f 13) years. Ail subjects were assessed for 
conventional risk factors and B-mode carotid ultrasound examination for 
intima-media thickness (IMT) and focal plaque. Increased IMT was defined 
as subjects with mean IMT in the upper quintile for the entire cohort. Plasma 
Lp(a) concentration was measured spectrophotometrically using the Lp(a) 
reagent kit from Beckman. 
Results: Plasma Lp(a) levels (mean f SD) were similar in males (24 i 31 
mg/dL) and females (28 * 36 mg/dL, P= 0.09). Plasma Lp(a) was correlated 
with LDL-cholesterol (Spearman Rho (rs) = 0.14, P = O.OOl), HDL (r, = 0.10, 
P = 0.001) and age (rs = 0.12, P = 0.001). Compared with other subjects, 
plasma Lp(a) was elevated in those with a family history of CAD (30 vs 25 
mg/dL, P= 0.02) and a personal history of vascular disease (30 vs 25 mg/dL, 
P = 0.005). Plasma Lp(a) was a univariate correlate of mean carotid IMT (rs = 
0.08, P= 0.01). However, plasma Lp(a) was not predictive of increased IMT 
or focal carotid plaque and there was no residual association with mean IMT 
in multivariate analysis. Plasma Lp(a) remained an independent predictor 
for history of vascular disease after adjustment for conventional risk factors 
including elevated LDL-cholesterol. 
Conclusion: While plasma Lp(a) is associated with clinical vascular 
events and a family history of premature CAD, we found no independent 
association with carotid atherosclerosis. This may support the hypothesis 
that Lp(a) increases the risk of vascular disease via prothrombotic pathways. 
II:45 a.m. 
I 841 4 Thromboxane AZ Potentiates Mitogenic Effect of 
Mildly Oxidized Low Density Lipoproteins on 
Vascular Smooth Muscle Cells 
Shinji Koba, Takuya Watanabe, Takashi Katagiri, Rajbabu Pakala, Claude 
Pi. Benedict. Showa Universifl: Tokyo, Japan; University of Texas, Houston, 
TX, USA 
Background: We have previously shown that mildly oxidized low density 
lipoprotein (mox-LDL) induced vascular smooth muscle cell (VSMC) prolif- 
eration. Since aggregating platelets at sites of atherosclerotic injury release 
thromboxane Aa (TX-AZ), a known mitogen for VSMC, we examined whether 
TX-As can potentiate the mitogenic effect of LDL or mox-LDL on VSMC. 
Methods: Mild oxidation of LDL was induced by incubation with Cu++ 
which increased the thiobarbituric acid reactive products (30 pmolimg protein) 
with no change in electrophoretic mobility. Primary aortic rabbit VSMCs were 
grown in 10% and then 0.1% fetal bovine serum for 72 hours. Then cells 
were incubated with different concentrations of LDL or mox-LDL for 24 hours 
followed by incubation withTX-As (U46619) for another 24 hours. The amount 
of 3H-thymidine incorporated into the DNA was then measured. 
Results: (Table) LDL or mox-LDL induced significant VSMC proliferation 
by themselves (ANOVA, p G 0.0001). Compared to native LDL, the effect of 
mox-LDL was potentiated by TX-As. The synergism between mox-LDL and 
TX-A* was observed at subthreshould concentration of TX-A*. 
Serum free 
TX-A* (-) TX-A, 0.5 WM TX-A2 5.0 fiM 
100 i 19 Gontroll 105f29 120*31* 
LDL 120 Il.glmL 168*37** 177 * 4a** 167 i 27”’ 
Max-LDL 120 uo/mL 184 zk 18”* 301 i 54*.** 316 i 65*+* 
Values are %3H-thymidine incorporation i SD. Control = 100%; *p < 0.05 compared 
with corresponding TX-As free group, ““p < 0.05 compared with corresponding serum 
free group (BonferroniiDunn) 
Conclusion: These results suggest that even low concentration of throm- 
boxane As released from aggretgating platelets may potentiate the mitogenic 
effect of mildly oxidized LDL at sites of vascular damage. 
Noon 
841-5 Cardioprotection, During Ischemia-Reperfusion in 
the Dog, Induced by Chronic Angiotensin II Type 1 
Receptor Blockade Involves Enhanced Angiotensin 
II Type 2 Receptor and Protein Kinase C Protein 
Expression 
Yi Xu, Darryl W. O’Brien, Vijayan Menon, Bodh I. Jugdutt. University of 
Alberta, Edmonton, Alberta, Canada 
Background: We hypothesized that cardioprotection, during ischemia-reper- 
fusion in the dog, induced by chronic angiotensin II (Angll) type 1 receptor 
blockade (AT, R) blockade involves enhanced Angll type 2 (ATsR), IPsR (I, 
4, 5-inositol trisphosphate type 2 receptor) and PKC, (protein kinase C-F) 
protein expression. 
Methods: We measured in vivo hemodynamics and left ventricular (LV) 
remodeling and function (2D-echocardiograms/Doppler) as well as ex vivo 
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infarct size (as percent risk region) and AT, R, ATsR, IPsR and PKC, proteins 
(immunoblots) in dogs with acute ischemia-reperfusion (IR). AT, R blockade 
was produced by losartan (Los) and WP269-6 (UP; UPSA, France) in optimal 
oral doses for 7 days to five groups of 3 dogs (sham; sham + Los or UP: 
IR alone; IR + Los; IR + UP). Acute IR consisted of 90 min of left anterior 
descending coronary artery occlusion followed by 90 min of reperfusion. 
Results: More marked ATtR blockade with UP (greater inhibition of 
Angll pressor responses) was associated with greater decrease in blood 
pressure, less increase in LV filling pressure and smaller LV diastolic and 
systolic volumes after IR. Both UP and Los reduced infarct size. Acute IR 
alone decreased ATI R, ATpR, IPsR and PKC, proteins while both Los and 
UP increased ATtR (mRNA, not protein) and ATaR (mRNA and protein) 
expression as well as IPsR and PKC, proteins during IR. 
Conclusion: Chronic AT, R blockade is cardioprotective during acute IR 
in the dog. The results suggest that this acute cardioprotective effect of 
chronic ATlR blockade on acute IR involves both ATt and AT2 receptors, 
and possibly ATaR activation and downstream signaling via IPsR and PKC,. 
ORAL 
I 842 Neurohormones and Advances in 
Hypertension and Heart Failure 
Monday, March 13, 2000, 11:OO a.m.-12:15 p.m. 
Anaheim Marriott, Marquis Northwest 
11:OO a.m. 
842-l The Superior Renal and Humoral Actions of Acute 
Dual NEPlACE Inhibition by Vasopeptidase Inhibitor 
Versus ACE Inhibition Alone in Experimental Mild 
Heart Failure: Properties Mediated Via Potentiation 
of Endogenous Cardiac Natriuretic Peptides 
Horng H. Chen, John G. Lainchbury, Gail J. Harty, John C. Burnett, Jr.. 
Mayo Clinic, Rochester, MN, USA 
Background: Mild heart failure (HF) is characterized by increases in the 
cardiac natriuretic peptides (NP), atrial natriuretic peptide (ANP) and brain 
natriuretic peptide (BNP), without activation of the renin-angiotensin-aldos- 
terone system (RAAS). The NP are degraded by the ectoenzyme neutral 
endopeptidase 24.11 (NEP) which is widely expressed in both the kidney 
and vascular wall. As the NP are activated in mild HF without the activation 
of RAAS, we hypothesized that the vasopeptidase (VP) inhibitor, Omapa- 
trilat (OMA) which co-inhibits both NEP and angiotensin-convening enzyme 
(ACE) would have superior renal and humoral actions in mild HF compared 
to ACE inhibition alone and that such actions would involve the NP. 
Methods: We defined the cardiorenal and tumoral actions of a) acute VP 
inhibition with OMA (Bristol-Myers Squibb, 1 kmol/kg iv bolus, n = 6), b) acute 
ACE inhibition (ACEI) alone with Fosinoprilat (1 +mol/kg iv bolus, n = 5) and 
c) acute VP inhibition with OMA (1 ymollkg iv bolus) together with intra-renal 
administration of natriuretic peptide receptor antagonist, HS-124-l (HS, 0.5 
mg/kg iv bolus, n = 5), in anaesthetized dogs with mild HF produced by 
pacing at 180 beatdmin for 10 days. 
Results: OMA resulted in a greater natriuretic response as compared 
with ACEI*. This OMA mediated natriuresis was associated with increased 
plasma cGMP*, ANP*, BNP*, urinary cGMP* and glomerular filtration rate* 
(* p < 0.05 OMA vs ACEI). Pulmonary capillary wedge pressure decreased 
only in the OMA group while plasma renin activity increased only in the ACEI 
group (p < 0.05 vs baseline). Intra-renal HS attenuated the favorable renal 
effects of OMA versus ACEI and was associated with decreased urinary 
cGMP excretion and increased renin activity despite similar increases in 
plasma ANP and BNP. 
Conclusions: This study reports for the first time that the favorable renal 
actions of acute VP inhibition as compared to ACE inhibition in mild HF is in 
part secondary to the potentiation of ANP and BNP. This study provides new 
insight into a unique new therapeutic strategy that has beneficial actions in 
mild heart failure beyond those observed with ACE inhibition alone. 
11:15 a.m. 
842-2 Angiotensin II Increases Superoxide Production in 
Human Arteries: An Angiotensin Type 1 Receptor 
Specific Mechanism 
Colin Berry, Carlene A. Hamilton, Anna F. Dominiczak, John J.V. McMurray. 
University of Glasgow, Glasgow, UK 
Background: Recent observations in humans both in vivo and in vitro sug- 
gest that angiotensin II (ang II) can increase vascular superoxide (0;) anion 
production. We sought to characterise the mechanisms involved in ang II 
mediated 0; production in human blood vessels. 
Methods: Internal mammary arteries (IMA) were collected from patients 
undergoing coronary revascularisation surgery. 5 mm rings were incubated 
in the absence (control) or presence 1 pmol/L of ang II, or 1 wmol/L of nore- 
pinephrine (NE) for 4 hours. Ang II-incubated rings were also co-incubated in 
the presence or absence of an NADH oxidase inhibitor, diphenyleneiodonium 
(DPI, 100 fimol/L) or a competitive and specific angiotensin II type 1 (AT,) 
receptor antagonist, losartan (1 PmoliL). 
Results: Ang II increased 0; production in IMA (control = 978 f 117 
pmol/min/mg, 1 wmol/L ang II 1690 f 213 pmol/min/mg; n = 27, p < 0.0001, 
95% Cl 336,925O) whereas NE 1 wmol/L, which was used as a positive 
control, did not (control 731 f 323 pmol/min/mg, NE 636 f 241; n = 10, 
p = 0.76). Losartan 1 pmol/L had no effect on basal 0; production but 
blocked the ang II-mediated increase of 0; production (losartan 947 Z!Z 245 
pmol/min/mg, losartan + angiotensin II 1037 pmol/min/mg tissue; n = 11, p = 
0.15). DPI 100 wmol/L inhibited the ang II mediated increase in 0; production 
(control 1124 pmol/min/mg, DPI 100 ~mol/L1055 pmol/min/mg; n = 8, p = 
0.9). Isometric tension studies in IMA rings confirmed losartan was effective 
in blocking angiotensin II-induced vasoconstriction. 
Conclusion: We report, for the first time in human arteries, that ang II 
increases 0; production by an ang II type 1 receptor specific, NADH oxi- 
dase-dependent mechanism. These observations suggest a therapeutic role 
for AT, receptor antagonists in reducing oxidative stress in cardiovascular 
disease. 
11:30 a.m. 
842-3 Tocopherols and Human Platelet Aggregation 
Dayuan Li, Tom Saldeen, Jawahar L. Mehta. University of Florida and VA 
Medical Center; Gainesville, Florida, USA; University of Uppsala, Uppsala, 
Sweden 
Background: Supplementation of diet with synthetic tocopherol (ol-toco- 
pherol) as well as natural tocopherol (y-tocopherol) has protective effect 
against coronary artery disease (CAD) events. Studies from our laboratory 
show that both a-tocopherol and v-tocopherol (v-tocopherol > a-tocopherol) 
inhibit arterial thrombogenesis (JACC, 1999). 
Methods: The present study was designed to examine the relative po- 
tentcies of a-tocopherol, v-tocopherol and S-tocopherol on human platelet 
aggregation. Human platelets were incubated with three different tocopherols 
(120, 240, 360, and 480 FM) for 30 minutes. 
Results: All three tocopherols markedly and similarly decreased ADP-in- 
duced platelet aggregation in a concentration-dependent manner. All three to- 
copherols also decreased lipid peroxidation product malondialdehyde (MDA) 
and increased platelet nitric oxide (NO) generation, measured as nitrite 
levels, in aggregated platelet supernatants (P < 0.05 vs. control). The com- 
bination of three tocopherols (relative concentrations as found in vegetables 
and fruits) had a more potent effect on platelet aggregation, and MDA and 
NO generation (P < 0.05.~~. each tocopherol alone). 
Conclusion: These observations suggest that tocopherols attenuate 
platelet aggregation via a decrease in free radicals and increase in NO gen- 
eration Combination of tocopherols, as found in nature, has a synergistic 
effect. 
11:45 a.m. 
842-4 Effect of Matrix Metalloproteinase Inhibitors on 
Atherogenesis 
R. Bashir, P. Mazola, D. Lucca, G. Grimes, E. Jonas, C. Saladino. St. 
Elizabeth Medical Center, Boston, MA; Nassau County Medical Center, 
East Meadow, NY and State University of New York at Stony Brook, USA 
Background: Recent studies have shown that matrix metalloproteinase 
(MMP) inhibitors may have a beneficial role in stabilizing an unstable coro- 
nary plaque. We studied the effect of Ro 31-9790 - a synthetic collagenase 
and gelatinase inhibitor on the process of atherogenesis using our Sprague 
Dawley rat model. 
Methods: Twenty-five rats were equally divided into following five groups: 
1) control group, 2) rats which received 20% lipofundin-S intravenously at 
a rate of 6 gms/kg/day for 10 days, 3) rats that received MMP inhibitor (Ro 
31-9790) intraperitoneally at a rate of 100 mgs/kg every other day’for 10 days, 
4) rats receiving both MMP inhibitor and lipofundin-S at the same rate as the 
above two groups, 5) rats that received only saline in the same volume as 
the lipids. On the Ilth day, rats were sacrificed and glutaralaldehyde-infused 
thoracic aorta was immediately removed and processed for transmission 
electron microscopy (TEM). 
Results: There were no differences seen between the control, saline and 
MMP inhibitor-only groups, both on light microscopic (LM) and on TEM. In 
the lipid-only group, LM revealed multiple focal areas of irregularity which 
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on TEM showed extensive endothelial damage with mononuclear cell inva- 
sion of the subendothelial space. At these sites large platelet aggregates 
were seen with a broken and fragmented internal elastic lamina (IEL). The 
smooth muscle cells (SMC) displayed stellate appearance, contained nu- 
merous pinocytic vesicles, and were seen penetrating or in close proximity to 
the luminal surface along with bundles of collagen. In the group that received 
both lipids and MMP inhibitor, the LM revealed very few irregular areas as 
seen in the lipid only group. TEM showed minimal endothelial damage or 
platelet aggregation. There was no evidence of SMC migration, the IEL was 
continuous without any breaks; however, the SMC were seen to have a per- 
pendicular orientation to the IEL. In addition, subendothelial space was filled 
with flocculent material. 
Conclusion: The animal study illustrates that MMP inhibitor (Ro 319790) 
may have a beneficial effect on the process of atherogenesis by reducing 
early myofibroelastic changes induced by elevated serum lipids. 
Noon 
I *_ 842 5 Cerwastatin Inhibits Inducible NO Synthase and Amekorates End-Organ Damage in Rats With High 
Human Hypertension 
J.K. Park, D.N. Muller, E.M.A. Mervaala, F. Schmidt, M. Bieringer, 
W.-H. Schunk, D. Ganten, H. Haller, F.C. Luft. Franz Volhard Clinic and Max 
Delbriick Center for Molecular Medicine, Humboldt University of Berlin, 
Germany 
Background: Recently, clinical trials showed that statins are effective in 
prevention of end-organ damage. However, the benefits could not be fully 
explained on the basis of cholesterol reduction. We tested the hypothesis 
that cerivastatin prevents induction of inducible NO synthase (iNOS) and 
ameliorates end-organ damage. 
Methods: We treated rats transgenic for human renin and angiotension 
(dTGR) chronically from week 4 to 7 with cerivastatin (0.5 mg/kg by gavage). 
Results: Untreated dTGR developed moderate hypertension, cardiac hy- 
pertrophy, severe renal damage with a IOO-fold increased albuminuria, and 
focal necrosis in heart and kidney. Mortality of untreated dTGR at week 7 was 
50%. Cerivastatin treatment decreased systolic blood pressure compared to 
dTGR (147 + 14 vs 201 f 6 mmHg, p < 0.001). Albuminuria was reduced 
by 60% (p = 0.001) and plasma creatinine was also lower (0.45 f 0.01 vs 
0.68 f 0.05 mg/dl, p = 0.003). Monocyte infiltration in heart and kidney was 
reduced by 60% and 70%, respectively. We then investigated if inflammation 
in the kidney is accompanied by induction of INOS. lmmunohistochemical 
analysis showed increased iNOS expression in the endothelium and media of 
small vessels, infiltrated cells, afferent arterioles, and glomeruli of dTGR. Im- 
munoreactivity was stronger in the cortex than medulla. Cerivastatin markedly 
reduced iNOS expression in both cortex and medulla. lmmunostaining of pro- 
liferative cells in the kidney detected by mAb MIB-5 (family member of the 
Ki-67 complex) was significantly reduced by cerivastatin compared to dTGR. 
Cerivastatin reduced inflammation, cell proliferation, and iNOS induction, 
which led to a reduction of cell damage. 
Conclusion: Our findings indicate that HMG-CoA reductase inhibition 
ameliorates angiotensin II-induced end-organ damage probably via the re- 
duction of iNOS expression. 
POSTER 
/ 1089 Endothelial Dysfunction 
Monday, March 13,2000, Noon-2:00 p.m. 
Anaheim Convention Center, Hall A 
Presentation Hour: 1:00 p.m.-2:OO p.m. 
L-.-z-i 1089 41 Influence of Aging on Vascular Effects of 
Thrombin: Role of Endothelium-Derived Nitric 
Oxide and Vasoconstrictive Prostaglandins 
Christine E. Barandier, Severin Urech, Thomas F. Liischer, Zhihong Yang 
Inst. of Physiology, Univ. Ziirich-lrchel; Univ. Hospital Ziirich, Switzerland 
Background: Thrombin (TB) possesses multiple functions on platelets and 
vascular wall cells. TB stimulates platelet activation and induces endothelial 
cell (EC)-dependent relaxation and causes smooth muscle cell (SMC) con- 
traction. In the present work, we studied the mediators released from EC and 
SMC stimulated by TB and the influence of aging. 
Methods: Two groups of rats (3 months = young and 9 months = old) 
were used. Isometric tension of isolated aortic rings was recorded. 
Results: In quiescent aortic rings of young rats, TB (2U/ml) induced only a 
marginal vasoconstriction (2.7 f 0.7% of 100 mM KCI), markedly enhanced 
by endothelial removal (26.8 f 3.3%, p < 0.05) and partially prevented 
by the thromboxaneiendoperoxide receptor antagonist X1-30741 (10-7M, 
16.2 f 4.3%, p c: 0.05). In the aortic rings with endothelium, inhibition of 
endothelial nitric oxide synthase (eNOS) by L-NAME (10m4M) did not fully 
unmask the vasoconstriction to TB (14.0 i 3.6%, p < 0.05) which was almost 
completely abolished by SO-30741 (6.2 f 1.5%). In the old rat aortic rings 
with endothelium, TB (2U/ml) evoked a more pronounced vasoconstriction 
than in young rats (8.7 & 3.2%, p < 0.05). This contraction was markedly 
enhanced by endothelial removal (22.76 f 2.81%) and almost completely 
prevented by SQ-30741 (5.7 i 0.60%). In contrast to the young rats, in 
the old rat aortic rings with endothelium, L-NAME (10e4M) induced a more 
pronounced vasoconstriction to TB (36.5 i 7.0%) than in the rings without 
endothelium (p < 0.05). This contraction was almost completely prevented 
by SQ-30741 (IO-‘M; and 3.5 + 0.8%), contrasting the results in the young 
rats. 
Conclusion: TB releases NO and possibly other endothelium-derived 
factors in young rats, as well as vasoconstrictive prostaglandins from EC 
and SMC, which antagonize the vasodilatoty effect of NO. Aging increases 
the production of vasoconstrictive prostaglandins from EC and SMC in re- 
sponse to TB. These effects of TB may contribute to the pathogenesis of 
cardiovascular diseases and complications in aging. 
1089-42 Adhesion Molecules in Patients With Coronary 
Artery Disease are Markers of the Extent of 
Disease 
Katja Pioch, Markus Nauck’, Christoph Dommke, Patrick Zuther, 
Barbel Klein, Michael Kempf, Ralf Winkler, Tina Winterbauer, Rahime Gok, 
Winfried M&z’, Jochen Senges, Bernhard R. Winkelmann, 
Herzzentrum Ludwigshafen. ‘Universitfitsklinikum Freiburg, Germany 
Background: Inflammatory markers are increased in stable coronary artery 
disease (CAD) as well as in unstable angina (UA). 
Methods: We evaluated the role of C-reactive protein (CRP), vascular 
adhesion molecule 1 (VCAM), and L-Selectin (LSEL) in LURIC, a prospective 
registry on environmental and genetic risk factors. 945 patients were enrolled 
and underwent coronary angiography. Fasting blood was obtained in the 
morning. inflammatory markers were measured with commercial test kits 
(CRP Boehringer Mannheim + R&D Systems, USA). Troponin T (tropT) was 
measured quantitatively (~0.1 mgil = negative). 
Results: 
no CAD 
n=203 
stable CAD UA tropT- UA tropT+ p-W3kE 
"=502 n=149 n=Ql Wilcoxon 
CRP 0.5 z!c 0.6 0.8i 1.3 1.2f2.7 3.4 i 3.9 0.0001 
VCAM 7465257 824zt262 816zt230 792+262 0.6 
LSEL 746i-162 672~'~ 145 656i162 6394~ 139 0.004 
UAex- no CAD 1 -vessel-CAD multi-vessel-CAD p-ValW 
eluded 
CRP 
n=193 n=l81 n=317 tiilcoxon 
0.5 zk 0.6 0.8 f 1.6 0.8S1.21 0.002 
VCAM 746h263 787i276 845h254 0.0001 
LSEL 743hl63 691 * 154 662i139 0.0001 
Conclusions: 1. CRP is predominantly a marker of unstability of CAD. 
2. VCAM is a marker of the extent of stable CAD. 3. L-Selectin is a marker 
of both instability and extent of CAD, however, decreased levels indicate 
disease, possibly due to widespread binding to activated endothelium. 
1 1089-43 1 The Selective Serotonin Reuptake Inhibitor 
Paroxetine Inhibits Endothelial-Dependent 
Vasodilatation 
Daichi Shimbo, Eliza Geer, Josiah Child, Annika Dronge, Michael Farkouh, 
Satish Reddy, Jonathan Halperin. fvlount Sinai School of Medicine, New 
York, NL: USA 
Background: Among survivors of myocardial infarction, major depression is 
associated with increased cardiac mortality. The selective serotonin reuptake 
inhibitors (SSRl’s) are considered the treatment of choice in depressed 
patients with underlying coronary, artery disease, however, previous in vitro 
and in vivo studies have shown that paroxetine may inhibit nitric oxide 
synthase (NOS) activity. The effect of paroxetine on endothelial function has 
not been evaluated. 
Methods: High resolution ultrasonography of the brachial artery was used 
to measure endothelial-dependent vasodilatation in five healthy subjects (2 
male and 3 female) from 26 to 34 years of age (mean age 30 & 4 years) before 
and after the administration of oral paroxetine, 20 mg/day, for 2 weeks. En- 
dothelial-independent vasodilatation was measured by determining percent 
change in diameter after the administration of sublingual nitroglycerin. 
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Results: Endothelial-dependent vasodilatation was significantly impaired 
after paroxetine administration (3.4 f 3.6% versus 14.3 + 2.8% baseline, p = 
0.046). In contrast, dilatation induced by nitroglycerin was similar before and 
after paroxetine administration (18.3 f4.6% versus 23.0 f 4.3% baseline, p 
= 0.217). 
Conclusions: Paroxetine significantly inhibits in vivo nitric oxide-depen- 
dent vasodilatation. This may have serious implications during the anti- 
depressant treatment of patients with atherosclerotic heart disease. 
!----I- 1089 44 Quantitative Relationship Between Cardiovascular Fitness and Endothelial Function 
Sammy Y. Chan, Anka Brozic, Kori J. Kingsbury, Frances Johnson, 
Sandra Barr, G.B. John Mancini, Jiri P. Frohlich, Andrew P. Ignaszewski. 
University of British Coluinbia, Vancouver, B.C., Canada 
Background: Cardiovascular fitness is predictive of long term coronaty event 
rates. Endothelial dysfunction is an early event in atherogenesis. The quan- 
titative relationship between cardiovascular fitness and endothelial function 
is not known. 
Methods: We measured cardiovascular fitness, metabolic risk factors 
and endothelial function in 86 non-smoking, non diabetic male subjects (age 
57 f 6 yrs) with known coronary artery disease. Cardiovascular fitness 
was estimated by the maximal workload on graded exercise stress test. 
Endothelial function was quantified with brachial artery flow mediated dilation 
(FMD). 
Results: There was no correlation between FMD and metabolic risk 
factors including cholesterol, HDL-C, LDL-C, triglycerides, apoB, glucose 
and homocysteine but there was a significant correlation between maximal 
workload and FMD (r = 0.55, p = 0.005; FMD: mean 5.4 * 3.0% range 
-0.4-17.3%, workload: mean 12.3 i 3.1 mets, range 4.0-20.0 mets). In 
subjects with negative exercise stress tests, FMD averaged 5.7 f 2.5%, 
workload averaged 13.1 f 2.6 Mets and the correlation between FMD and 
workload was statistically significant (r = 0.56, p < 0.05). In subjects with 
nondiagnostic or positive exercise stress tests, FMD was similar (5.0 f 
3.5%, p = NS vs negative stress test); workload was significantly lower (11.5 
f 3.4 Mets, p < 0.005 vs negative stress test) and there was only a trend 
between FMD and cardiovascular fitness (r = 0.51, p = 0.086). 
Conclusion: We conclude that there is a significant quantitative relation- 
ship between cardiovascular fitness and endothelial function. Intervention 
studies designed to modulate endothelial function or cardiovascular fitness 
are needed to further explore this relationship. 
/ 1089 45 Hypercholesterolemia and Hypertension Have a Synergistic Deleterious Effect on Coronary 
Endothelial Function 
Martin G. Rodriguez-Parcel, Lilach 0. Lerman, Darcy Richardson, Juan 
C. Romero, Amir Lerman. Mayo Clinic and Foundation, Rochester, 
Minnesota, USA 
Background: Hypercholesterolemia (HC) and hypertension (HT) are asso- 
ciated with endothelial dysfunction and are considered major dsk factors 
for the progression of coronary artery disease. This study was designed to 
test the hypothesis that HC and HT, when in combination, will have a greater 
deleterious effect on coronary endothelial function than each risk factor alone. 
Methods: Four groups of pigs were studied after twelve weeks of either 
normal diet (Group I), 2% HC diet (Group 2), HT (achieved by unilateral renal 
artery stenosis, Group 3), or combined HC and HT (Group 4). Cholesterol 
levels were similar in groups 2 and 4, but significantly higher compared to 
groups 1 and 2 (p < 0.02). Coronary epicardial arteries were pre-contracted 
with 10e7M of endothelin-I, and dose response relaxation to bradykinin 
(10-“-10-6 M), and calcium ionophore (10-i’-10~6 M) were obtained using 
organ chamber techniques. 
Results: 
N Chol MAP 
(maIdI) fmmHa1 
GrO.1 9 89.9 i 26 95.1 * 4 
GrO.2 9 439 zt 131t 89.9 i 6 
Gr0.3 9 66zt28 171.0+ 161 
Gr0.4 6 351 * 52t 141.7i 151 
. . . Bradykinin 
Vasodilatoty response to calcium ionophore was similarly impaired. 
Conclusion: The combination of HC and HT produced a more pro- 
nounced impairment in endothelium-dependent vasorelaxation than each 
risk factor alone. These results suggest that HC and HT have a synergistic 
deleterious effect on coronary endothelial function, and may contribute to 
the increased incidence of coronary artery disease and cardiac events seen 
when HC and HT co-exist. 
I 1089 46 Free Radicals Mediate Coronary Vascular Dvsfunction Associated With Direct Current 
Sliocks 
Christine L. Oltman, Craig B. Clark, Neal L. Kane, L. Ray Davies, Kevin 
C. Dellsperger, Richard E. Kerber. VAMC and U. of lowa, lowa City, IA 
52242, USA 
Background: DC shocks for cardioversion cause myocardial injury which 
may be free-radical mediated. We have shown that direct current (DC) 
shocks cause endothelial dysfunction in canine coronary conduit arteries 
and microvessels. 
Purpose: To determine if shock-induced free radicals contribute to coro- 
nary dysfunction following DC shocks. 
Methods: Ten dogs were studied; all received three 20 joule DC shocks 
to the epicardium. Five of these dogs received superoxide dismutase (SOD) 
(15,000 U/kg) and catalase (CAT) (55,000 U/kg) IV 5 min before shocks. 
Coronary conduit arteries and microvessels (131 f 6 pm) were isolated. Ten- 
sion of conduit arteries was measured after constriction with PGFzB. Internal 
diameter was measured in microvessels after constriction with endothelin. 
Responses to acetylcholine (Ach, 10-‘“-10~4 M), an endothelial dependent 
vasodilator and nitroprusside (NP, 10-‘“-10-4 M), a direct smooth muscle 
vasodilator, were measured. 
Results: % Maximal relaxation: mean & SEM, “p < 0.05 vs. shock. 
Ach 
NP 
Conduit Rings Microvessels 
Shock SOD/CAT shock Shock SOD/CAT shock 
65 zt 3 80 * 7 6953 92 * 2* 
135*7 129*3 97f3 99 f 4 
NP responses to shocks were not altered by SOD/CAT. Ach-induced 
dilation was attenuated in vessels that were isolated after shocks were 
given. SOD and CAT prevented this decreased response to shocks. 
Conclusion: DC shocks cause endothelial dysfunction. Since pretreat- 
ment with SOD/CAT protects against this damage, a free radical mechanism 
may contribute to endothelial dysfunction. 
l---i- i 089 47 Homocysteine in Patients is Associated With Surrogate Markers of Endothelial Dysfunction 
Christoph Dommke, Katja Pioch, BBrbel Klein, Ralf Winkler, 
Tina Winterbauer, Rahime Gbk, Herrmann Franz, Dietmar Nagel, 
Peter Hellstern, Jochen Senges, Bernhard R. Winkelmann. Herzzentrum 
Ludwigshafen, lnstitut fijr Hgmostasiologie, Ludwigshafen, Germany 
Background: Homocysteine (HCY) is discussed as a possible causal risk 
factor for atherosclerosis enhancing the prothrombotic risk. 
Methods: 2236 patients scheduled for coronary angiography were strat- 
ified by fasting HCY. Traditional coronary risk factors and homocysteine 
status, including parameters influencing HCY were assessed and the levels 
of multiple coagulation parameters were analyzed. Blood was obtained on 
ice while fasting in the early morning and immediatedly centrifuged. 
Homocysteine <Q 9%<12 12-<15 >15 
Groups (firno& n=426 fl=686 n=525 n = 599 
Age (years) 59* 10 61 fll 64511 66flO 
HCY (wmolll) 7.5* 1.1 10.4 f 0.8 13.3 * 0.8 20.1 * 7.1 
Fibrinogen (mg/dl) 379s 104 38OzkiOO 394f108 4OOilOl 
Thrombomod. (fig/l) 49117 51 * 21 55&25 64+30 
F VIII (%) 168f63 171 f64 181 f 70 196f82 
F VII (U/dl) 122128 121 128 llQzt31 124f34 
vWF (%) 153zk65 157 zk 67 174zt70 188zt80 
No difference between HCY groups was seen for factors II, XII, XII. 
p-value 
Wilcoxon 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
0.08 
< 0.0001 
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Results: As expected, a stepwise decrease in vitamins B6, B12 and folic 
acid was seen with increasing HCY levels (all p < 0.0001 between the four 
groups of HCY levels) and creatinine increased from 0.8 to 1.2 mg/dL (lowest 
vs. highest group, p < 0.0001) 
Conclusions: I-ICY levels above 12 pmol/L were associated with elevated 
levels of vWF and thrombomodulin, both markers of endothelial dysfunction 
and F VIII, whereas no impact of HCY was seen on other coagulation factors 
not associated with endothelial function. 
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11089-48 1 Endothelial Dysfunction Following Oral 
Methionine is Not Mediated by an Increase in Free 
Radicals 
Angus K. Nightingale, Fraser Harrold, Peter Gapper, Jayne 
A. Morris-Thurgood, Moira Brownlee, Michael P. Frenneaux. Wales Heart 
Research Institute, Card/E UK 
Background: The mechanism of vascular disease in hyperhomocysteinaemia 
is unclear but increased oxidative stress has been implicated. We tested the 
hypothesis that oral methionine loading (resulting in a rise in plasma homo- 
cysteine) would be associated with an increase in oxidative stress with a rise 
in lipid-derived free radicals (FR) and decreased platelet nitrate sensitivity. 
Methods: 14 healthy male volunteers mean age 41 i 15 years without 
atherogenic risk factors were studied following an overnight fast. Free radi- 
cals in plasma were measured by electron paramagnetic spectroscopy using 
the spin-trap N-t-Butyl-a-Phenyi Nitrone. Endothelial function was assessed 
using flow-mediated dilatation (FMD) of the brachial artery with a wall track- 
ing technique. Platelet sensitivity to nitroglycerine (NTG) was measured as 
% inhibition of ADP-induced aggregation in whole blood. Subjects were ran- 
domised to oral methionine (0.1 g/kg) or placebo. Four hours later FR, FMD 
and platelet responses were reassessed. A week later the subjects crossed 
over to the other treatment. 
Results: (Data expressed as mean i SEM). Despite a significant im- 
pairment of FMD four hours after methionine (AFMD, placebo -1.45 f 
0.70% v methionine -2.53 f 0.76%, p < 0.03), there was no change in 
lipid-derived free radicals (AFR, placebo IO f 15% vmethionine 9 f 20%, 
p = 0.9) or platelet nitrate sensitivity (ANTG inhibition, placebo 0.41 f 8.2% 
vmethionine -1.44 rt 6.01%, p = 0.67). 
Conclusion: These observations employing a direct measure of oxidative 
stress which is both sensitive and specific, show that the endothelial dys- 
function following oral methionine loading is not accompanied (or mediated) 
by enhanced oxidative stress. 
1090-50 Does Renal Failure Cause Endothelial 
Dysfunction and Atherosclerosis? 
Robert Kennedy, Colin Case, David Johnson, Nikki Isbel, Tom Marwick. 
Princess Alexandra Hospital/University of Queensland, Brisbane, Australia 
Background: Atherosclerotic cardiovascular disease is the main cause of 
morbidity and mortality in end-stage renal disease (ESRD). The cause of this 
atherosclerotic milieu is uncertain, as is the influence of type of dialysis. We 
sought to quantify severity of atherosclerosis and endothelial dysfunction as 
intima-medial thickness (IMT) and brachial artery reactivity (BAR) in uremic 
pts and controls. 
Methods: A full patient history and risk factor status was taken, including 
lipid profiles and homocysteine levels, in 57 pts on hemodialysis and 44 
on peritoneal dialysis, as well as 50 non-uremic controls. High resolution 
B-mode ultrasound was performed for measurement of IMT in the common 
carotid artery. IMT images where stored digitally for automated off-line anal- 
ysis (HDI Lab, Advanced Technology Laboratories). BAR was assessed by 
measurement of the lumen diameter of the brachial artery at rest, during 
reactive hyperemia, and after sublingual nitroglycerin. BAR images were an- 
alyzed on-line and stored digitally for similar off-line analysis. Reproducibility 
was assessed through i&a/inter-observer error. 
Results: The ESRD group had an greater IMT (0.80 f 0.02 vs 0.66 + 
0.02 mm; p < 0.001) than the controls. However, the ESRD group had a 
significantly greater risk factors than the controls (systolic BP 144 f 3 vs 126 
i 2 mmHg; homocysteine; 29 i 2 vs 9 i 0.5 pmol/L, diabetes 28 vs 1, p 
< 0.001). On multivariate analysis, risk factors were predictors of IMT but 
not the presence of renal failure (p > 0.6) or type of dialysis. There was no 
difference in BAR between the ESRD and control groups (6.8 f 0.9 vs 6.0 i 
0.9% dilatation: p > 0.5). 
Risk factors IMT (mm) BAR (%) 
ESRF control ESRF control 
1 1089-49 / Effect of Chronic Exercise and Long-Term 
Angiotensin-Converting Enzyme Inhibitors on 
Endothelial Function of Rat Thoracic Aorta 
Stephane Elkouri, Philippe Demers, Martin G. Sirois, Raymond Cartier. 
Montreal Heart Institute, Montreai, Quebec, Canada 
Introduction: Physical exercise modulates endothelial reactivity. Angiotensin- 
converting enzyme inhibitors (ACEI) used to treat many cardiovascular 
pathologies also modulate vascular reactivity. The aim of this study was 
to evaluate the effect of chronic exercise (EX) with or without the ACEI capto- 
pril (CAP) on the expression and activity of endothelial nitric oxide synthase 
enzyme (ecNOS). 
Methods: Over a 4-week period, 64 Sprague-Dawley male rats were 
randomized into 4 groups (n = 16) (group I: control; group II: CAP; group Ill: 
EX; group IV: EX and CAP). After IO weeks of treatment, rats were sacrificed 
and their thoracic aorta carefully harvested. Aortic reactivity was studied in 
organ chamber (n = 12) by recording relaxation and contraction responses 
to different mediators. Aortic ecNOS expression was determined by Western 
blot (n = 4). 
Results: Vascular reactivity: Endothelial-dependent relaxations to acetyl- 
choline, calcium ionophore, adenosine diphosphate and histamine were in- 
creased in both CAP and EX rats when compared to the control group. 
Maximal aortic relaxations were higher in CAP group. Potencies of these 
mediators were higher in EX group (p < 0.05 vs control). Combined treat- 
ment with EX and CAP did not result in any synergistic effect or other 
interaction on endothelial-dependent function. EcNOS relative expressions 
were: group I: 100%; group II: 241%; group Ill: 64% and group IV: 108%. 
Conclusions: CAP treatment as well as chronic exercise enhanced en- 
dothelium-dependent vascular relaxation. However, ecNOS protein expres- 
sion is upregulated in CAP-treated rats while it is downreguiated afar chronic 
exercise, ecNOS system regulation differs and probably depends on contri- 
bution and modulation of the other EDRF implicated, 
0 0.57 i 0.00 0.64 i- 0.08 9.1 i 6.7 
1 0.73 f 0.12 0.67 + 0.21 9.8 S 5.2 8.3 zt 7.2 
2 0.72 zt 0.12 0.66 rt 0.08 5.4 * 8.2 5.9 i 7.5 
3 0.74 * 0.17 0.63 i 0.11 10.5 zt 11.9 5.5 i 5.3 
4 0.84 + 0.26 0.78 + 0.17 4.3 f 6.7 3.9 i 6.6 
Inter-observer variability was low for both automated measures (Alpha = 
0.86 IMT and Alpha = 0.84 BAR). 
Conclusion: The greater atherosclerotic burden in pts with ESRD reflects 
risk factor prevalence rather than an independent effect of uremia of type of 
dialysis. BAR is no different in ESRD and controls. 
1 1090-51 1 Effects of Obesity on Coronary Atherosclerosis, 
Vascular Remodeling and Endothelial Function 
Jassim Al Suwaidi, Shuichi Hamasaki, Stuart T. Higano, Nelson A. Araujo, 
James L. Velianou, David R. Holmes Jr., Amir Lerman. Mayo Clinic, 
Rochester, MN, USA 
Background: The American Heart Association has recently classified obesity 
as a modifiable risk factor for coronary heart disease. However, to date the 
relationship of obesity to early coronary atherosclerosis, endothelial function 
and vascular remodeling is unknown. 
Method: One hundred and eleven patients with angiographically normal 
or mildly diseased coronary arteries were prospectively studied. Patients 
were divided into two groups based on the body mass index (BMI); Gp 1 
(n = 77) non-obese-BMI < 30 and Gp 2 (n = 34) obese-BMI p 30. Ves- 
sel area, lumen area, atherosclerotic plaque area and plaque morphology 
were evaluated with intravascular ultrasound. Coronary endothelial function 
was assessed with graded infusions of intracoronary acetylcholine (IO-” to 
IO-=’ M). 
Results: There were no significant differences between the groups in the 
prevalence of other cardiovascular risk factors. The response to acetylcholine 
was similar between the two groups. However, there were significant differ- 
ences in IVUS parameters even after adjustment for other cardiovascular 
risk factors (see figure). 
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Body mass index (BMI) 
Conclusibm: Obesity defined as BMI > 30 is independently associated 
with increased degree of coronary atherosclerosis and this study suggests 
that obesity is an independent risk factor for coronary atherosclerosis in 
humans. 
L.-l 1090 52 Serum Xanthine Oxidase and Nitric Oxide Synthase Activities and Malondialdehyde as 
Markers of Coronary lschemia During Stress Test 
John S. Vythoulkas, Vassiliki E. Villiotou, Sofia G. Pouliopoulou, Vassilios 
E. Votteas, Emmannuel B. Chronakis, Thomas K. Makris, Michael 
K. Kyriakidis, George H. Deliconstantinos. Cardiology Dept - LAlKON 
Hospital, University of Athens, Medical School, Athens, Greece 
In the present study the activities of xanthine oxidase (X0) and nitric ox- 
ide synthase (NOS), S-nitrosothiols, malodialdechyde (MDA) levels, and the 
serum antioxidant capacity (SAOC) were investigated in patients with coro- 
nary artery disease (CAD) during the stress test (ST). NOS and X0 activities 
were measured fluorophotometricaly. It was found that the activity of serum 
X0 in 25 patients after the ST (5.2 f 0.9 mu/ml) was higher than that before 
the ST (1.4 f 0.3 mu/ml, p < 0.05) while the activity of serum NOS after 
the ST (0.21 f 0.04 U/ml) was lower than that before the ST (0.75 f 0.10 
U/ml). Normal individuals (n = 15) showed no changes in X0 and NOS ac- 
tivities before (NOS: 0.07 f 0.02 U/ml. X0: 0.021 f 0.007 mu/ml) and after 
the ST (NOS: 0.08 & 0.01 U/ml, X0: 0.018 * 0.002 mU/ml). The levels of 
S-nitrosothiols, estimated by a chemiluminescence method, showed a statis- 
tically significant decrease (p < 0.05) in the same patients before (52 f 6.9 
PM) and after the ST (22.8 f 3.5 PM). Normal individuals showed a IO-fold 
increase in S-nitrosothiols after the ST. SAOC determined by a chemilumi- 
nescence method, showed an approximately 50% increase of SAOC after 
the ST in patients with CAD. MDA estimated by high pressure liquid chro- 
matography (HPLC) showed a considerable increase (p < 0.01) after the 
ST (before: 0.25 & 0.04 ELM and after 0.48 f 0.09 PM). The existence of 
CAD was confirmed by coronary angiography in 20 patients exhibiting higher 
activities of X0 and in parallel lower activities of NOS in serum after the ST. 
Conclusions: Our present results suggest that X0 is released into the 
circulation of the patients with CAD during ST and that the specific activities 
of X0 and NOS as well as MDA can be used as early markers for the 
estimation of the degree of coronary ischemia produced during the ST. 
1 1090-53 1 Evidence of Prolonged Inflammation in Patients 
With Unstable Angina and Non Q-wave 
Myocardial Infarction 
Niall Mulvihill, J. Brendan Foley, Ross T. Murphy, Peter Crean, 
Michael Walsh. Departmenf of Cardiology. St James’s Hospital, Dublin, UK 
Background: Coronary plaque inflammation is a critical component in the 
pathogenesis of acute coronary syndromes. Cellular adhesion molecules 
(CAMS) have been identified as mediators of endothelial inflammation. We 
measured soluble CAMS in patients with unstable angina (UA) and non 
Q-wave infarction (NQMI) up to 12 months after presentation. 
Methods: Patients with UA and NQMI had serum samples drawn at 
presentation and then 6 and 12 months after discharge. A group of age and 
x * sem (rig/m/) UA (n = 54) 
ICAM- (0 hr) 
ICAM- (6/12) 
LAM-1 (12/12) 
VCAM-1 (0 hr) 
VCAM-1 (6/12) 
VCAM-1 (12/12) 
E-selectin (0 hr) 
E-selectin (6/12) 
E-selectin (12/121 
350 rt 14 
349 rt 12 
300*1ot 
804 * 36 
892 + 48 
774 f 34t 
57*3 
52 f 3 
4312t 
NQMI fn = 371 Control (n = 241 
351 f 20 
359 f 26 
295* 157 
798 * 39 
860 Z!Y 63 
725 f 22t 
59 f 5 
56Lk4 
46 i 41 
232 + 9* 
226 i 8* 
249s 11 
554 f 25s 
579117’ 
574 i 28X 
33*3* 
33%2* 
38f5 
y2;, g < 0.05 for UA and NQMI vs Control); (t = p < 0.05 for level at T = 6112 vs T = 
sex matched controls were studied for comparison. Soluble ICAM-I , VCAM-I 
and E-selectin were measured using an ELISA technique. 
Results: 91 patients entered the study (male/female = 73/18, mean age 
62 f 11 years, 54 UA and 37 NQMI). Levels of SCAMS in both UA and 
NQMI groups were significantly elevated for up to 6 months in comparison to 
controls. Levels of all 3 soluble CAMS fell between 6 and 12 months in both 
the UA and NQMI groups (see table). 
Conclusion: These results suggest that the coronary vascular inflamma- 
toy process, critical in the pathogenesis of these syndromes, is persistent 
for up to 6 months after presentation with UA and NQMI and then subsides 
in the following 6 months. 
L.--d 1090 54 Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery 
Disease: Primary Clinical Results of the 
ACADEMIC Study 
Joseph B. Muhlestein, Jeffrey L. Anderson, John F. Carlquist, Benjamin 
D. Horne, Robert R. Pearson, Tami L. Bair, T. Jared Bunch, Kirti Salunkhe, 
Chloe Allen Maycock, Sunni K. Kim. LDS Hospital University of Utah, Salt 
Lake City Utah, USA 
Background: Chlamydia pneumoniae (Cpn) has been associated with coro- 
nay atherosclerosis although its causal role remains uncertain. A small 
preliminary study reported that ischemic events could be reduced by >50% 
with azithromycin (AZI), an antibiotic effective against Cpn, in seropositive 
patients. We tested this prospectively in a larger, randomized, double-blind 
study. 
Methods: CAD patients (pt) (n = 302) seropositive to Cpn (IgG titers 1:16) 
were randomized to placebo or AZI, 500 mg/d for 3 d, then 500 mg/wk for 3 
mo. The primary clinical endpoint was a composite of cardiovascular death, 
resuscitated cardiac arrest (RCA), nonfatal MI, stroke, unstable angina re- 
quiring hospitalization, and unplanned coronary intervention (catheter based 
or surgical) (UCI) at 2 yrs. The study was powered to determine large (?50%) 
differences between groups. 
Results: Treatment groups were balanced, with mean pt age = 64 yrs; 
89% were males. AZI was generally well tolerated. A total of 47 events 
occurred over the course of the trial (death = 9, RCA = 1, Ml = 11, stroke = 3, 
unstable angina = 4, and UCI = 19); 25 events occurred in the placebo group 
and 22 in the AZI group. There was no significant difference in the primary 
endpoint between the two groups (hazard ratio [HR] for AZI = 0.89; 95% 
confidence interval [Cl] = 0.511.60). However, a trend toward a reduction in 
events in the AZI arm was noted during the second year of the study (HR = 
0.56, 95% Cl = 0.19-1.66). 
Conclusion: The primary clinical results of ACADEMIC suggest that 
antibiotic therapy with AZI is not associated with marked early reductions 
(~50%) in ischemic events suggested by an initial published report. However, 
a clinically worthwhile benefit (i.e., 30 & 15%) is still possible. Also, consistent 
with our earlier report of a reduction in inflammatory markers with AZI that 
appeared first at 6 mo, clinical benefits (reduced ischemic events) may be 
delayed, appearing primarily after the first year. Larger (several thousand pt), 
longer term (>3-5 y) antibiotic studies are therefore indicated. 
I 1090 55 Complement Activation in Active Coronary 
Atherosclerotic Plaque 
David J. Clark, Michael W. Cleman, Steven E. Pfau, John F. Setaro, 
Habib Samady, Frank Giordano, Douglas Israel, Scott A. Rollins, 
Leonard Bell. Yale Universifx New Haven, CT; Alexion Pharmaceuticals, 
New Haven, C7; USA 
Background: Recent studies have identified inflammatory markers as out- 
come predictors in unstable angina patients. Complement activation is known 
to enhance platelet activation, smooth muscle cell proliferation, and cytokine 
release which may be involved in coronary plaque destabilization. The role 
of complement activation in modulating plaque stability and progression has 
not been investigated. The objective of this study was to define the presence 
of activated complement in both atherosclerotic plaque and the coronary 
circulation. 
Methods: Six patients (6 lesions) undergoing directional coronary atherec- 
tomy (DCA) serve as the patient cohort in this observational study. Four 
patients had unstable angina. DCA specimens were processed and frozen 
at -80 C. Specimens were sectioned and evaluated for C5b-9 using im- 
munofluorescence antibody staining. In .patients with proximal left anterior 
descending (LAD) artery stenoses, simultaneous coronary sinus (CS) and 
aortic (AO) blood samples were evaluated prior to intervention or heparin 
administration. 
Results: Five of six atherosclerotic plaque samples demonstrated sig- 
nificant C5b-9 deposition. In the patients with proximal LAD artery stenotic 
plaque, all of whom had unstable angina, serum C5b-9 levels were more 
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than 40% higher in the CS samples compared to the A0 samples indicating 
ongoing complement activation across the coronary bed. 
Conclusions: Preliminary data demonstrates complement activation in 
coronary plaque. The CS-A0 gradient demonstrates ongoing complement 
activation in the coronary bed, suggesting its active participation in modulat- 
ing atherosclerotic plaque activity. Inhibition of complement activation may 
be an important adjunctive therapy in patients with active coronary athero- 
sclerotic plaques. 
1090-56 Increased Neovascularization in Disrupted 
Human Atherosclerotic Plaques 
Pedro R. Moreno, K.-Raman Purushothaman, William N. O’Connor, David 
C. Booth, Valentin Fuster, James E. Muller. Gill Heart Institute, University of 
Kentucky, Lexington, KY; Mount Sinai Medical Center, New York, New York; 
Massachusetts General Hospital, Boston, MA, USA 
Background: It has been proposed that neovascularization may make a 
plaque vulnerable for disruption and thrombosis. This possible role of mi- 
crovessels may be important because there are agents proposed for clinical 
use that could enhance or inhibit microvessels growth. We tested the hy- 
pothesis that disrupted plaques have a higher number of microvessels than 
do advanced plaques that are not disrupted. 
Methods: Studies were performed on 182 histologic sections taken se- 
quentially at autopsy from 6 human aortas. The total number of microvessels 
in the intima per section was quantified using trichrome staining. Plaques in 
each section were categorized as early (type I-III) and advanced (types IV 
to VI) according to the AHA classification. Thin-cap fibroatheroma (TCFA), 
the most common type of vulnerable plaque was defined as a plaque with 
fibrous cap < 65 p in thickness (by microscopic morphometry)Z large lipid 
pool and macrophages. Calcification was also identified. 
Results: The number of microvessels was higher in disrupted (124 & 12) 
than in non-disrupted plaques (78 f IO) (p = 0.014) but was similar in TCFA 
(84 i: 17) and in non-TCFA (73 F 12) plaques (p = 0.58). The number of 
microvessels was also higher in densely calcified (131 f 19) than in non- 
calcified (38 f 4) plaques (p < 0.0001). Multiplelinear regression analysis 
identified calcification as the only independent predictor for microvessels (r 
= 0.47 p < 0.0001). 
Conclusion: lntimal neovascularization is greater in advanced disrupted 
than in advanced non-disrupted plaques but similar in TCFA and non-TCFA 
plaques. Calcification is associated with neovascularization. These results 
suggest that microvessels may play a role in plaque disruption, but further 
studies are needed to completely elucidate this issue. 
1090-57 Coronary Calcification and Biochemical Markers 
of Bone Turnover in Coronary Circulation 
Kouji Kajinami, Atsushi Nohara, Hiroyasu Seki, Hiroshi Mabuchi. 2nd 
Department of internal Medicine, School of Medicine, Kanazawa University 
and Kanazawa Cardiovascular Hospital, Kanazawa, Ishikawa, Japan 
Background: There is increasing evidence that vascular calcification is an 
active and regulated process similar to osteogenesis. However, little clinical 
evidence is known regarding this hypothesis. To investigate the potential role 
of molecules related to bone formation-resorption in coronary calcification, 
we determined the levels of circulating biochemical markers of bone turnover 
in coronary circulation, and compared the results with the quantification of 
coronary calcification using electron beam computed tomography. 
Methods: We enrolled consecutive 130 patients (M/F = 93/37, mean 
age 59 yrs) receiving elective coronary angiography. Blood samples were 
obtained simultaneously from aortic root (Ao) and coronary sinus (CS) just 
before angiography, Coronary calcification of whole coronary tree and of only 
left coronary artery were quantified as total calcification score (TCS) and left 
calcification score (LCS), respectively. 
Results: During coronary circulation, serum levels of osteocalcin (OC), 
procollagen type I C-terminal propeptide (PICP), tartrate resistant acid phos- 
phatase (TR-ACP), and collagen type I C-terminal telopeptide (ICTP) signifi- 
cantly increased, by 3 to 12%, whereas bone-specific alkaline phosphatase 
(B-ALP) remained unchanged (Table). Regarding markers of bone forma- 
tion, both TCS and LCS showed significantly positive correlation with the 
increases of both OC and PICP, but did not with that of B-ALP, By contrast, 
TCS and LCS never correlated with those of ICTP nor TR-ACP, both of which 
were bone resorption markers. 
06 (nghll) PICP @g/ml) B-ALP (N/L) TA-ACP (U/L) ICTP @g/ml) 
A0 6.7 zt 3.1 95 * 30 66f31 5.2 i 1 .o 3.6i1.4 
cs 7.2. zk 3.1 105*35 67 * 33 5.3 rt 1 .o 3.9i1.6 
Conclusion: Coronary calcification appears to be regulated by the moleculs 
related to bone formation, but not by those related to bone resorption. 
I 1090 58 Plasma Cholesterol Does Not Predict Fat Plaque 
Content: A Pathological Study 
Delia Braz Junior, Paulo S. Gutierrez, Protasio L. da Luz. Heart institute 
(InCor), University of Sso Paul0 Medical School, Brazil 
Background: Although hypercholesterolemia is a classical risk factor for 
coronary artery disease (CAD) the relationship of plasma cholesterol (Chol) 
to plaque composition is not clear. 
Objective: To study the relationship between plasma Chol and fat plaque 
content in pts who died from CAD. 
Methods: Frozen cross-sections from the initial third of RC, LAD, and Cx 
coronary arteries obtained from necropsy hearts of 51 adult pts (mean age 
61.6 * 10.9 years, 70% male) who died from CAD complications were stained 
with Sudan IV to reveal fat. Intima, media and fat areas were quantitated by 
planimetry with Quantimet-500 system adapted to a Leica optical system; 
fat content was expressed as percent of the intima. Plasma lipids had been 
measured by standard techniques, during life, in the absence of lipid lowering 
drugs. Pts were divided in low (I) and high (II) Chol groups. Data was 
compared by unpaired Student t test, Pearson chi square test and Fisher 
exact test. 
Results: Fat plaque content was not different between groups in any 
artery (Table). HDL was comparable (29.4 + 98 group I vs 35.3 i 11.2 group 
II), but LDL (104.8 & 31.9 vs 156.0 f 25.5 mg%) and triglycerides (138.0 * 
70.8 vs 183.5 i 90.4 mg%) were lower in group I than in II (p < 0.05). In 
addition, diabetes, hypertension and smoking incidence were similar in the 
groups. 
n Chol RC LAD CX 
mgldl Int IntfMd Fat Int In#Md Fat Int IntlMd Fat 
mm2 % mm* % mm’ % 
25 163 5957 2.8 23 4877 3.5 21 4110 2.6 19 
rt27 rt3196 il.1 lk9.5 12513 zk1.8 zt12 12257 11.8 &I4 
26 234" 5982 3x* 20 5560 3.9 22 5690* 3.6 24 
zt34 13094 *1.5 *9.8 12272 f2.0 zt9.9 zt2754 G?.O &I6 
Int = intima; Md = media. *P < 0.05. 
Conclusions: 1) plaque fat content is not only dependent on plasma 
Chol; additional factors are certainly operative; 2) the data could explain 
clinical syndromes in pts with low Chol. 
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1 1091-g ( A Non-Linear Model for Mortality Prediction in 
Patients With Type a Acute Aortic Dissection. A 
Study From the International Registry of Acute 
Aortic Dissection (IRAD) 
Rosario V. Freeman, David Bruckman, Peter Hagan, Toru Suzuki, 
Eric Isselbacher, Arturo Evangelista, Rossella Fattori, Jae K. Oh, Andrew 
G. Moore, Udo Sechtem, Alfred0 Llovet, Hans-Joseph Deutsch, Dan Gilon, 
Linda Pape, Patrick T. Q’Gara, Dean J. Karavite, Pamela L. Russman, 
William F. Armstrong, G. Michael Deeb, Christoph A. Nienaber, Kim 
A. Eagle. Coordinating Center for lRAD Investigators; University of Michigan 
Medical Center, USA 
Background: Acute type A aortic dissection (AD) is a clinical emergency 
associated with high morbidity and mortality. Neural networks (NNs) are 
nonlinear models that can identify complex variable relationships and have 
been used for outcomes modeling. 
Methods: Clinical features of presentation and management of AD were 
collected on 558 patients from 13 international tertiary centers. A series of 
NNs were developed to determine which variables tended to contribute to 
AD mortality prediction. To limit NN model training variable distraction, the 
NN variables selected frequently and variables from a univariate analysis 
formed a subset (n = 27 variables) on which a separate series of NNs 
were constructed. Cross validation (3 groups) was done on training data 
(400 patients) and independent validation was done on a separate cohort 
of 158 patients. Predictive accuracy was assessed using receiver operating 
characteristic (ROC) curves and model goodness of fit was assessed using 
the Hosmer-Lemeshow statistic. 
Results: In-hospital mortality for AD was 26% for both training and vali- 
dation data sets. The NN model for AD mortality included: 
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Presentation: Coma/altered consciousness, any pulse deficit, hemody- 
namic instability, age, and medical management of AD. 
Diagnostics: Widened mediastinum on chest radiograph and previous 
myocardial infarction on electrocardiogram. 
In-hospital complications: Renal failure, hypotension, cardiac tamponade, 
mesenteric ischemia and extension of aortic dissection. 
Area under the ROC curve was 0.84 f 0.02 for the training data. Predictive 
accuracy was relatively preserved on the independent validation data with 
an area under the ROC curve 0.74 f 0.04. The Hosmer-Lemeshow statistic 
was not significant, 5.64 and 12.73 respectively, indicating adequate model 
calibration. 
Conclusion: Neural networks provide a valid technique for modeling 
in-hospital mortality from acute type A aortic dissection with relatively pre- 
served predictive accuracy on independent data and may provide additional 
prognostic information to traditional linear modeling techniques. 
1091-I 0 Serum Cardiac Troponin I Increase in Acute Type 
a Aortic Dissection: A New Independent Predictor 
L.-.-Y2 1091 11 Epidemiology and Outcome of Aortic Intramural Hematoma: A Meta-Analysis of 123 Cases 
Reported in the Literature 
Rajiv Maraj, Pairoj Rerkpattanapipat, Porawat Makornwattana, Larry 
E. Jacobs, Morris N. Kotler. Albert Einstein Medical Center, Phi/ade$hia, 
PA, USA 
Background: Aortic intramural hematoma (IMH) is a diagnosis of exclusion 
and represents spontaneous, localized hemorrhage into the wall of the aorta 
in the absence of bona fide aortic dissection or intimal tear. Since IMH is a 
rarely diagnosed pathological condition that is not well characterized to date, 
we aimed to elucidate the epidemiology, presentation and outcomes of this 
condition. 
Methods: A Medline search was performed using the search terms “intra- 
mural hematoma”. A meta-analysis of 19 studies with a total of 143 patients 
(pts) with IMH was performed. 
Results: IMH was reported in 87 males (61%) and 56 females (39%). 
Mean age was significantly higher in the female group (68 yrs) vs male 
group (63 yrs) (p < 0.02). Hypertension was present in 76/143 pts (53%). 
Presenting symptoms were chest and/or back pain 115 (80%) and chest pain 
only 19 (13%) in the majority of pts. Type A IMH occurred in 81 (57%) pts 
vs type B in 62 (43%) pts. 81 pts (57%) received medical treatment vs 62 
pts (43%) who received surgical treatment. The overall mortality was 30 pts 
(21%) (see table). 
Conclusion: IMH has been reported more commonly in males than in fe- 
males (61%vs39%).Theaverage age of presentation is higher in females (68 
yrs) vs males (63 yrs). The overall mortality is 21%. Patients with Stanford type 
A IMH who receive surgery compared to medical management have a better 
prognosis. In type B patients, medical and surgical outcomes are similar. 
Mortality p value 
of Mortality 
Patrick Godon, Eric Bonnefoy, Gilbert Kirkorian, Philippe Chevalier, 
Marjaneh Fatemi, Paul Touboul. Hdpital Cardiovasculaire et Pneumologique 
Louis Pradel, Lyon, France 
Background: Cardiac troponin I (cTnl) is a known predictor of adverse 
events in unstable angina and in critical care patients (pts). In this work, we 
studied the incidence and prognostic signification of cTnl increase in pts with 
type A acute aortic dissection. 
Methods: Consecutive pts (n = 64,46 men, 62 f 15 yrs) were admitted in 
our ICU for type A aortic dissection from l/i 997 through 12/i 998. Type A aor- 
tic dissection was diagnosed by transesophageal echocardiography and/or 
computed tomography. In all pts, we measured serum cTnl on admission by 
an enzymoimmunoflurometric method (detection and myocardial infarction 
threshold: 0.4 rig/ml and 1.5 rig/ml respectively). 
Results: cTnl was detectable on admission in 15 pts (23%) and was 
beyond the 1.5 rig/ml threshold in 5 (8%). Six pts were not considered for 
surgery owing to advanced age or severe comorbidity and died (3 of them 
had detectable serum cTnl); they were excluded from statistical analysis. Of 
the 58 remaining pts, 12 (20%) died, 4 before surgery and 8 post-operatively. 
In-hospital mortality was significantly higher in pts with detectable serum cTnl 
levels (6/12 (50%) vs 6/46 (13%); p = 0.005). There was a trend toward a 
higher mortality for these pts in the pre-operative period (2/12 (17%) vs 2/46 
(4%)). Detectable serum cTnl was a strong predictor of early postoperative 
death rate (mortality 4/10 (40%) vs 4/44 (9%)). There was no significant 
relation between cTnl increase and ECG alterations, coronary involvement, 
tamponade, arterial pressure, shock, admission delay or age. 
Conclusion: Detectable serum cTnl levels constitute a strong indepen- 
dent predictor of in-hospital and post-operative mortality in pts with acute 
type A aortic dissection. 
POSTER 
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1091-I 2 Diagnostic Implications of Raised Smooth Muscle 
Myosin Heavy Chain Levels in Acute Aortic 
Dissection 
Toru Suzuki, Hirohisa Katoh, Ryozo Nagai. For the Smooth Muscle Myosin 
Heavy Chain (SMH) Investigators; The University of Tokyo, Tokyo, Japan 
Background: Aortic dissection is a catastrophic acute cardiovascular dis- 
ease. Early diagnosis and initiation of management remains critical for im- 
proved survival. To aid in the initial diagnosis, we focused on the hitherto 
unaddressed role of biochemical diagnosis and developed an assay of cir- 
culating smooth muscle myosin heavy chain, a protein specific to smooth 
muscle which is released from the damaged aortic media. A rapid 30-minute 
assay was developed for clinical use, and the diagnostic implications and 
performance of the assay were examined by a multicenter prospective in- 
vestigation 
Methods: Circulating smooth muscle myosin heavy chain levels in pa- 
tients with acute aortic dissection presenting at SMH centers were examined 
and analyzed against clinical characteristics. 
Results: Ninety-five patients with acute aortic dissection were examined. 
Ninety-one percent of patients within three hours after onset showed circulat- 
ing smooth muscle myosin heavy chain levels exceeding the clinical decision 
limit of 2.5 rig/ml (specificity 98% against healthy volunteers, 83% against 
acute myocardial infarction). Patients with proximal DeBakey types I and II 
lesions all showed raised levels with 100% sensitivity, and negative levels 
(~2.5 @ml) were restricted to distal DeBakey type Ill lesions with a reduced 
sensitivity of 82% in the initial three hours. 
Conclusion: As the first available biochemical diagnostic tool for aortic 
dissection, smooth muscle myosin heavy chain measurements as a diag- 
nostic parameter is feasible in the initial hours after onset with superior 
performance for proximal lesions. 
The SMH investigators are: Y Tsuchio & A Hasegawa, Gunma Univ; A 
Ohira & K Hiramori, lwate Univ; Y Sakomura & H Kasanuki, Tokyo Women’s 
Med Coil; S Hori & N Aikawa, Keio Univ; S Abe & C Tei, Kagoshima Univ; Y 
Nakagawa & M Nobuyoshi, Kokura Memorial Hosp; K Misu & T Sumiyoshi, 
Sakakibara Heart Inst. 
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1 1092-l 7 1 Arteriogenic Potency of CC- and 
CXC-Chemokines Produced by Monocytes 
Eva E. Katzer’ , Imo E. Hbfere, Ivo R. Buschmann, Niels van Royer?, 
0. RenneP, Matthias Heil, C.W. Hamm’, Matthias Clausse, J.J. Piek3, 
Wolfgang Schaper. Max Planck Instifufe, Exp. Cardiology; ‘Molecular Cell 
Biology; ’ Kerckhoti-Klinik, Bad Nauheim, Germany; 3Amsterdam Medical 
Center, The Netherlands 
Background: After slowly progressing stenosis of large arteries preexisting 
collateral arteries can ameliorate the detrimental effects of vascular occlusion. 
These bypassing arteries are invaded by monocytes and start to proliferate 
(arteriogenesis). Furthermore circulating monocytes are potent producers of 
several growth factors and chemokines. We now investigated the arteriogenic 
potency of several monocyte produced chemokines. 
Methods: Chemokine Expression profile of monocytes was analyzed 
via c-DNA Arrays. The following target proteins were identified: Interleukin 
8, Macrophage Inflammatory Protein 01 and b, Monocyte Chemoattractant 
Protein-l, Tumor Necrosis, Factor-a. Each protein was infused continously 
over a time-period of one week into the collateral circulation of the rabbit 
hindlimb. After one week hemodynamic (collateral conductance) as well as 
morphological measurements were obtained. 
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Results: Number of visible collateral arteries after one week: TNF-ol = 
13 f 2, MIP-lo( = 15 + 3, MIP-I/I = 12 * 3, IL8 = 16 i 4, MCP-1 = 33 
-fr 5. Hemodynamic measurements revealed that TNF-CY, MIP-lol and -p as 
well as IL8 are only weak arteriogenic inducers (collateral conductance 5 19 
ml/min/mmHg) whereas MCP-1 shows the strongest arteriogenic properties 
(35 ml/min/mmHg). 
Conclusion: MCP-I is significantly overexpressed by monocytes after 
stimulation with LPS. Among the CC- and CXC-Chemokines MCP-I is cur- 
rently the most powerful inducer of collateral artery growth measured via 
functional blood flow parameters (collateral conductance). 
L--L 1092 18 Increased Furin mRNA Expression Precedes Matrix Metalloprotease-2 Activation During 
Sustained Flow Changes in Rabbit Arteries 
Dominique P.V. de Kleijn, Joost P.G. Sluijter, Evelyn Velema, 
Arjan Schoneveld, Gerard Pasterkamp, Cornelius Borst. Lab. of 
Experimental Cardiology, University Medical Center, Utrecht, The 
Netherlands 
Background: Matrix metalloproteases (MMPs) are the only enzymes capa- 
ble of collagen degradation. They are activated via proteolytic cleavage of 
their propeptides. The MMP-2 proteolysis is mediated by Membrane Type-l 
MMP which in turn is activated by Furin. In arteries, MMPP plays an impor- 
tant role in remodeling following balloon dilation or sustained flow changes. 
Little is known about Furin expression in the arterial wall. We studied Furin 
expression during sustained flow changes in relation to MMP-2 activation. 
Methods: In rabbit carotid and femoral arteries, flow was decreased to 
30% by partial ligation (LIG) which induced arterial shrinkage or increased 
sevenfold by arterio-venous shunting (AV) which enlarged the artery. Furin 
mRNA levels were determined by semi-quantitative PCR at I, 3, 7 days after 
flow change (N = 5 arteries). cDNA synthesis was quantified by adding 32P 
dATP to 30% of the cDNA reaction. MMP-2 activation was determined by 
zymography at 1, 2, 7, 21 days (N = II-18 arteries). Contralateral arteries 
were used as control. 
Results: (See Table) 
Ratio oueratedlcontrol atterv for Furin mRNA levels and MMP-2 activitv 
1dAV 2d AV 7dAV 2ldAV Id LIG 2dLIG 7dLIG 21dLIG 
Furin 1.6i-0.2* 1.3&0.2 1.2~kO.5 1.010.2 0.810.2 2.2* 0.2* 
MMP-2 1.610.6 1.91-0.3* l.O+O.l 1.0&0.3 1.2kO.4 1.310.2 1.6ztO.3 2.0*0.3* 
Data are meanrtSEM, * = p < 0.05 
AV induced an increase of Furin mRNA at day 1. MMP-2 activation 
increased at day 2. LIG induced an increase of Furin mRNA at day 7 and of 
MMP-2 activation at day 21. 
Conclusions: Increase of Furin mRNA preceded MMP-2 activation. This 
shows the presence of Furin in the arterial wall and implies its involvement 
in collagen breakdown in arterial remodeling. 
L-L--i 1092 19 Inactivation of Nitric Oxide by Superoxide is a 
Mechanism Leading to Age-Related Endothelial 
Dysfunction 
Bernd van der Loo, Ralf Labugger, Juliane Kilo, Markus Bachschmid, 
Daniel Gygi, Jeremy N. Skepper, Dan Atar, Tadeusz Malinski, Volker Ullrich, 
Thomas F. Liischer. Cardiology, University Hospital Zurich and 
Cardiovascular Research, University of Zurich, Switzerland 
Background: Aging alters endothelial function but the underlying mecha- 
nisms have been incompletely explored. We investigated if increased inacti- 
vation of nitric oxide (NO) by superoxide (0;) might be involved. 
Methods: Aortas from 4-6 months old (Y; n = 8), 19 months old (M; n = 
7), and 32-35 months old (0; n = 8) normotensive male rats were cut into 
rings 0.5 cm long and mounted in organ chambers. After pre-contraction with 
norepinephrine, endothelium-dependent relaxation was tested using iO-‘O 
to 10M5 mol/L A 23187 or acetylcholine (ACh). For endothelium-independent 
relaxation, sodium nitroprusside (SNP) was used. NO release was directly 
measured on the endothelial surface using a porphyrinic microsensor. 0; 
measurements were carried out using a lucigenin enhanced chemilumines- 
cence method. Western blot was used for eNOS, MnSOD and CuiZnSOD 
protein expression. 
Results: Relaxation to both ACh and A 23187 was dramatically reduced 
in old aortas. Maximal relaxation to ACh was -95 i 2% in young, -89 * 3% 
in middle-aged, and -62 i 3% in old rats and to A 23187 -75 f 1% (Y), 
-74 f 4% (M), and -47 f 4% (0) (for both agonists Y v 0 and M v 0: p 
c: 0.0001: Y v M: ns). Relaxation to SNP was unaffected by age. Aortic NO 
levels were lower in old and middle-aged rats compared with young rats (Y: 
1197i76;M:831f119;0:340f54nmol/L;YvO:p~0.0001;MvO:p= 
0.0006; Y v M: p = 0.0064). In contrast, 0; production was nearly threefold 
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increased in aortas from old rats (Y: 6058 & 731; M: 2145 + 426; 0: 2302 f 
617 cpm/mg; Y v M: ns; Y v 0 and M v 0: p < 0.0001). eNOS expression 
markedly increased in old aortas (Y: 319 i 4; M: 714 f 2; 0: 1980 -4 14 
pixels/U; Y v 0: p i 0.0001). In contrast, both MnSOD (Y: 986 f 32; M: 1415 
f 21; 0: 849 f 12; p = 0.005) and Cu/ZnSOD (Y: 1236 + 23; M: 1738 k 27; 
0: 1504 f 44; p = 0.002) decreased. 
Conclusion: Oxidative stress may be a significant contributor to age- 
related endothelial dysfunction. O,, partly due to a breakdown of antiox- 
idative defense with age, leads to inactivation of NO, whereas eNOS is 
overexpressed in an inefficient attempt to counterbalance decreased NO. 
I 1092 20 Simultaneous Administration of Glycoprotein llb/llla Inhibitors With Low-Molecular-Weight 
Heparins Does Not Augment the Release of 
Tissue Factor Pathway Inhibitor: Implications in 
the Management of Cardiovascular Patients 
Debra A. Hoppensteadt, Aris Musabji, Fred Leya, Bruce E. Lewis, Eric 
D. Grassman, Erum Khan, Sarfraz Ahmad, Jawed Fareed. Loyola 
University Chicago, Maywood, U/inois, USA 
Background: It has been suggested that the glycoprotein (GP) llb/llla recep- 
tor inhibitors such as ReoPro augments the anticoagulant effects of heparins 
necessitating the reduction of their heparin dosage. In clinical practice, the 
recommended dosage of unfractionated heparin (UFH) and low-molecular- 
weight heparins (LMWHs) have been arbitrarily reduced when GPllbillla 
receptor antagonists are used simultaneously. Since one of the main mech- 
anisms by which heparin produces its anticoagulant/antithrombotic effect is 
the release of tissue factor pathway inhibitor (TFPI), a study was designed 
to determine the effect of GPllb/llla inhibitors such as ReoPro and Aggrastat 
on TFPI release by UFH and enoxaparin. 
Methods: Four group of patients were included in this study. The 1 st 
group comprised of patients (n = 60) undergoing percutaneous intervention 
receiving conventional heparin (12,000 U bolus), and the 2nd group received 
UFH + Aggrastat or ReoPro (with standard dose as 0.25 mgikg bolus fol- 
lowed by 0.125 wg/kg/min infusion for 12 h). The 3rd group comprised of 
patients receiving 0.75 mg/kg enoxaparin, and the 4th group received the 
same enoxaparin + standard dose of ReoPro. Blood samples were drawn at 
baseline and 5 min, post-administration. TFPI antigen levels were measured 
using an ELISA-based method (American Diagnostica, Greenwich, CT). 
Results: In the case of UFH, a prolonged activated clotting time (ACT) 
was noted (351 f 45 set) and with ReoPro, it was 338 f 60 sec. The LMWH 
enoxaparin produced a much weaker effect on the ACT (197 f 29 set) and 
simultaneously administration of ReoPro did not significantly increase the 
ACT (201 f 27 set). The TFPI levels were comparable in both the UFH 
group alone was 829 f 166 rig/ml and in the UFH + ReoPro group, it was 
861 f 90 rig/ml. Similarly, the TFPI levels in the Enoxaparin group alone 
was 674 f 192 rig/ml and in Enoxaparin + ReoPro group, it was 635 + 80 
rig/ml which did not differ significantly. Interestingly, in two separate studies 
at higher dosage of enoxaparin (1 mgikg) produced proportionately higher 
levels of TFPI (710 i 65 rig/ml). A review of the data on Aggrastat and 
Integralin when administered together with UFH also revealed that GPllb/llla 
inhibitors do not influence the release of TFPI. 
Conclusion: TFPI release is found to be specific for such polyelectrolytes 
as heparins and LMWHs. Co-administration of GPllb/llla receptor antago- 
nists does not alter the release of TFPI. Thus, an imperical reduction in the 
heparin dosage may compromise the therapeutic effects of heparins. On the 
contrary, in these situations a reduction of the GPllbillla dosage should be 
objectively considered. 
1092-21 Statins Enhance Flow Dependent Vasodilation in 
the Human Skin Circulation: A New Approach to 
Monitor Vascular Function During Cardiovascular 
Therapy 
Christian Binggeli, Lukas E. Spieker, Isabella Sudano, Vesna Stojanovic, 
Roberto Cot+, Daniel Hayoz’ , Thomas F. Liischer, Georg Nell. Cardiology: 
University Hospital Zurich; ‘Hypertension and Vascular Medicine, CHfJ\/: 
Lausanne, Switzerland 
Background: Endothelial dysfunction as an early feature of atherosclerosis 
in hypercholesterolemic patients can be improved by statin !herapy. There 
are several methods to assess endothelial function in vivo, none of them 
being practicable in everyday routine. The objective of this study was to 
investigate the value of laser Doppler flowmetry for assessment of vascular 
function as an easily practicable surrogate of existing techniques. 
Methods: Skin perfusion, measured by laser doppler flowmetry, was reg- 
istered at rest and during reactive hyperemia (RH) induced with a cuff inflated 
to suprasystolic pressure for 4.5 minutes. 11 patients (age 42-72 y, total 
cholesterol 5.5-9.6 mmolil) were studied before and during statin therapy 
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(atorvastatin IO-20 mg/d). To investigate the mechanisms of postischemic 
skin hyperemia in healthy volunteers, the NO synthase inhibitor L-NAME and 
its inactive isoform D-NAME (0.5 micromolil0 microliter each) were injected 
intradermally in the left and right forearm skin, respectively. After 40 minutes, 
skin RH was measured. On a separate day, they ware reexamined before 
and 2 hours after oral aspirin (1 g). 
Results: Postischemic skin blood flow was reduced in hypercholes- 
terolemic patients (40 j, 14%) compared to healthy controls (256 f 38%, 
p = 0.0002) and improved after ator-vastatin (136 & 24%, p = 0.002 vs. pre 
treatment). The hyperemic responses were not significantly different after 
L-NAME and D-NAME, but compared to D-NAME, basal skin flow was re- 
duced by L-NAME (-42%, p = 0.1). Aspirin reduced skin blood flow. Basal 
skin blood flow (-54%, p < 0.05) and peak hyperemic blood flow (-50%, p = 
0.031) significantly decreased and half-life of the hyperemic response tended 
to be shorter (-22%, n.s.). The measurements proved to be reproducible 
(data not shown). 
Conclusions: Laser Doppler flowmetry of skin reactive hyperemia is 
an easy and reproducible method to assess vascular function. Vasodila- 
tor prostaglandins are the major mediators of postischemic skin hyperemia, 
which is impaired in hypercholesterolemic patients and which can be en- 
hanced by cholesterol-lowering therapy. 
1092-22 Early Neutrophil Recruitment and lntimal 
Hyperplasia: Studies in a Murine Model of 
Femoral Artery Transluminal Injury 
Merce Roque, Harry Ma, Ernane D. Reis, John T. Fallon, Valentin Fuster, 
Juan J. Badimon, Joan Berman, Mark B. Taubman. Mount Sinai School of 
Medicine, and Albert Einstein School of Medicine, New York, New York, USA 
Background: Neutrophil activation after percutaneous coronary interven- 
tions has been related to development of restenosis in humans, suggesting 
neutrophils may drive the intimal response. Using a murine model of translu- 
minal arterial injury associated with early leukocyte recruitment to the injured 
surface, we studied whether specific inhibition of neutrophil margination 
would prevent the development of intimal hyperplasia. 
Methods: Twenty-four mice of the C57BU6 strain underwent bilateral 
femoral artery denudation by passage of a 0.25-mm angioplasty guidewire. 
Mice received two doses (48 hours and 1 hour before injury) of either a 
monoclonal antibody against mouse neutrophils (RB6-8C5) or isotype-match 
IgG. Histology and morphometry of the cross-sectioned femoral arteries were 
performed at 1 hour and 28 days after injury. 
Results: Mice treated with RB6-8C5 had a 62% decrease in the relative 
neutrophil count. One hour after injury, 24 & 15 neutrophils/section were 
found on the denuded luminal surface in the isotype-treated group, versus 1 
f 1 in the RB6-8C5 antibody-treated group. Twenty-eight days after injury, no 
significant differences were found in intimal-to-medial ratios between control 
group (1.0 i 0.2) and the group treated with RB6-8C5 (1.1 & 0.2) or in 
luminal narrowing (23 * 5% and 23 f 5%, respectively). 
Conclusions: Partial depletion of circulating neutrophils with RB6-8C5 
monoclonal antibody reduces early neutrophil margination on the luminal 
surface after injury but does not prevent intimal hyperplasia in this mouse 
model of transluminal arterial injury. 
1092-23 Is Arteriogenesis Inducible When Collateral 
Arteries are Already Recruited? 
Imo E. Hoefer, Ivo R. Buschmann, Niels van Royen, Matthias Heil, Eva 
E. Katzer, Wolfgang Schaper. Max-Planck-institute, Bad Nauheim, Germany 
Background: For the exogenous supply of several angiogenic growth factors 
only a brief time window is available for action, usually within hours or days 
following arterial occlusion. This would limit their therapeutic power in patients 
with a stable but functionally defective collateral circulation. 
Methods: Therefore we tested whether growth of collateral arteries can be 
restarted after long term femoral ligation in the rabbit. 24 New Zealand White 
rabbits were ligated for 3 weeks. Thereafter they were assigned to receive 
either PBS, MCP-1, and GM-CSF plus MCP-I via osmotic mini-pump and 
catheter into the proximal stump of the a. femoralis, the origin of the stem 
part of collaterals, for one week. After 7 days of infusion the animals were 
again anesthetized and a pump powered shunt between the carotid artery 
and the abdominal artery was installed. At 6 different perfusion pressures 
(40-90 mmHg), combined each with a single bolus of differently labeled 
microspheres, peripheral perfusion pressures, and total flow were measured. 
Results: Collateral conductance was calculated from pressure differ- 
ences and flows (via microspheres counted by FACS-Analysis): PBS 79.08 
vs MCP-1 90.03 (ns) vs GM-CSF + MCP-1 124.94 (p < 0.05) ml/min/lOO 
mmHg. Conductance value without ligation: 159.25 ml/min/lOO mmHg. 
Conclusion: The application of MCP-I alone at 3 weeks after ligation 
does not significantly increase collateral conductance. Additional infusion of 
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GM-CSF significantly enhances the arteriogenic potential to 78% of normal 
perfusion values. 
1 1092-24 ) Bone Marrow-Derived Endothelial Progenitor 
Cells Do Not Significantly Contribute to 
Angiogenesis in a Tumor Model 
Anjali Pathak, Andrew Lee, Sabine Patterson, Thomas Quertermous, 
Frances L. Johnson. Stanford University, Stanford, CA, USA 
Background: There is experimental evidence that bone marrow-derived 
cells participate in adult neovascularization, however the endothelial cell 
progenitor (EPC) phenotype and its proliferative potential remain unclear. 
We tested whether murine whole bone marrow or purified hematopoietic 
stem cells (HSCs) can give rise to endothelial cells in an adult model of 
tumor angiogenesis. 
Methods: Lineage tracking of whole bone marrow (WBM) and HSC 
progeny was accomplished using a congenic bone marrow transplantation 
(BMT) model in which donor HSC were isolated from male ROSA26 x 
C57BUKa-Thy1 .l mice which constitutively express the LacZ transgene. 
HSCs were isolated from the bone marrow by immunolabeling and fluores- 
cent activated ceil sorting of cells bearing the Thy1 .l”Lin-Sea+ phenotype, 
1 x IO6 WBM cells or 700 HSCs were transplanted into 8-10 week old wild- 
type female mice pretreated with 925 rads total body irradiation. Negative 
control animals received 1 x 10s male wildtype whole bone marrow. &I2 
weeks post-BMT, 1 x 1 O6 murine Lewis lung carcinoma cells were injected 
SQ and allowed to develop into palpable tumors. The tumors were removed 
and examined histologically for localization of beta-galactosidase express- 
ing cells using X-gal staining and immunohistochemistry. Tumor vasculature 
was identified by immunohistochemical staining of the endothelium using 
anti-PECAM monoclonal antibodies. 
Results: Bone marrow donor-derived endothelial cells were observed 
in l-3% of vessels examined in WBM recipients and in less than 1% of 
HSC recipients. Genetically marked groups of cells were never identified, 
suggesting that EPCs either do not have replicative potential or differentiated 
as they contributed to vessel formation. 
Conclusion: Murine WBM and HSC-derived EPCs do not contribute 
significantly to tumor angiogenesis. These data suggest that EPC contribution 
to tumor angiogensis is unlikely to be biologically significant, or that the true 
reservoir of EPCs is not in the marrow. We are testing other models to 
confirm these findings in additional forms of angiogenesis, and employing a 
parabiosis model to identify EPC reservoirs outside of the bone marrow. 
ORAL 
Cardiovascular Gene Therapy 
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2:00 p.m. 
III 852 1 Long Term (>l Year) High Level Myocardial Transgene Expression With an Adeno-Associated 
Virus 
Leonard Y. Lee, G. Farah Rahman, Xiaohuai Zhou, Dean R. Polce, 
Xuebin Yin, Neil R. Hackett, 0. Wayne Isom, Ronald G. Crystal, Todd 
K. Rosengart. Department of Cardiothoracic Surgery and Division of 
Pulmonary and Critical Care Medicine, New York Presbyterian 
Hospital-Wei// Medical Col/ege of Cornell University, New York, New York, 
USA 
Background: Adenovirus vectors have been successfully utilized to provide 
short term expression of therapeutic transgenes in a number of settings. For 
the purposes of treating chronic conditions such as heart failure, however, 
vectors which provide prolonged expression such as adeno-associated virus 
(AAV) would be more suitable. 
Methods: Sprague-Dawley rats underwent median sternotomy and re- 
ceived an apical intramyocardial injection of either AAV coding for the firefly 
luciferase (Luc) gene (AAV.Luc) or, as a control, AAV coding for the jelly- 
fish grin fluorescent protein (GFP) gene (AAV.GFP) at a dose of 5 x IO’ 
infectious units in a volume of 50 ~1. Animals were sacrificed at various time 
points after vector administration (n = 3 per time point), and the hearts were 
excised to assess luciferase activity by luciferase assay and luminometer. 
Results: AAV.Luc provided transgene expression which quickly rose to 
a high level of expression at 28 days after vector administration [1.8 i 0.2 
(x 1 05) RLU/mg protein], and was sustained for up to 420 days after vector 
administration [I .4 * 0.15 (x 106) RLU/mg protein; p = 0.001, comparison of 
day 28 to day 4201. In contrast, the control AAV.GFP vector demonstrated no 
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luciferase activity detectable above background at any time point assayed (p 
> 0.1). 
Conclusions: AAV provides an efficient means of delivering prolonged 
cardiac gene therapy. This vector may prove useful in conditions such as 
heart failure requiring chronic therapy. 
El. 
2:15 p.m. 
852-2 Microsphere Loaded Monocytes are Potential 
Vectors for Therapeutic Arteriogenesis 
Ivo R. Buschmann, Imo E. Hoefer, Matthias Heil, Niels van Royen’, 
Eva Katzer, Jan J. Pick’ , Wolfgang Schaper. Max-Planck-lnstifut, Dept. of 
Experimental Cardiology; Bad Nauheim, Germany: ‘Amsterdam Mededical 
Center, Dept. of Cardiology; The Netherlands 
Background: Direct injection of substances stimulating collateral artery 
growth (arteriogenesis) is limited by invasiveness and duration of effect. 
An alternative is the use of circulating monocytes, capable of homrng into the 
vessel wall of proliferating collateral arteries. In the present study we eval- 
uated the potential of these circulating monocytes as selective arteriogenic 
protein transporters.- 
Methods: Isolated rabbit monocytes were loaded with fluorescent mic- 
rospheres (0 2 &rn) and reinfused intravenously into four groups of rabbits 
after ligation of the a. femoralis and local infusion via osmotic minipumps, 
of either: 1) MCP-I alone; 2) MCP-1 plus monocional ICAM-antibodies 3) 
Nonligated animals and 4) ligated animals infused with PBS as control. 48 
hours after reinfusion animals were killed and biopsies were taken of the 
adductor and quadriceps muscle in both hindlimbs. With FACS analysis the 
total number of loaded monocytes/gram tissue was quantified. 
Results: total number of monocytes/gram tissue: unligated 35000 f 
7200, ligated 120000 f 10500, MCP-1 treatment 320000 f 28000, MCP-I 
treatment and anti-ICAM antibodies 132000 + 11000. The number of mono- 
cytes/gram tissue was significantly different for all groups except for the 
ligated group and the group treated with the combination of MCP-1 and 
a&CAM antibodies (see figure) 
0.031. However, significantly higher levels of p-gal were encountered in the 
RV with GP vs IM delivery [I .9 f 0.3 x 105) RLU/mg protein vs 5.6 i 0.9 
(~10~) RLUimg protein; p < 0.005]. Similar levels of expression were seen 
in the septum with either technique [IM; 1.9 + 0.6 (x IO’) RLU/mg protein vs 
GP; 9.5 f 0.5 (~10s) RLU/mg protein: p > 0.21 
Conclusions: Global delivery of myocardial gene therapy provides a rela- 
tively uniform distribution of an Ad vector throughout the heart, a consideration 
when treating global myocardial dysfunction as in CHF; while IM adminis- 
tration provides highly localized regional vector delivery which has potential 
advantages for regional therapies such as therapeutic angiogenesis. 
2:45 p.m. 
1 852-4 1 Adenoviral Gene Transfer of Cyxlooxygenase-1 
Improves Luminal Area and Blood Flow After Carotid 
Balloon-Injury in Atherosclerotic Watanabe Rabbits 
Pierre Zoldhelyi, Zhi-Qiang Chen, Harnath S. Shelat, Janice McNatt, James 
T. Willerson. Texas Heart lnsfitute and Dept. of Medicine, Univ. of Texas 
Medical School, Houston, Texas, USA 
Background: Endothelial cyclooxygenase (COX-I) is a key enzyme in 
prostacyclin synthesis and is deficient at sites of vascular injury and ath- 
erosclerosis We tested whether gene transfer of COX-I preserves blood 
flow and luminal area after balloon angioplasty (BA) in an atherosclerotic 
animal model. 
Methods: BA (5 inflations, 8 atm) was performed in the carotid arteries of 
12-I 8 month old Watanabe rabbits, a model of human familial hypercholes- 
terolemia, followed by local delivery of adenoviral vectors (1 x 10” pfu/mL) 
encoding the human COX-I gene (Ad-COX-1, N = 11) or no foreign gene 
(Ad-RR, N = 10). Plasma cholesterol was 383 f 52 and 403 f 101 mg/dL, 
resp., in Ad-COX-1 and Ad-RR treated rabbits (p = NS). 
Results: By immunohistochemistry, human COX-1 expression was ob- 
served 4 days after Ad-COX-I but not after Ad-RR delivery. Blood flow 
velocity (BFV), measured before BA and at sacrifice after 28 days, showed 
a 28 day/baseline ratio of 0.45 f 23 and 0.92 i 36, resp., in the Ad-RR and 
Ad-COX-I group (p = 0.006). The luminal area at the site of BA was 1 .O i 0.2 
and 0.5 f 0.3 mm*, resp., in Ad-COX-I and AdRR-control treated arteries 
(p < 0.001). Both the external carotid circumference and the outer medial 
diameter were larger in Ad-COX-I than Ad-RR treated arteries (resp., 5.0 
i 0.3 vs. 4.3 i 0.5 mm and 1.62 * 0.15 vs. 1.39 f 0.17 mm, p < 0.002 
and <0.006). In contrast, the neointimal areas in the two groups were not 
significantly different (0.37 f 0.17 vs. 0.41 & 0.24 mm’, resp., Ad-COX-1 vs. 
Ad-RR). On necropsy, a carotid thrombus was seen in 2110 and 0111 rabbits 
treated, resp., with Ad-RR and Ad-COXI. 
Conclusion: Adenoviral gene transfer of COX-1 to angioplasty injured 
atherosclerotic arteries exerts no cytostatic effect, but may improve blood 
flow by reducing vasoconstriction and thrombosis as late as 28 days after 
BA. 
Conclusion: This study shows that MCP-1 is a potent chemoattractant for 
loaded monocytes homing to collateral arteries. This process can be blocked 
by ICAM-antibodies. This new concept of selective local enhancement and 
blocking of accumulation of circulating loaded monocytes may be the basis 
of a new therapeutical concept to enhance arteriogenesis. 
2:30 p.m. 
852-3 Global Perfusion vs Regional Administration 
Strategies for Myocardial Gene Therapy 
Leonard Y. Lee, G. Farah Rahman, Kenneth T. Lee, Tarek El-Sawy, Neil 
R. Hackett, 0. Wayne Isom, Ronald G. Crystal, Todd K. Rosengart. 
Department of Cardiothoracic Surgery and Division of Pulmonary and 
Critical Care Medicine, New York Presbyterian Hospital- Weill Medical 
College of Come// Universifi: New York, New York, USA 
Background: Global perfusion (GP) and intramyocardial vector adminis- 
tration represent alternative strategies for cardiac gene therapy. While IM 
delivery has been shown to provide high local transgene concentrations, GP 
delivery may be an ideal method of gene transfer when global treatment is 
needed as in heart failure. 
Methods: Sprague-Dawley rats underwent sternotomy and either IM 
injection of an Ad vector coding for the fi-galactosidase marker gene at 
2 sites in the wall of the left ventricle (LV). [Adfigal;Ei x IO9 particle units 
(pu)/25 pL; total IO”’ pu/50 ~1) or GP via cross clamping of the aorta (10 
set) and the intraventricular administration of the same vector (AdDgal; lOi 
pui50 ~1). Animals were sacrificed 2 days after vector administration and the 
LV. septum, and right ventricle were assessed for ,&gal activity. 
Results: IM and GP administration yielded the greatest B-gal expression 
in the LV, but local expression was 5-fold greater after IM vs GP delivery 
[9.5 f 0.7 (x 1 Oc) RLU/mg protein vs 0.5 + 0.2 (x 1 Oe) RLUimg protein; p < 
3:00 p.m. 
852-5 Effect of Intramuscular Gene Transfer With VEGFlsl 
on Endothelial Function in Patients With Peripheral 
Atherosclerotic Occlusive Disease 
Sanjay Rajagopalan, Manan B. Shah, Ann Luciano, Robert J. Lederman, 
Margaret Samyn’ , Elizabeth G. Nabel. University of Michigan Medical 
Center and Parke-Davis Pharmaceutical Research; ’ Warner Lambert, Ann 
Arbor, Ml, USA 
Background: Previous studies have demonstrated that Vascular Endothelial 
Growth Factor (VEGF), a potent endothelial specific angiogenic agent also 
releases Nitric Oxide (NO) through stimulation of endothelial nitric oxide 
synthase. 
Methods: We investigated if adenoviral mediated gene transfer of VEGFla, 
(AdevVEGFtzj.,s), administered as part of a Phase I trial for symptomatic 
lower extremity ischemia in patients with PAOD, alters endothelial depen- 
dent and independent flow. The measurement was not protocol-specified. 
Four patients at one center were studied prior to and 4 weeks following 
AdevVEGF,z, 10 at concentrations of 4 x log-4 x 10” particle units. Lower 
extremity blood flow was measured in the injected limb with a thermodilution 
catheter in the femoral vein while acetylcholine (Ach, 150 and 300 fig/minute) 
and nitroglycerin (NTG, 100 @g/mm) were administered sequentially into the 
ipsilateral femoral artery. 
Results: Absolute baseline flows, pre and post gene therapy were 0.33 
f 0.03 and 0.31 + 0.04 Umin respectively (p = 0.39). In contrast, responses 
to Ach improved from 0.32 f 0.03 to 0.73 & 0.10 Umin with 150 @g/min 
and from 0.49 f 0.02 to 0.70 * 0.08 Umin with 300 wg/min (p < 0.01). 
Nitroglycerin responses did not differ significantly 0.58 & 0.06 vs 0.73 i 0.09 
Umin (p = 0.88). Percent change in flow (normalized to baseline flow) are 
reported below for all the patients: 
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Ach 150 Ach 300 NTG 100 Dose of 
I*g/min wglmin figlmin Ada/ VEG~PI.IO 
Patient A PE 100 275 156 4x 109 
Post 450 518 562 
Patlent 6 Pi-e 69 69 59 4 x 109.5 
Post 150 117 250 
Patient C Pre -50 -3 19 4 x 10’0 
Post 28 78 28 
Patient D PW -4 38 164 4 x 10’0 
Post 145 48 65 
Conclusion: Adenoviral mediated intramuscular gene transfer of VEGFlsr 
appears to improve endothelial function in this small number of patients with 
PAOD and may represent an additional benefit of treatment with VEGF. 
39 5 p.m. 
I 852 6 Inhibition of In-Stent Plaque Formation by Inducible Nitric Oxide Synthase-Lipoplex-Mediated Gene 
Therapy in a Pig Femoral Artery Stent Model 
Heiko E. “on der Leyen, Andreas Muhs, Jiirgen Schrader, Dirk Hausmann, 
Matthias Sturm, Bernd Heublein. Cardiogene, Erkrath; Hannover Medical 
School, Hannover, Germany 
Background: Whereas most of current gene transfer methods involve the 
use of viral vectors, we have developed a non-viral, liposome-based inducible 
nitric oxide synthase (iNOS) gene transfer method with high vascular trans- 
fection efficiency. We employed this gene therapy approach to determine 
the effect of iNOS overexpression on plaque formation after femoral artery 
stenting. 
Methods: iNOS gene transfer was performed in the femoral artery stent 
model in Gottingen-Mini-pigs (20-25 kg). Local femoral gene transfer was 
performed with the Infiltrator@ delivery device (InterVentional Technologies, 
San Diego, CA), using a volume of 400 @I (containing lipoplexes with the 
appropriate Fg quantity of iNOS cDNA vector; control: DNA vector/liposome 
complex lacking the iNOS coding sequence). After transfection, the stent 
(Wiktor@ stent) was deployed to induce locally vascular neointimal prolif- 
eration Transfection efficiency was determined at day 3 after transfection 
using iNOS specific immunohistochemistry. For determining efficacy in pre- 
vention of plaque formation, 4 weeks after transfection/stent implantation an 
intravascular ultrasound (IVUS) study was performed to measure in-stent 
plaque area and plaque ratio (= plaque area to total vessel area). 
Results: Using a concentration of 2 fig iNOS-lipoplexes, 40 f 6% (n = 
6) of the medial vessel area stained positive for INOS. IVUS showed that 
local transfection of iNOS lipoplexes resulted in a 39.6% reduction of in-stent 
plaque area (control: 40.85 f 6.37 mm’; iNOS: 24.69 f 1.8 mm’; p = 0.03) 
and a 41.8% reduction of plaque ratio (control: 38.29 + 6.89%; iNOS: 22.3 f 
2.39%: p = 0.037), respectively (n = 8). The distention factor and total vessel 
area showed no difference between both groups. In 7 out of 8 animals a 
reduction of plaque area was achieved (ranging from 21.8% to 62.9%). 
Conclusion: iNOS-Lipoplex mediated gene therapy employing the Infil- 
trator@ delivery device proved to be efficacious in reducing in-stent plaque 
formation and represents a promising approach to prevent in-stent restenosis 
after balloon angioplasty in the clinical setting. 
POSTER 
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1 1111-41 ) Induction of PAI- Synthesis by Growth Factors in 
Human Arterial Smooth Muscle Cells is 
Independent of the 4G15G Polymorphism in the 
Promoter of the PAI- Gene 
Thomas K. Nordt, Esther Eschenfelder, Johannes Ruef, Karlheinz Peter, 
Burton E. Sobel, Christoph Bode. University of Freiburg, Germany; 
University of Vermont, Burlington, Vermont, USA 
Background: Elevated PAI-I in blood is a cardiovascular risk factor. In a 
recent metaanalysis an association was found between the 4G allele of the 
4G/5G polymorphism in the promoter of the PAI-I gene and increased risk for 
myocardial infarction. We and others have demonstrated induction of PAI-I 
synthesis by growth factors in human arterial smooth muscle cells (HASMC). 
Thus, we sought to determine whether the 4G/5G polymorphism affects this 
interaction. 
Methods and Results: HASMC from 19 healthy donors were exposed 
to growth factors known to induce PAI-I synthesis (TGF-B, PDGF, bFGF, 
TNF-ol, thrombin) and genotyped by two PCR-based methods. One uses a 
mutated oligonucleotide inserting a new restriction site to the amplification 
product in the case of the 5G allele. The other uses oligonucleotides either 
amplifying the 4G or the 5G allele. In genotype 4G/4G (n = 7), 4G/5G (n = 
7), 5G/5G (n = 5) the induction of PAI- synthesis was 3.1 f 1 .O-, 2.7 & 1 .O-, 
3.1 i 1.6-fold by TGF-/3; 2.3 & 0.6-, 1.9 f 0.8-, 2.3 f 0.6-fold by PDGF; and 
1.9 f 0.5-, 1.7 f 0.4-, 1.9 ‘r 0.7-fold by thrombin (thus no differences were 
significant). In addition, the inducibility in response to bFGF and TNF-a did 
not differ among the three genotypes. 
Conclusions: The association between the 4G/5G polymorphism and 
myocardial infarction is not mediated by differential effects of growth factors 
on PAI-I synthesis in HASMC. Accordingly, other factors influencing fAI-1 
synthesis or other cells than arterial smooth muscle ceils may be responsible 
for the association. 
I 1111 42 A Recombinant Soluble P-Selectin Glycoprotein Ligand-1 Chimera has a Thrombolytic Effect in a 
Rat Model of Thrombosis 
Hong Zhang, Robert G. Schaub, James C. Keith, Jr., Anjali Kumar. 
Hemostasis/lmmunologl: Genetics Institute, Inc., Andover, MA, USA 
Background: P-selectin is a cell adhesion glycoprotein that is rapidly translo- 
cated to the surface of platelets and endothelial cells upon activation and 
mediates the interaction of these cells with leukocytes via its high affinity 
counter-receptor P-Selectin Glycoprotein Ligand-I (PSGL-I). P-selectin me- 
diated platelet-leukocyte adhesion has a role in thrombogenesis and in throm- 
bus stabilization and amplification. rPSGL-lg is a recombinant soluble form of 
PSGL-1, fusedto a human IgG, that has been mutated to prevent complement 
fixation and Fc receptor binding. We have recently shown that P-selectin an- 
tagonism using rPSGL-lg in conjuction with tPA, significantly enhanced throm- 
bolysis and prevented reocclusion in a porcine model. In the present study, 
the thrombolytic effect of rPSGL-Ig alone was investigated in a rat model. 
Methods: Thrombus formation was elicited in the inferior vena cava of 
male Sprague-Dawley rats between the left renal vein and the iliac bifurcation. 
A strand of wool yarn was introduced into the lumen of the vena cava using 
a small straight sewing needle such that 0.5 inch of the thread was inside 
the lumen. A vascular clamp was placed proximal to the thread to briefly 
stop blood flow and 1 U of bovine thrombin was injected into the vena 
cava near the wool thread. The clamp was then removed and the blood flow 
re-established. Thirty minutes following thrombus formation, 200 U of heparin 
was administered IV followed by a single IV bolus of vehicle (formulation 
buffer) or 500 fig/kg of rPSGL-lg (4 day half-life in rats). Two hours following 
this treatment, the thrombus, which was anchored to the wool thread, was 
harvested, dried for 48 hours at room temperature and weighed. 
Results: The weight of the thrombus in control rats was 10.5 & 4.4 mg 
(n = 9). In the rats that received rPSGL-lg, thrombus weight at the end of 
2 hours was reduced by 48% to 5.5 & 3.5 (n = 11; p = 0.01). No indication 
of increased bleeding tendency was observed in the rPSGL-lg group as 
compared to control animals. 
Conclusion: These results suggest that P-selectin antagonism using 
rPSGL-lg, is not only a useful adjunct therapy in enhancing exogenously 
stimulated thrombolysis as previously suggested, but it may also have throm- 
bolytic effects when used alone, by interfering with thrombus stabilization 
and/or amplification, hence allowing endogenous fibrinolysis to more rapidly 
reduce thrombus burden. 
u 1111 43 Targeted Magnetic Resonance Contrast Agent for 
Detection of Thrombus 
Gregory M. Lanza, Sebastian J. Flacke, Stefan E. Fischer, Christopher 
S. Hall, Michael J. Scott, Jon N. Marsh, Patrick J. Gaffney, Samuel 
A. Wickline. NBSC, Potters Bar, UK; Washington University, St Louis, MO, 
USA 
Background: Atherosclerotic plaque rupture and its clinical sequelae, stroke 
and myocardial infarction, are commonly preceded by the formation of fib- 
rin-filled, microfissures. These vulnerable plaques can not be detected by 
routine imaging methods. However, unstable plaques may be sensitively and 
specifically identified by molecular imaging with a novel, fibrin-targeted, lipid 
encapsulated, perfluorocarbon emulsion (250 nm) modified with thousands 
of gadolinium-DTPA complexes on the outer surface. In the present study, 
we determined the concentration of surface Gd-DTPA required to maximize 
the sensitivity of fibrin deposit detection with Ti-weighted MRI imaging. 
Methods: Lipid-conjugated Gd-DTPA was incorporated into the surfactant 
layer of biotinylated perfluorocarbon emulsions at concentrations a 0, 1.25, 
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2.5, 5, IO and 20 mole%. Biotinylated antifibrin monoclonal antibodies (NIB 
5F3) and avidin were used to couple the emulsion nanoparticles to fibrin clots. 
Magnetic resonance imaging of the targeted clots suspended in blood was 
performed with a Philips Gyroscan ACS-NT (1.5 T) and Tl was calculated 
using the Look-Locker technique. 
Results: Increasing concentrations of Gd-DTPA improved Tl shortening 
of targeted clots monotonically. Tl relaxation was decreased maximally (p < 
0.05) at the 20 mole% level (602 ms) vs. control (1218 ms). 
Conclusion: Detection of fibrin deposits, particularly microthrombi on the 
surface of vulnerable atherosclerotic plaques requires high concentrations 
of gadolinium to provide adequate sensitivity. Fibrin-targeted perfluorocar- 
bon emulsion nanoparticles can provide a stable platform ideally suited to 
deliver tens of thousands of gadolinium atoms into microscopic fissures in 
unstable plaques. This novel targeted MRI agent may allow sensitive, early 
detection of unrecognized vascular pathology in high-risk patients and allow 
implementation of preventative therapies to reduce associated morbidity and 
mortality. 
u 1111 44 Serum Glucose but Not Insulin Modulates Platelet-Dependent Thrombosis in Patients With 
Coronary Artery Disease 
Michael Shechter, Maura Paul Labrador, C. Noel Bairey Merz, Sanjay Kaul. 
Cedars-Sinai Medical Center. Los Angeles, CA, USA 
Background: Previously we demonstrated that elevated blood glucose (G) 
is associated with augmented platelet-dependent thrombosis (PDT). High 
plasma insulin (I) levels are associated with enhanced risk of CAD, however, 
the mechanisms are unknown. 
Methods: We prospectively measured PDT in 36 stable CAD patients 
(mean age 68 f 9 years) on aspirin with controlled lipid levels. Porcine aortic 
media was exposed to flowing non-anticoagulated venous blood using an 
ex-vivo perfusion (Badimon) chamber. PDT was measured by computerized 
morphometry. Total plasma immunoreactive I and G levels were measured 
after overnight fast. 
Results: Initial correlation analysis between I, G and PDTdemonstrated I 
(r = 0.015, p = 0.93) and G (r = 0.51, p = 0.002). Patients were divided into two 
groups: Group A 5 and Group B > the median I level (17 @U/ml). There were 
no significant differences in age, serum lipids platelet count or fibrinogen 
levels between the two groups. PDT was not significantly elevated in Group 
B vs Group A (103 f 128 vs 84 + 74 wm2/mm, p = NS). PDT, however, 
was significantly augmented in patients with G > compared to <median (90 
mg/dl) level (159 i 141 vs 67 & 69 ~m’/mm, p < 0.01). 
Conclusion: Elevated G but not I is associated with augmented PDT in 
stable CAD patients with controlled lipid levels. This finding suggests that the 
mechanism contributing to the enhanced thrombogenic risk of CAD may be 
related to hyperglycemia rather than hyperinsulinemia. 
1111-45 Thrombostatin, a PAR1 lnhibitorz Reduces Both 
Platelet Aggregation and Adhesron After Arterial 
Wall Injury With Balloon Angioplasty 
Hongbao Ma, Ruiping Huang, Alejandro R. Prieto, Gauhar Kahn, 
Elie Hage-Korban, John Davis, Kenneth A. Schwartz, George S. Abela, 
Alvin H. Schmaier, Ahmed A.K. Hasan. Michigan State University: East 
Lansing, Michigan; University of Michigan, Ann Arbor, Michigan, USA 
Background: Thrombostatin (TSTAT), the 1-5 (Arg-Pro-Pro-Gly-Phe) frag- 
ment of bradykinin, is a selective inhibitor of or-thrombin (Ila)-induced platelet 
(PLT) activation. This study examined the effects of TSTAT on PLT aggrega- 
tion and adhesion following balloon angioplasty (BA). 
Methods: Whole blood was collected from each of 16 Beagle dogs prior to 
sacrifice. PLT-rich plasma was labeled with “’ In. Carotid arteries (GAS) from 
each dog were isolated and mounted in a dual perfusion chamber. Both CAs 
were injured by a 3 mm balloon catheter and then perfused with “‘In-labeled 
PLTs with or without TSTAT for 60 min. Continuous measurement of panicle 
size was made by a new method using the ratio of laser-light scattering at 1 p 
to 5” spread on a diode array of a multichannel analyzer. This was confirmed 
by Coulter counter. Adhesion of ‘I1 In-labled PLTs to the CAs was determined 
by radioactive counts measured in a y-counter. 
Results: The mean ratio of PLT aggregation in the perfusate (without and 
with TSTAT) by laser-light scattering was 1.4 (240.7 f 80.3 vs. 177.8 i 67.2: 
p < 0.02) and particle size by Couiter counter was 1.5 (39.9 f 12.5 vs. 27.1 
f 11.5; p < 0.01) while the mean ratio of radioactive PLT adhesion was 2.3 
(4,148.g + 947.9 vs. L779.8 + 685.6; p < 0.05). 
Conclusion: This study shows that TSTAT significantly decreased PLT 
aggregation and adhesion in dog CAs injured with BA. 
/ 1111 46 Is There a Difference in Thrombogenesis Between Patients With Paroxysmal, Persistent and 
Permanent Atrial Fibrillation? 
Foo LiSaw-Hee, Andrew D. Blann, David Gurney, Gregory Y.H. Lip. 
Haemostasis, Thrombosis and Vascular Biology Unit, University Dept. of 
Medicine, City Hospital, Birmingham, B 18 7QH, UK 
Background: Although chronic atrial fibrillation (AF) is known to be asso- 
ciated with a hypercoagulable state, it is uncertain whether the subgroups 
of chronic AF, namely paroxysmal, persistent or permanent AF differ in their 
thrombogenic potential. 
Methods: We measured levels of von Willebrand factor (vWf IU/dL, a 
marker of endothelial dysfunction), soluble P-selectin (sP-sel rig/ml, an index 
of platelet activation) (both by ELISA) and fibrinogen (fib, g/L Clauss method) 
(all unaffected by warfarin) in 23 persistent AF patients taking warfarin (INR 
2.0-3.0) (16 men; mean age 65 + 13 years). Levels were compared to age- 
and sex-matched controls in sinus rhythm and with patients with paroxysmal 
and permanent AF (23 in each group and all fully anticoagulated). 
Results: 
Controls Paroxysmal AF Persistent AF Permanent AF p+ values 
sP-sel 34 (3&46) 36 (32-44) 51 (37-63) 210 (162-284)* <O.OOl 
VWf to1 130 130+34x 106&26 143*47* 0.018 
Fib 2.5 f 0.6 3.3 i 0.7* 2.7 zt 0.8 3.1 f 0.9* 0.077 
*p < 0.005 paired t-test (controls I/S AF); + oneway ANOVA (for paroxysmal, persistent 
and permanent AF) [Tukey’s post hoc analysis: p = 0.013 for vWf and p < 0.001 for 
sP-sel between permanent and persistent AF: p < 0.001 for sP-sel between permanent 
and paroxysmal AF]. 
Conclusions: Permanent AF is associated with a hypercoagulable state 
(vWf, sP-sel and fibrinogen p c 0.005). Paroxysmal AF was found to have 
significantly raised levels of vWf and fibrinogen (p < 0.005) but not sP-sei. 
There were no significant differences in levels of fibrinogen, vWf and sP-sel 
between controls and patients with persistent AF (p = NS). 
1 1111-47 1 Sustained Coronary Artery Recanalization With 
Adjunctive Infusion of a Novel PsT-Receptor 
Antagonist ARC69931 in a Canine Model 
Kai Wang, Xiaorong Zhou, Zhongmin Zhou, Eric Topol, A. Michael Lincoff. 
The C/eve/and Clinic Foundation, C/eve/and, OH 44195, USA 
Reperfusion therapy for acute Ml remains limited by significant reocclusion 
rate due to excessive platelet accumulation and recruitment at the sites 
of vascular injury. We assessed the influence of a potent, specific, selective 
and novel PPT-receptor antagonist (AR-C69931), which inhibits ADP-induced 
platelet aggregation, in conjunction with thrombolytic therapy on the preven- 
tion of platelet aggregation and thrombosis formation in the canine model. 
Methods: An electrolytic injury canine coronary thrombosis model was 
used in this study, including 20 hound dogs (20-22 kg) of either sex 
(ARC69931 = IO, placebo = IO). A 2 cm segment of left circumflex coronary 
artery was isolated, and a doppler ultrasonic flow probe was placed around 
it for the measurement of coronary blood flow. Thrombosis was induced us- 
ing the electrolytic injury technique. After thrombus formation, 30 min was 
allowed to elapse to confirm the stability of thrombosis. Ten minutes prior 
to administration of t-PA (1 mg/kg over 20 minutes), all animals received 
either saline or ARC69931 (4 &kg/min) intravenously for total of 2 hours. 
All animals received heparin (80 U/kg) as bolus iv followed by a continuous 
infusion of 17 U/kg/hr. 
Results: The incidences of reocclusion rate and cyclic flow variation were 
significantly decreased in the ARC69931 group (p < 0.05) (Table). Platelet 
aggregation in response to ADP was decreased by half in the placebo group, 
but nearly 20-fold in the AR-C69931 group (1 .I1 f 1.27 vs 10.25 i- 8.31 p < 
0.05). At the end of adjundive therapy, platelet aggregation in the AR-C69937 
was decreased further (8.56 i 1.33 vs 12.22 f 11.48, p < 0.05). PT and 
aPTT were increased in all dogs as expected without a difference between 
two groups. BT was significantly extended by AR-C69931. 
RR RT (mini RD (min\ CFV Reocclusion 
Placebo 100% 21.5 f 2.86 75 * 39.86 50% 60% 
AR-C69931 100% 20 zt 6.09 119.7 zk 0.67* O%* 0YO- 
* P < 0.05 compared to placebo group. RR-Fieperfusion rate; RT-Reflow time; RD-Reflow 
duration: CR/-Cyclic flow variation. 
Conclusion: The administration of ARC69931 in the canine coronary 
thrombosis model blocks ADP-mediated platelet activation, aggregation, and 
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recruitment and prevents platelet-mediated thrombosis, resulting in prolon- 
gation of reperfusion time, and a decrease in reocclusion and cyclic flow 
variation rate. 
I 1111 48 Platelet Inhibition by Sertraline and 
N-Desmethylsertraline: A Possible Missing Link to 
Explain Benefits of Selective Serotonin Reuptake 
Inhibitors in Depressed Patients After Acute 
Coronary Events 
Victor L. Serebruany, Paul A. Gurbel, Christopher M. O’Connor. Sinai 
Center for Thrombosis Research, Baltimore, Maryland; Duke Clinical 
Research Institute, Durham, North Carolina, USA 
Background: Recently, clinical depression has been identified as an inde- 
pendent risk factor for increased mortality in patients following acute coronary 
events. Sertraline hydrochloride is a selective serotonin reuptake inhibitor 
@SRI), and is .an effective antidepressant agent. We assessed the in vitro 
effects of sertraline and NDMS on human platelets Its major liver metabolite, 
N-desmethylsertraline (NDMS), which is known to be neurologically inactive. 
Methods and Results: Pretreatment of blood with sertraline and NDMS 
resulted in a dose-dependent inhibition of aggregation induced by 5 kM ADP 
(p = 0.002), by 10 FM ADP (p = 0.0017), by collagen (p = O.OOS), and by 
thrombin (p = 0.026) in platelet rich plasma; and by 20 KM ADP (p = 0.006), 
and by collagen (p = 0.01) in whole blood. Expression of CD9 (p = 0.004) GP 
lb (p = O.OOOl), GP Ilb/llla (p = 0.007), VLA-2 (p = O.Oi), P-selectin (p = 0.02), 
and PECAM-I (p = O.Ol), but not vitronectin receptor was also reduced in 
sertraline and NDMS pretreated blood samples. Closure time was delayed for 
the collagen-ADP cartridge (p = 0.009) and for collagen-epinephrin cartridge 
(p = 0.01) indicating platelet inhibition in whole blood under high shear 
conditions. Rapid Platelet-Function Assay revealed a decreased (p = 0.002) 
ability of platelets to agglutinate fibrinogen-coated beads, suggesting GP 
Ilb/llla inhibition. 
Conclusions: Both sertraline and NDMS exhibited significant dose- 
dependent inhibition of human platelets. The anti-platelet effects of sertraline 
and NDMS may be directly related to the mortality benefits of SSRl’s after 
ischemic events including myocardial infarction and stroke. 
LIZI i 111 49 The Anti-Depressant Nefazodone Inhibits 
Shear-Induced Platelet Aggregation 
Daichi Shimbo, Eliza Geer, Josiah Child, Julio I. Osende, Satish Reddy, 
Juan J. Badimon, Valentin Fuster. Mount Sinai School of Medicine, New 
York, NY USA 
Background: Among survivors of myocardial infarction, psychological de- 
pression is associated with increased risk of cardiac death. Serotonin (5-HT) 
has been implicated in shear-induced platelet aggregation and cyclic flow 
reductions in the canine model. This effect has been successfully blocked 
by ketanserin, a ~-HT~A receptor antagonist. We studied the effect of ne- 
fazodone, an anti-depressant with potent 5-HTsn receptor antagonism, on 
shear-induced platelet aggregation in human subjects. 
Methods: Shear-induced platelet aggregation was studied in nine healthy 
patients (mean age 29 + 6) following the addition of nefazodone (at a thera- 
peutic concentration 1 x 1 Om5 M) or saline (control) to whole blood samples 
using the previously described cone and platelet analyzer. Whole blood was 
placed in polystyrene wells and circulated for 2 minutes at 2 different shear 
rates (1300 s-’ and 1800 s-t). After washing and staining, each plate was 
then analyzed with light microscopy connected to an image analysis system. 
The results were expressed as percentage of platelet surface coverage (SC) 
and average size of the surface-bound objects (AS). 
Results: Nefazodone significantly reduced SC and AS at both shear rates 
(see table). 
Shear 
1300 S-l 
1800 s-i 
Variable 
SC 
AS 
SC 
AS 
Control 
7.9 * 4.4 
26.5 S 6.9 
9.2 5 4.1 
34.6 + 12.2 
Nefazodone 
4.8 + 3.3 
23.2 rt 6.6 
2.9 * 2.0 
22.6 zt 6.3 
Reduction P 
39.4% <O.OOl 
12.6% <O.OOi 
68.9% 0.006 
34.6% <O.OOl 
Conclusion: Nefazodone significantly inhibits shear-induced platelet ag- 
gregation Given the association between depression and coronary artery 
disease, nefazodone due to its anti-platelet effects would be more appropri- 
ate in the treatment of depressed patients with cardiovascular disease. 
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I 1112 9 Low Stroke Risk and Mortality Rate With Off-Pump Coronary Bypass in Patients With High-Risk Aortic 
Arch Atheromas 
Naresh Trehan, Valavanur A. Subramanian, Manisha Misra, Aubrey 
C. Galloway. For the NYC-New De/hi Aortic Atheroma-Coronary Bypass 
Group; Escorts Heart Institute, New Delhi, India; Lenox Hill Hospitab and 
NYU School of Medicine, New York, N\r: USA 
Background: We have previously shown that aortic arch atheromas (AA) 
as seen on transesophageal echocardiography (TEE) impart a high risk of 
stroke (12.6%) and death (14.9%) during surgery requiring cardiopulmonary 
bypass. The strokes occur because of aortic cannulation and trauma which 
dislodge atheromas and superimposed thrombi. The majority of deaths are 
a result of the embolic events. In a pilot report of 41 pts with AA having 
off-pump coronary bypass, there were no strokes or deaths. This study 
reports the results in a large series from 3 institutions. 
Purpose: To evaluate the risk of death, stroke and peripheral emboliza- 
tion in pts with high-risk AA on transesophageal echocardiography who are 
undergoing off-pump coronary artery bypass surgery. 
Methods: Between 1996-99, 268 pts (226 in India and 42 in New York) 
with AA z 5 mm or with superimposed mobile thrombi as diagnosed on pre- 
operative or intraoperative TEE were studied. All pts had off-pump coronary 
bypass surgery. The mean age in India was 53; in New York it was 72; overall 
mean age was 56. 
Results: Off-pump (beating heart) coronary artery bypass grafting was 
done via sternotomy in 190 pts (71%) and via minithoracotomy in 78 pts 
(29%). The total number of embolic events was 7 (2.6%). This included 
3 strokes (l.l%), 1 TIA, 2 mesenteric emboli, and 1 peripheral embolus. 
In-hospital mortality was 1.9% (5 pts). 
Conclusion: Pts with AA have a high risk of intraoperative stroke and 
death during cardiac surgery requiring cannulation of the aorta for the insti- 
tution of cardiopulmonary bypass. However, if the coronary bypass is done 
off-pump, on the beating heart, the risk of stroke is very low (l.l%), as is the 
in-hospital mortality rate (1.9%). 
I Ii 12 10 Is Aortic Valve Sclerosis by TEE Associated With Atherosclerotic Disease? 
Kirsten Tolstrup, Carlos A. Roldan, Michael H. Crawford. Veterans Affairs 
Medical Center and University of New Mexico, Albuquerque, New Mexico, 
USA 
Background: Recent data suggest that aortic valve sclerosis (AVS) detected 
by transthoracic echocardiography (TTE) in patients > 65 years old is asso- 
ciated with increased risk of cardiovascular death, myocardial infarction, and 
stroke. Thus, AVS is believed to be a marker of atherosclerosis. However, the 
accuracy of TTE for detecting AVS may be limited and the diagnostic value 
of AVS for atherosclerosis needs further evaluation. Therefore, we hypothe- 
sized that AVS on transesophageal echocardiography (TEE) correlates with 
aortic atheromatous disease (AAD). 
Methods: 74 patients age z 50 years (mean 68 * 9 years) underwent 
TEE with complete evaluation of the aortic valve and aorta. Two experienced 
observers unaware of the patients clinical data interpreted the TEES. Using 
quantitative criteria the aortic valve was defined as normal, mildly or mod- 
erately sclerotic, and the aorta as normal, mildly, moderately, or severely 
atheromatous. Fourteen other patients were excluded because of bicuspid 
aortic valves, rheumatic or infective valve morphology. 
Results: Of the 74 patients, 37 (50%) had trileaflet, degenerative AVS 
and 37 had normal aortic valves. Of the 37 patients with AVS, IO had 
diffuse and 28 had nodular sclerosis. Patients with AVS had similar age 
and atherogenic risk factors as those with normal aortic valves. AVS was 
significantly associated with AAD (P = 0.004 by Fisher’s Exact Test). 
AAD present AAD absent 
AVS present 32 5 
AVS absent 20 17 
Also, the severity of AVS correlated with the severity of AAD (P < 0.001). 
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In addition, the presence of nodular sclerosis correlated with the severity of 
AAD (P = 0.008). Although AVS had good specificity (17/22 = 77%) and high 
positive predictive value (32137 = 87%) for the detection of AAD, it had limited 
sensitivity (32152 = 62%) and low negative predictive value (17/37 = 46%). 
Conclusions: In patients older than 50 years the presence of aortic 
valve sclerosis by TEE, especially if nodular, is highly associated with aortic 
atheromatous disease, but its absence does not exclude it. Thus, the use of 
echocardiography, for the detection of aortic valve sclerosis as a marker of 
atherosclerosis, will be of llmited diagnostic value. 
1112-l 1 Vitamin C Deficiency and Acute Phase Response 
in Peripheral Arterial Occlusive Disease 
Michel R. Langlois, Marc L. De Buyzere, Joris R. Delanghe, Daniel 
A. Duprez. Deparfment of Cardiology: University Hospital Gent, Belgium 
Background: Peripheral arterial occlusive disease (PAOD) is a severe ath- 
erosclerotic condition and is frequently accompanied by acute phase re- 
sponse. As inflammation is associated with oxidative stress, we compared 
vitamin C antioxidant status in PAOD (acute phase response) with arterial 
hypertension (less acute phase response) and healthy subjects. 
Methods: The study groups were 45 PAOD patients (39 males, 6 fe- 
males), 105 patients with arterial hypertension (HT) (46 males, 59 fe- 
males), and 113 normotensive healthy controls (NT) (60 males, 53 females). 
Serum vitamin C concentrations were measured by an enzymatic-colorimet- 
ric method, sensitive C-reactive protein (CRP) by immunonephelometry. 
Results: Vitamin C levels were reduced among PAOD patients (Table). 
No significant gender-related differences of serum vitamin C were observed 
in the study groups. Smoking habits were comparable in all groups (30% 
smokers in PAOD, 32% in HT, 28% in NT). Serum CRP concentrations were 
higher in PAOD patients and negatively correlated with vitamin C levels (r = 
-0.632, p = 0.0001). 
n Vitamin C (mg/dl) CRP (mgil) 
PAOD 45 0.56 (0.25-0.83) 5.4 (2.1-13.q* 
HT 105 0.92 (0.75-1.29) 3.0 (0.5-6.i) 
NT 113 0.96 (0.78-i 5%) 2.9 (0.4-5.8) 
Data are median (interquartile range); * p < 0.01 (PAOD vs. HT; PAOD vs. NT) 
Conclusion: Vitamin C status is low among PAOD patients which fre- 
quently show true deficiency. This vitamin C depletion is related to inflamma- 
tion in PAOD patients and compromizes antioxidant status and endothelial 
function. Clinical trials with vitamin C supplements are needed to address 
reduction of oxidative stress in PAOD. 
r-1 1112 12 C677T Methylenehydrofolate Reductase (MTHFR) 
and Factor V Leiden Mutations in Patients With 
Premature Lower Extremity Atherosclerosis are 
Associated With Systemic Cardiovascular Disease 
Pave1 J. Levy, Carla Yunis, John Owen, Carlos M. Ferrario. The 
Hypertension and Vascular Disease Center, Wake Forest University School 
of Medicine, NC, USA 
Background: Premature atherosclerosis (PAS) involving peripheral arter- 
ies was recently reported with increasing frequency in young adults. Rapid 
progression of ischemic symptoms in these patients remains unexplained 
by traditional cardiovascular risk factors (CVRF). The expression of genetic 
mutations associated with thrombosis is a potential risk factor for PAS. To 
test this hypothesis, we examined the frequency of MTHFR and Factor V 
Leiden (FVL) mutations and their relationship to traditional CVRF in a group 
of patients (pts) with lower extremity (LE) PAS. 
Patients and Results: Between January 1998 and July 1999, 71 con- 
secutive pts (36 females; 35 males) with clinically severe LE-PAS diagnosed 
at 550 years of age (median 42.2, range 26-50 yrs) were studied. Their 
CVRF were: smoking (97%), dyslipidemia (72%), hypertension (45%), dia- 
betes (34%) and family history of cardiovascular disease (CVD) (75%). 34 
(48%) pts had clinical evidence of systemic CVD: coronary artery disease 
in 17 pts: cerebrovascular disease (CeVD), in 22. Of 59 pts with peripheral 
revascularizations, 27 (46%) had multiple procedures. At least one mutation 
was observed in 41 (58%) pts: 9 (13%) were heterozygous for FVL mutation; 
36 (51%) had MTHFR mutation (13 homozygotes and 23 heterozygotes). 
No association was found between the presence of mutation and gender, 
CVRF, and familial CVD. At least one mutation was documented in 24 of 
34 (71%) pts with PAS in more than one anatomic location and in 46% of 
pts with LE-PAS only (P < 0.05). Eighteen of 22 (82%) pts with CeVD had 
mutation (MTHFR in 16) compared with 47% of LE-PAS pts without CeVD 
(P = 0.006) 
Conclusion: Patients with LE-PAS have high prevalence of CVRF and 
systemic CVD. Increased frequency of MTHFR and FVL mutations is asso- 
ciated with clinical PAS in multiple anatomic location. Furthermore, MTHFR 
mutation was highly prevalent in young adults with lower extremity and cere- 
brovascular PAS. 
/ 1112 17 A Quantitative Study of Tobacco Addiction and Motivation to Quit Smoking in Patients With 
Peripheral Arterial Disease 
Sheri L. Baker, Diane J. Treat-Jacobson, Dorothy K. Hatsukami, Harry 
A. Lando, Larry C. An, Peg J. Atveson, Alan T. Hirsch. Minnesota Vascular 
Diseases Center, University of Minnesota Medical School, Minneapolis, MN. 
USA 
Tobacco serves as the most important cause of peripheral arterial disease 
(PAD) and continued smoking has been demonstrated to predict adverse 
outcomes. Tobacco cessation is known to improve symptoms, ischemic event 
rates, and survival. Nevertheless, tobacco cessation rates in PAD patients 
remain poor. We therefore evaluated the tobacco use history of a defined PAD 
population to aid in predicting those variables associated with an improved 
likelihood to achieve tobacco cessation. 
Methods: PAD patients who smoke (n = 34) were prospectively evaluated 
to define their PAD severity, smoking history, and addictiveness &depression 
indices. Standardized questionnaires were used to assess smoking history, 
claudication functional status (Walking Impairment Questionnaire, WIQ), ad- 
dictiveness (Fagerstrijm, FS), mood (CES-D), attitudes about their personal 
motivation to quit, confidence in quitting, skills to quit, and effort willing to put 
into quitting. 
Results: The study cohort was relatively young (54 i 2 years), predom- 
inantly male (65%), and included a spectrum of disease severity. Subjects 
smoked an average of 1.2 packs per day with a mean duration 38 + 2 years. 
Subjects reported an average of 6 previous serious smoking quit attempts 
(defined as having quit smoking for at least 24 hours). 50% of subjects were 
highly addicted to nicotine (mean FS score = 5.5). Depression was evident in 
36% of subjects. Walking distance and walking speed based on WI0 scores 
were 35 f 5 and 41 i 5, respectively. Subjects reporting a high level of 
addiction to nicotine were younger (50 f 3 vs. 59 i 2) and started smoking 
earlier (15 f 1 vs. 18 i 1) than subjects who reported a lesser addiction to 
nicotine (both p < 0.01). Willingness to exert a major effort to quit (7.5 on a 
I-10 scale, low-high) and motivation to quit smoking (6.6 on a I-10 scale, 
low-high) were high in this PAD cohort and were associated with intention 
to quit smoking. Individuals with the lowest stage of readiness or intention 
(precontemplation) were willing to exert the least effort and motivation than 
those in the contemplation and preparation stages (p < 0.001). Surprisingly, 
PAD severity did not predict willingness/motivation to quit. 
Conclusion: Patients with PAD who smoke are highly addicted, relatively 
young and disabled, and motivation and effort to quit are high regardless of 
disease severity. Therefore, smoking cessation programs for PAD may be 
most successful by targeting individuals who have an intention to quit. These 
patients are most motivated & willing to exert the major effort required to 
successfully quit smoking. 
1112-I 8 Differences in Cardiovascular Disease Between 
Ethnic Groups are Not Explained by Conventional 
Risk Factors or Atherosclerosis. The Study of 
Health Assessment and Risk in Ethnic Groups 
(SHARE) 
Sonia Anand, Salim Yusuf, Vlad Vuksan, Sudi Devanesen, Patty Montague, 
Linda Kelemen, Qilong Yi, Eva Lonn, Hertzel Gerstein, Matthew McQueen, 
Koon Teo. McMaster University, Hamilton, Canada 
The burden of cardiovascular disease (CVD) varies significantly between eth- 
nic groups in Canada. To determine if these differences are related to CVD 
risk factors and sub-clinical atherosclerosis (ATH), we conducted a popula- 
tion-based study of three ethnic groups; South Asian (SA), Chinese (CH), 
and European Canadians (EC) in Canada. 985 participants were recruited 
using a method of stratified random sampling. Clinical CVD was defined 
by history or ECG findings. Carotid ATH was measured using the B-mode 
ultrasound blind to clinical data. Conventional (smoking, hypertension, lipids) 
and novel risk factors (markers of a prothrombotic state). SA possessed 
the greatest prevalence of CVD (10.2%) compared to EC (7.1%) and CH 
Canadians (2.5%), overall P < 0.001. EC possessed the highest degree of 
ATH (intimal medial thickness (IMT) = 0.75 mm), it was intermediate in SA 
(IMT = 0.72 mm), and the lowest among the CH (IMT = 0.70 mm), overall 
P < 0.001. For any given level of ATH, SA had an excess of cardiovascular 
events compared to the other two groups. SA had an increased prevalence 
of glucose intolerance, higher LDL cholesterol, lower HDL cholesterol, and 
lower smoking rates. SA also possessed significantly greater abnormalities 
in novel risk factors including fibrinogen, homocysteine, lipoprotein (a), and 
plasminogen activator inhibitor-l. SA ethnicity was an independent predictor 
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of CVD after adjustment for the conventional CVD risk factors and subclinical 
ATH. 
Conclusions: Conventional risk factors and ATH only partly explain the 
higher rates of CVD among SA compared to EC and CH. The increased risk 
of cardiovascular events may be due to factors influencing plaque rupture, the 
interaction between prothrombotic factors and ATH, or other undiscovered 
factors. 
1112-l 9 Serum Uric Acid Independently Predicts Future 
Mortalitv in Patients With Severe, 
;;:mfrrphically-Defined Coronary Artery 
Troy E. Madsen, Joseph B. Muhlestein, Benjamin D. Horne, John 
F. Carlquist, Tami L. Bair, Jeffrey D. Jackson, Jason Lappe, Robert 
R. Pearson, Jordan B. Muhlestein, Jeffrey L. Anderson. LDS Hospifaland 
University of Utah, Salt Lake City, Utah, USA 
Background: Serum uric acid (SUA) has been proposed as a risk factor in 
the development of coronary artery disease (CAD). A recent report, how- 
ever, indicates that SUA may not predict coronary events in patients without 
cardiovascular disease, but does not address events in patients with known 
disease. We prospectively evaluated the effect of baseline SlJA levels on 
mortality in patients with severe CAD. 
Methods: Blood samples were collected from 1,675 consecutive, con- 
senting patients with severe, angiographically-defined CAD (stenosis p 
70%). Baseline and procedural variables were recorded and levels of SUA 
were measured by the uricase method. Patients were followed-up (f/u) for a 
mean of 2.6 years (range = I .8-5.0 years). 
Results: Patients averaged 65 + 11 years of age: 78% were males; 170 
(10.1%) died after a mean 1.3 years (range = O-4.8 years). In univariate 
analysis, SUA levels predicted all-cause mortality (5rh quintile vs. other four: 
hazard ratio [HR] = 1.77, p = 0.001). Other predictors included age, ejection 
fraction (EF), diabetes, and renal failure. In multivariate Cox regression 
controlling for 16 variables (including left ventricular hypertrophy, lipid levels, 
and smoking), independent predictive value for mortality was retained for 
SUA (HR = 1.6, p = 0.03), age (HR/year = 1.06, p < O.OOOl), EF (HR/% = 
0.98, p < O.OOOl), diabetes (HR = 1.9, p = O.OOl), and renal failure (HR = 
1.7, p = 0.04). Sub-analysis of 77 deaths with known cause showed higher 
risks for cardiovascular death due to each of these predictors (for SUA: HR 
= 1.8, p = 0.08). 
Conclusion: In this patient population with angiographically-defined se- 
vere CAD, baseline 5rh quintile SUA levels predicted an increased incidence 
of subsequent mortality independently of traditional risk factors, High serum 
uric acid levels may be an independent risk factor for future events in some 
CAD patients. 
L-L 1112 20 Three Year Survival in Patients With Multivessel 
Coronary Artery Disease and Peripheral Vascular 
Disease Undergoing Coronary Revascularization 
Daniel J. C’Rourke, David J. Malenka, Hebe B. Quinton, Winthrop D. Piper, 
Robert Clough, Jeremy R. Morton, John Robb, William A. Bradley, Gerald 
T. O’Connor. For the Northern New England Cardiovascular Disease Study 
Group, Lebanon, New Hampshire, USA 
Background: Peripheral vascular disease (PVD) is common in patients with 
coronary artery disease (CAD). Previous studies have reported poorer out- 
comes for patients with PVD following coronary revascularization, regardless 
of whether they undergo coronary artery bypass grafting (CABG) or a per- 
cutaneous coronary intervention (PCI). We compare short and long-term 
outcome for patients with multivessel CAD and PVD undergoing PCI or 
CABG. 
Methods: Data were collected prospectively on 1,842 consecutive pa- 
tients with PVD undergoing coronary revascularization either by PCI (n = 
353) or CABG (n = 1,489) in northern New England from 1994 to 1996. 
Patient records were linked to the National Death Index to assess long- 
term survival. Logistic and Cox proportional hazards regression (controlling 
for age, sex, procedural priority, three vessel CAD, heat-l failure, ejection 
fraction, chronic obstructive lung disease (COPD), renal failure, and dia- 
betes) were used to calculate adjusted rates for in-hospital mortality, and 
hazard ratios (HR) for long term survival, and 95% confidence intervals (95% 
Cl). 
Results: There were 208 deaths during 2,191 person-years of follow-up. 
PVD patients undergoing PC I were more often women, had more COPD, 
renal failure, history of prior coronary revascularization, and were more likely 
to undergo the procedure emergently; they were less likely to have diabetes 
or a history of heart failure. The adjusted in-hospital mortality rate for patients 
undergoing PCI was not statistically different from CABG patients (PCI 4.14% 
versus CABG 4.68%, p = 0.97). After adjustment for differences in baseline 
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characteristics, patients undergoing PCI had a poorer long-term outcome 
compared to CABG patients (HR 1.43, 95% Cl 1 .Oi, 2.01, p = 0.041). 
donclusions: Patients with multivessel CAD and PVD undergoing PCI in 
northern New England have a poorer long-term survival compared to patients 
with PVD who are surgically revascularized. This information may be useful 
in counseling patients with PVD requiring coronary revascularization. 
CLI 1112 21 Abdominal Adiposity as a Prognostic Factor for Persons at High Risk of Cardiovascular Events 
Gilles Dagenais, Jackie Bosch, Janice Pogue, C. Yi, Simon Kouz, 
Salim Yusuf. On behalf of the HOPE Study Investigators; McMaster 
University: Hamilton, Canada 
Background: Waist-to-hip ratio (WHR), a marker of abdominal adiposity, 
has been shown to be risk factor for cardiovascular diseases (CVD) in 
persons free of these diseases. However, the impact of this factor in high risk 
individuals for CVD has not been well defined. We assessed the impact of 
WHR and body mass index (BMI) on the composite outcomes of CVD death, 
myocardial infarction (Ml) and stroke, and congestive heart failure (CHF) in 
6993 men and 2543 women (mean age of 66), known to be at high risk 
for CVD because of vascular disease (88%) or diabetes with an additional 
risk factor for CVD (12%). During the mean 4-year follow-up, the composite 
outcomes and CHF were documented in 1042 and 250 men, and in 295 and 
101 women, respectively. For both genders, BMI was not a predictor of the 
total composite but was linearly related to CHF (P trend = 0.012) in women 
only. Women with a BMI p 30 kg/m* (grd tertile) had an adjusted relative risk 
(RR) (95% Cl) = 2.15 (1.16-3.97). WHR was not a predictor for the composite 
outcomes or CHF in men. By contrast, in women, WHR was linearly related 
to the total composite (P = O.OOOl), each event, CVD death (P = 0.004) Ml 
(P = 0.02) stroke (P = 0.02) and to CHF (P = 0. 006) A WHR P 0.90 (3”l 
tertile) doubled nearly the risk of each of these events. 
Conclusions: Among these high risk participants, WHR was a predictor 
CVD death, MI, stroke and CHF in women but not in men. 
I I I 12 22 Reduction of Events by Ramipril in High Risk 
Subiects is Laraelv Unrelated to Blood Pressure 
Deciease ” . 
Peter Sleight, Salim Yusuf, Janice Pogue. On behalf of the HOPE 
Investigators; McMaster University Hamilton, Canada 
Background: In the Hear-l Outcomes Prevention Evaluation (HOPE) study (of 
9541 high risk patients followed for an average of 4.5 years). Ramipril (10 mg 
OD) reduced cardiovascular (CV) deaths by 25% stroke by 32% and non-fatal 
myocardial infarction (Ml) by 20% (composite primary endpoint of CV death, 
Ml and stroke was reduced by 22%) compared to placebo. Hospitalization 
for heart failure (CHF) and the need for revascularization procedures were 
also reduced by 16% and 15% respectively. The mean entry BP was 139/79. 
Total events in the placebo group were linearly related to baseline systolic BP 
(P < 0.001) but not to diastolic BP. The mean difference in BP in the trial was 
3.5/l .5 mmHg between Ramipril and placebo. The BP difference between 
active and control was similar across all BP quartiles. The reductions in 
the risks of the primary outcome and secondary outcomes were strongly 
related to initial systolic, but not diastolic BP. There was no relationship to 
the degree of BP reduction. In comparison with meta-analyses of previous 
trials of antihypertenisve drugs (largely diuretics and/or beta blockers) this 
modest reduction in BP accounts for only about half the stroke reduction and 
one quarter of the Ml reduction seen with Ramipril. 
Conclusion: In this elderly population of high risk individuals (mean age 
66 years, 27% female, 53% non-hypertensives, 38% diabetic) treatment with 
the ACE-Inhibitor Ramipril, strikingly reduced future risk, even in subjects 
with normal to high normal systolic BP at baseline. Less than half of the risk 
reduction could be attributed to the reduction in BP. 
L-L 1112 23 Acute Aortic Dissection in Women: Comparative 
Analysis Among Genders - Results from the 
International Registry of Acute Aortic Dissection 
(IRAD) 
Rossella Fattori, Gabriella Napoli, David Bruckman, Eric Isselbacher, 
Arturo Evangelista, Jae K. Oh, Joseph Malouf, Udo Sechtem, 
Alfred0 Llovet, Hans-Joseph Deutsch, Holger Diedrichs, Dan Gilon, 
Linda Pape, Patrick T. D’Gara, Dean J. Karavite, Pamela L. Russman, Peter 
G. Hagan, William F. Armstrong, G. Micheal Deeb, Toru Suzuki, Kim 
A. Eagle, Christoph A. Nienaber. University Hospital S. Orsola, Bologna, 
Ifaly; The University of Michigan Health System, IRAD Coordinating Center, 
Ann Arbor, Michigan, USA 
Background: Aortic dissection (AAoD) is a life-threatening condition in which 
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clinical presentation and causes may affect management and outcome. How- 
ever data concerning differences in genders are limited. The IRAD registry 
was established to assess the presentation, management and outcome of 
AAoD. 
Methods: 558 consecutive patients (360 males, 198 females) were en- 
rolled between January 1996 and March 1999 in 13 international tertiary 
ceniers with presentation occurring within 14 days of symptom onset. 
Results: Females with AAoD were older and a prior history of hyperten- 
sion was more often elicited compared to males. Among the clinical findings, 
hypotension, neurological deficit, pericardial effusion and cardiac tamponade 
were more frequently present in females. Among 145 deceased patients, 67 
were females (in-hospital mortality 33.8%). Mortality was higher in females 
both in medical and surgical management groups. Within 6 hrs after onset, 
62% of males and 51% of females presented for care, p = 0.11. 
Presentation/outcome 
Meanaae (SD) 
OVW3ll M&S Females p, MvsF 
63.4C12.81 61.0 (13.51 67.9 (12.6) <0.0001 
Hypert&sibn & 76.9 66.6 79 0.002 
Peric. Effusion % 26.9 21.8 36.2 <O.OOl 
Neurolog. deficit % 17.5 13 25.8 <0.0001 
Preop. hypotension % 17.7 14.4 31.2 <0.0001 
Cardiac tamponade % 3.3 1.6 9.9 0.005 
Mortality % 26 21.7 33.8 0.902 
Opera& mortality % 26.7 22.9 37.1 0.011 
Conclusion: 1) In AAoD differences in gender exist in clinical presentation 
and outcome. 2) Similar to other cardiovascular diseases, females with aortic 
dissection tend to have a poor outcome both with medical and surgical 
management. 3) This difference may reflect both greater age and a tendency 
to present later. 
L-L-! 1112 24 Association Between Mitral Annulus Calcification and Peripheral Arterial Atherosclerotic Disease 
Y. Adler, U. Levinger, A. Koren, Y. Shapira, M. Vaturi, N. Fink, I. Herz, 
A. Zelikovski, A. Sagie. Dept of Cardiology Echocardiography Unit, & Dept. 
of Vascular Surgery, Rabin Medical Center, Beilinson Campus, Petah Tikva, 
lsrael 
Background: We previously demonstrated a significant association between 
the presence of mitral annulus calcification (MAC) and aortic atheroma, 
carotid atherosclerotic disease and coronary artery disease. This study was 
designed to determine whether an association exists between MAC and 
peripheral arterial atherosclerotic disease. 
Methods: Of the 805 pts in whom the diagnosis of MAC was made by 
transthoracic echocardiography between 1995 and 1997, 77 pts (40 males 
and 37 females, mean age, 73.1 f 11.4 yrs; range, 44-90 yrs) underwent 
peripheral arterial testing for various indications and comprised the study 
group. They were compared with 58 age- and sex-matched pts without MAC 
(30 males and 28 females; mean age, 73.2 f 11.8 yrs; range 31-93 yrs) 
who underwent peripheral arterial testing during the same period for the 
same indications (control group). MAC was defined as a dense, localized, 
highly reflective area at the base of the posterior mitral leaflet detected by 
transthoracic echocardiography. An ankleibrachial systolic pressure index 
(ABI) was calculated by dividing the higher dorsalis pedis or posterior tibia1 
Doppler derived pressures by the higher of the 2-arm systolic pressures. ABI 
was graded as follows: normal 2 1, abnormal < 1, mild 0.71-0.99, moderate 
0.41-0.7, and severe 50.4. 
Results: No differences were found between the groups in indications for 
referral for peripheral arterial testing and in risk factors for atherosclerosis 
but hypertension, which was significantly more prevalent in the study group 
(66% vs. 41%, p = 0.004). The study group included 151 limbs and the control 
group included 113 limbs. The mean ABI was significantly lower for all limbs 
in the MAC group (0.56 ‘i 0.27 vs. 0. 87 i 0.24, p = O.OOOl), abnormal ABI 
< I (94% vs. 68%, p = O.OOl), moderate peripheral arterial disease (44% vs. 
25%, p = O.OOl), and a severe disease (27% vs. I%, p = 0.001). Of the 77 
pts with MAC, 73 (95%) had a disease (right and/or left limbs) compared to 
40 of 58 (69%) in the control group (p = 0.001). Bilateral disease (Doppler 
index 5 1 for both, right and left limb), and severe bilateral disease (Doppler 
index 5 0.4 for both, right and left limb) were also found to be significantly 
more prevalent in the MAC group (87% vs. 60%, p = 0.001; and 12% vs. O%, 
p = 0.007, respectively). 
Conclusion: There is a significant association between the presence 
of MAC and peripheral arterial disease. This information strengthens our 
hypothesis that MAC may be an important marker for generalized vascular 
atherosclerotic disease. 
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/ 1113 50 Increased Endothelin-1 Concentrations in Response to Pulmonary Hypertension in the 
Newborn Lamb 
Lennard G.H. van den Boom, Maartje de Vroomen, Paul Steendijk, Robert 
H. Lopes Cardozo, Jan Baan, Frank van Bel. Leiden University Medical 
Center; University Medical Center Utrecht, The Netherlands 
Background: Elevated levels of Endothelin-I (ET) concentrations are seen 
with pulmonary hypertension in the situation of Respiratory Distress Syn- 
drome (RDS). Further more its known that in the fetal circulation, where 
pulmonary arterial pressure (Pap) is high, ET cone are much higher than 
levels seen 1 week after birth. In the present study we investigated how 
ET concentration changes after induction of pulmonary hypertension, in an 
experimental model of RDS. 
Methods: RDS was induced by lung lavages in 8 newborn lambs. Another 
6 lambs underwent the same experiment without lung lavages, to serve as 
controls. Blood samples were taken before and during RDS from right atrium 
(RA), pulmonary artery (PA) and aorta (Ao). ETconcentration was measured 
by a radioimmunoassay kit. 
Results: With lung lavages, a twofold increase of mean pulmonary arterial 
pressure (from 16 to 35 mmHg) was achieved during 4 hrs. In RDS animals, 
ET concentration showed a significant increase 15 minutes after induction of 
RDS (RA 63%, PA 95% and Ao 79%). This increased concentration remained 
high at 1 hr and 4 hrs of RDS. In control animals no significant changes in ET 
concentrations were seen. Plotting, all values of ET concentration, in RDS 
and control animals at all conditions, against mean Pap a correlation is found 
between the severity of the pulmonary hypertension and the increase of ET 
concentrations. 
0 50 oPap(mmEg)m 0 50 
Conclusion: This experimental model of RDS shows that in response to 
pulmonary hypertension ET concentration increases, and with a more severe 
pulmonary hypertension, a stronger increase of ET concentration is seen. 
Whether ET is a mediator or a marker of pulmonary hypertension remains 
unclear. 
L-2 1113 51 Effect of Inhaled Nitric Oxide on Exercise Pulmonary Pressure in Patients With Pulmonary 
Hypertension 
Rafael Kuperstein, Zion Sasson, Joan Persaud, Jonh Granton. Mount Sinai 
Hospital and The Toronto Hospital, Toronto, Canada 
Background: Pulmonary hypertension (PHT) is characterized echocardio- 
graphicaly by an increase in resting right ventricular systolic pressure (RVSP). 
Inhaled nitric oxide (iNO) has been used to determine the degree of va- 
soresponsiveness in patients with PHT and recently also as a therapeutic 
modality. We sought to characterize the change in RVSP with exercise and to 
determine if iN0 could reduce the resting RVSP and also blunt the increase 
in RVSP with exrcisae. 
Methods: Fifteen patients (6 men) with pulmonary hypertension of dif- 
ferent etiologies (6 primary), age 53.2 f 13.9 (24 to 74 years) underwent a 
rest and exercise echocardiographic (Echo) evaluation of their RVSP by the 
tricuspid regurgitation method, using echo contrast agents when necessary. 
Exercise consisted of symptom limited supine bicycle exercise stress test 
using 25 W load/2 minute stages on room air (RA), repeated after 1 hour to 
the same workload with increasing doses of iN0 (10, 20, 40 and 80 ml/min 
from a 800 ppm NO in Na). Heart rate (HR), blood pressure (BP) and RVSP 
where continuously monitored at rest and during exercise, before and after 
NO inhalation, 
Results: Patients exercised for 4.6 f 1.9 minutes, 63.3 f 26.5 W. Resting 
RVSP was significantly reduced by iN0 at 10 mlimin and higher doses of iN0 
did not lead to any additional drop in RVSP (p = n.s. for comparing RVSP 
between 10, 20, 40 and 80 mUmin). 
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Table: Effects of NO at rest and at maximal exercise. in patients with severe PHT, significantly elevated in comparison to controls 
(p < 0.005). Urine and serum VEGF levels as well as urine IL-8 levels were 
not significantly elevated in comparison to controls. 
Rest Peak Exercise 
HR BP RVSP HR BP RVSP 
bpm mmHg mmHg bpm mmHg mmHg 
RA r 84516 128/i? 65.5 i 21 128 * 21 146/89 84&23 
NO 87112 127177 61.1 + 21* 131 zt 23 161188 77 * 24* 
*p < 0.05. 
Conclusion: 1) In patients with PHT iN0 induces asignificant reduction in 
RVSP at rest which persists at maximal exercise, with no significant systemic 
effects, 2) Supine bicycle exercise Echo is a useful tool for the evaluation of 
therapy in patients with pulmonary hypertension 
[ 1113-52 1 Preserved Long-Term Efficacy of lloprost 
Inhalation Therapy Over 2 Years in Patients With 
Primary Pulmonary Hypertension 
C.F. Opitz, R. Wensel, R. Ewert, L. Bruch, F.X.‘ Kleber. Unfallkrankenhaus 
Berlin, Deutsches Herzzenfrum Berlin, Germany 
Background: In Primary Pulmonary Hypertension (PPH) inhalation of Ilo- 
prost (long-acting prostacyclin-analogon) selectively dilates the pulmonary 
vascular bed due to ventilation-matched deposition. Although the benefi- 
cial short-term effects on hemodynamics and exercise capacity have been 
documented in PPH, long-term data are lacking. 
Methods and Results: Described are 12 PPH pts on chronic inhaled 
lloprost therapy (6 x 17 bg/24 h) with complete 1 -year data, of whom the first 
4 pts finished their 2-year visit. Hemodynamic profiles were obtained prior to 
and after inhalation of 17 fig lloprost at 0, 3, 12 and 24 months: 
Baseline RA PAP CO PVR HR 
mmHg mmHg Umin WU llmin 
0 months 6+5 63* 17 2.8 i 0.9 24zk 11 82fl6 
3 months 7*5 67&22 2.7 k 0.6 24 zt 9 84zkl5 
1 year 9+6 63zkl3 2.8 rk 0.8 22 * 8 SO&l1 
2 “ears 827 57*12 2.4fl.i 241-12 80fll 
Acute effects (in %) following inhalation of 17 Kg lloprost (* = p < 0.05): 
PAP CO PVR 
0 months 
3 months 
1 year 
2 “ears 
-15% (fl7%)* +15% (112%)* -26% (f22%)* 
-15% (*20%)* ~20% (*24%)* -28% (zt27%)* 
-14% (*17%)* +17% (A-17%)* -26% (&22%)* 
-16% (124%) +47% (z!z55%1 -36% l&33%1 
Conclusions: These are the first long-term datadocumenting asignificant 
beneficial hemodynamic effect of inhaled lloprost that is preserved over a 
2-year period of chronic inhalation therapy in a group of patients with PPH. 
Although not controlled, the stable hemodynamic data over the 2-year period 
in this seriously il l patient group suggest a positive effect of chronic lloprost 
inhalation on the commonly observed downhill course of PPH. Controlled 
studies are needed to define the role of lloprost inhalation in comparison to 
continuous prostacyclin infusion in the treatment of PPH. 
1 1113-53 1 Angiogenic growth factor levels are abnormal in 
patients with severe pulmonary hypertension 
Jacques I. Benisty, Judah Folkman, Susan Connors, Jeffrey A. Feinstein, 
Michael J. Landzberg. BACH Service/Children’s Hospital, Brigham and 
Women’s Hospital, Harvard Medical School, Boston, Massachusseffs, USA 
Background: Histopathological evidence exists to suggest a link between 
severe pulmonary hypertension (PHT) and abnormal angiogenesis. The role 
of angiogenesis-related molecules such as basic fibroblast growth factor 
(bFGF) and vascular endothelial growth factor (VEGF) in the development of 
pulmonary hypertension is still unclear. We sought to examine the relation- 
ship between circulating levels of angiogenic growth factors and pulmonary 
hypertension in conscious humans. 
Mettiods: We analyzed serum and urine concentrations of bFGF, VEGF 
and interleukin-8 in 25 patients with severe pulmonary hypertension, both pri- 
mary (6) and secondary (19). VEGF and bFGF was measured in the serum 
and urine using an enzyme-linked immunoassay. Urine concentrations of 
bFGF were adjusted for urine creatinine. Hemodynamic and clinical parame- 
ters were collected on all patients. Comparison to values for normal controls 
was done using nonparametric statistical tests. 
Results: Median age of the patients was 33 years. Median PVR was 19.5 
wood unitsm’. Median adjusted urinary bFGF was4338 (range 631-47,349) 
pgfg in patients with severe PHT, significantly elevated in comparison to 
controls (p < 0.0001). The median serum bFGF was 4.0 (range O-26) pg/ml 
Conclusion: Severe pulmonary hypertension is an active and ongoing 
inflammatory and angiogenic process. Serum and urine levels of bFGF are 
significantly elevated in affected patients. Further understanding of the mech- 
anism involved in this inflammation and abnormal angiogenic activity may 
lead to novel therapeutic approaches in this group of patients. 
I 1113 54 The Response to Inhaled Nitric Oxide in Adult Patients With Primary Pulmonary Hypertension 
and Pulmonary Hypertension From Secondary 
Causes 
Richard A. Krasuski, John J. Warner, Andrew Wang, J. Kevin Harrison, 
Victor Tapson, Cynthia Pierce, Thomas M. Bashore. Duke University 
Medical Center, Durham, NC, USA 
Background: Nitric oxide (NO) is an important mediator of pulmonary vascu- 
lar tone. While NO has been extensively studied in neonates and in primary 
pulmonary hypertension (PPH), little is known about its hemodynamic effects 
in adult patients, especially if the pulmonary hypertension is due to secondary 
causes. 
Methods: We examined the hemodynamics resulting from inhalation of 
NO at 10, 20 and 40 ppm during cardiac catheterization in 16 patients (pts.) 
with primary pulmonary hypertension (PPH) and compared these data to 
15 pts. with pulmonary hypertension from secondary causes (SPH). Causes 
in the latter group included atrial septal defect (3), sarcoid (I), idiopathic 
pulmonary fibrosis (2), CRESTsyndrome (2), and COPD (7). Cardiac outputs 
and resistances were calculated using the Fick equation. 
Results: Groups did not differ by age, gender, aortic pressure, or RVEDP. 
The mean PA pressure was higher in the PPH group (51 vs. 41 mmHg; p = 
NS), as was the PVR (11.2 vs. 5.7 Wood units; p = 0.03). Positive response 
to NO (220% decrease in PVR) was seen in 69% (11 of 16) of PPH pts. and 
80% (12 of 15) of SPH pts. No patients became hypotensive or experienced 
any untoward effects during drag administration. The mean PA pressure 
decreased from 51 to 41 mmHg (p = NS) in the PPH group and from 41 to 
33 mmHg (p = NS) in the SPH group. PVR decreased from 11.1 to 8.3 Wood 
units (Wu) in the PPH group (p = NS) and from 5.7 to 4.0 Wu (p = NS) in 
the SPH group. The SVR did not change with NO in either group (20.6 to 
20.3 Wu in the PPH group and 24.2 to 23.4 Wu in the SPH group). Among 
positive responders the mean PA pressure decreased from 45 to 33 mmHg 
(p = 0.02) in the PPH group and from 40 to 30 mmHg (p = 0.01) in the SPH 
group. No patients in either group (0 of 4) experienced a decrease in their 
PA pressures with NO when the RVEDP exceeded 20 mmHg. 
Conclusions: Adults with secondary pulmonary hypertension have a 
surprisingly high degree of pulmonary vasoreactivity that can be unmasked 
by the use of nitric oxide. Those with significant RV diastolic dysfunction 
likely have longstanding disease and respond less well. These data suggest 
pulmonary vasodilators may have a potential therapeutic role in patients with 
secondary as well as primary pulmonary hypertension. 
1113-55 Orally Active Prostacyclin Analogue Improves 
Exercise Capacity in Patients With Primary or 
Thromboembolic Pulmonary Hypertension 
Yoshito Shimizu, Noritoshi Nagaya, Toru Satoh, Masaaki Uematsu, 
Shingo Kyotani, Fumio Sakamaki, Norifumi Nakanishi, Kunio Miyatake. 
National Cardiovascular Center, Osaka, Japan 
Background: Patients with primary, or thrombpembolic pulmonary hyper- 
tension (PH) have severe exertional limitation due to cardiopulmonary fac- 
tors. We have recently shown that beraprost sodium (BPS), an orally active 
prostacyclin analogue, significantly decreases pulmonary, vascular resis- 
tance in patients with primary PH. However, whether BPS improves exercise 
capacity in such diseases remains unknown. 
Method: To clarify, this, symptom-limited cardiopulmonary exercise test- 
ing was performed before and 3 months after BPS therapy in 14 subjects 
comprising 6 patients with primary, PH and 8 patients with thromboembolic 
PH (mean age, 54 f 17 years; mean pulmonary artery pressure, 35 & 12 
mmHg). This study was designed to maintain BPS therapy at the highest 
dose tolerated (96 f 60 pg/day). 
Results: Long-term therapy with BPS significantly increased maximal 
load (88 f 26 to 100 & 26 watt, p < 0.01) and peak VC2 (962 + 297 to 1077 
f 35 mi/min, p < 0.05). Ventilatory equivalent for carbon dioxide, an index 
of physiological dead space, decreased significantly (36.9 f 8.5 to 33.7 f 
7.2, p < 0.05). Furthrmore, incremental rate of peak V02 showed significant 
positive correlation with incremetnal rate of AV02/Awork, which was defined 
as the increase in oxygen uptake in response to simultaneous increase in 
work rate (r = 0.8, p < 0.01). 
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Conclusion: Administration of BPS improved parameters of exercise ca- 
pacity and elevation of ventilation in patients with primary or thromboembolic 
PH. These results may suggest that improvement of exercise capacity in the 
patients administrated with BPS is, in part, associated with improvement of 
impaired pulmonary circulation. 
I 1113 56 Long-Term Effects of Prostacyclin on Hemodynamics in Primary Pulmonary 
Hypertension: Are Continued Dose Increases 
Necessary? 
Vallerie V. McLaughlin, Peter M. Meyer, Stuari Rich. Rush Medical Co/&e, 
Chicago, IL, USA 
Background: Prostacyclin (PGl*) causes acute vasodilation in Primary Pul- 
monary Hypertension (PPH). Hemodynamic effects after one year of therapy 
generally exceed the acute effects, suggesting pulmonary vascular remod- 
eling occurs in response to increasing doses. Our objective was to evaluate 
the chronic (~2 years) effects of PGIz on hemodynamics with yearly right 
heart catheterization (RHC), and attempt to define the optimal dose. 
Methods: 41 patients (31 female, 10 male, mean age 40.6 f 13.1 years) 
with PPH (FC Ill/IV) were treated with PGl2 and followed with annual RHC 
for a mean of 31.1 & 13.5 months. PGl2 dose was increased periodically 
based on symptoms of PPH and side effects of PG12. 
Results: 
MPAP CO (Umin) PVR Dose PGle 
WW Wood Units (nglkgimin) 
Baseline 61.3 * 15.6 3.65i 1.29 16.2 zt 6.7 N/A 
18.2 i 12.6 mo 51.6111.1" 6.00 zt 2.13* 8.2 i 3.9* 41.7i 34.1 
31 .l i 13.5 mo 48.5 * iz.o*t 6.03 z!c 2.32* 7.8 f 4.5* 60.6 * 37.4** 
(’ = P < 0.001 compared to baseline) (7 = P < 0.01 compared to 18.2 + 12.6 mo); (‘” = 
P < 0.001 compared to 18.2 i 12.6 mo) 
Conclusion: The hemodynamic effects of PGl2 in PPH are achieved in the 
first year of treatment. Subsequent years show stabilization (neither further 
improvement or deterioration) despite continued PGlp dose escalation. This 
has important implications for decisions regarding dosing, quality of life, and 
listing for transplantation. The need to increase PGl2 beyond the first year of 
therapy should be questioned in light of its high expense and adverse side 
effects. 
1113-57 Role of Alprostadil (PGEI) in Acute Drug Testing 
for Pulmonary Hypertension (PH) 
Arif Ahmad, Ronald Siegal, Kenneth Presberg, Dianne Zwicke. University of 
Wisconsin and Medical College of Wisconsin, Milwaukee, Wisconsin, USA 
Background: Previous studies using PGEI have shown beneficial hemody- 
namic effects in patients with PH. We utilized PGEI for acute drug testing for 
pulmonary vascular reactivity in patients with vascular PH. 
Methods: Our study population was comprised of 42 patients, 7 with 
primary PH and 35 with secondary PH due to a variety of causes. During a 
right heart catheterization PGEI was infused at 12.5 ngikglmin with further 
increments of 25 ng/kg/min every IO-15 minutes. A positive vasodilator 
response was defined as an increase in cardiac output (CO) by IO%, a 
decrease in pulmonary vascular resistance (PVR) by 25% or a decrease 
in mean pulmonary artery pressure (PAP) by 10% or any combination of 
above. The test was stopped when a positive vasodilator response, significant 
decrease in blood pressure, maximum dose of 100 nglkgimin, or significant 
side effects were observed. 
Results: For CO 30 of 42 (71.4%) were responders, 7 of 7 (100%) in 
the primary PH group and 23 of 35 (65.7%) in the secondary PH group. For 
PVR 21 of 42 (50%) were responders, 5 of 7 (71.4%) in primary PH group 
and 16 of 35 (45.7%) in secondary PH group. For PAP 21 of 42 (50%) were 
responders, 4 of 7 (57.1%) in primary PH group and 17 of 35 (48.5%) in 
secondaty PH group. Overall 36 of 42 (85.7%) patients were responders, 
7 of 7 (100%) in primary PH group and 29 of 35 (82.8%) in secondary PH 
group. The mean dose of PGEI used was 53.13 ngikglmin. 
Conclusion: PGEI can be used as a screening agent for assessment of 
pulmonary vascular reactivity in primary and secondary causes of PH. It is 
readily available, easy to titrate and cost effective. 
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/ 860 1 Effects of Single-Drug Antihypertensive Therapy on 
Endothelium-Dependent Vasodilation in 
Hypertensive Postmenopausal Women 
Rosario Rossi, Rosella Molinari, Pietro Aveta, Nicola Muia Jr., Maria 
Grazia Modena. Depf of Cardiology /I, University, of Modena, Modena, Italy 
Background: Antihypertensive therapy improves endothelial function (EF) 
in hypertensive patients. 
Purpose: To determine if there is a blood pressure lowering agent superior 
to others in improving EF in a population of hypertensive postmenopausal 
women treated with a single-drug therapy. 
Methods: 106 postmenopausal women with mild to moderate hyperten- 
sion (diastolic blood pressure from 95 to 110 mmHg) received: diuretic (Group 
I, n = 19), ,&blocker (Group II, n = 21), calcium antagonist (Group Ill, n = 
31) or ACE-inhibitor (Group IV, n = 35). Patients achieving a diastolic blood 
pressure of <90 mmHg during drag titration, entered a 6 month maintenance 
period. We assessed, at baseline and after 6 months of treatment, flow-medi- 
ated endothelium dependent vasodilation (EdVD) by measuring the diameter 
of the brachial artery (DBA) before and during reactive hyperemia,(induced 
after deflation of a blood pressure cuff inflated to suprasystolic pressure for 
5 minutes). 
Results: There were no baseline intergroup differences regarding age, 
cardiovascular risk factors and use of hormonal replacement therapy. After 
6 months of therapy. EdVD was significantly greater in patients treated with 
ACE-inhibitors (Group IV) compared to other groups (table). 
Group I Group II Group Ill Group IV 
(Diuretic) (j&blocker) (calcium antagonist) (ACE-inhibitor) 
Baseline 
DBA, mm 3.8 iO.2 3.9 * 0.3 4.1 * 0.3 4.0 i 0.2 
EdVD, % 13.2 & 2.6 12.6 * 3.0 13.4 * 3.1 13.Oi2.8 
6 months 
DBA. mm 3.9 * 0.2 3.9 + 0.2 4.0 f 0.3 4.1 * 0.3 
EdVD, % 12.5 * 2.8 13.1 zt 3.1 15.0 f 3.5 18.9 i 3.8* 
‘p < 0.01 versus other groups. 
Conclusion: ACE-inhibitors in postmenopausal hypertensive women 
seems to better contribute to improve endothelial function. 
4:15 p.m. 
I 860 2 Vitamin E Prevents Resistance Vessel Endothelial Dysfunction Induced by Experimental 
Hyperhomocysteinemia in Human Subjects 
Geetha Raghuveer, Christine A. Sinkey, William G. Haynes. University of 
lowa, lowa Cifx lowa, USA 
Background: Homocysteine is a potential risk factor for atherosclerosis. Ho- 
mocysteine appears to increase lipid peroxidation in vitro. We tested whether 
vitamin E, a fat-soluble antioxidant, prevents resistance vessel endothelial 
dysfunction caused by experimentally induced hyperhomocystememia. 
Methods: Ten healthy adults (6 male: ages 19-42) received oral placebo 
(p), L-methionine alone (M: 100 mgmikg at 7AM), and L-methionine +vitamin 
E (M & E, Mat 7AM preceded by 1200U Eat midnight) on 3 separate days. 
L-methionine in this dose increases plasma homocysteine to 25 mcmol/L 
in young, healthy subjects. Forearm vasodilatation in response to intraar- 
terial infusions of acetylcholine (endothelium dependent), nitroprusside and 
verapamil (endothelium independent) was measured at 2PM. 
Results: Baseline BP and forearm blood flows (FBF) did not differ be- 
tween study days. Methionine administration resulted in a significant de- 
crease in vasodilatation to acetylcholine but not to nitroprusside or verapamil. 
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This impairment was completely reversed by pretreatment with vitamin E 
(Figure; * p < 0.05 vs methionine alone). 
Conclusions: Methionine induced hyperhomocysteinemia causes en- 
dothelial dysfunction which can be reversed by a fat-soluble antioxidant. 
These findings suggest that endothelial dysfunction caused by homocys- 
teine involves increased lipid peroxidation. 
4:30 D.m. 
860-3 Comparative Effects of Captopril and Losartan on 
Endothelial Function and Vascular Endothelial 
Growth Factor 
Bo-qing Zhu, Yi-ping Sun, Richard E. Sievers, Amanda E.M. Browne, 
Phuljhuri Chakrabo, Randall J. Lee, Tony M. Chou, Kanu Chatterjee, 
William W. Parmley. University of California San Francisco, San Francisco, 
California, USA 
Background: ACE inhibitors and angiotensin II receptor blockers exhibit car- 
diovascular protection in a rat model of ischemia-reperfusion. The compar- 
ative effects of pretreament on endothelial function and vascular endothelial 
growth factor (VEGF) are unknown. 
Methods: 48 Sprague-Dawley rats were randomized into 3 groups: a 
control and the two pretreatment groups in which captopril and losartan were 
given 40 mg/kg/day in drinking water for 10 weeks. The rats were subjected 
to 17 min of left coronary artery occlusion and 2 hr of reperfusion. The aortic 
rings were removed for vascular reactivity studies. VEGF proteins in the 
ischemic myocardium were measured by Western blot analysis. 
Results: Endothelium-dependent maximal relaxation induced by a cal- 
cium ionophore (A23187) and slope were significantly increased by captopril 
(vs control: -79 f 16 vs -43 & 7%, p = 0.02; -5.6 f 2 vs -1.2 f 0.3, 
p = 0.03). Losartan decreased VEGF 30% in the ischemic myocardium (p 
= 0.04). There was a positive correlation between VEGF changes in the 
ischemic myocardium and infarct size (r = 0.52, p < 0.05). VEGF Changes = 
Captopril (Losartan) - Control/Control x 100%. 
Conclusion: Captopril improved endothelial function. Losartan decreased 
VEGF in the ischemic myocardium perhaps by reducing the ischemic stim- 
ulus for VEGF production. Both captopril and losartan’decreased ischemic 
damage. 
4:45 p.m. 
860-4 Effect of Angiotensin AT1 Receptor Inhibition on 
Circulating Markers of Endothelial Dysfunction 
Abhiram Prasad, Kwang K. Koh, William H. Schenke, Rita Mincemoyer, 
Richard 0. Cannon Ill, Arshed A. Quyyumi. NHLBI, National institutes of 
Health, Bethesda, MD, USA 
Background: Increased circulating levels of cell adhesion molecules (CAMS) 
and plasminogen activator inhibitor (PAI-I) are characteristic features of en- 
dothelial dysfunction associated with coronary atherosclerosis (CAD) and 
may be predictors of acute coronary events. Activation of the tissue renin- 
angiotensin system is a hallmark of CAD and may contribute to PAI-I pro- 
duction and to endothelial dysfunction by activation of oxidases, superoxide 
anions, and transcription factors that express CAMS. We hypothesized that 
inhibition of angiotensin AT-I receptors by losartan would improve vascular 
function, reduce PAI- expression, increase nitric oxide (NO) activity, and 
reduce expression of CAMS. 
Methods: 31 patients with CAD were given oral losartan 25-50 mg qd 
(mean 44 ;t 2 mg) for 8 weeks and serum nitrate levels (by chemilumi- 
nescence), PAI-I levels, serum vascular cell adhesion molecule (VCAM-I), 
intercellular adhesion molecule (ICAM-I), and E-selectin levels were mea- 
sured (by ELISA). 
Results: There was an increase in serum nitrate levels but no change in 
CAMS or PAI- levels after losartin. 
Conclusion: AT-I receptor inhibition with losartan increases NO activity 
but does not alter other markers of endothelial dysfunction including CAMS 
Nitrates ICAM- 
Baseline 21 + 1.7 301 f 17 
LOS%tW 26.7 -i 2.4* 306f16 
*P = 0.008 (Nitrate PM, others ng/inL) 
VCAM-1 
661 z!z 44 
675 zt 33 
E-selectin 
46 zk 3 
47*3 
PAI- 
31 +4 
38 * 4 
and PAI-I. Previously observed reduction in CAMS and PAI- levels with 
converting enzyme inhibitors suggests involvement of other angiotensin re- 
ceptors or of bradykinin in activation of inflammatory or fibrinolytic markers 
in CAD. 
5:00 p.m. 
I 860 5 The Effects of Oral Methionine and Homocysteine on Endothelial Function 
Colm G. Hanratty, Lawrence T. McGrath, Daniel F. McAuley, Ian S. Young, 
G. Dennis Johnston, Dept of Therapeutics and Pharmacology and Dept of 
Clinical Biochemistry, The Queen’s University of Belfast, UK 
Background: Elevation of total homocysteine concentration (tHcy) is an in- 
dependent risk factor for coronary artery disease. Homocysteine is formed 
during methionine metabolism; dietary manipulation of homocysteine in pri- 
mates and in humans with oral methionine is associated with impaired en- 
dothelial-dependent vasodilatation. A cause/effect relationship has not been 
clearly defined. To investigate this relationship further we studied the effect 
of oral methionine and then oral homocysteine on endothelial function. 
Methods: Nineteen healthy, non-smoking adults took part in two ran- 
domised crossover studies. Endothelial function was determined by measur- 
ing forearm blood flow (FBF) in response to intra-arterial infusion of acetyl- 
choline (endothelial-dependent) and sodium nitroprusside (endothelial-inde- 
pendent). Subjects received methionine (100 fig/kg) or placebo (Study 1) 
or, L-homocysteine (67 kg/kg) or placebo (Study 2). Methionine and tHcy 
were determined at baseline and t = 4 hours. Endothelial function was then 
determined at 4 hours. The responses to the vasoactive substances are ex- 
pressed as the area under the curve (AUC) of change in FBF from baseline. 
Data are mean plus 95% Confidence Intervals. 
Results: Study 1: Plasma concentrations of methionine and homo- 
cysteine increased significantly versus placebo. These were associated 
with a significant reduction in endothelial-dependent responses, (29.9 units 
[13.3-46.5] vs. 49.1 units [19.9-78.41, p < 0.04); endothelial-independent re- 
sponses were unchanged. Study 2: tHcy increased significantly from base- 
line, methionine concentration remained unchanged. Endothelial-dependent 
responses were significantly reduced compared to placebo at this time (22.7 
[6.2-39.21 vs. 32.6 [10.3-54.91, p < 0.03). 
Conclusions: This study clearly demonstrates that homocysteine and 
not methionine is responsible for the changes in endothelial function. This 
supports the hypothesis that homocysteine promotes atherosclerosis by in- 
ducing endothelial dysfunction. 
5:15 p.m. 
860-6 The Direct Effects of Canola, Olive, and Fish Oils on 
Endothelial Function 
Robert A. Vogel, Mary C. Corretti, Gary D. Plotnick. University of Maryland 
School of Medicine, Baltimore, Maryland, USA 
Background: The Lyon Diet Heart Trial found that a Mediterranean diet 
containing ol-linolenic acid (omega-3) enriched canola oil significantly re- 
duced cardiovascular events without changing serum lipoproteins. Whereas, 
omega-3 rich fish oils are known to have beneficial effects on endothelial 
function, a major factor in atherogenesis, the effects of canola and olive oil 
(omega-g) on endothelial function are unknown. 
Methods: We measured serum lipoproteins and brachial artery flow- 
mediated vasodilation (index of endothelial function) before and 3 hours after 
three 50 g fat meals, composed of canola oil and bread, olive oil and bread, 
and salmon, in 10 normolipidemic, healthy subjects. 
Results: All 3 meals increased serum triglycerides (p < 0.05), but did not 
alter other lipoproteins. The olive oil meal reduced flow-mediated vasodilation 
34% (14.3 f 4.2% to 9.9 f 4.5%, p = 0.008), the canola oil meal reduced 
flow-mediated vasodilation 11% (13.0 f 3.4% to 11.6 f 4.4%, p = NS), and 
the salmon meal reduced flow-mediated vasodilation 2% (13.1 & 5.2% to 12.8 
f 5.1%, p = NS). A significant inverse correlation was observed between 
postprandial changes in triglycerides and flow-mediated vasodilation, (r = 
0.47, p < 0.05). 
Conclusions: These data suggest that part of the cardioprotective effect 
of the Lyon Diet Heart Trial diet may be due to its substitution of omega-3 
rich canola oil for omega-9 rich olive oil, in addition to its recommendation for 
increased fish consumption. 
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ORAL 
El 861 Prognostic Implications of Cardiovascular 
Risk Factors 
Monday, March 13, 2000,4:00 p.m.-5:30 p.m. 
Anaheim Marriott, Marquis Northwest 
4:00 p.m. 
/ 861 1 Undertreatment of Hyperlipidemia in Patients With Combined Coronary Artery Disease and Congestive 
Heart Failure 
Carla A. Sueta’*“, Mark W. Massing’, David P. Biggs’ , Ross J. Simpson 
Jr.i.2. ‘Medical Review of North Carolina, Raleigh, NC; ‘University of Norfh 
Carolina, Chapel Hi//, NC, USA 
Background: Patients with combined coronary artery disease (CAD) and 
congestive heart failure (CHF) are at high risk for death and myocardial 
infarction (Ml). Progression of CAD may contribute to this risk. We hypoth- 
esized that patients with CAD and CHF are less aggressively treated with 
lipid-lowering therapy compared to patients with CAD alone. 
Methods: We examined the Merck-sponsored Quality Assurance Pro- 
gram II administrative database which includes data collected on outpatients 
with CAD or CHF from 296 US practices. The sample analyzed included 
42,176 patients 2 21 years of age whose last visit was between January 
1997 and April 1998 and who had ICD-9 codes (410-414) or chart documen- 
tation consistent with CAD. One-third of these patients (n = 14,800) also had 
CHF, according to ICD-9 codes or chart documentation. 
Results: Patients with CAD and CHF were older (72 f 0.1 vs 68 i 0.1 
years), more often women (40% vs 35%), and more often diabetic (30% vs 
20%) all p < 0.001, compared to patients with CAD alone. LDL was doc- 
umented less frequently in patients with CAD and CHF (53% vs 70%): p 
< 0.001. Of the 7,787 CHF patients with a documented LDL cholesterol, 
only 31% were at the goal of ~100 mg/dl. Patients with combined CAD 
and CHF were 27% less likely to be given prescriptions for lipid-lowering 
drugs. Other multivariate predictors of lipid-lowering medication prescription 
included: age 2 65 years OR (95% Cl), 0.54 (0.51-0.56); LDL measure- 
ment 3.95 (3.77-4.14); previous Ml 1.21 (1.16-I .26) or revascularization 2.15 
(2.05-2.24); ACE-Inhibitor use 1.07 (1.02-I .12); and region of the US, South 
0.91 (0.86-0.96). 
Conclusion: Patients with combined CAD and CHF are less likely to 
be treated for hyperlipidemia. Undertreatment may contribute to the poor 
outcome of patients with CAD and CHF. 
4:15 p.m. 
861-2 Primary Prevention of Coronary Heart Disease in the 
Elderly: Implications of National Health and Nutrition 
Examination Survey Ill 
Su-Min Chang, Terry A. Jacobson, Jennifer C.Y. Sung, Godfrey G. Griffiths, 
Cristina Varas, Christie M. Ballantyne. Bay/or Colege of Medicine, Houston 
TX, USA 
Background: Individuals aged >65 years have the greatest mortality, mor- 
bidity, and expenses from CHD and are the fastest growing segment of the 
US population. Since ATP II publication, statin trials have shown benefit on 
CHD morbidity and mortality in 2” prevention, including elderly pts, but there 
is a paucity of data on 1” prevention in the elderly. 
Methods: Using 1988-94 NHANES data, we reexamined the prevalence 
of elevated LDL-C in US adults with a focus on those aged >65 and estimated 
how many require drug therapy on the basis of ATP II. ATP II recommends 
“clinical judgment” to decide whether to initiate drug therapy in pts with LDL-C 
above goal on diet but below the initiation level for drug therapy: CHD pts 
with LDL-C 100-130 mgidl, pts without CHD who have 22 risk factors (RF) 
and LDL-C 130-160 mg/dl, and middle-aged or older pts without CHD who 
have ~2 RF and LDL-C 160-190 mg/dl. 
Results: Of the 22.7 million Americans > 65 yrs, 11.8 million have LDL-C 
above the ATP II’s initiation level for diet therapy, including 7.0 million with- 
out CHD but with 22 RF (see Table). Assuming a 10% J- LDL-C with diet, 
3.2-9.0 million require drug therapy, depending on clinical judgment. The 
largest potential increase with more aggressive “clinical judgment” is in indi- 
22 RF (millions) 
Hypertension 
Diabetes 
Smoking 
HDL-C < 35 
,3RF 
LDL-C 130-159 (n = 3.9) LDL-C > 160 (n = 3.1) 
3.4 (86.9%) 2.4 (78.2%) 
0.9 (23.2%) 0.6 (18.7%) 
0.8 (19.9%) 0.7 (22.2%) 
0.4 (10.1%) 0.3 (10.9%) 
1.4 (35.2%) 0.9 (28.4%) 
viduals without CHD who have p2 RF and mildly increased LDL-C, but these 
individuals also have the greatest incidence of comorbidity (Table). 
Conclusion: With the increased number of high-risk elderly individuals 
without CHD needing drug therapy by applying clinical judgment as defined 
in ATP II, optimizing cost-effectiveness of treatment is required to extend 
appropriate therapy to the most pts. 
4:30 fxm. 
El 861 3 Do the Major CHD Risk Factors Predict Long-Term 
CHD Mortality in Young Men? 
Elena L. Navas-Nacher, Laura Colangelo, Craig Beam, Philip Greenland. 
Department of Preventive Medicine, Northwestern University Medical 
School, Chicago, Illinois, USA 
Background: Very few studies have evaluated the long-term predictive 
power of CHD risk factors (cigarette smoking (Smk), serum total choles- 
terol (Chol), and systolic blood pressure (SBP)) on CHD mortality in young 
men (under age 40 at baseline). Nearly all prior reports focus on persons age 
40+ at baseline. Data from the Chicago Heart Association (CHA) Detection 
Project in Industry were used to assess the risk and predictive power of these 
major CHD risk factors in 11,016 men ages 18-39 at baseline followed for 
mortality endpoints for over 20 years. 
Methods: By Cox regression we fitted multivariate models that included 
Smk, Chol, and SBP in addition to age, education, race and ECG abnormali- 
ties. We evaluated predictive ability using Receiver Operating Characteristic 
(ROC) curves. 
Results: Mean age at baseline was 29 years. Cox regression showed 
that the major CHD risk factors (age, Chol, SBP, and Smk) were all highly 
significantly associated with CHD mortality (all p < 0.005). ROC curve for 
the best predictive model yielded an area-under-the-curve (AUC) of 0.82, 
indicating that risk assessment is highly predictive in young men. 
Conclusion: These findings indicate that modifiable major risk factors are 
strong contributors to risk prediction in young men. These unique data should 
be helpful in supporting a screening policy that identifies young individuals at 
higher risk of CHD mortality. Thus, the current data provide empiric support 
for current NCEP guidelines. 
4:45 p.m. 
861-4 Lipoprotein(a) and Risks of Stroke, Fatal Coronary 
Heart Disease, and Mortality in Older Adults: 
A Prospective Study 
Abraham A. Ariyo, Daniel O’Leary, Russ Tracy, Chau Thach, Peter Savage. 
For the Cardiovascular /-/ea/th Study Investigators; Johns Hopkins Hospital, 
Baltimore, MQ USA 
Background: Laboratory research indicates that lipoprotein(a) [Lp(a)] plays 
an important role in athero-thrombogenesis. However, the relationship be- 
tween Lp(a) and cardiovascular events in older adults (265 yrs) is unknown. 
Methods: In a prospective study of 5201 older adults, 2375 women and 
1597 men who were free of cardiovascular disease (CVD) at study entry 
provided baseline serum samples for assessment of Lp(a). This group was 
followed for a median of 7.4 years for the development of stroke, fatal 
coronary heart disease (CHD) and total mortality. 
Results: Using Cox-proportional hazards models, we assessed the haz- 
ards (risks) associated with each quintile level of Lp(a) using the first quintile 
as the reference group. Among men, the hazard ratios for the highest quintile 
tripled for stroke (3.0; P = 0.02); almost triple (2.5; P < 0.001) for fatal CHD, 
and doubled (1.8; P < 0.001) for total mortality. Adjustment for age, gender, 
total-cholesterol (Tc), low-density lipoprotein cholesterol (LDL), smoking, di- 
abetes, systolic and diastolic hypertension, and estrogen use for women had 
little effect. Similar analyses for women were null for all the cardiovascular 
outcomes. 
Conclusions: An elevated serum level of Lp(a) was an independent 
predictor of stroke, fatal CHD and total mortality in men, but not in women. 
These data support the measurement of Lp(a) as a cardiovascular event 
predictor in older men. 
500 p.m. 
I 861 5 Beta-Blockade is Associated With Depressed C-Reactive Protein in Coronary Artery Disease 
Nicholas P. Jenkins, Brian G. Keevil, Ian V. Hutchinson, Nicholas H. Brooks. 
Department of Cardiology: Wythenshawe Hospital, Manchester: UK 
Background: Elevated C-reactive protein (CRP) is associated with an ad- 
verse prognosis in coronary artery disease (CAD). Aspirin and Hydroxy- 
methyl-coenzymeA (HMGCoA) inhibitors reduce plasma CRP, but the in- 
fluence of other cardiovascular medications is unknown. We assessed the 
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effects of other anti-angina1 medications on plasma CRP in 188 consecu- 
tive Caucasian adults with confirmed CAD undergoing coronary angiogra- 
phy. 
Methods: Patients with recent myocardial infarction, or additional autoim- 
mune, infectious and neoplastic diseases were excluded. CRP was assessed. 
by a commercial particle enhanced immuno-nephelometric assay. Stepwise 
forward multiple linear regression was used to control for demographic vari- 
ables, cardiovascular risk factors, history of myocardial infarction, QRS score 
(as a surrogate for left ventricular function), and vessel score. 
Results: Mean (SD) age was 59.4 (8.86) years, and 77% were male. 
51% had a history of confirmed myocardial infarction. Beta-blockade was 
associated with a significant reduction in plasma CRP (mean (SD) 2.6 (2.7) 
mg/l with beta-blockade vs 6.2 (8.8) mg/l without; P < 0.001). This association 
remained highly significant in a multivariate model (P = 0.001) which included 
previous myocardial infarction, body mass index, and plasma triglyceride 
concentration as independent co-predictors (R* = 0.316). Post-hoc exclusion 
of patients with asthma from the sample (n = 16) did not affect the association 
(mean (SD) 2.8 (3.1) ms/l with beta-blockade vs 6.1 (8.9) mg/l without: P = 
0.002). 78% (68/108) of these patients were taking atenolol, and there was 
no significant correlation between CRP and type or dosage of beta blocker. 
Aspirin, HMGCoA inhibitors, angiotensin convening enzyme inhibitors, and 
other anti-angina1 medications did not affect CRP. 
Conclusions: Beta blockade is associated with depressed CRP in pa- 
tients with CAD. The mechanism for this association is unknown, but could 
result from either altered hepatocyte metabolism, or direct immuno-modu- 
lation. These findings suggest a novel way by which beta-blockers improve 
cardiovascular prognosis. 
515 p.m. 
861-6 A Correlation Between Plasma Oxidized Low Density 
Lipoprotein (Ox-LDL) Levels and C-Reactive Protein 
Levels in Patients With Acute Myocardial Infarction 
Shouichi Ehara, Takahiko Naruko, Makiko Ueda, Ryushi Komatsu, 
Akira Itoh, Kazuo Haze. Osaka City Genera/ Hospital, Osaka City Universify 
Medical School, Osaka, Japan 
Background: Several lines of evidence indicate that active inflammatory 
processes are associated with plaque rupture or erosion which precedes 
the onset of acute coronary syndromes. Clinical studies have reported a 
step-up in inflammatory markers in the blood, such as C-reactive protein 
(CRP). Oxidized low density lipoprotein (ox-LDL) is considered a key factor 
in the genesis of the inflammatory process in atherosclerotic plaques. Using a 
sandwich ELISA method that has been developed recently, we have already 
reported that plasma levels of ox-LDL in acute myocardial infarction (AMI) 
patients were significantly (p < 0.001) higher than in patients with unstable 
angina pectoris, stable angina pectoris or control subjects (Ehara et al. 
Circulation 98: l-765, 1998). The purpose of this study is to investigate 
whether a correlation is present between plasma levels of ox-LDL and blood 
levels of CRP in patients with AMI. 
Methods: Plasma ox-LDL levels and CRP levels were measured in 27 
patients with AMI, who did not show an elevated creatine kinase level on ad- 
mission. Plasma levels of ox-LDL were also measured in 22 control subjects. 
Results: Plasma ox-LDL levels in AMI patients were significantly (p < 
0.001) higher than in control subjects. Of the 27 patients with AMI, 7 showed 
an increased level of CRP (>0.3 mg/dl) (elavated CRP group). Plasma levels 
of ox-LDL in the elevated CRP group were significantly higher than in the 
normal CRP group (p < 0.01) (elevated CRP group: 3.2 f 2.24; normal CRP 
group: 1.34 f 1 .I6 ng/5 fig LDL protein, mean f SD). 
Conclusions: Elevation of plasma ox-LDL levels in patients with AMI may 
reflect progression of an ox-LDL-mediated inflammatory process in coronary 
atherosclerotic lesions. 
ORAL 
I 868 Endothelial Regulation of Vascular Tone in 
Humans 
Tuesday, March 14, 2000, 8:30 a.m.-l 0:OO a.m. 
Anaheim Marriott, Marquis Northeast 
8:30 a.m. 
1 868-l 1 Baroreceptor Dysfunction Induced by Nitric Oxide 
Synthase Inhibition in Man 
Lukas E. Spieker, Christian Binggeli, Roberto Corti, Thomas F. Ltischer, 
Georg Nell. Cardiology University bfospita!, Zijricb, Swifzerland 
Background: Both the sympathetic nervous system and endothelium-derived 
substances play essential roles in cardiovascular homeostasis and diseases. 
Little is known about their interactions. The aim of this study was to investigate 
baroreceptor regulation of sympathetic nerve activity and hemodynamics af- 
ter inhibition of nitric oxide (NO) synthesis. 
Methods: In healthy volunteers, we recorded muscle sympathetic nerve 
activity (MSA) with microneurography and central hemodynamics measured 
at different levels of central venous pressure induced by lower body negative 
pressure. 
Results: After administration of the NO synthase inhibitor NG-monome- 
thyl-L-arginine (L-NMMA, 1 .mglkg/min), systolic blood pressure increased by 
24 mmHg (P = 0.01) and diastolic blood pressure by 12 mmHg (P = 0.009), 
while stroke volume index (measured by thermodilution) fell from 53 to 38 
mUmin/m* (P < 0.002). Administration of L-NMMA prevented the compen- 
satory increase of heart rate, but not MSA, to orthostatic stress. The altered 
response of hearf rate was not due to higher blood pressure, since heart 
rate responses were not altered during infusion of the alpha-I-adrenoceptor 
agonist phenylephrine (titrated to an equal increase of systolic blood pres- 
sure). In the presence of equal systolic blood pressure and central venous 
pressure, we found no difference in MSA during phenylephrine and L-NMMA 
infusion. 
Conclusions: This study demonstrates a highly specific alteration of 
baroreceptor regulation of heart rate but not muscle sympathetic activity after 
inhibition of NO synthesis in healthy volunteers. This suggests an important 
role of NO in reflex-mediated heart rate regulation in man. 
8:45 a.m. 
1 868-2 1 Selective Impairment of Endothelium-Dependent 
Vasodilation of Resistance Vessels in Patients With 
Obstructive Sleep Apnea 
Masahiko Kato, Bradley G. Phillips, Philip Roberts-Thomson, William 
G. Haynes, Mikolaj Winnicki, Valentina Accurso, Virend K. Somers. 
University of Iowa, Iowa Cifl: Iowa; Mayo Clinic, Rochester, Minnesota, USA 
Background: Patients with obstructive sleep apnea (OSA) experience repet- 
itive episodic hypoxemia with consequent sympathetic activation and marked 
blood pressure surges, each of which may impair endothelial function. We 
tested the hypothesis that patients with OSA have impaired endothelium- 
dependent vasodilation, even in the absence of overt cardiovascular disease. 
Methods: We studied 8 patients with OSA (aged 44 f 4 years) and 9 
obese control subjects (aged 48 f 3 years). Patients with OSA were newly 
diagnosed, never treated for OSA, on no medications and free of any other 
known diseases. All obese control subjects underwent complete overnight 
polysomnographic studies to exclude occult OSA. Resistance vessel func- 
tion was tested using forearm blood flow (FBF) responses to intra-arterial 
infusions of acetylcholine (ACh; a vasodilator that stimulates endothelial re- 
lease of nitric oxide (NO)), sodium nitroprusside (SNP; an exogenous NO 
donor), and verapamil (VER; a calcium channel blocker). Conduit vessel 
function was also evaluated, using ultrasonography. Brachial artery diameter 
was measured under baseline conditions, during reactive hyperemia (with 
flow increase causing endothelium-dependent dilatation), and after sublin- 
gual administration of nitroglycerin (an endothelium-independent vasodila- 
tor). 
Results: Patients with OSA had a blunted vasodilation in response to 
ACh (p = O.Ol), but responses to SNP and VER were similar to obese control 
subjects. No differences in conduit vessel dilation was evident between OSA 
and obese controls. 
Conclusion: Patients with OSA have a selective impairment of resis- 
tance vessel endothelium-dependent vasodilation. This may contribute to 
the pathogenesis of hypertension in this condition. 
9:00 a.m. 
868-3 The Contribution of Endothelin to Pulmonary 
Vascular Tone Under Normoxic and Hypoxic 
Conditions 
Wendy Johnson, Anju Nohria, Leslie Garrett, James Igo, Peter Ganz, Mark 
A. Creager. Brigham & Women’s Hospifd, Boston, Massachusetts, USA 
Background: Endothelin levels are elevated in patients with pulmonay hy- 
pertension and in animals with hypoxia-induced pulmonary vasoconstriction 
The contribution of endothelin to the regulation of pulmonary vascular tone 
in healthy humans is not known. Accordingly, we studied the hemodynamic 
effects of BQ-123, an endothelin-A receptor antagonist, on healthy humans 
under normoxic and hypoxic conditions. 
Methods: Eleven healthy subjects underwent placement of a radial ar- 
terial cannula and a Swan-Ganz catheter in order to measure oxygen satu- 
ration, systemic blood pressure (BP), right atrial pressure, pulmonary artery 
pressure (PAP), pulmonary artery wedge pressure, cardiac output (CO, in 
Umin), systemic vascular resistance (SVR), and pulmonary vascular resis- 
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lance (PVR, resistances expressed in dynes-s-cm~5). Hemodynamics were 
assessed under room air conditions (0s saturation 99%, paOs 100 mmHg) 
and after 15 minutes of exposure to an OsINa mixture designed to reduce 
02 saturation to 84% and paOp to 50 mmHg. After normoxic conditions were 
reestablished, subjects received BQ-123, 200 nmol/min, by central venous 
catheter for 60 minutes. Hemodynamic measurements were then repeated 
before and after 15 minutes of hypoxia. 
Results: Hypoxia significantly increased mean PAP by 50% (9.7 & 1 .I to 
14.6 f 1.2 mmHg), CO by 28% (5.3 + 0.3 to 6.7 & 0.4), and PVR by 95% 
(64 f 5 to 119 & IO) (each p c O.Ol), while it decreased mean BP by 3% 
(90 * 4 to 86 i 4 mmHg, p < 0.05) and SVR by 23% (1368 f 52 to 1050 f 
57, p < 0.01). During normoxia, BQ-123 infusion decreased PVR by 27% (to 
46 i 5), and SVR by 22% (to 1069 i 38) while increasing CO by 22% (to 
6.4 i 0.3) (each p < 0.05 compared to baseline). Mean BP and PAP did not 
change. During the BQ-123 infusion, reinstitution of hypoxia increased mean 
PAP by 57% (to 14.1 & 0.9 mmHg), CO by 29% (to 8.3 f 0.6) and PVR by 
97% (to 86 XIZ 9) (each p < 0.01) and decreased SVR by 22% (to 828 i 43) 
(p < 0.01 compared to BQ-123 without hypoxia). Mean BP did not change. 
Thus endothelin A receptor antagonism with BQ-123 decreased both PVR 
and SVR comparably during normoxic and hypoxic conditions, but did not 
attenuate the percent increase in PVR caused by acute hypoxia. 
Conclusions: Endothelin contributes to the regulation of basal pulmonary 
vascular tone in healthy subjects via the endothelin-A receptor but does not 
mediate the pulmonary vasoconstriction that occurs during acute hypoxia. 
9:15 a.m. 
868-4 Physical Exercise Corrects Coronary Endothelial 
Function and Enhances Coronary Flow Reserve in 
Patients With Coronary Artery Disease 
Rainer Hambrecht, Anamaria Wolf, Stephan Gielen, Axel Linke, 
Sandra Erbs, Jiirgen Hofer, Nina Schoene, Gerhard Schuler. Universify of 
Leipzig -Heart Center, Leipzig, Germany 
Background: Research efforts to determine the physiological mechanisms 
mediating cardioprotective effects of exercise training in patients (pts.) with 
coronary artery disease (CAD) have yielded contradictory results: Even in 
pts. with progression of coronary artherosclerosis myocardial perfusion was 
significantly increased. We therefore analyzed the effect of exercise training 
(ET) on endothelial dysfunction and coronary flow reserve in pts. with mild 
CAD. 
Methods: 19 pts. with coronary endothelial dysfunction as documented 
by acetylcholine (ACH) induced vasoconstriction were prospectively random- 
ized to a training group (T, n = 10, high intensity ergometer ET Gxiday in 
hospital) or an inactive control group (C, n = 9). At baseline and after 4 weeks 
endothelium-mediated vasodilation in response to intracoronary infusions of 
ACH (0.072, 0.72, 7.2 Fgimin) and coronary flow reserve (CFR) after adeno- 
sine (2.4 mg/min) were invasively assessed, Average peak velocity (APV) 
was measured by Doppler flow wire, vessel diameter was determined by 
quantitative coronary angiography. 
Results: After 4 weeks ET oxygen uptake increased by 29% at the 
ventilator-y threshold and by 12% at peak exercise. ACH-induced coronary 
artery constriction was significantly attenuated after 7.2 wgimin ACH by 54% 
(from -0.41 i 0.05 to -0.19 f 0.07 mm; p < 0.05 vs. control). In training 
pts. 7.2 pgimin ACH increased APV 78 i 16% at baseline, and by 142 f 
28% after ET (p < 0.01 vs. C). CFR increased by 29% (from 2.8 f 0.2 to 3.6 
i 0.2; p < 0.01 vs. C). Baseline internal coronary artery diameter remained 
unchanged in both groups before and after training (T: 2.77 & 0.11 mm vs. 
2.77i0.14mm,p=ns;C:2.84+0.10mmvs.2.81 fO.ll mm,p=ns). 
Conclusion: High intensity physical exercise training improves endothe- 
iium-dependent vasodilation of coronary conduit and resistance vessels and 
enhances CFR in pts. with coronary artery disease even without affecting 
iuminal diameter. 
9:30 a.m. 
868-5 Oral Folic Acid Treatment Improves Endothelial 
Function in Patients With Hyperhomocysteinemia 
T. Holm, K. Holven, P. Aukrust, B. Christensen, F. Brosstad, 
A.K. Andreassen, L. Ose, L. Gullestad, J. Kjekshus, M.S. Nenseter. 
Department of Cardiology: Lipid Clinic, Research institute for internal 
Medicine and MSD Cardiovascular Research Center, Rikshospitalet, 
University of Oslo, Norway 
Elevated plasma concentration of total-homocysteine (t-Hey) is an inde- 
pendent risk factor for cardiovascular diseases associated with impaired 
endothelial function. The mechanisms by which t-Hey modulates cardiovas- 
cular function are at the present largely unknown. The aim of the study was 
to examine whether folic acid supplementation improve endothelial function 
in subjects with hyperhomocysteinemia. 
Methods: Endothelial function was determined in 22 subjects with hyper- 
homocysteinemia (range 10.0-52.6 ~molil) by both forearm laser Doppler 
perfusion measurements in the skin microcirculation [vasodilatory responses 
to acetylcholine (Ach) (endothelium-dependent) and sodium nitroprusside 
(SNP) (endothelium-independent)], and by total forearm reactive hyperemic 
blood flow response [strain-gauge venous occlusion pletysmography tech- 
nique], before and after 6 weeks of folic acid supplementation (5 mgid first 
week; 1 mg/d following 5 weeks). Biochemical markers of endothelial function 
were determined by ELISA in venous blood samples [von Willebrand factor 
(vWF), plasma NO; and NO; (NO) and big-endothelin (B-ET)]. 
Results: Folic acid treatment reduced serum concentrations of t-Hey 
by 44% [from 21.3 (range 10.0-52.6) to 9.7 (range 7 to 13) wmol/L, p < 
O.OOi]. Microvascular vasodilatory responses to Ach increased 20% (range 
-56-440%, P < 0.05) while the response to SNP remained unchanged. By 
strain-gauge pletysmography technique, peak reactive hyperemia and pos- 
tocclusive t/2 recovery time increased by 23% (range -4O-82%, P < 0.05) 
and 18% (range -23-116%, P < O.Ol), respectively. Plasma concentrations 
of NO increased from 12.1 gmol/L (range 4.4-41.8 PmoliL) to 18.0 &mol/L 
(range 5.4-39.2 pmol/L, P < 0.05) and vWF decreased from 84% (range 
44 to 198%) to 67% (range 23-195%, P < 0.05). No significant changes 
occurred in B-ET concentration. 
Conclusion: Oral folic acid treatment reduces plasma t-Hey and concomi- 
tantly improves endothelial function in patients with hyperhomocystenemia. 
Our findings suggest that t-Hey at least partly induce its atherogenic effect by 
depressing endothelial function and that this effect is reversed by folic acid 
supplementation. 
9:45 a.m. 
868-6 Sustained Improvement in Homocyst(e)ine Levels 
and Arterial Endothelial Function After One-Year 
Folic Acid Supplementation 
Kam S. Woo’, Ping Chook’, Lindy L.T. Char-r’, Alice S.P. Cheung’ , Yvette 
I. Lolin’ , John E. Sanderson’, David Celermajerz. ‘The Chinese University 
of Hong Kong, China; “Royal Prince Alfred Hospital, Sydney Australia 
Background: Hyperhomocyst(e)inemia is a novel atherosclerosis risk factor, 
and is associated with arterial endothelial dysfunction in asymptomatic adults, 
which can be improved with folic acid (FA) supplementation over short-term. 
Methods: To evaluate the long-term effect of FA supplementation, 29 
asymptomatic subjects (mean age 52.1 i 8.4 years) were randomly selected 
from 89 volunteers enrolled in an on-going community-based atherosclerosis 
screening project. 23 (79.3%) were males and 4 (13.8%) were active smok- 
ers. All were given FA IO mg/day. Fasting total plasma homocyst(e)ine (HC) 
were measured by high performance liquid chromatography and endothelial 
function by flow-mediated dilatation of brachial artery (FMD % change in 
diameter) using high resolution B-mode ultrasound. 
Results: FA supplementation for 1 year was associated with a significant 
drop in HC (9.0 i 1.6 to 7.9 f 2.0 mmol/L)(p < 0.001) and elevation in plasma 
folate (23.9 * 4.7 to 40.4 i 4.8 nmol/L) (p < 0.001). 2 subjects (6.9%) had 
no significant changes in HC inspite of a significant rise in folate levels. Of 
the 15 subjects having FMD measured at baseline and 1 year, FMD were 
significantly improved from 5.9 & 1.4% to 8.4 & 1.4% (p < O.OOOl), but there 
were no changes in the nitroglycerin (endothelium-independent) response. 
No significant changes in body mass index, renal function or lipid profiles 
were observed. 
Conclusion: Long-term FA supplementation produces a sustained de- 
crease in HC level and improvement in arterial endothelial function. 
ORAL 
/ 869 Prognosis in Hypertension: Lessons From the 
Major Studies 
Tuesday, March 14, 2000, 8:30 a.m.-lo:00 a.m. 
Anaheim Marriott, Marquis Northwest 
8:30 a.m. 
869-l The Relation of Blood Pressure to Coronary Heart 
Disease Risk as a Function of Age: The Framingham 
Heart Study 
Stanley S. Franklin, Shehzad A. Khan, Nathan D. Wong, Martin G. Larson, 
Daniel Levy. University of California, Irvine, Irvine, California; Framingham 
Heart Study/NHLBI, Framingham, Massachusetts, USA 
Background: The relative importance of diastolic (DBP), systolic (SBP) and 
pulse pressure (PP), as cardiovascular risk factors has been controversial. 
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We examined the relations of these 3 blood pressure (BP) indices to coronary 
heart disease (CHD) risk in different age groups of men and women from the 
Framingham Heart Study. 
Methods: We studied 3152 men and 3566 women between the ages 
of 20 and 79 years of age and not taking antihypettensive drug therapy at 
baseline. Cox regression, adjusted for age, sex, and other risk factors, was 
used to assess the relations of BP indices to CHD risk over a 20-year follow 
up. Four age groups were defined: <40, 40-49, 50-59, and >60 years of 
age. 
Results: In age group < 40 years, Sex differences were noted: 
BP Indices 
SBP 
DBP 
PP 
Hazard Ratio/l0 mmHg (95%CI) 
Men Women 
1.05 (0.89-1.24) 1.54 (1.24-l.Ql)*** 
1.43(1.15-1.78)** 1.94(1.37-2.73)*** 
0.71 (0.55-0.92)* 1.59 (1.02-2.50)” 
SexDifferences 
x2 p value 
8.1 0.005 
2.3 0.13 
9.3 0.002 
When both sexes were combined, hazard ratios/IO mmHg, (95%CI) were 
as follows: 
AgeGroup SBP 
c40 1.16(1.01-1.34)* 
40-49 1.15(1.06-1.25)** 
50-59 1.09 (1.03-1.16)*’ 
360 1.17(1.11-1.24)*** 
*p < 0.05, *‘p < o.o1,***p < 0.001 
DBP PP 
1.54 (1.26-1.67)*** 0.84 (0.67-1.06) 
1.26 (l.ll-1.47)** 1.16 (1.00-1.34) 
1.14(1.03-1.27)* 1.12(1.03-1.22)” 
1.12(0.99-1.27) 1.24(1.16-1.33)**” 
When SBP and DBP were jointly entered in the multivariate model for 
age group p 60 years, the association with CHD risk was positive for SBP 
(HR 1.24; 95% Cl, 1.15 to 1.33) and negative for DBP (HR 0.83; 95% Cl, 
0.70-0.97). This negative relation was only observed in the 160 group. 
Conclusions: With aging, the best predictors of CHD risk shift from DBP 
to SBP and PP. In young subjects, DBP and SBP (or DBP alone) may predict 
risk because they are indicators of small vessel resistance; in older subjects, 
SBP and PP are superior predictors because they are indicators of large 
vessel stiffness. 
8:45 a.m. 
869-2 Evolution of Hypertension From Non-Hypertensive 
Blood Pressure Levels: Rates of Progression in the 
Framingham Heart Study 
Ramachandran S. Vasan, Martin G. Larson, William B. Kannel, Daniel Levy. 
NHLBl’s Framingham Heart Study: Framingham, MA, Boston; University 
School of Medicine, Boston, MA, USA 
Background: Subjects with optimal, normal and high normal blood pressure 
(BP) [as defined by JNC V/j may progress to hypertension (HTN) over time. 
The rates of progression to HTN, though presently unclear, are important 
for recommendations regarding the frequency of measurement of BP in 
non-hypertensive individuals. 
Methods: We evaluated repeated BP measures in Framingham Study 
subjects who were non-hypertensive (BP < 140/90 mm Hg) and who attended 
more than 1 examination during the period 1978-1998; 4327 men, 5754 
women (mean age 53 yrs). We constructed 4-year transition matrices to 
study the progression of the 3 non-hypertensive BP categories to HTN. We 
also examined the impact of age, and gender on the rates of progression to 
HTN. 
Results: A step-wise increase in progression to HTN was noted across 
the 3 non-hypertensive BP categories; 6% of optimal BP, 20% of normal BP 
and 41% of high normal BP subjects progressed to HTN over 4-yr periods 
of observation. Age, but not gender, was the most important determinant of 
progression to HTN for all non-hypertensive BP categories. 
BPCategory* % 4.Yr Progression to HTN (95% Cl) 
Men Women 
35-64Yrs 65-94 Yrs 35-64Yrs 65-94 Yrs 
Optimal BP 5 (4-6) 15(12-20) 5(4-6) 16(12-21) 
Normal BP 18(15-20) 25 (2031) 18(15-21) 26(21-31) 
High Normal BP 37(33-41) 47(41-54) 37(33-42) 49(42-55) 
*Optimal BP = systolic < 120 & diastolic < 80 mm Hg; Normal BP = systolic < 130 & 
diastolic < 85 mm Hg; High Normal BP = systolic 130-139or diastolic 85-89 mm Hg. 
Conclusions: High norms/BP and normal BP frequently progress to HTN 
over a period of 4 years, especially so in older adults. Our findings strengthen 
current recommendations for annual monitoring of BP in individuals with high 
normal BP and biennial measurements of BP in subjects with optima/ and 
normal BP. 
/ 869-3 1 
9:00 a.m. 
Impact of Coronary Artery Disease on Left 
Ventricular Systolic Function and Geometry in 
Hypertensive Patients With Left Ventricular 
Hypertrophy: The Losartan Intervention for 
End-Points (LIFE) Study 
Miguel Zabalgoitia, Jens Berning, Michael J. Koren, Asbjorn Stoylen, 
Markku S. Nieminen, Bjorn Dahlof, Richard B. Devereux. For the L/FE 
Study; University of Texas Health Science Center at San Antonio, Texas, 
USA 
Background: We hypothesized that a close relation exists between clinical 
evidence of coronary artery disease (CAD) and alterations in left ventricular 
(LV) structure and function that contribute to high-risk of cardiovascular (CV) 
events in hypertensive LV hypertrophy. 
Methods: M-mode and 2-D echoes were recorded in 964 hypettensives 
with ECG LV hypertrophy (Cornell or Sokolow-Lyon criteria). Patients (mean 
age 66 f 7 years, women 41%) were divided into those with and without 
clinical CAD (angina pectoris, prior myocardial infarction). 
Results: Patients with clinical CAD had larger LV internal dimensions (5.5 
& 0.6 vs 5.2 f 0.6, p < O.OOOl), increased LV mass (135 i 30 vs 122 f 24 
s/m* p c: 0.0001; and 61.7 f 15.1 vs55.9 f 13.4 g/m2r7, p < O.OOi), lower 
relative wall thickness (0.39 vs 0.41, p < 0.02) and fractional shortening 
(30 f 6% vs 33 f 5%, p < O.OOOl), higher circumferential end-systolic wall 
stress (cESS) (204 f 59 vs 179 f 43, p < O.OOOl), lower cESS/end-systolic 
volume index ratio (6.2 f 1.7 vs 6.8 f 1.4, p < O.OOOl), and higher total 
peripheral resistances (2101 f 63 vs 1964 f 55, p < 0.02). LV mass cESS 
ejection time, an index of myocardial oxygen demand per beat, was higher 
in the CAD group (graph). Although in both groups eccentric hypertrophy 
predominated over other LV geometric forms, the CAD group had a greater 
prevalence, of this pattern than the non-CAD group (56% vs 45%, p < 0.02). 
N .  c*D C*D 
Conclusions: Clinical evidence of CAD in hypertensive patients with 
ECG LV hypertrophy identifies those with structural and functional LV ab- 
normalities of high-risk. The LV mass cESS ejection time product is a 
useful noninvasive index to calculate myocardial oxygen demand per beat in 
hypertensive patients with ECG evidence of LV hypertrophy. 
9:15 a.m. 
869-4 Inappropriate Left Ventricular Mass is Associated 
With High Cardiovascular Risk Profile in 
Hypertensive Subjects: The LIFE Study 
Vittorio Palmieri, Kristian Wachtell, Jonathan N. Bella, Eva Gerdts, 
Vasilios Papademetriou, Markku S. Nieminen, Mary Paranicas, 
Bjorn Dahlof, Richard 6. Devereux. Weill Medical College of Cornell 
University New York, N. Y, USA; Copenhagen County University Hospital, 
Glostrup, Denmark 
Background: In normal adults, gender(G), hemodynamic load and height*,7 
(ideal body size) are determinants of left ventricular (LV) mass (M). LVM 
exceeding predicted values for G, body size and hemodynamic load is termed 
inappropriate (I) LVM. Cardiovascular risk profile associated with ILVM is 
incompletely described. 
Methods: We used an equation developed in 393 apparently healthy 
adults to predict LVM adequate (A) for G, height2,7 and stroke work (hemo- 
dynamic load to predict LVM in 811 hypertensive subjects (HYP) enrolled in 
the LIFE study (JNC-V stage I-III and LV hypertrophy (H) by Cornell voltage 
duration or Sokolow Lyon criteria), without significant valve diseases. Percent 
of predicted LVM (%PLVM) was derived dividing observed by predicted LVM. 
%PLVM > 128% (95th %ile of %PLVM in reference subjects) discriminated I 
from A LVM. 
Results: Age (66 vs 67 yrs/old, p = ns), and proportion of women (41 vs 
45%, p = ns) were similar in HYP with I-LVM or A-LVM. Obese were 17% and 
overweight 31% of HYP with I-LVM, compared to 9% and 26% in HYP with 
A-LVM (p < 0.001). Prevalences of diabetes (DM), coronary disease (CAD) 
and angina were higher within I-LVM than A-LVM (12 vs 8%, 16 vs 9%, and 
10.8 vs 5.3%, all p < 0.04). 92% of HYP with I-LVM had echo-LVH vs 58% in 
those with A-LVM (p < 0.001). I-LVM was associated with low ejection fraction 
(EF < 54%) or low stress-corrected midwall shortening (<89.2%) adjusting 
for age, G, diastolic BP, CAD, DM (adjusted OR: 3.4 and 4.8, p < 0.001). 
Creatinine was higher in HYP with I-LVM than A-LVM (1.03 vs 0.99 mg/dl, p 
JACC Febnwy 2000 ABSTRACTS - Hypertension, Vascular Disease & Prevention 293A 
< 0.05) while total cholesterol/HDL-cholesterol ratio did not differ (4.3 vs 4.1, 
p = 0.1). Prevalence of microaibuminuria (urinary albumin/creatinine 30-300 
mg/g) was higher in I-LVM than A-LVM (26.2 vs 19.3%, p < 0.05). 
Conclusion: In HYP with ECG-LVH, inappropriate LVM was associated 
with higher prevalence of DM, obesity, echo-LVH, CAD, LV systolic dysfunc- 
tion and renal dysfunction. 
9:30 a.m. 
869-5 Prognostic Significance of Abnormal Peak Early to 
Late Diastolic Filling Ratio in Middle-Aaed to Elderlv 
Adult American Indians: The Strong Heart Study * 
Jonathan N. Bella, Uittorio Palmieri, Mary J. Roman, Jennifer E. Liu, 
Thomas K. Welty, Elisa T. Lee, Richard R. Fabsitz, Barbara V. Howard, 
Richard B. Devereux. Weill Medical College of Cornell University, NY New 
York, USA 
Background: Among older adults. left ventricular (LV) filling tends to de- 
crease in early diastole, resulting in reduced peak early to late diastolic filling 
ratio (E/A ratio). However, the prognostic significance of this abnormality in 
older adults remains to be elucidated. 
Methods: Doppler echocardiograms were analyzed in 2,888 American 
Indian participants in the second Strong Heart Study (SHS) examination 
with no more than mild mitral or aortic regurgitation. SHS participants were 
followed for a mean of 3 years to assess risks of cardiovascular death and 
all-cause death. E/A ratio < 0.8 or >I .5 was considered abnormal. 
Results: The mean E/A ratio was lower in participants age 2 60 than in 
those age ~60 (0.75 f 0.25 vs. 0.92 f 0.33, p < 0.001). The prevalence 
of reduced and increased E/A ratios were 38.7% and 3.5% for age < 60 
and 67.8% and 1.6% for age 1 60 (p < O.OOl), respectively. There was 
an increase in death from any cause associated with reduced or increased 
E/A ratio (5.1 and 8.6% vs. 2.5, p < 0.001) as well as cardiovascular death 
(1.4 and 4.3% vs. 0.4, p = O.OOi). Nonfatal cardiac events were similarly 
increased with reduced or increased E/A ratio (2.9 vs. 4.7 and 11.4%, p = 
0.009). The relative risk of death from any cause was 1.8 (95% Cl: 1 .ll-2.89, 
p = 0.02) for those with reduced E/A ratio and 3.7 (95% Cl: 1.32-10.54, p 
= 0.01) for those with increased E/A ratio compared to those with normal 
E/A ratio after adjustment for age, gender, blood pressure, diabetes, ejec- 
tion fraction and LV mass. The relative risk of cardiovascular death was 
1.8 (95% Cl: 0.64-5.44, p = NS) for reduced E/A ratio and 11.5 (95%CI: 
2.06-64.65, p = 0.005) for increased E/A ratio after adjustment for similar 
covariates. 
Conclusion: In a population-based sample of middle-aged to elderly adult 
American Indians, the presence of abnormal E/A ratio at baseline Doppler 
echocardiography is independently associated with a 2 to 4-fold increase in 
ail-cause mortality, and E/A >- 1.5 predicting high cardiovascular mortality. 
9:45 a.m. 
869-6 Relation of Left Ventricular Mass and Geometry to 
Cardiovascular Risk Factors in American Indians: 
The Strong Heart Study 
Annamaria Municinb, Richard B. Devereux, Vittorio Palmieri, Mary 
J. Roman, Elisa T. Lee, Thomas K. Welty, Richard R. Fabsitz, Barbara 
V. Howard. Weill Medica/ College of Cornell Universifl: New York, Nx USA 
Background: Left ventricular hypertrophy (LVH) predicts morbidity and mor- 
tality in adults. However relations of LV mass and geometry to traditional 
cardiovascular risk factors have not been fully elucidated in population-based 
samples. 
Methods: Relations of risk factors to echocardiographic LV mass and 
geometry were evaluated in 3182 American Indians participants in the 2”d 
Strong Heart Study examination. LVH = LV mass/height2,’ 149.2 in men 
and 46.7 g/m2.7 in women; relative wall thickness [RWT] (2X LV posterior 
wall/diastolic diameter) ? 0.43 = concentric (C) LV geometry. Normal LV 
geometry (Nl LV) = normal RWT and LV mass; C remodeling (CR) = CLV 
geometry without LVH; eccentric LVH (E-LVH) = LVH with normal RWT; CLVH 
= CR plus LVH. Body adiposity was calculated by bioimpedance. 
Results: Compared to participants with Nl LV, those with CR (n = 96), 
E-LVH (n = 737) and C-LVH (n = 83) were older (59 vs 62-63 years p < 
0.001). Prevalence of women increased from the Ni -LV to C-LVH (58 vs 66 vs 
77 vs 82%, p < 0.001). Adipose body mass was higher with E-LVH (35 vs 30 
kg) and lower with CR (27 vs 30 kg) (all p < 0.001) without difference between 
C-LVH (31 kg) and NI-LV. Prevalence of hypertension (39 vs 52 vs 65 vs 
69%) and of diabetes (49, 73, 68 & 90%) increased from NI-LV to CR, E-LVH 
and C-LVH (all p < 0.01). After adjusting for age and gender, systolic (127 vs 
i32 vs 137 vs 145 mmHg), diastolic (74 vs 76 vs 76 vs 79 mmHg) and pulse 
pressure (53 vs 56 vs 61 vs 66 mmHg) increased from NI-LV to CR, E-LVH 
and C-LVH. Heat-f rate was highest with CR (73 bpm) and lowest with the 
NI-LV (67 bpm, p < 0.01) without difference between LVH groups (p z 0.1); 
total cholesterol (TC) was lowest with E-LVH while triglycerides, glycosylated 
hemoglobin and log ratio urinary albumin/creatinine, were higher with CR and 
C-LVH than E-LVH or Nl -LV. In multiple regression analysis, RWT increased 
with age (beta = O.ll), female gender (beta = O.lO), diabetes (beta = 0.07), 
systolic pressure (beta = O.lO), heart rate (beta = 0.08), triglycerides (beta = 
0.05) and log (albumine/creatinine) (beta = 0.11). 
Conclusion: Older age, female gender, higher systolic pressure and 
heart rate, presence of diabetes, higher levels of triglycerides and albu- 
minjcreatinine are associated with abnormal LV geometry. 
POSTER 
111331 Vascular Biology: Basic I 
Tuesday, March 14, 2000, 9:00 a.m.-11:OO a.m. 
Anaheim Convention Center, Hall A 
Presentation Hour: IO:00 a.m.-l 1:OO a.m. 
i i 33-41 Galectin-3 Accumulation in Foam Cells of 
Atherosclerotic Lesions and Lipid Loaded Mouse 
Peritoneal Macrophages 
M. Reza Movahed S.P., Eugene P. Mayer, Koanhoi Kim, Constantine 
A. Hassapoyannes, Maurice Nachtigal. University of South Carolina School 
of Medicine, Columbia, South Carolina, USA 
Background: Galectin-3 (Gal3), a member of p-galactose binding lectin has 
been found in atherosclerotic plaques. We Investigated the expression and 
localization of GaB in variety of atherosclerotic lesions. 
Method: The expression of Gal3 was studied in atherosclerotic lesions 
from carotid, lower limb and coronary arteries. Fresh specimens from carotid 
endarterectomy and lower limb were examined by Western blot and re- 
verse transcription polymerase chain reaction. Umbilical arteries were our 
control. 
Results: A higher level of Gal3 transcripts was detected in atherosclero- 
tic lesions as compared to the control. lmmunostaining with the monoclonal 
antibody M3/38 has localized galectin-3 in the atherosclerotic plaques of all 
specimens obtained from carotid and lower limb arteries and 67% of coro- 
nary artery lesions. Gal3 was localized predominantly in the foam cells and 
macrophages and rarely in smooth muscle cells. The media of atheroscle- 
rotic and umbilical cord arteries was negative for gal3 staining. The effect 
of lipid loading on Gal3 expression was investigated in mouse resident peri- 
toneal macrophages (M@) incubated with acetylated low density lipoprotein 
(AcLDL) or oxidized low density lipoprotein (OxLDL). Western blot analysis 
showed that MQ, treated with AcLDL or OxLDL contained more Gal3 than M@ 
incubated with acetylated bovine serum albumin (AcBSA). The intensity of 
fluorescence measured in MQ, loaded with lipids and immunostained for Gal3 
was 70% higher after incubation with AcLDL and 22% higher after treatment 
with OxLDL compared to M@ incubated with AcBSA. 
Conclusion: These results show that foam cells and macrophages in 
human atherosclerotic lesions have a higher expression of Gal3, and that 
lipid loading of MQ, resulted in increased intracellular Ga13. 
1133-42 Aortic Smooth Muscle Cells Chemotaxis is 
Promoted by a New Tenascin-C lsoform 
Kurt Wallner’ , Stephen. M. Schwait?, P. Prediman K. Shah’, Behrooz. 
G. Sharifi’ Cedars-Sinai Medical Cenfel; UCLA School of Medicine, Los 
Angeles, CA; “Dept. Pathology, University of Washington, Seattle, USA 
Background: Tenascin-C, a counter-adhesive extracellular matrix protein, is 
comprised of several isoforms with distinct biological activities. Neither the 
structure nor function of these isoforms in smooth muscle cells (SMCs) has 
been defined. 
Methods: We have used primers and RT-PCR to fully identify tenascin-C 
isoforms expressed by SMCs. Cloning and sequence analysis of the PCR 
product indicated that SMCs express a tenascin-C isoform with only re- 
peats Al and A2 of fibronectin type Ill repeats. Northern blot and RNase 
protection showed that this isoform is predominantly expressed by cultured 
SMCs derived from aorta of newborn rats, and its expression is up-regu- 
lated by PDGF-BB. In contrast, the expression of this isoform is markedly 
down-regulated in the SMCs derived from adult rat aorta. To determine if the 
AiA2-isoform protein is produced in vitro and in viva, we made the full-length 
recombinant Al A2 protein in E. coli and raised AlA2-isoform-specific anti- 
bodies. This antibody recognized the AlA2-isoform both in the conditioned 
media of cultured newborn SMCs and in balloon-injured rat carotid arteries. 
Using cultured SMCs, we found that the recombinant Al A2 protein promotes 
SMC chemotaxis. 
294A ABSTRACTS - Hypertension, Vascular Disease & Prevention JACC February 2000 
Conclusion: We conclude that tenascin-C isoforms are expressed in a 
regulated fashion in vascular system. Our findings suggest a potential role of 
tenascin-C isoforms in the remodeling of vascular wall. 
1 Anaiotensin II Induces the NADPH Oxidase \ ’ %&nit p22phox in Endotheiial Cells: Effect on 
Platelet Derived Growth Factor Dependent 
Production of Reactive Oxygen Species 
Jdrg Kreuzer, Daniela Durst, Martina Werle, Lothar Jahn. Medizinische 
Klinik 111, Universit2t Heidelberg, Germany 
Background: Inflammatory response of endothelial cells (EC) plays an im- 
portant role in atherogenesis. This activation may partially be triggered byfor- 
mation of reactive oxygen species @OS) through the nonphagocytic NADPH 
oxidase. Short time exposure with angiotensin II (Ang II) has been shown 
to induce ROS formation and activation of mitogen activated protein kinases 
(MAP-kinases) in smooth muscle cells. We now wanted to get closer to an in 
vivo situation and investigated the effect of chronic exposure of ECs to Ang 
II on ROS formation and MAP-kinase activation. 
Methods: Human umbilical vein endothelial cells were exposed to Ang 
II for 18 h at a concentrations between 10-s-10-8 M. Afterwards basal 0; 
platelet derived growth factor (PDGF) induced ROS production was mea- 
sured by intraviti DCF fluorescence, mRNA levels of NADPH oxidase sub- 
units p22phox and p47phox were quantitated by RT-PCR. Activation of mito- 
gen activated protein kinases (MAP-kinases) was assessed by Western Blot 
and lmmunocomplex kinase assay. 
Results: Treatment of HUVEC with Ang II resulted in a highly significant 
induction of both subunits p22phox and p47phox. In parallel with increased 
mRNA levels, around 3-fold increased basal ROS production was detected. 
When Ang II pretreated cells were stimulated with PDGF for IO minutes 
compared to control cells a marked increase in PDGF dependent ROS 
formation was detected. In Ang II treated cells extracellular signal regulated 
kin&e (ERK) was highly activated and could not be further induced by PDGF. 
p38MAPK however, was only slightly stimulated by angiotensin pretreatment 
for 18 hours and could be markedly induced by PDGF. 
Conclusion: Chronic exposure of endothelial cells to Ang II induces 
NADPH oxidase subunits in concert with increased basal and inducible levels 
of reactive oxygen species. This may result in altered signal transduction 
mediated through MAP-kinases which can contribute to the proatherogenic 
effects of elevated angiotensin II levels. 
1133-44 The Angiotensin Receptor Blocker, Candesartan 
Reduces Atherosclerosis in a Dose-Dependent 
Manner 
Michael T. Johnstone, Alexandra Perez, Robert Stewart, David Cole, 
Jennifer Weissberg, William Quist. Beth Israel Deaconess Medical Center, 
Harvard Medical School, Boston, MA, USA 
different from the medium and low dosage (p = 0.001; Mann-Whitney Rank 
Sum Test). 
Conclusion: These results show that in this animal model, the angiotensin 
receptor blocker candesartan reduces atherosclerosis in a dose dependent 
manner and may have an effect on plaque disruption. 
1 1133-45 ] Obesity, a Cardiovascular Risk Factor, is 
Associated With Tissue-specific Activation of 
Renal Angiotensin Converting Enzyme Activity In 
Viva. Evidence for a Regulatory Role of Endothelin 
Matthias Barton, Sidney Shaw, Henning Morawietz, Livius V. d’Uscio, 
Heinz Hillen, Thomas F. Liischer, Renata Carmona, Jose E. Krieger. 
Cardiology: Unversity Hospital Zurich, Switzerland; Laboratory of Genetics 
and Molecular Cardiology, Heart Institute, University of SaZo Paula, Brazil 
We determined whether obesity is associated with activition of the tissue 
renin angiotensin system in mice and investigated the potential involvement 
of endothelin (ET)-I. We measured tissue angiotensin converting enzmye 
(ACE) activity in vitro and in viva after acute and chronic treatment with 
LU135252, a selective ETA-antagonist. 
ACE activity (nmol His-Leu/mg protein) was measured in kidneys, lungs, 
and liver in male C57BL6 mice after 30 weeks of treatment with standard or 
high fat diet (0.15% cholesterol, 42% from fat) alone or in combination with 
LU135252 (50 mg/kg/d).-Human ACE (huACE) was purified from plasma 
(J Biol Chem 1985; 260: 2963) and enzymatic purity was assured using a 
panel of enzyme inhibitors. Tissue ET-1 protein content was measured by 
RIA/HPLC (pg ET-l/g tissue). 
In C57BU6 mice on regular diet, tissue ACE activity was comparable in 
lung and kidney (33 f 2 vs. 33.3 f 3 nmol) and about 1 OO-fold higher than in 
the liver (0.33 f 0.01 nmol). Fat-treated mice were obese (weight increase: 
257% vs. 53% after 30 weeks, p < O.OOOl), this was associated with a 72% 
increase of renal ACE activity (55 * 4 vs. 33 f 3 nmol, p < 0.0001 vs. regular 
diet) without affecting pulmonary or hepatic ACE activity (34 f 3 and 0.03 
i 2 nmol, n.s.). Chronic ETA-receptor blockade with LU135252 completely 
prevented increased ACE activity in the kidney (13.3 f 0.3 vs. 55 f 4 nmoi, 
p < 0.0001) but not in lung or liver (33.7 f 2 and 0.30 i 0.01 nmol, n.s). 
incubation of huACE in vi& with I-100 mmol/L LU135252 had no affect on 
ACE activity (n.s.). Obesity was also associated with a slight increase of renal 
ET-1 tissue levels (from 188 f 18 to 267 f 19 pg/g), which were unaffected 
by chronic LU135252 treatment (256 f 23 pg/g). 
We here demonstrate for the first time that ET-I - independent from its 
tissue levels - is involved in the regulation of tissue ACE activity in viva 
in an organ-specific fashion. Furthermore, these data indicate that obesity 
is associated with selective activation of tissue ACE activity in the kidney. 
These effects appear to require chronic actions of ET-I since acute incubation 
with LU135252 had no effect on purified ACE. ACE inhibition may be novel 
mechanism by which ET antagonists exert organ protection. 
Background: Several animal studies have shown that angiotensin convert- 
ing enzyme inhibitors reduce atherosclerosis. While the mechanism is not yet 
known, it is suspected that angiotensin II suppression may be the underlying 
etiology. However little is known as to whether angiotensin receptor block- 
ers can also reduce atherosclerosis and its complication, plaque rupture. 
One animal model in which to study these processes is the modified Con- 
stantinides animal model in which a rabbit is first made atherosclerotic with 
aottic balloon injury and a cholesterol diet then undergoes pharmacologic 
triggering with histamine, a vasoconstrictor and Russell’s viper venom, a pro- 
coagulant. Our aim, therefore was to evaluate the effect of the angiotensin 
receptor blocker, candesartan, on both the development of atherosclerosis 
and plaque disruption in this animal model. 
Methods: Ten rabbits were divided into three groups, A (0.01 mgikg) (n 
= 3) B (0.1 mg/kg) (n = 3) and C (0.5, 1 .O and 1.5 mg/kg) (n = 4). Rabbits 
received the drug for two days and then underwent aortic balloon injury. 
The rabbits were then fed a 1% cholesterol diet for 8 weeks. At the end 
of 8 weeks, the rabbits underwent pharmacologic triggering in which the 
rabbits were infused with histamine and Russell’s viper venom at both 48 
and 24 hours before sacrifice. Once the rabbits were sacrificed, their aortas 
were analyzed both for the presence of plaque disruption and thrombosis 
along with the degree of atherosclerosis. The degree of atherosclerosis was 
determined by obtaining 40 aortic cross sections per rabbit and calculating 
intima: media ratios. 
Results: In both Groups A and B, 2 of 3 rabbits developed plaque 
disruption and thrombosis after pharmacologic triggering while in Group C, 
none of the 4 rabbits developed plaque disruption or thrombosis ((p = 0.08), 
Fisher Exact Test). Atherosclerosis as determined by the intimal: media ratios 
(mean + SD) are: A - 0.91 f 0.35, B - 0.84 f 0.29, and C - 0.41 i 0.14, 
with those rabbits receiving the high dosage (Group C) being significantly 
(_I 1133 46 Induction of Endothelin-1 Expression by Oxidative Stress in Vascular Smooth Muscle Cells 
Johannes Ruef, Martin Moser, Meike Schwarz, Karlheinz Peter, Thomas 
K. Nordt, Wolfgang Ktibler, Christoph Bode. University of Heidelberg, 
Heidelberg; University of Freiburg, Freiburg, Germany 
Background: Endothelial dysfunction is involved in atherogenesis and re- 
sults in impaired vasomotor function. This is partially due to NO depiction 
caused by oxidative stress. Since the vasoconstrictor endothelin-I (ET-i) 
might also be involved in endothelial dysfunction, we investigated whether 
oxidative stress regulates ET-I expression in vascular smooth muscle cells 
(VSMC). 
Methods: Human aortic VSMC were treated with HsOs (200 FM). mRNA 
expression of preproendothelin was analyzed by quantitative RT-PCR. ET-l, 
heme-oxygenase 1 and 8-isoprostane were determined by immunoblotting 
and ELISA, respectively; activity of cytosolic phospholipase Az (cPLAz) was 
measured photometrically. 
Results: Stimulation of VSMC with H202 resulted in increased expression 
of preproendothelin mRNA after 3 h (4-fold), similar to treatment with Angio- 
tensin II. ET-1 protein was significantly increased by Hz02 treatment with a 
maximum after 8 h (p < 0.05). This effect was inhibited by grape-derived 
antioxidants resveratrol (100 PM) and quercetin (50 PM). In quiesced VSMC, 
incubation with HzOs-conditioned medium resulted in increased cPLAs activ- 
ity compared to the controls (p < 0.05). This activity was partially inhibited by 
the ET-1 receptor antagonist, PD 142893 (10 PM), indicating functional ET-l 
in the conditioned medium. The presence of oxidative stress in HsOz-treated 
VSMC was indicated by increases in heme-oxygenase 1 protein and for- 
mation of 8-isoprostane after 6 h of stimulation (p < 0.05), both serving as 
suitable markers for oxidative stress. 
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Conclusion: The data suggest that oxidative stress increases ET-1 gen- 
eration and autocrine ET-I activity in vascular smooth muscle cells, a mech- 
anism that might contribute to endothelial dysfunction in atherosclerosis, 
11133-47 1 Estrogen Attenuates Osteopontin Production by 
Activated Smooth Muscle Cells: A Potential 
Mechanism of Estrogen-Induced Vasoprotection 
Guohong Li, Stephen E. Bakir, Suzanne Oparil, John A. Thompson. 
University of Alabama at Birmingham, Birmingham, AL, USA 
Background: Mounting evidence suggests that adventitial activation con- 
tributes to neointima formation in response to endoleminal vascular injury 
in vivo. Our previous observations suggested a novel mechanism of estro- 
gen-induced vasoprotection, wherein estrogen directly modulates vascular 
smooth muscle cell (VSMC) expression of factor(s) controlling migration of 
adventitial fibroblasts via an estrogen receptor (El?)-dependent mechanism. 
The current study tested the hypotnesis that the extracellular matrix molecule 
osteopontin (OPN) is such a factor. 
Methods and Results: Using RT-PCR and Western blotting, we demon- 
strated high levels of OPN mRNA in serum-activated rat VSMCs in culture 
and OPN protein in VSMC-conditioned media. OPN production by VSMCs 
was inhibited by 17/I-estradiol in a dose-dependent fashion (10-9-10-7 M). 
Using fluorescent activated cell sorer (FACS) analysis, we demonstrated high 
levels of CIV and PI integrin subunit expression in both VSMCs and adventitial 
fibroblasts and significantly higher levels of 83 integrin subunit expression 
in adventitial fibroblasts. Fibroblast migration was performed using Tran- 
swell cell culture chambers. Pretreatment of fibroblasts with either anti-p3 
integrin antibody (IO-80 pgiml) or the synthetic RGD peptides (cyclic Gly- 
Pen-Gly-Arg-Gly-Asp-Ser-Pro-Cys-Ala and linear Gly-Arg-Gly-Asp-Ser-Pro 
at 10-1000 PM) blocked haptotaxis migration stimulated by both exoge- 
nous OPN (1.0-Z pgiml) and VSMC-conditioned media. The inactive control 
peptide (linear Gly-Arg-Ala-Asp-Ser-Pro) did not affect fibroblast migration 
induced by either stimulus. 
Conclusions: These findings suggest that OPN is one of the chemoat- 
tractant factors released by activated VSMCs that direct the migration of 
fibroblasts. Estrogen-mediated inhibition of OPN may modulate the migra- 
tion of adventitial fibroblasts into neointima following endoluminal vascular 
injury and thus blunt the vascular injury response. 
/ 1133-48 1 Creating Lipid-Rich Lesions in Porcine Coronary 
Arteries; A Novel Model of Vulnerable Plaque 
Paul C. Keelan, Antonio Bayes-Genis, Birgit Kantor, LaDonna J. Camrud, 
Jill Allen, Michael A. Jorgenson: Janis Donovan, Paula J. Carlson, Allan 
Ft. Camrud, Debra A. Lewis, Robert S. Schwartz Mayo Clinic and 
Foundation, Rochester, MN, USA 
Background: Rupture of vulnerable plaque frequently results in acute coro- 
nary syndromes. This lesion is characterized by a high lipid content at its 
core. Early identification of vulnerable plaque prior to its destabilization is not 
currently feasible. The lack of a large animal model has hampered efforts to 
understand this problem. We created such a model in pigs by injecting lipid 
directly into the wall of coronary arteries, 
Methods: Using an endovascular catheter designed for coronary intra- 
mural drug delivery, we directly injected 0.5-I .O ml of a lipid-rich compound 
into the coronary arterial wall. A total of 28 coronary arteries in 15 swine 
were treated in this manner. Sacrifice times were 14 and 28 days. Following 
sacrifice, hearts were removed and treated coronary arteries excised. Seg- 
ments were stained with standard H + E and Oil-Red-O stains and a porcine 
macrophage immunostain. 
Results: Oil-Red-O staining confirmed the presence of significant suben- 
dothelial lipid deposition in treated arteries at all time points following treat- 
ment. Significant localized inflammatoy reactions occurred around these 
deposits. lmmunohistochemistry confirmed this reaction was mediated by 
macrophages and lymphocytes. In two animals, we observed spontaneous 
endothelial disruption with an overlying adherent thrombus. These sites 
co-localized with the areas of greatest subendotheliai lipid deposition and 
macrophage infiltration. Sudden death occurred in one of these animals sev- 
eral days following the procedure. Neointima formed at the treatment sites 
and its extent correlated with the degree of treatment-induced vessel wall 
injury. 
Conclusions: This model shows significant subendothelial lipid depo- 
sition and macrophage infiltration. It may be complicated by spontaneous 
endothelial disruption and thrombus formation, similar to clinical syndromes. 
Each of these is a prominent feature of vulnerable plaque in humans. This 
model may be useful to assess the efficacy of imaging modalities to identify 
vulnerable plaque in humans. 
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L-l.--- 1134 50 Antisense Directed at Endothelial Oxidized LDL 
Receptor LOX-l Inhibits Apoptosis in Human 
Coronary Artery Endothelial Cells 
Jawahar L. Mehta, Dayuan Li. University of Florida and VA Medical Center, 
Gainesville, Florida, USA 
Background: Accumulation of oxidized LDL (ox-LDL) has been identified in 
atherosclerotic tissues. Ox-LDL also has been shown to induce apoptosis 
in endothelial cells. A specific lectin-like OX-LDL receptor (LOX-l) is ex- 
pressed in human coronary artery endothelial cells (HCAECs). While LOX-I 
is upregulated by ox-LDL (BBRC, 1998; 248: 511-514), its precise patho- 
physiological significance is unknown. This study was designed to examine 
the role of LOX-I in apoptosis in HCAECs. 
Methods: Fifth generation HCAECs were incubated with OX-LDL (IO-60 
@g/ml) for 6 to 24 hours to induce apoptosis, determined by TUNEL and 
DNA laddering. Parallel group of HCAECs were pre-incubated with phos- 
phorothioate antisense or sense-oligonucleotides directed at LOX-I mRNA 
(0.5 nmol/L for 48 hours), and then the HCAECs were exposed to ox-LDL for 
24 hours. 
Results: Ox-LDL induced apoptosis in HCAEC in concentration- and 
time-dependent manner. Antisense-LOX-l inhibited (P < 0.01) basal and 
ox-LDL-induced expression of LOX-l mRNA and protein, determined by 
RT-PCR and Western analysis, by >80%. Importantly, antisense LOX-1 
abolished ox-LDL-induced apoptosis, whereas sense-LOX-1 had no effect. 
Antisense-LOX-l, but not sense-LOX-l, also decreased (P < 0.01) ox-LDL- 
mediated activation of NF-KB (Western analysis). 
Conclusions: LOX-1 mediates ox-LDL-induced apoptosis in HCAECs, 
since antisense-LOX-l can inhibit this cell injurious effect of ox-LDL. Anti- 
sense-LOX-l also inhibits the signal transduction mechanism, i.e. activation 
of NF-KB, in this process. 
1134-51 Inhibition of Angiogenesis by Peptides Derived 
From Kininoaen Domain 5 & bv a Monoclonal 
Antibody to Kininogen Domain 5 
Shaker A. Mousa, Seema Mohamed, John Powell, Robert W. Colman. 
DuPont Pharmaceuticals, Wilmington, DE; Sol Sherry Thrombosis Research 
Center, Temple University School of Medicine, Philadelphia, PA, USA 
Background: Recent studies from our laboratory have shown that cleaved 
high molecular weight kininogen (HKa) binds specifically, saturably and re- 
versibly in a zinc-dependent fashion to the human umbilical vein endothe- 
lial cell (HUVEC) urokinase receptor (uPAR). We therefore postulated that 
peptide sequences from HKa could complete and modulate endothelial cell- 
mediated angiogenesis processes by inhibiting the interaction of HKa with 
uPAR. 
Methods: The effects of HKa peptide sequences and monoclonal anti- 
bodies on endothelial functions (migration, proliferation, and tube formation) 
as well as angiogenesis efficacy using the chick chorioallantoic membrane 
(CAM) model were examined. 
Results: For migration studies, HUVEC migration toward vitronectin was 
measured using a modified Boyden chamber (96 well plate) fitted with a 
chemotaxis membrane and migrated cells were permeabilized, stained with 
Rhodamine and the fluorescence quantified. The recombinant polypeptide, 
HK domain 5 (Lys420Ser513), at a concentration of 270 nM, inhibited (85%) 
the migration of HUVEC to vitronectin. For proliferation studies, HUVEC 
cells were stimulated with basic fibroblast growth factor (FGF2) for 48 hours 
at 37°C and proliferation measured by the fluorescence enhancement of 
CytQUANT GR dye bound to nucleic acid of lysed cells. HK domain 5 in- 
hibited HUVEC proliferation (100%) at 270 nM. It also blocked new vessel 
formation (stimulated by FGF2) in the CAM model. Deletion mutagenesis 
indicated that the domain 5 peptide Lys420-Asp474 inhibited HUVEC prolif- 
eration 94% at 360 nM. Removal of amino acids Lys420-Asp464 completely 
abolished the inhibition of proliferation and angiogenesis. Additionally, mon- 
oclonal antibody CIlCI to domain 5 inhibited HUVEC proliferation (IC50 = 
50 nM) and angiogenesis in the CAM model induced by FGF2 by 71 * 8%. 
Conclusions: The results suggest that peptides from domain 5 of HK 
may be potent inhibitors of angiogenesis, which could have potential for 
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inhibiting solid tumor growth, metastasis and invasion, diabetic retinopathy, 
inflammatory disorders and the abnormal remodeling in atherosclerosis. 
I 1134 52 Homocysteine is Associated With Surrogate Markers of Endothelial Dysfunction 
Bernhard R. Winkelmann, Markus Nauck’, Gunnar Taubert, 
Christoph Dommke, Katja Pioch, Ralf Winkler, Tina Winterbauer, 
Rahime Gok, Winfried Mar-z’, Jochen Senges. Herzzentrum Ludwigshafen; 
’ lnstitut fiir Klinische Chemie, Uni-Klinikum Freiburg, Germany 
Background: Severe increases in plasma homocysteine (HCY) are associ- 
ated with advanced atherosclerotic disease in patients. The pathophysiologic 
role of minor increases is less clear. 
Methods: We investigated 981 patients scheduled for coronary angiog 
raphy stratified by fasting homocysteine. Cell adhesion molecules and in- 
flammatory cytokines as surrogate markers of endothelial function were 
measured in parallel to the assessment of homocysteine status (including 6 
vitamines and folic acid). Fasting blood was obtained on ice in the morning 
and immediatedly centrifuged. 
Results: A stepwise positive association of HCY with age and creatinine, 
and a negative correlation with vitamins B6, B12 and folic acid was seen (all 
p < 0.0001). 
Homocysteine <9 9-<12 12-<15 >15 p-V.&e 
level (~mol/L) n=197 n=307 n=219 n=258 Wilcoxon 
VCAM-1 (mg/L) 716&256 779&248 824i234 9OOzk2284 0.0001 
ICAM- (mg/L) 239*70 254i79 253rt 84 2711125 0.001 
E-selectin (mg/L) 36i15 37121 37*118 37124 0.9 
L-selectin (mg/L) 689i156 696+ 160 6725156 683il63 0.2 
TNF oi @g/L) 8.5 * 4.9 8.8 i 4.2 9.9 + 9.2 10.5i 6.2 0.0001 
slL 2 R (U/mL 3875136 441 i407 465zk273 533i.266 0.0001 
*TNF and slL2R only measured in 180/297/204/244samples 
No difference between HCY groups was seen for P-selectin and ferritin. 
Conclusions: A linear positive increase in adhesion molecules VCAMI 
and ICAM-1, and cytokines TNF 01 and soluble IL 2 receptor occurs in 
the presence of hyperhomocysteinemia, indicating an ongoing inflammatory 
endothelial process. 
ELI 1134 53 Transforming Growth Factor Beta 1 (TGF-bl) 
Induces a Growth Factor Cascade That Results in 
Extracellular-Regulated Kinase (ERK) and p38 
Mitogen-Activated Protein Kinase Activation in 
Endothelial Cells 
Graziano Seghezzi, Giuseppe Pintucci, Jaime Yun, Bryan M. Steinberg, 
Brett Ferdinand, Eugene A. Grossi, F. Gregory Baumann, Stephen 
B. Colvin, Aubrey C. Galloway, Paolo Mignatti. New York University Medical 
School, New York, NL: USA 
Background: The role of TGF-bl is controversial. In vivo TGF-bl stimu- 
lates angiogenesis, but in vitro TGF-bl inhibits endothelial cell proliferation, 
The effect of TGF-bl on endothelial cell expression of fibroblast growth fac- 
tor-2 (FGFQ) and vascular endothelial growth factor (VEGF) as well as on 
the intracellular signaling pathways activated by these growth factors was 
studied. 
Methods and Results: Recombinant human TGF-bl (10 rig/ml or 10 
pgiml) increased VEGF mRNA levels 5-fold and VEGF,as protein over 3-fold 
in cultured endothelial cells. Neutralizing FGF-2 antibody blocked this effect. 
Recombinant human TGF-bl also induced activation of ERK-1 and -2 and 
~38 with two peaks of activation after 1 h and 8 h of incubation. No activation of 
cJun-N-terminal Kinase (JNK) kinase was detected. Both peaks of ERK and 
p38 activation were abolished by neutralizing FGF-2 antibody. Conversely, 
neutralizing VEGF antibody only inhibited ERK and p38 activation seen at 8 
h but not the 1 h activation peak. 
Conclusion: TGF-bl induces endothelial cell expression of FGF-2 that 
in turn stimulates VEGF expression through an autocrine mechanism. This 
growth factor cascade result in an early (1 h) FGF-2-dependent ERK and 
p38 activation and in a late (8 h) VEGF-dependent ERK and p38 activation. 
Thus, TGF-bl contributes directly to angiogenesis by inducing endothelial 
cell expression of FGF-2 and VEGF and by modulating the signaling pathway 
elicited by these two potent angiogenic growth factors. 
L-3 i i 34 54 Recombinant Adenoviral Vectors do not Increase Thrombosis and Neointima Formation at Sites of 
Arterial Injury. Importance of 
Hypercholesterolemia 
Zhi-Qiang Chen, Harnath S. Shelat, Janice McNatt, James T. Willerson, 
Pierre Zoldhelyi. Texas Heart Institute and Dept. of Medicine, Univ. of 
Texas-Houston Medical School, Houston, Texas, USA 
Adenoviral vectors are effective gene transfer vehicles. To study if adenoviral 
vectors per se promote thrombosis and neointima formation at sites of severe 
vascular injury, we performed carotid balloon injury (2.5 mm balloon, 5 infla- 
tions, 8 atm) in New-Zealand White rabbits (NZWs) fed a normal (N = 8) or 
cholesterol (C)-rich chow (N = 10, followed by a 30-min local exposure of the 
injured site to adenovirus containing no foreign gene (Ad) or viral suspension 
buffer alone. The injured arteries were evaluated 28 days after surgery by 
quantitative histomorphometry. 
Results: 
Groups Plasma C§ Treatment Thrombus lntimal Area 
1. NZW” 
2.NZW# 
3.NZW# 
(wW 
<lOO 
1149z!zl6 
1018f205 
pfu/mL 
Ad, 1 x lOi 
Buffer only 
Ad, 1 x 1O’O 
(“4 (mm”) 
018 (0) 0.25 zk 0.1 
2/10 (20) 0.73 + 0.67 
3/11 (27) 0.57& 0.211 
SPlasma cholesterol (C) on day of surgery: *Normal Chow; ‘1% C diet; gp < 0.001 
compared to Group 1. 
These findings stress the importance of hypercholesterolemia in throm- 
bogenesis and neointima formation at sites of severe balloon injury, whether 
exposed or not to high-titer Ad. In contrast to observations in uninjured or 
minimally injured vessels, Ad per se does not appear to promote thrombosis 
or neointima formation at severely injured vascular sites. 
1 1134-55 1 Feasibility and Safety of a Novel Intravascular 
Brachytherapy Device 
Jay P. Ciezki, Samir R. Kapadia, Khaled Ziada, Fernando Cura, Urs 
0. Hafeli, E. Murat Tuzcu, Patrick Whitlow. The Cleveland Clinic 
Foundation, C/eve/and, Ohio, USA 
Background: Intravascular brachytherapy is gaining currency as a prophy- 
lactic therapy for restenosis. Analyses from the initial clinical trials demon- 
strate that success of brachytherapy is dependent on achieving adequate 
radiation dose to the entire vessel wall. This prevents late thrombotic occlu- 
sion and an “edge effect”. 
Methods: We used a novel catheter, with integrated IVUS, that modified 
a typical concentric radiation dose profile (A) to an eccentric profile (B) by 
partially shielding radiation on the wall closest to the source. This helped to 
increase the dose to the far vessel wall. In the porcine model of restenosis, 
this catheter was used to prescribe 30 Gy to the adventitia after balloon 
injury, Animals were sacrificed at 4 days (acute group, n = 6) and 6 months 
(long-term group, n = 16). 
Results: In the acute group, there was no evidence of vessel wall necrosis 
or other atypical damage on histological examination or angiography. The 
long-term group showed no evidence of late thrombotic events or “edge 
effect” on angiogram. 
Conclusion: This new device appears safe on pre-clinical testing and 
improves effectiveness of brachytherapy by allowing adequate dosing to 
the entire vessel wall. Accordingly, this device can prove to be useful in 
minimizing thrombotic events and “edge effect” after brachytherapy. 
1134-56 Association of a Genetic Polymorphism in the 
Interleukin-1 Gene Cluster of Chromosome 2 
(2ql3) With Coronary Artery Disease on 
Angiography 
Peter B. Berger, Martha Nunn, Katherine Stephenson, Julian Sorrell, 
Franc0 Di Giovine, Gordon W. Duff. Mayo Clinic, Rochester, MN; 
lnterleukin Genetics, Inc., San Antonio, TX, USA; The University of 
Sheffield, UK 
Background: An inflammatory component in coronary disease (CAD) has 
been established. However, the strength of the association between cy- 
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tokines of the interleukin-1 (IL-l) family (which play a pivotal role in the 
inflammatory process) with CAD after accounting for traditional and emerg- 
ing risk factors is unclear. 
Methods & Results: Genotyping of the IL-1 B (-511) gene was performed 
in 504 consecutive patients (pts) undergoing clinically-indicated angiography 
for chest pain, valve disease, abnormal noninvasive tests, etc. using a PCR- 
based method with Taq polymerase. Pts with diabetes, ~50 pack years 
of smoking, prior PTCA or CABG, and those refusing to provide informed 
consent were excluded. Significant disease (>50% diameter stenosis) was 
present in 271 pts (54%). Standard risk factors (age, fibrinogen, APO-B, 
APO-AI, Lp(a), total cholesterol, LDL, 8 HDL) were significantly associated 
with CAD in the study population, but the IL-I B (-511) polymorphism was not. 
However, since different risk factors were associated with CAD in younger 
and older patients, we analyzed subjects 560 years of age (104 cases and 
135 controls) separately. In a multiple logistic regression analysis, the IL-1 B 
(-511) allele 2 was significantly associated with disease (OR = 3.88; 95% Cl 
= 1.27-I 1.80; p = 0.0171) in these pts. 
Conclusions: These data indicate that the IL-1 B (-511) polymorphism 
of the IL-1 cluster is significantly associated with CAD, supporting a role of 
genetic regulation of inflammation in the development of CAD. 
l-L--l 1134 57 Growth Hormone Administration Enhances Regional Coronary Blood Flow in Aged Rats 
Amir S. Khan, Colieen D. Lynch, David C. Sane, Eiisabeth A. Tallant, 
William E. Sonntaq. Department of fbysio/o.qy and Pharmacology, Wake 
Forest University .&boo/ of Medicine, ~Winsfc%a/em, North Ca;b/ina, USA 
Background: Blood flow decreases in many tissues with age including the 
brain, heart, skin, and skeletal muscle, concomitant with a rarefaction of 
blood vessels. The heart is particularly at risk for ischemic damage. Studies 
in rodents and humans have demonstrated an age-related decline in the pulse 
amplitude release of growth hormone (GH), and recent studies in rodents 
have shown that GH administration improves myocardial contractility and 
energy metabolism. However, the effects of GH on regional blood flow in the 
aged rat heart have not been investigated. 
Methods: We examined coronary blood flow using “C-iodoantipyrine in 
three groups of Brown Norway x Fischer 344 rats administered either bovine 
GH (400 ugikglday) or saline by subcutaneous injection twice daily for 30 
days. The three groups of rats were: young saline (YSAL, 6 months, n = 13) 
old saline (OSAL, 30 months, n = 9) and old GH (OGH, 30 months, n = 7). 
Results: Heart weights corrected for body weight were not significantly 
different between the groups. Regional coronary blood flow (ml/g-min) de- 
creased between YSAL and OSAL groups (p < 0.05), and administration 
of GH resulted in a significant increase in blood flow in OGH animals as 
compared to OSAL (p < 0.05) in all analyzed areas: Apex (YSAL 4.86 5 
0.32; OSAL 3.64 + 0.34; OGH 5.18 f 0.44), Right ventricle (YSAL 4.62 * 
0.49; OSAL 2.73 i 0.32; OGH 4.44 f 0.37), Middle (YSAL 5.07 f 0.39; 
OSAL 3.59 f 0.46; OGH 5.55 + 0.51) Base (YSAL 5.25 i 0.36; OSAL 3.62 
i 0.44; OGH 6.03 i 0.32), Papillary Muscle (YSAL 4.62 i 0.50; OSAL 2.54 
f 0.44; OGH 4.96 f 0.58). 
Conclusions: Our studies confirm that aged rats have reduced myocar- 
dial blood flow. Furthermore, we demonstrate that GH replacement increases 
coronary blood flow and may be able to reduce the risk of ischemia in aged 
hearts. Studies are underway to determine if the increase in blood flow as- 
sociated with GH administration is due to angiogenesis and/or a modulation 
of coronary vascular tone. 
1134-58 Chemokine Expression Profile of Human 
Monocvtes After Stimulation with LPS: New 
Insighiby Gene-Arrays 
Eva E. Katzer’ , 0. Renner, Ivo R. Buschmann, Matthias Heil”, 
Eiisabetii Deindl’, Imo E. Hofers, W. Klein’, Matthias Clauss3, 
Wolfgang Schape?. Max P/an& Institute; “Exp. Cardiology; 3Mo/ecu/ar Cell 
Bioiogl: Bad Nauheim, Germany: ‘Universify of Graz, Dept. for Cardiology 
Graz, Ausfria 
Background: The invasion of monocytes into proliferating collateral arteries 
is a key-event during early arteriogenesis. Once matured to macrophages 
these cells secrete a variety of growth factors. To elucidate this complex 
biological cascade Human cDNA-Arrays were used to analyze the chemokine 
expression-pattern of monocytes after treatment with LPS. 
Methods: Monocytes were isolated from b&y-coats by density-gradi- 
ent centrifugation. Cells were further isolated by elutriation. The final cell- 
supension contained >90% of monocytes. Monocyte-stimulation was done 
for 6 and 12 h with LPS (100 rig/ml). Total-RNA was isolated, revels tran- 
scribed and radio-labelled. The probes were hybridized to CytokinelReceptor 
cDNA-Arrays. Signal evaluation was done by phosphorimaging. Verification 
was done via RT-PCR and Northern-Blot-Analysis. To our knowledge this 
is the first monocyte gene-expression study analyzrng the simultaneous 
chemokine expression-pattern of 266 genes at the m-RNA level after LPS 
stimulation. 
Results: MCP-I, Macrophage lnflammatoy Protein-l alpha (MIP-la) and 
beta (MIP-Ifi) are significantly upregulated as compared to control while the 
housekeeping genes show an unchanged control LPS stim. pattern (left row 
of cDNAs). Other chemokines like lnterleukin 8 and TNF-o/ are upregulated 
in the same time window. 
control LPS stim. 
Conclusion: The host response to Gram-negative LPS is characterized 
by an influx of inflammatory cells into host tissues, which is mediated, in 
part, by localized production of chemokines. The upregulation of MCP-1 in 
combination with lnterleukin 8 may contribute to firm adhesion of monocytes 
to vascular endothelium under flow conditions. 
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I 1135 9 Aortic Distensibility Predicts Exercise Arm/Leg Gradients and Hypertension in Repaired 
Coarctation of the Aorta 
Curt J. Daniels, Kelley Clem, Tonia Caserta, Douglas Knight, Hugh D. Allen. 
The Ohio State University and Children’s Hospital, Columbus, Ohio. USA 
Background: Long-term data in patients (pts) with repaired coarctation of 
the aorta (rCOA) demonstrate premature cardiovascular events and early 
mortality despite good operative results. Potential risk factors may include 
arm-leg BP gradients (arm/leg ASP) and hypertension with exercise. Aortic 
distensibility (Di), as a potential intrinsic property of the aorta, may remain 
abnormal despite adequate repair of the coarctation. Therefore, we investi- 
gated the role of aortic Di in the development of exercise arm/leg ABP and 
hypertension in rCOA. 
Methods: Pts with rCOA and a good operative result-arm/leg ABP x 20 
mm Hg and normotensive at rest-underwent baseline simultaneous arm/leg 
ABP, echocardiography of the ascending (AAo) and descending (DAo) aorta 
for Di and Doppler gradient across the rCOA (Doppler AP). Pts performed 
a bicycle exercise protocol. Post exercise, measurements were repeated. 
Pts were compared to a control population by unpaired t-test. Correlation 
analysis and stepwise regression compared data. 
Results: Twenty pts (mean age 23.7 f 5.2 years) and IO controls (mean 
age 24.2 f 7.8) participated. No difference existed in resting arm BP between 
groups. Pts vs controls had a higher baseline arm/leg ABP (8.8 f 10.3 vs 
-6.1 + 6.7 mm Hg and Doppler aP (14.4 * 4.6 vs 5.3 ?I 3.2 mm Hg). AAo 
Di was significantly lower (non-compliant) in pts vs controls (2.3 & 1 .O vs 5.2 
i 1.7 cm2 x dynes-’ x 10-a). There was no difference in DAo Di. Exercise 
capacity was similar. Mean peak exercise systolic BP was greater in pts vs 
controls (217 f 38 vs 158 f 28 mmHg. Post exercise, pts vs controls had 
a higher arm/leg ABP (62.2 f 29.5 vs -5.4 ZIZ 15.9 mm Hg) and Doppler 
AP (44.6 f 19.9 vs 11.6 * 2.6 mm Hg). Decreased AAo Di correlated and 
predicted arm/leg ABP, Doppler +P and BP response to exercise. All p 
values were < 0.001. 
Conclusion: With exercise, pts with rCOA develop significant arm/leg 
gradients and hypertension that correlates with decreased AAo distensibility. 
Abnormal aortic distensibility may represent an intrinsic rather than acquired 
defect of the AAo and therefore remain abnormal despite adequate repair. 
These findings should lead to further testing in pts with rCOA and treatment 
modalities directed toward prevention of long-term cardiovascular events and 
early mortality. 
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tIIl 1135 10 Fetal Origins of Reduced Arterial Distensibility in I i 135 12 Distensibility of the Medium-Sized Muscular the Donor Twin in Twin-Twin Transfusion Arteries in Polyarteritis Nodosa 
Syndrome 
Yiu-fai Cheung, Andrew N. Redington, Helena M. Gardiner, Myles 
J.O. Taylor, Nicholas M. Fisk. Royal Brompton and Harefield NHS TrosS 
Queen Charlotte’s and Chelsea Hospital, London, UK 
Yiu-fai Cheung, Paul A. Brogan, Mike J. Dillon, Andrew N. Redington. Great 
Ormond Street Hospital for Children NHS Trust and Institute of Child Health, 
London, UK 
Background: Abnormal volume load and increased placental resistance 
constitute a hostile intrauterine environment for the developing vascular sys- 
tem of both the donor and recipient twins in twin-twin transfusion syndrome 
(TTTS). To determine whether adaptive mechanisms in-utero result in per- 
manent alteration of the vascular mechanical properties, we assessed the 
distensibility, by measuring pulse wave velocity (PWV cxl/Jdistensibility), of 
the conduit arteries in twins with and without TTTS postnatally. 
Background: Polyarteritis nodosa (PAN) is a necrotizing vasculitis of the 
medium-sized and small muscular arteries. To determine whether the in- 
flammatory and subsequent reparative processes may alter the arterial me- 
chanical properties, we assessed the arterial distensibility, using pulse wave 
velocity (PWVctllJdistensibility), of the brachio-radial arterial segment in 
children with PAN and compared with that in healthy children. 
Methods: Eighteen sets of surviving twins were studied, including 6 pairs 
of monochorionic (MC) twins with TTTS, 7 pairs of MC twins without TTTS 
and 5 pairs of dichorionic twins. Fetal data were collected prospectively. 
Brachio-radial arterial PWV was measured at a median corrected postnatal 
age of 9 (range 0.25 to 14) months using a photoplethysmographic tech- 
nique, while the blood pressure in the right upper arm was measured by an 
automated device (Dinamap). 
Methods: Eight children with PAN (as defined by American College of 
Rheumatology classification criteria) were studied at a median age of 8.1 
(range 4.9 to 15.5) years, while 155 healthy children aged 5 to 18 years were 
studied as a control group. Clinical and laboratory data on the activity of PAN 
were assessed. PWV in the brachio-radial arterial segment was assessed 
using a photoplethysmographic technique, while the blood pressure was 
measured by an automated device (Dinamap). Data from the two groups were 
expressed as z scores (mean i 95%CI), adjusted for age, and compared by 
unpaired Student’s f test. 
Results: MC twins with TTTS were born more prematurely (p < 0.01) and 
had the greatest birth weight difference. The mean PWV in the donor twins 
was 98% higher than that of their recipient co-twins (6.25 i 2.67 vs 3.15 & 
1.22 m/s, p = 0.03). No such difference was found between twins I and II 
in the other two groups, nor was any blood pressure difference identified in 
all three groups. Multiple regression analysis identified the donor status (B = 
2.50, p < 0.01) and corrected postnatal age (B = 0.32, p < 0.01) as significant 
determinants of PWV. The donor status accounted for 47% of the variance 
of PWV, while the recipient status had no influence on the age-dependent 
PWV. Discordance in the PWV between the donor and recipient twins was 
significantly related to the duration of TTTS (r = 0.94, p = 0.005). 
Results: Five of the children with PAN were in clinical remission, while 
three had active disease at the time of assessment. Their medications in- 
cluded steroid (n = 8), cyclosporin A (n = 2), cytotoxics (n = 4), anti-platelet (n 
= 6) and antihypertensive drugs (n = 2). The z score of PWV in children with 
PAN was significantly greater than that in healthy children (1.73 & 0.80 vs 
0.0 * 0.15, p < O.OOi), while the z-scores of the systolic and diastolic blood 
pressure were similar (p = 0.92 and 0.31, respectively). Raised C-reactive 
protein level (>2 mg/dl) in the three patients with active disease was asso- 
ciated with a higher z-score of PWV (2.78 t 1.84), compared with those in 
remission (1.30 f 0.69, p < 0.01). 
Conclusion: Arterial distensibility in the brachio-radial artery was de- 
creased in the donor twin in TTTS during infancy. These data suggest that 
vascular remodeling in-utero, intended to be adaptive, results in persistent 
functional vascular abnormalities that increase cardiac afterload and may 
prejudice later cardiovascular health. 
Conclusion: Increased PWV, and hence decreased distensibility, of the 
medium-sized muscular arteries occurs in polyarteritis nodosa and is ampli- 
fied during acute inflammatory exacerbation. This abnormal arterial mechan- 
ical property, presumably resulting from persistent structural abnormality, 
increases cardiac afterload that may prejudice later cardiovascular health. 
LI.-J 1135 11 Aortic Infarction and Deteriorated Elastic 
Properties due to Impaired Blood Supply to the 
Aortic Wall 
Charalambos Vlachopoulos, Christodoulos Stefanadis, Eleftherios Tsiamis, 
Costas Stratos, Dorothea Tsekoura, Pavlos Toutouzas. Hippokration 
Hospital, Athens Medical School, Athens, Greece 
Background: Vasa vasorum flow contributes substantially to the nutrition of 
the aortic wall. In this study we investigated the long-term effect of interruption 
of vasa vasorum supply on the function and structure of the aorta. 
Methods: In 6 mongrel dogs the periaortic fat of the ascending aorta 
which contains the nutritional vasa vasorum network was removed with a 
fine surgical technique. After the operation, the animals recovered and were 
sacrificed 6 weeks later. Hemodynamic measurements were obtained at 
baseline, and 60 minutes and 6 weeks after the removal of vasa vasorum. 
Aortic diameters were measured with a special gauge consisting of an elastic, 
air-filled ting connected to a transducer. Aortic pressures were measured with 
a fluid-filled catheter, 
Results: Aortic elastic properties (distensibility = 2 x pulsatile change 
in diameter/[pulse pressure x diastolic aortic diameter]) deteriorated pro- 
gressively during the experiment (left figure). Moreover, in the outer half of 
the aortic media which is nourished by the vasa vasoram, infarction was 
observed consisting of necrosis of the smooth muscle cells, uncoiling and 
fragmentation of the elastin fibers and increased collagen-to-elastin ratio 
(right figure). 
Viable zone 1 
Conclusions: Blood supply to the aortic wall is a significant determi: 
nant of aortic function and structure. This finding has important implications 
in conditions where flow through the vasa vaserum may be altered (e.g. 
hypertension, CAD, shock, administration of vasoactive agents). 
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1136-l 7 Procoagulant Risk Factors for Atherosclerosis: 
The Coronary Artery Bypass Risk Assessment 
(CARA) Study 
Hisham Dokainish, Fraser Rubens, Heather Doelle, Ruth McPherson. 
University of Ottawa Heart Institute, Ottawa, Canada 
Background: We examined homocyst(e)ine (Hey), Lp(a), PAI-I antigen (a), 
TPAa and Factor VII coagulant activity (FVllc) as risk factors for CHD in 
patients requiring CABG as compared to age-matched controls. We also 
determined the prognostic value of these variables in patients post CABG. 
Methods: Cases consisted of patients (20 to 75 y) scheduled for elective 
CABG. Age-matched healthy controls were recruited from the community. 
In controls and in clinically stable patients prior to CABG, baseline lipid and 
procoagulant variables were measured and clinical data recorded. Clinical 
events (hospitalization for UA, AMI or cardiac death) were recorded in pa- 
tients post CABG treated to an LDL-C < 100 mg/dl. 
Results: Baseline data were obtained from 376 CABG patients and 187 
controls 62 f 9.3 vs 64 f 11.4 yrs). 
Variable 
Hcv h~mol/L) 
I ,  
Lp(a) (nmol/L) 
PAI- (ng/mL) 
TPAa (ng/mL) 
FVllc (%) 
CABG M 
N=316 
12.6 
zk6.3* 
67.4 
Lk80.0 
29.0 
zkl4.7” 
9.5 
*5.2* 
109.7 
Control M 
N=79 
9.6 
CABG F 
N=60 
12.0 
Control F 
N=lOB 
10.2 
h2.3 *4.1* i2.9 
53.2 94.4 38.3 
f73.4 *94.4* 153.7 
21.8 28.1 27.8 
zk16.7 114.6 k-28.1 
7.2 9.6 7.6 
13.2 h11.3 13.4 
98.2 109.6 98.8 
*25.5* -1-19.7 zk25.7* 120.3 
* p < 0.05 for eases vs controls [by sex) 
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In 336 patients followed for I year post CABG, those who experienced 
major coronary events had higher baseline Hey levels (13.9 vs 12.1 umol/L, 
p < 0.05). Other hemostatic variables ware not of prognostic significance 
post CABG. 
Conclusions: Baseline plasma Hey was significantly higher in CABG 
patients vs controls. In male patients, PAI-la, TPAa and FVllc ware also 
higher compared to controls. In female patients, Lp(a) and FVllc ware also 
higher compared to controls. Plasma Hey is a risk factor for cardiac events 
post CABG. 
I 1136 18 Cardiovascular Risk Profile in the HIV/HAART 
Lipodystrophy (HAL) Syndrome 
Julian Falutz, Diane Turcot. lMontrea/ General Hospital, Montreal, Quebec, 
Canada 
Background: New combinations of anti-HIV drugs (highly active antiretro- 
viral therapy-HAART), are associated with markedly improved clinical out- 
comes as well as significant side effects. These include a new syndrome 
(HIV/HAART associated lipodystrophy-HAL) of dyslipidemia, insulin resis- 
tance, and changes in body fat distribution, which may pose an increased 
risk of atherosclerotic complications. 
Methods: We describe cardiac risk factors and fasting lipid profiles in 
140 HIV+ men, with or without HAL, which was diagnosed clinically. Patients 
were on various stable HAART regimens. 
Results: Patients without (n = 63) or with (n = 77) HAL, respectively, had 
similar mean ages (43 vs 45) duration of HAART (21 m. vs 25 m.), and CD4 
T cell counts (360/mm3 vs 310/mm3). In men without HAL vs those with HAL, 
there was no difference between those who smoked cigarettes (54% vs 44%), 
had hypertension (5.7% vs 6&i%), diabetes (6% vs 3%), or a family history 
of premature CAD (30% vs 33%). No patients in either group were obese. In 
patients without HAL, l/l 3 (8%) had an elevated APO-B level vs 7123 (30%) 
in those with HAL [p = 0.21]. On the basis of CVS risk factors and levels of 
LDL, Chol/HDL, and Trig’s (~5.0 mmol/L), 9163 (14%) in those without HALvs 
23/77 (30%) in those with HAL [p = 0.041 met guideline criteria for lipid lowering 
treatment, although only a minority of patients were actually on therapy. 
Conclusion: In patients on effective long-term HAART, those with HAL 
may have an increased cardiac risk because of a more atherogenic lipid 
profile. Few patients actually received appropriate lipid-lowering therapy. 
Evaluation of modifiable cardiac risk factors in patients on HAART, and espe- 
cially in those with HAL-associated dyslipidemia, requires greater recognition 
and investigation for possible long-term sequelae, including accelerated ath- 
erosclerosis 
L-l 1136 19 A High School Students Vascular Wall is Associated With Heart Disease Risk Factors for 
Adults 
Jacques D. Barth, Albert Sanchez, Ling Zhang, Maud M. Zonjee. PC/ 
Research lnsfitute and the Pacific Health Education Center, Los Angeles 
and Bakersfield Caiifomia, USA 
Introduction: If in High School students cardiovascular risk factors are 
present, a correlation with clinical endpoints seems clear. Surrogate vascular 
endpoints have not yet been tested in this population with different food 
intake patterns. 
Hypothesis: The Quantitative carotid intima media thickness (QIMT), a 
surrogate endpoint, is correlated with diet related cardiovascular risk factors. 
Methods: In adults, risk factors for cardiovascular disease (CVD) are as- 
sociated with morbidity and mortality from atherosclerosis. While atheroscle- 
rosis has been found in teenagers, there is a need to study the relationship 
between diet. CVD risk factors and the early stages of atherosclerosis in 
teenagers. A Latin0 high school, an Adventist Academy and a Caucasian 
high school were tested in Kern County, California. In addition to a blood 
pressure measurement, age, weight, gender, blood lipid profile and dietary 
food intake were acquired. These findings were correlated with QIMT of the 
far wall of the common carotid artery in 249 students. 
RSSUk 
Age (years) 
Weight (kg) 
LDL-cholesterol (mmol/l) 
HDL-cholesterol (mmol/l) 
BP systole/diastole (mmHG) 
QIMT k-4 
XfSD 
15.8f 1.07 
65.0 f 16.2 
2.42 f 0.67 
1.33 5 0.32 
116/71 + 1419 
522+132 
Conclusion: The data show that CVD factors of adults are significantly 
associated with QIMT in teenagers. QIMT may be a reliable, noninva- 
sive, portable screening tool to study the early phases of atherosclerosis 
in teenagers. 
1136-20 Prediction of Postprandial Triglyceride-Rich 
Lipoprotein Response from Fasting Triglyceride 
Levels 
Herbert J. Marx, Paul L. Jenkins, Tara A. Erb, Debra Wolff, Leslie 
K. Davidson, Roberta G. Reed. Marylmogene Bassett Hospital, 
Coopersfown, N’r: USA 
Background: Increasing evidence suggests that postprandial (PC) triglyc- 
eride-rich lipoproteins (TRL) are atherogenic and may be an independent 
predictor of atherosclerotic cardiovascular disease. However, accurate mea- 
surement of the pc lipid response requires multiple blood samples over about 
12 hours which is arduous and time consuming. 
Methods and Results: We examined the extent to which fasting lipid 
levels correlated with pc TRL following a standard oral fat load (50 gm/m’) 
containing retinyl palmitate (RP) in a two-phase study. Phase one involved 
55 adults with a wide range of fasting lipid levels. In univariate analyses, 
fasting triglyceride (TG) had the strongest correlation with the area under 
the pc curve (AUC) for total TG (r = 0.97). In stepwise regression analysis, 
fasting TG accounted for 94.6% of the variance in AUC. Other fasting lipids 
did not contribute significantly. For RP (a measure of intestinally-derived 
lipoproteins), there was no dominant variable. Results were strikingly similar 
with the SG < 1.006 fraction (a measure of chylomicrons) for both TG and RP. 
In phase twoof the project, 40 of these subjects were treated with gemfibrozil 
1200 mg in a slow release form each AM for 6 weeks followed by a repeat fat 
loading test. For those with elevated fasting TG and pc TRL before therapy, 
94% of the reduction in AUC for total TG following gemfibrozil was accounted 
for by their decrease in fasting TG level. The SG < 1.006 fraction showed 
the same pattern. In summary, for the overall group of 55, fasting TG was 
a strong predictor of pc TRL. In the subgroup with elevated fasting TG who 
were treated with gemfibrozil, the reduction in fasting TG accounted for the 
major portion of their decrease in pc TRL. 
Conclusion: This implies that for clinical assessment, fasting TG can 
serve as an useful indicator of a patients pc TRL. Also, if treated with 
gemfibrozil, the change in fasting TG will predict the degree of pc TRL 
response to therapy. 
L-4. 1136 21 Relations of Lipoprotein Subclass Levels and LDL Size to Reduction in Coronary Atherosclerosis in 
the PLAC-I Trial 
Robert S. Rosenson, lrina Shalaurova, James D. Otvos. 
Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL; North Carolina 
State University, Raleigh, NC, USA 
This study evaluated the influence of pravastatin therapy on coronary ath- 
erosclerosis in subjects who have predominantly large (pattern A, LDL size 
1 20.6 nm) or small LDL (pattern B, LDL size < 20.6 nm) at baseline. Frozen 
plasma samples were analyzed frorn a subset of participants in the PLAC-I 
trial at baseline and after 6 months treatment with pravastatin (n = 119) or 
placebo (n = 104). Lipids, lipoprotein subclasses, and LDL and HDL particle 
size were analyzed by NMR spectroscopy, The primary angiographic end- 
point was minimum lumen diameter (MLD). The total number of coronary 
segments was 825 and 1023 in placebo and pravastatin-treated subjects, 
respectively. In the placebo group, subjects classified as pattern B had MLD 
that decreased more than pattern A (0.08 vs 0.03 mm/y, p = 0.01). As 
compared to placebo, pravastatin limited atherosclerosis progression in the 
entire treatment group (0.01 vs 0.05 mm/y; p = O.OOOl), and this response 
was greater for pattern B (0.02 vs 0.08 mm/y; p = 0.002) as compared to 
pattern A subjects (0.01 vs 0.02 mm/y; p = 0.01). For the whole group, 
progression was correlated positively with on-trial levels of triglycerides (p 
= O.Oi), LDL cholesterol (p = 0.0003), LDL particles (p = O.OOOl), small 
LDL (p = 0.0001) and small HDL (p = 0.007). Negative associations were 
observed for LDL size (p = O.OOlB), HDL size (p = 0.0009) and large HDL 
(p = 0.01). These data indicate that (1) LDL pattern 6 subjects have more 
coronary atherosclerosis progression than pattern A subjects; (2) pravastatin 
reduces progression rates in both pattern A and B subjects; and (3) LDL and 
HDL particle size and subclass levels are important predictors of coronary 
atherosclerosis progression. 
Multiple Regression analysis showed the following significant correlations 
between QIMT and dietary cholesterol (p c 0.005), weight (p < 0.005), 
Systolic BP (P < 0.005), LDL-cholesterol (p < 0.05), Diastolic BP (p < 0.05). 
300A ABSTRACTS - Hypertension, Vascular Disease & Prevention JACC February 2000 
1 1136-22 1 Conventional Coronary Risk Factors are More 
Frequent in Coronary Artery Bypass Recipients 
With Premature Atherosclerosis 
Scott Kinlay, Brian Burgess, Robert Rizzo, Nancie Cordella, Vivian Cabral, 
Chris O’Donnell, Jorge Plutzky. Partners Premature Atherosclerosis Center 
Brigham and Women’s Hospital and Massachuseffs Genera/ Hospifal, 
Boston, Massachusetts, USA 
Background: Although premature atherosclerosis is often considered to be 
due to an underlying genetic abnormality or emerging risk factor, it may 
also stem from a greater prevalence of conventional coronary risk factors. 
The prevalence of conventional risk factors will influence the preventive 
management of these patients. 
Methods: We compared the prevalence of risk factors m men and women 
who had their first coronary artery bypass grafting (CABG) across increasing 
5year age groups from 45-80 years of age. The data were from a prospec- 
tive database of 7206 patients having their first CABG between 1990 and 
1999. Current smoking status, history of high cholesterol, hypertension, dia- 
betes, and family history of coronary artery disease (CAD) were obtained by 
self-report and interview from all patients. 
Results: Patients < 45 years had the highest prevalence high choles- 
terol (61%) and current smoking (32%) with a progressive decline in the 
prevalence of these risk factors with increasing age (p < 0.001). There was 
a similar gradient across age groups in the prevalence for family history of 
CAD (p < 0.001). In contrast, there was less hypertension in younger age 
groups and no significant gradient with diabetes. 
Conclusions: Patients with premature atherosclerosis who require CABG 
have higher rates of several modifiable risk factors than older patients. These 
results argue for the importance of programs that integrate modification of 
conventional risk factors (especially for smoking cessation and dyslipidemia) 
with studies regarding underlying genetic predisposition and emerging risk 
factors. 
f-r-J 1136 23 Threshold for Effect of Triglycerides and LDL-c on 
Lipoprotein(a) 
JoAnne Micale Foody, Gregory L. Pearce, Dennis L. Sprecher. The 
Cleveland Clinic Foundation, Cleveland, Ohio, USA 
Background: Lipoprotein(a) (Lp(a)), triglycerides (TG) and LDL-c have all 
beenlidentifikd as important independent predictors of atherosclerosis. While 
it is known that elevations of TG and LDL-c influence Lp(a) levels, it is 
unclear whether thresholds for these effects exist. We sought to determine 
the relationship of TG and Lp(a) in a high risk CAD population. 
Relationship BetweenTftglyceriderand Lp(a) 
I, -~ 
Methods and Results: We evaluated 895 patients (556 men, 339 men) 
not on lipid lowering drugs in whom an LDL, TG, HDL and Lp(a) were 
available. The mean age was 56 & 13. Adjusted Spearman’s correlation 
coefficient between Lp(a) and TG was -0.29 (p = 0.0001). When TG < 
150, there was no correlation (r < O.Ol), but when TG > 150, a significant 
correlation existed (r= 0.26, ptiO.0001). This continuous, inverse relationship 
remained consistent adjusting for age, sex, DM and LDL in via ANOVA using 
ranked data. A smilax relationship is seen between LDL and Lp(a) such that 
for LDL < 140 a significant correlation exists (r = 0.14, p = 0.004) whereas 
no such correlation is seen when LDL is 2140 (r = 0.06, p = 0.15). 
Conclusions: A relationship exists between Lp(a) and both TG and 
LDL-c. We describe a significant correlation between Lp(a) and TG above 
150 as well as a correlation between Lp(a) and LDL > 149 mg/dL. We 
hypothesize that a threshold effect may exist for Lp(a) production such that 
Lp(a) catabolism is mediated by ambient levels of both TG and LDL. These 
results provide further insights into determinants of abnormal Lp(a) and 
may suggest mechanisms by which Lp(a) may exert its effects in coronary 
atherosclerosis. 
I 1136 24 The Effectiveness of a Dietary Change Challenge 
With Plant Stanol Ester to Recruit Participants 
and Lower Serum Cholesterol 
Thomas E. Kottke, Tu T. Nguyen, Lowell C. Dale, Catherine L. Brandel, 
Stephen W. DeBoer, Karen A. Hurtis. Mayo C/inic, Rochester, Minnesota, 
USA 
Background: Lowering serum cholesterol on a population-wide basis has 
the potential to significantly reduce the burden of cardiovascular disease for 
both individuals and populations. The purpose of this study was two-fold: 
to determine the extent to which parents of elementary students would 
participate in a cholesterol lowering challenge featuring dietary saturated fat 
reduction and use of plant stanol ester (Benecol@); and to determine the 
extent to which the challenge would result in lower serum cholesterol levels 
for the participants. 
Methods: We attempted to recruit all parents of 5rh grade students in a 
small Minnesota school district to take part in a 5-week cholesterol lowering 
challenge. Initial participation was 48% of 157 parents, and 24 men and 42 
women completed all phases of the challenge including completing a dietary 
questionnaire before and after the challenge. Benecol@ was offered free of 
charge to the participants. 
Results: The self-reported changes in fat consumption are listed in the 
table. Most of the participants described their dietary changes as small or 
moderate. 
Men (n = 24) Women (n = 42) 
Initial Final Initial Final 
Total fat (%) 37.6 32.9 32.6 30.1 
Saturated fat (%) 13.9 12.0 12.0 10.7 
Chol (ma/dav) 369 324 250 226 
Initial average (SD) finger-stick cholesterol was 214.6 (38.1) mg/dl and 
average post-intervention cholesterol was 195.2 (38.3) mgfdl. The average 
decline in fingerstick cholesterol was 8.6% (11.7) (P < 0.0001). The 20 
parents who used ~2.5 servings of plant stanol ester per day reduced their 
cholesterol by an average of 31.7 mg/. The Spearman correlation between 
the decline in cholesterol and self-reported amount of plant stanol ester used 
was 0.33 (P = 0.008). On multivariate analysis, the only variable correlated 
significantly with reduction in total serum cholesterol was the amount of plant 
stanol ester used by the participant. 
Conclusion: A cholesterol-lowering challenge will stimulate a large pro- 
portion of a community to make clinically significant dietary-changes. If a 1% 
decline in cholesterol translates into a 2% decline in risk of heart disease, 
the average participants in this trial experienced a decline in risk >17%. 
I 1136 49 Niacin But Not Gemfibrozil Increases LP-AI, a 
Cardioprotective Subfraction of HDL, in Patients 
With Low HDL-Cholesterol 
Takaaki Sakai, Vaijinath S. Kamanna, Moti L. Kashyap. Cholesferol 
Research Center, Department of Veterans Affairs Healthcare System, Long 
Beach, CA, and the University of California, Irvine, CA, USA 
Background: High density lipoproteins (HDL) bear an inverse relationship to 
coronary heart disease (CHD). HDL particles exist as: LP-AI and LP-AI+AII 
(i.e., without and with apo-All, respectively). Current evidence indicates that 
LP-AI is more effective in reverse cholesterol transport and more anti-athero- 
genie than LP-AI+AII. Niacin and fibrates (e.g., gemfibrozil) increase HDL- 
Cholesterol concentration; however, their clinical effects and the mechanism 
of action on LP-AI levels are unknown. 
Study Design and Methods: A total of 139 patients were randomized 
equally to niacin or gemfibrozil in a multicenter, double-blind trial. The eligi- 
bility criteria for inclusion were: HDL-C < 40 mg/dl, triglycerides x 400 mgidl, 
and LDL-C < 160 mg/dl. Patients were dose escalated with an Extended- 
Release niacin formulation (Niaspan; to I-2g, once-a-night) or gemfibrozil 
(600mg, twice daily) for up to 19 weeks. Plasma LP-AI concentrations were 
measured by Hydragel LP-AI kit (Sebia, Inc.) according to the manufac- 
turer’s instructions. Additionally, the in-vitro effects of niacin and gemfibrozil 
on i*51-LP-AI and [3H]Cholesterol ester (CE)-labeled LP-AI uptake by human 
hepatoblastoma cells (Hep G2) were also investigated to understand the 
mechanisms of action of these drugs to modulate LP-AI uptake/removal by 
hepatocytes. 
Results: Niacin (29) and gemfibrozil raised HDL-C by 26% and 13% 
respectively. Niacin, at 1 and 2 g doses, significantly increased LP-AI levels 
by 8.7 +/- 3.9% (p=O.O33) and 24.0 +/- 4.43% (p<O.OOl) respectively. Gem- 
fibrozil had no consistent effect on LP-AI levels. The results of in-vitro uptake 
studies showed that niacin, but not gemfibrozil, significantly decreased the 
uptake of LP-AI by Hep G2 cells. Both niacin and gemfibrozil had no effect 
on the uptake of [3H]CE-labeled LP-AI by Hep G2 cells. 
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Conclusions: The data indicate that unlike gemfibrozil, niacin by selective 
inhibition of hepatic Lp-AI uptake/removal significantly elevates the HDL 
subfraction LP-AI concentration in patients with the isolated low HDL state. 
The lack of effect on hepatic cholesterol ester uptake suggests an important 
additional mechanism by which niacin promotes reverse cholesterol transport 
and explains its cardioprotective role in coronary disease. 
terolemia and smoking. LV dysfunction, incidence of multivessel disease, 
vessel site stented and number of stents per vessel or types of stent were 
similar. The long-term outcome is shown in the table. 
Conclusions: Estrogen replacement therapy in postmenopausal women 
reduces target lesion revascularization after intracoronaty stenting. Fur- 
ther substantiation by large randomized studies is needed to confirm this 
study. 
ORAL 
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El 807 2 Ramipril Prevents Cardiovascular Events in High 
Risk Diabetic Participants: Results of the HOPE 
Study 
Hertzel C. Gerstein, Johannes F.E. Mann, Bernard Zinman, Jackie Bosch, 
Janice Pogue, Salim Yusuf. On behalf of the HOPE Sfudy lnvestigafors; 
McMaster UniversiQ Hamilton, Ontario, Canada 
11:15 a.m. 
807-d Does Hypothalmic Hypoestrogenemia Explain CAD 
in Premenopausal Women?: The NHLBI-Sponsored 
WISE Study 
C. Noel Bairey Merz, B. Delia Johnson, Barry L. Sharaf, Vera Bittner, 
Sarah Berga, Glenn Braunstein, T. Keta Hodgson, Carl J. Pepine, Steven 
E. Reis, Nathaniel Reichek, William J. Rogers, Sheryl F. Kelsey, 
George Sopko. Cedars-Sinai Med Ctr, Los Angeles, CA, USA 
Background: Younger women with CAD have a less favorable prognosis 
compared to older women, although the pathophysiology of this is unknown. 
Animal data suggest that premenopausal CAD is strongly determined by 
estrogen status (hypothalamic hypoestrogenemia). 
Background: ACE inhibitors may prevent cardiovascular (CV) outcomes in 
high risk people, and diabetes is a strong risk factor for CV events. The 
cardioprotective effect of ramipril in diabetes was assessed in the HOPE 
(Heart Outcomes Prevention Evaluation) Study. 
Methods: We evaluated 128 premenopausal participants of the Women’s 
lschemia Syndrome Evaluation (WISE) study without a prior diagnosis of 
CAD who underwent coronary angiography for suspected ischemia. 
Methods: 3578 people (i.e. 38% of all HOPE study participants) aged 
55 or over with diabetes and either coronary disease, peripheral vascular 
disease, nondebilitating stroke, or one other cardiovascular risk factor (one 
or more of microalbuminuria, hypertension, high total cholesterol, low HDL 
cholesterol or current smoking) were randomize! to either ramipril IO mg/day 
(1808) or placebo (1770). The study was stopped by the independent moni- 
toring board after a mean of 4.5 years because of a clear benefit of ramipril. 
Results: When stratified by angiographic CAD (270% luminal stenosis 
z 1 epicardial coronary artery), there was no difference in age, cardiac risk 
factors, lipids and lipid lowering medication use, body mass index, history of 
polycystic ovary disease or irregular menstrual cycling, or comorbid illnesses 
between the 12 subjects with CA0 and the 116 with no CAD (all p = NS). 
Assessment of available blood hormone levels in a subset of 81 subjects 
demonstrated that women with CAD had lower mean levels of estradiol, 
bioavailable estradiol, and hypothalamic hormones compared to women with 
no CAD (Table). 
Results: 19.6% of placebo-treated participants had either a myocardial 
infarction or stroke, or died from cardiovascular causes during the study (i.e. 
developed the primary outcome). By intention-to-treat analysis, participants 
on ramipril experienced a 24% relative risk reduction (RRR) of the primary 
composite outcome (95% Cl il-35), a21% RRR (95%CI 4-35) in myocardial 
infarction, a 32% RRR in stroke (95%CI g-49), a 38% RRR in cardiovascular 
death (95%CI 21-51), and a 17% RRR (95%CI 2-30) in revascularization 
procedures. There was also a 25% RRR in total mortality (95%CI 10-38). 
Ramipril also decreased the risk of diabetic nephropathy by 25% (95%CI 
6-40) and new microalbuminuria by 10% (95%CI I-18). 
Conclusion: This study strongly supports the use of ACE inhibitors for 
cardioprotection in middle-aged patients with diabetes and one or more other 
cardiovascular risk factors. 
Hormone Levels 
Estradiol (pg/ml) 
Bio Estradiol (pg/ml) 
FSH (mlU/ml) 
LH (mlU/ml) 
No CAD (n = 72) 
90 * 75 
46 + 40 
11 i 16 
8110 
CAD (n = 9) P 
4oi2a 0.02 
21+17 0.04 
4i3 0.03 
2i2 0.09 
Of note, 6/9 (67%) of the subjects with CAD vs 17/72 (24%) with no CAD 
(p = 0.007) were categorized as having hypoestrogenemia on a hypothalamic 
basis (estradiol < 50 pg/ml, FSH < IO mlU/ml, LH < IO mlU/ml). 
Conclusion: Among premenopausal women undergoing coronary an- 
giography for suspected ischemia, hypothalamic hypoestrogenemia appears 
to play a role in angiographic CAD. 
11:30 a.m. 
11:00 a.m. 
807-S Estrogen Replacement Therapy Reduces Major 
Adverse Cardiac Events (MACE) in Post Menopausal 
Women After lntracoronary Stenting: A Long Term 
(>3 Years) Follow-Up 
807-5 Tamoxifen is Not Associated With Decreased 
Cardiac Event Rates in Women With or Without 
Preexisting Heart Disease 
Masroor A. Khan, Ming W. Liu, D. Singh, Ashish Pal, Francisco L. Chio, 
David Lawson, Larry S. Dean. University of Alabama at Birmingham, 
Birmingham, Alabama, USA 
Steven E. Reis, Joseph P. Costantino, D. Lawrence Wickerham, 
Maureen Kavanah. For the NSABP Breast Cancer Prevention Trial 
Investigators; University of Pittsburgh, Pittsburgh, PA, USA 
Background: Estrogen replacement therapy has been shown to reduce 
coronary morbidity and mortality in postmenopausal women. This study was 
performed to determine if estrogen therapy improves the long-term outcome 
after successful coronary stenting. 
Background: Tamoxifen is a mixed estrogen agonist and antagonist that has 
antiatherosclerotic properties and is also effective in breast cancer preven- 
tion. Because estrogen might provide primary but not secondary cardiopro- 
tection, we postulated that tamoxifen has cardioprotective effects in women 
without heat-t disease but not in those with a prior cardiac event. 
Methods: Ninety two postmenopausal patients who had a successful 
coronary stenting procedure between June 1993 and March 1996 were 
followed long term for major adverse cardiac events (target lesion revascu- 
larization, myocardial infarction and death). Half of the patient population had 
been on estrogen therapy before the procedure and continued to be on it 
throughout follow-up (FU). 
Methods: Women randomized to tamoxifen (20 mgid) or placebo in the 
NSABP Breast Cancer Prevention Trial (BCPT) were divided into groups of 
those with a prior history of myocardial infarction (Ml) or angina (N = 1,045) 
and those without a cardiac history (N = 12,130). Adjudicated cardiac events 
in the tamoxifen and placebo cohorts were compared within each group 
during a mean followup of 4 years. 
Results: Between the two groups, there was no significant difference in 
baseline demographics including age, hypertension, diabetes, hypercholes- 
No. of Patients 
F/U (Months) 
PTCA + CABG 
MI 
Death 
MACE 
Estrogen 
46 
48 * 9.7 
12 (26%) 
5 (11%) 
1 (2.2%) 
i a (39%) 
No Estrogen 
46 
46 zk 9.1 
23 (50%) 
6 (13%) 
1 (2.2%) 
30 (65%) 
p value 
0.38 
0.032 
n.s 
n.s 
0.022 
Results: Among the women without preexisting cardiac disease (mean 
age 53.6 years), tamoxifen was not associated with statistically significant 
reductions in risks for cardiovascular disease. When considering traditional 
cardiovascular endpoints, the relative riskcomparing the rate in the tamoxifen 
group to that in the placebo group was 1.05 with a 95% confidence interval 
(Cl) of 0.68 to 1.62. When considering only Ml, the relative risk was 1.32 (Cl 
= 0.70-2.53). Analysis of women with preexisting cardiac disease (mean age 
57.7 years) demonstrated similar lack of treatment effect. The relative risks 
for all cardiovascular events was 1.49 (Cl = 0.77-2.87) and for Ml was 0.70 
(Cl = 0.02-2.22). 
Conclusion: Tamoxifen is not associated with decreased short-term risks 
of cardiovascular events in women with or without preexisting cardiac dis- 
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ease. Therefore, tamoxifen use for breast cancer prevention might not be receptor blockers may be potent in inhibiting the accelerated progression of 
associated with a cardioprotective effect. vascular diseases such as atherosclerosis. 
II:45 a.m. 
El :. 807 6 lncrdence of Myocardial Infarction and Death in 53 
Clrmcal Trials of Viagra@ (Sildenafil Citrate) 
IO:45 a.m. 
877 2 El . . Evrdence of Arterial Wall Inflammation by MRI in 
Patrents With Preclinical or Established 
Murray A. Mittleman, Dale B. Glasser, John Orazem, Michael Collins. 
Harvard Medical School, Boston, MA; Pfizer Inc, New York, NL: USA; Pfizer 
Inc, Sandwich, UK 
Atherosclerosis 
Background: Due to recent advances in the treatment of erectile dysfunction 
(ED), there is great interest in the potential cardiac risks of resuming sexual 
intercourse among men treated for ED. 
Methods: We pooled the results of 53 studies (30 double-blind [DB], 
placebo-controlled; 23 open-label [OL] trials of sildenafil), in which treatment 
was taken for 6 weeks to 2 years. Exclusion criteria included: hypotension 
(blood pressure [BP] < 90/50 mm Hg), uncontrolled hypertension (BP > 
170/110 mm Hg), a recent (56 months) history of unstable cardiovascular 
disease, myocardial infarction (Ml), or stroke, and regular nitrate treatment. 
Results: As of March 31, 1999, total exposure in the 53 clinical trials was 
6884 patient-years for sildenafil (964 DB, 5920 OL) and 543 patient-years 
for placebo. There were 44 nonfatal and 11 fatal MIS among sildenafil users 
versus 5 nonfatal and 1 fatal MIS for the placebo group. There were 29 
deaths from any cause among those receiving sildenafil and 4 among those 
receiving placebo. The incidence rates of MI and death were comparable and 
not significantly different for patients receiving sildenafil and those receiving 
placebo (Table). Incidence rates for the combined endpoint of Ml or death 
also were not significantly different. 
Treatment group (patient-yr) 
Placebo (543) 
Sildenafil DB (964) 
Sildenafil OL (5920) 
Sildenafil total (6884) 
Incidence (95% Cl) per 100 patient-yr 
MI Death 
1.11 (0.41-2.40) 0.74 (0.20-I 29) 
1.45 (0.79-2.44) 0.83 (0.36-l .64) 
0.69 (0.50-0.94) 0.35 (0.22-0.54) 
0.80 (0.60-1.04) 0.42 (0.28-0.61) 
Conclusion: The rates of Ml and death among men with ED treated 
with sildenafil were low and similar to those observed in men randomized 
to placebo. These data are reassuring and suggest that treatment of ED 
and resumption of sexual activity are not associated with even a moderate 
increase in cardiac risk. 
ORAL 
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Atherosclerotic Events 
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lo:30 a.m. 
1 877-l 1 The Renin Angiotensin System Regulates the 
Mechanisms of Inflammation in Patients With 
Accelerated Atherosclerosis 
Bobby V. Khan, Sushant R. Navalkar, Sampath Parthasarathy, R. 
Wayne Alexander. Emory University School of Medicine, Atlanta, Georgia, 
USA 
The renin angiotensin system (RAS) is a powerful mediator in the patho- 
genesis of vascular diseases such as hypertension, congestive heart failure, 
and atherosclerosis. The pathogenesis of atherosclerosis is not clearly un- 
derstood, but recent findings suggest that inflammatory mechanisms are 
involved, notably in patients with early atherosclerosis. We tested the hy- 
pothesis that inhibition of the RAS may suppress the inflammatory mediators 
in atherogenesis. We treated 24 male and female non-diabetic, normoten- 
sive subjects with the angiotensin type I receptor blocker irbesattan (75 
mg/day, n = 13) or a placebo (n = 11) for a 12 week period. All had docu- 
mented coronary atherosclerosis and were below the age of 55. Using ELISA 
technique, treatment with irbesadan reduced the gene expression of serum 
soluble VCAM-I (pretreatment: placebo-544 + 70, irbesartan-550 i 52; 
posttreatment: placebo-532 i 65, irbesartan-300 i 66 ng/dl. p < 0.05). 
Treatment with irbesartan reduced the levels of serum soluble TNFol in early 
atherosclerosis patients (pretreatment: placebo-326 f 61, irbesartan-340 + 
59; posttreatment: placebo-320 f 69, irbesartan-172 5 45 ng/dl, p < 0.05). 
These results suggest that suppression of the RAS by angiotensin type I 
Clifford R. Weiss, Andrew E. Arai, Kwabena 0. Agyenan, Arnon Blum, 
Gyorgy Csako, Robert S. Balaban, Richard 0. Cannon Ill. NHLBI, National 
Institutes of Health, Bethesda, MD, USA 
Background: Inflammation contributes importantly to atherosclerosis, but 
detection in humans is limited to surrogate inflammatory markers in blood. 
We assessed whether 1.5 T cardiac MRI using a double inversion recovery 
fast spin echo sequence could detect vascular inflammation in vivo, by means 
of 3 potential imaging characteristics of vascular inflammation: 1) arterial 
wall contrast agent enhancement with gadolinium-DTPA (0.1 mmol/kg) as an 
indexof intramural vasovasorum dilation and increased capillary permeability, 
2) increased T2 values as an index of arterial wall edema, and 3) increased 
wail thickness as an index of arterial wall edema and infiltration. 
Methods: Twenty-seven subjects >40 years of age underwent carotid 
artery and infrarenal aorta MRI: IO had coronary artery disease (CAD), 6 
had LDL cholesterol ,160 mg/dL, and 11 had no conventional risk fac- 
tors for CAD (normals). The following surrogate inflammatory markers were 
measured in serum: vascular cell adhesion molecule (VCAM-I), intercellu- 
lar adhesion molecule (ICAM-I), E-selectin (E-S), interleukin-6 (IL-6), and 
C-reactive protein (CRP). 
Results: Fifteen subjects (including 7 CAD patients and 5 normals) had 
1 or more MRI indices of vascular inflammation (PI SD. above group 
mean values) in carotid and/or aortic walls: 8 had increased T2 values or 
contrast enhancement without increased wall thickness, 4 had increased wall 
thickness only, and 3 had combinations of indices. Compared with remaining 
subjects, the 15 subjects with MRI indices of inflammation had higher levels 
of VCAM-I (510 & 128 vs. 385 f 84 ng/mL, p < O.Ol), ICAM-I (246 f 80 
vs. 186 f 24 ng/mL, p < O.Ol), and IL-6 (3.1 f 2.0 vs. 1.5 i 0.6 pg/mL, 
p < 0.01); and had nonsignificant elevations in E-S (48 f 18 vs. 434 f 14 
ng/mL), and CRP (0.31 f 0.27 vs. 0.20 * 0.41 mg/dL). 
Conclusion: MRI characteristics of large arteries may permit in vivo 
noninvasive detection of vascular inflammation, even in apparently healthy 
middle-aged and older subjects without conventional risk factors for CAD. 
1l:OO a.m. 
I 877 3 Increase in Coronary Artery Matrix 
Metallo-Proteinases Induced bv lntranasal 
Chlamydia Pneumoniae Infection in a Mini-Pig 
Model 
Michael A. Lauer, Stephen D. Mawhorter, D. Geoffrey Vince, Mamdouh 
D. Al-Ahmadi, Deepak L. Bhatt, Gerri S. Hall, Kiyotaka Fukamachi, A. 
Michael Lincoff, Eric J. Topol, Stephen G. Ellis. C/eve/and Clinic Foundation, 
Cleveland, Ohio, USA 
Background: Chlamydia pneumoniae (CP) has been associated with in- 
creased serum cholesterol and coronary disease in humans, shown to ac- 
celerate aortic thickening in mice and rabbits, and increase matrix metal- 
loproteinases (MMPs) in cell culture. MMPs have been implicated in the 
progression of atherosclerotic plaques. An animal model of CP induced 
coronary disease has not been reported. 
Methods: Eight mini-pigs were fed a 2% cholesterol diet. Half were 
inoculated with CP. Copper (Cu) bands of 3 doses were placed on the 
RCA and LAD as a noninfectious inflammatory stimulus. One month after 
Cu banding, animals underwent angiography and were sacrificed. Samples 
from coronary, aorta, trachea, lung, liver and spleen were taken for culture 
and histologic studies. At Cu sites, percent stenosis was determined by cine- 
graphic calipers and medial area was determined by histologic morphometric 
analysis. At non-Cu sites, intracellular presence of MMP 1, 2, 3, and 9 was 
determined by immunohistochemistry. 
Results: 
Non-infected Chlamydia Inoculated 
Tracheal culture, number+ o/3 314 
Cholesterol, mgidl 91540 158 i 22X*” 
MMP 1 + + 
MMP 2 +++ 
MMP 3 + +++ 
MMP 9 - +l- 
Friability - +++ 
Angiographic stenosis, % 32zt 12 32&31 
Medial area, mm* 28zt19 43f 16* 
**p = 0.03, *p = 0.08 
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Conclusion: Mini-pigs were successfully infected with C. pneumoniae, 
producing increased serum cholesterol levels and coronary artery inflamma- 
tion with increased presence of MMP 2, 3, and 9. Compared to non-infected 
animals, infected animals showed an increase in copper induced medial 
area undetectable by angiography suggesting outward remodeling. These 
changes induced by C. pneumoniae may play a role in the progression of 
human atherosclerotic coronary artery disease. 
ii:15 a.m. 
877-4 Increased Serum Matrix Metalloproteinase-9 
Expression in Postmenopausal Women on Estrogen 
Therapy 
Richard 0. Cannon 111, Benjamin K. Yang, Jeanette Ardans, William 
H. Schenke, Diane Zanger, Arnon Blum, Gyorgy Csako, Larry M. Wahl. 
NHLBI, National Institutes of Health, Bethesda, MD, USA 
Background: Early increased risk of myocardial infarction was reported 
recently in women with coronary artery disease (CAD) who were random- 
ized to hormone therapy in a secondary prevention clinical trial. Increased 
matrix metailoproteinase (MMP) activity could promote coronary thrombo- 
sis by enzymatically digesting the fibrous caps of vulnerable atherosclerotic 
plaques. According, we determined whether estrogen administered to post- 
menopausal women affects MMP-9 (gelatinase B), which is expressed in 
human atherosclerotic plaques. 
Methods: Thirty-three postmenopausal woman - 10 with angiographi- 
tally defined CAD and 23 healthy subjects participated in randomized, dou- 
ble-blind, crossover trials with conjugated equine estrogens (CEE) 0.625 mg 
or placebo daily, each for one month MMP-9 levels in serum were measured 
by ELISA and by gelatin zymography. Plasminogen activator inhibitor type-l 
(PAI-1) was measured in plasma by ELISA. 
Results: On placebo treatment, serum levels of MMP-9 were higher in 
women with CAD than in healthy women (501 & 95 vs. 335 * 110 ng/mL, 
p = 0.018). Compared with placebo treatment, levels of MMP-9 were higher 
on CEE treatment both in woman with CAD (648 f 116 vs. 501 f 95 ng/mL, 
p = 0.02) and in healthy women (435 + 142 vs. 335 i 110 ng/mL, p = 
0.002). Gelatin zymography showed geater MMP-9 levels in serum from 
CEE treatment relative to placebo in 8 of 10 women with CAD and in 19 of 23 
healthy women. PAI-I was lowered by CEE in women with CAD (28.5 f 21 .O 
vs. 42.3 + 26.8 ng/mL, p = 0.03), a response previously shown to enhance 
the activity of plasmin, a principal activator of MMPs. 
Conclusion: Estrogen therapy increases serum MMP-9 in postmenopausal 
women, including those with CAD in whom basal levels are higher than those 
of healthy postmenopausal women. MMP-9 activation by plasmin in the ar- 
terial wall could digest fibrous caps of vulnerable atheromatous plaques, 
provoking thrombosis. 
Ii:30 a.m. 
m 877 5 Coronary Artery Calcification Extent is Directly Related to Clinical Stability in Patients With 
Coronary Artery Disease 
Joshua A. Beckman, Jason Ganz, Mark A. Creager, Peter Ganz, 
Scott Kinlay. Cardiovascular Division, Brigham and Women’s Hospital, 
Boston, Massachusetts, USA 
Background: Histologic studies of atherosclerotic plaque suggest that the 
site of plaque rupture may be influenced by the mechanical strength of 
the fibrous cap. However, the relationship and prognostic value of coronary 
artery calcification to unstable ischemic syndromes remains unclear. We 
hypothesized that arterial calcification would act as a stabilizing force and 
therefore clinically stable lesions would have a greater calcium content than 
unstable lesions. 
Methods: We reviewed all patients who undetwent coronary artery stent- 
ing and had intravascular ultrasound (IVUS) performed from 1997 until June 
1999. Patients were divided prospectively according to clinical presentation 
into angina, unstable angina, and myocardial infarction. IVUS was employed 
to ensure adequate stent deployment in all patients. We excluded patients 
with in-stent restenosis. The s VHS IVUS images of 80 patients were digi- 
tized and greatest arc of calcium in the target lesion was measured using the 
implanted stent to denote target lesion boundaries. 
Results: There was a progressive decline in the angle of calcium from 
patients with stable angina (83” + 43), unstable angina (77” * 37), and 
myocardial infarction (50” & 47), (p = 0.01). There was no relationship 
between diabetes mellitus or other risk factors for extent of calcification. 
Conclusion: The extent of target lesion calcification is directly related to 
coronary syndrome stability. Arterial calcification may be a stabilizing force 
in atherosclerosis and may be more common in stable coronary syndromes. 
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El 877 6 Lack of Association Between Calcification and 
Vulnerability in Human Atherosclerotic Plaques 
Pedro R. Moreno, K-Raman Purushothaman, William N. O’Connor, 
Valentin Fuster, James E. Muller. Giil Heart Institute, Universi(v of Kenfucky, 
Lexington, KY; Mount Sinai Medical Center, New York, New York; 
Massachusetts General Hospital Boston, MA, USA 
Background: Non-invasive detection of coronary artery calcification is useful 
in identifying individuals with an increased risk of coronary events. However, 
the predictive value of this technique is limited. We hypothesied that these 
limitations are due to a weak association between detectable calcium and 
plaques vulnerable for rupture. 
Methods: Detectable calcium was determined using H&E and trichrome 
staining in 347 non-decalcified plaques obtained at autopsy from 8 human 
aortas. Plaques were categorized as early and advanced according to the 
AHA classification and as vulnerable (fibrous cap ~65 fi in thickness by 
microscopic morphomety, large lipid pool and macrophage infiltration) and 
non-vulnerable (fibrous cap >65 or. in thickness). 
Results: Detectable calcium was more likely to be absent (62%) than 
present (38%) in vulnerable plaques (n = 60) (p = O.Ol), and was similar in 
vulnerable (38%) and in non-vulnerable (27%) plaques (n = 110) (p = 0.17). 
There was a strong relationship between detectable calcium and the AHA 
classification. Detectable calcium was present in 2% of early plaques (n = 
177) and in 31% of advanced plaques (n = 170) (P < 0.0001). 
Conclusion: calcification is significantly greater in advanced atheroscle- 
rotic plaques and therefore non-invasive detection of calcification by EBCT 
may help to identify patients with advanced disease. However, within the 
universe of advanced plaques, the incidence of detectable calcium is similar 
in vulnerable and in non-vulnerable plaques, limiting the predictive value of 
the technique. The optimal strategy for identification of vulnerable plaques 
may include a method of screening for advanced disease such as EBCT 
followed by testing for vulnerability by a more accurate method. 
POSTER 
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1 1156-41 1 Interaction of homocysteine, 
Methylenetetrahydrofolate Reductase (MTHFR) 
C677T Mutation, Plasma Folate and the Risk of 
Coronary, Artery Disease (CAD): Results of a 
Cross-Sectional Study 
Christoph Bickel, Hans J. Rupprecht, Stefan Blankenberg, Peter Gohl’, 
Dirk Pee@, Gerd Rippin3, Juergen Meyer. II. Medicai C/inic, ‘Bioscientia, 
/nge/heim; ‘Clinic of Clinical Chemistry; 3/nstitute for Medical Statistics, 
University-Clinic Mainz, Germany 
Background: Elevated plasma homocysteine (hey) is established as an 
independent cardiovascular risk factor in coronary artery disease (CAD). 
The common C677T genetic mutation of MTHFR may result to elevated hey 
levels and an increased risk of CAD. We determined the association between 
the C677T mutation of MTHFR, hey, folate status and the risk of CAD. 
Methods: In 1045 consecutive patients (pts) with suspected CAD coro- 
nary angiography was performed. Hey was determined by HPLC and MTHFR 
genotyping by PCR (wild type -/-, heterozygote +/-, homozygote +/+). Folic 
acid was assessed also. CAD was defined as at least one stenosis ~50%. 
Results: In 904 of 1045 pts (86.5%) CAD was diagnosed (see tables). 
Quartiles hcv lumollll# <10.5 >10.5-13.1 >13.1-16.4 >16.4 D 
cases [n = 9041’ 208 (23) 238 (26.3) 226 (25) 232 (25.7) 
Controls [n = 1411" 53 (37.6) 32 (22.7) 33(23.4) 16(16.3) 0.001 
MTHFR /- +/- +I+ P 
cases [rl = 9041* 352 (43) 375(45.8) 92 (11.2) 
Controls In = 
hey [~m;l/l]# 
1411" 
’ 
53 f41.71 29 0.749 
12.2 (16.3/2;5.2) 
62 (48.81 
13.3 (1‘0.4/16.5) 
19.4) 
14.4 (16.9/;7.3) 0.0001 
hey (if folate ~7.2)~ 13.4(11.2/16.8) 13.8(11.3/17.4) 15.9(12.8/18.4) 0.003 
hey (if folate a7.2)’ 11.3 (9.7114.3) 12.3 (9.W15.1) 12.3 (9.7/15.2) 0.123 
folate lnolmll# 7.5 (5.8110.2) 7.3 kT.619.4) 6.7 /4.8/9.3) 0.138 
Data represented as *number (percent) of pts or #mean values (25/75% interquartiles) 
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Conclusion: In conclusion elevated level of hey is an independent risk 
factor for CAD. Even the homozygote MTHFR Cs7rT mutation is not associ- 
ated with presence of CAD, but results in moderate elevation of hey levels 
especially in pts with low folate level. There is an important genetic environ- 
mental interaction between folic acid and MTHFR resulting in elevation of 
hey levels. 
I 1156 42 C-Reactive Protein Predicts Coronary Mortality Over Ten Years in a Community-Based Study 
Filomena Valente’ , Michele Dramaix’ , Dirk De Bacquer*, Guy De Backers, 
Marcel Kornitzer’ ‘School of Public Health, Free University of Brussels; 2 
Department of Public Health, University of Ghent, Belgium 
Background: An elevated level of C-reactive protein (CRP), a marker of 
.inflammation, has been reported as an independent risk factor for myocardial 
infarction. However this association requires further evaluation in long-term 
population-based prospective studies. 
Methods: A nested case-control study was conducted within a popula- 
tion-based cohort of 11,302 subjects aged 25-74 years who where involved 
in the Belgian interuniversity Research on Nutrition and Health (B.I.R.N.H.) 
survey. Blood samples were taken at baseline from all participants and stored 
at -70°C. One hundred and seventeen cases were selected among all in- 
cident coronary deaths (sudden and non sudden) within a IO-year follow-up 
period. For each case, 3 controls matched for gender and age were selected 
at random from those at risk at time of case incidence. Conditionnal logistic 
regression (Cox model) was applied to analyse these data. 
Results: In univariate analysis, a high baseline level of CRP was associ- 
ated with significantly increased risk of coronary death: subjects with levels 
of CRP in the highest tertile of the CRP distribution had a P-fold increase in 
risk of coronary death (RR = 2.1; 95% Cl: 1.3 to 3.3; p = 0.002) as compared 
to subjects in the 2 lowest tertiles. After adjusting for significant coronary risk 
factors (HDL cholesterol, systolic blood pressure and level of education) and 
including an interaction term between coronary heart disease at baseline 
(CHD) and CRP, the risk estimate remained similar (RR = 2.2; 95% Cl: 1.1 
to 4.4) among subjects without CHD. However for those presenting CHD 
at baseline, an elevated baseline level of CRP is no longer a predictor of 
coronary mortality (RR = 1 .I; 95% Cl: 0.5 to 2.5). 
Conclusion: These prospective data suggest that among subjects free 
of CHD, baseline level of CRP is an independent risk factor for coronary mor- 
tality. However for those presenting CHD at baseline, CRP is not associated 
with future coronary mortality. 
1 1156-43 1 Divergent Effect of Eating Fat and Carbohydrate 
on Endothelial Function 
Paul J.L. Ong’, Tracey S. Deans, Christopher S. Hayward’, Paola 
Lilla Della Monica’, Thomas A.B. Sanders’, Peter Collins’. ‘Department of 
Cardiac Medicine, National Heart and Lung Institute, Imperial Co//ege 
School of Medicine, London; “Nutrition Food & Health Research Centre, 
King’s College London, UK 
Background: It has been argued that a low-fat, high-carbohydrate (LFHC) 
diet should be recommended to everyone. 
Methods: A randomised, double-blind, crossover study was performed 
in 16 healthy men (age 30 f 5 yr). They were given 2 isoenergetic meals 
(3.2 MJ) consisting of a muffin and a milkshake of a similar volume (450 
ml) which were either high in monounsaturated fat and low carbohydrate 
(HFLC) (50 g fat, 48 g carbohydrate) or LFHC (5 g fat; 218 g carbohydrate). 
We measured brachial artery diameter responses to hyperemic flow and 
glyceryl trinitrate at 0 h and 3 h after consuming the test meal. The study was 
repeated the following day at the same time with the opposite meal. Blood 
was collected for lipid analysis and endothelial function (EF) was assessed 
by imaging the brachial artery using an ultrasound machine equipped with a 
7 MHz linear-array transducer (Acuson 128XP/lO). 
Results: Values for flow-mediated reactivity (FMR) and plasma triglyc- 
eride (TG) concentrations in the fasting state were similar prior to each of the 
test meals. Plasma TG increased significantly following the HFLC meal but 
not following the LFHC meal (2.4 [SE 0.441 mmol/l and 1.3 [SE 0.201 mmol/l, 
respectively p < 0.01). FMR after the HFLC meal was significantly less 1.2 
[SE 0.71% than after the LFHC meal 4.3 [SE 1.41% (p = 0.02). There was no 
difference in nitrate induced vasodilatation. 
Conclusion: Compared with carbohydrate, monounsaturated fats have 
an adverse effect on FMR at least in the postprandial period. Our finding 
would support the importance of a LFHC diet in the preservation of endothelial 
function. 
I 1156 44 Glutathione-Mediated Biotransformation of Glyceryl Trinitrate to Nitric Oxide. A Potential Role 
for Peroxynitrite in Nitrate Tolerance in Patients 
With Unstable Angina 
George H. Deliconstantinos, Vassiliki E. Villiotou, Sofia G. Pouliopoulou, 
John S. Vythoulkas, Vassilios E. Votteas, Michael K. Kyriakidis. University of 
Athens, Medical School, Cardiology Dept., LAIKON Hospital Athens, 
Greece 
Glyceryl trinitrate (TNG), glyceryl dinitrate (DNG), 3nitrotyrosine (3-NT) and 
the levels of glutathione (GSH) and its oxidized form GSSG were estimated in 
serum of five. patients suffering of unstable angina. TNG, DNG, and 3-NT were 
estimated by high pressure liquid chromatography (HPLC). TNG/DNG was 
0.8 after eight hours of continuous i.v. infusion of TNG (nitrolingual) which was 
change to 1.5,48 hours later, indicating the development of nitrate tolerance. 
At the same time the amount of 3-NT was 0.5 f 0.04 PM that was increased 
up to 12.5 f 1.7 KM after 48 hours. The ratio GSH/GSSG and the levels 
of S-nitrosoglutathione (GSNO) were determined by a fluorophotometricaly 
and by a chemiluminescence method, respectively. They were decreased 
from 1.7 to 0.4 and from 55.5 + 5.0 FM to 12.5 + 1.5 wM, respectively, 
between 8 and 48 hrs of continuous i.v. infusion of TNG. The ability of GSH 
to metabolize TNG, thus releasing NO was assessed in vitro experiments. NO 
and peroxynitrite (ONOO-) were estimated by a chemiluminescence method. 
It was shown that in the presence of GSH and tyrosine, TNG released NO 
and 0; that react together to form ONOO- causing the formation of 3-NT. 
0; was estimated by the reduction of cytochrome C. TNG was transformed 
to DNG by GSH with its subsequent oxidation to GSSG. GSSG was unable 
to release NO from TNG. Furthermore, 3-NT formation was inhibited by 
superoxide dismutase (SOD) indicating that 0s was a key intermediate of 
tyrosine nitration, 
Conclusion: This study suggests that GSH mediated the conversion of 
TNG to NO with subsequent formation of ONOO- that produced 3-NT and 
caused the oxidation of GSH to GSSG. The increased amounts of 3-NT and 
the high ratio of TNG/DNG in the serum could be used as indexes of nitrate 
tolerance. 
1 1156-45 1 Long Term Therapy With Enalapril Augments 
Endothelium Dependent Vasodilation in a Dose 
Dependent Manner in Patients With Congestive 
Heart Failure 
John N. Nanas, Christos Papamichael, George E. Alexopoulos, Stavros 
G. Drakos, John Stathopoulos, Ageliki E. Eleftheriou, Argiris Dalianis, Maria 
I. Anastasiou-Nana, Stamatios F. Stamatelopoulos. Dept. of Clinical 
Therapeutics, University of Athens, Athens, Greece 
Background: The angiotensin-converting enzyme (ACE) inhibitors improve 
endothelium dependent vasodilation in patients with advanced congestive 
heart failure (CHF). The purpose of the present study was to determine 
whether the improvement of endothelium-dependent vasodilation caused by 
ACE inhibitors is dose-related. 
Methods: Eleven patients (2 women, 9 men) with advanced CHF ran- 
domly receiving either IO mg (low dose) or 30 mg (high dose) of enalapril 
twice per day for more than 1 year, underwent high resolution ultrasound 
imaging of the right brachial artery to evaluate arterial dilatation during hy- 
peremic flow (endothelium-dependent dilatation) and after nitroglycerin ad- 
ministration (endothelium-independent dilatation). Subsequently, the dosage 
of enalapril was changed to 30 mg bid in those previously receiving IO mg 
bid and to IO mg bid in those previously receiving 30 mg bid for IO clays and 
the endothelial function was reassessed. 
Results: Patients were in NYHA functional class 1.73 +Z 0.47, and had 
a radionuclide left ventricular ejection fraction 30 ZIZ 12%, a max VOn 19 f 
17.6 ml/kg/min, mean right atrial pressure 6 f 4 mmHg and mean pulmonary 
capillary wedge pressure 13.0 f 6 mmHg. 
The baseline arterial diameters and blood flow were similar in the low 
and high enalapril dose groups. The degree of reactive hyperemia was 
291 f 141.5% in the low and 335.9 + 124.5% in the high enalapril dose 
groups, respectively. Flow-mediated dilatation FMD was 0.69 f 1.02% in the 
low and 2.93 + 2.57% in the high enalapril dose group (p = 0.012), while 
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nitroglycerin-induced dilatation was comparable between the two groups 
(11.29 i 3.67 “s 14.72 f 10.02, p = NS). 
Conclusion: This study provides evidence that the augmentation of en- 
dothelium dependent vasodilatation by the ACE inhibitors in patients with 
congestive heart failure is dose dependent. 
/ 1156 46 Rapidly Progressive Coronary Artery Disease and C-Reactive Protein. Is There Any Relation? 
Michael N. Zairis, Leonidas K. Hadjinikolaou, Stavros J. Manoussakis, 
Alexander S. Stefanidis, George K. Andrikopoulos, George K. Hadjiioakim, 
Kostas E. Katsaros, Evangelos G. Pisimisis, Constantin N. Fakiolas, 
Christopher D. Olympios, Stefanos G. Foussas. Department of Cardiology: 
Tzanio Hospital of Piraeus, Greece 
Background: Recent reports have shown the presence of CRP molecules 
in the coronary atherosclerotic plaques and infarcted myocardial cells. This 
could indicate the direct participation of CRP in the pathogenesis of coronary, 
events. The underlying mechanism could be associated with instability of ath- 
erosclerotic plaques and/or a rapid progression of the coronary artery disease. 
The aim of our study was to compare the serum concentrations of CRP among 
patient with or without rapid progression of coronary artery disease. 
Methods: One hundred and thirty-seven patients, who were re-admit- 
ted due to conditions attributed to coronary disease within 12 months after 
PTCA with or without stent implantation, underwent repeat coronary angiog- 
raphy. Median angiographic follow-up time was 6 months (range 10 days-12 
months). Two independent and experienced observers, who were blind to the 
study, conducted quantification of coronary vessel stenosis degree on an- 
giographic studies. “Rapidly progressing coronary artery disease” (RPCAD) 
was defined as the presence of a new lesion a known non-treated lesion by 
at least 25%. Thus the patients were classified into two groups: a group of 
111 patients without RPCAD (aged 56.2 f 9.1 years, group A), and a group 
of 26 patients (aged 56.6 * 9.6 years, group B) with RPCAD. 
Results: 
Patients characteristics GroupA(n=lil) 
on first admission 
Age [mean * SD, years] 
Male gender 
Hypertension 
Smoking 
Hypercholesterolemia 
Diabetes mellitus 
Family history of CAD 
Unstable angina 
Stable angina 
Myocardial infarction 
CRP > 5 mgidl 
58.2 * 9.1 
90(81.1%) 
53 (47.7%) 
70 (63.1%) 
51 (45.9%) 
16 (14.4%) 
34 (30.6%) 
31 (27.9%) 
23 (20.7%) 
57 (51.4%) 
61 (55.0%) 
Group B (n = 26) P 
56.6 -+ 9.6 0.63 
20 (76.9%) 0.63 
10 (38.5%) 0.39 
16 (61.5%) 0.88 
12 (46.2%) 0.98 
3 (11.5%) 0.70 
9 (34.6%) 0.69 
7 (26.9%) 0.91 
5 (19.2%) 0.86 
14 (53.9%) 0.91 
23 (88.5%) 0.002 
Treatment in the groups did not differ during first hospitalization and 
after discharge until the second admission. Pts with RPCAD had statistically 
significant higher CRP levels, on their first admission, than those without 
RPCAD (p = 0.002). 
Conclusions: High serum levels in patients with coronary artery disease 
could possibly identify patients in high risk for the development of RPCAD. 
These patients may benefit from a more aggressive antithrombotic and/or 
anti-inflammatory treatment. 
L-L- 1156 47 Breast Artery Calcifications on Routine 
Mammography: A Potential Marker for Increased 
Risk of Cardiovascular Disease 
Eugene Crystal, Pave1 Crystal, Jonathan Leor, George Katsenovich, 
Michael Friger, Selwyn Strano. Comprehensive Breast Center, Department 
of Radiology: Cardiology Department, Soroka Medical Center and Faculty of 
Health Sciences, Ben Gurion University, Beer Sheva; Rachel Nash 
Comprehensive Breast Center, Jerusalem, Israel 
Background: The existence of cardiovascular risk factors should be dis- 
covered early since atherosclerotic cardiovascular disease (ASCVD) is the 
single largest killer of women in the Western world. We examined breast 
artery calcification at routine mammography as an effective and non-expen- 
sive screening tool for detection of cardiovascular risk in women. 
Methods: 865 consecutive women referred for mammography were 
asked to complete a questionnaire assessing major risk factors for ath- 
erosclerosis and history of ASCVD. Mammograms were analyzed for the 
presence of breast arterial calcification (BAC) by two experienced mammo- 
graphers independently. The association between BAC and the abovemen- 
tioned risk factors and cardiovascular morbidity was examined. 
Results: 152 (18%) women had BAC positive mammograms. The com- 
parison of characteristics between BAC positive and BAC negative patients 
revealed higher prevalence of hypertension (52% vs. 25%, p < O.OOOl), 
diabetes mellitus (15% vs 6%, p = 1X002), dyslipidemia (35% vs. 25%, p = 
0.615), amenorrhea (91% vs. 68%, p < 0.0001). BAC was associated with 
almost twofold increased possibility of the existence of ASCVD or two or more 
major risk factors (42% vs. 23%, p < 0.001). Multivariate analysis showed 
that the presence of BAC has a higher odds ratio (2.1 I, Cl 1.22-3.66) for 
ASCVD morbidity than any of the examined risk factors. 
Conclusions: Our findings suggest an effective and non-expensive screen- 
ing tool for detection of cardiovascular risk in women. The presence of BAC 
on mammography may be a useful marker of women at higher cardiovascular 
risk or with ongoing disease. 
1156-48 Elevated Levels of Soluble Fas in 
Postmenopausal Women 
Martina Briickmann’ , Birgitt Salbach’, Dorothea Kijchler’ , Thomas von 
Hoist*, Wolfgang Kiibler’ , Peter B. Salbach’. ‘Dept. of Cardiology & 
2GynaecologE University of Heidelberg, Heidelberg, Germany 
Background: Premenopausal women are at lower risk of coronary head dis- 
ease compared to age-matched males. After menopause the rate of athero- 
genesis accelerates progressively. Female sexual hormones are considered 
to modulate progression of cardiovascular disease. Soluble Fas (sFas), an 
inhibitor of apoptosis, is known to be associated with the pathogenesis of ath- 
erosclerosis as it plays an important role in the regulation of proatherogenic 
inflammatory mechanisms. The present study was designed to evaluate the 
impact of menopause on serum levels of sFas and on markers of endothelial 
dysfunction. 
Methods: Healthy pre- (n = 50) and postmenopausal (n = 45) women were 
included in this study. Postmenopausal women had FSH levels >30 mu/ml 
and estradiol (E2) levels ~25 pg/ml. Serum levels of sFas, soluble vascular 
cell adhesion molecule-l (sVCAM-I) and Endothelin-I (ET-l) were analyzed 
in duplicate by commercially available ELISA kits. Statistical analysis was 
performed by unpaired students t-test, Pearson’s correlation and multiple 
regression analysis. 
Results: In postmenopausal women levels of sFas increased by 33% 
compared to the premenopausal group (7469.5 f 283.7 pg/ml vs 5618.5 
?Z 196.9 pg/ml, p < 0.0001). Markers of endothelial dysfunction were also 
elevated in postmenopausal women (+44.9% for sVCAM-I: 434.7 f 21.3 
rig/ml vs 629.9 f 29.2 rig/ml, p < 0.0001; +23.1% for ET-I: 1.49 i 0.07 
vs 1.21 rt 0.0 6 pg/ml, p = 0.002). Soluble Fas levels were significantly 
correlated with sVCAM-1 levels (r = 0.42, p < 0.0001) and ET-1 levels (r 
= 0.32, p = 0.002). A multivariable analysis revealed that sFas levels were 
positively associated with both FSH levels (+14.26 pg/ml sFas per 1 mu/ml 
FSH, p = 0.002) and age (+71.25 pg/ml sFas per year, p = 0.001). There was 
an inverse relationship between serum levels of E2 and sFas (-6.15 pg/ml 
sFas per 1 pg/ml E2, p = 0.019). 
Conclusion: The onset of menopause results in a significant increase 
in serum levels of sFas. This finding is likely due to 1) age and 2) the lack 
of female sexual hormones in postmenopausal women. Elevation of sFas 
levels is accompanied by an increase of VCAM-1 and ET-I as representative 
markers of endothelial dysfunction. The lack of female sexual hormones 
and the increase of sFas may contribute to the development of endothelial 
dysfunction and atherosclerosis in postmenopausal women. 
I 1156 49 Endothelial Dysfunction in Patients With Systemic 
Lupus Erythematosus 
Valter C. Lima, Domingos S. Lima, Emilia I. Sato, Francisca Hatta, 
Faust0 Miranda Jr.. Universidade Federal de SFJO Paula, S3io Paula, Brazil 
Background: Impaired endothelial function is present in early stages of 
atherosclerosis. Flow-mediated dilation (FMD) of the brachial artery is an 
accepted noninvasive method to assess endothelial function and has been 
used to study patients with risk factors for coronary artery disease and in 
therapeutic clinical trials. The purpose of this study was to test the hypoth- 
esis that endothelial dysfunction occurs in premenopausal Systemic Lupus 
Eythematosus (SLE) women and may be an important early event in the 
accelerated atherosclerosis of this disease. 
Methods: High resolution ultrasound was used to measure the brachial 
artery diameter at rest, during reactive hyperemia (with increased flow caus- 
ing endothelium-dependent dilation) and 3 minutes after 400 pg sublingual 
nitroglycerin (GNT). 
Results: Forty nine premenopausal SLE (ACR criteria) women (17-46 
years old; mean SLE duration 6.4 - 5 years) were compared to 28 age 
and sex-matched healthy controls (17f45 years old). Baseline diameter was 
similar in SLE patients and controls (3.5 f 0.4 vs 3.4 f 0.3 mm, p = 0.17). 
The percentage of flow-mediated dilation in SLE patients was significantly 
reduced compared to controls (4.7 * 4 vs 12.4 i 5, p < 0.0001). In contrast, 
GNT dilation response was similar in both groups (13.5 f 6 vs 13.6 f 6 p 
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= 0.94). The mean age, blood pressure and cholesterol level were similar in 
the two groups. 
Conclusion: Endothelial function is impaired and endothelial independent 
dilation is normal in SLE women without overt coronary artery disease. 
This novel finding suggests that the SLE pathogenetic mechanism or the 
drugs used in its treatment (eg corticosteroids) may be related to endothelial 
dysfunction, and contribute to the early atherosclerosis seen in this condition. 
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I 1157 50 VEGF Gene Delivery to Myocardium: Deleterious 
Effects of Unregulated Overexpression 
Randall J. Lee, Matthew L. Springer, William Blanco-Bose, Robin Shaw, 
Philip C. Ursell, Helen M. Blau. University of California, San Francisco, CA; 
Stanford University Stanford, CA, USA 
Background: Vascular endothelial growth factor (VEGF) is being investi- 
gated for therapeutic angiogenesis in ischemic myocardium. The goal of 
this study was to investigate the effects of myoblast-mediated expression of 
VEGF in myocardium. 
Methods: Primary murine myoblasts (5 x IO5 cells in 10 ml of PBS with 
0.5% BSA) expressing both the murine VEGF gene and the b-galactosidase 
(b-gal) gene from a retroviral promoter were implanted in the ventricular 
wall of immunodeficient mice (n = 9) via a subdiaphragmatic approach. 
Control immunodeficient mice (n = 9) were injected with the same number of 
myoblasts expressing only the b-gal gene. Between days 14-16, surviving 
mice were sacrificed and the hearts processed for histology. 
Results: In the experimental group, 9 of 9 mice demonstrated failure-to- 
thrive by day 12; 5 deaths occurred between days 8-15. There were no 
complications in the control mice. Histochemistry documented successful 
implantation of myoblasts (positive b-gal reaction product) in 4/4 surviving 
experimental mice and 9/9 controls. Histology disclosed intramural vascu- 
lar tumors resembling hemangiomas in the VEGF-myoblast-injected my- 
ocardium in 4 of 4 surviving mice. b-gal-expressing nuclei were present at 
the site of the vascular tumors. lmmunohistochemistry localized abundant 
endothelial nitric oxide synthase and antibody to CD31 (PECAM) within the 
lesion, consistent with endothelial cells. 
Conclusion: In this model, unregulated overexpression of VEGF is as- 
sociated with: 1) a high rate of failure-to-thrive/death, and 2) formation of 
endothelial cell-derived intramural vascular tumors in the implantation site. 
These results underscore the importance of regulating VEGF expression for 
therapeutic angiogenesis. 
I i i 57 51 Lentivirus Vector Delivery for Cardiac Myocytes and Vascular Smooth Muscle Cells 
Tsuyoshi Sakoda, Nori Kasahara, Yasuo Hamamori, Larry Kedes. University 
of Southern California, Los Angeles, CA, USA 
Background: Human immunodeficiency virus (HIV, lentivirus) type-l based 
vectors is known to transduce non-dividing cells and to express transgene for 
a long time. However, there is no reports regarding application of lentivirus 
to cardiovascular system. 
Methods: We used a three-plasmid expression system to generate pseu- 
dotyped lentivirus-based vectors using sodium butyrate, which is known to 
activate HIV. We examined the applicability of these improved vectors for the 
efficient transduction of non-dividing cells. We also investigated the effect 
of calcium phosphate (CaPi) on transduction efficiency of lentivirus-based 
vectors. 
Results: Lentivirus-based vectors efficiently transduced cardiac myocytes 
and yielded titers of (6.3 f 1.2) x 1 O5 Transducing Units/ml (TU/ml); however 
murine retrovirus-based vectors showed low transduction efficiency with titers 
only [8.9+2.1] x IO” TU/ml. Furthermore, even 12 days after induction of dif- 
ferentiated L6 myofibers, lentivirus-mediated transduction of B-galactosidase 
was higher than that of retrovirus-based ones. In vascular smooth muscle 
cells (VSMC) and cardiac myocytes, delivery of lentivirus-based vectors with 
CaPi coprecipitates increased transgene expression up to 13 fold. The mag- 
nitudes of enhancement of transgene expression by CaPi coprecipitates 
were greater during brief periods (10 minutes and 120 minutes) of virus-cell 
contact than that of long periods (16 hours). 
Conclusion: We successfully generated versatile high titer lentivirus us- 
ing sodium butyrate. In consideration of direct arterial gene transfer or cardiac 
myocyte gene transfer through a dynamic coronary circulation, efficient gene 
transduction is needed to achieve in a short time. Lentivirus with CaPi co- 
precipitates increase both the efficiency and speed of gene transfer. These 
approaches provide efficient and improved method for research and therapy 
for cardiovascular diseases. 
1 Ii 57-52 / VEGF Promoter Polymorphisms and the Risk of 
lschaemic Heart Disease 
Patrick E. Owens, Carolyn J. Watson, Ann E. Canfield, Sheila E. Francis, 
David C. Crossman, Paul E. Brenchley. Department of Medicine, University 
of Manchester; Divisions of Clinical Sciences, University of Sheffield, UK 
Background: VEGF is an angiogenic polypeptide, linked to coronary vessel 
neovascularisation. Regulation of production depends in part on the promoter 
sequence upstream of transcription start. A number of stabilising regions in 
the pre- and post-transcription start area also modulate VEGF expression. 
We have identified this area to be polymorphic, and here we examined the 
prevalence of three common polymorphisms in a population of subjects with 
angiographically-proven ischaemic heart disease, and in an angiographically 
normal population. 
Methods: Blood was drawn from subjects at the time of their angiographic 
study, and DNA extracted by standard techniques. Angiographic normality 
was defined a priori as absence of atheromatous coronary stenosis > 30% 
’ of luminal diameter in any epicardial coronary artery. The area of interest of 
the VEGF gene was amplified using appropriate DNA primers by PCR, and 
the presence of the polymorphisms was identified using restriction enzyme 
digestion. The following polymorphisms were identified: A-141C; C-4607 
C+405G (measured from transcription start). 
Results and Conclusions: When analysed for genotype and allelic fre- 
quency, neither the A-141C or C+405G polymorphism was differentially 
represented between the two groups. Below are the results for C-460T 
(n(%)): 
GWWWJe Normal lschaemic 
cc 17 (32%) 6 (10%) 
CT 27(51%) 43 (56%) 
TT 9 (17%) 26 134%) 
Allt+S Normal lschaemic 
c 61(57%) 59 (38%) 
T 45(43%) 95 (62%) 
The C-460T genotype differed significantly between normal and is- 
chaemic subjects (x2 = 11.1, p = 0.004). The T allele was significantly 
over-represented in the ischaemic group (p = 0.002), and was associated 
with an odds ratio of 2.2 (95%Cl 1.3-3.6) for the presence of atheromatous 
coronary artery disease. A logistic regression model confirmed that the T al- 
lele at -460 remained a significant independent predictor of ischaemic heat-l 
disease (p = 0.001, R = 0.22, OR = 3.1 (95%CI 1.5-6.2) after controlling for 
possible confounding variables (age, sex, a history of hypertension, prior Ml, 
smoking status and a family history of ischaemic heart disease). This pro- 
vides the first evidence of a link between VEGF sequence polymorphisms 
and coronary disease expression. 
1 1157-53 1 SQ885, A Novel Non-Peptide lntegrin Antagonist 
for Vascular Cell lntegrins arvp3, 0rvp5, and 0r5,Bl 
Potently Inhibit Angiogenesis-Mediated Disorders 
Shaker A. Mousa, Seema Mohamed, Prabhakar K. Jadhav, William Pitts. 
DuPont Pharmaceuticals Co., Wilmington, DE, USA 
Background: Angiogenesis depends on the cooperation of growth factors 
and cell adhesion proteins. The integrins olvp3 and olvg5 have been shown 
to play critical roles in two distinct pathways of angiogenesis. Furthermore, 
recent evidence showed that angiogenesis induced by growth factors in ani- 
mal models was blocked by monoclonal antibodies to the cell-binding domain 
of fibronectin. The present study was undertaken to define the additional role 
of olvg5 and a5,5’1 integrins to that of the avg3 integrin in the modulation of 
angiogenesis using potent non-peptide inhibitors of integrin 0lvB3,0lvfi5, and 
oi5pl and a specific anti-avg3. 
Methods: The anti-angiogenesis efficacy of SQ885, a potent non-peptide 
antagonist of olvp3, ruvp5, and 015Bl integrins as compared to equipotent 
and specific orvg3 integrin antagonist, XT199 was determined using en- 
dothelial cell migration assay, (HUVEC) tube formation assay, and the chick 
chorioallantoic membrane (CAM) model of angiogenesis. In the CAM model 
angiogenesis was induced by various angiogenic factors including FGF2, 
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VEGF. Addi?ionally, the efficacy of SQ885 and XT199 on tumor-induced 
angiogenesis and tumor growth was determined. 
Results: SQ885, a potent inhibitor for the integrin crvB3 (IC50 = 25 nM), 
0lvfi5 (1650 = 35 nM), and C&II (IC50 = 100 nM) and XTI99, a specific 
ant&v@3 (IC50 = 40 nM) but not control compounds, inhibited endothelial 
cell (HUVEC) migration and tube formation. In the CAM, SQ885 inhibited 
angiogenesis induced by FGF2 and VEGF. In contrast, XT1 99 completely 
blocked FGF2 but not VEGF-induced angiogenesis in a dose-dependent 
manner. SQ885 demonstrated greater potency in inhibiting different tumor 
types-induced angiogenesis and tumor growth as compared to XT199. Thus, 
integrin antagonist for olvg3, ~yv,!I5, and 015Bl might provide greater efficacy 
in the inhibition of angiogenesis associated with solid tumor growth, neo- 
vascular eye diseases, inflammatory diseases, and abnormal remodeling in 
atherosclerosis. 
1 1157-54 1 Asymmetric Dimethylarginine Inhibits Vascular 
Enclothelial Growth Factor Synthesis by Cytokine- 
Stimulated Vascular Smooth Muscle Cells 
Jozef Dulak’ 2, Alicia Jozkowicz’ , Robert Krzesz’ , Otmar Pachinger’, 
Franz WeidingeP. Jagiellonian University, Krakow, Poland; Department of 
Cardioiogy University of Innsbruck, Innsbruck, Austria 
Background: Reciprocal relationships between nitric oxide (NO) and VEGF 
include the enhancement of NO release by endothelial cells stimulated with 
VEGF. Recently, we demonstrated that NO, produced either by: 1) iNOS in 
vascular smooth muscle cells (VSMC), or by 2) ecNOS after its gene transfec- 
tion, or, 3) released from certain NO-donors, can enhance VEGF production 
in VSMC. Thus, we tested whether asymmetric dimethylarginine (ADMA), 
an endogenous NO-synthase inhibitor, can influence VEGF synthesis by 
cytokine-induced iNOS. 
Methods: Rat confluent VSMC were stimulated with IL-1B (5 ngiml) for 24 
hours, in the presence or absence of ADMA (0.13 mM) or L-NAME (2 mM). 
Additionally, some of such treated cells were supplemented with L-arginine (5 
mM). Media were collected for measurements of NO generation (using Griess 
reagent), VEGF production (ELISA test) and cell viability (LDH release ELISA 
test). RNA was isolated and used for RT-PCR detection of INOS, VEGF and 
GAPDH gene expression. Additionally, in some experiments the cells were 
stimulated as above, and the cell protein extract was isolated 6 hours later, 
and used for determination of AP-1 transcription binding activity in a gel-shift 
assay: 
Results: IL-lp induced iNOS expression and NO generation in VSMC, 
which correlated with enhanced VEGF production (200-400% of basal VEGF 
production, n = 9 independent experiments). Abrogation of NO generation 
by L-NAME resulted in 3040% inhibition of VEGF synthesis (n = 9). ADMA 
down-regulated (0.1-0.3 mM) or totally inhibited (at l-3 mM) IL-la-induced 
NO generation. Down-regulation of VEGF synthesis by 36.4 f 2.3% (n = 6) 
was caused by higher (l-3 mM) ADMA concentrations. Supplementation with 
L-arginine partially restored NO generation, and concomitantly upregulated 
VEGF production. ADMA slightly down-regulated VEGF gene expression, 
which may be related to weakened AP-I binding, enhanced by IL-lj3 and 
inhibited by ADMA. 
Conclusions: NO-mediated induction of VEGF synthesis might be inhib- 
ited by ADMA, an endogenous antagonist of L-arginine. Positive influence of 
L-arginine supplementation on endothelial function in hypercholesterolemic 
animals, as well as inhibition of restenosis after angioplasty, may partially 
rely on stimulation of VEGF synthesis by nitric oxide. 
L-L 1157 55 Activation of Protein Kinase A Inhibits Endothelial 
Cell Apoptosis Induced by Stimulation of the p 
Subtype of the Thromboxane Receptor 
Ryoji Yokota, Yukitaka Shizukuda, Yunling Gao, Anthony W. Ashton, J. 
Anthony Ware. Albert Einstein College of Medicine/Montefiore Medical 
Center, Bronx, New York, USA 
Background: Thromboxane A2 (TxA2) is a known mediator of unstable 
angina and acute myocardiai infarction. Because of the importance of new 
vessel formation and function in the response to myocardial ischemia, we 
tested whether TxAZ mimetics and TxA2 receptor (TP) activation could induce 
endothelial cell (EC) apoptosis, and whether stimulation of the endothelial 
subtype of the TP (TPfi) is sufficient to induce this effect. The roles of the 
protein kinase A (PKA) and C (PKC) cascades in mediating the TPfl effect 
were also tested. 
Methods: The TxA:! mimetic IBOP was added to human umbilical vein 
EC (HUVEC) that had formed tube structures on a basement membrane 
matrix. To investigate the specific role of TPP in TxAninduced EC apoptosis, 
TPP was stably overexpressed in rat capillary EC (TP,&EC), which do not 
normally express TP. Both control and TP,&EC were treated with or without 
30 nM IBOP. In addition, TP,&EC were treated with IBOP in the presence of 
either IO fiM forskolin (F), 1 mM dibutyry cyclic AMP (dcAMP), 1 JLM H-89, 
or 0.1 PM calphostin C (CA). Apoptosis was assessed by DNA laddering and 
TdT-mediated deoxyuridine triphophate nick end-labeling (TUNEL). 
Results: IBOP increased apoptosis in HUVEC as determined by TUNEL 
(11.3 i 1.2 vs. 6.9 & 0.8% in untreated controls, P < 0.05). EC apoptosis 
by IBOP was increased in TP/3-EC compared to controls (3.5 f 0.2 vs. 1 .l 
f O.l%, respectively: P < 0.01). Both F and dcAMP, which increase the 
activity of PKA, lessened the effect of IBOP in TP/7-EC (1 .l f 0.1 and 1.2 & 
O.l%, respectively, P < 0.05). Conversely, the PKA inhibitor H-89 enhanced 
IBOP-induced apoptosis (4.5 f 0.4%, P < 0.05). On the other hand, the PKC 
inhibitor CA inhibited IBOP-induced apoptosis in TPB-EC (2.3 + 0.2%, P < 
0.05). 
Conclusion: TxA2 induces EC apoptosis, and thus could damage existing 
vessels and delay new vessel formation following ischemia. Stimulation of the 
TPB subtype is sufficient to induce EC apoptosis, which requires activation 
of PKC but can be inhibited by PKA activation. 
I Ii 57 56 Transforming Growth Factor-P is a Powerful 
Promotor of Arteriogenesis 
Niels van Royen”, Imo Hoefer’ , Ivo Buschmann’, Sawa Kostin’, 
Matthias Heil’, Eva Katzer’ , Jan J. Pick”, Wolfgang Schaper’. ‘Max Planck 
Institute, Dept. for Experimental Cardiology, Bad Nauheim, Germany; ’ 
Academic Medical Center Amsterdam, Department of Cardiology, the 
Netherlands 
Introduction: After birth two forms of vessel growth can be recognized. 
Angiogenesis is the sprouting of endothelial cells leading to a capillary net- 
work. Arteriogenesis is the formation of functional collateral arteries from 
preexisting arteriolar connections and is the only satisfactory adaptation to 
restore an efficient blood flow to ischemic territories. TGF-fi stimulates the 
process of angiogenesis. However, it is not known whether TGF-p influences 
arteriogenesis. 
Methods: The right femoral artery was ligated in 24 New Zealand White 
rabbits. TGF-p or PBS was directly infused into the collateral circulation 
via an osmotic minipump. Seven days after ligation the number of visible 
collateral arteries was evaluated with angiographies in one group (PBS n = 
6, TGF-B n = 6). In the other group the collateral conductance was calculated 
with the use of fluorescent microsphere infusion and FACS analysis. 
Results: Collateral conductance strongly increases with TGF-/I treatment 
compared to the PBS control group (see figure). This was also confirmed by 
the number of collateral arteries that were visible on the angiograms. 
P B S  TGFMta 
Conclusion: This is the first repot-l showing that TGF-b is a powerful 
promotor of arteriogenesis. The number of visible collateral arteries increases 
and the conductance of the collateral circulation is threefold as high as 
compared to the control group. 
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1158-9 What is the Appropriate Loading Dose of 
Clopidogrel Prior to Stent Implantation? Insights 
From a Platelet Inhibition Study 
Daniel Soffer, Gurkan Taviloglu, Gishel New, Edward Kreps, Michael Collins, 
Sriram lyer, Gary Roubin, Antonio Colombo, Jeffrey Moses, Neil Coplan, 
lssam Moussa. Lenox Hi// Heart and Vascular Institute, New York, NL: USA 
Background: The optimal loading dose of clopidogrel prior to coronary 
stenting is still undetermined. Therefore, we prospectively compared the 
degree of platelet inhibition (PI) following administration of 300 mg and 450 
mg of clopidogrel in pts referred for coronary stenting. 
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Methods: Clopidogrel was administered as a loading dose of 300 mg in 25 
pts and 450 mg in 66 pts followed by a maintenance dose of 75 mg/day. Blood 
was collected at various time intervals after loading. ADP-mediated platelet 
aggregation was measured with the lchor CBC analyzer (Array Medical) 
utilizing 20 micromole of ADP. Pts were divided according to the loading 
dose received (300 mg vs 450 mg) and according to the time interval from 
drug loading (< 3 hrs, 3-9 hrs, 9-24 hrs). Repeated measures ANOVA with 
Bonferroni multiple comparison test was used to determine whether there 
was any difference among groups. 
Results: Pts treated with 450 mg of clopidogrel had sig higher level of PI 
(37 & 5% vs 18 f 5%, p c 0.05) only in the time window 3-9 hrs post loading 
with no difference before 3 hrs and after 9 hrs as shown below: 
45 
Time Post Clopidogrel Bolus 
Time Post Clopidogrel Bolus 
Conclusion: These preliminary data suggest that when clopidogrel is 
administered as a loading dose prior to coronary intervention, a dose of 450 
mg appears to double the effect on platelet inhibition compared to 300 mg in 
the time window of 3 to 9 hrs post bolus. The clinical impact of these findings, 
if validated by randomized trials, should be considered when planning the 
time of coronary intervention. 
L-l- 1158 10 The Effect of Sibrafiban, an Oral Ilb/llla Platelet Receptor Antagonist, on Platelet Function in 
Patients With Chronic Renal Failure 
Timothy D. Henry, Charles A. Herzog, Domenic A. Sica, James Reimann, 
William Novotny. Hennepin County Medical Center, University of Minnesota, 
Minneapolis MN; Virgina Commonwealth University, Richmond VA; 
Genetech, Inc., San Francisco, CA, USA 
Background: While cardiac disease is the major cause of death in pts with 
chronic renal failure (CRF), these pts are routinely excluded from clinical tri- 
als. Ilb/llla platelet receptor antagonists have been shown to reduce ischemic 
events in non-CRF pts. Almost no data exist on the use of llbillla antagonists 
in pts with CRF. Sibrafiban is a promising oral Ilb/llla antagonist currently in 
Phase Ill trials and like other oral Ilb/llla antagonists is cleared renally. 
Methods: Safety and pharmacokinetic data were obtained in an open- 
label, dose-escalation trial in 23 pts with using single dose (1 to 10 mg) and 
multiple dose (1 to 5 mg for IO days) protocols in 3 groups: GPI (normal 
CRC1 z 75; N = 6); GP2 (CRCl30-50; N = 9) and GP3 (CrCI < 30 without 
dialysis, N = 8). 
Results: Baseline characteristics were well-matched except CRF pts 
were slightly older. Sibrafiban was well-tolerated with only one significant 
bleeding event (anemia). Results of peak inhibition of ADP-induced platelet 
aggregation (PK-ADP), maximum drug concentration (cmax) and elimination 
half-life (T 112) are listed in the table for the 5 mg dose. 
5 mg dose 
Serum Cr (mean) 
CrCl (mean) 
Cmax (mgiml) 
T l/2 (hrs) 
PK-ADP inhibition 
Group 1 
0.9 * 0.1 
103 * 11 
21.5 zk 2.7 
10.5 i 2.2 
50% 
Group 2 
1.8 zt 1.2 
54115 
29.8 zt 6.3 
12.3 zk 4.0 
70% 
Group 3 
3.9 i 1.6 
16+8 
55.1 + 19.7 
26.2 h a.4 
90% 
Conclusions: Sibrafiban can be given safely to pts with CRF after dose 
adjustment. This may have important implication for pts with coronary disease 
who develop renal insufficiency as well as for pts with CRF. Randomized 
controlled clinidal trials are warranted in this high-risk population. 
1158-I 1 Second Generation Oral Ilb/llla Receptor 
Blockade: Phase II Experience With Roxifiban 
Anatoly Langer, Shaun G. Goodman, Thomas M. Reilly, Shaker A. Mousa, 
Adrienne L. Fiacanelli, Christopher O’Connor, William W. O’Neill, Neal 
S. Kleiman, Paul Gurbel, Robert N. Daly. St, Michael’s Ho.sp/ta/, Toronto, 
Canada; DuPont Pharmaceuticals, Wilmington, DE, USA 
Background: The safety and efficacy of oral Ilb/llla receptor blockers is 
debatable to date. Accordingly we studied a new synthetic non-peptide com- 
pound, roxifiban in pts with high risk stable CAD. Roxifiban is converted by 
esterase to the active drug, XV459, with high potency and affinity for the 
Itb/ltla receptor. Compared to first generation oral drugs, roxifiban has the 
following advantages: I. Slow rate of dissociation from receptor with half-life 
of 7 minutes (Kd = 0.0002 uM), 2. Long terminal half-life with drug detection 
to up to 10 days, 3. Stable drug concentration with doses larger than 1 .O mg, 
suggesting greater safety, 4. No increase in platelet microaggregation seen 
with other short acting oral compounds, 5. Stable pharmacokinetic profile in 
relation to tight platelet binding on one hand and rapid renal clearance on 
the other, 6. Superior antithrombotic effect with significant inhibition of clot 
retraction. 
Methods: We enrolled 614 pts (previous acute coronary syndrome ~3 
mos, >65 years, or diabetic) into a six months, blind, randomized phase II 
trial which studied two doses of roxifiban and the potential benefit of aspirin 
interaction. Preliminary and incomplete follow-up data are shown: 
Prellminaty Results (full results to follow): 
ASA 1 mg+ASA 
Roxifiban 
1.5 mq 1.5mgcASA 
Death 
n=154 n= 160 n=150 n=150 
0% 0.6% 0.7% 0% 
MI 
Rec. lschemia 
Composite 
0.6% 2.5% 0% 0% 
5.8% 0.6% 2.7% 1.3% 
6.5% 3.8% 3.3% 1.3% 
No significant safety problems were identified: major bleeding of 1% and 
thrombocytopenia (< 50,000) of 0.5%. 
Conclusion: Results of phase II experience with roxifiban suggests ac- 
ceptable safety and a promise of greater efficacy than that seen with other 
oral Ilb/ltla receptor blockers. Larger experience from phase Ill study is now 
underway. 
1158-l 2 Home-Based Training on a Whole Blood 
Prothrombin Time Monitor 
JoAnn McDonnell, Ryan Keefe, Joanne Avila, Frederick G. St. Goar. 
Cardiovascular Instifufe, Mountain View, California, USA 
Background: Effective oral anticoagulation therapy requires routine monitor- 
ing of patient prothrombin times (PT), generally performed on venous plasma 
in a clinical laboratory. The recent availability of capillary blood PT monitors 
now offers patients the convenient (and less expensive) option of self-testing 
at home. The potentially harmful consequences of faulty PT testing (incorrect 
dosage leading to thromboses or excessive bleeding), underscore the need 
for effective patient training. Our study evaluated training that took place in 
the patient’s home. The goal of this study was to determine patients’ ability to 
self-monitor using a capillary blood PT monitor (AvocetpT) after participating 
in a training session conducted by a home healthcare nurse in the patients’ 
homes. 
Methods: Twenty oral anticoagulant patients, selected by their managing 
physician, were trained in the home on the AvocetpT by a home heatth- 
care nurse (Olsten Health Services). Training consisted of demonstration, 
explanation and coaching as the patient independently performed all steps 
necessary in PT self-testing. The nurse left a video, reference guides with 
pictures, and a user’s manual in the home. Patients tested on the monitor 
twice a week for the next ten weeks. Every fourth test, the patient traveled to 
the physician’s office where both the patient and a trained healthcare provider 
(HCP) tested. Additionally, the HCP and the patient alternated performing a 
second replicate test to assess repeatability. Control testing was performed 
on each test day to ensure proper monitor performance. 
Results: ,The patient results showed strong correlation with HCP results 
(y = 1.02x - 0.07, r = 0.94, n = 91, orthogonal regression). The percentage of 
HCP/patient International Normalized Ratio (INR) results which fit a clinically 
relevant expanded and narrow agreement criteria were 96.7% and 91.2%, 
respectively. The patient’s first result showed strong correlation with the 
patient’s second result (y = 0.98x + 0.04, r = 0.95, n = 62). The average 
standard deviation for duplicate patient tests was 0.15. The HCP’s first result 
showed strong correlation with the HCP’s second result (y = 0.89x + 0.32, r 
= 0.88, n = 52). The average standard deviation for duplicate HCP tests was 
0.19. 
Conclusion: Results demonstrate that lay users can be effectively trained 
in the home by a home nurse to use a patient self-test PT device with the 
same accuracy and precision as a healthcare professional. 
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CII’ 1159 17 Trrglycerides Influence Mortality Primarily in the 
Setting of Elevated LDL: Cleveland Clinic 
Post-CABG 8 Year Follow-Up 
Dennis L. Sprecher, Gregory L. Pearce. The Cleveland Clinic Foundation, 
Cleveiand, Ohio, USA 
Background: In previous reports triglyceride (TG) values have been found 
relevant to the onset of CVD primarily when the LDUHDL ratio is greater than 
5, but often not when only HDL is included in the analyses. We are examining 
the overall impact of TG values on long-term mortality post-CABG, and to 
characterize the relevance of the LDUHDL ratio vs. the actual values of LDL 
and HDL related to the influence of TG. 
Methods: Subjects were identified with isolated CABG who had complete 
lipid profiles (performed 1987-1992, N = 6208, 1190 women) and followed 
an average of 8 years for mortality. Kaplan-Meier survival curves (all cause 
mortality) were constructed to evaluate the risk of high TG values (>I 90 
mg/dL) in various settings of low HDL (~40 mg/dL), and high LDL (2130 
mg/dL) adjusted for traditional (age, sex, BMI, diabetes, hypertension, history 
of Ml) and surgical variables (left ventricular function, extent of disease, 
internal thoracic artery conduit). 
Results: The adjusted TG effect is estimated to be 1 .I5 (Cl = 0.99-1.33) 
without consideration for HDL and LDL. When all three lipid components are 
entered into the model, none approach significance (TG HR = 1.11, Cl = 
0.94-I .30; HDL HR = 1 .Ol, Cl =0.86-i 20; LDL HI? = 0.87, Cl =0.73-l .05). 
When limiting the analyses to patients with LDL:HDL > 5, (an alternative to 
adjusting for the effects of LDL and HDL) high TG showed an adverse impact 
on survival (HR = 1.41, Cl = 1.09-1 X2). However, very similar TG related 
risk was observed in patients with LDL > 130 mg/dL alone (HR = 1.38, Cl = 
1.14-I .66). HDL did not contribute significantly to the explanation of mortality 
in either setting. These results were equivalent for a high TG cutpoint of 150 
or 200 mgidl. 
Conclusions: The LDUHDL ratio itself does not define the effect of TG 
on mortality beyond that of the specific value of LDL. In the setting of high 
LDL, high TG significantly increases the risk of mortality, regardless of the 
HDL-c level. Therefore, the increased mortality risk post-CABG based on a 
high TG vaiue is predicated on the coincident elevation of LDL. 
1 1 Z 59-I 8 / LATIN (Lipid Assessment Trial in an Italian 
Network) 
Aldo F? Maggioni. Latin Investigators; ANMCO Research Center, Florence, 
My 
The treatment of acute coronary syndromes (ACS) changed dramatically in 
the last few years. in this context lipid lowering therapy has became a rec- 
ommended treatment for all pts with elevated level of serum LDL cholesterol. 
Several reports coming from small studies suggest that lipid levels may be 
underestimated if measured in the first few days after the beginning of ACS 
symptoms. If true, this may unnecessarily delay the start of the treatment 
Therefore, we prospectively evaluate serum concentration of total choles- 
terol, LDL cholesterol, HDL cholesterol and triglycerides in 1275 pts with 
AMI (within 12 hours from symptom onset) and in 589 pts with unstable 
angina (UA) with an episode of typical pain in the preceding 12 hours and 
with concomitant ischemic ECG modifications. Blood samples were taken at 
hospital admission, the morning after the admission, at discharge and at 3 
months. Lipid variations are presented for 565 pts with AMI and 266 pts with 
UA. Pts who died, had AMI, underwent a revascularization procedure during 
the follow up or received a lipid lowering agent during the same period were 
excluded from the analysis. 
Lipid levels measurements were performed centrally by a laboratory cer- 
tified by the Centre for Disease Control, Atlanta. In this laboratory measure- 
ment variability of serum lipids was less than 1%. 
Results: 
Total Cholest. HDL Cholest. Triglycerides LDLCholest. 
IMA ANGINA IMA ANGINA IMA ANGINA IMA ANGINA 
Admission 211 206 48 49 150 158 136 129 
Day 1 197 196 48 47 143 150 123 121 
Discharge 197 199 41 46 159 155 120 121 
3 Months 212 207 50 53 172 158 132 125 
Additional data on selected and prespecified subgroups will be presented, 
in particular: (a) Pts with AMI treated vs not with thrombolysis; (b) Pts with 
AMI treated vs not with beta-blockers; (c) Diabetic vs non diabetic pts; (d) Pts 
with elevated C-reactive protein vs pts with normal values; (e) Pts with large 
versus small infarctions. The evaluation of the serum lipid profile in the first 3 
months after an acute coronary event will allow the identification of the most 
appropriate (a) cohort of pts in whom starting the lipid lowering treatment and 
(b) time to start the management of this risk factor. This strategy should allow 
an improvement of the level of application of treatment guidelines in clinical 
practice and, hopefully, of patient outcome. 
Li 1159 19 The Association of FERHDL With Gender, Age, Body Mass index, and Coronary Artery Disease 
(CAD) 
Bo Zhang, Keijiro Saku, Kazuyuki Shirai, Makiko Takao, Kikuo Arakawa. 
Fukuoka University: Fukuoka, Japan 
Background: The fractional esterification of cholesterol in the HDL fraction 
of plasma (FERHDL) is a newly established functional measure of HDL 
heterogeneity. 
Methods: We investigated the association of FERHDL with gender, age, 
BMI, and CAD in 204 patients with angiographically proven CAD (cases, F/M: 
46/158) and 94 subjects without evidence of CAD (controls, F/M: 41/53). 
Results: In control subjects, males had higher values of FERHDL (11.5 
f 3.9 vs. 9.1 * 3.5%/hr, p < 0.05) and lower ratios of HDLP-C and HDLB-C 
(HDL2-C/HDL3-C) than females, while in case patients, males were younger 
and had lower HDL-C than females. FERHDL was strongly and inversely (p 
< 0.001) related to both HDLC and HDL2-C/HDLB-C, and positively related 
to BMI (p < 0.001) in both cases and controls. The negative relation between 
FERHDL and age was strong (r = -0.36, p < 0.001) in cases but weak (r = 
-0.21, p < 0.05) in controls. In female subjects, low HDL-C (Wald x2 = 5.2, p 
.z 0.05), high FERHDL (15.7, p < O.llOi), and low HDL2-C/HDLBC (10.7, p 
< 0.01) were significantly associated with the risk of CAD after adjusting for 
age, BMI, and smoking status, while in male subjects, only low HDL-C was 
significantly associated with the risk of CAD. A stepwise logistic regression 
analysis showed that FERHDL and age were independent indicators for CAD 
in female subjects, while low HDL-C was an independent indicator for CAD 
in male subjects. In all of the subjects, males with low HDL-C had the highest 
CAD risk [odds ratio (95%CI): 6.4 (3.0-14.2)] and females with low FERHDL 
had the lowest risk of CAD (figure). 
Conclusion: Gender differences should be considered when assessing 
the risk of CAD associated with low quantity and high function of HDL. 
1159-20 Risk Factor Profile of Coronary Artery Disease in 
Patient With Low Cholesterol Level 
Y.S. Lee, H.J. Chang, S.H. Kim, Y.R. Chung, D.H. Hong, H.W. Na, 
Juliet Jacobson, S.Y. Choi, J.E. Song, Byung-il Choi. Department of 
Cardiology: Ajou University School of Medicine, Sowon, Korea 
Hypercholesterolemia is the major risk factor associated with high incidence 
of coronary artery, disease in western hemisphere and USA. To correlate 
lipid profile and coronary, artery disease in Korea, we analyzed 1310 patients 
(male 812, female 480) with cath proven CAD, age ranging from 28 to 81 (58 
h 24) for risk factor profile. 737/1310 had cholesterol level below 200 mg/dL. 
Patient were divided into two groups, ie group A with chol > 200 mg/dL and 
group B with chol x 200 mg/dL. The measurement of triglyceride (TG), LDL, 
HDL, Lp(A), ApoAl and ApoB is shown on the table. Patients in group A had 
more hypertension (49 vs 37, P < 0.001) and diabetes meilitus (24% vs 18%, 
P < 0.03), whereas group B had more male gender (76% vs 61% p < 0.001) 
and higher incidence of smoking (67% vs 57%, P c: 0.002). There was no 
difference in alcohol consumption (32% vs 288% P:NS) and family history 
(74 vs 75, P:NS). More than half patients (56%) had cholesterol level below 
age TG LDL HDL Lo(A) ApoAl ApoB 
groupA 58122 22Oi159 149&42 43f31 26-t23 109126 129*40 
group B 58 +21 143h99 102&27 39f19 22iZO 103119 90+40 
P ns <O.OOi <O.OOi <0.05 <0.05 co.05 <O.OOi 
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200 mg/dL (166 f 23 mg/dL) in group B, and 238 f 37 mg/dL in group A the influence of the HDL-PONI B-allele of homozygous carriers (phenotype 
(P < 0.05). Multiple regression analysis showed a significant correlation with BB) on the lipid profil was quantified independent of established CAD risk 
smoking age > ApoAl in group A and age > male gender > DM > smoking factors and medication as multiple linear regression coefficient (in units of 
in group B (P < 0.05). respective dependent variables) (see table). 
Thus, it appears that CAD patients with low cholesterol may have different 
risk profile and further investigation is needed to evaluate the pathogenesis 
of CAD, other than cholesterol screening. 
Conclusions: In CAD patients homozygous for the HDL-PONl B-allele 
(in our study 13%), quantitative HDL composition differs from that of phe- 
notype AA and AB individuals. Reduced HDL-PONI arylesterase of HDLe 
and HDLs may contribute to CAD prevalence, incidence, and progress in 
phenotype BB patients. 
1 1159-21 1 Improvement of Cholesterol Levels by a 
Structured and Standardized Cholesterol 
Physiology and Diet Education Program 
Johannes Schaar, Olaf Oldenburg, Peter Hunold, Stephanie Kopp, 
Daniela Brehm, Raimund Erbel. Department of Cardiology, University 
Essen, Germany 
According to the guidelines of several heart associations the aim of lipid treat- 
ment is specified concerning target levels of lipids for secondary prevention. 
A standardized teaching program for pathophysiology of lipid and diet tips 
was introduced to reach this guideline recommendations. 
Methods: We enrolled 122 Patients (60 male, 62 female, 48-73 y/o) with 
coronary heart disease (CHD) and dyslipidaemia (Chol > 160 mg/dl, LDL 
> 100 mg/dl). Patients were randomized to a teaching and a control group. 
Following coronary intervention or bypass surgery, statins were prescribed 
to all patients in a standard dosage. In the teaching group on their first visit 
59 patients were educated by a dietitian in the pathophysiology of lipids over 
4 hours. On the following day every patient received a personal consultation 
and an individual diet plan in this group. For further dietary questions every 
patient could call a hotline number in the next 6 month. 
The other 63 patients (control group) underwent a routine briefing on lipid 
lowering therapy during the daily rounds. After 6 months lipid levels were 
measured again in both groups and compared. 
Results: 
First Visit 6 Month f6M) 
Chol Control group 260 * 29 211 f 23 p < 0.008 
Teaching group 249 + 25 168f20 (Teaching vs. Control group) 
LDL Control group 136414 128f13 p < 0.005 
Teaching group 132115 102114 (Teaching vs. Control group) 
In both groups lipid lowering was achieved. The teaching group has a 
significant lower level of cholesterol and LDL as the control group. 
Conclusion: In a population whit CHD and statin-medication, a lipid 
teaching program leads to significant lower lipid levels in the teaching com- 
pared to the control group. 
[1159-22 1 Patients With Coronary Artery Disease (CAD) 
Homozygous for the B-Allele of High Density 
Lipoprotein (HDL) Paraoxonase (PONl) Exhibit 
Reduced HDL-PONl Arylesterase Activities of 
HDL Subfractions HDL2 and HDL3 
Joerg M. Chemnitius, Holger Winkel, Victor W. Armstrong, Ronald Zech. 
Georg-August University GBttingen, Germany 
Background: The HDL-PONI gene polymorphism (GPM) has been pro- 
posed to influence the risk for CAD and atherosclerosis in the general popu- 
iation. HDL-PONI GPM is based on two alleles with co-dominant inheritance, 
two alloenzymes (192-Gln-Arg-interchange), and three phenotypes AA, AB, 
and BB. In vitro, HDL-PONI of B-allele carriers confers less protection 
against lipid peroxidation to low density lipoproteins. However, only six of 12 
case-control studies have demonstrated an association ofCAD and the HDL- 
PONI B-allele. We investigated HDL-PONI GPM as a possible predictor of 
PONI activity and HDL cholesterol in CAD patients. 
Methods and Results: 151 patients (127 men, 24 women; 61 f 8 years) 
with angiographically significant CAD were HDL-PONI-phenotyped (45% 
AA, 42% AB, 13% BB) and the lipid profil including total, LDL, and HDL 
cholesterol, triglycerides, and HDL-PONI arylesterase of HDL subfractions 
HDLp and HD4 was determined. Using multiple linear regression analysis, 
I 1159 23 Cholesterol Reduction Through Weight Loss is 
Not Influenced by Dietary Protein Source 
Jason P. Gootman, Susan M. Williams, Amy G. Myrdal, Theodore F. Towse, 
Angela H. Kirkpatrick, Ryan J. Milley, Timothy N. Bilodeau, Nancy 
R. Rodriguez, Greg M. Kline, Diane P. O’Brien, James M. Rippe. The Center 
for Clinical and Lifestyle Research, ShrewsburL: Massachusetts, USA 
Background: One of the major risk factors for developing heart disease is 
hypercholesterolemia. Previous research has demonstrated that weight loss 
programs can be effective in lowering blood cholesterol levels. The purpose 
of this study was to compare the improvement of blood cholesterol levels in 
subjects on a hypocaloric diet with a primary protein source of lean red meat 
to a hypocaloric diet with a primary protein source of chicken. 
Methods: Women (n = 61) aged 28 to 59 yr who were 120-I 50% of ideal 
body weight participated in the weight loss program involving reduced caloric 
intake and a progressive walking program. Subjects were randomly assigned 
to the beef or chicken group for a 12-wk intervention period. lsocaloric diets, 
which were identical in macronutrient composition, were designed to produce 
an energy deficit of 500 kcal/day (3500 kcal/wk). By week 4, subjects in both 
groups were walking 5 d/wk at a rate resulting in an additional calorie deficit 
of 300 kcal/day (1500 kcaliwk). Body weight and blood lipid values were 
determined at baseline and post-intervention. 
Results: Change scores (means * SD) for both groups are shown below 
(a = significantly different from baseline p c 0.05). There were no significant 
between group differences. 
Beef Chicken 
Weight (Ibs) 
Total Cholesterol (mgidl) 
LDL Cholesterol (mg/dl) 
HDL Cholesterol (mg/dl) 
-12.3 * 1.3a -13.21k l.Oa 
-21.3 + 8.52a -19.2 i 4.8a 
-9.7 zk 5.2a -14.4 *4.1a 
+0.4 5 2.3 -1.8f1.4 
Conclusion: These findings support existing literature demonstrating 
favorable changes to blood lipid levels with weight loss in overweight individ- 
uals. The findings also demonstrate that improvements in cholesterol levels 
can be achieved through hypocaloric diet plan for which lean beef provides 
the majority of the protein. 
ORAL 
I 886 Vasculai Biology 
Tuesday, March 14, 2000, 2:00 p.m.-3:30 p.m. 
Anaheim Marriott, Marquis Northeast, 
2:00 p.m. 
886-l Suppression of the Renin ,Angiotensin System 
Regulates Endothelial Expression of Inflammatory 
Molecules Through Selective Inhibition of MAP 
Kinases 
Lipid parameter Mean 5 SD Influence of homozygous HDL-PONI S-allele 
Multiple linear rearession coefficient D < 
Total cholesterol (mgidl) 235 i 42 
LDL cholesterol (mg/dl) 156140 
HDL cholesterol (mgidl) 0” 46 + 11 
Q 55+16 
+11.9 n. s. 
+10.4 n. s. 
12.5 n. s. 
HDL2 arylesterase (kU/I) 2417 
HDL3 atylesterase (kU/l) 89 + 24 
Triglycerides (mgidl) 172&88 
n. s.: not significant (p > 0.05) 
-2.8 0.05 
-13.2 0.01 
-20.6 n. s. 
Bobby V. Khan, Sushant R. Navalkar, Brandon Copeland, 
Sampath Parthasarathy, R. Wayne Alexander, Emory University School of 
Medicine, Atlanta, Georgia, USA 
Activation of the renin angiotensin system (RAS) induces endothelial dys- 
function via upregulation of angiotensin II receptors. Inflammatory cytokines 
such as TNFa and interleukin 1 /YI (IL-l /I) activate the endothelial gene expres- 
sion of inflammatory molecules such as vascular cell adhesion molecule-l 
(VCAM-I) through a redox-sensitive mechanism. The signaling mechanism 
which is responsible for these effects is not well understood. Our data suggest 
that the MAP kinase pathway is involved in cytokine-induced VCAM-I gene 
expression. Using Northern blot analysis, pretreatment of human umbilical 
vein endothelial cells (HUVEC) with the angiotensin type receptor blocker 
losartan (100 nM) suppressed the mRNA expression of VCAM-1 but not 
ICAM-I induced by TNFol or IL-1,5. Using ELISA technique, losartan reduced 
the gene expression of VCAM-I and E-selectin but not ICAM-I induced by 
TNFol. Pretreatment with losartan suppressed the activity of p38 MAP kinase 
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induced by TNFo. interestingly, neither the activity of ERKI or ERK2 induced 
by TNFcl was suppressed by losartan. These results suggest that selective 
activation of the MAP kinase pathway in endothelial cells may mediate the 
expression of inflammatory molecules. Furthermore, these results indicate 
that activation of the angiotensin type I receptor induces oxidation-sensitive 
nuclear regulatory events in vascular diseases such as atherosclerosis. 
2:15 p.m. 
886-2 Modification of Growth Factor induced Expression 
of Piasminogen Activator inhibitor Type-l in Human 
Arterial Smooth Muscle Ceils by intracellular CAMP 
Thomas K. Nordt, Susanne Baurie, Karlheinz Peter, Johannes Ruef, Button 
E. Sobei, Christoph Bode. University of Freiburg, Germany; University of 
Vermdnf, Burlington, Vermont, USA 
Background: Among the growth factors implicated in atherogenesis TGF-p, 
PDGF, thrombin, and TNF-ol have recently been identified to induce the 
synthesis of plasminogen activator inhibitor type-l (PAI-1) in human arterial 
smooth muscle ceils (HASMC). However, the signal transduction involved 
has not yet been elucidated. Since cyclic mononucleotides are prominent 
regulators of gene expression their contribution to this setting was investi- 
gated. 
Methods and Results: HASMC in culture were exposed to TGF-B and 
agents modulating intracellular CAMP and cGMP levels. Agents increasing 
intracellular CAMP levels (verified by direct measurements) including the 
activators of adenylcyclase PgE, and forskolin, the CAMP analog dibutyryl- 
CAMP, and the inhibitor of phosphodiesterase IBMX decreased basal PAI- 
expression by 32, 55, 46, and 26%, and attenuated the TGF-p-induced in- 
crease by 47, 72, 73, and 65% (without attenuating total protein synthesis). 
The latter did not depend on the TGF-B concentration, the agonist (other 
growth factors), or the period of incubation used. Combined incubation with 
PgE, and IBMX led to additive inhibition of PAI- expression. Somatostatin, 
known to increase intracellular CAMP, did not affect PAI-I expression nor 
did sodium nitroprusside or 8-bromo-cGMP which to decrease intracellular 
cGMP. 
Conclusions: Expression of PAI-I in HASMC induced by growth fac- 
tors is modified by reduction of intracellular CAMP levels and is independent 
of intracellular cGMP levels. Thus, pharmacologic interventions increasing 
intracellular CAMP may be beneficial in nomalizing pathophysiologically in- 
creased expression of PAI-I 
2:30 p.m. 
886-3 Novel Model to Study Regression of Advanced 
Atherosclerotic Lesions in Apolipoprotein-E . . . 
Knockout Mice 
Ernane D. Reis, Jie Li, John T. Fallon, Mohamed Z. Siddiqui, James Rong, 
Edward A. Fisher. li/lounf Sinai School of Medicine, New York, New York, 
USA 
Background: Stabilization and/or regression of atherosclerosis are important 
therapeutic goals; however, extensive experimental evidence does not exist 
that these can be achieved for advanced lesions. The aim of this study 
was to develop and study a model to test the reversibility of such lesions. 
The approach was to normalize the plasma lipoprotein (Lp) environment of 
advanced arterial lesions in hyperlipidemic mice. 
Methods: Apolipoprotein E knockout (E-‘-) mice on a Western diet for 
38 weeks had a plasma total cholesterol (TC) of 1334 f 219 (rtSEM) mg/dL 
and large, complex atherosclerotic lesions throughout the arterial tree (AHA 
class Ill-IV). Thoracic aortas containing such plaques were transplanted 
heterotopically (replacing a segment of abdominal aorta) into either E-‘- or 
wild type (WT, normal plasma Lp profile, TC of 42 rt 5 mg/dL) syngeneic 
recipients. The aortic grafts were harvested after nine weeks, and processed 
for histology, immunohistochemistry, and morphometry. The results from the 
two transplant groups and pretransplant group were analyzed. 
Results: Compared to the lesions established before transplant (lesion 
area = 0.08 f 0.01 mms; macrophage content = 25%) lesion size tended to 
increase in E-‘- to Em grafts (area = 0.24 & 0.06 mm*; P= 0.06), whereas 
significant reduction was seen in E-‘- to WT grafts (area = 0.02 f 0.004 
mms; P = 0.02). In addition, foam ceils, as assessed by immunostaining for 
macrophages (MOMA-2), were decreased in E-‘- to WT grafts compared to 
E-‘- to E-‘- grafts, and to aortas before transplant. 
Conclusions: (1) Regression and remodeling of advanced atheroscle- 
rotic lesions can be achieved by sustained normalization of the plasma Lp 
profile; and (2) syngeneic arterial transplantation in mice is a novel model 
system to study mechanisms regulating changes in plaques. 
2:45 p.m. 
I 886 4 HMG-CoA Reductase inhibitors Affect the 
Fibrinoiytic System of Human Vascular Smooth 
Muscle Cells lnllitro 
Franz Wiesbauer, Christoph Kaun, Gerd Bodlaj, Gerald Maurer, Kurt Huber, 
Johann Wojta. Department of lnfemal Medicine II, University of Vienna; 
Austria 
Background: The antiatherothrombotic potential of HMG-CoA reductase 
inhibitors (statins) seems to be based not only on their lipid lowering prop- 
erties but also on their effects on the coagulation and fibrinolytic systems, 
on their ability to modulate endothelial cell and macrophage function as well 
as smooth muscle cell growth. Proliieration and migration of smooth muscle 
cells are key events in the development of atherosclerotic lesions. On the 
other hand studies with gene deficient mice have implicated the plasmino- 
gen/plasmin system in these processes. Therefore it was the aim of this 
study to investigate the effect of different statins on the plasminogen/plasmin 
system of human vascular smooth muscle cells (HUVSMC) in vitro. 
Methods: Human umbilical vein smooth muscle cells were isolated and 
characterized using well established procedures. Such cells were incubated 
with different doses of simvastatin, lovastatin or cerivastatin, respectively 
for 24 hours. Thereafter conditioned media were collected and tissue type 
plasminogen activator (t-PA), urokinase type PA (u-PA) and PA inhibitor-l 
(PAI-I) were determined using commercially available ELlSAs. 
Results: All three statins tested caused a dose dependent reduction in 
PAI-I antigen production by HUVSMC, whereas t-PA antigen increased dose 
dependently. Maximum effects were achieved with 0.5 KM cerivastatin (CS) 
and 2.5 WM lovastatin (LS) and simvastatin (SS), respectively and are shown 
in the table. Values are given in ng/lOs cells/24 hours. 
Chltr01 cs 0.5 /AM Control LS 2.5 WM Control SS 2.5 pM 
PAIL1 2424+ 98 957zk13.2 2362ilOi 706i184 3783i130 792h2289 
t-PA 2.4iO 6 6.1 + 1.1 1.8 5 0.1 8.2 i 0.3 1.310.1 8.5 * 1.0 
u-PA could not be detected in the conditioned media by the assay system 
used. 
Conclusion: Our results indicate that statins increase the profibrinoiytic 
potential of smooth muscle cells by increasing their production of t-PA and 
simultaneously decreasing the secretion of PAI-I. If such an effect is operative 
in viva statins might exert a beneficial effect by creating a profibrinolytic and 
antithrombotic environment in the area of the atherosclerotic lesion. 
3:00 p.m. 
886-5 Angiotensin ii Regulates Monocyte Survival 
Through the Angiotensin Subtype-2 Receptor 
Philip F. Binkley, Clay B. Marsh, Mark S. Kotur, David S. Bromet, Mark 
D. Wewers, Pascal J. Goldschmidt-Clermont. The Ohio Sfafe Universifx 
Columbus, OH, USA 
Monocytes are a primary effector cell in atherogensis mediating vascular 
smooth muscle cell injury and arterial remodeling through monocyte death 
and release of inflammatory cytokines. Angiotensin II (All) has been shown 
to participate in atherogenesis through its capacity to stimulate vascular 
smooth muscle cell growth and migration via the subtype 1 (AT-I) receptor 
and promote cell death via the subtype 2 (AT-2) receptor. However, the pos- 
sibility that some of the atherogenic effects of All might be mediated by the 
pro-apoptotic AT-2 receptor is unexplored. We therefore examined the ca- 
pacity of All to promote monocyte apoptosis acting through the AT-2 receptor. 
Purified mononuclear cell suspensions from normal subjects were isolated. 
Presence of the AT-I and AT-2 receptor was demonstrated flowcytometrically 
using polyclonal antibody to the specific receptors. Monocyte survival stud- 
ies were then performed in suspended mononuclear cells incubated with All, 
All plus macrophage colony stimulating factor (MCSF), or All plus the AT-2 
receptor blocker PD-123. In cells treated with All alone, there was a marked 
decrease in the number of AT-I receptors but a marked increase in AT-2 
receptor abundance at 18 hours. In cells with both MCSF and All, a small 
decline in survival from 95% at baseline to 85% at 18 hours was observed. 
All alone markedly decreased cell survival to 55%. However, blockade of the 
AT-2 receptor in the presence of All markedly improved this survival to 75%. 
Since expression of AT-I receptors decreased and AT-2 receptor expression 
increased over the 18 hours, our data suggest that All acting through the 
pro-apoptotic AT-2 receptor markedly diminished monocyte survival. This 
may constitute a novel mechanism by which All promotes attherogensis 
through regulation of monocyte apoptosis and release of proinflammatory 
cytokines. 
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LIEI 886 6 Microvascular Reactivity, Blood Pressure, and Survival are Improved in Septic iNOS-Deficient 
Knockout Mice 
Steven M. Hollenberg, Marque Broussarcl, Jailan Osman, 
Andrew Dumasius, Joseph E. Parrillo. Rush Medical College, Chicago, IL, 
USA 
Introduction: Persistent vasodilation characteristic of septic shock may re- 
sult from overproduction of nitric oxide, and can lead to pressor-refractory 
hypotension and death. To evaluate the significance of cytokine-inducible 
nitric oxide synthase (INOS) in the pathogenesis of sepsis, we used a clin- 
ically relevant model of sepsis and compared mortality and microvascular 
reactivity in wild-type mice and transgenic knockout mice deficient in INOS. 
Methods: Both wild-type (WT) C57Bl/6 mice and iNOS-deficient knockout 
mice were made septic by cecal ligation and puncture. Mice were treated with 
fluids (50 ml/kg SQ) and antibiotics (ceftriaxone and clindamycin IM) every 
6 hours. Microvascular vasoconstriction in response to topically suffused 
norepinephrine (NE) was measured in mouse cremasteric arterioles (1.520 
pm) using in viva videomicroscopy. 
Results: All septic mice were bacteremic with Gram-negative enteric 
organisms. Survival at 48 hours was significantly higher in treated septic 
iNOS deficient mice (55%) than in treated septic WT mice (24%), untreated 
septic iNOS-deficient mice (13%) or untreated WT (0%) mice (p < 0.01). 
Mean arterial pressure was lower in septic WT (79 & 11 mm Hg) than in 
septic iNOS-deficient mice (85 + IO mm Hg). NE-induced vasoconstriction 
was decreased in WT septic mice (EC50 2.0 f 0.42 FM) compared to WT 
and iNOS-deficient sham animals (0.16 f 0.02 and 0.14 f 0.03 wM), and 
was significantly improved in septic iNOS-deficient mice (0.35 + 0.09 pM, p 
< 0.05 by ANOVA). 
Conclusions: Microvascular catecholamine responsiveness was improved 
in iNOS-deficient septic mice, and survival was increased in a clinically rele- 
vant model of sepsis. This suggests that inducible NOS plays an important 
role in the refractory vasodilation and hypotension that can lead to mortality 
in patients with septic shock. 
ORAL 
I 887 Infection, Inflammation, and Coronary Artery 
Disease 
Tuesday, March 14, 2000, 2:00 p.m.-3:30 p.m. 
Anaheim Marriott, Marquis Northwest 
2:00 p.m. 
1 887-l 1 IgA Seropositivity to Mycoplasma fneumoniae 
Predicts the Diagnosis of Coronary Artery Disease 
Benjamin D. Horne, Joseph B. Muhlestein, John F. Carlquist, Bella Ohana, 
Mark Lipson, Nazia Kahn, Jessica Habashi, Tami L. Bair, Jeffrey 
L. Anderson. LDS Hospital and University of Utah, Salt Lake Cifl: Utah, 
USA; Savyon Diagnostics, Ashdod, Israel 
Background: Infection is increasingly viewed as a possible contributor to 
coronary artery disease (CAD). Several infectious agents have already been 
implicated in CAD, yet it is possible that others may contribute. Mycoplasma 
pneumoniae (Mpn), a common intracellular respiratory pathogen possessing 
distinctive characteristics, has not been examined for an association with 
CAD. We examined, in a retrospective case-control study, whether Mpn 
seropositivity predicts angiographically severe CAD. 
Methods: Blood samples were collected from 498 consenting patients, 
including 307 patients (cases) with documented CAD (stenosis ? 70% in 
at least one major coronary artery) and 191 consecutive patients (controls) 
with angiographically normal coronaries. Blood levels of I@pn IgG, IgA, and 
IgM antibodies were determined by ELISA and assigned as seropositive or 
seronegative according to product specifications. 
Results: Patients averaged 62 f 12 years of age and 73% were male. 
Seropositivity to Mpn was found for IgG in 57% of cases vs. 37% of controls 
(odds ratio [OR] = 2.2, p < O.OOOl), for IgA in 50% vs. 29% (OR = 2.4, p < 
O.OOOl), and for IgM in 1.6% vs. 1.0% (p = 0.59). Other predictors of CAD 
(all p < 0.001) included family history (OR = 8.4), gender (males: OR = 5.1), 
smoking history (OR = 4.7), and age (OR = l.O3/year). In multivariate logistic 
regression, Mpn IgA remained significant (OR = 2.2, p = 0.005) but Mpn 
IgG did not (OR = 1.3, p = 0.30), while the traditional risk factors retained 
significance (all p < 0.003). 
Conclusion: IgA seropositivity to Mycoplasma pneumoniae indepen- 
dently predicts CAD diagnosis. The independent predictive value of IgA 
antibodies suggests an association for Mpn with CAD, perhaps via unre- 
solved or chronic infection. Mpn deserves attention as another possible 
atherogenic infectious agent. 
2:15 p.m. 
887-2 Intramural Injection of Chlamydia Pneumoniae 
Leads to Coronary Artery lntimal Proliferation in 
Normal Pigs 
Sorin Pislaru, Marc Van Ranst, Cristina Pislaru, Zsolt Szelid, 
Gregor Theilmeier, J.M. Ossewaarde, Paul Holvoet, Erik Verbeken, 
Frans Van de Wet-f. From the University of Leuven, Leuven, Belgium 
Background: The role of Chlamydia pneumoniae (CP) in atherogenesis 
remains controversial. We evaluated whether injection of CP suspension 
into the coronary artery wall is associated with enhanced atherosclerotic 
lesion formation. 
Methods: In 6 pigs, CP (0.25 ml of 2 x IO7 IFU/ml) and vehicle (0.25 
ml) were injected into the wall of the left anterior descending (LAD) and 
circumflex (CX) coronary arteries, respectively. Intramural injections were 
given at 3 different times (0, 14, and 28 d) with a balloon catheter with 3 
strips of low-profile injector ports that penetrate the internal elastic lamina 
upon low-pressure inflation (2 atm). To minimize oversizing we matched 
the targeted arterial segments and catheter size by IVUS. The pigs were 
fed normal diet, and sacrificed at 42 d. Maximal intimal thickness (MIT), 
neointimal area, and external elastic lamina area (EELA) were measured on 
5 pm sections every 30 pm of the targeted segments (spanning 15 mm). 
The presence of CP was tested by immunostaining (RR402 antibody). All 
animals were tested for previous CP infection (complement fixation). 
Results: See table. The presence of CP antigen was detected in the 
endothelial and neointimal smooth muscle cells of infected arteries, but not 
in control vessels. There was no inflammatory infiltrate or fracture of the ex- 
ternal elastic lamina. All pigs were seronegative at baseline; seroconversion 
occurred in 3 animals. 
Table. CoronawArten/ Morphometrv 
Ai-tWV MIT imml Neointima (mm’) EELA (mm21 
LAD (CP) 15Ozt84" 220 * 132+ 3202~k365 
CX (vehicle) 63zk33 88zk69 2829zk385 
*p < 0.05 vs. placebo: +p = 0.056 vs. placebo; data are mean * SD. 
Conclusions: This is the first report of the direct contribution of CP to 
lesion development in the coronary arteries. CP induced moderate intimal 
proliferation even in the absence of a lipid-rich diet or of the presence of 
inflammatory cells. 
2:30 p.m. 
El 887 3 The Adventitia of Atherosclerotic Coronary Arteries 
Frequently Contains Chlamydia Pneumoniae 
Aryan Vink, Gerard Pasterkamp, Marieke Poppen, Arjan H. Schoneveld, 
Dominique P.V. de Kleijn, Paul J.M. Roholl’, Cornelius Borst. Experimental 
Cardiology Laboratory, University Medical Center Ufrechf; 7 National 
Institute of Public Health and the Environment, Bilfhoven, The Netherlands 
Background: A role for Chlamydia pneumoniae (Cp) in the atherosclero- 
tic process has been suggested. Thus far, most studies have focused on 
the presence of Cp in the atherosclerotic plaque. In the present study, the 
presence of Cp was studied in the different layers of atherosclerotic and 
non-atherosclerotic arteries. 
Methods: From 24 corpses (age 81.9 f 9.9 years), the coronary arteries 
(LAD, LCX and RCA) and right and.left brachial arteries were dissected. 
Sections were stained using a monoclonal antibody (RR402) against Cp 
specific membrane protein. A vessel layer (intima/plaque, media, adventitia) 
was considered positive for Cpwhen more than one cell was stained and this 
staining was cell associated. Adjacent sections were stained forthe presence 
of macrophages (CD68). Percent cross sectional stenosis was calculated as 
the percentage of the internal elastic lamina area occupied by the plaque. 
Results: 
artery % cross sectional 
stenosis 
Cp membrane 
Drotein olaoue 
Cp membrane 
orotein adventitia 
LAD, LCX, RCA 40.8 zt 19.0* 24/72 (33%) * 
brachial 12.4 zk 11.9 5/48 (10%) 
’ = p < 0.01 versus brachial artery, t = p < 0.01 versus plaque 
50/72 (69%)*t 
8148 (17%) 
In both plaque and adventitia of coronary arteries, cross sections with 
cross sectional stenosis of ~25% contained less frequently Cp membrane 
protein positive cells compared to cross sections with cross sectional stenosis 
of >50% (l/15 versus 14/19 and 7/15 versus 19/19 arteries for plaque and 
adventitia, respectively (p < 0.01)). Cp membrane protein positive cells ware 
frequently found in regions that contained CD68 positive cells. 
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Conclusions: 1) Not only in the plaque, but also in the adventitia Cp 
membrane protein was observed and associated with plaque mass. 2) Ad- 
ventitial Cp membrane protein was more often observed in arteries that are 
prone to develop clinically relevant atherosclerotic disease. 
3:15 p.m. 
887-6 Cigarette Smoking Increases Tissue-Factor 
Expression in Human and Murine Atheroclerotic 
Plaques 
2:45 p.m. Shlomi Matetzky, Shigemasa Tani, Paul Dimayuga, Simon Kangavari, 
I 887 4 
Jenny Zhu, Helen Xu, Juliana Yano, Kuang-Yuh Chyu, Michael Fishbein, 
Is C-Reactive Protein a Marker for First and Sanjay Kaul, Prediman K. Shah, Bojan Cercek. Cedars-Sinai Medical 
Recurrent Acute Coronary Events in Very Different Center, Los-Angeles, California, USA 
Subsets of Stable lschemic Heart Disease? 
Peter b’ogaty, Paul Poirier, Lute Boyer, Serge Simard, Fernand Bertrand, 
Gilles R. Dagenais. Quebec Heart Institute/Lava/ Hospital Quebec City 
Canada 
Smoking is associated with increased risk of atherothrombosis but the mech- 
anisms are not fully understood. In this study we examined the effect of 
smoking on tissue-factor (TF) expression in plaques since TF is critical for 
thrombosis followina olaaue ruDture. 
Background: We previously showed elevated C-reactive protein (CRP) in 
stable subjects with prior multiple acute coronary events (MACE; n = 50) 
compared io subjects with longstanding (13 years) stable angina (SA; n = 58) 
who had never been unstable. The 2 groups had similar extent of coronary 
atherosclerosis and clinical vascular disease. Would CRP identify acute 
coronary events on follow-up in these distinct coronary disease subsets? 
Methods and Results: We followed these 2 groups over 3.4 f 0.7 (mean 
f SD) years. Myocardial infarction (Ml) and unstable angina (UA) occurred 
in 30% MACE and 8.6% SA subiects lo = 0.006). Time to first occurrence 
was 1.6 f 1 .I years. CRP (median; 25%-75% q&tiles) was 5.0 (3.0-10.5) 
mg/L in those with UAiMl and 1.9 (1.2-4.2) mg/L in those without follow-up 
UA/MI (p = 0.0001). In MACE subjects, CRP was 6.1 (2.6-10.9) mg/L in 
those with and 3.3 (1.8-5.4) mg/L in those without UA/MI (p = 0.03). In 
SA subjects, CRP was 4.3 (3.4r4.7) mgfL in those with and 1.5 (1.0-2.4) 
mg/L in those without UA/MI (p = 0.04). Current smoking, LDL cholesterol 
and serum fibrinogen were associated with occurrence of UA/MI (p = 0.002, 
0.03, and 0.05, respectively). After controlling for these and other possible 
confounders, CRP remained significantly raised in those who had UA/MI. 
Methods: TF ext;ession was studied in: (1) carotid endarterectomy speci- 
mensfrom IOsmokersand IOsexandagematchednon-smokers byimmuno- 
histochemistry. (2) aortic plaques of 33 Apo E -/- mice. Twenty-three mice 
were exposed to smoke, with (n = IO) and without (n = 13) aspirin treatment 
(SC. ASA, 50 mgikglday). Ten mice were exposed to filtrated air (non-smok- 
ers). TF, VCAM-I expression, and macrophage content were assessed by 
immunohistochemistry and expressed as % stained plaque area. 
Results: Smoking was associated with increased TFexpression in human 
carotid plaques (8.9 f 4.2 vs. 3.0 & 2.8% plaque area, p = 0.03). 
In the Apo E -I- model: NSlTl S”l 
TF (% plaque area) 1.9 & 1.2” 7.9 i 2.4 
VCAM-I (% plaque area) 2.8 f 1.9# 9.7 i 5.5 
Macrophage (% plaque area) 1.6 zt 0.8" 12.5 + 4.5 
NSm-non smokers, Sm-smokers. *p < 0.01, #p < 0.05 vs smokers. 
SmiASA 
1.1 zt 1.6* 
2.5 f 1.5* 
3.4 f 3.2' 
Conclusion: Smoking is associated with increased TF expression in 
atherosclerotic plaques. The increased TF expression is likely mediated by 
macrophage recruitment and attenuated by high dose ASA. Conclusion: In stable subjects at the extremes of the clinical spectrum 
of ischemic heart disease, those with MACE and those with SA, CRP was 
a oroanostic marker of acute coronarv events on medium-term follow-uo. 
subg&ting that chronic subclinical inflammatory activity is associated wi;h 
vulnerability to coronary instability. 
MODERATED POSTER SESSION 
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I. 887 5 Inflammatory and Immune Response Markers in 
Tuesday, March 14, 2000, 3:00 p.m.-%00 p.m. 
Patients With Stable Angina, Unstable Angina and Anaheim Convention Center, Hall A 
Controls 3:00 km. 
Rahime G6k, Bsrbel Klein, Pattrick Zuther, Ralph Winkler. Tina Winterbauer, 
Michael Kempf, Bernhard 0. Boehm’, Jochen Senges, Bernhard 
R. Winkelmann. ’ Herzzentrum Ludwigshafen, UniversifZtsklinik U/m, 
Germany 
Background: Inflammatory markers have been shown to be elevated in 
acute coronary syndromes. The role of cytokines remains to be clarified. 
Methods: LURIC udwigshafen Risk and Cardiovascular Health Study) 
is a study to investigate risk factors in patients with angiographically docu- 
mented coronary artery disease (CAD > 20% stenosis). C-reactive protein, 
fibrinogen, ferritin, leukocytes, lymphocytes, interleukin 4 (IL 4), IL 12 were 
measured in 1821 patients without CAD, stable angina pectoris (SA) and 
unstable angina pectoris (UA). Exclusion criteria were acute myocardial in- 
farction, malignancy, kidney or any acute or chronic infectious disease. 
Results: 
value are median or mea” i SD 
no CAD 
n=401 
SA UA UA P 
Trop T neg Trop T pos 
“Z956 n=297 "=I67 
Age 
Sex(%female) 
CRP (mg/l) 
Fibrinogen (mg/dl) 
Fe&in (“g/ml) 
Leukocytes (/“I) 
Lymphocytes (/nl) 
IL 4 (“g/l)” 
58hl2 6419 64zk9 62+11 <O.OOl 
49 25 28 23 <O.OOi 
0.3 0.4 0.5 1.6 <0.001* 
346i79 374i a7 393i103 514s 131 <0.001* 
144 147 148 202 <0.001* 
6.6 5 1.9 6.9 i 2.0 7.1 * 2.0 7.6 + 1.8 <0.001* 
1.6i 0.65 1.8 ho.66 1.8 5 0.65 1.8 zk 0.59 0.4' 
0.3 0.2 0.2 0.2 0.091 
IL 12 (ngn)" 70 78 a2 50 0.i* 
# measurement only in a subset (n = 127/393/l 00/54), * adjusted for sex and age 
Conclusion: 1) a stepwise rise in the acute phase reactants C-reactive 
protein, fibrinogen, ferritin, leukocytes was found between the groups 2) 
no difference was seen in lymphocyte count and in the Thl (lL12)1Th2 
(IL4) balance, indicating no significant change in the lymphocytes and in 
T-helper-cell immune response. 
I 1009 167 Air Force/Texas Coronary Atherosclerosis Prevention Studv IAFCAPS/TexCAPS1- Benefits 
of Lovastatin TrGaiment in Risk Subgioups 
Defined by Framingham Risk Equations 
Antonio M. Gotto Jr., Polly A. Beere, Shannon E. Allen, John R. Cook, John 
R. Downs, Michael Clearfield, Stephen Weis, Alexandra Langendotfer. 
Wilford Ha// Medical Center, San Antonio, TX; University of North Texas 
Health Science Center, Fort Worth, TX, USA 
Background: AFCAPSmexCAPS was a randomized, double-blind, placebo 
(Pbo)-controlled primary prevention trial of 6605 men (85%) and women 
without evidence of atherosclerotic disease. Because total cholesterol c 240 
mg/dL was an inclusion criteria, 83% of the cohort would not be recommended 
for drug intervention by current National Cholesterol Education Program 
guidelines. Lovastatin (Lova) 20-40 mg daily reduced the risk of acute major 
coronary events (AMCE; myocardial infarction, or unstable angina or sudden 
cardiac death) by 37% (p 5 0.001) and first coronary revascularizations 
(REVASC) by 33% (p = 0.001). 
Methods: Treatment benefit (reduced AMCEs or REVASCs), categorized 
by deciles of 5-yr Framingham Risk (FR) estimates, was explored in a 
post hoc analysis. Relative risk for each FR decile subgroup was estimated 
using the Cox Proportional Hazards model; significance of risk reduction was 
assessed using the log-rank test. 
Results: The cohort had above average risk for an event. Men in the 
6-10th FR deciles had over 90% of the total AMCEs or REVASCs. The 
majority of women fell within the 9-10th FR deciles, but the number of events 
(9 Pbo/5 Lova) were too few to detect a significant treatment benefit. 
FR decile by gender 
N -Pbo/Lova 
Estimated 5-yr FR 
Observed5-yrevent 
crude rate Pbo/Lova 
Relative Risk 
Between treatment 
“rnlln n-VRIIIPS 
l-5 Me” 6-lOMen l-8 Women 9-10W0men 
424/390 237912415 91/103 4071396 
<4.5% 24.5% 55.4% >5.4% 
1.4%12.0% 7.3%/5.2% 5.5%/2.9% 2.2%/l .3% 
1.471 0.709 0.529 0.574 
” 47 <” n1 0.38 0.32 
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Conclusion: Men classified above the 5’h FR decile significantly benefit 
from lipid modifying treatment. These results provide a rationale for extending 
current guidelines for drug intervention. 
3:12 p.m. 
I 1009 168 Statin Therapy Reduces Restenosis After Percutaneous Transluminal Angioplasty by 
inducing Vascular Enlargement: 
An Intravascular Ultrasound Study 
Tjebbe Hagenaars, Elma J. Gussenhoven, Steven E. Kranendonk, Lukas 
C. van Dijk, J. Wouter Jukema. Erasmus University Medical Cenfer, 
Rotterdam; Leiden University Medical Centec Leiden, The Netherlands 
Background: It has been shown that statin therapy prevents lumen area 
reduction after percutaneous transluminal angioplasty (PTA) in both animal 
and clinical studies. This intravascular ultrasound (IVUS) study evaluated 
the basic mechanism of statin therapy on the vascular response after PTA in 
human peripheral arteries. 
Methods: Patients (n = 18) with obstructive disease of the femoropopliteal 
artery underwent standard PTA. Angiographic and IVUS records following the 
intervention and at 1 -year follow-up were acquired. A comparison was made 
between patients with and without statin therapy in clinical and angiographic 
restenosis and in lumen, vessel and plaque area change seen with IVUS at 
l-year follow-up. 
Results: At follow-up no clinical or angiographic restenosis was evi- 
denced in patients with statin therapy (n = 7); in patients without statin 
therapy (n = 11) there was evidence for clinical restenosis (n = 4) and/or 
angiographic restenosis (n = 8). IVUS revealed a significant difference in 
lumen area change between patients with and without statin therapy (-5% 
and -25%, respectively): this difference was due to a significant difference in 
vessel area change (4% and -2%, respectively). In both groups of patients 
a similar increase in plaque area (15%) was encountered. 
Conclugion: Plaque growth is a universal response following PTA re- 
gardless of the use of statin therapy; statin therapy has a positive effect on 
vascular remodeling, thereby reducing the occurrence of restenosis. 
3:24 p.m. 
LIEI 1009 169 Comparing Treatment Success With Statins: 
Results From the Atorvastatin Comparative 
Cholesterol Efficacy and Safety Study (ACCESS) 
Daniel Edmundowicz, Thomas C. Andrews, Charles L. Shear. For fhe 
ACCESS Investigators; University of Pittsburgh Medical Center, Pittsburgh, 
PA: UT Southwestern Medical Center, Da//as, TX; Pfizer Central Research, 
Groton, CT; USA 
Background: Studies suggest that the majority of patients is not treated 
to the LDL-C goals recommended by the National Cholesterol Education 
Program (NCEP). The ACCESS study was designed to evaluate the efficacy 
and safety of atorvastatin versus other statins and to compare their ability to 
treat patients to NCEP goals. 
Methods: 3,916 patients at 154 US sites who met NCEP criteria for drug 
treatment were randomized to either atorvastatin (IO-80 mg), simvastatin 
(IO-40 mg), pravastatin (IO-40 mg), fluvastatin (20-80 mg) or lovastatin 
(20-80 mg). Patients were randomized in a 4 (atorva, n = 1958) to 1 (simva, 
n = 482; prava, n = 481; fluva, n = 497; lova, n = 498) ratio and were treated 
at initial doses for 6 weeks. Thereafter, patients were titrated if they did not 
achieve NCEP LDL-C goals and were followed to 54 weeks. Primary efficacy 
parameters were % change from baseline in LDL-C at week 6 and the % of 
patients attaining NCEP targets at initial dose. 
Results: The groups were well balanced at baseline. After 6 weeks, 
reductions from baseline in LDL-C were significantly greater with atorvastatin 
IO mg (-36.1%) compared with other statins at their initial doses (simva, 
-29.5%; prava, -19.6%; fluva, -18.8%; lova, -26.7%: all p < 0.0001). At 
the same time point, reductions in TG and TC were also significantly greater 
with atorvastatin vs other statins (p < 0.0001) and increases in HDL-C seen 
with atorvastatin were similar to those seen with simvastatin and lovastatin, 
but significantly greater than those recorded for pravastatin and fluvastatin 
(p < 0.01). At week 6, the proportion of patients reaching NCEP goals was 
significantly greater with atorvastatin 10 mg than with simvastatin 10 mg, 
pravastatin 10 mg, fluvastatin 20 mg and lovastatin 20 mg (all p < 0.0001). 
These differences were maintained at week 54 (p < 0.0001, atorvastatin vs 
other statins). All statins were well tolerated. Persistent ALT/AST elevations 
> 3 x ULN were infrequent in all treatment groups (iO.51%). Drug-related 
adverse events resulted in withdrawal of 4.2% of atotvastatin patients and 
2.9-7.8% of patients in other groups. 
Conclusion: A significantly greater proportion of atONaStatin-treated pa- 
tients achieved NCEP goals compared with patients treated with the other 
statins tested. These data further support the excellent efficacy of atorvas- 
tatin in treating patients to LDL-C targets at starting dose and over the full 
dose range. 
3:36 p.m. 
I 1009 170 Impact of the Results of the Landmark 45 Lipid Lowering Trial on Prescribing Habits for an 
Elderly Population 
Cynthia A. Jackevicius, Jack V. Tu, Lawrence Leiter, Geoff M. Anderson. 
Institute for Clinical Evaluative Sciences, Toronto, Ontario; University of 
Toronto, Toronto, Ontario, Canada 
Background: This study compared the use of lipid lowering agents in 
42,628 elderly (>65 y) patients post myocardial infarction (Ml), before and 
after the publication of the first landmark statin trial, the Scandinavian 
Simvastatin Survival Study (4s) using the Ontario Myocardial Infarction 
Database. 
Methods: The study used a quasi-experimental design. Multivariate re- 
gression models were created to estimate changes in the rate of statin use 
over time in monthly cohorts of elderly post-MI patients in Ontario from 
April 1992 to March 1997. Changes in the rate of statin use over time were 
estimated using patient (age, sex and comorbidities) and prescriber charac- 
teristics. 
Results: We found a 3.6-fold significant increase in the monthly rate of 
statin use post-4S as compared to pre-4s (p = 0.0001) and specifically the 
rate of increase in simvastatin and pravastatin was higher post-4S (p = 0.0001 
for each). Before 4S, the rate of increase in statin use in younger patients 
(65-74 years) was 2.7 times higher than in older patients (~75 years) (p = 
0.02) whi!e after 4S, the rate of increase in statin use was only 1.8-fold higher 
in the younger group (p = 0.0004). Post-4S there was a 1.6-fold higher rate 
of increase in statin use in male as compared to female patients (p = 0.006). 
After 4S, specialists (cardiologists and internists) had a 2-fold higher rate of 
increased use of the statins than generalists (p = 0.0001). 
Conclusions: Prescription rates of statins remain lower than might be 
optimal in a post Ml population. Slower rates of uptake in statin use were 
shown in older patients, females and patients admitted by non-specialists 
post-4s. Assuming the current rates of increase in use of statins, it would take 
until September 2000 for specialists and November 2008 for nonspecialists 
to prescribe statins to 60% of a post-Ml population, a potentially desirable 
target rate for statin use. 
3:48 p.m. 
1 1009-l 71 1 Is Use of a Statin Agent at the Time of 
Presentation for Acute Myocardial Infarction 
Associated With a Favorable Outcome? 
Kevin A. Bybee, R. Scott Wright, Brent A. Williams, Joseph P. Grill, Stephen 
L. Kopecky. Mayo Clinic and Foundation, Rochester, MN, USA 
Background: Treatment with a statin agent (HMG-CoA reductase inhibitor) 
is effective as primary and secondary prevention for coronary artery disease 
(CAD). There is little available data to determine if treatment with a statin 
agent reduces mortality during an acute myocardial infarction (Ml). 
Methods: Between 1993 and 1998, 728 patients from Olmsted County, 
Minnesota presented to the Mayo Clinic Coronary Care Unit (CCU) with 
the primary diagnosis of acute myocardial infarction. Using the Mayo Clinic 
CCU database, 66 consecutive patients (Statin Group) were retrospectively 
identified as being on a statin drug at the time of the index Ml (n = 44) or 
having been started on a statin drug within the first 24 hours after admission 
(n = 22). They were matched (3:i matching, n = 198) for age, gender, and 
history of CAD to a group who had not received a statin drug before or within 
24 hours after admission. 
Results: The median age was comparable between the statin group (64.8 
years) and the control group (65.9 years), p = ns. The prevalence of prior 
MI, diabetes mellitus, tobacco use, rate of ST elevation Ml and utilization of 
thrombolysis/PTCA did not differ between groups. In-hospital mortality was 
significantly lower in the statin group (1.5%) compared to the control group 
(8.6%), p = 0.05. The rate of ischemic complications was non-significantly 
reduced in the statin group (16.7% vs 26.3%, p = 0.11) as was the rate 
of electrical and/or mechanical complications (10.6% vs 18.7%, p = 0.13). 
Median peak creatine kinase (CK) concentration was significantly lower in 
the statin group (416 U/L) compared to the control group (699 U/L), p = 0.02. 
The use of ACE inhibitors and nitrates were significantly higher in the statin 
group. We observed less utilization of lidocaine for ventricular arrhythmia in 
the statin group (6.1%) compared to controls (18.2%), p = 0.017. The Odds 
Ratio for in-hospital mortality suggested a benefit for statin treatment even 
after adjustment for Killip Class and diabetes: OR 0.17 (0.02-1.7), p = 0.13. 
Conclusion: Our data suggest that use of a statin agent on admission 
and/or during the initial 24 hours of an acute Ml is associated with lower 
in-hospital mortality, lower peak CK concentrations, and a reduced need for 
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lidocaine treatment of ventricular arrhythmias. These data suggest a potential 
role for early statin treatment in acute Ml. 
4:00 p.m. 
/ 1009 172 Effect of Simvastatin Treatment on Postprandial Hypertriglyceridemia in Type 2 Diabetes Mellitus 
Patients With Combined Hyperlipidemia 
Ying-Tsung Chef?, Wayne Huey-Herng Sheu, Wen-Jane Lee. T&bung 
Veterans General Hospital, Taichung, Taiwan, ROC 
Background: Recent studies have shown that statins are effectively in re- 
ducing fasting LDL cholesterol (C) and triglyceride levels. However, it is 
remain unknown if statins treatment also lower postprandial daily triglyceride 
concentrations which was shown to promote atherogenesis in type 2 diabetic 
subjects. 
Methods: Forty-one type 2 diabetic subjects with combined hyperlipi- 
demia and stable glycemic control were randomized assigned to take slm- 
vastatin 20 mg (add to 40 mg if their LDL-C did not reach goal) or placebo 
(2:l) once daily for 8 weeks. Meals tolerant test with isocaloric mixed meals 
(carbohydrate 52%, fat 33% and protein 15% of daily calories intake) were 
carried out from 8 AM to 4 PM before and after administration of medications. 
Results: Simvastatin treatment reduced fasting total C from 237 It 5 
to 178 i 6 mg/dl (-25%), LDL-C from 150 i 6 to 87 f 5 mg/dl (-40%) 
while raised HDL-C from 36 f 2 to 40 f 2 mgidl (+ll%) (all p < 0.001). 
Fasting and daily ambient triglyceride concentrations decreased significantly 
to simvastatin administration (p < 0.001) but not to placebo (p = NS). 
Conclusion: Simvastatin treatment not only decreased total C, LDL-C, 
increased HDL-C but also decreased fasting as well as postprandial daily 
triglyceride concentrations while had no effect on glycemic control in type 2 
diabetic subjects with combined hyperlipidemia. 
4:12 txm. 
1009-l 73 Simvastatin Increases HDL-C and 
Aoolipoarotein A-l Levels Sianificantlv More 
Ti-ian’Atbrvastatin 
I 
John P. Kastelein, Evan A. Stein, Michael A. Davidson, John R. Grouse, 
Leiv Ose, Minzhi Liu, Michael R. Melino, Laura O’Grady, Michele Mercuri, 
Yale B. Mitchel. For the Simvastatin Atorvastatin HDL Study Group; 
Academic Medical Center, Amsterdam, The Netherlands; Merck Research 
Laboratories, Rahway, New Jersey USA 
Background: High density lipoprotein cholesterol (HDL-C) and apolipopro- 
tein (apo) A-l levels are inversely related to the risk of coronary heart disease. 
Recently, the VA-HITstudy suggested that modest increases in HDL-C could 
have significant benefits on cardiovascular events. Statins, in addition to 
lowering low density lipoprotein cholesterol (LDL-C) and triglycerides (TG), 
increase HDL-C levels. However, recent data suggest a differential effect of 
simvastatin (S) and atorvastatin (A) on HDL-C, in that at higher doses of both 
drugs S raises HDL-C more than A. 
Methods: This multi-center, double-blind, dose titration study was de- 
signed to evaluate the effects of S and A on HDL-C and apo A-l levels. 
Following a 4 week diet run-in period, 827 patients (47% female) with LDL-C 
> 160 mg/dL and TG < 350 mg/dL were randomized to S or A for 36 weeks. 
Patients on S received S 40 for 6 weeks followed by 80 mgiday for 6 weeks, 
and 80 mgiday for the final 24 weeks. Patients on A received A 20 for 6 
weeks followed by 40 mgiday for 6 weeks, and 80 mg/day for the final 24 
weeks. 
Results: A pre-defined interim analysis using data from the first 12 weeks 
was performed to determine the % change in HDL-C and apo A-l across both 
6 week periods combined (primary endpoint), S increased HDL-C and apo 
A-l significantly more than A (see Table). S and A lowered LDL-C by 45.4 
and 48.8% (p < 0.001) and TG by 23.0 and 27.6% (p < O.OOi), respectively. 
Parameter S A 
(% change) (% change) 
HDL*C 9.0* 6.7 
ape A-l 5.5” 2.6 
“p x 0.001 between treatment groups 
Summary: S increased HDL-C and apo A-l significantly more than A, 
although the mechanism for this differential effect remains unknown. These 
results are confirmatory of another large randomized comparative trial where 
similar HDL-C and apo A-l differences were observed. 
4:24 p.m. 
/ 1009 174 Effects of Atorvastatin on Fasting and 
Postprandial Plasma Lipoproteins in 
Postinfarction Patients With Combined 
Hyperlipidemia 
Susanna Boquist, Fredrik Karpe, Karin Dane&Toverud, Anders Hamsten. 
King Gustaf V Research Institute, Karolinska Institutet, Stockholm, Sweden 
Background: Postprandial lipids and lipoproteins are related to coronary 
and carotid artery disease. However, the effects of lipid-lowering compounds 
on alimentary lipemia has not been defined in detail. 
Methods: We examined the effects of atorvastatin (40 mg o.d. or match- 
ing placebo) on subfractions of triglyceride-rich lipoproteins in the fasting 
state and up to 6 hours after a mixed meal-type of oral fat tolerance test in 
16 middle-aged male postinfarction patients with combined hyperlipidemia. 
A randomized, double-blind cross-over design was used with two treatment 
periods of 8 weeks each. Very low density lipoproteins (VLDL) and chylomi- 
cron remnants were quantified as apolipoprotein (apo) B-100 and apo B-48 
concentrations in Svedberg flotation rate (Sf) 60-400 and 20-60 lipoprotein 
fractions using sodium dodecyl sulphate polyacrylamide gel electrophoresis. 
Results: Fasting plasma low density lipoprotein (LDL) cholesterol and 
plasma triglyceride concentrations were significantly reduced on atorvastatin 
treatment compared with placebo and baseline (median change -44.1% 
and -25.5%, respectively, compared with baseline) whereas high density 
lipoprotein (HDL) cholesterol increased (+19.4%). The plasma concentra- 
tions of large (Sf 60-400) and small (Sf 20-60) VLDL panicles and large 
and small chylomicron remnants were significantly reduced by atorvastatin 
(median change -48.1%, -45.6%, -46.3% and -26.6% for averaged fast- 
ing and postprandial plasma levels of Sf 60-400 apo B-100, Sf 20-60 apo 
B-100, Sf 60-400 apo B-48 and Sf 20-60 B-48, respectively, compared with 
baseline). 
Conclusions: Atorvastatin has profound effects on the postprandial 
plasma concentrations of all subfractions of triglyceride-rich lipoproteins. 
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/ 1178-50 / The Terminal Complement Complex C5b-9 
Potently Stimulates Cytokine Production in 
Human Smooth Muscle Cells: Involvement of 
Nuclear Factor-& Activation 
Christiane Viedt, Brigitta Week, JBrg Kreuzer, Gertrud M. Hsnsch. 
Medizinische Klinik 111, UniversEit Heidelberg; lnstitut Wr Immunologic, 
Universitst Heidelberg, Germany 
Background: Recent studies provide evidence that activation of the com- 
plement system contributes to the pathogenesis of atherosclerosis. Since 
arteriosclerosis is a chronic inflammation of the vessel wall, the complement 
might exert its proatherogenic effect through inflammatory activation of vas- 
cular cells. Our study was undertaken to determine whether C5b-9 could 
induce the proinflammatory cytokine IL-6 in smooth muscle cells. 
Methods and Results: Stimulation of human vascular smooth muscle 
cells (VSMC) with C5b-9 resulted in a rapid and transient (2-4 h) in- 
crease in the level of IL-6 transcript, determined by Northern analysis, 
which was followed by enhanced production of IL-6. The effect was se- 
lective for the C5b-9 complex, whereas complement components without 
C7 had no effect. Pretreatment of cells with pertussis toxin or the nu- 
clear factor-c6 (NF-KB) inhibitor pyrrolidine dithiocarbamate (PDTC) inhib- 
ited CSb-S-induced IL-6-mRNA expression and IL-6 release, suggesting the 
involvement of G protein and NF-KB. Electrophoretic mobility shift assay 
revealed that formation of CSb-9 induced binding activity for the NF-KB site. 
lmmunocytochemical analyses confirmed the nuclear translocation of the 
NF-xB subunit ~65 in VSMC after CSb-9 treatment. To further prove involve- 
ment of NF-KB in C5b-9 mediated signal transduction, we attempted to block 
the transcription factor with decoy oligonucleotides (ODN) corresponding to 
the NF-KB consensus sequence. When cells were preincubated with ODN 
a complete inhibition of C5b-S-induced NF-KB binding activity and nuclear 
translocation was observed. Pretreatment with ODN, but not control ODN, 
inhibited the effect of C5b-9 induced IL-6 gene expression and secretion. 
Conclusion: These results suggest that the terminal complement com- 
plex C5b-9 induces IL-6 gene expression and release in human VSMC 
largely via the activation of NF-KB. These data may explain how chronic in- 
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flammation in concert with complement activation and deposition of activated 
complement factors contributes to atherogenesis. 
)_I 1178 51 Lack of Thrombocytopenic Response After Low-Molecular-Weight Heparins Usage is Due to 
the Generation of Non-Functional 
Anti-Heparin-Platelet Factor 4 Antibodies 
Satfraz Ahmad, Jeanine M. Walenga, Walter P. Jeske, Debra 
A. Hoppensteadt, Erum Khan, Giuseppe Cellar, Harry L. Messmore. Loyola 
University Chicago, Maywood, Illinois, USA; ’ University of Padua Medical 
School, Padova, Italy 
Backoround: Heoarin-induced thrombocvtooenia (HIT) remains a catas- 
trophic syndrome associated with the generation of anti-heparin-platelet fac- 
tor 4 (AHPF4) antibodies (Abs). While the i.v. and S.C. use of low molecular 
weight heparin (LMWH) is associated with the generation of AHPF4 Abs 
at a similar frequency to that observed with unfractionated heparin (UFH), 
the prevalence of clinical thrombocytopenia is markedly less than with UFH 
(6.2% “ss. 0.8%). 
Methods and Results: A review of several clinical trials in which LMWHs 
were used to treat 970 patients with deep vein thrombosis and acute coronary 
syndromes revealed that 16.9% of these patients exhibited a positive AHPF4 
Ab titer as measured by ELISA (Diagnostica Stago, Genneveilles, France). 
Analysis of 100 patients treated with UFH for identical indications provided 
similar data (18.2% +ve AHPF4 Ab titer). Only 3 patients in the LMWH- 
treated group developed HIT in contrast to 12 patients in the UFH-treated 
group. The “C-serotonin release assay (SRA) in these patients revealed 
only 7 patients in the LMWH-treated group and 27 in the UFH-treated group 
to be +ve. 1.8% of 1 ,I 00 normal volunteers had +ve sera by ELISA, and 
none were +ve by SRA. To further investigate the functional heterogeneity of 
the AHPF4Abs, immunoglobulins (Ig) were isolated by an ammonium sulfate 
precipitation/affinity chromatography methods from the sera of UFH-treated 
(n = 27) and LMWH-treated (n = 37) patients. In addition, Ig’s were isolated 
from a pool of sera obtained from UFH-treated (all ELISA +ve), from LMWH- 
treated (all ELISA +ve), from ELISA/SRA +ve, and from normal human sera 
(-ve control). The titers of AHPF4 Abs were adjusted to comparable levels 
in all HPIA positive groups. Functional analyses of these individual lg prepa- 
rations included platelet aggregation, SRA, and flow cytometric studies, In 
comparison to Ig’s from UFH-treated patients, LMWH-treated patients’ Ig 
showed a markedly decreased response in all the HIT assays. Even the 
lg prepared from the SRAIELISA titer’+ve in LMWH-treated patients were 
relatively weaker than the comparable UFH-treated group. Dilution studies 
revealed that the ability of Ig from UFH-treated patients to activate platelets 
was much higher than Ig isolated from the LMWH-treated group. 
Conclusion: These studies suggest that LMWHs capable of generating 
AHPF4 Abs (measurable by ELISA-based methodology), exhibit low patho- 
geneicity in viva. The presence of an ELISA-detectable AHPF4 Ab titer does 
not predict a clinical HIT syndrome. 
1 1178-52 1 Singlet Oxygen Inhibits and Reverses 
Agonist-Induced Formation of Platelet 
Aggregates and P-Selectin Expression 
Thomas W. Stief, Walter P. Jeske, Omer Iqbal, Sarfraz Ahmad, 
Lara Bakhos, Jeanine M. Walenga, Jawed Fareed. Loyola University 
Chicago, Maywood, Illinois, USA; institute of Clinical Chemistry: 
Philipps-University: Marburg, Germany 
Background: Hemostasis is a coordinated interplay of plasma with blood 
cells, Major mediators of activated polymorphonuclear leukocytes (PMN) are 
the oxidants HOCI and chloramine which are a source for the nonradical 
photon-emitting oxidant singlet oxygen. Recently, we demonstrated that sin- 
glet oxygen induces selective thrombolysis in vivo in rabbits. We became 
interested in a possible platelet modulating effect of singlet oxygen. 
Methods: As a stable singlet oxygen source we chose chloramine T’ 
(CT) that mimics the natural chloramine N-chloro-taurine. Freshly drawn 
native whole blood from donors (n = 5) was incubated at O-3 mM CTfor 1 mm 
at 37°C. Then saline, 10 pM ADP, 5 kg/ml collagen, or 6.25 FM TRAP were 
added and the mixtures were allowed to incubate for 3 mm at 37°C. Control 
experiments consisted in oxidation of blood previously supplemented with 30 
mM of the oxy-radical scavenger mannitol. Aliquots of activated blood were 
fixed in 1% para-formaldehyde. After removal of the fixative, platelets were 
labeled with anti-CDGI-FITC and anti-CD62P-PE antibodies and analyzed 
by flow cytometry. 
Results: An oxidant concentration dependent decrease in the formation 
of platelet aggregates appeared (at 3 mM CT to 8, 12, and 13% of the 100% 
saline control level for ADP, collagen, and TRAP, respectively; the 50% ef- 
fective dose (EDsc) is 1.0-I .5 mM chloramine). There was also a decrease 
in the expression of P-selectin (at 3 mM chloramine to 39, 23, and 20% of 
the 100% saline control level for ADP, collagen, and TRAP, respectively). In 
TRAP and ADP stimulated platelets an increase in platelet fragments ap- 
peared (at 3 mM CT 3-4 fold of the initial value). Addition of mannitol to 
blood did not antagonize these oxidative modulations of platelet activation. 
The results were confirmed, using equimolar concentrations of NaOCl and 
N-chloro-taurine. Singlet oxygen reverses agonist-induced platelet aggrega- 
tion: 2.5 mM CT added 1 min after the agonist reverses about 70% of the 
platelet aggregation. Within the first 3 min after agonist addition more than 
80% of the aggregation response is reversed by singlet oxygen. 
Conclusion: This study shows that the nonradicalic phagocyte oxidant 
singlet oxygen inhibits platelets, decreasing the agonist induced formation 
of platelet aggregates and the expression of CD62P. It is suggested that 
activated PMN modulate hemostasis, shifting it into an antithrombotic state. 
The physiologic signal action of the phagocyte oxidant singlet oxygen (re- 
leased by chloramines such as vancomycin) might be a new principle for 
pharmacologic intervention in atherothrombotic diseases. 
1 1178-53 1 Chronic Endothelin A Receptor Antagonism 
Improves Vasorelaxations to Natriuretic Peptides 
in Atherosclerosis 
Hanna Leskinen, Alessandro Cataliotti, Michihisa Jougasaki, Virginia 
M. Miller, John C. Burnett Jr.. Mayo Clinic and Foundation, Rochester, 
Minnesota, USA 
Background: Atherosclerosis is associated with impairment of endothelial 
function, which has been linked to increased tissue endothelin-I (ET-I). The 
natriuretic peptides oppose the vascular actions of ET-1 by causing vasodi- 
latation and by inhibiting growth of vascular smooth muscle cells. The aim 
of the present study was to determine the vasorelaxing actions of all known 
four natriuretic peptides (ANP, BNP, CNP and DNP), if atherosclerosis impairs 
their vasorelaxations and the role of chronic oral ETA-receptor antagonism 
in the modulation of natriuretic peptide mediated vasorelaxations. 
Methods: New Zealand White rabbits were treated for 8 weeks: 1) normal 
diet (n = 5), 2) 1% cholesterol diet (n = 5) and 3) 1% cholesterol diet + 
ETA-antagonist LU 302146 (30 mg/kg/day po, Knoll AG, Germany) (n = 5). 
Aortic rings in organ baths were constricted with phenylephrine and incubated 
with cumulative concentrations of natriuretic peptides. 
Results: The potency of vasorelaxations in control rabbit aortas were 
BNP > ANP, DNP > CNP. Vasorelaxations to ANP, BNP and DNP were 
similar in rinqs with and without endothelium, whereas relaxations to CNP 
were attenu$ed by the presence of endothelium (p < 0.05). Atherosclerosis 
impaired vasorelaxations only to DNP and enhanced relaxations to CNP in 
rings without endothelium (p ; 0.05). fnterestingly, ETA-receptor antagonism 
during development of atherosclerosis further enhanced endothelium-depen- 
dent relaxations to all four natriuretic peptides (p < 0.05). 
Conclusion: This study demonstrates that all four natriuretic peptides 
function, as endothelium-independent vasorelaxing factors, Secondly, athero- 
sclerosis enhances CNP mediated vasorelaxations. Lastly, chronic ETA-re- 
ceptor antagonism improves endothelium-dependent vasodilatory responses 
to the natriuretic peptides in experimental atherosclerosis, These findings 
support an important vasoprotective action for CNP in atherosclerosis and 
additional beneficial properties for ETA-antagonism in the enhancement of 
endothelial function. 
I 1178 54 Activated T-Cells Stimulate Endothelial Cells to Release Proinflammatory Cytokines in a 
Contact-Dependent Manner: A Clue About the 
Pathogenesis of Atherosclerosis? 
Claudia Monaco, Sylvia Young, Ewa Paleolog, Marc Feldmann. Kennedy 
Institute of Rheumatology London, UK 
Background: Inflammation plays a key role in the pathogenesis of ath- 
erosclerosis Although many pro-inflammatory reactions are mediated by 
soluble mediators such as cytokines, cell contact is also an important means 
of communication. In this study we examined whether T cells can activate 
endothelial cells in a contact-dependent manner. 
Methods: Peripheral blood T cells were stimulated with either immobilised 
anti-CD3 antibody or a combination of IL-6, TNFol and IL-Z, before fixation 
in 0.05% glutaraldehyde. Fixed T cells were added to human umbilical vein 
endothelial cells (HUVEC), at a ratio of between I:1 and 7:l T cells:HUVEC. 
Results: Unstimulated T cells failed to induce cytokine release by HU- 
VEC. In contrast, fixed T cells, activated either through the T cell receptor 
or in an antigen-independent manner, induced release from HUVEC of IL-6, 
IL-8 and MCP-1. Maximal stimulation was observed at a ratio of 5:l T 
cells:HUVEC. Maximal induction of IL-8 release (4-fold relative to HUVEC 
only) was observed at 24 hours, while maximal induction of IL-6 release 
(3-fold) was observed at 72 hours, for both fixed CD3 and cytokine-activated 
lymphocytes Release of IL-6 and IL-8 was enhanced to a similar extent in 
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the presence of either group of T ceils. in contrast, production of MCP-I was 
upregulated to a greater extent by CD3-activated T cells (5-fold increase) 
than by cytokine-activated T cells (3-fold increase). 
Conclusion: Our data demonstrate that activated T-cells stimulate en- 
dothelial cells to release pro-inflammatory cytokines in a contact-dependent 
manner. Therefore, T cells regulate functions of the endothelial cells such 
as leukocyte recruitment and induction of acute phase cytokines, not only 
via soluble mediators, but also via cell contact. Cell-cell contact interactions 
could be relevant in the pathogenesis of atherosclerosis. 
1178~551 CYV@~ tntegrin-Mediated Synergy in the Promotion 
of Human Smooth Muscle Cell Migration by 
Platelet Derived Growth Factor (PDGF) and the 
Matrix Proteins Vitronectin or Osteopontin 
Shaker A. Mousa, Jeffrey M. Bozarth, Marc Cohen. DuPont 
Pharmaceuticals Co., Wilmington, DE; Hahnemann University Hospital, 
Philadelphia, PA, USA 
Background: Migration of smooth muscle cells (SMC) into the intimal layer 
is an important contributor to intimal thickening in atherosclerotic lesions 
and restenosis post-coronary interventional procedures. Several factors that 
augment migration of SMC have been identified, including PDGF and the 
matrix proteins (vitronectin osteopontin) circulating in human blood or in 
atherosclerotic lesions. The present study was undertaken to determine the 
chemattractant effects of combining PDGF with vitronectin or osteopontin at 
different levels on human SMC migration and the role of the avg3 Integrin. 
Additionally, the present study examined the chemoattractant effect of plasma 
obtained from patients with coronary artery diseases (CAD) pre- and post- 
angioplasty/stenting and the role of the CYVB~ Integrin. 
Methods: Migration of human sonic SMC was assayed by a modification 
of Boyden’s chamber method using membrane filter with neuroprobe 96 
well plate chamber. Additionally, plasma levels of PDGF in CAD and normal 
healthy subjects were measured with a sensitive and specific ELISA. 
Results: PDGF-BB resulted in relatively greater SMC migration as com- 
pared PDGF-AA or PDGF-AB. Both vitronectin and osteopontin resulted in a 
concentration-dependent SMC migration. Addition of PDGF-BB to vitronectin 
or osteopontin at’sub-threshold concentrations resulted in synergistic effects 
in the promotion of SMC migration. The effects of PGDF-BB, vitronectin, 
osteopontin or their synergistic combinations on SMC migration were totally 
blocked by the specific non-peptide 0lvfl3 antagonist, XT199. A significant 
(P < 0.01) increase in plasma PDGF level in CAD patients as compared 
to healthy subjects was shown. Additionally, a significant increase in the 
extent of SMC chemotaxis toward plasma from CAD patients both pre- and 
post- angioplastyistent as compared to plasma from healthy subjects was 
demonstrated. XT199 blocked the SMC migration induced by circulating 
chemoattractant in CAD patients. 
Conclusions: These data demonstrated the efficacy of XT1 99 in blocking 
SMC migration. These data also suggest the potential role of avfi3 integrin as 
the final common pathway in pathological processes involving SMC chemo- 
taxis in CAD patients, 
1 1178-56 1 Platelet GPllb/llla Antagonist, Roxifiban in Heparin 
or Low Molecular Weight Heparin-Induced 
Thrombocytopenia 
Shaker A. Mousa, Mark Forsythe, Jeffrey Bozarth, Jeanine M. Walenga’ , 
Jawed Fareed. DuPont Pharmaceutical Co., Wilmington, DE; ‘Loyola 
University Medical Center, Maywood, IL, USA 
Background: Heparin-induced thrombocytopenia (HIT) is a serious side ef- 
fect associated with heparin therapy. One of the severe manifestations of the 
syndrome is the development of thrombotic events in some subjects due to 
platelet activation and aggregation. Despite the use of potent anticoagulants 
such as r-hirudin, the morbidity and mortality of HIT patients remains high. 
Platelet GPllbillla antagonists have been shown to be the final common 
pathway for platelet aggregation regardless of the activator. The effects of 
various GPllb/llla antagonists such as free acid form of Roxifiban (XV459), 
a potent GPllbillla antagonist (Kd = 1-2 nM for resting and activated human 
platelets) on HIT-mediated platelet activation, platelet fibrinogen binding and 
platelet aggregation were examined. 
Methods: The efficacy of Roxifiban in blocking platelet activation (alpha 
and dense granular secretion) upon platelet adhesion to von Willebrand 
factor (vWf) beads under shear, platelet micropanicle formation by flow cy- 
tometry, platelet fibrinogen binding and aggregation in the presence of HIT 
positive serumiheparin was determined. We have used a specific ELISA as- 
says to measure platelet-released serotonin and beta-thromboglobulin, light 
transmittance aggregometry, laser scatter aggregometry and fz51-fibrinogen 
binding to activated human platelets, 
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Results: HIT positive serum/heparin in a comparable fashion to ADP 
or other platelet agonist induced ‘asI-fibrinogen binding to human platelets, 
enhanced platelet aggregate formation, and platelet microparticle formation. 
XV459 at 20-40 nM maximally inhibited ‘251-fibrinogen binding, platelet de- 
granualtion, and platelet micro-and macro-aggregate formation in response 
to HIT positive serum as determined by light transmittance and laser scat- 
ter aggregometry. In contrast, Aspirin was weakly effective in attenuating 
macro-aggregation and without any effect on micro-aggregation induced by 
HIT serum. 
Conclusions: These data demonstrated a potent efficacy for Roxifiban 
in limiting platelet reactivity induced by serum from positive HIT patients. 
These data also suggest that Roxifiban might have potential benefit in the 
management of heparin-induced thrombotic thrombocytopenia. 
/ 1178 57 Inhibition of Oxidative Damage to Human Low Density Lipoproteins and Isolated Membranes by 
Atorvastatin and its Active Metabolite 
Ft. Preston Mason. Cardiovascular and Pulmonary Research Institute, MCP 
Hahnemann Universifl: Allegheny Campus, Pittsburgh, Pennsylvania, USA 
Background: Oxidative modification of lipids associated with low-density 
lipoproteins (LDL) and vascular cell membranes contributes directly to athe- 
roma development. As a result, agents that can retard oxidative damage to 
lipids are considered antiatherogenic. 
Methods: In the present study, the antioxidant effects of atorvastatin and 
its active metabolite were examined in human LDL and lipid vesicles enriched 
with polyunsaturated fatty acids (PUFA) and cholesterol. Lipid peroxide for- 
mation was systematically measured by spectrophotometric analysis under 
physiologic-like conditions. 
Results: The results of these experiments demonstrated that the ator- 
vastatin metabolite significantly (p < 0.001) inhibited oxy-radical damage 
to isolated membranes enriched with cholesterol at low, nanomolar levels. 
Membrane antioxidant activity was also demonstrated for atorvastatin, but 
not with lovastatin, mevastatin, pravastatin or simvastatin. In human LDL, 
the atorvastatin metabolite was a very effective inhibitor of oxy-radical dam- 
age following stimulation with CuSO.+, significantly delaying the lag phase of 
oxidation. The basis for the strong antioxidant activity of atorvastatin and its 
metabolite is attributed to specific physicochemical interactions with phos- 
pholipid molecules, as directly determined in isolated membranes by small 
angle X-ray diffraction and molecular modeling analyses. 
Conclusion: In addition to its favorable effects on lipid metabolism, the 
potent antioxidant effects of atotvastatin, and especially its active metabolite, 
represents a distinct antiatherogenic mechanism of action. 
1178-58 Role of ET-I in Foam Cell Formation by Human 
Macrophages In Vitro 
Amir Ravandi, Saeid Babaei, Juan Carlos Monge, Asif Ansari, Duncan 
J. Stewart. Jerrence Donnelly Heart Center, St. Michael’s Hospital, 
University of Toronto, Toronto, Ontario, Canada 
Endothelin expression is markedly increased in neointimal atherosclerotic 
lesions, mainly in association with macrophages and foam cells. Endothelin 
receptor (ETR) blockade has been shown to inhibit atherogenesis in ani- 
mal models. We hypothesized that the anti-atherogenic mechanism of ETR 
blockade was due to inhibition of foam cell formation. THP-1 human mono- 
cytes were differentiated into macrophages by phorbol myristate acetate and 
subsequently incubated with 100 kg/ml of native (nLDL) or oxidized LDL 
(OxLDL), in the presence of ET-I (IO-’ M) or an ETR antagonist. After 24 
h, cellular cholesteryl ester (CE) and triacylglycerol (TG) was quantitated by 
gas chromatography with internal standardization. Treatment of cells with 
ET-I and nLDL resulted in 3-fold increase in CE and TG levels compared to 
nLDL alone (p < 0.01 and p < 0.05 respectively). OxLDLsimilarly increased 
macrophage lipid accumulation by 3-fold, which could be partially inhibited 
by ETR blockade with either a selective ETs receptor antagonist, BQ788 
(10e7 M), or a mixed ETnIETs receptor antagonist, LU224332 (1O-7 M); 
(46% or 51%, p < 0.05; p < 0.01, respectively), suggesting an important role 
for endogenous ET-I in macrophage activation. High pressure liquid chro- 
matography with online electrospray mass spectrometry revealed a 4-fold 
increase in phospholipid oxidation products, including phosphatidylcholine 
(PC) hydroperoxides, PC isoprostanes and PC aldehydes in ceils incubated 
with nLDL in presence of ET-I vs. the absence of ET-I. Therefore, our re- 
sults indicate that ET-I contributes to the macrophage neutral lipid deposition 
by promoting both oxidation of nLDL and uptake of OxLDL by these cells, 
and this may play an important role in macrophage activation and foam cell 
formation in early atherosclerosis. 
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I 1179 41 Atrial Septal Aneurysm as a Cardioembolic Source in Adult Patients With Stroke and Normal 
Carotid Artery. A Multicenter Study 
Anna Vittoria Mattioli, Michele Aquilina’ , Antonio Oldani’, Carlo Longhini’, 
Giorgio Mattioli. On behalf of the Investigators; Dpt of Cardiology University 
of Modena; ‘Dpt of cardiology Pierantoni Hospital, For/i, Italy 
Background: The atrial septal aneurysm (ASA) has been considered a 
potential source of cardiogenic embolism for many years. The present study 
evaluated the prevalence and characteristcs of ASA in patients (pts) with 
stroke and normal carotid artery compared to a control population without 
stroke. 
Methods: A total of 606 pts were enrolled between November 1990 
and December 1996, they included 245 pts with a previous cerebral em- 
bolic attack and normal carotid study and a control group of 316 pts. They all 
underwent transthoracic and transesophageal echocardiography. The preva- 
lence and the morphologic characteristics of ASA were evaluated and com- 
pared. 
Results: We reported an higher prevalence of ASA in the group who 
experienced cerebral ischemic attacks (68 pts (27.7%) versus 36 (9.9%) 
from control group; p < 0.001). The echocontrast evaluation allowed the 
detection of interatrial shunt in 58.8% of the pts with stroke compared to 33% 
in control (p < 0.01). A patent forame ovale was detected in the 22.8% of 
the pts versus 9.8% of controls (p < 0.001). Mitral valve prolapse was similar 
in the 2 groups. Statistical analysis revealed that the presence of thrombus 
in the left atrium (odds ratio 4.2, 95% Cl. 2.7-7.8, p c O.Ol), mitral anulus 
calcification (OR 2.8, 95% Cl. 3.3-12.5, p < 0.05) paradoxic shunt (OR 3.3, 
95% 1.8-6.5, p < 0.05) and ASA (OR 3.0, 95% Cl. 1.8-4.8, p < 0.05) were 
independent predictors of embolic events. 
Conclusion: ASA is more common in pts with stroke and normal carotid 
artery. The most common abnormality associated with ASA is interatrial 
shunt. ASA was the only potential cardiac source in young pts less than 45 
years. 
1 1179-42 1 The Role of Plasma D-Dimer in the Early 
Diagnosis of Stroke Subtypes 
Walter Ageno, Sergio Finazzi, Barbara Secco, Maria R. Petro&o, 
Deborah Garganico, Fabio Ambrosini, Barbara Nardo, Luigi Steidl, Maria 
G. Biotti, Gian V. Melzi d’Eril, Achille Venco. University of Insubria, Varese, 
lfaly 
Background: The long-term outcome after an ischemic cerebrovascular 
event depends on its severity and on the subtype. Clinical and instrumental 
diagnoses of stroke subtype are not always definite, thus potentially mislead- 
ing therapeutic strategies for secondary prevention. Different coagulation 
abnormalities according to stroke subtypes have been reported. D-Dimer, 
a product of fibrin degradation, is currently widely used in the diagnosis of 
venous thromboembolism and is now easily available in most hospitals. 
Methods: Patients hospitalized for an acute ischemic cerebrovascular 
event underwent a brain CT scan, an echocardiogram, a duplex ultrasound 
of the cervical arteries and had D-Dimer levels measured on days I,6 i 1 and 
12 i 1 using a new quantitative rapid assay based on agglutination of latex 
microparticles (Liatest D-D, Diagnostica Stago, normal level x 0.5 @g/mL). 
Stroke severity was evaluated using the Unified form for Neurological Stroke 
Scale. Patients with known deep vein thrombosis, sepsis, malignancy, recent 
trauma or surgery were excluded. 
Results: Forty-two patients with a high probability diagnosis of lacunar, 
atherothrombotic or cardioembolic stroke or transient ischemic attack (TIA) 
were included. In all 3 measurements D-Dimer levels were significantly higher 
in the cardioembolic group (4.16 f 1.08; 3.37 + 0.78; 3.66 f 0.98) than in 
the atherothrombotic (1.02 f 0.16; 1.60 f 0.29; 1.45 f 0.32) and in the 
lacunar groups (0.65 f 0.13; 0.52 & 0.10; 0.63 & O.iO), and the difference 
was also significant between these 2 groups. D-Dimer levels were not related 
to stroke severity, but there was a significant difference when we compared 
strokes (28) to TIA, (14) (mean of the 3 samples: 2.53 f 0.42 vs 1.36 f 
0.39) although this finding was explained by a different distribution in stroke 
subtypes between the 2 groups. Interestingly, mean D-Dimer levels in TIA 
patiens remained abnormal in all 3 measurements (1.22 & 0.37; 1 .I5 i 0.32; 
1.07 f 0.24). 
Conclusion: D-Dimer levels are significantly related to the subtype of 
a cerebrovascular event. The now easy availability and the relatively low 
costs of the measurements suggest a possible use in the early diagnosis 
of the pathogenesis of a TIA or a stroke when the clinical and instrumental 
diagnosis is not considered as definite. 
/ 1179 43 G-33A Mutation in the Promoter Region of Thrombomodulin Gene: A Risk Factor for Carotid 
Atheroma but not lschemic Stroke 
Yi-Heng Li, Chih-Hung Chen, Poh-Shiow Yeh’, Huey-Juan Lin’ , 
Hua-Lin Wu, Guey-Yueh Shi, Ming-Liang Lai, Jyh-Hong Chen. National 
Cheng Kung University Medical Center, Tainan; ’ Chi-Mei Foundation 
Hospital, Tainan, Taiwan 
Background: Thrombomodulin (TM) is an endothelial anticoagulant protein 
which decreases thrombin activity and activates protein C. Our recent study 
has shown that the G-33A promoter mutation of TM gene is associated with 
coronary artery disease. However, its relation with ischemic stroke or carotid 
atheroma remains unknown. This study was conducted to determine whether 
the G-33A mutation in the promoter region of TM gene is a genetic risk factor 
for ischemic stroke or carotid atheroma. 
Methods.: In this case-control study, we investigated 333 patients (mean 
age 64 years, 59% male) with ischemic stroke and 257 age- and sex-matched 
control subjects. In all study participants, carotid atheroma was assessed by 
Duplex scanning. TM G-33A promoter mutation was detected by polymerase 
chain reaction, single-strand conformation polymorphism and confirmed by 
direct sequencing. 
Results: There was no significant difference in the TM G-33A mutation 
frequency (GA + AA genotypes) between stroke and control group (18.3% 
vs 24.1%, p = NS). There was also no relationship between the mutation 
and any particular stroke subtype: 18 (19.4%) of 93 in large vessel disease; 
36 (17.9%) of 201 in small vessel disease; and 7 (17.9%) of 39 in cardiac 
embolism or undetermined origin. All study participants were reclassified 
into 2 groups according to the presence or absence of carotid atheroma. 
The G-33A mutation frequency was similar between the subjects with and 
without carotid atheroma (22.2% vs 19.8%, p = NS). But when only younger 
subjects (age 5 60 years, n = 201) were included, the mutation occurred 
more frequently in carotid atheroma group (33.0% vs 16.7%, odds ratio 
[OR] = 2.38, p = 0.029). Logistic regression analysis demonstrated that only 
diabetes mellitus (OR = 3.11, 95% confidence interval [Cl] = 1.33-7.30, p 
= 0.009) and G-33A mutation (OR = 2.46, 95% Cl = 1.14-5.29, p = 0.021) 
were independently associated with carotid atheroma in younger subjects. 
Conclusion: These findings suggest that the TM G-33A promoter muta- 
tion is a genetic risk factor for carotid atheroma in younger subjects. However, 
it is not associated with the occurrence of ischemic stroke. 
L---L 1179 44 Alcohol Use and Risk of Hospitalization for lschemic Stroke 
Arthur L. Klatsky, Mary Anne Armstrong, Stephen Sidney, Gary 
D. Friedman. Kaiser Permanente Medical Care Program, Oakland, CA, USA 
Background: Several studies have found lighter drinkers at lower risk of 
ischemic stroke (IS) than abstainers, but details about clinical and population 
subsets have been sparse. 
Methods: We studied IS prospectively in 128,934 persons (44% men, 
56% White, 27% Black, 11% Asian, mean baseline age = 41 yrs.) in relation 
to traits determined at prior health examinations. Of 2014 different persons 
hospitalized for IS, 219 had code 433 (“extracranial”), 247 had code 434.1 
(“cardioembolic”), 1235 had codes 434.0, 2-9 (“intracerebral thrombosis”) 
and 263 had code 435 (“TIA’s”). Cox proportional hazards models with 12 
covariates were used. 
Results: Multivariate model relative risks (RR) vs. lifelong abstainers 
(RR = 1 .O) with (95% Cl’s) for all IS follow: exdrinkers = 1.0 (0.8; 1.2); 
drink: ~1 drink/ma. = 0.9 (0.8; l.O), >l/mo; <l/day = 0.9 (0.8; 1.0, p < 
0.05) I-2/day = 0.8 (0.7; 0.9, p < O.OOl), 3+/day = 1.2 (1.0; 1.4). These 
relationships were similar in the sexes, races (White, Black, Asian), and 
age, smoking, and baseline coronary risk yes/no subsets. However, lower 
IS risk of persons taking l-2 drinks/day was limited to the intracerebral 
thrombosis subset (RR = 0.7, p < 0.001); at l-2 drinks/day RR’s = 0.9, 1 .O, 
and 1 .I, for extracranial, cardioembolic, and TIA groups, respectively. There 
were no significant independent relationships of drinking variability (day/day, 
week/week, etc.) or of beverage choice (wine, liquor, beer) to all IS or to 
intracerebral thromboses. 
Conclusion: Lighter alcohol drinking is associated with lower risk of in- 
tracerebral thromboses, but not. of other IS clinical subsets (extracranial, 
cardioembolic, TIAs). This may indicate a protective effect of alcohol upon 
intracerebral vascular disease development rather than primarily an an- 
tithrombotic effect. 
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1 118045 1 Potential of Contrast Ultrasound Imaging in the 
Detection of Deep Vein Thrombosis - 
Experimental Studies in a Canine Model 
lnes V. Pinto, Masaaki Takeuchi, Malachi Sheahan, 
Santhinidevi Ramasamy, Joachim Nesser, Stefano DeCastro, 
Raymond Connolly, Natesa Pandian. Tufts - New England Medical Center, 
Boston, MA, USA 
Background: Current methods used to diagnose deep vein thrombosis 
(DVT) of lower extremities have known limitations. We wondered whether 
transit behavior of ultrasound contrast agent would be affected by DVT. 
Methods: To explore the diagnostic potential of ultrasound contrast imag- 
ing in the detection of DVT, we created an experimental model of DVT in 10 
dogs. Both before and after DVT, we injected an ultrasound contrast agent 
(0.1 ml of Qptison) from a lower extremity peripheral vein in the foot at both 
sides, while imaging the inferior vena cava. Time to contrast appearance 
(TCA) and time to peak intensity (TPI) in the inferior vena cava were mea- 
sured after both right and left extremity injections. Videointensity analysis of 
the contrast in the inferior vena cava was also performed. 
Results: At baseline, the:e was no difference in TCA or TPI in the inferior 
vena cava after contrast injection in the control leg or the leg subsequently 
planned for DVT (2.3 i 0.4 set vs. 2.4 i 0.7 set (p = NS). Following induction 
of venous thrombosis, TCA in the inferior vena cava was significantly delayed 
when contrast was injected at the DVT leg (5.0 f 1.2 set) compared to the 
control leg (2.4 * 0.5 set, p < 0.001). Likewise, TPI was significantly delayed 
(11.5 i 6.2 set vs. 5.3 i 2.9 set, p c 0.01) when contrast was injected at the 
DVT side compared to the control leg. These findings were observed in every 
dog. There was no difference in the actual peak intensity measurements of 
contrast in the inferior vena cava however. 
Conclusions: Transit dynamics of ultrasound contrast could aid in the 
diagnosis of deep vein thrombosis. This potential may be of use in humans 
as an adjuvant technique to ultrasound imaging for the diagnosis of DVT. 
1 1180-46 / Is Doppler-Echocardiography Useful in the 
Diagnostic Work-Up of Pulmonary Embolism? 
Lorenza Pratali, Massimo Miniati, Simonetta Monti, Maria de Lorenzo, 
Giorgio Di Ricco, Bruno Formichi, Carlo Marini, Renato Prediletto, 
Massimo Pistolesi. CNR institute of Clinical Physiology, Piss, /ta/y 
Background: To assess the value of Doppler-echocardiography in the diag- 
nosis of pulmonary embolism (PE), we evaluated 110 consecutive patients 
with suspected PE (mean age 63.6 f 17.3 yr; inpatients 72%) who were en- 
rolled in the Prospective Investigative Study of Acute Pulmonary Embolism 
Diagnosis (PISA-PED). 
Methods: Prior to perfusion lung scanning, patients were examined in- 
dependently by six pulmonologists; clinical probability of PE was rated as 
low (lo%), intermediate (50%), or high (90%) according to a standardized 
diagnostic algorithm. Pulmonary angiography was required in patients with 
abnormal perfusion scans. In all patients, a 2-D echocardiographic study 
was performed by a cardiologist who was blind to clinical and lung scan 
data. The coexistence of right ventricular dilatation (end-diastolic diameter 
> 27 mm) and tricuspid regurgitation velocity > 2.7 m/s was used as a 
criterion to diagnose PE by echocardiography, Bayes’ theorem was applied 
to calculate the probability of PE conditioned by echocardiographic results 
(post-test probability) as a function of the clinical probability of PE (pretest 
probability). 
Results: PE was diagnosed by pulmonary angiography in 43 (39%) of 
110 patients. Both right ventricular dilatation and tricuspid regurgitation ve- 
locity > 2.7 m/s were present in 23 (53%) of 43 patients with confirmed PE 
and in 7 (10%) of 67 without PE (sensitivity 53%, specificity 90%). Among 
patients with PE, those who were correctly classified as having PE by echo- 
cardiography had a significantly higher number of unperfused lung segments 
on the lung scan (8.8 i 2.4) than those who were misclassified as not having 
PE (5.9 f 2.3, p =Z 0.001). For pretest (clinical) probabilities of 10, 50, and 
90%, the post-test probabilities of PE conditioned by echocardiographic find- 
ings compatible with PE were 37, 84, and 99%, respectively; the post-test 
probabilities of PE conditioned by echocardiographic findings not compatible 
with PE were 5, 34, and 82%: respectively. 
Conclusions: Our data indicate that: 1) echocardiographic findings of 
right ventricular dilatation with tricuspid regurgitation velocity > 2.7 m/s make 
the diagnosis of PE very likely on/yin patients with high clinical probability; 2) 
absence of these two echocardiographic abnormalities makes the diagnosis 
of PE unlikely only in patients with low clinical probability; 3) when clinical 
probability and echocardiographic findings are discordant (nearly 50% of the 
cases in our study), the post-test probability of PE is neither sufficiently high 
nor sufficiently low to permit therapeutic decisions without the aid of further 
diagnostic testing. 
/ 1180-47 1 The Immunologic Form of Heparin Induced 
Thrombocytopenia: Incidence and Outcome in 
1000 Consecutive Cardiovascular Patients 
Uwe Janssens, Ritu Khanduja, Nice Lorenz, Jijrgen vom Dahl, 
Josefina Janssens, Andreas Greinacher’ , Peter Hanrath. Medical Clinic /, 
University Hospital of Aachen, Aachen; ’ lnsfitute for Immunology and 
Transfusion Medicine, Ernst-Moritz-Arndt University, Greifswald, Germany 
Background: The immunologic form of heparin induced thrombocytopenia 
(HIT) is a life-threatening side-effect of heparin therapy. Patients (pts) with 
HIT may subsequently develop severe arterial and venous thromboembolic 
complications (TECs). The reported frequency of HIT varies widely and 
ranges from 0% to 30%. Therefore we carried out a prospective study to 
evaluate the incidence of HIT in pts admitted to a cardiology department. 
Methods: All consecutive pts who received subcutaneous (SC) or intra- 
venous (iv) heparin were included in the study. Platelet counts were obtained 
on admission and thereafter every second day. Clinical signs of thrombo- 
sis were screened daily. HIT was defined as a) a drop of platelet counts 
more than 50% of baseline values and b) a positive heparin induced platelet 
activation assay (HIPA) and/or c) clinical signs/proof of arterial and/or ve- 
nous thromboembolism. Heparin therapy was discontinued in all pts with 
a significant thrombocytopenia and replaced by danaparoid sodium or lep- 
irudin when necessary and in all serologically proven HIT pts or pts with 
thrombocytopenia and TECs. 
Results: Between 12196 and 6/97 1000 pts (62.7 + 12.3 years, 71% 
male, 270 pts SC heparin, 730 pts iv heparin) were included in this study. 
35 pts (3.5%) developed a thrombocytopenia with a nadir of 82 f 37 Giga/l 
on day 4 (3-11). HIPA was positive in 7 of these pts (0.7%). Lowest platelet 
counts in HIPA positive pts were 57 f 31 Gigail on day 10.6 * 5.6 versus 
89 * 36 Giga/ (p < 0.01) in HIPA negative patients. 4/7 HIPA positive pts 
exhibited venous TECs, two of them pulmonary embolism. Heparin was re- 
placed by Danaparoid Natrium Orgaran@ in 4 HIPA positive pts and lepirudin 
(Refludan”) in 3 pts. There was no arterial thrombosis nor limb amputation 
or even death.in HIT pts. 
Conclusion: Incidence of HIT in 1000 consecutive medical pts was 0.7%. 
The low rate of disabling or life-threatening complications and no HIT related 
death in our patient series may be attributed to the close monitoring of platelet 
counts and early recognition of this adverse event of heparin therapy. 
1180-48 Noninvasive Extracorporeal Venous Thrombolysis 
With Shock Waves 
Gianni Belcaro, Maria Fi. Cesarone, Maria T. DeSanctis, Giuseppe Laurora, 
Lucrezia Incandela, Andrew N. Nicolaides, Ernst H. Marlinghaus. Angiology 
and Vascular Surgery & Clinical Trials Unif, Pierangeli C/ink, Pescara, Italy; 
Irvine Laboratory, St. Mary’s Hospital at imperial College, London, UK 
Background: Shock waves (SW) have been mainly developed, and used 
for noninvasive treatment of kidney and gallbladder stones and for other 
applications (i.e. orthopedics). Experimental and early clinical cardiovascular 
applications of SWs have been recently reported. 
Methods: A new method defined noninvasive SW thrombolysis (NISWT) 
has been experimentally attempted in in-vitro experiments and in a clinical 
setting using a modified SWs generator prototype. A group of 24 patients 
were considered for noninvasive shock waves thrombolysis in subjects with 
femoral vein thrombosis. Patients with the following characteristics were in- 
cluded into the study: a. stable, ecogenic thrombus; effective anticoagulation; 
no previous episodes of pulmonary embolism; complete, stable thrombotic 
occlusion of the iliac veins (abolishing the risk of embolization); absence of 
other serious cardiovascular disorder requiring medical treatment (concomi- 
tant with anticoagulants); age range between 35 and 65; thrombosis not 
lasting more than 6 months and not less than 4 weeks. Of these 15 patients 
gave their informed consent. NISWT was attempted in 8 patients; 7 patients 
were randomized for follow-up only. NISWT was attempted in a randomized 
protocol using SWs (1000 shots) applied to 6 different levels of focusing 
within the femoral thrombus. Venous NISWT was possible in 7 cases. In one 
case randomized for NISWT local inguinal scarring, due to previous surgery 
made impossible the visualization of the femoral vein and therefore SWs 
focusing. 
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Results: No side effects were reported after SWs administration and 
during the 6-month follow-up. In patients treated with NISWT it was possible to 
observe just after the SWssession the presence of ecolucent “acoustic holes” 
and flow (by color and power-Doppler) within the “holes”: All “echolucent 
holes” produced at the first session were still present at 6 months and color 
flow imaging also detected new flow channels in echogenic areas of thrombi 
previously not visible. In one patient thrombolysis was achieved after the 
first treatment but at 3 and 4 months the thrombus was again completely 
avascular. 
Conclusion: Thrombolysis using SWs was obtained in 6 selected cases 
and it was still persisting at 6 months in 5 out of the 7 treated patients. NISWT 
appears feasible and promising. These results should be confirmed by larger, 
prospective trials. 
I 1180 49 Noninvasive Extracorporeal Arterial Thrombolysis With Shock Waves 
Gianni Belcaro, Andrew N. Nicolaides, Ernst H. Marlinghaus. 
Cardiovascular Institute, Chieti University: Chieti, Italy; St. Mary’s Hospital, 
Imperial College, London, UK 
Background: Shock waves (SW) have been mainly developed for the treat- 
ment of kidney stones. Vascular applications have recently been proposed 
and “noninvasive venous shock waves thrombolysis” (NISWT) has been re- 
cently achieved in selected cases using a modified lithotripter coupled to a 
focusing ultrasound system which probe is inserted within the SW reflec- 
tor. 
Methods: A group of 10 patients with acute thrombosis (echolucent 
thrombi) of the femoral artery and critical limb ischemia were included in a 
randomized study. Five patients were treated with NISWT and 5 were used 
as controls. SW were used at the dosage of 800 shots The SW reflector was 
coupled to the skin with a silicon water cushion. No pain was observed. All 
patients received treatment with PGEI according to the short-term infusion 
protocol and were under oral anticoagulant (INR 2-3) for the follow-up period 
of 2 months. 
Results: NlSWTwas possible in all attempted cases. No side effects were 
reported at 2 months One patient in each group was treated with surgery 
and therefore considered as drop-out. In the SW treated patients the femoral 
artery had visible flow (color duplex), thrombus breaks were visible and.some 
perfusion was visible. In the control group thrombi appeared solid, without 
flow and the segment was not perfused. After two months in the treated group 
limb flow measured by straingauge plethysmography was on average 88% 
(range 12-258%) higher than in controls and no limb underwent amputation 
(2 minor amputations in the control group). 
Conclusion: NISWT has been achieved extracorporeally in arterial throm- 
bosis (after preliminary experience in venous thrombosis). Its clinical value 
should be assessed in a larger study. 
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p < 0.001. ASP was zero (peripheral = AR systolic pressure) at AA Al of 
160%, and RA Al of 103%. The group absolute value of AA systolic pressure 
(Y) was closely related to brachial systolic pressure (X) with Y = 0.93X ~ 
2.7 (R = 0.96). In 35 patients at cardiac surgery, RA and AA waves were 
recorded directly under different conditions, and simultaneous wave trains 
compared (N = 80). Relationship between estimated AA (Y) and RA (X) 
systolic pressure was similar to the large group (Y = 0.88X - 0.8, R = 0.94). 
However relationship between estimated AA (Y) and directly recorded AA 
(X) approximated unity (Y = 0.99X + 2.6, R = 0.97). While for a large group, 
the relationship between recorded and estimated AA (and left ventricular) 
systolic pressure can be calculated from simple regression, the substantial 
individual difference between the two values, (and scatter in the group) is 
dependent on the shape of the RA pressure waveform. 
Conclusion: For individuals, an accurate estimation of AA and left ven- 
tricular systolic pressure requires consideration of both upper limb systolic 
pressure and contour of the peripheral waveform. Central systolic pressure 
can be inferred from the contour (late systolic shoulder) of the peripheral pres- 
sure pulse, but can be determined more accurately from waveform analysis 
in the frequency domain. 
1 1181-I 8 1 Large Artery Structure and Function in Geriatric 
Patients With Isolated Systolic Hypertension: 
The I CARe Dicomano Study 
Riccardo Pini, M. Chiara Cavallini, Elisabetta Tonon, Richard B. Devereux, 
Giulio Masotti, Mary J. Roman. University of Firenze, Firenze, Italy; Weill 
Medical College of Cornell University: New York, N. Y!, USA 
Background: Several studies demonstrated that patients with isolated sys- 
tolic hypertension (ISH) have a higher incidence of cardiovascular diseases 
when compared to normotensive subjects (NL) but no data are available 
regarding arterial remodeling associated with ISH. 
Methods: Carotid artery structure (wall thickness [IMT], diastolic diameter, 
atherosclerosis [presence of discrete plaque, maximum plaque thickness]) 
and function (stiffness index [beta]) were compared in 611 participants (199 
NL [BP 5 140/90 mmHg]; 80 borderline hypertensive [BP 141-‘160/>90 
mmHg]; 265 essential hypertensive [BP P 160/90 mmHg]; 67 ISH [BP > 
160/590 mmHg]) in the I CARe Dicomano Study of congestive heart failure 
(CHF) in a geriatric home-dwelling population ? 65 years old. 
Results: Essential hypertensive patients exhibited similarly abnormal 
carotid structure and function as borderline hypertensive patients; also the 
presence and extent of plaques was similar in the two groups. In contrast, 
when compared to essential hypertensives, ISH patients were older (77 f 6 
vs 73 5 6 years, p < 0.0001) and exhibited a tendency to higher IMT (0.92 
i 0.16 vs 0.87 f 0.17 mm) and maximum plaque thickness (2.13 f 1.01 
vs 1.73 f 1 ,I 6 mm) with a significant increase in diastolic carotid diameter 
(6.57 f 1.03 vs 6.09 f 0.96 mm, p = 0.016), beta (6.39 i 3.18 vs 4.45 f 
2.15, p < O.OOOl), and number of plaques (3 + 2 vs 2 & 2, p = 0.007); these 
differences remained significant after correcting for age. The four groups had 
similar prevalence of coronary artery disease and myocardial infarction while 
the prevalence of stroke and clinical peripheral arterial disease showed a 
progressive increase from NL (5% and 7%, respectively) to the ISH group 
(15% and 20%, respectively). 
Conclusions: In our unselected geriatric population, ISH patients ex- 
hibited a greater carotid remodeling than essential hypertensive patients 
associated with a more extendive atherosclerotic involvement. These carotid 
modifications were associated with a higher clinical prevalence of stroke and 
peripheral arterial disease. 
1 1181-i 7 1 Assessment of a System for Generating the 
Central Aortic Pressure Waveform and Left 
Ventricular Systolic Pressure From Brachial Cuff 
Sphygmomanometric Pressure Plus Tonometric 
Radial Pressure Wave Contour 
Michael F. C’Rourke, Xion-Jing Jiang, Alfred0 Pauca. Medical Professorial 
Unit, St. Vincent’s Hospital, Sydney Australia 
Background: Generation of the ascending aortic (AA) pressure waveform 
from calibrated radial (RA) tonometric waveform constitutes a potential ad- 
vance fur non-invasive determination of left ventricular load in humans 
Method: This study used a commercial system (SphygmoCor, PWV Med- 
ical, Sydney Australia) and comprised 15,608 individual reports from 1,604 
different subjects/patients. Estimated AA waves were compared with directly 
recorded RA tonometric waves, calibrated by brachial cuff sphygmomanom- 
etry. Univariate analysis confirmed the relationships between AA augmenta- 
tion index (Al), (amplitude from wavefoot to second systolic peak divided by 
amplitude to first systolic peak or shoulder) with RA Al (R = 0.81) ejection 
duration (R = 0.47) age (R = 0.35) and mean pressure (R = 0.35), all p 
c 0.001. AA Al was closely related to the difference between brachial and 
estimated AA systolic pressure (ASP) with Al = 160 - 2.33 x ASP, R = 0.56, 
1181-I 9 Pulse Pressure, Carotid Atherosclerosis and 
Microalbuminuria in Essential Hypertensive 
Patients 
_. 
Roberto Pedrinelli’ , Giulia Dell’Omo’ , Danilo Giannini’, Vitantonio Di 
Belle*, Alessio Bertini2, Albeit0 Balbarini’ , Mario Mariani’ ‘Dipartimento 
Cardiotoracico; “Medicina Interna, Universita di Pisa, Italy 
Background: Because of consistent associations with atherosclerotic com- 
plications, the occurrence of microalbuminuria (MA, UAE p 15 pg/min) in 
non diabetic hypertensive subjects is frequently postulated to reflect directly 
a systemic alteration in capillary permeability due to atherosclerosis. 
Methods: Urinary albumin excretion (UAE, the mean of three overnight 
collections, nephelometry), common carotid intima-media thickness (IMT, 
the mean of 6 right and left far wall measurements, high resolution ultra- 
sonography), an accepted surrogate measure of systemic atherosclerosis, 
BP (indirect method), left ventricular mass index (echocardiography), total 
and fractionated cholesterol were measured in 101 mild-moderate essential 
hypertensive males (162 & 17/96 + 11 mmHg). All were normoglycaemic 
(plasma glucose < 120 mg/dl), with normal cardiac (EF > 50%) and renal 
(creatininemia < 1.2 mg/dl) function, untreated for at least four weeks. 
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Results (Means & SD or Medians & Range): MA [UAE: 34 (15-220) 
&g/min] was found in 32 patients characterised by somewhat older age (58 
& 12 vs 54 f IO, p .Z 0.04), greater IMT (1.1 * 0.2 vs 0.9 & 0.1, p < 0.005) 
and LVMI (163 i 29 vs 149 i 29 9/m, p < 0.04), reduced HDL cholesterol 
(39 i 12 vs 43 i 12 mg/dl, p < 0.05). Systolic (S) BP (161 Z!Z 15 vs 149 & 14 
mmHg, p < 0.001) was higher, diastolic (D) BP superimposable (95 f 11 vs 
94 i 9 mmHg), and, as a consequence, pulse pressure (PP, 67 f 13 vs 55 
i 15 mmHg p < 0.001) elevated in the presence of MA. IMT and PP showed 
a strong positive association (r = 0.45, p < 0.001); both (r = 0.37, p < 0.001, 
r = 0.46, p < 0.001, respectively) correlated with UAE in univariate analyses. 
In a multivariate stepwise logistic regression analysis, relative risk of MA 
increased with widening PP values (1.58/10 mmHg PP increase, 95% Cl: 
1.24-1.88, p < 0.001); IMT, LVMI, HDL cholesterol showed no indipendent 
influence. 
Conclusions: UAE levels do not appear to reflect directly the presence 
of atherosclerosis as assessed by carotid ultrasonography in non diabetic 
hypertensive subjects. Rather, wider PP, an index of the pulsatile hemody- 
namic load and a primary cardiovascular risk factor, may represent a chain 
in the link between the two parameters. 
1181-20 In Hypertensive Patients With Left Ventricular 
Hypertrophy Inappropriately High Left Ventricular 
Mass identifies a Hiah Risk Phenotvoe: The LIFE en 
Study 
Vittorio Palmieri, Jonathan N. Bella, Kristian Wachtell, Eva Gerdts, 
Vasilios Papademetriou, Markku S. Nieminen, Bjorn Dahlof, Richard 
B. Devereux. Weill Medical College of Cornell University. New York, N. Y, 
USA; Copenhagen County University Hospital, G/o&up, Denmark 
Background: Left ventricular (LV) hypertrophy (H) is both an adaptation to 
increased hemodynamic load and an independent cardiovascular risk factor. 
Methods: To explore whether LVH that is inappropriate (I) in relation to 
hemodynamic needs is associated with more severe cardiovascular abnor- 
rnalities than LVH that is adequate (A) for hemodynamic load, we used an 
equation developed in 393 apparently healthy adults to predict LV mass ade- 
quate for gender, heights7 (ideal body size) and stroke work (hemodynamic 
load). Observed echo LV mass was divided by predicted LV mass to obtain 
the percent of predicted LV mass (%PLVM) in 685 hypertensive subjects 
with echo LVH (LV mass > 49.2 in men or ~46.7 g/m*.7 women, aged 67 
* 7) enrolled in the LIFE study (JNC-V stage I-III hypertension and LVH by 
Cornell voltage duration or Sokolow Lyon criteria). %PLVM z 128% (95”’ 
%ile of %PLVM distribution in reference subjects) distinguished I-LVH from 
A-LVH. 
Results: Mean age (both 67 years, p = ns) or proportion of women (43 vs 
51%, p = 0.06) did not differ between I-LVH (n: 380, 60%) and A-LVH (n: 257, 
40%). Patients with I-LVH had lower systolic and diastolic BP (168/94 mmHg) 
than those with A-LVH (184197 mmHg, both p < O.OOl), but higher body 
mass index (28.3 vs 27.3, p < 0.01) and higher LV mass even accounting for 
impact of obesity (131 vs 121 g/m2, p < 0.001). I-LVH was also associated 
with lower ejection fraction (58 vs 63% in A-LVH), lower stress-corrected 
midwall shortening (92 vs 102% of predicted for stress), lower cardiac index 
(2.6 vs 3.1 I/minim*), and htgher total peripheral resistance (3818 vs 3428 
dynes’sec*cm-5”m*) (all p < 0.001). 
Conclusions: Among hypertensive patients with EGG and echo LVH, 
those with inappropriate LV mass had lower LV systolic function and car- 
diac pump function and higher peripheral resistance, suggesting that I-LVH 
represents an especially high cardiovascular risk phenotype. 
/ 1181-21 1 Parallel Cardiac and Renal End-Organ Damage in 
Hypertensive Patients With ECG Left Ventricular 
Hypertrophy: The LIFE Study 
Kristian Wachteil, Vittorio Palmieri, Michael H. Olsen, Jonathan N. Bella, 
Tapio Aalto, Bjdrn Dahldf, Eva Gerdts, Knut Borch-Johnsen, Jens Rokkedal, 
Hans Ibsen, Richard B. Devereux. Glostrup Universify Hospital, Glostrup, 
Denmark; The New York Hospital-Cornell Medical Center, NYj USA 
Background: Left ventricular (LV) geometric abnormalities and microal- 
buminuria (MIC) predict increased cardiovascular morbidity and mortality. 
However, the relation between LV geometric patterns and markers of renal 
glomerular damage has not been evaluated in a large hypertensive popula- 
tion with electrocardiographic (ECG) LV hypertrophy (LVH). 
Methods: Echocardiograms were obtained after 14 days placebo treat- 
ment in 833 patients with stage I-III hypertension and ECG-LVH. MIC was 
evaluated by u-albuminicreatinine ratio (UACR). MIC was defined as UACR 
> 3.5 g/mol and macroalbuminuria (MAC) as UACR > 35 gimol. 
Results: Mean age was 66 i 7 years, 42% were women and 19% had 
normal LV geomety, 11% had concentric remodeling, 47% had eccentric 
hypertrophy and 23% had concentric hypertrophy. Patients with abnormal 
LV geometry had significantly higher prevalence of MIC (25 vs. 9%, p < 
0.001) and MAC (6 vs. O%, p < 0.001) as compared to patients with normal 
geometry. In univariate analyses, UACR correlated positively to LV mass 
(r = 0.21) systolic blood pressure (SBP) (r = 0.22) and age (r = 0.14), all 
p < 0.001. Patients with MIC were older (p < O.Oi), had higher SBP (p 
< O.OOl), higher LV mass (p < O.OOl), lower endocardial (p < 0.05) and 
lower midwall shortening (p < 0.01) and higher prevalence of diabetes (p 
< 0.001) as compared to patients with normal UACR. Multiple regression 
analysis showed that MIC was associated with higher LV mass (,,?I = 0.180, p 
< O.OOl), older age (fl = 0.101, p < 0.05), higher SBP (6 = 0.079, p < 0.05) 
and presence of diabetes (,9 = 0.246, p < 0.001). 
Conclusion: Hypertensive patients with ECG-LVH and abnormal LV ge- 
ometry on echocardiography have high prevalences of MIC and MAC. LV 
mass is associated with MIC independent of other known renal risk factors 
related to impaired glomerular permeability suggesting parallel cardiac and 
renal end-organ damage. 
L-i 1181 22 Endothelin-1, Nitric Oxide Metabolites, Left 
Ventrrcular Mass and Hemodynamic Responses 
to Vasoconstrictive Stress in Normotensive Youth 
George A. Mensah, Frank A. Treiber, Robert W. Jackson, Jennifer 
S. Pollock, David M. Pollock, Jonas del Rosario, Harry Davis, Gaston 
K. Kapuku. Georgia Prevention Institute and the Vascular Siology Center. 
Medical College of Georgia, Augusta, Georgia, USA 
Background: Endothelin-1 (ET-I) and nitric oxide (NO) are vasoactive 
agents that play crucial roles in cardiovascular health and disease. Although 
ample evidence suggests that they are interdependent and co-regulated, 
ET-I and NO are rarely evaluated simultaneously. To test the hypothesis that 
a pattern of simultaneous increase in ET-1 and decrease in NO (in response 
to vasoconstrictive stress) is exaggerated in blacks with a family history of 
hypertension, we studied 12 normotensive adolescent males. 
Methods: There were 6 black and 6 white males (mean age = 17.4 * 1.7 
vears). We measured echocardioaraphic left ventricular mass index (LVMI), 
blood’ pressure (BP), heart rate,-bibimpedance-determined cardiac index 
(Cl) and total peripheral resistance index (TPRI) and levels of ET-I and NO 
metabolites (NOx) in response to forehead cold’and hand cold immersion. 
Results: Baseline clinical, demographic and hemodynamic parameters 
were similar in Blacks and Whites. The pattern and magnitude of BP, Cl 
and TPRI increase in response to stress were also similar. LVMI, posterior 
wall and septal thickness were all significantly higher in blacks. Of the 28 
samples taken at pre-specified time points, ET-I was generally higher and 
NOx lower in blacks but in only 2 of these 28 samples were these findings 
statistically significant. However, the ratio of ET-IINOx was statistically sig- 
nificantly higher in Blacks after catheter insertion (7 vs. 3.8; p c 0.02) and at 
most time points during the study (range = 4.1-7.0 vs. 3.0-5.0;). 
Conclusions: The relationship between the response of vasoactive 
agents to vasoconstrictive stress is better assessed by the ratio of ET-IINOx 
rather than the levels of either agent alone. This ratio is significantly higher in 
normotensive black youth with a family history of hypertension and it is inde- 
pendently associated with greater LVMI and wall thicknesses. Confirmation 
in a larger sample size is necessary. 
i i 81-23 Enhanced Inhibition of Matrix Metalloproteinase 
is Key Regulatory Mechanism of Angiotensin II 
Induced Ventricular Fibrosis in Hvpertensive 
Heart 
_. 
Yasushi Sakata, Tohru Masuyama, Kazuhiro Yamamoto, Hiroya Kondo, 
Nagahiro Nishikawa, Keiko Ono, Tsunehiko Kuzuya, Takeshi Miwa, 
Masatsugu Hori. Osaka Univ. Graduate School of Medicine, Suita, Japan 
Background: Angiotensin (AT) II causes LV fibrosis leading to diastolic 
dysfunction. However, regulation of fibrosis by ATII is not well understood in 
hypertensive hearts. In this study, ATII type 1 receptor antagonist (ATlRa) 
(Candesartan; 1 mgikglday) was given in hypertensive rats to assess the 
role of AT II in the regulation of production and degradation of collagen. 
Methods: Thirteen Dahl salt sensitive rats were placed on 8% NaCl diet 
from 7 wks old. ATlRa were given from 8 wks in 6 rats (group AT(+)). 
Placebo were given in 6 rats (group AT(-)). The rats fed on 0.3% NaCl diet 
were defined as control rats (group N, n = 6). In addition to LV end-diastolic 
pressure (LVEDP) and LV hydroxyproline content (Pro-OH), the amount 
of mRNA for collagen-l, matrix metalloproteinase-I (MMP-1) and tissue 
inhibitor of metalloproteinase-I (TIMP-I) were determined by quantitative 
RT-PCR at 19 wks. 
Results (expressed as mean value i SEM; *p < 0.05 vs N tp < 0.05 vs 
AT(-)): 1) AT1 Ra administration prevented the elevation of LVEDP and the 
transition to heart failure (N; 9 f I, AT(-): 19 f 2*, AT(+); 9 i It mmHg). 2) 
AT1 Ra administration reduced the increase in Pro-OH (N; 2.3 i 0.3, AT(-); 
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4.0 f O.Z*, AT(+); 2.7 i 0.4t pmol/g). 3) The amount of mRNA for collagen-i 
increased in AT(-) by 4.7 fold as compared with N and was reduced in 
AT(+) by 65% as compared with AT(-). 4) The amount of mRNA for MMP-1 
increased in AT(-) by 3.7 fold as compared with N. The expression was 
reduced in AT(+) but was still larger by 2.2 fold compared to N. In contrast, a 
5.8-fold increased expression of TIMP-1 in AT(-) was reduced to the normal 
level by AT1 Ra administration. 
Conclusions: Enhanced inhibition rather than decreased transcription, 
of matrix metalloproteinase, is a key regulatory mechanism of AT H induced 
LV fibrosis in hypertensive heart. 
1 1181-24 ) Functional Implications of Elevated Collagen 
Markers in Untreated Hypertension 
M. Mitchell Lindsay, Peter Timms, Vingamaur Srikanthan, Paul Maxwell, 
Francis G. Dunn. Departments of Cardio/ogy and Biochemistry Sfobhill 
HospikY, Glasgow, UK - 
Interstitial fibrosis occurring in hypertensive heart disease is an important 
pathological entity An understanding of both the pathophysiological pro- 
cesses involved in interstitial fibrosis and a non-invasive means of assessing 
fibrosis are the sources of considerable research. We investigated the role 
of inhibition of degradation as mediated by TIMP-I. We studied a group of 
untreated patients with essential hypertension and a matched control group. 
All patients underwent echocardiography with estimation of LV mass and 
24 hr BP monitoring. Diastolic filling was assessed as a marker of fibrosis. 
We measured plasma markers of procollagen type I carboxyterminal pep- 
tide (PICP) as marker of collagen synthesis, carboxy-terminal telopeptide of 
collagen type I (ITCP) as marker of extracellular collagen type I degradation 
and TIMP-I as marker of inhibition of degradation. ‘Ninety-nine untreated 
patients with sustained hypertension (HBP) (24 hr BP 151/93) were studied 
in addition to 50 normal subjects (N) (mean BP 129/79). LV mass index was 
significantly higher in the HBP group (132 g/m2 Vs 96 g/m’ p < 0.001). 
Doppler variables of diastolic filling were prolonged in the HBP group, E: A 
ratio (HBP 0.96 Vs N 1 .I p = 0.003) and IVRT (HBP 0.12 Vs N 0.099 p = 
0.0002). Biochemical markers of collagen synthesis (PICP HBP 200 @g/l Vs 
N 166 &g/l p = 0.01) and inhibition of degradation (TIMP-I HBP 385 rig/ml 
Vs N 281 rig/ml p = 0.001) were significantly elevated in the HBP group. 
Measurements of ITCP, reflecting collagen degradation, were also elevated 
in the HBP cohort. (ITCP; HBP 5.2 fig/l Vs N 2.9 fig/l p < 0.0001). Elevated 
plasma TIMP-1 levels reflected the presence of diastolic dysfunction. Pa- 
tients with hypertension but without diastolic filling abnormalities had normal 
TIMP levels (mean 288 ngiml) whilst the remainder of the hypertensive group 
with demonstrable diastolic dysfunction had significantly elevated TIMP lev- 
els in comparison (mean 421 ngiml p = 0.006). In addition Timp-1 levels 
correlated with E:A ratio. As would be expected no relationship with diastolic 
dysfunction was seen with the other collagen markers. Therefore; TIMP-I 
would seem to be a potential candidate for the non-invasive assessment of 
fibrosis in hypertensive LVH but inhibition of degradation would not appear 
to play a key role in the development of fibrosis. 
ORAL 
Mechanisms and Treatment of Pulmonary 
Hypertension 
Tuesday, March 14, 2000, 4:00 p.m.-500 p.m. 
Anaheim Marriott, Marquis Northeast 
4:00 p.m. 
894-l High Prevalence of Patent Foramen Ovale at an 
Altitude of 4559 m in Subjects Susceptible to High 
Altitude Pulmonary Edema 
Yves Allemann, Ernst Lipp, Damian Hutter, Claudio Sattori’, 
Hervb Duplain’, Marc Egli’, Urs Scherrer’ , Christian Seiler. Swiss 
Cardiovascular Center, University Hospifal Bern; ‘Department of Internal 
Medicine, University Hospital Lausanne, Switzerland 
Background: Subjects prone to high-altitude pulmonary edema (HAPE-P) 
have an accentuated pulmonary vasoconstrictor response to hypoxia and 
consequently an augmented pulmonary vascular resistance At sea level, a 
patent foramen ovale (PFO) is present in approximately 25% of the general 
population, and in clinical conditions associated with temporary right-to-left 
shunting it aggravates hypoxemia We hypothesized that at high altitude, 
exaggerated pulmonary hypertension in HAPE-P may be associated with an 
augmented prevalence of PFO, which in turn could contribute to more severe 
arterial oxygen desaturation. 
Methods: Sixteen HAPE-P and 19 age-matched subjects resistant to 
this condition (HAPE-R) were studied at high-altitude (4559 m) Contrast 
trans-esophageal echocardiography (TEE) was performed with imaging of 
the interatrial septum in 2 orthogonal planes PFO was considered present 
if microbubbles were seen in the left atrium within 3 cardiac cycles after 
opacification of the right atrium (RA) The right ventricular (RV) to RA pres- 
sure gradient was assessed with Doppler echocardiography Arterial oxygen 
saturation (SaO,) was measured by finger pulse oxymety. 
Results: 
HAPE-P 
Mi?ll/W0~Wl 
Blood pressure, mmHg 
SaO* , % 
RV-RA, mmHg 
PFO present, % 
HAPE-,R 
1016 
118/m* 19111 
75516 
56i12 
56 
P 
1712 
128/72 + 19117 ns 
63f7 0.04 
36h 10 0.0001 
21 0.03 
Conclusions: At high-altitude, exaggerated pulmonary vasoconstriction 
in HAPE-P subjects is associated with a more than 2.5fold augmentation of 
the prevalence of a PFO. We speculate that right-to-left shunting through the 
PFO contributes to the more severe hypoxemia observed in these subjects, 
and, therefore, may be a relevant factor in the pathogenesis of HAPE. 
4:15 p.m. 
I 894 2 Impact of Prostacyclin on Five Year Survival for 
Primary Pulmonary Hypertension 
Vallerie V. McLaughlin, Peter M. Meyer, Stuart Rich. Rush Medical College, 
Chicago, IL, USA 
Background: The National Institutes of Health (NIH) Registry on Primary 
Pulmonary Hypertension (PPH) established the natural history of PPH in the 
1980’s, prior to current therapy. Prostacyclin has been shown to increase 
survival in PPH for at least one year, however longer term data has not yet 
been reported. Our objective was to determine the impact of Prostacyclin 
(PGlp) on survival in PPH for 5 years by comparing our experience to the 
NIH Registry and to survival with lung transplantation. 
Methods: 116 patients (88 women, 28 men, mean age 42.4 + 13.8 years) 
were followed for 29.7 f 21.2 months. 56 patients were NYHA FC Ill and 60 
were NYHA FC IV. All were treated with PG12. Actual survival was computed 
by Kaplan-Meier estimates. Expected survival was determined from the NIH 
Registry of PPH. Survival following lung transplantation was extracted from 
the International Heart and Lung Transplantation Registry. 
Results: 
1 year 
3 years 
5 years 
Actual (%) 
88 
79 
62 
Expected (%) 
66 
46 
34 
Transplantation (%) 
72 
56 
43 
Conclusion: PGl2 significantly improves survival in patients with PPH for 
up to 5 years and has a better 5 year survival than lung transplantation. PGl2 
should be the preferred therapy for PPH, with transplantation reserved for 
those who deteriorate despite optimal therapy or do nOt tolerate the drug. 
4:30 p.m. 
I 894 3 Pulmonary Vascular Response to Priming With 
Inhaled Nitric Oxide During Hyperoxia, Normoxia 
and Hypoxia 
Theo M. Hoorntje, Narayanswami Sreeram, Carlos E. Blanco. Departments 
of Pediatric Cardiology University Medical Cenfer Ufrechf, and of 
Neonatologl: University Hospifal of Maastricht, The Netherlands 
Background: Inhaled Nitric Oxide (iNO) administered after hypoxic vaso- 
constricton has set in, only partially prevents pulmonary vasoconstriction. 
Futhermore it is unclear if iN0 dilates pulmonary arteries during normoxia 
and hyperoxia. Aim of the study was to assess the effect of continuous 
administration of iN0 under conditions of graded hyperoxia, normoxia and 
hypoxia. 
Methods: Eight newborn piglets (11-18 days, 3.2-5.2 kg) were instru- 
mented under anesthesia with catheters m the femoral artery, vein, and left 
atrium. Transonic flowprobes were placed around the main pulmonary trunk 
and ascending aorta. A fiberoptic catheter was inserted in the pulmonary 
artery for continuous measurement of mixed venous saturation (p02mv) and 
pulmonary artery pressure. The piglets were mechanically ventilated with a 
gas mixture of N2/02, starting with Fi02 of 1 .O and gradually decreasing to 
Fi02 of 0.1. After a recovery period continous inhalation with NO at 80 ppm 
was started and the same protocol was repeated. The relationship between 
p02mv and PVR was studied. 
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Results: The figure shows two regression lines (with 95% Cl.) before and 
after iN0 during hyperoxia, normoxia and hypoxia. As shown, iN0 exerts a 
continuous influence on PVR, with the greatest effect being observed during 
hypoxia (PVR = 0.214-0.29 x p02mv; R = 0.974 and PVR iN0 = 0.94-0.12 
x p02mv; R = 0.906). 
Conclusions: 1. iN0 dilates pulmonary vessels during hyperoxia, nor- 
moxia and hypoxia. 2. The relationship between PVR and p02mv is such that 
the vasodilator response of iN0 increases with increasing degree of hypoxia 
4:45 p.m. 
1 894-4 / Superiority of Mixed ETA/~ Over Specific ETA 
Antagonist in Treatment of Pulmonary Hypertension 
and Right Ventricular Hypertrophy in the 
Monocrotaline Rat Model 
Jean-Fran@ Jasmin, Jocelyn Dupuis. Montreal Heart Institute, Montreai, 
Quebec, Canada 
Background: Both mixed and specific endothelin (ET) receptor antagonists 
can reduce pulmonary hypertension (PH) and fight ventricular hypertrophy 
(RVH) in various animal models, Direct comparison of mixed versus specific 
antagonists has however never been done, Depending on their net effects 
after blockade of endothelial and smooth muscle ETa receptors, mixed an- 
tagonist could be more or less effective than specific ETA antagonist. 
Methods: Two weeks after injection of either 0.5 ml 0.9% saline or 0.5 
ml 60 mg/kg monocrotaline (MCT), rats were treated with 50 mg/kg/day 
of either a specific (LUI 35252) or a mixed (LU420627) antagonist for a 
period of 3 weeks. This resulted in four groups; control (n = 15), MCT (n 
= 40) MCT + ETA antagonist (n = 39) and MCT + ETA/~ antagonist (n = 
30). Mortality was determinated and hemodynamic measurements, isolated 
lungs pressure-flow (P-Q) curves and measures of RVH were obtained in 
surviving rats. 
Results: There were no deaths in the control rats. Five weeks survival 
was 38% in the MCT group; this was increased, although not significantly 
to 56% in MCT + ETA group with further significant improvement to 67% in 
the MCT + ETA/B group (p < 0.015). The MCT group developed severe PH 
wi?h a RV systolic pressure of 87 ?t 1 mmHg (p < 0.001). This was similarly 
improved in both MCT + ET,.+ and MCT + ETA/~ groups with 72 f 3 mmHg 
and 67 f 3 mmHg respectively (p =z 0.05). The MCT group displayed severe 
RVH with a mean RV/Left Ventricle + Septum weight ratio of 72 i 1%; this 
was not affected by the specific antagonist (70 & 2%) but reduced to 54 f 
3% in the MCT + ETN~ group (p < 0.001). Pulmonary resistive properties 
were similarly improved in both treatment groups (p < 0.05); on raising flow 
rate from 5 mlimin to 25 miimin, the pulmonary pressure increased from 19 
Anaheim 
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i 0.4 mmHg to 67 f 2 mmHg in the MCT group, from 15 i 1 mmHg to 49 i 
3 mmHg in the MCT + ETA group and from 15 i 1 mmHg to 47 f 4 mmHg 
in the MCT + ETN~ group. 
Conclusion: The mixed ET+.,, antagonist LU420627 is superior to the 
specific ETA antagonist LU135252 in this model of PH. This suggests that 
blocking the smooth muscle ETa receptors provides additional benefits that 
outweigh possible harmful effect of endothelial ETa blockade. 
ORAL 
El 905 Outcomes and Effect of Treatment of Aortic, 
Peripheral, and Cerebrovascular Disease 
Wednesday, March 15, 2000, 8:30 a.m.-l 0:OO a.m. 
Anaheim Marriott, Marquis Northeast 
8:30 a.m. 
905-l Association of Coronary and Cerebrovascular 
Events With Aortic Atherosclerosis: Insights From a 
Population-Based Study 
Yoram Agmon, Bijoy K. Khandheria, Irene Meissner, Gary L. Schwartz, 
Tanya M. Petterson, W. Michael Q’Fallon, Federico Gentile, Jody L. Covalt, 
Jack P. Whisnant, David 0. Wiebers, James B. Seward. Mayo Clinic and 
Mayo Foundation, Rochester, Minnesota, USA 
Background: An association of coronary artery disease (CAD) and cere- 
brovascular disease (CVD) with atherosclerosis of the thoracic aorta (ATA) 
has been previously described in selected patient groups. This association 
has not been confirmed in the general population. 
Methods: Transesophageal echocardiography was performed in 581 
subjects, a random sample of the Olmsted County population aged 2 45 
yrs (stratified by age and sex), as part of the SPARC study (Stroke Preven- 
tion: Assessment of Risk in a Community). The presence of ATA (ATA of 
any degree, in any segment of the thoracic aorta) and complex ATA (pro- 
truding atheroma > 4 mm in thickness, and/or mobile debris or ulceration) 
was determined, and the association of prior CAD and CVD with ATA was 
assessed. 
Results: ATA was present in 298 subjects (51% of the total population), 
and complex ATA in 44 subjects (15% of subjects with ATA). The age- and 
sex-adjusted odds ratios (OR) of ATA for various clinical variables, and their 
95% confidence intervals (Cl), are presented in the Table. 
ATAt ComplexATA* 
Variable OR (95% Cl) P OR(95% Cl) P 
Angina pectoris 2.69 (1.31-5.53) 0.007 2.44 (1.13-5.28) 0.02 
Myocardial infarction 7.18 (2.23-23.1) 0.001 3.11 (1.37-7.09) 0.007 
Coronary revascularization 4.75(1.72-13.1) 0.003 3.20 (1.30-7.87) 0.01 
CAD' 3.37 (1.67-6.81) 0.001 2.94(1.43-6.06) 0.004 
Cerebral infarction 3.01 (0.52-17.4) 0.22 1.68 (0.57-4.95) 0.35 
Transient ischemic attack 1.05 (0.27-4.06) 0.94 1.61 (0.45-5.68) 0.46 
Carotid endarterectomy not applicable 3.10 (0.48-19.9) 0.23 
CVD"" 1.67(0.63-5.58) 0.26 1.95 (0.81-4.70) 0.14 
t ORs for ATA (any degree) vs no ATA; * ORs for complex vs non-complex ATA; * angina 
pectoris, myocardial infarction, and/or revascularization; xI cerebral infarction, transient 
ischemic attack, and/or carotid endarterectomy. 
Conclusions: Prior coronary events are strongly associated with ATA 
and complex ATA, suggesting the presence of common risk factors for both 
pathologies. A similar trend, albeit weak and statistically non-significant, was 
noted for CVD and ATA, suggesting a relatively minor role for ATA in the 
pathogenesis of clinical CVD in the general population. 
8:45 a.m. 
/ 905 2 Predictive of Morality in Patients With Type A Acute Aortic Dissections - Results From the international 
Registry of Acute Aortic Dissection (IRAD) 
Kim A. Eagle, David Bruckman, Eric Isselbacher, Arturo Evangelista, 
Rossella Fattori, Jae K. Oh, Andrew G. Moore; Joseph Malouf, 
Udo Sechtem, Alfred0 Llovet, Hans-Joseph Deutsch, Dan Gilon, 
Linda Pape, Patrick T. O’Gara, Dean Karavite, Pamela Russman, Peter 
G. Hagan, William F. Armstrong, G. Michael Deeb, Christoph A. Nienaber, 
Toru Suzuki. Coordinating Center for /RAD Investigators; University of Tokyo 
Hospital and University of Michigan Medical Center, M/, USA 
Background: Acute aortic dissection is a clinical emergency associated 
with high morbidity and mortality. Data are limited regarding the clinical 
factors predicting mortality. The IRAD registry was developed to assess the 
presentation, management and outcomes of acute aortic dissection (AAoD). 
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Methods: At 13 international tertiary centers, data on 556 patients (pts) 
with AAoD (presenting within 14 days of symptom onset) between January 
1996 and March 1999 were collected. 
Results: On average pts were referrals (63%), 63 years of age, male, 
presenting with abrupt (66%), severe (75%) chest pain (75%). 63% were 
type A dissections. Overall in hospital mortality was 26%. 73% of type A AoD 
were treated surgically, with an in hospital mortality 27%. Among type A not 
receiving surgery (typically due to age and comorbidity), in-hospital mortality 
was 53%. Mortality of patients with type 6 dissection treated medically was 
9%. Surgery was performed in 20% of pts with type B AoD and mortality was 
26%. A predictive model among type A pts to identify prognostic factors of 
mortality, excluding management, revealed five major factors (univariates, p 
< 0.006)*. Area under ROC curve was 0.74. Mortality was 70% in those with 
at least 3 of 5 factors (p x 0.001.) 
Variables at presentation Overall % among % among Model OR, mortality 
or by imaging modality’ type A% survivors deaths p-value 95% Cl 
Gender (female) 62.9 31.2 4a.7* 0.047 1.74 
(male, baseline) 37.1 68.8 51.3* [I .01,2.99] 
Age > 65 yrs 42.9 37.7 52.9* 0.016 1.93[1.1,3.3] 
SPB < 100 mmHg 26.7 16.8 45.5* <O.OOl 3.28[1.9,5.7] 
Periaortic hematoma’ 19.9 15.9 30.9* 0.021 2.14[1.1,4.1] 
Anv Dulse deficits 15.1 10.5 27.4* 0.004 2.6511.4.5.11 
9:15 a.m. 
/ 905-4 / Impact of Ramipril and Vitamin E on 
Cerebrovascular Events in the HOPE (Heart 
Outcomes Prevention Evaluation) Trial 
Jackie Bosch, Salim Yusuf, Janice Pogue, Jeff Probstfield, Rafael Diaz, 
Robert Hoeschen, Jan Ostergren. On behalf of fhe HOPE Invesfigators; 
MeMaster University: Hamilton, Canada 
Background: We randomized 9541 high risk patients, ~55 years of age with 
either previous cardiovascular disease or diabetes plus one risk factor to 
receive either Ramipril (up to 10 mg/day) or equivalent placebo; and vitamin 
E (400 IU/day) or placebo for a mean of 4.5 years. Ramipril reduced the risk 
of strokes, transient ischemic attacks (TIA) and carotid endatterectomy (CE). 
Results: 
Relative Risk 
RamiDril Placebo (Confidence Interval) P 
All strokes 
Fatal strokes 
Nonfatal strokes 
TIA 
CE 
Anv cerebrovascular event 
3.3% 4.8% 0.68 (0.56-0.84) 0.0002 
0.4% 0.9% 0.41 (0.24-0.73) 0.0015 
3.0% 4.0% 0.74(0.59-0.92) 0.0076 
4.1% 4.9% 0.82 (0.68-1.00) 0.046 
1.2% 1.4% 0.82 (0.58-1.18) 0.29 
7.5% 9.6% 0.76 (0.66-0.88) 0.0001 
’ Imaging modalities: TEEilTE, CT, MRI, aortogram. 
Conclusions: Despite recent advances, in hospital mortality due to acute 
aortic dissection remains high. Prior to medical or surgical care, several 
clinical factors are associated with lower survival. As the registry adds pa- 
tients, stronger models should provide clinicians with better data in diagnosis, ’ 
management and outcomes of AAoD 
9:00 a.m. 
905-3 Presentation, Clinical Findings and Outcomes 
Among Patients With Acute Definitive Intramural 
Hematoma - Results From the International Registry 
of Acute Aortic Dissection (MAD) 
Ariuro Evangelista, David Bruckman, Charlene Gaca, Peter G. Hagan, Jae 
K. Oh, Joseph Malouf, Andrew G. Moore, Udo Sechtem, Alfred0 Llovet, 
Hans-Joseph Deutsch, Holger Diedrichs, Dan Gilon, Christoph A. Nienaber, 
Patrick T. O’Gara, Dean J. Karavite, Pamela L. Russman, William 
F. Armstrong, G. Michael Deeb, Toru Suzuki, Eric lsselbacher, Kim A. Eagle, 
Linda Pape. General Hospital-University Vail d’Hebron, Barcelona, Spain; 
University of Michigan Health System, IRAD Coordinating Center, Ann 
Arbor, Ml, USA 
Background: Little is known of the differences in the acute presentation aortic 
dissection and definitive intramural hematoma (dlMH). The IRAD registry 
was established to evaluate the presentation, diagnosis, management and 
outcomes of acute aortic dissection (AAoD). 
Methods: Data on 556 patients presenting within 14 days of symptom 
onset were identified at 13 international tertiary centers. Definitive IMH ex- 
cluded the presence of a double lumen or intimal flap by imaging modalities 
(TEETTTE, CT, MRI, Aortogram). 
Results: Of 550 cases with imaging studies, 9.6% (n = 54) of patients (pts) 
in the registry had a dlMH. 21.6% of pts had hematoma documented along 
with evidence of intimal flap and/or double lumen. On average, patients with 
dlMH were older (66.9 y vs. 62.7 y, p = 0.0016), type B (61.1% vs 34.7% for 
classic AAoD, p 5 0.001). Severity, and location (chest, back, or, abdomen) 
of pain at presentation, prior surgery (CABG, valve replacement), chest x-ray 
or electrocardiogram findings did not differ between AAoD and dlMH (all p 
> 0.05). Medical management (70.4% of cases) was preferred over surgical 
intervention (70.4% vs 44.0%, p 5 0.001). CT was the initial image modality in 
70.4%, with TEE/TTE as the initial study in 25.9% of pts. In hospital mortality 
(22.2%) did not differ from overall registry mortality (26.0%, p = 0.52). Mortality 
rates per type/management did not differ from those with classic AAoD (all p 
z 0.05): Type A treated surgically, 40.0%; Type A treated medically, 36.4%; 
Type B treated surgically, 16.7%; Type f3 treated medically, 11 .I %. 
Conclusion: 1) Definitive IMH represents up to 10% of patients presenting 
with an acute aottic syndrome. 2) Definitive IMH is more likely to be in the 
descending aorta as compared to classic acute aortic dissection. 3) Overall 
outcomes are similar to those of pts with classic acute aortic dissection, 
emphasizing the role of surgery in ascending definitive intramural hematoma. 
Ramipril was similarly effective in reducing the risk of a stroke in those 
patients with previous cerebrovascular disease (RR of 0.63, 95% Cl of 0.55 
to 1.25) and those without it (RR of 0.64, 95% Cl of 0.50 to 0.61). Benefit 
was also observed in those with and without hypertension. Vitamin E did not 
reduce the risk of strokes (4.3% vs 3.7%, P = 0.16), either fatal (0.7% vs 
0.5%, P = 0.41) or nonfatal (3.7% vs 3.2%, P = 0.26). 
Conclusions: Ramipril, but not vitamin E, reduces the risk of strokes and 
other cerebrovascular events by about i/3 in bofh primary and secondary 
prevention and among those with and without hypertension. 
9:30 a.m. 
905-5 Effect of Estrogen and Progestin on Clinical 
Peripheral Arterial Disease in Women With Coronary 
Heart Disease 
Judith Hsia, Joel Simon, Feng Lin, William B. Applegate, Molly Vogt, 
Donald Hunninghake, Margaret Carr. George Washington Universif): 
Washington, DC, USA 
Background: Observational studies, including the Cardiovascular Health 
Study and the Asymptomatic Carotid Atherosclerotic Progression Study, 
have reported slower progression of peripheral arterial atherosclerosis in 
postmenopausal women taking estrogen, but this relationship has not been 
confirmed in a clinical trial. 
Methods: 2763 postmenopausal women with coronary heart disease, 
mean age 67 i 7 years, were randomly assigned to conjugated equine es- 
trogens (0.625 mg) with medroxyprogesterone acetate (2.5 mg) daily (E + P) 
or to placebo in the Heart & Estrogen/Progestin Replacement Study (HERS). 
Peripheral arterial disease was a predefined secondary endpoint of HERS, 
and was not assessed at baseline. For this analysis, peripheral arteries were 
defined as all arteries except the coronaries. Incident peripheral arterial pro- 
cedures and deaths were identified at four month intervals during 4.1 years 
of follow up, and confirmed by central review of supporting ,documentation 
by adjudicators blinded to treatment assignment. 
Results: 311 peripheral arterial events were reported in 213 women, an 
annual incidence of 2.9%. Overall, 22 aortic, 119 carotid, 6 cerebral, 143 
extremity, and 21 mesenteric/renal arterial procedures (revascularization, 
amputation) or deaths were reported. The number of women who had pe- 
ripheral arterial events was 99 among those assigned to E + P and 114 
among those assigned to placebo, a non-significant difference (relative haz- 
ard 0.67; 95% Cl 0.66-l .14). Lower extremity arterial events were about 11 
times more frequent in this cohort of women with coronary heat-l disease than 
repotted for the general population. HERS reported more coronary events 
during the first year of treatment among women assigned to active E + P; this 
early excess risk was not observed for peripheral arterial events. In multivari- 
ate analysis, independent determinants of peripheral arterial events in this 
cohort included diabetes, hypertension, current smoking and statin use (all p 
< 0.05); body mass index was inversely related to peripheral arterial events 
(p < 0.05). Incident peripheral arterial events were associated with subse- 
quent coronay events (non-fatal myocardial infarction + coronary death + 
revascularization), p < 0.001. 
Conclusion: During mean follow up of 4.1 years, daily treatment with E 
+ P did not reduce peripheral arterial events significantly in postmenopausal 
women with preexisting coronary heart disease. Risk factors for peripheral 
arterial events included diabetes, hypertension and smoking, and the periph- 
eral arterial events predicted subsequent coronary events. 
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905-6 1 Low Molecular Weight Heparin Versus Minidose 
Unfractionated Heoarin for ProohvlaxiS Aaainst 
Venous Thromboe*mbolism in tie&Cal Int&sive Care 
Unit Patients: A Randomized Controlled Trial 
Samuel Z. Goldhaber, Daniel H. Kett, Christopher J. Cusumano, Cesar 
A. Kuroki. On behalf of the Enoxaparin Medical Intensive Care Unit 
Investigators; Brigham and Women’s Hospital, Harvard Medical School, 
Boston, MA, USA 
Background: Prc$ious studies of venous thromboembolism prophylaxis 
have focused on patients undergoing surgery or general medical patients. 
However, Medical Intensive Care Unit (MICU) oatients at Brigham and 
Women’s Hospital had a high overall in-hospital mortality rate OF 27% and 
a high rate of venous thrombosis of 33% (JAMA 1995; 274: 335). These 
findings prompted us to undertake a trial of more intensive pharmacological 
prophylaxis in this high-risk population. 
Methods: In a 28-institution collaborative trial, we enrolled MICU patients, 
all of whom received prophylactic graduated compression stockings, and 
randomized them to: open label enoxaparin 30 mg subcutaneously twice 
daily versus unfractionated heparin 5,000 Units subcutaneously twice daily. 
The principal endpoint was development of deep venous thrombosis (DVT) 
on ultrasound, which was performed on MICU days # 3, 7, IO, and 14. 
Analyses on all randomized patients in an “intention-to-treat” population 
are repotted, but the results do not change appreciably when analyzed in 4 
alternative ways, according to quality of the ultrasound examination or receipt 
of at least six doses of study drug. 
Results: 325 patients were randomized of approximately 11,000 screened. 
There was no difference between enoxaparin and minidose heparin, respec- 
tively, for the rate of all DVT, 16% versus 13%, and no difference for the 
proximal DVT rate, 7% versus 5%. There was a trend toward decreased 
mortality in the enoxaparin group, 1% versus 5% (p = O.lO), but this must be 
interpreted with utmost caution. There was no difference in all bleeding (12% 
versus 11%) or major bleeding (2% versus 2%) between the 2 groups. 
Conclusions: Among the medical patients enrolled in this trial, enoxa- 
parin 30 mg twice daily and unfractionated heparin 5,000 Units twice daily 
were equally effective and safe. The low overall mortality rate and the high 
exclusion rate suggest that this trial did not enroll MICU patients of typical 
high acuity. 
ORAL 
/9Q6j Drug Therapy of Hyperlipidemia: Clinical 
Benefits 
Wednesday, March 15,2000, 8:30 a.m.-g:45 a.m. 
Anaheim Marriott, Marquis Northwest 
8:30 a.m. 
906-l Is the Risk of Cardiovascular Events the Same for 
WOSCOPS Patients and Hypercholesterolemic US 
Men? 
Gilbert L’ltalien, Jaime Caro, Krista Huybrechts, Jenifer Ehreth, 
Joseph Jackson, James Shepherd. Bristol-Myers Squibb, Princeton, New 
Jersey; Caro Research, Concord, Massachusetts, USA; The West of 
Scotland Coronary Prevention Trial (WOSCOPS) Study Group, Glasgow, UK 
Background: The general applicability of economic analyses and risk as- 
sessments derived from the West of Scotland Coronary Prevention Trial 
(WOSCOPS) is often questioned because it is assumed that the Scottish 
population is at higher risk for cardiovascular events. The goal of this study 
was to address this question by comparing risk in the WOSCOPS patients to 
NHANESIII subjects of the same age and LDL-C levels. 
Methods: A subset was created from the NHANESIII population (1988-94) 
of men aged 45 to 64 years with an LDL-C 156 to 254 mg/dl. The five year 
risk of a cardiovascular event (fatal CHD, non-fatal Ml, CABG, PTCA) was 
computed for each NHANES individual and each WOSCOPS patient using 
an exponential risk equation derived from WOSCOPS patients. Subjects 
were grouped according to risk levels in five year increments (e.g. <5%, 
5-9%, IO-14%, etc.). Both the proportion of subjects who fell within each 
risk category and the mean risk for subjects in each category were com- 
pared. 
Results: The risk distributions and mean risk is shown for both the 
WOSCOPS and NHANESIII in Figures 1 and 2. The average risk for the 
WOSCOPS patients and NHANESIII subjects was 14.0% and 14.4% respec- 
tively. There was close correspondence between WOSCOPS and NHANES 
subjects at all risk levels 
Conclusion: Among US men aged 45-64 with LDL levels from 156-254 
mg/dl the five year risk of a major cardiovascular event is remarkably similar 
to that of WOSCOPS patients. This finding supports the general applicability 
of the results of the WOSCOPS study and bi cost-effectiveness -analyses 
and risk assessments. 
8:45 a.m. 
El 906 2 Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPSTTexCAPS) -The Effect 
of Treatment With Lovastatin on the Utilization of 
Invasive Cardiac Procedures and the Extent of 
Angiographic Disease 
William B. Kruyer, Vladimir Zagrebelsky, Edwin J. Whitney, Qinfen Yu, 
Alexandra Langendorfer, Polly A. Beere, Deborah Ft. Shapiro, John 
A. Farmer, John R. Downs, Michael Clearfield, Stephen Weis, Antonio 
M. Gotto, Jr.. Wi/ford Ha// Medical Center, San Antonio, TX; University of 
North Texas Health Science Center, Fort Worth, TX, USA 
Background: AFCAPWexCAPS was a randomized, double-blind, placebo 
(PBO)-controlled primary prevention trial of 6605 men and women, without 
clinical evidence of atherosclerotic disease; after a mean treatment period of 
5.2 years, lovastatin (LOVA) 20-40 mg daily reduced the risk of a first acute 
major coronary event (fatal or nonfatal myocardial infarction, or unstable 
angina or sudden cardiac death) by 37% (p < 0.0001) and first coronary 
revascularization by 33% (p = 0.001). 
Methods: Total revascularization was pre-specified as a secondary end- 
point. Separate exploratory analyses were performed for surgical (CABG) 
& catheter-based (PTCA) revascularization & diagnostic coronary angiogra- 
phy (CATH). Extent of disease was examined by exploratory analyses of all 
patients with CATH, regardless of endpoint status. Interpretation of CATH 
was made in a blinded manner and included the following: % stenosis, # of 
major vessels with stenosis ~50%. Left ventricular function was assessed 
by ejection fraction and regional wall motion abnormalities. 
Results: Treatment with LOVA significantly reduced first CATH by 22% 
(188 LOVA; 238 PBO, p = 0.012), first revascularization by 33% (106 LOVA; 
157 PBO, p = 0.001) and first PTCA by 43% (50 LOVA; 87 PBO, p = O.OOl), 
but not first CABG (17% reduction; p = 0.263). Like the primary endpoint 
rates, the observed between group difference in revascularization rates was 
evident early in the study. For those with CATH, the proportion of patients with 
multi-vessel disease (GI%LOVA; 86% PBO) and with stenoses 150% (74% 
LOVA; 84%PBO) appeared to be less with LOVA than PBO. Left ventricular 
function was unaffected by treatment group; however data were not available 
for 220% of patients. 
Conclusion: LOVA reduced the incidence of invasive cardiac procedures 
and appeared to reduce both the incidence and severity of significant coro- 
nary artery disease. 
9:00 a.m. 
906-3 High Dose Simvastatin Treatment Reduces 
Apolipoprotein B Production in Patients With 
Diabetic Dyslipidemia 
Merle Myerson, Colleen Ngai, Lars Berglund, Jeff Jones, 
Rajasekhar Ramakrishnan, Henry N. Ginsberg. Columbia University, New 
York, New York, USA 
Background: Individuals with type 2 diabetes melltius (DM) typically have a 
dyslipidemia characterized by hypertriglyceridemia, low levels of high density 
lipoprotein cholesterol, and variable low density lipoprotein (LDL) choles- 
terol levels. Overproduction of very low density lipoprotein (VLDL) and LDL 
apolipoprotein B (apoB) is a consistent metabolic abnormality in these pa- 
tients. High doses of HMG CoA reductaste inhibitors like simvastatin (Z) 
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can lower both triglycerides and LDL cholesterol in patients with type 2 DM, 
raising the possibility that 2 treatment may lower apoB production. 
Methods: We studied the effects of 80 mg/day of Z on VLDL and LDL 
apoB metabolism in 2 women and 2 men with well controlled DM (age 
64.3 i 7.4 yr). They were not receiving lipid-lowering drugs at the time 
of study. Subjects received 80 mg 2 or placebo for 8 weeks each in a 
double-blind crossover design. In the last 2 weeks of each period, VLDL and 
LDL apoB fractional catabolic rates and production rates were determined 
using autologous radiolabeled lipoproteins. 
Results: All 4 subjects had consistent results. Compared to placebo, Z 
lowered VLDL triglyceride by 40% (186 * 100 vs 315 f 187 mg/dl), VLDL 
cholesterol by 51% (40 i 20 vs 84 f 53), and LDL cholesterol by 43% (51 + 
IO vs 93 f 26). On 2, VLDL apoB levels fell by 40% (17.0 & 3.9 vs 28.3 f 
13.2 mg/dl) and LDL apoB levels by 48% (42.5 f 7.4 vs 82.0 * 16.2) There 
was no effect of Z treatment on fractional catabolic rates for VLDL apoB 
(3.38 i 1.2 vs 2.95 + 1.5 pools/day) or for LDL apoB (0.85 & 0.44 vs 0.83 
f 0.43). In contrast, Z treatment reduced production rates of VLDL apoB by 
20% (25.3 f 9.4 vs 31.7 f 9.8 mg/kg/day) and of LDL apoB by 42% (17.0 f 
10.6 vs 29.1 i 14.3). 
Conclusion: Treatment with high dose 2 corrects the dyslipidemia of 
type 2 DM by reducing the assembly and secretion of apoB-containing 
lipoproteins. 
9:15 a.m. 
906-4 New Combination Niacin/Statin Formulation Shows 
Pronounced Effects on Major Lipoproteins and is 
Well Tolerated 
Moti L. Kashyap, Rosemary Evans, Phillip D. Simmons, Roger M. Kohler, 
Mark E. McGovern. Long Beach Veterans Administration Medical Center, 
Long Beach, California; Kos Pharmaceuticals, Inc., Miami Lakes, Florida, 
USA 
Background: To reach National Cholesterol Education Program (NCEP) 
LDL-C goals, many patients require combination therapy. NCEP also em- 
phasizes the importance of HDL-C as well as LDL-C. Thus we undertook 
development of a convenient once-daily combination niacinnovastatin formu- 
lation to achieve enhanced effects on LDL-C while retaining niacin’s potency 
in raising HDL-C while reducing triglycerides (TG) and lipoprotein (a) [Lp(a)]. 
Methods: This is an ongoing, one-year, multi-center, open-label study. 
Entry criteria for LDL-C followed NCEP guidelines after appropriate diet. 
An initial dose of 500/10 (500 mg niacin/IO mg lovastatin) is increased to 
1000/20, 1500/30, and 2000/40 at monthly intervals, if tolerated. 
Results: The average age at baseline is 60 years; 39% are women. The 
table below shows interim results. Values at baseline are in mg/dL. N for 
Lp(a) is 90 at each visit. 
Parameter Week 
N 
Baseline 
818 
Mean (SE) 
4 8 12 16 
754 685 646 600 
Mean % Chance from Baseline (SE) 
LDL-C 195 (1.4) -25 (0.5) -34 (0.6) -41 (0.6) -47 (0.6) 
HDL-C 48 (0.4) 11 (0.5) 18 (0.7) 26 (0.6) 30 (0.9) 
TG 199 (3.2) -16 (1.0) -26 (1 .O) -35 (0.9) -42 (1.0) 
LPb) 43 (4.4) -5 (1.8) -13 (1.8) -18 (2.0) NA 
NA = not available. SE = standard error. 
Flushing has caused approximately 7% of patients to withdraw. No cases 
of myopathy have been observed. The incidence of elevated liver enzymes 
>3 times upper limit is ~1%. 
Conclusion: This new combination tablet formulation is highly effective 
and well tolerated. These results suggest that the effects of niacin and 
lovastatin are additive for LDL-C and TG. 
9:30 a.m. 
1906-5 1 Complementary, Additive Benefit of Clopidogrel and 
Lipid-Lowering Therapy in Patients With 
Atherosclerosis 
Deepak L. Bhatt, JoAnne M. Foody, Alan T. Hirsch, Peter Ringleb, 
Werner Hacke, Eric J. Topol. Cleveland Clinic, Cleveland, Ohio, USA 
Background: Lipid lowering therapy and antiplatelet therapy have each been 
individually shown to improve outcomes when used for secondary prevention 
of ischemic events in patients with atherosclerotic vascular disease. We 
sought to determine whether the ADP receptor antagonist clopidogrel would 
be more efficacious than aspirin in preventing ischemic events in patients with 
atherosclerosis who were already being treated with lipid lowering therapy. 
Methods: With no double-counting of events, the rates of vascular death, 
myocardial infarction (Ml), all-cause stroke, and rehospitalization for ischemic 
events (angina, transient ischemic attack, limb ischemia) or for bleeding 
were determined for 2204 hypercholesterolemic patients being treated with 
lipid-lowering therapy who were randomized to either clopidogrel or aspirin 
in the CAPRIE study. 
Results: There were 1080 treated hypercholesterolemic patients ran- 
domized to clopidogrel and 1014 randomized to aspirin. The Table depicts 
the relative risk reduction (RRR) in rates of vascular death, MI, stroke, or 
rehospitalization. A reduction in events was also seen for each of the indi- 
vidual endpoints examined, but the relative risk reduction for Ml of 56.0% 
was the most marked, p = 0.010. In multivariate modeling that controlled for 
baseline features, clopidogrel therapy in patients being treated for hyperc- 
holesterolemia was associated with a 20.0% reduction in vascular death, MI, 
stroke, and rehospitalization for ischemia or bleeding, p = 0.026. 
No T Chol. 
f Chol. (on any drug) 
t Chol. (on statin) 
n Clopidogrel Aspirin RRR p value 
11217 12.8% 13.7% 6.8% 0.097 
2094 11.9% 14.6% 18.6% 0.038 
1460 12.2% 15.1% 19.3% 0.070 
Conclusion: Clopidogrel is superior to aspirin in patients with vascular 
disease who are also on lipid lowering therapy. Furthermore, the benefit of 
anti-platelet therapy with clopidogrel appears to be independent and com- 
plementary to benefits provided by lipid-lowering. 
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1201-41 Local and Systemic Hemostatic and Fibrinolytic 
Effects of Intra-Arterial Desmopressin in Vivo in 
Man: Role of Monocyte Activation 
David E. Newby’, Andrew Stewa&, Susan Grieve’, Fraser N. Witherow’, 
Christopher A. Ludlam*, Nicholas A. Boon’, Keith A.A. Fox’, ‘Departments 
of Cardiology: “Haematology, Royal InfirmarK Edinburgh, Scotland, UK 
Background: Recent studies have suggested that local desmopressin (DDAVP) 
infusion can directly release tissue plasminogen activator (t-PA) from the en- 
dothelium of the forearm without causing changes in plasma von Willebrand 
factor (vWf) concentrations. However, this may be mediated through mono- 
cyte/manrophage activation. The aims of the present study were to determine 
the release of t-PA and vWf in response to local and systemic DDAVP admin- 
istration, and correlate these responses with a marker of monocyte activation 
(interleukin-6, IL-6). 
Methods: In 16 healthy males volunteers, forearm blood flow (FBF) 
and plasma IL-6, haemostatic (vWf and Factor VIII:C) and fibrinolytic (t-PA 
and plasminogen activator inhibitor type 1, PAI-1) factors were measured in 
both forearms using venous occlusion plethysmography and blood samples 
withdrawn from 17-G cannulae sited in the antecubital fossae. Eight subjects 
received brachial artery infusions of DDAVP at IO, 30, 100, 300, 1000 ng/mih 
for IO min at each dose and 8 subjects received 70 and 700 ngimin for 
30 min at each dose. Systemic-hemodynamic effects (rise in heart rate and 
non-infused FBF) were seen with DDAVP infusions > 100 ng/min. DDAVP 
caused dose and time dependent increases in FBF (all doses) and plasma 
t-PA (DDAVP z 70 ng/min) antigen and activity concentrations (p < 0.001 for 
all). Although plasma t-PA concentrations rose in both forearms, there was 
a modest local release of t-PA in the infused forearm (up to 14 ng/lOO mL 
of tissue/min, p 4 0.05). Plasma vWf, Factor VIII:C and IL-6 concentrations 
rose in both forearms (p < O.Ol), 20-30 min after the rise in t-PA. Plasma 
PAI-I concentrations did not change throughout the studies. Plasma vWf, 
Factor VIII:C and t-PA concentrations correlated closely with the rise in IL-6 
concentrations (r = 0.92, p < 0.001; r = 0.85, p = 0.002; r = 0.81, p = 0.005 
respectively). 
Conclusions: We conclude that DDAVP appears to release t-PA, vWf 
and Factor VIII: C via systemic mechanisms which may be mediated by 
monocyte activation. The modest local release of t-PA induced by DDAVP 
may be mediated by a direct action on the endothelium or indirectly via 
monocyte action. 
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/ 1201 42 Common Genetic Variants of the the key fibrinolytic control mechanism in man. However, the concept, based Thrombomodulin Gene as a Risk Factor for upon data obtained by infusing pharmacological concentrations of endothe- 
Mvocardial Infarction lial-mediated vasodilators. needs testina under more ahvsioloaical condi- 
Hyun-Young Park’, Yangsoo Jang’.*, Youngmi Kim’, Won Heum 
Shim’.2, Hyuck Moon Kwon”. ‘Cardiovascular Research Institute; ‘Dept. of 
Infernal Medicine, Yonsei University College of Medicine, Seoul, Korea 
Background: Thrombomodulin (TM) is thrombin receptor present on the 
luminal surface of endothelial cells. The thrombin-TM complex acts as an 
anticoagulant, therefore the functional variants or deficiency of TM may lead 
to increment of thrombotic tendency. In this study, we evaluated the effects 
of genetic variations in TM gene on myocardial infarction (MI). 
Methods: We screened the promoter region and the coding sequence 
of TM gene using single strand conformation polymorphism-heteroduplex 
analysis, and identified two common genetic variants, G-33A and Ala455Val. 
The genotype frequencies were investigated in the patients with MI (n = 
234, mean age 58.6 years) and control subjects with normal coronary artery 
(n = 114, mean age 55.3 years) by the method of allele-specific oligomer 
hybridization. 
Results: There was a significant linkage disequilibrium between two 
genetic variants (IDI = 0.98, ,$ = 11.6, p c 0.05). The frequencies of G-33A 
mutation (GA -I- AA) and Ala455Val substitutions (AN + V/V) were higher 
in patient gfoup (22.6% vs. 14.9%, P = 0.09, and 42.7% vs. 3X%, p = 
0.06, respectively). In younger patients (age 5 55 years), the carriers of 
mutant alleles of G-33A and Ala455Val variants had an increased risk of MI 
compared with the non-carriers (Odds ratio 1.5, 95% Cl 0.9 to 2.3, p = 0.07, 
and Odds ratio 1.5,95% Cl 1 .O to 2.1, p = 0.03, respectively). In the presence 
of smoking, the carriers of mutant alleles had an increased risk of Ml (Odds 
ratio 1.7, 95% Cl 0.8 to 3.6, p = 0.17, and Odds ratio 1.6, 95% Cl 1.0 to 2.6, 
p = 0.08, respectively). 
Conclusion: There was a significant association of the Ala455+Val vari- 
ant with Ml, and this result suggests the genetic variant is a risk factor for Ml, 
especially in young age and smokers. 
Li 1201 43 Neither Previous Chlamydia Pneumoniae infection nor Elevated C-Reactive Protein are 
Associated With Endothelial Dysfunction in 
Healthy Young Adults 
Ali Fard, Todd A. Bryant, Catherine H. Tuck, John A. Vest, Robert Sciacca, 
Marco R. Di Tullio, Neim-Tzu Chen, Lars Berglund, Henry N. Ginsberg, 
Shunichi Homma. Columbia UniversiQ New York, N\r: USA 
Niraj Sharma, Thomas C. Andrews. University of Texas Southwestern 
Medical Center at Da//as, TX, USA 
Background: Infection and inflammation may play an important role in 
atherogenesis and its clinical manifestations. Vascular endothelial dysfunc- 
tion occurs in early atherosclerosis and may further promote atherogenesis. 
We performed an observational study to determine whether markers of in- 
fection and inflammation are associated with endotheiial dysfunction. 
Methods: We measured brachial artery flow mediated vasodilation during 
reactive hyperemia in 100 healthy male and female subjects (18 to 49) 
using high resolution ultrasonography. Subjects with cardiovascular disease, 
diabetes, hypertension, or dyslipidemia were excluded. Female subjects 
were studied during active menses. Correlation coefficients were calculated 
for known predictors of endothelial function as well as for C-reactive protein 
and anti-Chiamydia pneumonia IgG and IgA titers. 
Background: Asymmetric dimethylarginine (ADMA) is a recently discov- 
ered endogenous inhibitor of nitric oxide (NO) synthase detectable in human 
plasma. Nitric oxide synthesized by the constitutive isoform of NO synthase 
has several anti-atherosclerotic actions. Thus, when NO synthase enzyme 
activity is inhibited, the anti-atherosclerotic effects of NO are reduced. In this 
study, we sought to correlate various known risk factors for atherosclerosis 
[hypertension (HTN), cholesterol, gender, body mass index (BMI), smoking, 
glycosylated hemoglobin (glycoHB)] with plasma levels of ADMA in 35 volun- 
teers with type 2 diabetes mellitus. It is hypothesized that increased plasma 
levels of ADMA may be a mechanism by which some of the above risk factors 
contribute to the atherosclerotic process in type 2 diabetics. 
Results: For the entire cohort, mean age (&SD) was 30 ‘r 7 years, body 
mass index 25 * 4, LDL-cholesterol 104 f 27 mgidl, HDL-cholesterol 46 + 
13 mg/dl, homocysteine 8.6 & 5.2 nmol/ml. Lp (a) 23 f 40 mgidl, systolic 
BP 115 i 11 mmHg and diastolic BP 74 + 8 mmHg. Mean flow-mediated 
vasodilation was 4.7 * 5.1%. Of the baseline variables, homocysteine was 
weakly associated with flow mediated vasodilation (r = 0.18, p = 0.07). Neither 
Chlamydia pneumoniae antibody titers, nor measurements of C-reactive 
protein by sensitive assay correlated with flow mediated dilation (IgG: r = 
0.16, p=O.il; IgAr=(-)0.13, p=O.2; CRPr=O.lO, p=O.29). 
Methods: Thirty five volunteers with type 2 diabetes were randomly 
selected for the study. There were 14 females and 6 smokers. Those with 
hepatic or renal dysfunction were excluded. Various factors including history 
of smoking, gender, BMI, systolic (SBP) and diastolic (DBP) blood pressures 
as well as plasma lipid profile and glycoHB were correlated with plasma levels 
of ADMA, symmetric dimethylarginine (SDMA), and L-arginine measured by 
high-performance liquid chromatography. 
Results: The subjects age ranged from 42 to 75 years averaging 61 f 9 
years. The mean glycoHB was 9.8 f 2.7 mg/dl, creatinine was 0.91 f 0.28 
mg/dl, BMI was 29.7 f 4.7, SBP was 126 & 14 mmHg, and DBP was 71 i 
8 mmHg. Of all the risk factors, a significant correlation was found between 
smoking and plasma ADMA levels (r = 0.55, p = 0.0007) where plasma 
ADMA levels were 0.83 + 0.64 umol/L in the nonsmokers and 2.55 & 1.71 
umol/L in the smokers. No correlations were present between plasma SDMA 
or L-arginine levels and the risk factors studied. 
Conclusion: In this cohort of 100 healthy subjects at low risk for vascu- Conclusions: 1. Smoking is associated with a significantly increased 
lar disease, neither serologic evidence of previous Chlamydia pneumoniae plasma ADMA level in patients with type 2 diabetes. 2. Increased plasma 
infection nor elevated levels of C reactive protein correlate with endothelial ADMA level and inhibition of NO synthesis may be a mechanism by which 
dysfunction of the brachial artery. smoking contributes to atherosclerosis in type 2 diabetics. 
1201-441 Blunted Reactive Hyperaemia is Associated With 
Reduced Tissue Plasminogen Activator Release 
in Atherosclerotic Men 
Giulia Dell’Omo’ , Laura Ferrini”, Ferdinand0 De Negri”, Franc0 Carmass?, 
Roberto Pedrinelli’ I Mario Mariani’. ‘Dipartimenfo Cardiotoracico; 
“Medicina Interna; Universiti di Piss, Italy 
Background: Endothelial dysfunction increases atherothrombotic risk, but 
the mechanisms of this association are unclear. An interesting hypothesis 
postulates a direct relationship between defective endothelial-mediated va- 
somotion and reduced local release of tissue plasminogen activator (t-PA), 
tions. For this reason, we evaluated t&A release (Rio during reactive 
hyperaemia (RH), a physiological local vasodilator response mediated by 
endothelial-derived compounds produced in response to ischemia. 
Methods: Forearm blood flow (FBF, strain-gauge plethysmography), ar- 
terial (A) and venous (V) t-PA and plasminogen activator inhibitor (PAI)-l 
antigen concentrations (ELISA) to derive REL (V-A x FBF), were measured 
in the right forearm of 7 uncomplicated males (CON, 42 i 9 yrs, total choles- 
terol: 190 f 40 mg/dl) and 6 older (60 f 8 yrs), hypercholesterolemic (260 
i 15 mg/dlj male patients with atherosclerotic vascular disease (ATH), i.e. 
a group at high risk for endothelial dysfunction. Data were measured before 
and 1, 5, IO minutes after release of a 1 O-min cuff inflation at the midpoint 
between systolic and diastolic values. 
Results (Means f SD or Medians&Range): Baseline (A) t-PA was higher 
in ATH than CON (18.6 & 6.2 vs 9.4 f 2.4 rig/ml, p < 0.01). 1 minute after 
cuff release, FBF (from 3.2 f 1.6 to 18. & 3 ml/min x dl’ , p < 0.001) and 
t-PA REL [from 1.4 (-7.4/8.3) to 49 (-38/195) rig/ml x mini (p < O.OOl)] 
increased in CON, while minor FBF increases (from 2.9 f 0.7 to 4.7 f 1.3 
ml/min x dl’, p > 0.02) without changes in t-Pa REL [from 0.4 (-3000) to 
6.3 (-44/54) rig/ml x min’] characterised ATH. PAI-I REL did not change. 
Conclusions: Blunted RH, a likely expression of dysfunctional endothe- 
lial-mediated vasomotion, is associated with reduced t-PA release, possibly 
as a consequence of a lesser production of endothelial derived metabolic 
products, although defective vasodilatation per se may also contribute. A 
reduced fibrinolytic potential may perhaps explain the atherothrombotic ten- 
dency in presence of a dysfunctional endothelial-mediated vasomotion. 
I 1201 45 Smoking is Associated With Increased Plasma Asymmetric Dimethylarginine (ADMA) Levels in 
Patients With Type 2 Diabetes Mellitus 
1 1201-46 1 Comparison of the Evaluation of Endothelial 
Function by Flow Mediated Dilatation Using 
Brachial Artery or Popliteal Artery 
Giuseppe M.C. Rosano, Francesco Pelliccia, Elena Cerquetani, 
Filippo Leonardo, Paolo Pagnotta, Sergio Chierchia. lstitufo H San Raffaele, 
Roma and Milano, ltaly 
Background: Flow mediated dilatation (FMD) of conductance vessels is 
used for the assessment of endothelial function in healthy individuals, in 
those at risk of coronary events, and in patients with atherosclerosis. The 
brachial artery is often used as the artery of choice for the evaluation of 
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FMD. This artery however, is often small and is located in a position which 
commonly causes its diplacement during blood pressure cuff inflation. The 
popliteal artery is more easily accessible, is bigger and more superficial and 
therefore should be preferable for the study of endothelial function. 
Methods: We compared FMD of brachial and popliteal arteries in 16 
subjects (7 women, 9 men, mean age 27 ;t 4 years) using a 7.5-11 MHz 
ultrasound as well as upper and lower estremities occlusions. Diameters 
were measured continuously for 120 seconds and samplings of blood flow 
velocity were obtained at IO second intervals. 
Results: In all subjects, FMD was greater in the popliteal artery compared 
with brachial artery (18 i 5% vs 12 f 3%, p < 0.01). Also, peak hyperemic 
flow was greater in the popliteal artery (480 * 125% vs 405 Z!Z llO%, p < 
0.05). A trend towards a significant statistical difference in both FMD and 
peak hyperemic flow was noted between smokers and non smokers only 
with the study of popliteal artery (20 f 4% vs 16 i 2%, p = 0.07, p for trend 
= 0.001) but not with the study of brachial artery (13 f 3% vs 11 * 5%, p = 
NS). 
Conclusions: Evaluation of endothelial function using the popliteal artery 
is feasible, gives a greater FMD and hyperemic flow than the study of brachial 
artery, and separates better subjects with or without risk factors for coronary 
artery disease. 
1 1201-47 1 Persistence of Chlamydia Pneumoniae in 
Coronary Atheroma - A Clue to the Pathogenesis 
of Unstable Angina? 
Gerhard Bauriedel, Rene Andrie, Dirk Skowasch, Ulrich Welsch, 
Berndt Liideritz. Dept. of Cardiology; Univ. of Bonn, Bonn, Germany 
Background: Increasing evidence supports a causal link between infec- 
tious agents and atheroma formation/complication. Based on the concept 
of a chronic persistent Chlamydia pneumoniae infection, indicated by the 
presence of chlamydial heat shock protein 60 (cHSP 60)‘ and of endoge- 
neous human (h) HSP 60 that responds to variable stressors with increased 
TNF-w and matrix proteinase expression, we sought to assess the concurrent 
presence of either HSP 60 in coronary atheroma. 
Methods: Coronary atherectomy specimens retrieved from 47 primary 
target lesions of patients with unstable angina (UA; n = 32) or stable angina 
(SA; n = 15) were assessed immunohistochemically for the presence of cHSP 
60 and hHSP 60. These data were correlated with plaque morphology and 
assessed for prevalence in either UA or SA lesion group. 
Results: Coronary plaques showed immunoreactive criSP 60 in 31 (66%) 
and hHSP 60 in 38 of 47 (81%) lesions vs. none of 20 undiseased control 
samples. Both HSPs were present in 29 (62%) of the cases and partially colo- 
calized with macrophages/foam cells. Predilection sites were intimal regions 
with foam cell accumulation, sparse cellularity or inflammatory infiltrates. As 
the central finding of the present study, both cHSP 60 and hHSP 60 were 
more prevalent (p = 0.011 and p < 0.001) in UA compared to SA lesions (78% 
vs. 40%, and 97% vs. 47%). Within the UA group, the prevalence of either 
HSP 60 was similar for each Braunwald class and independent of previous 
myocardial infarction. 
Conclusion: Chlamydial and endogeneous HSP 60 colocalize within 
coronary primary atheroma, most prevalent in lesions associated with un- 
stable angina. Thus, our data suggest a role of persistent C. pneumoniae in 
human coronary plaque instability via antigenic mimicry. 
I-I 1201 48 Noninvasive Measurement of Blood Flow in the Left Anterior Descending Artery and Great 
Cardiac Vein 
W.L.F. Bedaux’ , M.B.M. Hofmar?, AC. van Rossurn’, CA. Visser’ ‘Dept 
of Cardiology; *Clinical Physics & Informatics, University Hospital Vrije 
Universiteit, Amsterdam, The Netherlands 
Purpose: With magnetic resonance (MR) flow mapping it is possible to 
quantify flow velocity and volume flow in the coronary vessels in a noninvasive 
way. The close anatomic relationship of the Left Anterior Descending Artery 
(LAD) with the Great Cardiac Vein (GCV) allows imaging both in one view. 
We examined the feasibility to discriminate between these two vessels and 
to measure the flow quantitatively. 
Methods: Eleven individuals with a normal LAD and 8 patients with a 
diseased LAD underwent MRI. Three suffered from LAD stenosis, 5 had 
sustained anterior myocardial infarction treated with trombolysis or primary 
PTCA of whom one with an occluded LAD and collateral supplv. From MR 
images, using connectivity to the aortic root, differentiation between the LAD 
and GCV was made. Perpendicular to the LAD MR phase contrast velocity 
mapping was performed within a breath-hold. A Region of Interest (ROI) was 
drawn around the LAD, GCV and myocardial tissue, to analyze the flow. The 
data were corrected for Body Surface Area and the timing was normalized to 
a heart rate of 60 bpm. 
Results: After correction for cardiac motion of the vessel, differentiation 
can be made between the GCV and the LAD using the flow pattern. The 
flow in the GCV is mainly systolic and points in the inverse direction as the 
flow in the LAD, which is mainly diastolic. These criteria appeared valid in 
all individual subjects, even in cases of highly stenotic arteries. Volume flow 
measurements corrected for BSA; 
LAD (mllminlm’) GCV (ml/min/m2) 
Normal (n = 11) 31 f15 -23 zt 19 
Diseaseb (n = i) 
Occluded LAD with collaterals (n = 1) 
21&10 -19ztl6 
-7 
Conclusion: Magnetic resonance is a unique tool for noninvasive, simul- 
taneous measurement of the flow pattern and volume flow in the GCV and 
LAD. A possible clinical application of measuring venous coronay flow is the 
assessment of collateral supply in case of occluded coronary arteries. 
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L-2 1202 50 Increased Mortality Risk in African-Americans With Coronary Heart Disease, Treated With 
Calcium Channel Blockers 
Andreas Pittaras, Peter Kokkinos, Ross Fletcher, Vasilios Papademetriou. 
Veterans Affairs & Georgetown University Medical Centers Washington, DC, 
USA 
Background: Calcium channel blockers (CCB) are widely used in African- 
Americans (AA) for the treatment of hypertension and coronary heart disease 
(CHD). This preference in mostly based on favorable antihypertensive effects 
and symptom relief. However, the influence of CCB therepy on outcomes in 
AA patients with CHD has not been assessed. 
Methods: We retrospectively studied the interaction of treatment on mor- 
tality rates in 812 AA men who underwent diagnostic cardiac catheterization. 
Of these patients, 309 were treated with CCB, 87 with beta blockers (BB), 
151 with both (CCB + BB) and 265 were on neither BB or CCB. 
Results: Patients treated with CCB were older (69 f 9 vs 66 jc 11; p = 
0.000) and had higher resting diastolic BP (83 i 11 vs 77 f 8; p < 0.002) but 
had higher ejection fraction (56 i 17~s 51 f 17; p < O.OOl), when compared 
to those not treated with CCB, BB or combination. Over a period of 84 f 
35 months, a total of 286 deaths occurred. Mortality rates were significantly 
higher in patients treated with CCB when compared to those not treated with 
CCB, BB or combination (47.9% vs 28%: Long Rank = 19.5; p = O.OOO)., 
This relationship persisted after adjusting for confounding factors, including 
severity of CAD (RR = 1.75; Cl: I .2-2.4; p x 0.004). When patients treated 
with BB and a combination of CCB + BB were compared to those in other 
therapies, mortality rates were not significantly different. 
Conclusions: These findings indicate that AA patients with CAD treated 
with CCB are ,at increased mortality risk. Further prospective studies are 
needed to confirm these findings. 
( 1202-51 ) Receiver Operating Characteristic (ROC) Curve 
Analysis of the Ability of Apolipoprotein(a) 
lsoform Polymorphism and Serum Lipoprotein(a) 
Levels to Predict the Risk of CHD in Men 
Bo Zhang, Keijiro Saku, Kikuo Arakawa. Fukuoka Univ., Fukuoka, Japan 
Background: We investigated the association among ape(a) phenotype (P), 
serum Lp(a) levels, and CHD in 286 male patients aged between 40 and 
70 yrs. 
Methods: Cases (n = 123) and controls (n = 163) were defined as patients 
with and without angiographically proven CHD. Ape(a) phenotyping was per- 
formed by a sensitive, high-resolution technique using SDS-agarose/gradient 
PAGE (3-6%), which identified 25 different ape(a) P (Al-A25). The abilities 
of Lp(a) and ape(a) P to diagnose CHD were analyzed with ROC curves. 
Results: Cases had significantly (p c 0.01) higher levels of Lp(a) (38.0 
f 40.2 vs. 16.8 rt 17.0 mg/dl) and TC, and lower HDL-C levels than con- 
trols Cases had a different frequency distribution of ape(a) P than con- 
trols, with more low-molecular-weight ape(a) P than controls (iA9/AlO-A15/ 
A16-A19/zAZO: 23.6%/32.5%/39.8%/4.1% vs. 7.4%/35.0%/42.3%115.3%, 
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x2 = 22, p < 0.01). ROC curve analysis indicated that both Lp(a) and ape(a) 
P were significant discriminators of CHD and that the diagnostic accuracy of 
Lp(a) was moderate and significantly higher than that of ape(a) P (ROC area: 
0.712 and 0.616, respectively). Astrong inverse relationship existed between 
Lp(a) and ape(a) P (r = -0.66, p < O.OOl), however, ape(a) P accounted for 
only 48% of the total variance of Lp(a). The slopes of the regression lines in 
cases and controls were similar (-0.13 f 0.01 and -0.14 f 0.01, p < O.OOl), 
however, Lp(a) in cases was higher than that in controls over the entire range 
of ape(a) P. Multivariate logistic regression analysis indicated that Lp(a) was 
associated with CHD independent of ape(a) P (Wald x2 = 16.5, p < 0.001). 
Conclusion: Lp(a) predicts CHD risk better than ape(a) phenotype 
Ape(a) P contributes significantly, but only partly. to the association between 
Lp(a) and CHD. 
/ 120.2 52 A Double-Blind, Parallel Group Study of . . 
Amlodmme Versus Lona Actina Nitrate in the 
Management of Elderly Patients With Stable 
Angina 
Roger Hall. On behalf of the Investigators’ Group; Hammersmith Hospital, 
London, UK 
Objectives: to compare the effects of amlodipine (Istin’“) (5-10 mg o.d.) 
with long-acting (25-50 mg) isosorbide mononitrate (Elantan’” LA) (o.d.), 
in elderly patients (~65 years) with stable angina, with regard to exercise 
tolerance, incidence of angina and side effects. 
Design: Double-blind, randomised, parallel group study. 
Methods: Following a 4 week run-in, patients entered a 28week treat- 
ment phase, during which they were randomised to amlodipine (A) or isosor- 
bide mononitrate (IS). The primary efficacy assessment was change (from 
baseline) in total exercise time, as limited by angina. Secondary assess- 
ments included; time to 1 mm ST depression, number of angina attacks 
and quality-of-life. Safety was assessed by the incidence of adverse events 
and laboratory abnormalities recorded during the study, as well as effects 
on haematology, clinical chemistry and urinalysis which were performed at 
screening and at the end of the study. 
Results: A total of 196 patients entered the study, all of whom had 
a primary diagnosis of stable angina. The mean age of each group was 
identical (72.1 years), and the demographics of each group at entry were 
generally well matched. The mean duration of treatment in each group was 
169 days. 
Parameter 
Exercrse time (mean) (sets) 
Baseline visit 
Final visit 
Difference between means 
Intention-to-treatpop”. 
A (n) 1s m 
436.1 (97) 462.4 (94) 
548.3 (78) 494.6 (79) 
5504secs (p= 0,016) 
Efficacy pop”, 
A (N 1s m 
417.6 (57) 431.7 (60) 
532.9 (57) 485.1 (58) 
49.73 sets (p = 0.043) 
The most commonly reported adverse events were; peripheral oedema 
(A 14%; IS 0%) and headache (A 2%; IS 13%), the majority of which were of 
moderate intensity. 
Conclusions: Compared to isosorbide mononitrate, amlodipine signifi- 
cantly increased (both statistically and clinically) the exercise tolerance in 
this group of elderly patients. 
/ 1202-53 ] Do Different P-Blockers Cause Different Mortality 
Effects Following a Myocardial Infarction? 
Stephen S. Gottlieb, Robert J. McCaner, Universify of Mary/and School of 
Medicine, Baltimore, ivlCJ, USA 
The benefits of /j-blockade following a myocardial infarction are well known. 
However, there have been few investigations as to the importance of proper- 
ties which differ among p-blockers. Thus, whether lipophilicity or selectivity 
affect the benefit of @blockers is controversial. We used the Cooperative Car- 
diovascular Project (CCP), a HCFA program to evaluate the care of Medicare 
patients with a diagnosis of myocardial infarction, to delineate whether dif- 
ferent ,!I-blockers have a different impact on mortality following a myocardial 
infarction. 
We have previously shown that the 34% of 201,752 CCP patients who 
were discharged from the hospital on fi-blockers had a 40% improvement in 
sun!ival when multiple demographic, treatment, and physiologic parameters 
were controlled. Of patients on /r-blockers, most received either atenolol 
or metoprolol: 25% received atenolol, 65% received metoprolol, and 6% 
received propranolol. Other b-blockers accounted for only 4%. We compared 
patients treated with different B-blockers on numerous characteristics, among 
which were the following: mean ejection fraction (EF, %), age (years), histoy 
of heart failure (CHF, %) aspirin use (ASA, %) and bypass surgery (CABG, 
%). 1 and 2 year mortality was then determined, adjusting for multiple factors. 
n we CHF CABG ASA EF 1 year 2 year 
mortality mortality 
atenolol 17411 73 11.6 7.0 89.5 48 8.2 13.4 
metoprolol 44865 73 12.1 6.3 90.5 47 6.3 13.5 
There was no difference in mortality or characteristics of the patients 
receiving the lipophilic drug metoprolol and the non-lipophilic drug atenolol. 
There were too few patients receiving non-specific B-blockers to evaluate 
the importance of specificity. 
We conclude that although administration of ,&blockade is clearly bene- 
ficial following a myocardial infarction, there is no evidence that lipophilicity 
impacts upon the beneficial effects of fi-blockade. 
1202-54 Efficacy and Safety of Viagrae (Sildenafil Citrate) 
in Men With Cardiovascular Disease and Erectile 
Dysfunction 
Arne M. Olsson, Carl-Axe1 Persson. For the Swedish Sildenafil investigators 
Group: University Hospital, Lund; Pfizer AB, Tgby, Sweden 
Background: Erectile dysfunction (ED) is a highly prevalent condition in pa- 
tients with cardiovascular (CV) disease. This 12-week, double-blind, placebo- 
controlled study evaluated the efficacy and safety of sildenafil in patients with 
CV disease and ED. 
Methods: 224 men (n = 136 sildenafil, n = 88 placebo) with ED and CV 
disease, who were not taking nitrate therapy, were randomized to treatment. 
83% of the men had hypertension, 19% previous myocardial infarction; 17% 
coronary artery disease, 17% angina, 14% previous coronary bypass, 12% 
peripheral vascular disease, and 5% congestive heart failure, Patient medical 
histories included 32 CV diseases; approximately 50% of the patients had 
22 CV diseases. Patients received 50 mg sildenafil (Sild) or placebo (Pbo), 
with the dose adjusted to 100 mg or 25 mg based on efficacy and tolerability. 
Efficacy was assessed using Question 3 (Q3; ability to achieve erections) 
and Question 4 (Q4; ability to maintain erections) of the International Index 
of Erectile Function (IIEF). Adverse events (AEs) were recorded throughout 
the study. 
Results: Sildenafil treatment significantly improved erectile function in 
men with CV disease and ED (table; *P < 0.0001 versus placebo). 
Baseline Week 12 
IIEF Q3 (achieve 
erections) 
IIEF Q4 (maintain 
erections) 
Sild 
Pbo 
Sild 
Pbo 
N Mean i SD Mean * SE 
130 1.8 i 0.14 3.9 i 0.16* 
80 2.2 * 0.19 2.4 zt 0.19 
130 1.5io.12 3.5 i 0.18* 
80 1.6iO.14 2.1 i 0.21 
The most common treatment-emergent AEs were flushing (17% Sild, 2% 
Pbo), headache (15% Sild, 1% Pbo), and dyspepsia (4% Sild, 0% Pbo), with 
nearly all of these being mild or moderate. The incidence of CV AEs other 
than flushing was 2% for the sildenafil group and 1% for the placebo group. 
Ten patients (7%) in the sildenafil group and 8 patients (9%) in the placebo 
group discontinued treatment; only 1 patient discontinued because of an AE 
(placebo group). Four patients (3%) in the sildenafil group and 2 patients 
(2%) in the placebo group had serious AEs; none was considered by the 
investigator to be treatment related. 
Conclusion: Oral sildenafil is an effective and well-tolerated treatment 
for ED in patients with CV disease who are not taking nitrate therapy. 
1202-55 Effect of Estrogen Replacement Therapy on the 
Extent of Coronary Calcification and 
Atherosclerosis in Menopausal Women: 
A Histopathologic Study 
Rose C. Christian, Sean Harrington, William D. Edwards, Lorraine 
A. Fitzpatrick. Mayo Clinic and Mayo foundation, Rochester, Minnesota, 
USA 
Background: The impact of estrogen replacement therapy (ERT) on the 
development of coronary atherosclerosis and calcification remains contro- 
versial. We have previously demonstrated that histologic coronary artery 
calcium (CAC) content correlates with plaque area in human coronary speci- 
mens. The purpose of this study was to assess the effect of ERT on coronary 
calcification in autopsy specimens from menopausal women. 
Methods: Coronary arteries were collected from 38 deceased menopausal 
women age 50-98 years. 9 women had documented current ERT use, and 29 
women had no history of ERT use. These clinical coronary risk factors were 
obtained from chart review: age, smoking, diabetes mellitus (DM), hyperten- 
sion Undecalcified intact segments of all three major coronary arteries were 
embedded in plastic. 196 sections were evaluated for true calcium content 
by contact microradiography and then stained to measure plaque area. 
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Results: Significant differences in coronary risk between the 9 ERT and 
29 non-ERT women were mean age (64.7 vs 75.2 years) and DM (25% 
vs 0%). Mean CAC and plaque area were significantly lower in ERT than 
in non-ERT women (see table: n = sections, data expressed as mean & 
SD). After controlling for age and DM, ERT status remained significantly 
associated with CAC and plaque area. 
Variable 
CAC (mm*) 
Plaque (mm*) 
No ERT (n = 154) ERT (n = 42) P 
1.57 * 0.23 0.17 f 0.23 <O.Ol 
4.69 f 3.22 1.09f 1.03 <0.005 
Conclusion: ERT use is associated with lower CAC and atherosclerotic 
plaque area in menopausal women independent of other clinical predic- 
tors of atherosclerosis. The inverse association of ERT use with CAC and 
plaque burden suggests a modulating effect of estrogen on atherogenesis 
and coronaty calcification in women. Further research into the mechanisms 
of estrogen’s modulation of vascular calcification may demonstrate a novel 
cardioprotective effect. 
I 1202 56 Effects of Low Dose Simvastatin and Hormone 
Replacement Therapy on Serum Lipids in 
Postmenopausal Women With 
Hypercholesterolemia 
Michael H. Davidson, Kevin C. Maki, Donald B. Hunninghake, Robert 
H. Knopp, Anne C. Goldberg, David Waters, Adrian S. Dobs, 
MarySue Cyrowski. Chicago Center for Clinical Research, Chicago, Illinois; 
Heart Disease Prevention Clinic, Minneapolis, MN, USA 
This double-blind, randomized, placebo-controlled, multicenter clinical trial 
was designed to assess the separate and combined effects of hormone 
replacement therapy (HRT, 0.625 mg conjugated equine estrogens + 2.5 
mg medroxyprogesterone acetate) and simvastatin 10 mg/d (SIM) on serum 
lipids in 139 postmenopausal women with hypercholesterolemia (mean base- 
line LDL-C = 194.1 mg/dL). After 4 weeks of low-fat diet and 2 weeks of 
placebo run-in, subjects were assigned to one of the following regimens for 
a 6-week treatment period: placebo, SIM, HRT, or HRT + SIM. Mean or 
median % changes in lipids from baseline to the end of the treatment period 
are shown in the table below. 
Variable Placebo’ SIM” HRT3 
TC -0.g 3>4 -22.0’3 3 _10,41,2>4 
LDL-C -&g 3*4 -2g,!gs 3.4 -17,gl.Z4 
HDL-C -3.2’. 3,4 5.3’ 11.2’ 
TRIG 3.12 -18.3’m3 0.72 
i’2,3,4p < 0.05~. placebo, SIM, HRT, HRT + SIM, respectively 
HRT + SIM4 
-24.5’, 3 
-37,21,2 3 
12.2’ 
-14.1 
More women in the HRT + SIM group achieved their LDL-C goal (79%) 
than with SIM (58%) or HRT (36%) alone (p < 0.05). In conclusion, both 
HRT and SIM produced favorable changes in the serum lipid profile, and 
their combination was more effective than monotherapy with either agent, 
supporting the National Cholesterol Education Program recommendation to 
consider HRT as an option for the management of hypercholesterolemia in 
postmenopausal women. 
1202-57 Sublingual Androstenedione (The “Mark 
McGwire” Supplement) Increases Forearm Blood 
Flow in Men 
Christian Zellner, Satya Pulukutthy, Amanda E.M. Browne, 
Gowriharan Thaiyananthan, Kanu Chatterjee, Krishnankutty Sudhir, Tony 
M. Chou. University of California at San Francisco, San Francisco, CA, USA 
1 1203-g 1 Low Serum Cholesterol Levels Independently 
Predict Heart Failure Mortality: Immunological 
Importance of Lipoproteins? 
Background: Androstenedione (ANDRO) received nationwide attention when Mathias Rauchhaus, Veronika Koloczek, Hans-Dieter Volk’, 
athlete Mark McGwire admitted to using the hormone. It is frequently used as Josef Niebauer, Andrew J.S. Coats, Stefan D. Anker. Cardiac Medicine, 
a legal alternative to anabolic steroids with unclear physiologic effects in men. NHLl London, UK; ‘Clinical Immunology, Charit& Berlin, Germany 
Methods: We studied vascular responses to ANDRO in 11 male subjects 
(mean age 34 + 9 years, range 22-49 years) without cardiac risk factors. 
We used venous occlusion plethysmography to measure changes in forearm 
Background: We have demonstrated endotoxin (LPS) action as a potential 
cause of immune activation in patients with chronic heat-l failure (CHF). 
Lipoproteins bind LPS and can reduce its bioactivity. 
Vascular Responses 
Forearm blood flow 
(ml/100 mllmin) 
Forearm vascular resistance 
(mmHg/ml/lOO mllmin) 
Gold pressor response 
(% decrease in blood flow) 
Cold pressor response 
(% increase in vascular resistance) 
Before ANDRO 
2.6 * 0.5 
35.6 zt 9.4 
-47.2 i 6.0 
48.7 zk 5.6 
120 minutes after ANDRO 
4.0 * 1.4” 
24.1 zk 9.2’ 
-14.9 * 15.5* 
25.8 f 12.9* 
mean i SD, *p < 0.05 
blood flow at baseline and 120 minutes after administration of ANDRO (50 
mg sublingual). Cold pressor test was used to study sympathetic vascular 
before and after administration of ANDRO in 5 subjects. 
Results: ANDRO induced a significant increase in forearm blood flow and 
reduction in forearm vascular resistance 120 minutes after administration. 
Cold pressor-induced decreases in forearm blood flow were attenuated after 
administration of ANDRO. 
Conclusions: ANDRO induces vasodilation in the peripheral circulation 
in men. Attenuation of cold-pressor responses suggest a potential cardiopro- 
tective effect of ANDRO. These findings warrant further investigation after 
chronic administration. 
I 1202 58 Pravastatin and Glucose Intolerance: Evidence for a Protective Treatment Effect in the West of 
Scotland Coronary Prevention Study 
Allah Gaw, John Norrie, Naveed Sattar, R. Dermot G. Neely, Stuart 
M. Cobbe, Ian Ford, Christopher Isles, A. Ross Lorimer, Peter 
W. Macfarlane, James H. McKillop, Christopher J. Packard,’ 
James Shepherd, Dilys J. Freeman. Glasgow Royal infirmary and University 
of Glasgow, Glasgow, UK 
Background: We examined in detail the development of glucose intolerance 
in men aged 45-64 years either receiving pravastatin 40 mg/day or matching 
placebo during the West of Scotland Coronary Prevention Study. 
Methods: We defined glucose intolerance as at least two post-randomi- 
sation measurements > 6.5 mmol/l and at least one post-randomisation 
measurement 1.5 mmol/l greater than baseline, or the prescription of hypo- 
glycaemic drugs post-randomisation. Subjects who self-reported diabetes at 
baseline were excluded from the analyses as were those with a baseline 
glucose > 6.5 mmol/l. A total of 5,940 of the 6,595 randomised subjects were 
included in the analysis and 192 subjects became glucose intolerant during 
the study. 
Results: The baseline predictors of this transition to glucose intolerance 
from normality were studied. In the univariate model body mass index (BMI), 
log triglyceride, log white cell count (WCC), systolic blood pressure, total and 
high-density lipoprotein cholesterol, glucose and randomised treatment as- 
signment to pravastatin were significant predictors. In a stepwise multivariate 
model BMI, log triglyceride, glucose, log WCC and pravastatin therapy were 
retained as predictors of declining glucose tolerance in this cohort. 
Conclusion: We concluded that assignment to pravastatin therapy re- 
sulted in a 26% reduction (P = 0.037) in the hazard of becoming glucose 
intolerant. Baseline WCC is a marker for low grade inflammatory processes 
which may influence the development of glucose intolerance and ultimately 
diabetes. Pravastatin therapy, by lowering plasma triglyceride may favourably 
influence the development of glucose intolerance, but other explanations 
such as the anti-inflammatory properties of this drug in combination with its 
lipid lowering effects cannot be excluded by these analyses. 
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Methods: Cholesterol levels and concentrations of tumor necrosis factor-a 
(TNFa) and soluble TNF receptor 1 and 2 (sTNFR1/2) were studied in 58 
CHF patients (age 60 f 1 y, peak VOn 16 f 1 ml/kg/min, NYHA 2.7 f 0.1, 
EF 26 ZIZ 3%; mean * SE) and 14 controls (age 59 f 2 y). 
Results: Concentrations of sTNF-RI were higher in patients than in 
controls (1237 f 96 vs 632 f 72 pg/ml, p = 0.005), whereas those of TNFol 
(9.2 f 1.1 vs 6.7 f 0.6 pg/ml), sTNF-R2 (2464 f 145 vs 1920 & 303 pg/ml) 
and cholesterol (5.6 f 0.1 vs 5.5 f 0.2 mmol/l) were not. Etiology was not 
related to lipoprotein levels (ischemic CHF vs others, p > 0.20). In a subgroup 
of 41 patients, soluble CD14 (sCD14, mediating LPS bioactivity) were also 
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measured. Correlations in patients: cholesterol vs TNFol (r = -0.40, p = 
0.003), vs sTNF-RI (r = -0.24, p = 0.08) and vs sTNFR2 (r = -0.29, p < 
0.04);sCD14vsTNFol(r=0.45,p=0.003),vssTNF-R1: (r=0.64, p<O.OOOl) 
and vs sTNFR2 (r = 0.58, p < 0.0001). A ratio potentially indicating LPS 
bioactivity per unit lipoproteins (sCD14itotal cholesterol) related powerfully to 
TNFcl (r = 0.60), sTNFR1 (r = 0.74) and sTNFR2 (r = 0.65, all p + 0.0001). 
The lowest cholesterol tertile (~5.2 mmol/l, n = 18) significantly predicted 
a poor clinical outcome (p = 0.013) independently of peak VOp (p = 0.008) 
and NYHA class, TNFol, age or cardiac cachexia (all p > 0.20, follow-up 12 
months, event rate 26%). 
Conclusicm: Our data show a relationship between lower cholesterol 
levels, higher cytokine concentrations and impaired prognosis in CHF. They 
are indicative for a possibly beneficial immunological impact of lipoproteins 
in CHF patients. 
LIII 1203 10 High Affinity Extracellular Matrix Retention of LDL 
and HDL + E is Mediated by Biglycan 
Glycosaminoglycans - - - 
Kevin D. O’Brien, Katherine L. Olin, Hugh Ft. Barrett, Jens W. Fischer, 
Mike Kinsella, Alan Chait, Thomas N. Wight. University of Washington, 
Seattle, Washingfon, USA; University of Wesfern Australia, Perth, Ausfrblia 
Background: Previous studies have shown that the proteoglycan, biglycan, 
binds both low density lipoprotein (LDL) and apoE-containing high density 
lipoprotein (HDL + E) and increases their retention on extracellular matrix 
(ECM). 
Methods: To investigate whether the biglycan core protein or its gly 
cosaminoglycans (GAGS) mediates lipoprotein binding to ECM, site-directed 
mutagenesis was performed to generate a human biglycan cDNA encoding 
for alanines rather than serines at the GAG attachment sites of biglycan, 
thus encoding for a biglycan protein to which GAGS cannot be attached. 
Rat aortic smooth muscle cells (RASMC) were transduced with a retroviral 
vector containing the mutant biglycan cDNA (LmBSN), the wild-type human 
biglycan cDNA (LBSN), or an empty retroviral vector (LXSN). 
Results: Both LmBSN- and LBSN-transduced RASMC produced human 
biglycan mRNA and protein, as confirmed, respectively, by Northern and 
Western blotting. Binding assays were performed using either HDL + E or LDL 
on ECM produced by LmBSN-, LBSN- or LXSN-transduced RASMC grown to 
confluence. Analyses of both HDL + E and LDL binding to ECM, performed 
with the SAAM kinetic analysis program, demonstrated distinct, high- and 
low-affinity components of LDL and HDL + E binding. Low-affinity binding 
was similar for LBSN-, LmBSN-, and LXSN-produced ECM. In contrast, 
high-affinity binding was increased only for LBSN-produced ECM. Thus, 
high-affinity binding to ECM was increased only by GAG-containing biglycan 
and not by the biglycan core protein alone. 
Conclusion: These results demonstrate the presence of both high-affin- 
ity and low-affinity lipoprotein binding sites in ECM, show that high-affinity 
binding is mediated by GAGS, and confirm the importance of sophisticated 
modeling techniques in characterizing the interactions of lipoproteins with a 
complex, macromolecular ECM. 
L-A 1203 11 Differential Expression of Proinflammatory 
Cytokines in Endotoxin-Treated Isolated Adult 
Cardiac Myocytes and Cardiac-Derived 
Fibroblasts 
James T. Colston, Bysani Chandrasekar, Gregory L. Freeman. Medicine 
and Physiology, Univ: Texas HSC, San Antonio, Texas, USA 
Background: Prior work has shown that control of myocardial expression of 
the cytokine interleukin (IL)-6 is unique from other proinflammatory cytokines. 
We found serum levels of TNF-a, IL-lb and IL-6 to be elevated 6 hours after 
i.p. injection of 4 mg/kg endotoxin (LPS) in adult rats, and investigated if 
they are differentially expressed in cardiac myocytes (CMyo) and fibroblasts 
(CFib) following LPS exposure in vitro. 
Methods: CMyo and CFib were isolated from adult rat hearts and exposed 
to 1 wg/ml LPS for various times. Cells treated with vehicle for 6 hours were 
used as controls. Effects of phorbol ester (PMA), staurosporine (STA) and 
HsOs were also tested. Protein release was measured by ELISA and relative 
mRNA levels determined by comparative RT-PCR. 
Results: TNF-ol release was unchanged from controls (-10 pg/ml) in 
both cell types over 24 hours and TNF-a mRNA levels were not significantly 
changed. Treatment with PMA, STA or HsOs had no effect on TNF-a release 
at 6 hours. For IL-lb neither mRNA nor protein was detected in CMyo or 
CFib cultures under any condition. IL-6 release increased in CMyo cultures 
from 100 f 5 pgiml in controls to 268 + 18 pgiml (p < 0.01) 12 hours after 
LPS exposure, coinciding with a sharp increase in mRNA between 6 and 12 
hours. IL-6 release by CFib increased from 759 f IO pgiml in controls to 
>I700 pg/ml by 12 hours (p < 0.01) without changes in mRNA levels. On a 
per cell basis, CFib released over iwice as much IL-6 as CMyo. IL-6 release 
increased 2-fold (p < 0.01) in PMA-treated CFib cultures. STA had no effect 
on IL-6 release by CFib but did induce a Z-fold increase in release from CMyo 
in vitro (p < 0.01). Thus, there is limited expression of TNF-or and IL-lb from 
cardiac myocytes and fibroblasts following LPS stimulation in vitro. 
Conclusions: IL-6 is upregulated following LPS stimulation, with greater 
release from fibroblasts than myocytes. Cardiac IL-6 expression differs from 
other cytokines, and is differentially regulated in cardiac constituent cell types. 
I_/ 1203 12 Esmolol Causes Paradoxical Supine Tachycardia Response in a Subgroup of Pediatric Chronic 
Fatigue: Disturbance of Adrenergic 
Ligand-Receptor Pathway in Blood Pressure 
Control? 
Li Fan, Deborah M. Friedman, Anniece Woods-Brown, Martin Fisher, 
Leonard Krilov, Arshed Quyyumi, Marc Ovadia. North Shore U. Hasp/NYU 
Scbl of Med., Ped Rsch Cfr of Long /s/and Jewish Med. Cft, C/in. Rsch Cfrs 
of Cornell U Med. Co//., NY & National lnsfifufes of Health, Bethesda, MD, 
USA 
The short-acting B-blocker esmolol is a nonspecific PI-, &receptor ligand in 
the heart and vessels and decreases heart rate and blood pressure in normal 
children, After observing a paradoxical supine tachycardic response in 1 
pediatric chronic fatigue syndrome (CFS) patient, we prospectively sought 
evidence for this esmolol response. 
Methods: 31 Consecutive pediatric patients (age 15.8 i 2.0 yr) diagnosed 
with CFS by Centers for Disease Control (CDC) criteria underwent cardiologic 
evaluation including echocardiography, Holter monitoring and head-upright 
tilt (HUT) after 3 days of salt-abstinence. Physiologic HUT included (1) control 
HUT (60”, 49 min), (2) supine esrnolol load (500 pgikg bolus) followed by 
(3) HUT during esmolol B-blockade (200-350 bglkglmin, 60”). Patients with 
paradoxical supine tachycardic (PST) response were compared with the 
larger CFS group. 
Results: A subgroup of 4 patients (age 17 f 0.6 yr) had the paradoxi- 
cal supine tachycardic response to esmolol, a prevalence of 13%. The PST 
subgroup had mean CFS duration of 33 mos. All had severe presyncope (me- 
dian # presyncope 52 events). None of them were taking sympathomimetic 
medications prior to tilt. There were no other differences in historical fea- 
tures or echo findings. Supine control HUT responses were the same as 
in other CFS patients. Esmolol caused supine tachycardia, HR 109.5 f 35 
bpm (maximum 144 bpm) in comparison to 64 +I1 bpm for other CFS pts 
(p < 0.005). Esmolol caused an increase of 48 bpm over control HR, in 
other CFS patients esmolol lowered supine HR by a mean of 6 bpm. The 
heart rate decreased on tilt to 60’ in the PST patients, whereas it increased 
by 14 f 10 bpm in other CFS pts (p < 0.05). No difference in supine or 
tilt blood pressure occurred to explain these findings physiologically. From 
historical HUT data, no non-CFS patients ever had this paradoxical esmolol 
response. 
Conclusion: Esmolol causes paradoxical changes of heart rate (para- 
doxical supine tachycardia) in a particularly severely affected subgroup of 
chronic fatigue patients with profound presyncopal and fatigue symptoms. 
Because these children have appropriate responses to control tilt, this sug- 
gests a disturbed adrenergic ligand-receptor interaction in the pathogenesis 
of their syndrome, or a receptor-subtype hypersensitivity due to partial den- 
ervation, causing an unopposed pi-stimulation by esmolol. (Supported by 
CFIDS Association and NIH grant MO1 RW06020/08) 
POSTER 
Hypertension: Miscellaneous Observations 1 1204 1 
Wednesday, March 15, 2000, 9:00 a.m.-11 :00 a.m. 
Anaheim Convention Center, Hall A 
Presentation Hour: 1O:OO a.m.-II :00 a.m. 
Ll--- 1204 17 Relationships Between Genetic Predispositions 
to Hypertension and Coronary 
Endothelium-Dependent Vasodilation in Essential 
Hypertension 
Yuji Shigematsu, Mareomi Hamada, Yuji Hara, Makoto Suzuki, 
Osamu Sasaki, Tomoaki Ohtsuka, Go Hiasa, Akiyoshi Ogimoto, 
Hideyuki Saeki, Kunio Hiwada. Ehime UniversifK Ehime, Japan 
Background: Essential hypertension is characterized by impaired coronary 
response to acetylcholine (ACh). To investigate whether this abnormality is 
primary or a consequence of blood pressure increases. 
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Methods: Fifty eight hypertensive patients with chest pain and angio- 
graphically normal coronary arteries were divided into the two groups ac- 
cording to the severity of genetic predispositions to hyp&tension. Group 1 
included 33 patients (58 f 10 yrs) with at least one essential hypertensive 
first relative. Group 2 included 25 patients (60 + 11 yrs) without essential 
hypertensive first relatives. Coronaty artery djameter responses to intracoro- 
nary ACh were examined at proximal segment of three principal coronary 
arteries. Echocardiographically determined left ventricular mass (LVM) as a 
marker of progression of hypertension and other coronary risk factors were 
also compared between the two groups. 
Results: 1) 18 patients showed coronary spasm in group I and 4 patients 
showed in group 2. The prevalence of coronary spasm in the group 1 was 
significantly higher than that in group 2 (55% vs 16%, p < 0.01). Furthermore, 
ACh significantly decreased coronary diameter in group 1 (-20.3 f 11.2%) 
than in group 2 (-9.7 f 7.3%). The LVM index in group 1 was significantly 
higher than that in group 2 (128 i 30 vs 103 x 18 g/m’, p < 0.01). 3) There 
were no significant differences in office blood pressure, total cholesterol 
levels, HDL-cholesterol levels and the prevalence of smokers or diabetes 
mellitus between the two groups. 
Conclusion: Hypertensive patients with severe genetic predispositions 
to hypertension are characterized by severely impaired coronary responses 
to ACh and progression of left ventricular hypertrophy. 
1204-l 8 Restenosis Rate - Effects on Renal Function and 
Blood Pressure After Primary Stenting of Ostial 
Renal Artery Stenosis 
Thomas Zeller, Ulrich Frank, Siegfried Haag-Wildi, Jens Petersen. 
Herz-Zentrum Bad Krozingen, Germany 
Background: About two percent of hypertension (HT) is caused by renal 
artery stenosis (RAS). About 80% of these are arteriosclerotic ostial RAS. 
Methods: We studied the initial success and follow up data over a 3-year- 
period in 133 patients (193 RAS). Mean age was 66.4 f 7.8 (44-84) years. 
Follow-up studies were done before primary stenting (PTRA), before hos- 
pital discharge, and 6, 12, and 24 months after intervention (color doppler 
sonography, 24-h blood pressure (BP) monitoring, creatinine [Crea], drug 
analysis). Risk factors: HT 98%, hypercholesterolemia 92%, smoking 61%, 
obesity 63%, diabetes mellitus 38%. 
Results: Primary success rate was 98.8% with a reduction of RAS from 
84% to 7%, one major complication occurred. Restenosis rate: 8.3%. Blood 
pressure decreased significantly despite of reduced antihyljettensive drug 
therapy. Creatinine decreased from 1.54 to 1.05 mg/dl (p < 0.001). 
Drugs 24-h BP Crea total Cm Ch?a Crea Restenosis 
n ImmHgl [w/dU <1.2 1.2-3 >3.0 n 
Pre-PTRA 3.1 143/79/101 1.54 0.91 1.61 4.15 - 
Discharge 2.5 129/72/93 1.30 0.91 1.45 3.20 0 
6 months 2.3 134/75/96 1.18 0.89 1.29 3.10 10 
12 month 2.3 125/72/89 1.04 0.95 1.21 - 1 
24 month 2.3 1.05 0.98 1.28 - 0 
Conclusion: PTRA of ostial RAS is safe and effective in treatment of 
hypertension and leads to improved renal function. 
1 1204-l 9 1 Is Thallium Scintigraphy a Reliable Test in 
Hypertensive African-Americans? 
Stephan Danik, William Lyons, Edward M. Dwyer. Columbia Presbyterian 
Medical Center, New York, NY; The New Jersey Medical School, Newark, 
NJ, USA 
Backround: Most analyses of stress SPECT Thallium-201 Scintigraphy 
(SSTS) for the diagnosis of coronary artery disease (CAD) are in pre- 
dominantly white populations. A clear understanding of the false positive 
(FPOS) rate of the test has been further confounded by “work-up” bias. 
The purpose of the study was to characterize features of our predominantly 
African-American population which may contribute to the occurrence of FPOS 
tests. 
Methods: From 1996 tq 1999, all patients (pts) with a normal coronary an- 
giogram, who also underwent a SSTS, were included (n = 114). Exercise was 
performed in 54 pts and persantine infused in 60 pts. We excluded pts with 
CAD, drug abuse, left bundle branch block, and hypertrophic cardiomyopa- 
thy. Diastolic and systolic dysfunction were determined with hemodynamic 
and angiographic catheterization data. Obesity was defined as a body mass 
index of ~27 kg/m’. 
Results: FPOS SSTS occurred in 97 pts and a true negative SSTS 
in 17 pts. Redistribution abnormalities were present in 86 pts (18 anterior, 
27 inferior, 1 lateral, and 51 multiple sites). Fixed defects were present 
in 11 patients. Comparison of the two groups demonstrated a significantly 
increased prevalence of hypertension in pts with a FPOS test (p = 0.03). All 
other factors were similar. 
Variable 
Age (mean 
Female 
Black 
Hypertension 
Obesity 
Diabetes 
Diastolic dysfxn 
Systolic dysfxn 
% Nrml Thall Scan 
(n = 17) 
54 
76 
71 
71 
47 
35 
31 
19 
% Abnrml Thall Scan 
(n = 97) 
55 
53 
74 
92 
57 
31 
26 
20 
p value 
0.56 
0.3 
0.9 
0.03 
0.6 
0.96 
0.8 
0.9 
Conclusion: Frequent FPOS SSTS in our predominantly African-Ameri- 
can population appears to be attributable to the high prevalence of hyperten- 
sion. 
I 1204 20 Gender Difference in Diastolic Function in a Population-Based Sample of Hypertensive 
Adults: The HyperGEN Study 
Jonathan N. Bella, Vittorio Palmieri, Dalane W. Kitzman, Jennifer E. Liu, 
Albert Oberman, Paul Hopkins, D.C. Rao, Donna Arnett, Richard 
8. Devereux. Weill Medical College of Cornell University, New York, NL: USA 
Background: Although several studies have indicated that there are gender 
differences in systolic function, it remains unclear whether similar differences 
exist with regard to diastolic function. 
Methods: Doppler echocardiograms were analyzed in 481 male and 832 
female, mostlytreated (95%) hypertensive adults enrolled in the Hypertension 
Genetic Epidemiology Network (HyperGEN) Study with no evidence of ab- 
normal wall motion or significant valvular heat-l disease. 
Results: Men had lower body mass index (BMI: 29.8 f 5.2 vs. 32.3 + 
7.5 kg/m*) and hear-l rate (HR: 66 f 11 vs. 69 f 11 bpm) and higher systolic 
and diastolic blood pressures than women (SBP: 134 f 20 vs. 130 f 20 
and DBP: 79 & 11 vs. 72 + 11 mm Hg, all p < 0.001). Among measures 
of diastolic filling, both mitral E and A velocities were lower in men than in 
women but the E/A ratio was identical in both genders. Both deceleration 
time (DT) and isovolumic relaxation time (IVRT) were longer in men than 
women. 
Variable 
E velocity 
A velocity 
WA Ratio 
DT (cmfsec) 
IVRT (cm/set) 
Men Women P 
71.3i 17.8 77.8 + 18.8 <O.OOl 
73.7 + 15.1 79.1 h 16.5 <O.OOl 
1.03 f 0.35 1.03 * 0.28 NS 
219.4 * 54.4 213.5 zk 46.9 0.04 
86.0 f 18.2 80.8 * 17.7 <O.OOl 
In multivariate analyses, prolonged DT was related to male gender (B = 
0.08, P = 0.006) independent of the effects of older age, race and heart rate. 
Similarly, prolonged IVRT was related to male gender (j? = 0.102, p < 0.001) 
independent of the effects of lower heart rate, higher blood pressure, older 
age and the presence of concentric LV geometry. 
Conclusion: In this population-based sample of hypertensive adults, 
men had more impaired diastolic filling than women. This gender difference in 
diastolic function may provide insight into the gender difference in congestive 
heart failure and other specific cardiovascular diseases. 
1204-21 Relation of Mitral and/or Aortic Insufficiency to 
Body Size and Myocardial Energy Expenditure in 
Hypertensive Adults: The HyperGEN Study 
Vittorio Palmieri, Donna K. Arnett, Jonathan N. Bella, Dalane W. Kitzman, 
Albert Oberman, Paul N. Hopkins, D.C. Rao, Mary Paranicas, Richard 
B. Devereux. For HyperGEN Investigators; Weill Medical College of Cornell 
University: New York, NY USA 
Background: Relation of Aortic (A) or Mitral (M) regurgitation (R) to body 
composition is controversial. Few data are available in population-based 
samples of hypertensive adults. 
Methods: Among ambulatory hypertensive participants ([HYP]; blood 
pressure [BP] 1 140 or 90 mmHg, or treatment) in the mension Genetic 
Epidemiology Network, 2087 were selected for the study, 96% were on 
treatment, 20% had also type II Diabetes. A and/or M stenosis > than mild 
by echocardiography were exclusion criteria. Fat-free body mass (FFM) was 
assessed by bio-impedance and adipose mass derived as body weight-FFM. 
Color-Doppler was used to grade MR. Left ventricular (LV) mass, end-systolic 
stress and Doppler LV ejection time were used to estimate myocardial energy 
expenditure (MEE) in Cal/beat. 
Results: 1613 HYP had no AR and no MR (reference group); 360 HYP 
(17%) had no more than mild AR and/or MR; 114 HYP (5%) had moderate 
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to severe AR and/or MR. From the reference group to those with moderate- 
severe AR and/or MR, age increased (53 vs 58 vs 61 y, p < 0.01) while body 
mass index (32.5 vs 30.2. vs 28.6 kg/m”, p < O.Ol), FFM (56 vs 54 vs 53 kg, p 
< 0.05 for trend) and adipose mass (34 vs 30 vs 26 kg, p c 0.01) decreased; 
systolic BP did not differ, diastolic BP decreased (75 vs 74 vs 71 mmHg) and 
pulse pressure increased (57 vs 60 vs 62 mmHg) (both p < 0.05 for trend). 
From the reference group to those with moderate to severe AR and/or MR, 
LV mass index (43 vs 47 vs 52 g/m* 7), end-systolic stress (163 vs 172 vs 198 
kdynes/cm2), and MEE (198 vs 224 vs 283 calimin) increased (all p < 0.01) 
while ejection fraction (62 vs 60 vs 55%, p < 0.01) decreased. Prevalences 
of self-reported heart attack (7 vs II vs 21%) and LV hypertrophy (29 vs 40 
vs 60%) increased from the reference group to those with moderate-severe 
valve disease (both p c 0.01). 
Conclusions: in hypertensive adults, AR and/or MR are common. Even 
mild AR or MR is associated with tendency to greater LV hypertrophy and 
myocardial energy expenditure, and lower body adiposity. The increase in 
MEE contributes to change in body composition and lower body weight while 
LV hypertrophy increases risk of morbidity. 
1204-22 Exercise Hypertension and Angiographic 
Coronary Disease Among Active Air Force Pilots 
Patrick J. Fitzsimmons, William B. Kruyer, Michael S. Lauer. US Air Force 
School of Aerospace Medicine, Brooks Air Force Base, TX; Cleveland Clinic 
Foundation, C/eve/and, OH, USA 
Background: Exercise hypertension, or an exaggerated systolic blood pres- 
sure response to exercise, has been associated with subsequent resting 
hypertension, but its association ‘with coronary disease and with overall 
prognosis is uncertain. 
Methods: Consecutive United States Air Force Pilots who underwent 
symptom-limited exercise testing, thallium scintigraphy, and coronary an- 
giography as part of a standard cardiovascular evaluation (N = 967, age = 
43 f 6, all male, 53% smokers, none with diabetes) were studied. Exercise 
hypertension was defined as a peak systolic blood pressure during exercise 
of 2220 mm Hg. 
Results: Exercise hypertension was present in 140 subjects (14%). The 
resting systolic blood pressure was 125 * 13 mm Hg. Exercise hypertension 
was associated with a higher resting systolic blood pressure (135 f 14 vs 
123 f 12 mm Hg, P < 0.0001). Significant coronary disease (CAD), that is 
at least a 50% lesion of a major vessel, was present in 168 (17%), while 
thallium perfusion defects were present in 401 (42%). Subjects with exercise 
hypertension were slightly more likely to have coronary disease (24% vs. 
16%, unadjusted odds ratio [OR] 1.58, 95% Cl 1.03-2.43). However, after 
adjusting for age, resting systolic blood pressure and heart rate, smoking 
status; thallium abnormalities, and body mass index, exercise hypertension 
was no longer associated with coronary disease (adjusted OR 1.34, 95% Cl 
0.81-2.23, P = 0.25), while resting systolic pressure was still associated (P 
= 0.02). 
Conclusions: Among active Air Force pilots. the association between 
exercise hypertension and angiographic coronary disease is a weak one and 
appears to be largely confounded by resting systolic blood pressure and 
other variables. 
1 1204-23 / Betas-Adrenoceptor Polymorphisms are 
Associated With Nocturnal Blood Pressure 
Decline in Hypertensives 
Larisa M. Humma, B. Nhi Nguyen, William G. Farmerie, Margaret 
R. Wallace; Julie A. Johnson. University of Florida, Gainesville, Florida, USA 
Background: Nondippers, whose blood pressures decline <IO% from day- 
time to nighttime, have a higher incidence of hypertensive end organ dam- 
age and mortality than dippers. We hypothesized that dipper status is as- 
sociated with ,5aAR genotype. There are common polymorphisms of the 
&-adrenoceptor &AR) gone at codon 19 of the gene’s 5’-leader cistron and 
at coding block codons 16 and 27. These polymorphisms are in linkage dise- 
quilibrium resulting in only three chromosomal haplotypes, and our analysis 
was based only on haplotype. Haplotypes are defined as RGE (Arg-I 9/Gly 
16/Glu27), CRQ (Cys-19/Argl6/Gln27), and CGQ (Cys-19/Glyl6/Gln27). 
Methods: Twenty-seven hypertensives, withdrawn from antihypertensive 
drugs for ~2 weeks underwent 24-hour ambulatory BP monitoring. Nondip- 
pers and dippers were those with <IO% and 2 10% decline in day to night 
SBP, respectively. BAR genotype was determined by PCR of genomic DNA 
and direct sequencing. Haplotypes were determined by T-vector cloning with 
sequencing. 
Results: Seventeen patients (63%) were nondippers. Mean f SD day to 
night SBP decline was 13 f I .8% and 4.7 * 3.7% in dippers and nondip- 
pers, respectively. Allele frequencies of the RGE haplotype for dippers and 
nondippers were 10% and 41%, respectively (p < 0.05). Fourteen patients 
carried an RGE haplotype; 86% of these were nondippers. The odds ratio 
(OR) for association of the RGE haplotype with nondipper status was 6.3 
(95% Cl 1.3-32). The OR for being a dipper if homozygous for C(R or G)Q 
was 9.6 (95% Cl 1.5-62). 
Conclusion: The RGE haplotype was strongly associated with the nondip- 
per phenotype while C(R or G)Q homozygosity associated with the dipper 
phenotype. We conclude that the &AR gene plays an important regulatory 
role in determining nocturnal BP decline. 
L--L--! 1204 24 Development of Diastolic Dysfunction and Exercise Intolerance in Hypertensive Hypertrophy 
Marco Guazzi, Kurt W. Saupe, Daniel Brenner, Carl S. Apstein. Cardiac 
Muscle Research Laboratory, Boston University School of Medicine, 
Boston, MA, USA 
Background: Exercise capacity is known to correlate poorly with ejection 
fraction and other indices of systolic function. We tested whether indices 
of diastolic dysfunction were better predictors of exercise intolerance in the 
Dahl salt-sensitive rat (DS) during its natural history of hypertension, left 
ventricular hypertrophy (LVH) and transition to cardiac failure. 
Methods and Results: With high salt diet, systolic BP (144 * 3 mmHg 
at baseline) increased 26 f 4 after 1 week and 53 f 4 after 9 weeks (both 
p < 0.05) in DS (n = IO). In control Dahl salt-resistant rats (DR, n = IO), 
systolic BP remained ~150 mmHg. Despite hypertension in the DS group, 
exercise capacity (EC) (time to exhaustion during a weekly treadmill test) was 
unchanged for 8 weeks, but at 9-10 weeks decreased to 16 f 2 min from a 
baseline value of 26 i 2 (p < 0.01). Despite the decreased EC, echo studies 
at IO weeks showed compensatory concentric LVH for DS as compared as 
DR, with no differences in LV end-diastolic diameter, a 30% increase in LV 
wall thickness, greater LV mass (1.2 i 0.1 vs 0.8 f 0.1 gm, p < O.Ol), similar 
systolic function as assessed by both fiber fractional shortening (52 vs 44%, 
p = ns) and velocity of circumferential shortening (4.6isec vs 4.3/set, p = 
ns). However, diastolic function was abnormal in the DS group: isovolumic 
relaxation time (IVRT) was longer (35 f 2 vs 29 f 1 ms, p < 0.05) and 
early filling deceleration time (DT) was shorter (57 f 2 vs 77 i 3 ms p < 
0.05). In both DS and DR, EC correlated inversely with IVRT (r = -0.82, p = 
0.002) and LV mass (r = -0.69, p = O.OOl), and positively with DT (r = 0.63, 
p = 0.003). No correlation was found between EC and indices to of systolic 
function. 
Conclusion: Diastolic rather than systolic dysfunction appears to be 
responsible for the initial limitation of exercise capacity and the first sign of 
“heart failure” during the natural history of hypertensive heart disease. 
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lo:30 a.m. 
913-l Mortality Differences Between ACE Inhibitor and 
Calcium Channel Blocker Treated Hypertensive 
Patients 
Gordon T. Mclnnes, David J. Hole, Anthony F. Lever, Peter A. Meredith, 
Lilian S. Murray, John L. Reid. Departments of Medicine and Therapeutics 
and Public Health, University of Glasgow, UK 
Background: In hypertensive patients attending the Glasgow Blood Pres- 
sure Clinic (GBPC), treatment with ACE inhibitors is associated with a re- 
duction in all cause, cancer, vascular and coronary artery disease (CAD) 
mortality. The objective of this study was to compare the influences on mor- 
tality of ACE inhibitors (ACEIs) and calcium channel blockers (CCBs). 
Methods: The GBPC holds a computerised data base of 11,000 hy- 
pertensive patients record-linked with the Registrar General Scotland for 
information on death and cause of death. Between 1 January 1980 and 31 
December 1995, 5,207 patients received prescriptions for antihypertensive 
drugs: ACEls n = 1,559; CCBs n = 2,295. Risk of all cause, CAD and vas- 
cular mortality was assessed by reference to expected risk in the general 
population of Glasgow (n = 0.8 m). 
Results: Compared with risk in patients never treated with ACEls or 
CCBs, all cause, CAD and vascular mortality was reduced in patients treated 
with ACEls (but never CCBs) and increased in patients treated with CCBs (but 
never ACEIs). Patients exposed to both ACEls and CCBs had intermediate 
levels of risk. Results using Cox’s proportional hazards model are presented 
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in the Table. Risk for patients receiving each drug class is expressed relative 
to that in patients never receiving that class. 
Table: Relative risk in treated hypertensive patients 
ACEI 
CCB 
All cause 
(857 deaths) 
0.73 (p = 0.009) 
1.35 (p = 0.0002) 
CAD 
(349 deaths) 
0.72 (p= 0.03) 
1.72 (p=O.OOOl) 
All vascular 
(564 deaths) 
0.77 (p = 002) 
1.54 (p = 0.0001) 
Conclusions: Hypertensive patients treated with ACE inhibitors have 
a survival advantage. In contrast, treatment with CCBs is associated with 
a poorer outcome. The large number of well-documented fatal events and 
the prolonged duration of follow-up, may have allowed the demonstration 
of mortality differences not apparent in relatively short-term prospective tri- 
als. 
IO:45 a.m. 
1 913-21 Spontaneous Changes in Systolic and Diastolic 
Blood Pressure Can Predict Risk for Cardiovascular 
Mortality in Men 
Athanase Benetos, Mahmoud Zureik, Michel Safar, Frederique Thomas, 
Kathryn Bean, Louis Guize. Cenfre cf’lnvesfigafions Pr&entives et Cliniques 
(IPC), INSERM U337 and lJ258, France 
Background: Long-term longitudinal changes in blood pressure (BP) may be 
a more accurate determinant of BP-related risk since changes in systolic BP 
(SBP) or Diastolic BP (DBP) over a period of time depend on the evolution of 
arterial and arteriolar’systems. The present study aimed to evaluate the risk of 
cardiovascular mortally according to combined spontaneous (non-treatment 
related) changes in both SBP and DBP. 
Methods: Two independent French male cohorts were studied: the IPC 
cohort, composed of 15,561 men aged 20-82 years who had had two visits 
spaced 4 to IO years apart, and the Paris Prospective Study composed 
of 6246 men aged 42-53 years, examined every year for a period of 4 
years. None of the subjects were taking antihypertensive medication. Annual 
changes in BP were estimated and subjects were divided into groups accord- 
ing to the increase, lack of change, or decrease of systolic or diastolic BP. 
Nine groups were formed by combining the changes of systolic and diastolic 
BP. Cardiovascular mortality was assessed after the last visit for a mean 
period of 13.5 years for the IPC Study and 17 years for the Paris Prospective 
Study. 
Results: In both cohorts, after adjustment for age and major risk factors, 
the group with an increase in systolic and a decrease in diastolic BP presented 
the highest relative risk of cardiovascular mortality compared to all other 
groups. Compared to the group with no changes in either SBP or DBP, the 
relative risk of cardiovascular mortality was 2.07 (1.05-4.06) in the IPC Study 
and 2.16 (1.164.01) in the Paris Prospective Study 
Conclusion: Assessment of spontaneous changes of BP over a long 
period of time can contribute to the evaluation of cardiovascular risk Subjects 
whose systolic BP increased while their diastolic BP absolute values of BP 
and other risk factors. 
11:00 a.m. 
913-3 The Need to Focus on Systolic Hypertension: 
Analysis of NHANES Ill Blood Pressure Data 
Stanley S. Franklin, Millie Jacobs, Nathan D. Wong, Gilbert J. Cltalien, 
Pablo Lapuerta. University of California, Irvine, Irvine, California; 
Bristol-Myers Squibb, Pharmaceutical Research Institute, Princefon, New 
Jersey USA 
Background: Approximately one-half of all hypertensive patients receive 
therapy; however, less than 50% are treated to an adequate goal [cl40 
mmHg systolic blood pressure (SBP) and 190 mmHg diastolic blood pressure 
(DBP)]. The prevalence of systolic and diastolic hypertension in both treated 
and untreated patients was examined to determine where to direct efforts to 
better control hypertension. 
Methods: The National Health and Nutrition Examination Survey (NHANES) 
Ill (1988-94) population was compared according to age (~50 years or 250 
years), antihypertensive treatment status, and hypertension type [isolated 
diastolic hypertension (IDH), SBP < 140 mmHg and DBP p 90 mmHg; 
systolic/diastolic hypertension (SDH), SBP 2 140 mmHg and DBP 2 90 
mmHg; or isolated systolic hypertension (ISH), SBP > 140 mmHg and DBP 
< 90 mmHg]. Outcome variables included prevalence of systolic and dias- 
tolic hypertension stratified by age and treatment status and distribution of 
hypertension type. 
Results: 74% of both treated and untreated hypertensives were >50 
years of age, where as only 26% were ~50 years of age. In both untreated 
and treated patients ?50 years of age, there was a greater prevalence of 
systolic than diastolic hypertension; ISH was the predominant hypertension 
type found in 80% of each population (See Table). 
Population Prevalence (%) 
Svstolic Diastolic IDH 
TYPO (%) 
SDH ISH 
Untreated, <50 years 2.9 4.4 46.9 32.5 20.6 
Untreated. >50 vears 30.0 6.4 3.7 16.6 79.7 ,- , 
Treated, ~50 years 28.6 28.3 26.7 45.1 28.2 
Treated. >50 “ears 56.0 11.6 4.4 15.5 80.1 
Conclusions: Selection bias was observed in favor of treating DBP over 
SBP. A treatment bias was observed in focusing on DBP rather than on 
SBP goal. Greater efforts must be made to identify and effectively monitor 
treatment regimens in high-risk individuals. 
11:15 a.m. 
913-4 Regression of Electrocardiographic Left Ventricular 
Hypertrophy is More Strongly Related to Change in 
Blood Pressure Than to Target Blood Pressure 
Achieved: The LIFE Study 
Peter M. Okin, Richard B. Devereux, Sverker Jern, Sverre E. Kjeldsen, 
Bjorn Dahltif. Cornell Medical Center, New York, NL: USA 
Background: The ECG is widely used for the detection of left ventricular 
hypertrophy (LVH), but little is known about regression of ECG LVH criteria in 
relation to change in blood pressure (BP) during treatment of hypertension. 
Methods: Baseline and l-year ECGs were assessed in 7,507 hyper- 
tensive patients with ECG LVH by Cornell voltage-duration product (CP) or 
Sokolow-Lyon voltage (SLV) criteria on a screening ECG who underwent 
blinded treatment with either losartan or atenelol. The target BP for treat- 
ment was <140/90, but BP control was considered adequate if ~160/95 and 
>140/90. Regression of ECG LVH was defined as a ~15% decrease in CP. 
Results: After 1 -year of therapy, 2,197 patients (29%) had achieved target 
BP control, 3,652 (49%) had adequate BP control, and only 1,658 (22%) had 
inadequate BP control. There was regression of ECG LVH by CP in 34% of 
patients. Compared with patients with inadequate BP control, patients with 
adequate BP control had a greater likelihood of regression of ECG LVH by 
CP (odds ratio [OR] 1.4, 95% confidence interval [Cl] 1.2-I .5) and patients 
who achieved target BP control the greatest likelihood of regression of ECG 
LVH (OR 1.6, 95% Cl 1.4-1.8; overall x2 = 46.3, p < 0.0001). However, 
ECG LVH regression was more strongly related to quartile of systolic BP 
(SBP) change (x2 = 88.6, p i 0.000): compared with the quartile with the 
smallest change in SBP, patients in the second quartile had an OR of 1.3 
(95% Cl l.i-1.5), those in the third quartile an OR of 1.6 (95%CI l&1.9), 
and those with the greatest change in SBP an OR of 1.8 (95% Cl 1.6-2.1). In 
multivariate logistic regression analyses including standard risk factors and 
rest BP, quartile of SBP change (x2 = 49.4, p < 0.0001) was a stronger 
predictor of regression of ECG LVH than achievement of target BP (x2 = 6.9, 
p = 0.03). 
Conclusions: Both achievement of target BP and decrease in SBP with 
treatment predict regression of ECG LVH, but decrease in SBP is a stronger 
predictor of ECG LVH regression during active treatment of hypertension. 
11:30 a.m. 
913-5 Age-time-estrogen Interactions in Longitudinal 
Changes in Systolic Blood Pressure in 
Postmenopausal Women 
Angelo Scuteri, Angelo J.G. Bos, Larry J. Brant,‘Jerome L. Fleg, Edward 
G. Lakatta. Lab. of Cardiovascular Science, National institute on Aging/NIH, 
Baltimore, MD, USA 
Background: After menopause, systolic blood pressure (SBP) rises more 
rapidly than in men, the incidence of hypertension in women (F) exceeds 
that in age-matched men and Fare at higher risk of cardiovascular diseases 
(CVD). Estrogen replacement therapy (ERT) may reduce the risk of CVD in 
postmenopausal F (PM-F), but the effects of ERT on blood pressure (BP) are 
still controversial. The effects of ERT on longitudinal changes in BP, whether 
these effects differ on the basis of the age at which ERT is started or whether 
different BP at baseline influence the effects of ERT, remain unresolved. 
Methods: In 154 healthy, normotensive PM-F from the Baltimore Longi- 
tudinal Study of Aging (BLSA), aged 63 f IO yrs, resting BP was measured 
biennially over a 6.3 rt 5.5 yrs (maximum 19 yrs) follow-up period. 90 PM-F 
never used ERT and 64 used ERT. 
Results: The graph illustrates age-time-ERT interactions in longitudinal 
changes of SBP predicted via linear mixed effects model for different starting 
ages and ERT status. SBP at baseline was higher in ERT users than in 
nonusers. Nonetheless, increases in SBP over time were significantly lower 
in PM-F on ERT than in those not on ERT. These changes were more evident 
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in F starting ERT at older age, No significant effect of ERT on diastolic BP 
was found. 
Conclusion: PM-F on ERT have an attenuated rise in SBP over time 
compared to PM-F not on ERT, in spite of higher SBP at baseline. The 
beneficial effects of ERT on SBP are even stronger if ERT is started at older 
age. 
II:45 a.m. 
El 913 6 Transient Hypertension Directly Impairs Endothelium-Dependent Vasodilation in Human 
Resistance Arteries 
Oscar A. Paniagua, Melissa B. Bryant, Julio A. Panza. Cardiology Branch 
National Institutes of Health, Bethesda, Mary/and, USA 
Background: Hypertension is associated with decreased endothelium-depen- 
dent vasodilation; however, whether this abnormality is primary or secondary 
to the elevated blood pressure itself is unknown. Therefore, the purpose 
of this study was to determine whether transient increases in intravas- 
cular pressure affect endothelial vasodilator function of human resistance 
arteries. 
Methods: Subcutaneous resistance arteries (internal diameter: 202 i 75 
Km; length ~2 mm) were isolated from gluteal fat biopsies in 12 healthy 
normotensive subjects (8 men and 4 women; age: 46 ZIZ IO years) Arterial 
preparations were cannulated and perfused in 15 mL chambers oxygenated 
at 37 “C. Dose-response curves to the endothelium-dependent agent acetyl- 
choline (Ach;l Om9 to 1O-4 M) and the endothelium-independent agent sodium 
nitroprusside (SNP; 10e9 to 1O-4 M) were obtained after preconstriction with 
norepinephrine (NE;10-5 M). Separate dose-response curves to Ach and 
SNP were performed after incubating the vessels with incremental intravas- 
cular pressure of 50, 80, and 120 mmHg for 60 min each. Three additional 
dose-response curves to Ach were obtained in different arteries from 10 of 
the 12 subjects after 3 consecutive periods of incubation at 50 mmHg for 
60 min each. Arterial internal diameter was measured directly from amplified 
images and data expressed as percent of NE-induced contraction. 
Results: A significant reduction in the vasodilator response to Ach was 
observed with increases in intravascular pressure (median vasodilation to 
Ach: 69%, 50%, and 36% at 50, 80, and 120 mmHg, respectively; P = 
0.0002). In contrast, the response to SNP showed a nonsignificant trend 
toward greater vasodilation with increases in pressure (median vasodilation 
to SNP: 36%, 48%, and 51% at 50: 80, and 120 mmHg, respectively; P 
= 0.08). There was no difference in the consecutive dose-response curves 
to Ach obtained at identical intravascular pressures (median vasodilation to 
Ach: 57%, 51%, and 58% at 50 mmHg each; P = 0.65). 
Conclusions: Transient increases in intravascular pressure significantly 
depress endothelium-dependent vasodilation in human resistance arteries. 
These findings suggest that elevated blood pressure per se may cause 
endothelial dysfunction in humans and may partly explain the changes in 
vascular homeostasis observed during hypertensive crises. 
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